Resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
interferon	B-Protein
gamma	I-Protein
production	O
and	O
expression	O
of	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
1	I-Protein
in	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
rheumatoid	O
arthritis	O

IL	B-Protein
-	I-Protein
10	I-Protein
has	O
been	O
shown	O
to	O
block	O
the	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
cytokine	O
response	O
by	O
inhibiting	O
the	O
CD28	B-Protein
signaling	O
pathway	O
.	O

We	O
found	O
that	O
peripheral	O
blood	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
were	O
able	O
to	O
produce	O
greater	O
amounts	O
of	O
interferon	B-Protein
gamma	I-Protein
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
than	O
were	O
normal	O
control	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
although	O
their	O
surface	O
expression	O
of	O
the	O
type	B-Protein
1	I-Protein
IL	I-Protein
-	I-Protein
10	I-Protein
receptor	I-Protein
was	O
increased	O
.	O

The	O
phosphorylation	O
of	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
was	O
sustained	O
in	O
both	O
blood	O
and	O
synovial	O
tissue	O
CD4	B-Protein
+	O
T	O
cells	O
of	O
RA	O
,	O
but	O
it	O
was	O
not	O
augmented	O
by	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Sera	O
from	O
RA	O
patients	O
induced	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
phosphorylation	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
which	O
was	O
mostly	O
abolished	O
by	O
neutralizing	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
antibody	O
.	O

Preincubation	O
of	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
IL	B-Protein
-	I-Protein
6	I-Protein
reduced	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
inhibition	O
of	O
interferon	B-Protein
gamma	I-Protein
production	O
.	O

Blood	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
contained	O
higher	O
levels	O
of	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
1	I-Protein
but	O
lower	O
levels	O
of	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
3	I-Protein
mRNA	O
compared	O
with	O
control	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
as	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
.	O

These	O
results	O
indicate	O
that	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
become	O
resistant	O
to	O
the	O
immunosuppressive	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
before	O
migration	O
into	O
synovial	O
tissue	O
,	O
and	O
this	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
may	O
be	O
associated	O
with	O
sustained	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
activation	O
and	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
1	I-Protein
induction	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
is	O
a	O
key	O
cytokine	O
in	O
regulating	O
inflammatory	O
responses	O
,	O
mainly	O
by	O
inhibiting	O
the	O
production	O
and	O
function	O
of	O
proinflammatory	O
cytokines	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
binds	O
to	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
receptor	I-Protein
(	O
IL	B-Protein
-	I-Protein
10R	I-Protein
)	O
complex	O
that	O
is	O
composed	O
of	O
two	O
subunits	O
,	O
the	O
primary	O
ligand	O
-	O
binding	O
component	O
type	B-Protein
1	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
(	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
)	O
and	O
the	O
accessory	O
component	O
type	B-Protein
2	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
[	O
1	O
]	O
.	O

The	O
interaction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
10R	I-Protein
engages	O
the	O
Janus	O
kinase	O
(	O
JAK	O
)	O
family	O
tyrosine	O
kinases	O
Jak1	B-Protein
and	O
Tyk2	B-Protein
,	O
which	O
are	O
constitutively	O
associated	O
with	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
and	O
type	B-Protein
2	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
,	O
respectively	O
[	O
2	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
the	O
latent	O
transcriptional	O
factors	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
(	I-Protein
STAT	I-Protein
)	I-Protein
3	I-Protein
and	O
STAT1	B-Protein
[	O
3	O
]	O
.	O

Upon	O
phosphorylation	O
,	O
STAT1	B-Protein
and	O
STAT3	B-Protein
proteins	O
form	O
homodimers	O
or	O
heterodimers	O
,	O
rapidly	O
translocate	O
into	O
the	O
nucleus	O
,	O
and	O
modulate	O
gene	O
transcription	O
.	O

Intriguingly	O
,	O
STAT3	B-Protein
is	O
indispensable	O
for	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
derived	O
anti	O
-	O
inflammatory	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
derived	O
proinflammatory	O
responses	O
[	O
4	O
]	O
.	O

Studies	O
of	O
cell	O
-	O
type	O
-	O
specific	O
STAT3	B-Protein
-	O
deficient	O
mice	O
have	O
shown	O
that	O
STAT3	B-Protein
activation	O
is	O
essential	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
anti	O
-	O
inflammatory	O
reactions	O
in	O
macrophages	O
and	O
neutrophils	O
[	O
5	O
]	O
,	O
but	O
is	O
responsible	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
mediated	O
prevention	O
of	O
apoptosis	O
in	O
T	O
cells	O
[	O
6	O
]	O
.	O

The	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
)	O
proteins	O
have	O
been	O
identified	O
as	O
a	O
family	O
of	O
endogenous	O
JAK	O
kinase	O
inhibitors	O
that	O
can	O
act	O
in	O
classic	O
feedback	O
inhibition	O
loops	O
,	O
but	O
their	O
roles	O
as	O
the	O
mediators	O
of	O
crosstalk	O
inhibition	O
by	O
opposing	O
cytokine	O
signaling	O
pathways	O
have	O
been	O
clarified	O
[	O
7	O
]	O
.	O

Recent	O
studies	O
indicate	O
that	O
SOCS3	B-Protein
plays	O
a	O
key	O
role	O
in	O
regulating	O
the	O
divergent	O
action	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
by	O
specifically	O
blocking	O
STAT3	B-Protein
activation	O
induced	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
but	O
not	O
that	O
induced	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
8	O
,	O
9	O
]	O
.	O

The	O
synovial	O
membrane	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
characterized	O
by	O
an	O
infiltrate	O
of	O
a	O
variety	O
of	O
inflammatory	O
cells	O
,	O
such	O
as	O
lymphocytes	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
,	O
together	O
with	O
proliferation	O
of	O
synovial	O
fibroblast	O
-	O
like	O
cells	O
.	O

Numerous	O
cytokines	O
are	O
overproduced	O
in	O
the	O
inflamed	O
joint	O
,	O
and	O
macrophages	O
and	O
synovial	O
fibroblasts	O
are	O
an	O
important	O
source	O
of	O
proinflammatory	O
cytokines	O
.	O

Tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
two	O
major	O
macrophage	O
products	O
,	O
are	O
crucial	O
in	O
the	O
process	O
of	O
chronic	O
inflammation	O
and	O
joint	O
destruction	O
,	O
and	O
they	O
give	O
rise	O
to	O
effector	O
components	O
,	O
including	O
other	O
inflammatory	O
cytokines	O
,	O
chemokines	O
,	O
growth	O
factors	O
,	O
matrix	O
proteases	O
,	O
nitric	O
oxide	O
,	O
and	O
reactive	O
oxygen	O
species	O
[	O
10	O
]	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
is	O
a	O
pleiotropic	B-Protein
cytokine	I-Protein
produced	O
substantially	O
by	O
activated	O
fibroblasts	O
,	O
and	O
its	O
proinflammatory	O
actions	O
include	O
simulating	O
the	O
acute	O
-	O
phase	O
response	O
,	O
B	O
-	O
cell	O
maturation	O
into	O
plasma	O
cells	O
,	O
T	O
-	O
cell	O
functions	O
,	O
and	O
hematopoietic	O
precursor	O
cell	O
differentiation	O
[	O
11	O
]	O
.	O

However	O
,	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
cytokine	O
inhibitors	O
are	O
also	O
present	O
in	O
large	O
quantities	O
in	O
RA	O
joints	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
,	O
produced	O
by	O
macrophages	O
and	O
partly	O
by	O
T	O
cells	O
in	O
the	O
synovial	O
tissue	O
(	O
ST	O
)	O
,	O
is	O
best	O
known	O
as	O
a	O
negative	O
regulator	O
for	O
macrophage	O
and	O
Th1	O
cells	O
,	O
but	O
the	O
expression	O
level	O
is	O
insufficient	O
to	O
counterbalance	O
the	O
cascade	O
of	O
proinflammatory	O
events	O
[	O
12	O
]	O
.	O

In	O
addition	O
,	O
the	O
anti	O
-	O
inflammatory	O
action	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
appears	O
to	O
be	O
modulated	O
at	O
the	O
level	O
of	O
signal	O
transduction	O
during	O
chronic	O
inflammation	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
is	O
impaired	O
in	O
macrophages	O
upon	O
chronic	O
exposure	O
to	O
proinflammatory	O
cytokines	O
such	O
as	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
immune	O
complexes	O
[	O
13	O
,	O
14	O
]	O
.	O

Cell	O
surface	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
is	O
decreased	O
in	O
synovial	O
fluid	O
dendritic	O
cells	O
due	O
to	O
the	O
presence	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
[	O
15	O
]	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
may	O
be	O
activated	O
by	O
arthritogenic	O
antigens	O
,	O
in	O
conjunction	O
with	O
CD28	B-Protein
-	O
mediated	O
costimulatory	O
signaling	O
,	O
in	O
RA	O
.	O

The	O
significance	O
of	O
this	O
autoimmune	O
process	O
has	O
been	O
supported	O
by	O
the	O
linkage	O
of	O
the	O
MHC	O
class	O
II	O
antigens	O
HLA	B-Protein
-	I-Protein
DRB1	I-Protein
*	I-Protein
0404	I-Protein
and	O
HLA	B-Protein
-	I-Protein
DRB1	I-Protein
*	I-Protein
0401	I-Protein
with	O
disease	O
susceptibility	O
and	O
severity	O
[	O
16	O
,	O
17	O
]	O
,	O
and	O
by	O
the	O
high	O
-	O
level	O
expression	O
of	O
MHC	O
class	O
II	O
molecules	O
and	O
both	O
CD28	B-Protein
ligands	O
,	O
CD80	B-Protein
and	O
CD86	B-Protein
,	O
in	O
the	O
inflamed	O
ST	O
[	O
18	O
-	O
20	O
]	O
.	O

The	O
continuing	O
emergence	O
of	O
activated	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
even	O
though	O
few	O
in	O
number	O
,	O
may	O
be	O
crucial	O
in	O
sustaining	O
the	O
activation	O
of	O
macrophages	O
and	O
synovial	O
fibroblasts	O
through	O
cell	O
surface	O
signaling	O
by	O
means	O
of	O
cell	O
surface	O
CD69	B-Protein
and	O
CD11	B-Protein
,	O
as	O
well	O
as	O
the	O
release	O
of	O
proinflammatory	O
Th1	O
cytokines	O
such	O
as	O
interferon	B-Protein
gamma	I-Protein
(	B-Protein
IFN	I-Protein
)	I-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
[	O
21	O
,	O
22	O
]	O
.	O

In	O
addition	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
could	O
stimulate	O
B	O
-	O
cell	O
production	O
of	O
autoantibodies	O
such	O
as	O
rheumatoid	O
factor	O
and	O
osteoclast	O
-	O
mediated	O
bone	O
destruction	O
.	O

Their	O
obligatory	O
role	O
in	O
RA	O
synovitis	O
was	O
recently	O
proved	O
by	O
successful	O
treatment	O
of	O
active	O
disease	O
by	O
selective	O
inhibition	O
of	O
T	O
-	O
cell	O
activation	O
with	O
fusion	O
protein	O
of	O
cytotoxic	B-Protein
T	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
associated	I-Protein
antigen	I-Protein
4	I-Protein
(	I-Protein
CD152	I-Protein
)	I-Protein
-	I-Protein
IgG	I-Protein
,	O
which	O
can	O
block	O
the	O
engagement	O
of	O
CD28	B-Protein
on	O
T	O
cells	O
by	O
binding	O
to	O
CD80	B-Protein
and	O
CD86	B-Protein
with	O
high	O
avidity	O
[	O
23	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
efficiently	O
blocks	O
the	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
cytokine	O
response	O
by	O
inhibiting	O
the	O
CD28	B-Protein
signaling	O
pathway	O
[	O
24	O
]	O
,	O
as	O
well	O
as	O
indirectly	O
by	O
downregulating	O
the	O
function	O
of	O
antigen	O
-	O
presenting	O
cells	O
.	O

To	O
elucidate	O
the	O
resistance	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
this	O
direct	O
inhibition	O
in	O
RA	O
,	O
we	O
investigated	O
the	O
production	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
the	O
induction	O
of	O
STAT1	B-Protein
and	O
STAT3	B-Protein
phosphorylation	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
the	O
expression	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
mRNA	O
in	O
peripheral	O
blood	O
(	O
PB	O
)	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
.	O

Patients	O
and	O
samples	O

The	O
total	O
patient	O
population	O
consisted	O
of	O
32	O
patients	O
with	O
RA	O
(	O
25	O
women	O
and	O
seven	O
men	O
;	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
age	O
,	O
52	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
4	O
years	O
)	O
diagnosed	O
according	O
to	O
the	O
revised	O
1987	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Rheumatology	O
(	O
formally	O
,	O
the	O
American	O
Rheumatism	O
Association	O
)	O
[	O
25	O
]	O
.	O

All	O
patients	O
were	O
receiving	O
prednisolone	O
(	O
<	O
=	O
7	O
.	O
5	O
mg	O
/	O
day	O
)	O
and	O
disease	O
-	O
modifying	O
antirheumatic	O
drugs	O
.	O

Clinical	O
parameters	O
in	O
the	O
study	O
patients	O
were	O
as	O
follows	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
:	O
erythrocyte	O
sedimentation	O
rate	O
,	O
55	O
.	O
9	O
+	O
/	O
-	O
35	O
.	O
4	O
mm	O
/	O
hour	O
;	O
serum	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
level	O
,	O
32	O
.	O
0	O
+	O
/	O
-	O
32	O
.	O
0	O
mg	O
/	O
l	O
;	O
and	O
IgM	O
class	O
rheumatoid	O
factor	O
titer	O
,	O
142	O
+	O
/	O
-	O
158	O
U	O
/	O
ml	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
24	O
patients	O
with	O
active	O
disease	O
,	O
who	O
had	O
multiple	O
tender	O
and	O
/	O
or	O
swollen	O
joints	O
and	O
elevated	O
serum	O
CRP	O
level	O
(	O
>	O
=	O
10	O
mg	O
/	O
l	O
)	O
;	O
and	O
eight	O
patients	O
with	O
inactive	O
disease	O
,	O
who	O
satisfied	O
the	O
American	O
College	O
of	O
Rheumatology	O
preliminary	O
criteria	O
for	O
clinical	O
remission	O
[	O
26	O
]	O
.	O

Sixteen	O
healthy	O
volunteers	O
(	O
11	O
women	O
and	O
five	O
men	O
;	O
age	O
,	O
45	O
.	O
8	O
+	O
/	O
-	O
11	O
.	O
2	O
years	O
)	O
served	O
as	O
controls	O
.	O

ST	O
samples	O
were	O
obtained	O
from	O
three	O
RA	O
patients	O
undergoing	O
total	O
knee	O
replacement	O
.	O

All	O
patients	O
gave	O
informed	O
consent	O
.	O

Isolation	O
of	O
CD4	B-Protein
+	O
T	O
cells	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
prepared	O
from	O
heparinized	O
blood	O
samples	O
by	O
centrifugation	O
over	O
Ficoll	O
-	O
Hypaque	O
density	O
gradients	O
(	O
Pharmacia	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
were	O
purified	O
from	O
PBMC	O
by	O
positive	O
selection	O
using	O
anti	O
-	O
CD4	B-Protein
mAb	O
-	O
coated	O
magnetic	O
beads	O
(	O
Miltenyi	O
Biotec	O
,	O
Gladbach	O
,	O
Germany	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
were	O
isolated	O
from	O
ST	O
samples	O
,	O
as	O
previously	O
described	O
[	O
27	O
]	O
.	O

Briefly	O
,	O
fresh	O
ST	O
samples	O
were	O
fragmented	O
and	O
digested	O
with	O
collagenase	O
and	O
DNase	O
for	O
1	O
hour	O
at	O
37degreesC	O
.	O

After	O
removing	O
tissue	O
debris	O
,	O
ST	O
cell	O
suspensions	O
in	O
culture	O
medium	O
(	O
RPMI	O
1640	O
medium	O
;	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
supplemented	O
with	O
25	O
mM	O
HEPES	O
(	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
2	O
%	O
nonessential	O
amino	O
acids	O
,	O
100	O
IU	O
/	O
ml	O
penicillin	O
,	O
and	O
100	O
mg	O
/	O
ml	O
streptomycin	O
;	O
Life	O
Technologies	O
)	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FCS	O
(	O
Life	O
Technologies	O
)	O
were	O
incubated	O
at	O
37degreesC	O
in	O
six	O
-	O
well	O
plates	O
(	O
Coster	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
for	O
45	O
min	O
.	O

Non	O
-	O
adherent	O
cells	O
were	O
harvested	O
and	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
purified	O
by	O
positive	O
selection	O
as	O
already	O
described	O
.	O

Culture	O
of	O
CD4	B-Protein
+	O
T	O
cells	O

PB	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
populations	O
were	O
resuspended	O
at	O
a	O
density	O
of	O
1	O
x	O
106	O
cells	O
/	O
ml	O
in	O
culture	O
medium	O
with	O
10	O
%	O
FCS	O
,	O
and	O
0	O
.	O
5	O
ml	O
cell	O
suspensions	O
were	O
dispensed	O
into	O
the	O
wells	O
of	O
24	O
-	O
well	O
microtiter	O
plates	O
(	O
Coster	O
)	O
coated	O
with	O
1	O
mug	O
/	O
ml	O
anti	O
-	O
CD3	O
mAb	O
(	O
Immunotech	O
,	O
Marseille	O
,	O
France	O
)	O
.	O

The	O
cells	O
were	O
incubated	O
with	O
1	O
mug	O
/	O
ml	O
anti	O
-	O
CD28	B-Protein
mAb	O
(	O
Immunotech	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indicated	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Becton	O
Dickinson	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
at	O
37degreesC	O
in	O
a	O
humidified	O
atmosphere	O
containing	O
5	O
%	O
CO2	O
[	O
28	O
]	O
.	O

Culture	O
supernatants	O
were	O
collected	O
36	O
hours	O
later	O
and	O
cell	O
-	O
free	O
samples	O
were	O
stored	O
at	O
-	O
30degreesC	O
until	O
cytokine	O
assay	O
.	O

To	O
examine	O
the	O
effect	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
on	O
T	O
-	O
cell	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
healthy	O
controls	O
were	O
incubated	O
in	O
culture	O
medium	O
with	O
10	O
%	O
FCS	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
Becton	O
Dickinson	O
)	O
for	O
36	O
hours	O
.	O

Cells	O
were	O
then	O
stimulated	O
for	O
36	O
hours	O
with	O
anti	O
-	O
CD3	O
mAb	O
and	O
anti	O
-	O
CD28	B-Protein
mAb	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Culture	O
supernatants	O
were	O
measured	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
concentrations	O
.	O

Flow	O
cytometric	O
analysis	O
for	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O

A	O
sample	O
of	O
5	O
x	O
105	O
cells	O
of	O
PBMC	O
was	O
resuspended	O
in	O
PBS	O
with	O
1	O
%	O
FCS	O
.	O

PBMC	O
were	O
incubated	O
with	O
saturating	O
concentrations	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
mAb	O
(	O
IgG1	O
;	O
R	O
&	O
D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
or	O
with	O
isotype	O
-	O
matched	O
control	O
mAb	O
(	O
Immunotech	O
)	O
,	O
followed	O
by	O
incubation	O
with	O
FITC	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG1	O
polyclonal	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnologies	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cells	O
were	O
then	O
incubated	O
with	O
phycoerythrin	O
-	O
conjugated	O
anti	O
-	O
CD4	B-Protein
mAb	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Cells	O
were	O
washed	O
well	O
with	O
1	O
%	O
FCS	O
/	O
PBS	O
between	O
incubations	O
.	O

Analysis	O
was	O
performed	O
on	O
a	O
FACScan	O
flow	O
cytometer	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Immunoassay	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein

Concentrations	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
culture	O
supernatants	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
measured	O
in	O
duplicate	O
by	O
the	O
quantitative	O
sandwich	O
ELISA	O
using	O
cytokine	O
-	O
specific	O
capture	O
with	O
biotinylated	O
detection	O
mAb	O
and	O
recombinant	O
cytokine	O
proteins	O
(	O
all	O
from	O
Becton	O
Dickinson	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
detection	O
limits	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
were	O
15	O
pg	O
/	O
ml	O
.	O

Isolation	O
of	O
mRNA	O
and	O
real	O
-	O
time	O
PCR	O

Total	O
cellular	O
RNA	O
was	O
extracted	O
from	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
using	O
an	O
RNA	O
isolation	O
kit	O
(	O
RNeasy	O
Mini	O
kit	O
;	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

cDNA	O
was	O
synthesized	O
from	O
total	O
RNA	O
with	O
Molony	O
murine	O
leukemia	O
virus	O
reverse	O
transcriptase	O
(	O
US	O
Biochemical	O
,	O
Cleveland	O
,	O
OH	O
,	O
USA	O
)	O
and	O
oligo	O
-	O
(	O
dT	O
)	O
15	O
primers	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
the	O
LightCycler	O
Instrument	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
in	O
glass	O
capillaries	O
.	O

The	O
reaction	O
mix	O
containing	O
Taq	B-Protein
DNA	O
polymerase	O
and	O
DNA	O
double	O
-	O
strand	O
-	O
specific	O
SYBR	O
Green	O
I	O
dye	O
(	O
Lightcycler	O
FastStart	O
DNA	O
Master	O
SYBR	O
Green	O
I	O
;	O
Roche	O
Diagnostics	O
)	O
and	O
specific	O
primers	O
were	O
added	O
to	O
cDNA	O
dilutions	O
.	O

The	O
cDNA	O
samples	O
were	O
denatured	O
at	O
95degrees	O
C	O
for	O
10	O
min	O
,	O
and	O
were	O
then	O
amplified	O
for	O
40	O
-	O
50	O
cycles	O
:	O
at	O
95degrees	O
C	O
(	O
10	O
s	O
)	O
,	O
at	O
65degrees	O
C	O
(	O
15	O
s	O
)	O
,	O
and	O
72degrees	O
C	O
(	O
22	O
s	O
)	O
for	O
beta	B-Protein
-	I-Protein
actin	I-Protein
;	O
at	O
95degrees	O
C	O
(	O
10	O
s	O
)	O
,	O
at	O
62degrees	O
C	O
(	O
15	O
s	O
)	O
,	O
and	O
at	O
72degrees	O
C	O
(	O
10	O
s	O
)	O
for	O
SOCS1	B-Protein
;	O
and	O
at	O
96degrees	O
C	O
(	O
10	O
s	O
)	O
,	O
at	O
68degrees	O
C	O
(	O
15	O
s	O
)	O
,	O
and	O
at	O
72degrees	O
C	O
(	O
15	O
s	O
)	O
for	O
SOCS3	B-Protein
.	O

Amplification	O
curves	O
of	O
the	O
fluorescence	O
values	O
versus	O
cycle	O
number	O
were	O
obtained	O
,	O
and	O
a	O
melting	O
curve	O
analysis	O
was	O
then	O
performed	O
.	O

The	O
levels	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
expression	O
were	O
determined	O
by	O
normalizing	O
relative	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
expression	O
.	O

The	O
forward	O
and	O
reverse	O
primers	O
were	O
as	O
follows	O
:	O
for	O
beta	B-Protein
-	I-Protein
actin	I-Protein
,	O
5	O
'	O
-	O
GTGGGGCGCCCCAGGCACCA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
CTCCTTAATGTCACGCACGATTTC	O
-	O
3	O
'	O
;	O
for	O
SOCS1	B-Protein
,	O
5	O
'	O
-	O
AGACCCCTTCTCACCTCTTG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCACAGCAGAAAAATAAAGC	O
-	O
3	O
'	O
;	O
and	O
for	O
SOCS3	B-Protein
,	O
5	O
'	O
-	O
CCCGCCGGCACCTTTCTG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
AGGGGCCGGCTCAACACC	O
-	O
3	O
'	O
.	O

Western	O
blot	O
analysis	O

CD4	B-Protein
+	O
T	O
cells	O
were	O
stimulated	O
for	O
20	O
min	O
by	O
the	O
indicated	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells	O
in	O
0	O
.	O
5	O
ml	O
culture	O
medium	O
with	O
10	O
%	O
FCS	O
.	O

To	O
examine	O
the	O
effect	O
of	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
on	O
STAT	O
phosphorylation	O
,	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
stimulated	O
for	O
20	O
min	O
with	O
30	O
%	O
active	O
RA	O
serum	O
in	O
culture	O
medium	O
with	O
40	O
mug	O
/	O
ml	O
neutralizing	O
goat	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
polyclonal	O
antibody	O
(	O
IgG	O
;	O
Techne	O
,	O
Princeton	O
,	O
NJ	O
,	O
USA	O
)	O
or	O
control	O
goat	O
IgG	O
(	O
Techne	O
)	O
.	O

Whole	O
cell	O
lysates	O
were	O
prepared	O
by	O
placing	O
cells	O
in	O
100	O
mul	O
SDS	O
lysing	O
buffer	O
(	O
62	O
.	O
5	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
6	O
.	O
8	O
]	O
,	O
2	O
%	O
SDS	O
,	O
10	O
%	O
glycerol	O
,	O
50	O
mM	O
dithiothreitol	O
,	O
0	O
.	O
1	O
%	O
bromphenol	O
blue	O
)	O
.	O

Then	O
20	O
mul	O
protein	O
samples	O
were	O
fractionated	O
on	O
10	O
%	O
SDS	O
-	O
polyacrylamide	O
gels	O
and	O
were	O
transferred	O
to	O
nitrocellulose	O
membranes	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
,	O
and	O
the	O
membrane	O
was	O
blocked	O
with	O
5	O
%	O
skim	O
milk	O
in	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
1	O
%	O
Tween	O
20	O
.	O

Tyrosine	O
phosphorylation	O
of	O
STAT1	B-Protein
and	O
STAT3	B-Protein
was	O
detected	O
using	O
commercial	O
available	O
kits	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Briefly	O
,	O
the	O
membrane	O
was	O
incubated	O
with	O
the	O
antibodies	O
(	O
rabbit	O
IgG	O
)	O
anti	O
-	O
STAT1	B-Protein
antibody	O
,	O
anti	O
-	O
phosphorylated	O
tyrosine	O
701	O
of	O
STAT1	B-Protein
antibody	O
,	O
anti	O
-	O
STAT3	B-Protein
antibody	O
,	O
and	O
anti	O
-	O
phosphorylated	O
tyrosine	O
705	O
of	O
STAT3	B-Protein
antibody	O
,	O
diluted	O
as	O
recommended	O
at	O
1	O
/	O
2000	O
with	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
1	O
%	O
Tween	O
20	O
with	O
5	O
%	O
BSA	O
.	O

Antibody	O
binding	O
was	O
detected	O
by	O
horseradish	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
rabbit	O
IgG	O
antibody	O
diluted	O
at	O
1	O
/	O
4000	O
with	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
1	O
%	O
Tween	O
20	O
with	O
5	O
%	O
BSA	O
,	O
and	O
was	O
revealed	O
using	O
the	O
chemiluminescence	O
system	O
.	O

Protein	O
bands	O
were	O
quantified	O
by	O
densitometry	O
using	O
NIH	O
-	O
Image	O
analysis	O
,	O
and	O
STAT	B-Protein
phosphorylation	O
was	O
compared	O
with	O
the	O
total	O
amount	O
of	O
STAT	O
protein	O
.	O

IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
stimulated	O
Hela	O
cells	O
were	O
used	O
as	O
a	O
positive	O
control	O
for	O
STAT1	B-Protein
phosophorylation	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
the	O
mean	O
value	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
or	O
box	O
plots	O
.	O

The	O
statistical	O
significance	O
of	O
differences	O
between	O
two	O
groups	O
was	O
determined	O
by	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
or	O
the	O
Wilcoxon	O
signed	O
rank	O
test	O
.	O

P	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

Resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

The	O
CD28	B-Protein
costimulatory	O
pathway	O
is	O
crucial	O
for	O
effective	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
cytokine	O
production	O
,	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
can	O
directly	O
suppress	O
this	O
response	O
by	O
inhibiting	O
CD28	B-Protein
tyrosine	O
phosphorylation	O
and	O
binding	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
[	O
24	O
]	O
.	O

To	O
evaluate	O
the	O
responsiveness	O
of	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
purified	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
three	O
patients	O
with	O
active	O
RA	O
and	O
from	O
three	O
healthy	O
controls	O
were	O
stimulated	O
by	O
immobilized	O
anti	O
-	O
CD3	B-Protein
antibody	O
and	O
anti	O
-	O
CD28	B-Protein
antibody	O
with	O
or	O
without	O
diluted	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
for	O
36	O
hours	O
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
was	O
measured	O
by	O
ELISA	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

1	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
activated	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
mostly	O
inhibited	O
at	O
concentrations	O
as	O
low	O
as	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

However	O
,	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
able	O
to	O
produce	O
significant	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
the	O
maximal	O
but	O
not	O
complete	O
inhibition	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
obtained	O
at	O
10	O
-	O
100	O
ng	O
/	O
ml	O
.	O

We	O
thus	O
compared	O
the	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
CD3	B-Protein
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
RA	O
patients	O
with	O
active	O
disease	O
(	O
multiple	O
inflammatory	O
joints	O
,	O
CRP	O
level	O
>	O
=	O
10	O
mg	O
/	O
l	O
)	O
and	O
inactive	O
disease	O
(	O
in	O
remission	O
,	O
CRP	O
level	O
<	O
10	O
mg	O
/	O
l	O
)	O
[	O
26	O
]	O
and	O
in	O
healthy	O
controls	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
without	O
IL	B-Protein
-	I-Protein
10	I-Protein
among	O
these	O
three	O
groups	O
(	O
Fig	O
.	O
2a	O
)	O
,	O
but	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
on	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
was	O
significantly	O
limited	O
in	O
the	O
active	O
RA	O
group	O
as	O
compared	O
with	O
the	O
inactive	O
RA	O
group	O
and	O
healthy	O
controls	O
(	O
percentage	O
decrease	O
:	O
active	O
RA	O
,	O
2	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
4	O
%	O
;	O
inactive	O
RA	O
,	O
45	O
.	O
6	O
+	O
/	O
-	O
14	O
.	O
4	O
%	O
;	O
controls	O
,	O
65	O
.	O
8	O
+	O
/	O
-	O
7	O
.	O
9	O
%	O
)	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

As	O
a	O
consequence	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
produced	O
higher	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
than	O
did	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

In	O
addition	O
,	O
we	O
compared	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
active	O
RA	O
patients	O
and	O
in	O
healthy	O
controls	O
.	O

Similarly	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
was	O
not	O
affected	O
by	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
RA	O
patients	O
(	O
percentage	O
decrease	O
,	O
-	O
2	O
.	O
1	O
+	O
/	O
-	O
13	O
.	O
8	O
%	O
)	O
,	O
while	O
it	O
was	O
significantly	O
reduced	O
in	O
healthy	O
controls	O
(	O
61	O
.	O
1	O
+	O
/	O
-	O
13	O
.	O
7	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
become	O
less	O
susceptible	O
to	O
the	O
immunoregulatory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
during	O
the	O
active	O
phase	O
.	O

Increased	O
expression	O
of	O
cell	O
surface	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
on	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

The	O
functional	O
receptor	O
complex	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
consists	O
of	O
two	O
subunits	O
,	O
the	O
primary	O
ligand	O
-	O
binding	O
component	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
and	O
the	O
accessory	O
component	O
type	B-Protein
2	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
[	O
1	O
]	O
.	O

IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
plays	O
a	O
critical	O
role	O
in	O
cellular	O
responses	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
29	O
]	O
.	O

To	O
examine	O
whether	O
the	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
due	O
to	O
limited	O
receptor	O
expression	O
,	O
the	O
cell	O
surface	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
on	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
and	O
from	O
healthy	O
controls	O
was	O
determined	O
by	O
flow	O
cytometric	O
analysis	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

3a	O
,	O
3b	O
,	O
the	O
intensity	O
of	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
on	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
significantly	O
increased	O
in	O
RA	O
patients	O
compared	O
with	O
in	O
healthy	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
the	O
intracellular	O
signal	O
transduction	O
pathway	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
be	O
impaired	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
of	O
active	O
RA	O
.	O

Defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
phosphorylation	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

The	O
interaction	O
of	O
IL	B-Protein
-	I-Protein
10R	I-Protein
with	O
IL	B-Protein
-	I-Protein
10	I-Protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
the	O
latent	O
transcription	O
factors	O
STAT1	B-Protein
and	O
STAT3	B-Protein
[	O
3	O
]	O
.	O

Macrophage	O
-	O
specific	O
STAT3	B-Protein
-	O
deficient	O
mice	O
demonstrated	O
that	O
STAT3	B-Protein
plays	O
a	O
dominant	O
role	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
anti	O
-	O
inflammatory	O
responses	O
[	O
5	O
]	O
,	O
which	O
has	O
recently	O
been	O
confirmed	O
in	O
human	O
macrophages	O
by	O
studies	O
of	O
dominant	O
-	O
negative	O
STAT3	B-Protein
overexpression	O
[	O
30	O
]	O
.	O

The	O
induction	O
of	O
STAT1	B-Protein
and	O
STAT3	B-Protein
phosphorylation	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
and	O
from	O
healthy	O
controls	O
was	O
examined	O
using	O
western	O
blotting	O
.	O

STAT3	B-Protein
phosphorylation	O
was	O
dose	O
-	O
dependently	O
induced	O
after	O
IL	B-Protein
-	I-Protein
10	I-Protein
activation	O
for	O
20	O
min	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
4a	O
,	O
4b	O
)	O
.	O

In	O
contrast	O
,	O
STAT3	B-Protein
was	O
phosphorylated	O
in	O
freshly	O
isolated	O
PB	O
CD4	B-Protein
+	O
cells	O
from	O
RA	O
patients	O
and	O
this	O
STAT3	B-Protein
phosphorylation	O
was	O
detectable	O
for	O
up	O
to	O
6	O
hours	O
.	O

STAT3	B-Protein
phosphorylation	O
was	O
augmented	O
only	O
when	O
activated	O
by	O
as	O
much	O
as	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Both	O
sustained	O
STAT3	B-Protein
phosphorylation	O
and	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
phosphorylation	O
were	O
found	O
in	O
RA	O
ST	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
4c	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT1	B-Protein
phosphorylation	O
was	O
not	O
detected	O
in	O
either	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
or	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
4a	O
)	O
.	O

These	O
results	O
indicate	O
that	O
STAT3	B-Protein
is	O
the	O
major	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
activated	O
STAT	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
activation	O
may	O
be	O
diminished	O
in	O
active	O
RA	O
,	O
in	O
association	O
with	O
sustained	O
STAT3	B-Protein
phosphorylation	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
-	O
mediated	O
STAT3	B-Protein
phosphorylation	O
and	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
effect	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O

STAT3	B-Protein
is	O
activated	O
by	O
many	O
cytokines	O
and	O
growth	O
factors	O
such	O
as	O
the	O
IL	O
-	O
6	O
family	O
of	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
11	I-Protein
,	O
leukemia	B-Protein
inhibitory	I-Protein
factor	I-Protein
,	O
and	O
oncostatin	B-Protein
M	I-Protein
)	O
,	O
platelet	B-Protein
-	I-Protein
derived	I-Protein
growth	I-Protein
factor	I-Protein
,	O
and	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
,	O
in	O
addition	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
4	O
]	O
,	O
but	O
previous	O
studies	O
have	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
the	O
major	O
factor	O
in	O
RA	O
synovial	O
fluid	O
that	O
induces	O
constitutive	O
activation	O
of	O
STAT3	B-Protein
in	O
mononuclear	O
cells	O
[	O
31	O
]	O
.	O

Since	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
also	O
abundant	O
in	O
sera	O
of	O
active	O
RA	O
patients	O
,	O
frequently	O
detected	O
at	O
>	O
1	O
ng	O
/	O
ml	O
[	O
27	O
]	O
,	O
we	O
examined	O
whether	O
persistent	O
exposure	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
high	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
the	O
blood	O
circulation	O
was	O
responsible	O
for	O
their	O
sustained	O
STAT3	B-Protein
activation	O
and	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
in	O
active	O
RA	O
.	O

Both	O
STAT1	B-Protein
and	O
STAT3	B-Protein
phosphorylation	O
was	O
activated	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
data	O
not	O
shown	O
)	O
,	O
in	O
agreement	O
with	O
previous	O
observations	O
[	O
4	O
]	O
.	O

Normal	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
thus	O
incubated	O
for	O
20	O
min	O
with	O
culture	O
medium	O
containing	O
30	O
%	O
serum	O
from	O
active	O
RA	O
patients	O
and	O
neutralizing	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
antibody	O
or	O
control	O
antibody	O
,	O
and	O
STAT	O
phosphorylation	O
was	O
examined	O
by	O
western	O
blot	O
analysis	O
.	O

RA	O
serum	O
was	O
able	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-Protein
but	O
not	O
STAT1	B-Protein
,	O
and	O
this	O
STAT3	B-Protein
activation	O
was	O
mostly	O
abolished	O
by	O
neutralization	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
activity	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

These	O
results	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
the	O
dominant	O
STAT3	B-Protein
-	O
activating	O
factor	O
contained	O
in	O
sera	O
of	O
active	O
RA	O
patients	O
.	O

The	O
lack	O
of	O
STAT1	B-Protein
activation	O
by	O
RA	O
serum	O
suggests	O
that	O
much	O
higher	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
may	O
be	O
required	O
for	O
STAT1	B-Protein
activation	O
as	O
compared	O
with	O
STAT3	B-Protein
activation	O
,	O
or	O
that	O
inhibitors	O
of	O
STAT1	B-Protein
signaling	O
may	O
be	O
present	O
in	O
RA	O
serum	O
.	O

We	O
next	O
examined	O
whether	O
IL	B-Protein
-	I-Protein
6	I-Protein
could	O
suppress	O
the	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
to	O
inhibit	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

After	O
preincubation	O
with	O
or	O
without	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
6	I-Protein
for	O
36	O
hours	O
,	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
stimulated	O
by	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
for	O
36	O
hours	O
,	O
and	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
was	O
measured	O
by	O
ELISA	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
pretreatment	O
of	O
normal	O
cells	O
reduced	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
(	O
Fig	O
.	O
5b	O
)	O
,	O
indicating	O
that	O
high	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
could	O
modulate	O
T	O
-	O
cell	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
persistent	O
exposure	O
to	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
may	O
have	O
a	O
role	O
in	O
both	O
the	O
induction	O
of	O
STAT3	B-Protein
activation	O
and	O
the	O
resistance	O
to	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

High	O
expression	O
of	O
SOCS1	B-Protein
mRNA	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

IL	B-Protein
-	I-Protein
6	I-Protein
induces	O
two	O
potent	O
inhibitors	O
of	O
JAKs	O
(	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
proteins	O
)	O
that	O
not	O
only	O
act	O
as	O
mediators	O
of	O
negative	O
feedback	O
inhibition	O
,	O
but	O
also	O
play	O
a	O
major	O
role	O
in	O
crosstalk	O
inhibition	O
by	O
opposing	O
other	O
cytokine	O
-	O
signaling	O
pathways	O
[	O
7	O
]	O
.	O

SOCS3	B-Protein
has	O
recently	O
been	O
shown	O
to	O
specifically	O
inhibit	O
STAT3	B-Protein
activation	O
induced	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
but	O
not	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
thereby	O
regulating	O
the	O
divergent	O
action	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
8	O
,	O
9	O
]	O
.	O

On	O
the	O
contrary	O
,	O
SOCS1	B-Protein
is	O
able	O
to	O
partially	O
inhibit	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
and	O
cellular	O
responses	O
,	O
as	O
well	O
as	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
mediated	O
STAT1	B-Protein
activation	O
[	O
32	O
]	O
.	O

To	O
determine	O
whether	O
SOCSs	O
were	O
involved	O
in	O
the	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
activation	O
of	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
the	O
levels	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
mRNA	O
expression	O
in	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
and	O
from	O
healthy	O
controls	O
were	O
compared	O
by	O
semiquantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
contained	O
higher	O
levels	O
of	O
SOCS1	B-Protein
but	O
lower	O
levels	O
of	O
SOCS3	B-Protein
transcripts	O
than	O
did	O
control	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
6a	O
)	O
.	O

Constitutive	O
expression	O
of	O
SOCS1	B-Protein
mRNA	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
comparable	O
with	O
the	O
expression	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
stimulated	O
by	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
Fig	O
.	O
6b	O
)	O
,	O
supporting	O
its	O
functional	O
significance	O
.	O

Defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
activation	O
therefore	O
appears	O
to	O
be	O
due	O
at	O
least	O
in	O
part	O
to	O
an	O
abundance	O
of	O
SOCS1	B-Protein
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
orchestrate	O
the	O
Th1	O
-	O
type	O
cell	O
-	O
mediated	O
immune	O
response	O
in	O
RA	O
[	O
22	O
]	O
.	O

Activated	O
CD4	B-Protein
+	O
T	O
cells	O
stimulate	O
macrophages	O
,	O
synovial	O
fibroblasts	O
,	O
B	O
cells	O
,	O
and	O
osteoclasts	O
through	O
the	O
expression	O
of	O
cell	O
surface	O
molecules	O
and	O
Th1	O
cytokines	O
,	O
thereby	O
contributing	O
to	O
both	O
the	O
chronic	O
inflammation	O
and	O
the	O
joint	O
destruction	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
require	O
two	O
signals	O
to	O
be	O
activated	O
;	O
antigen	O
receptor	O
occupancy	O
and	O
CD28	B-Protein
-	O
mediated	O
costimulation	O
.	O

In	O
the	O
ST	O
lesion	O
,	O
the	O
CD28	B-Protein
ligands	O
,	O
both	O
CD80	B-Protein
and	O
CD86	B-Protein
,	O
together	O
with	O
MHC	O
class	O
II	O
antigens	O
,	O
are	O
substantially	O
expressed	O
by	O
antigen	O
-	O
presenting	O
cells	O
such	O
as	O
macrophages	O
and	O
dendritic	O
cells	O
[	O
18	O
-	O
20	O
]	O
.	O

The	O
significance	O
of	O
CD28	B-Protein
engagement	O
in	O
the	O
T	O
-	O
cell	O
-	O
mediated	O
disease	O
process	O
has	O
recently	O
been	O
proven	O
by	O
the	O
clinical	O
efficacy	O
of	O
its	O
blocker	O
cytotoxic	B-Protein
T	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
associated	I-Protein
antigen	I-Protein
4	I-Protein
(	I-Protein
CD152	I-Protein
)	I-Protein
-	I-Protein
IgG	I-Protein
in	O
RA	O
patients	O
[	O
23	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
plays	O
a	O
predominant	O
role	O
in	O
limiting	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
function	O
of	O
both	O
macrophages	O
and	O
Th1	O
cells	O
[	O
1	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
inhibits	O
the	O
tyrosine	O
phosphorylation	O
of	O
the	O
CD28	B-Protein
molecule	O
and	O
the	O
subsequent	O
phosphatidylinositol	O
3	O
-	O
kinase	O
binding	O
in	O
T	O
cells	O
,	O
and	O
thereby	O
directly	O
acts	O
on	O
T	O
cells	O
[	O
24	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
active	O
RA	O
,	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
are	O
able	O
to	O
produce	O
higher	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
than	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

Despite	O
high	O
-	O
level	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
and	O
constitutive	O
STAT3	B-Protein
activation	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-Protein
is	O
suppressed	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
in	O
contrast	O
to	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
where	O
STAT3	B-Protein
phosphorylation	O
is	O
dose	O
-	O
dependently	O
inducible	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
from	O
RA	O
patients	O
induces	O
STAT3	B-Protein
but	O
not	O
STAT1	B-Protein
phosphorylation	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
and	O
exogenous	O
IL	B-Protein
-	I-Protein
6	I-Protein
induces	O
the	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
.	O

RA	O
CD4	B-Protein
+	O
T	O
cells	O
contain	O
higher	O
levels	O
of	O
SOCS1	B-Protein
but	O
contain	O
lower	O
levels	O
of	O
SOCS3	B-Protein
transcripts	O
in	O
comparison	O
with	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
become	O
resistant	O
to	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
before	O
migration	O
into	O
the	O
inflamed	O
ST	O
,	O
and	O
suggest	O
that	O
this	O
resistance	O
may	O
be	O
attributable	O
to	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
dependent	O
STAT3	B-Protein
activation	O
,	O
in	O
association	O
with	O
sustained	O
STAT3	B-Protein
phosphorylation	O
and	O
SOCS1	B-Protein
induction	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
inhibition	O
of	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
cytokine	O
production	O
is	O
principally	O
dependent	O
on	O
its	O
inhibition	O
of	O
macrophage	O
antigen	O
-	O
presenting	O
cell	O
function	O
[	O
1	O
]	O
.	O

However	O
,	O
this	O
indirect	O
inhibitory	O
effect	O
is	O
thought	O
to	O
be	O
restricted	O
at	O
the	O
site	O
of	O
T	O
-	O
cell	O
activation	O
in	O
RA	O
,	O
because	O
macrophages	O
in	O
the	O
ST	O
express	O
high	O
levels	O
of	O
cytokines	O
,	O
CD80	B-Protein
and	O
CD86	B-Protein
molecules	O
,	O
and	O
MHC	O
class	O
II	O
antigens	O
[	O
10	O
,	O
18	O
-	O
20	O
]	O
.	O

More	O
recently	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
has	O
been	O
shown	O
to	O
induce	O
the	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
unresponsiveness	O
by	O
inhibiting	O
CD28	B-Protein
tyrosine	O
phosphorylation	O
[	O
33	O
]	O
.	O

This	O
direct	O
effect	O
also	O
may	O
be	O
limited	O
in	O
active	O
RA	O
patients	O
,	O
because	O
their	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
showed	O
a	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
CD28	B-Protein
-	O
costimulated	O
production	O
of	O
both	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Numerous	O
cytokines	O
,	O
both	O
proinflammatory	O
and	O
anti	O
-	O
inflammatory	O
,	O
have	O
been	O
detected	O
in	O
the	O
ST	O
of	O
RA	O
,	O
and	O
the	O
balance	O
between	O
these	O
opposing	O
cytokine	O
activities	O
regulates	O
disease	O
severity	O
[	O
10	O
]	O
.	O

Endogenous	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
produced	O
mainly	O
by	O
macrophages	O
and	O
T	O
cells	O
,	O
inhibits	O
proinflammatory	O
cytokine	O
production	O
by	O
ST	O
cells	O
[	O
12	O
]	O
.	O

However	O
,	O
this	O
regulatory	O
activity	O
seems	O
to	O
be	O
restricted	O
during	O
chronic	O
inflammation	O
.	O

The	O
activation	O
of	O
both	O
the	O
extracellular	O
stimulus	O
-	O
regulated	O
kinase	O
and	O
p38	O
kinase	O
pathways	O
,	O
induced	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
inhibits	O
the	O
Jak1	B-Protein
-	O
STAT3	B-Protein
signaling	O
pathway	O
shared	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
adhered	O
macrophages	O
[	O
13	O
]	O
.	O

More	O
importantly	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
is	O
mostly	O
undetectable	O
in	O
RA	O
synovial	O
macrophages	O
.	O

This	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
is	O
probably	O
induced	O
by	O
chronic	O
exposure	O
to	O
immune	O
complexes	O
in	O
vivo	O
,	O
because	O
both	O
cell	O
surface	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
Jak1	B-Protein
activation	O
are	O
suppressed	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
primed	O
macrophages	O
by	O
a	O
protein	O
kinase	O
C	O
-	O
dependent	O
pathway	O
following	O
ligation	O
of	O
the	O
IgG	O
Fc	O
gamma	O
receptor	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
dendritic	O
cells	O
from	O
RA	O
synovial	O
fluids	O
are	O
resistant	O
to	O
the	O
immunoregulatory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
due	O
to	O
decreased	O
transport	O
of	O
intracellular	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
in	O
the	O
presence	O
of	O
proinflammatory	O
cytokine	O
stimuli	O
such	O
as	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
[	O
15	O
]	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
resistance	O
of	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
be	O
associated	O
with	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
dependent	O
STAT3	B-Protein
activation	O
,	O
but	O
not	O
with	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
.	O

Inhibitory	O
effects	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
on	O
these	O
inflammatory	O
cell	O
types	O
are	O
therefore	O
differentially	O
modulated	O
at	O
the	O
signal	O
transduction	O
level	O
under	O
the	O
inflammatory	O
environment	O
in	O
RA	O
.	O

In	O
association	O
with	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
,	O
STAT3	B-Protein
was	O
found	O
to	O
be	O
tyrosine	O
phosphorylated	O
persistently	O
(	O
up	O
to	O
6	O
hours	O
)	O
in	O
freshly	O
isolated	O
PB	O
and	O
ST	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
.	O

STAT3	B-Protein
is	O
activated	O
by	O
a	O
variety	O
of	O
cytokines	O
,	O
notably	O
the	O
IL	O
-	O
6	O
family	O
of	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
11	I-Protein
,	O
leukemia	B-Protein
inhibitory	I-Protein
factor	I-Protein
,	O
and	O
oncostatin	B-Protein
M	I-Protein
)	O
and	O
growth	O
factors	O
,	O
in	O
addition	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
4	O
]	O
.	O

Of	O
these	O
cytokines	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
plays	O
a	O
predominant	O
role	O
in	O
eliciting	O
a	O
systemic	O
reaction	O
such	O
as	O
the	O
acute	O
phase	O
response	O
in	O
active	O
RA	O
,	O
due	O
mainly	O
to	O
its	O
abundance	O
in	O
the	O
blood	O
circulation	O
[	O
27	O
]	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
was	O
the	O
major	O
STAT3	B-Protein
-	O
activating	O
factor	O
contained	O
in	O
the	O
serum	O
of	O
active	O
RA	O
patients	O
,	O
and	O
the	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
suppressed	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
36	O
hours	O
of	O
incubation	O
with	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

These	O
results	O
suggest	O
that	O
both	O
the	O
sustained	O
STAT3	B-Protein
activation	O
and	O
the	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
found	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
may	O
be	O
induced	O
after	O
chronic	O
exposure	O
in	O
vivo	O
to	O
high	O
concentrations	O
of	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

However	O
,	O
it	O
is	O
also	O
possible	O
that	O
STAT3	B-Protein
activity	O
could	O
be	O
constitutively	O
induced	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
by	O
their	O
own	O
IL	B-Protein
-	I-Protein
10	I-Protein
secretion	O
,	O
leading	O
to	O
the	O
loss	O
of	O
sensitivity	O
to	O
exogenous	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
because	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
the	O
ST	O
are	O
capable	O
of	O
producing	O
significant	O
levels	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
34	O
]	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
isolated	O
from	O
the	O
ST	O
of	O
RA	O
also	O
showed	O
a	O
defect	O
in	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
signaling	O
pathway	O
.	O

It	O
is	O
most	O
probable	O
that	O
the	O
resistance	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
can	O
be	O
even	O
augmented	O
after	O
migration	O
into	O
the	O
inflamed	O
ST	O
,	O
because	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
highly	O
concentrated	O
compared	O
with	O
the	O
blood	O
level	O
[	O
27	O
]	O
.	O

In	O
addition	O
,	O
the	O
involvement	O
of	O
other	O
essential	O
proinflammatory	O
cytokines	O
in	O
this	O
process	O
was	O
suggested	O
by	O
our	O
preliminary	O
experiments	O
demonstrating	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
inhibition	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
reduced	O
by	O
pretreatment	O
with	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
although	O
less	O
effectively	O
than	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
data	O
not	O
shown	O
)	O
.	O

Furthermore	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
themselves	O
could	O
be	O
responsible	O
for	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
in	O
the	O
ST	O
,	O
because	O
T	O
-	O
cell	O
infiltrates	O
produce	O
both	O
cytokines	O
[	O
34	O
,	O
35	O
]	O
.	O

In	O
an	O
autocrine	O
fashion	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
persistently	O
stimulate	O
STAT3	B-Protein
activation	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
can	O
induce	O
SOCS1	B-Protein
protein	O
as	O
a	O
crosstalk	O
inhibitor	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
[	O
32	O
]	O
.	O

The	O
T	O
-	O
cell	O
-	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
therefore	O
be	O
modulated	O
complicatedly	O
upon	O
exposure	O
to	O
an	O
inflammatory	O
environment	O
in	O
RA	O
joints	O
,	O
where	O
many	O
cytokines	O
are	O
present	O
substantially	O
[	O
10	O
]	O
.	O

STAT3	B-Protein
activation	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
RA	O
.	O

Active	O
STAT3	B-Protein
is	O
constitutively	O
expressed	O
in	O
synovial	O
fluid	O
mononuclear	O
cells	O
from	O
RA	O
patients	O
[	O
36	O
]	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
is	O
the	O
major	O
STAT3	B-Protein
-	O
activating	O
factor	O
present	O
in	O
synovial	O
fluid	O
,	O
which	O
has	O
a	O
crucial	O
role	O
in	O
the	O
activation	O
of	O
monocyte	O
functions	O
such	O
as	O
gene	O
expression	O
of	O
the	O
Fc	B-Protein
gamma	I-Protein
receptor	I-Protein
type	I-Protein
I	I-Protein
and	O
type	B-Protein
III	I-Protein
and	O
of	O
HLA	O
-	O
DR	O
[	O
31	O
]	O
.	O

More	O
recently	O
,	O
high	O
levels	O
of	O
activated	O
STAT3	B-Protein
,	O
thought	O
to	O
be	O
induced	O
mainly	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
have	O
been	O
detected	O
in	O
the	O
ST	O
,	O
and	O
STAT3	B-Protein
activation	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
synovial	O
fibroblast	O
proliferation	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
[	O
37	O
]	O
.	O

In	O
this	O
regard	O
,	O
STAT3	B-Protein
is	O
critical	O
in	O
the	O
survival	O
and	O
expansion	O
of	O
growth	O
factor	O
-	O
dependent	O
synovial	O
fibroblasts	O
[	O
38	O
]	O
.	O

Furthermore	O
,	O
the	O
significance	O
of	O
persistent	O
STAT3	B-Protein
signaling	O
in	O
Th1	O
-	O
cell	O
-	O
dominated	O
autoimmune	O
arthritis	O
has	O
been	O
suggested	O
by	O
studies	O
of	O
the	O
gp130F759	B-Protein
/	O
F759	O
mice	O
,	O
in	O
which	O
the	O
Src	O
homology	O
phosphatase	O
-	O
2	O
binding	O
site	O
of	O
gp130	B-Protein
(	O
the	O
transmembrane	B-Protein
glycoprotein	I-Protein
beta	I-Protein
subunit	I-Protein
of	I-Protein
the	I-Protein
IL	I-Protein
-	I-Protein
6	I-Protein
family	I-Protein
cytokine	I-Protein
receptor	I-Protein
)	O
,	O
tyrosine	O
759	O
,	O
was	O
mutated	O
to	O
phenylalanine	O
[	O
39	O
]	O
.	O

In	O
the	O
gp130F759	B-Protein
/	O
F759	O
mice	O
,	O
T	O
cells	O
,	O
particularly	O
the	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
subset	O
,	O
are	O
chronically	O
activated	O
and	O
resistant	O
to	O
activation	O
-	O
induced	O
cell	O
death	O
through	O
gp130	B-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
.	O

The	O
longevity	O
of	O
cytokine	O
signals	O
transduced	O
by	O
the	O
JAK	O
-	O
STAT	O
pathway	O
is	O
regulated	O
by	O
the	O
SOCS	O
family	O
proteins	O
[	O
7	O
]	O
.	O

We	O
found	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
active	O
RA	O
expressed	O
higher	O
levels	O
of	O
SOCS1	B-Protein
,	O
but	O
lower	O
levels	O
of	O
SOCS3	B-Protein
,	O
compared	O
with	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

SOCS1	B-Protein
prevents	O
activation	O
of	O
JAK	O
by	O
directly	O
binding	O
to	O
JAK	O
,	O
and	O
SOCS3	B-Protein
inhibits	O
the	O
action	O
of	O
JAK	O
by	O
binding	O
to	O
the	O
Src	O
homology	O
phosphatase	O
-	O
2	O
-	O
binding	O
domain	O
of	O
receptors	O
such	O
as	O
gp130	B-Protein
[	O
40	O
]	O
.	O

SOCS1	B-Protein
and	O
SOCS3	B-Protein
are	O
induced	O
by	O
various	O
cytokines	O
,	O
including	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
as	O
mediators	O
of	O
negative	O
feedback	O
and	O
crosstalk	O
inhibition	O
[	O
7	O
]	O
.	O

Recent	O
studies	O
with	O
mice	O
lacking	O
SOCS3	B-Protein
or	O
SOCS1	B-Protein
revealed	O
that	O
SOCS3	B-Protein
is	O
a	O
negative	O
regulator	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
signaling	O
but	O
not	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
.	O

Studies	O
of	O
conditional	O
SOCS3	B-Protein
-	O
deficient	O
mice	O
have	O
shown	O
that	O
SOCS3	B-Protein
deficiency	O
,	O
but	O
not	O
SOCS1	B-Protein
deficiency	O
,	O
results	O
in	O
sustained	O
activation	O
of	O
STAT3	B-Protein
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
6	I-Protein
[	O
8	O
,	O
41	O
]	O
.	O

The	O
analysis	O
of	O
SOCS3	B-Protein
-	O
deficient	O
macrophages	O
has	O
indicated	O
that	O
SOCS3	B-Protein
is	O
a	O
crucial	O
inhibitor	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
induced	O
transcriptional	O
response	O
[	O
42	O
]	O
.	O

However	O
,	O
SOCS3	B-Protein
is	O
dispensable	O
for	O
both	O
the	O
negative	O
feedback	O
inhibition	O
and	O
the	O
immunoregulatory	O
action	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
macrophages	O
[	O
41	O
]	O
.	O

On	O
the	O
contrary	O
,	O
SOCS1	B-Protein
was	O
found	O
to	O
directly	O
inhibit	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
signaling	O
[	O
43	O
]	O
.	O

Increased	O
SOCS1	B-Protein
expression	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
may	O
therefore	O
be	O
associated	O
with	O
both	O
the	O
impaired	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
,	O
and	O
defective	O
SOCS3	B-Protein
expression	O
may	O
be	O
responsible	O
for	O
persistent	O
STAT3	B-Protein
activation	O
in	O
response	O
to	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

There	O
is	O
a	O
possibility	O
that	O
SOCS1	B-Protein
induction	O
may	O
be	O
associated	O
with	O
the	O
ability	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
produce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
because	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
could	O
produce	O
high	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
because	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
has	O
been	O
known	O
as	O
a	O
potent	O
inducer	O
of	O
SOCS1	B-Protein
[	O
32	O
]	O
.	O

It	O
is	O
of	O
interest	O
in	O
this	O
regard	O
to	O
indicate	O
that	O
polarized	O
Th1	O
and	O
Th2	O
cells	O
express	O
high	O
levels	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
mRNA	O
,	O
respectively	O
[	O
44	O
]	O
.	O

IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
activation	O
is	O
inhibited	O
by	O
SOCS3	B-Protein
induction	O
in	O
Th2	O
cells	O
,	O
whereas	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
induced	O
STAT6	B-Protein
signaling	O
is	O
diminished	O
by	O
SOCS1	B-Protein
induction	O
in	O
Th1	O
cells	O
.	O

SOCS1	B-Protein
and	O
SOCS3	B-Protein
may	O
thus	O
have	O
important	O
roles	O
as	O
Th1	O
-	O
specific	O
and	O
Th2	O
-	O
specific	O
,	O
mutually	O
exclusive	O
,	O
cross	O
-	O
talk	O
repressors	O
of	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
STAT6	B-Protein
and	O
the	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
STAT4	B-Protein
signaling	O
pathways	O
,	O
respectively	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
PB	O
T	O
cells	O
from	O
patients	O
with	O
allergic	O
diseases	O
significantly	O
express	O
high	O
levels	O
of	O
SOCS3	B-Protein
transcripts	O
,	O
and	O
the	O
SOCS3	B-Protein
expression	O
correlates	O
well	O
with	O
serum	O
IgE	O
levels	O
and	O
disease	O
pathology	O
[	O
45	O
]	O
.	O

Higher	O
SOCS1	B-Protein
expression	O
with	O
lower	O
SOCS3	B-Protein
expression	O
in	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
,	O
compared	O
with	O
healthy	O
controls	O
,	O
is	O
therefore	O
probably	O
consistent	O
with	O
their	O
systemic	O
bias	O
towards	O
a	O
Th1	O
phenotype	O
,	O
as	O
has	O
previously	O
been	O
demonstrated	O
[	O
46	O
-	O
49	O
]	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
are	O
characterized	O
by	O
their	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
due	O
to	O
constitutive	O
STAT3	B-Protein
phosphorylation	O
and	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
.	O

The	O
defective	O
STAT3	B-Protein
signaling	O
is	O
possibly	O
associated	O
with	O
SOCS1	B-Protein
predominance	O
over	O
SOCS3	B-Protein
.	O

These	O
abnormalities	O
in	O
active	O
RA	O
are	O
thought	O
to	O
be	O
induced	O
mainly	O
after	O
chronic	O
exposure	O
to	O
high	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

The	O
limited	O
efficacy	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
treatment	O
of	O
RA	O
patients	O
[	O
50	O
]	O
may	O
be	O
explained	O
in	O
part	O
by	O
the	O
unresponsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
of	O
inflammatory	O
cells	O
,	O
including	O
T	O
cells	O
.	O

On	O
the	O
contrary	O
,	O
the	O
therapeutic	O
efficacy	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
receptor	I-Protein
antibody	O
has	O
been	O
reported	O
in	O
RA	O
patients	O
[	O
51	O
]	O
,	O
and	O
one	O
of	O
the	O
effects	O
of	O
this	O
therapy	O
may	O
be	O
to	O
normalize	O
T	O
cells	O
through	O
the	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
dependent	O
STAT3	B-Protein
activation	O
.	O

More	O
specific	O
therapy	O
targeting	O
STAT3	B-Protein
activation	O
will	O
be	O
awaited	O
;	O
for	O
example	O
,	O
the	O
induction	O
of	O
the	O
SOCS3	B-Protein
gene	O
,	O
the	O
efficacy	O
of	O
which	O
has	O
been	O
demonstrated	O
in	O
animal	O
models	O
[	O
37	O
]	O
.	O

Increased	O
interleukin	B-Protein
-	I-Protein
17	I-Protein
production	O
via	O
a	O
phosphoinositide	O
3	O
-	O
kinase	O
/	O
Akt	B-Protein
and	O
nuclear	O
factor	O
?	O
B	O
-	O
dependent	O
pathway	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O

Inflammatory	O
mediators	O
have	O
been	O
recognized	O
as	O
being	O
important	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
17	I-Protein
is	O
an	O
important	O
regulator	O
of	O
immune	O
and	O
inflammatory	O
responses	O
,	O
including	O
the	O
induction	O
of	O
proinflammatory	O
cytokines	O
and	O
osteoclastic	O
bone	O
resorption	O
.	O

Evidence	O
for	O
the	O
expression	O
and	O
proinflammatory	O
activity	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
has	O
been	O
demonstrated	O
in	O
RA	O
synovium	O
and	O
in	O
animal	O
models	O
of	O
RA	O
.	O

Although	O
some	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
IL	B-Protein
-	I-Protein
23	I-Protein
)	O
have	O
been	O
reported	O
to	O
regulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
,	O
the	O
intracellular	O
signaling	O
pathways	O
that	O
regulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
remain	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	B-Protein
pathway	O
in	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
patients	O
with	O
RA	O
(	O
n	O
=	O
24	O
)	O
were	O
separated	O
,	O
then	O
stimulated	O
with	O
various	O
agents	O
including	O
anti	O
-	O
CD3	O
,	O
anti	O
-	O
CD28	B-Protein
,	O
phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
)	O
and	O
several	O
inflammatory	O
cytokines	O
and	O
chemokines	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
were	O
determined	O
by	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

The	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
was	O
significantly	O
increased	O
in	O
cells	O
treated	O
with	O
anti	O
-	O
CD3	O
antibody	O
with	O
or	O
without	O
anti	O
-	O
CD28	B-Protein
and	O
PHA	B-Protein
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
tested	O
cytokines	O
and	O
chemokines	O
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
upregulated	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
or	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
did	O
not	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
was	O
also	O
detected	O
in	O
the	O
PBMC	O
of	O
patients	O
with	O
osteoarthritis	O
,	O
but	O
their	O
expression	O
levels	O
were	O
much	O
lower	O
than	O
those	O
of	O
RA	O
PBMC	O
.	O

Anti	O
-	O
CD3	O
antibody	O
activated	O
the	O
PI3K	O
/	O
Akt	B-Protein
pathway	O
;	O
activation	O
of	O
this	O
pathway	O
resulted	O
in	O
a	O
pronounced	O
augmentation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
DNA	O
-	O
binding	O
activity	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
activated	O
RA	O
PBMC	O
is	O
completely	O
or	O
partly	O
blocked	O
in	O
the	O
presence	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
PI3K	O
/	O
Akt	B-Protein
inhibitor	O
wortmannin	O
and	O
LY294002	O
,	O
respectively	O
.	O

However	O
,	O
inhibition	O
of	O
activator	B-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
and	O
extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
kinase	I-Protein
1	I-Protein
/	O
2	B-Protein
did	O
not	O
affect	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
.	O

These	O
results	O
suggest	O
that	O
signal	O
transduction	O
pathways	O
dependent	O
on	O
PI3K	O
/	O
Akt	B-Protein
and	O
NF	O
-	O
kappaB	O
are	O
involved	O
in	O
the	O
overproduction	O
of	O
the	O
key	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
.	O

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
characterized	O
by	O
infiltrations	O
of	O
macrophages	O
and	O
T	O
cells	O
into	O
the	O
joint	O
,	O
and	O
synovial	O
hyperplasia	O
.	O

Proinflammatory	O
cytokines	O
released	O
from	O
these	O
cells	O
are	O
known	O
to	O
be	O
important	O
in	O
the	O
destruction	O
of	O
joints	O
in	O
RA	O
[	O
1	O
]	O
.	O

The	O
favorable	O
clinical	O
benefits	O
obtained	O
with	O
inhibitors	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
(	I-Protein
TNF	I-Protein
)	I-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
suggest	O
that	O
the	O
blockade	O
of	O
key	O
inflammatory	O
cytokines	O
has	O
been	O
the	O
important	O
issue	O
in	O
the	O
development	O
of	O
new	O
therapeutic	O
applications	O
[	O
2	O
]	O
.	O

A	O
little	O
over	O
a	O
decade	O
ago	O
,	O
the	O
primacy	O
of	O
T	O
cells	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
disease	O
such	O
as	O
RA	O
was	O
undisputed	O
because	O
they	O
are	O
the	O
largest	O
cell	O
population	O
infiltrating	O
the	O
synovium	O
.	O

However	O
,	O
a	O
series	O
of	O
studies	O
demonstrated	O
paucity	O
of	O
T	O
cell	O
-	O
derived	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
joints	O
of	O
RA	O
,	O
whereas	O
macrophage	O
and	O
fibroblast	O
cytokines	O
including	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
were	O
abundant	O
in	O
rheumatoid	O
synovium	O
.	O

This	O
paradox	O
has	O
questioned	O
the	O
role	O
of	O
T	O
cells	O
in	O
the	O
pathogenesis	O
of	O
RA	O
[	O
3	O
]	O
.	O

Because	O
we	O
have	O
already	O
demonstrated	O
the	O
enhanced	O
proliferation	O
of	O
antigen	O
specific	O
T	O
cells	O
,	O
especially	O
to	O
type	O
II	O
collagen	O
,	O
and	O
the	O
skewing	O
of	O
T	O
helper	O
type	O
1	O
(	O
Th1	O
)	O
cytokines	O
in	O
RA	O
[	O
4	O
]	O
,	O
the	O
role	O
of	O
T	O
cells	O
needs	O
to	O
be	O
elucidated	O
in	O
different	O
aspects	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
is	O
one	O
of	O
the	O
inflammatory	O
cytokines	O
secreted	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
which	O
can	O
induce	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
by	O
fibroblasts	O
[	O
5	O
]	O
.	O

This	O
cytokine	O
is	O
of	O
interest	O
for	O
two	O
major	O
reasons	O
:	O
first	O
,	O
similarly	O
to	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
has	O
proinflammatory	O
properties	O
;	O
second	O
,	O
it	O
is	O
produced	O
by	O
T	O
cells	O
[	O
6	O
]	O
.	O

Recent	O
observations	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
17	I-Protein
can	O
also	O
activate	O
osteoclastic	O
bone	O
resorption	O
by	O
the	O
induction	O
of	O
RANKL	B-Protein
(	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
nuclear	I-Protein
factor	I-Protein
kappaB	I-Protein
[	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
]	I-Protein
ligand	I-Protein
)	O
,	O
which	O
is	O
involved	O
in	O
bony	O
erosion	O
in	O
RA	O
[	O
7	O
]	O
.	O

It	O
also	O
stimulates	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
leukemia	B-Protein
inhibitory	I-Protein
factor	I-Protein
by	O
synoviocytes	O
,	O
and	O
of	O
prostaglandin	O
E2	O
and	O
nitric	O
oxide	O
by	O
chondrocytes	O
,	O
and	O
has	O
the	O
ability	O
to	O
differentiate	O
and	O
activate	O
the	O
dendritic	O
cells	O
[	O
8	O
-	O
10	O
]	O
.	O

Levels	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
synovial	O
fluids	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
RA	O
than	O
in	O
patients	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
,	O
and	O
it	O
was	O
produced	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
the	O
synovium	O
[	O
11	O
,	O
12	O
]	O
.	O

IL	B-Protein
-	I-Protein
15	I-Protein
,	O
secreted	O
from	O
activated	O
macrophages	O
,	O
has	O
been	O
reported	O
to	O
be	O
an	O
important	O
trigger	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
by	O
cyclosporine	O
and	O
steroid	O
sensitive	O
pathways	O
[	O
13	O
]	O
.	O

Recently	O
,	O
Happel	O
and	O
colleagues	O
also	O
showed	O
that	O
IL	B-Protein
-	I-Protein
23	I-Protein
could	O
be	O
an	O
efficient	O
trigger	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
from	O
both	O
CD4	B-Protein
+	O
and	O
CD8	B-Protein
+	O
T	O
cells	O
[	O
14	O
]	O
.	O

Although	O
the	O
contribution	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
joint	O
inflammation	O
in	O
RA	O
has	O
been	O
documented	O
in	O
earlier	O
studies	O
[	O
12	O
,	O
15	O
,	O
16	O
]	O
,	O
the	O
intracellular	O
signal	O
transduction	O
pathway	O
for	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
remains	O
uncertain	O
.	O

In	O
the	O
present	O
study	O
we	O
used	O
various	O
stimuli	O
to	O
investigate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
of	O
patients	O
with	O
RA	O
and	O
its	O
signaling	O
transduction	O
pathway	O
.	O

We	O
found	O
that	O
the	O
intracellular	O
signaling	O
pathway	O
involving	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	B-Protein
and	O
NF	O
-	O
kappaB	O
might	O
be	O
involved	O
in	O
the	O
overproduction	O
of	O
the	O
key	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
.	O

These	O
results	O
might	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
of	O
RA	O
and	O
future	O
directions	O
for	O
new	O
therapeutic	O
strategies	O
in	O
RA	O
.	O

Patients	O

Informed	O
consent	O
was	O
obtained	O
from	O
24	O
patients	O
(	O
5	O
men	O
and	O
19	O
women	O
)	O
with	O
RA	O
who	O
fulfilled	O
the	O
1987	O
revised	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Rheumatology	O
(	O
formerly	O
the	O
American	O
Rheumatism	O
Association	O
)	O
[	O
17	O
]	O
.	O

The	O
age	O
of	O
the	O
patients	O
with	O
RA	O
was	O
50	O
+	O
/	O
-	O
8	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
years	O
(	O
range	O
23	O
-	O
71	O
years	O
)	O
.	O

All	O
medications	O
were	O
stopped	O
48	O
hours	O
before	O
entry	O
to	O
the	O
study	O
.	O

Comparisons	O
were	O
made	O
with	O
14	O
patients	O
with	O
OA	O
(	O
3	O
men	O
and	O
11	O
women	O
)	O
and	O
with	O
14	O
healthy	O
controls	O
(	O
3	O
men	O
and	O
11	O
women	O
)	O
who	O
had	O
no	O
rheumatic	O
diseases	O
.	O

The	O
mean	O
ages	O
of	O
the	O
patients	O
with	O
OA	O
and	O
the	O
healthy	O
controls	O
were	O
50	O
+	O
/	O
-	O
8	O
years	O
(	O
range	O
34	O
-	O
68	O
years	O
)	O
and	O
30	O
+	O
/	O
-	O
6	O
years	O
(	O
range	O
24	O
-	O
57	O
years	O
)	O
.	O

Informed	O
consent	O
was	O
obtained	O
,	O
and	O
the	O
protocol	O
was	O
approved	O
by	O
the	O
Catholic	O
University	O
of	O
Korea	O
Human	O
Research	O
Ethics	O
Committee	O
.	O

Reagents	O

Recombinant	O
IL	B-Protein
-	I-Protein
17	I-Protein
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
MCP	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
(	I-Protein
MIP	I-Protein
)	I-Protein
-	I-Protein
1alpha	I-Protein
,	O
MIP	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
were	O
purchased	O
from	O
R	O
&	O
D	O
systems	O
(	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
.	O

Recombinant	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
(	I-Protein
TGF	I-Protein
)	I-Protein
-	I-Protein
beta	I-Protein
was	O
purchased	O
from	O
Peprotech	O
(	O
London	O
,	O
UK	O
)	O
.	O

Recombinant	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
were	O
purchased	O
from	O
Endogen	O
Inc	O
.	O

(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Cyclosporin	O
A	O
was	O
provided	O
by	O
Sandos	O
Ltd	O
.	O

(	O
Basel	O
,	O
Switzerland	O
)	O
.	O

Phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
)	O
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
rapamycin	O
,	O
dexamethasone	O
and	O
curcumin	O
were	O
all	O
obtained	O
from	O
the	O
Sigma	O
Chemical	O
Co	O
.	O

(	O
St	O
Louis	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Anti	O
-	O
CD3	O
monoclonal	O
antibody	O
and	O
anti	O
-	O
CD28	B-Protein
monoclonal	O
antibody	O
were	O
obtained	O
from	O
BD	O
Biosciences	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

LY294002	O
,	O
SB203580	O
,	O
FK506	O
,	O
wortmannin	O
and	O
PD98059	O
were	O
obtained	O
from	O
Calbiochem	O
(	O
Schwalbach	O
,	O
Germany	O
)	O
.	O

Production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
by	O
T	O
cell	O
receptor	O
activation	O
,	O
cytokines	O
or	O
chemokines	O

PBMC	O
were	O
prepared	O
from	O
heparinized	O
blood	O
by	O
Ficoll	O
-	O
Hypaque	O
(	O
SG1077	O
)	O
density	O
-	O
gradient	O
centrifugation	O
.	O

Cell	O
cultures	O
were	O
performed	O
as	O
described	O
previously	O
[	O
18	O
]	O
.	O

In	O
brief	O
,	O
the	O
cell	O
suspensions	O
were	O
adjusted	O
to	O
a	O
concentration	O
of	O
106	O
/	O
ml	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
100	O
U	O
/	O
ml	O
penicillin	O
,	O
100	O
mg	O
/	O
ml	O
streptomycin	O
and	O
2	O
mM	O
L	O
-	O
glutamine	O
.	O

Cell	O
suspension	O
(	O
1	O
ml	O
)	O
was	O
dispensed	O
into	O
24	O
-	O
well	O
multi	O
-	O
well	O
plates	O
(	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
,	O
and	O
incubated	O
for	O
24	O
hours	O
at	O
37degreesC	O
in	O
5	O
%	O
CO2	O
.	O

Subsequently	O
,	O
various	O
concentrations	O
of	O
cyclosporin	O
A	O
(	O
10	O
-	O
500	O
ng	O
/	O
ml	O
)	O
were	O
added	O
to	O
the	O
medium	O
and	O
cells	O
were	O
incubated	O
for	O
24	O
hours	O
.	O

To	O
each	O
well	O
was	O
added	O
FK506	O
,	O
rapamycin	O
,	O
curcumin	O
,	O
PDTC	O
,	O
LY294002	O
,	O
SB203580	O
,	O
PD98059	O
,	O
dexamethasone	O
or	O
wortmannin	O
.	O

After	O
incubation	O
for	O
24	O
hours	O
(	O
unless	O
otherwise	O
stated	O
)	O
,	O
cell	O
-	O
free	O
media	O
were	O
collected	O
and	O
stored	O
at	O
-	O
20degreesC	O
until	O
assayed	O
.	O

All	O
cultures	O
were	O
set	O
up	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
expressed	O
as	O
means	O
+	O
/	O
-	O
SEM	O
.	O

CD4	B-Protein
+	O
T	O
-	O
cell	O
isolation	O
by	O
MACS	O

Anti	O
-	O
CD4	B-Protein
microbeads	O
were	O
used	O
essentially	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
Miltenyi	O
)	O
[	O
19	O
]	O
.	O

PBMC	O
were	O
resuspended	O
in	O
80	O
mul	O
of	O
FBS	O
staining	O
buffer	O
.	O

Anti	O
-	O
CD4	B-Protein
microbeads	O
(	O
20	O
mul	O
)	O
were	O
added	O
and	O
incubated	O
for	O
15	O
min	O
at	O
6	O
-	O
12degreesC	O
.	O

Saturating	O
amounts	O
of	O
fluorochrome	O
-	O
conjugated	O
antibodies	O
were	O
added	O
for	O
a	O
further	O
10	O
min	O
.	O

Cells	O
were	O
diluted	O
in	O
2	O
.	O
5	O
ml	O
of	O
FBS	O
staining	O
buffer	O
,	O
pelleted	O
,	O
resuspended	O
in	O
500	O
mul	O
and	O
magnetically	O
separated	O
,	O
usually	O
on	O
an	O
AutoMACS	O
magnet	O
fitted	O
with	O
a	O
MACS	O
MS	O
column	O
.	O

Flow	O
-	O
through	O
and	O
two	O
1	O
ml	O
washes	O
were	O
collected	O
as	O
the	O
negative	O
fraction	O
.	O

Enriched	O
cells	O
were	O
collected	O
in	O
two	O
0	O
.	O
5	O
ml	O
aliquots	O
from	O
the	O
column	O
after	O
removal	O
from	O
the	O
magnet	O
.	O

Alternatively	O
,	O
cells	O
stained	O
with	O
anti	O
-	O
CD4	B-Protein
-	O
phycoerythrin	O
were	O
washed	O
,	O
magnetically	O
labeled	O
with	O
anti	O
-	O
phycoerythrin	O
microbeads	O
(	O
20	O
mul	O
added	O
to	O
80	O
mul	O
of	O
cell	O
suspension	O
;	O
15	O
min	O
,	O
6	O
-	O
12degreesC	O
)	O
,	O
and	O
magnetically	O
separated	O
as	O
described	O
above	O
.	O

The	O
purity	O
of	O
cells	O
was	O
assessed	O
by	O
flow	O
cytometric	O
analysis	O
of	O
stained	O
cells	O
on	O
a	O
FACS	O
Vantage	O
sorter	O
.	O

Most	O
(	O
more	O
than	O
97	O
%	O
)	O
of	O
the	O
isolated	O
cells	O
had	O
the	O
CD4	B-Protein
T	O
cell	O
marker	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein

IL	B-Protein
-	I-Protein
17	I-Protein
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
as	O
described	O
previously	O
[	O
20	O
]	O
.	O

In	O
brief	O
,	O
a	O
96	O
-	O
well	O
plate	O
(	O
Nunc	O
)	O
was	O
coated	O
with	O
4	O
mug	O
/	O
ml	O
monoclonal	O
antibodies	O
against	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
at	O
4degreesC	O
overnight	O
.	O

After	O
blocking	O
with	O
phosphate	O
-	O
buffered	O
saline	O
/	O
1	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
/	O
0	O
.	O
05	O
%	O
Tween	O
20	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
(	O
22	O
-	O
25degreesC	O
)	O
,	O
test	O
samples	O
and	O
the	O
standard	O
recombinant	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
were	O
added	O
to	O
the	O
96	O
-	O
well	O
plate	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
2	O
hours	O
.	O

Plates	O
were	O
washed	O
four	O
times	O
with	O
phosphate	O
-	O
buffered	O
saline	O
/	O
Tween	O
20	O
,	O
and	O
then	O
incubated	O
with	O
500	O
ng	O
/	O
ml	O
biotinylated	O
mouse	O
monoclonal	O
antibodies	O
against	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
,	O
streptavidin	O
-	O
alkaline	O
phosphate	O
-	O
horseradish	O
peroxidase	O
conjugate	O
(	O
Sigma	O
)	O
was	O
incubated	O
for	O
2	O
hours	O
,	O
then	O
washed	O
again	O
and	O
incubated	O
with	O
1	O
mg	O
/	O
ml	O
p	O
-	O
nitrophenyl	O
phosphate	O
(	O
Sigma	O
)	O
dissolved	O
in	O
diethanolamine	O
(	O
Sigma	O
)	O
to	O
develop	O
the	O
color	O
reaction	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
the	O
addition	O
of	O
1	O
M	O
NaOH	O
and	O
the	O
optical	O
density	O
of	O
each	O
well	O
was	O
read	O
at	O
405	O
nm	O
.	O

The	O
lower	O
limit	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
detection	O
was	O
10	O
pg	O
/	O
ml	O
.	O

Recombinant	O
human	O
IL	B-Protein
-	I-Protein
17	I-Protein
diluted	O
in	O
culture	O
medium	O
was	O
used	O
as	O
a	O
calibration	O
standard	O
,	O
ranging	O
from	O
10	O
to	O
2000	O
pg	O
/	O
ml	O
.	O

A	O
standard	O
curve	O
was	O
drawn	O
by	O
plotting	O
optical	O
density	O
against	O
the	O
log	O
of	O
the	O
concentration	O
of	O
recombinant	O
cytokines	O
,	O
and	O
used	O
for	O
determination	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
test	O
samples	O
.	O

Quantification	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
mRNA	O
by	O
semiquantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O

PBMC	O
were	O
incubated	O
with	O
various	O
concentrations	O
of	O
anti	O
-	O
CD3	O
in	O
the	O
presence	O
or	O
absence	O
of	O
inhibitors	O
(	O
LY294002	O
,	O
PDTC	O
)	O
.	O

After	O
16	O
hours	O
of	O
incubation	O
,	O
mRNA	O
was	O
extracted	O
with	O
RNAzol	O
B	O
(	O
Biotex	O
Laboratories	O
,	O
Houston	O
,	O
TX	O
,	O
USA	O
)	O
in	O
accordance	O
with	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Reverse	O
transcription	O
of	O
2	O
mug	O
of	O
total	O
mRNA	O
was	O
performed	O
at	O
42degreesC	O
using	O
the	O
Superscript	O
(	O
TM	O
)	O
reverse	O
transcription	O
system	O
(	O
Takara	O
,	O
Shiga	O
,	O
Japan	O
)	O
.	O

PCR	O
amplification	O
of	O
cDNA	O
aliquots	O
was	O
performed	O
by	O
adding	O
2	O
.	O
5	O
mM	O
dNTPs	O
,	O
2	O
.	O
5	O
U	O
of	O
Taq	B-Protein
DNA	O
polymerase	O
(	O
Takara	O
)	O
and	O
0	O
.	O
25	O
muM	O
of	O
sense	O
and	O
antisense	O
primers	O
.	O

The	O
reaction	O
was	O
performed	O
in	O
PCR	O
buffer	O
(	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
50	O
mM	O
KCl	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8	O
.	O
3	O
)	O
in	O
a	O
total	O
volume	O
of	O
25	O
mul	O
.	O

The	O
following	O
sense	O
and	O
antisense	O
primers	O
for	O
each	O
molecules	O
were	O
used	O
:	O
IL	B-Protein
-	I-Protein
17	I-Protein
sense	O
,	O
5	O
'	O
-	O
ATG	O
ACT	O
CCT	O
GGG	O
AAG	O
ACC	O
TCA	O
TTG	O
-	O
3	O
'	O
;	O
IL	O
-	O
17	O
antisense	O
,	O
5	O
'	O
-	O
TTA	O
GGC	O
CAC	O
ATG	O
GTG	O
GAC	O
AAT	O
CGG	O
-	O
3	O
'	O
;	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
(	O
GAPDH	B-Protein
)	O
sense	O
,	O
5	O
'	O
-	O
CGA	O
TGC	O
TGG	O
GCG	O
TGA	O
GTA	O
C	O
-	O
3	O
'	O
;	O
GAPDH	B-Protein
antisense	O
,	O
5	O
'	O
-	O
CGT	O
TCA	O
GCT	O
CAG	O
GGA	O
TGA	O
CC	O
-	O
3	O
'	O
.	O

Reactions	O
were	O
processed	O
in	O
a	O
DNA	O
thermal	O
cycler	O
(	O
Perkin	O
-	O
Elmer	O
Cetus	O
,	O
Norwalk	O
,	O
CT	O
,	O
USA	O
)	O
through	O
cycles	O
for	O
30	O
s	O
of	O
denaturation	O
at	O
94degreesC	O
,	O
1	O
min	O
of	O
annealing	O
at	O
56degreesC	O
for	O
GAPDH	B-Protein
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
,	O
followed	O
by	O
1	O
min	O
of	O
elongation	O
at	O
72degreesC	O
.	O

PCR	O
rounds	O
were	O
repeated	O
for	O
25	O
cycles	O
each	O
for	O
both	O
GAPDH	B-Protein
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
;	O
this	O
was	O
determined	O
as	O
falling	O
within	O
the	O
exponential	O
phase	O
of	O
amplification	O
for	O
each	O
molecule	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
was	O
presented	O
as	O
a	O
ratio	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
PCR	O
product	O
over	O
GAPDH	B-Protein
product	O
.	O

Western	O
blot	O
analysis	O
of	O
Akt	B-Protein
,	O
phosphorylated	O
Akt	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein

PBMC	O
were	O
incubated	O
with	O
anti	O
-	O
CD3	O
(	O
10	O
mug	O
/	O
ml	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LY294002	O
(	O
20	O
muM	O
)	O
.	O

After	O
incubation	O
for	O
1	O
hour	O
,	O
whole	O
cell	O
lysates	O
were	O
prepared	O
from	O
about	O
107	O
cells	O
by	O
homogenization	O
in	O
the	O
lysis	O
buffer	O
,	O
and	O
centrifuged	O
at	O
14	O
,	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O

(	O
19	O
,	O
000	O
g	O
)	O
for	O
15	O
min	O
.	O

Protein	O
concentrations	O
in	O
the	O
supernatants	O
were	O
determined	O
with	O
the	O
Bradford	O
method	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Protein	O
samples	O
were	O
separated	O
by	O
10	O
%	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
.	O

For	O
western	O
hybridization	O
,	O
membrane	O
was	O
preincubated	O
with	O
0	O
.	O
1	O
%	O
skimmed	O
milk	O
in	O
TBS	O
-	O
T	O
buffer	O
(	O
0	O
.	O
1	O
%	O
Tween	O
20	O
in	O
Tris	O
-	O
buffered	O
saline	O
)	O
at	O
room	O
temperature	O
for	O
2	O
hours	O
,	O
then	O
primary	O
antibodies	O
against	O
Akt	B-Protein
,	O
phosphorylated	O
Akt	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
Cell	O
Signaling	O
Technology	O
Inc	O
.	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
,	O
diluted	O
1	O
:	O
1000	O
in	O
5	O
%	O
BSA	O
/	O
TBS	O
-	O
T	O
,	O
were	O
added	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
.	O

After	O
washing	O
four	O
times	O
with	O
TBS	O
-	O
T	O
,	O
horseradish	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibodies	O
were	O
added	O
and	O
allowed	O
to	O
incubate	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
.	O

After	O
TBS	O
-	O
T	O
washing	O
,	O
hybridized	O
bands	O
were	O
detected	O
with	O
the	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
)	O
detection	O
kit	O
and	O
Hyperfilm	O
-	O
ECL	O
reagents	O
(	O
Amersham	O
Pharmacia	O
)	O
.	O

Gel	O
mobility	O
-	O
shift	O
assay	O
of	O
NF	O
-	O
kappaB	O
binding	O
site	O

Nuclear	O
proteins	O
were	O
extracted	O
from	O
about	O
5	O
x	O
106	O
PBMC	O
.	O

Oligonucleotide	O
probes	O
encompassing	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
of	O
the	O
human	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
(	O
5	O
'	O
-	O
ATG	O
ACC	O
TGG	O
AAA	O
TAC	O
CCA	O
AAA	O
TTC	O
-	O
3	O
'	O
)	O
were	O
generated	O
by	O
5	O
'	O
-	O
end	O
labeling	O
of	O
the	O
sense	O
strand	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
dATP	O
(	O
Amersham	O
Pharmacia	O
)	O
and	O
T4	O
polynucleotide	O
kinase	O
(	O
TaKaRa	O
)	O
.	O

Unincorporated	O
nucleotides	O
were	O
removed	O
by	O
NucTrap	O
probe	O
purification	O
columns	O
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Nuclear	O
extracts	O
(	O
2	O
mug	O
of	O
protein	O
)	O
were	O
incubated	O
with	O
radiolabeled	O
DNA	O
probes	O
(	O
10	O
ng	O
;	O
100	O
,	O
000	O
c	O
.	O
p	O
.	O
m	O
.	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
in	O
20	O
mul	O
of	O
binding	O
buffer	O
consisting	O
of	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
9	O
,	O
50	O
mM	O
KCl	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
,	O
5	O
%	O
glycerol	O
,	O
1	O
mg	O
/	O
ml	O
BSA	O
,	O
0	O
.	O
2	O
%	O
Nonidet	O
P40	O
and	O
50	O
ng	O
/	O
mul	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
.	O

Samples	O
were	O
subjected	O
to	O
electrophoresis	O
on	O
nondenaturing	O
5	O
%	O
polyacrylamide	O
gels	O
in	O
0	O
.	O
5	O
x	O
Tris	O
-	O
borate	O
-	O
EDTA	O
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
at	O
100	O
V	O
.	O

Gels	O
were	O
dried	O
under	O
vacuum	O
and	O
exposed	O
to	O
Kodak	O
X	O
-	O
OMAT	O
film	O
at	O
-	O
70degreesC	O
with	O
intensifying	O
screens	O
.	O

Rabbit	O
polyclonal	O
antibodies	O
against	O
NF	O
-	O
kappaB	O
subunits	O
p50	B-Protein
,	O
p65	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
were	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cell	O
viability	O
(	O
Trypan	O
blue	O
dye	O
exclusion	O
assay	O
)	O

For	O
cell	O
viability	O
assays	O
,	O
the	O
trypan	O
blue	O
dye	O
exclusion	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
potential	O
of	O
direct	O
cytotoxic	O
effect	O
of	O
inhibitors	O
on	O
cells	O
.	O

After	O
incubation	O
for	O
24	O
hours	O
,	O
the	O
cells	O
were	O
harvested	O
and	O
the	O
percentage	O
cell	O
viability	O
was	O
calculated	O
with	O
the	O
formula	O
100	O
x	O
(	O
number	O
of	O
viable	O
cells	O
/	O
number	O
of	O
both	O
viable	O
and	O
dead	O
cells	O
)	O
[	O
21	O
]	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
means	O
+	O
/	O
-	O
SEM	O
.	O

Statistical	O
analysis	O
was	O
performed	O
with	O
Student	O
'	O
s	O
t	O
-	O
test	O
for	O
matched	O
pairs	O
.	O

P	O
values	O
less	O
than	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
from	O
patients	O
with	O
RA	O
,	O
patients	O
with	O
OA	O
and	O
normal	O
individuals	O

PBMC	O
were	O
separated	O
and	O
cultured	O
with	O
PHA	B-Protein
(	O
5	O
mug	O
/	O
ml	O
)	O
from	O
patients	O
with	O
RA	O
,	O
patients	O
with	O
OA	O
,	O
and	O
age	O
-	O
matched	O
normal	O
controls	O
;	O
IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
were	O
then	O
determined	O
in	O
the	O
culture	O
supernatants	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Although	O
the	O
amounts	O
of	O
basal	O
IL	B-Protein
-	I-Protein
17	I-Protein
secretion	O
were	O
not	O
different	O
between	O
RA	O
,	O
OA	O
and	O
normal	O
controls	O
(	O
62	O
+	O
/	O
-	O
31	O
,	O
43	O
+	O
/	O
-	O
19	O
and	O
43	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
,	O
respectively	O
)	O
,	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
stimulated	O
by	O
PHA	B-Protein
was	O
significantly	O
higher	O
in	O
RA	O
PBMC	O
than	O
in	O
those	O
from	O
OA	O
and	O
controls	O
(	O
768	O
+	O
/	O
-	O
295	O
versus	O
463	O
+	O
/	O
-	O
211	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
05	O
]	O
and	O
241	O
+	O
/	O
-	O
29	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
001	O
]	O
)	O
.	O

Increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
of	O
patients	O
with	O
RA	O
by	O
anti	O
-	O
CD3	O
and	O
/	O
or	O
anti	O
-	O
CD28	B-Protein
,	O
and	O
PHA	B-Protein

Because	O
IL	B-Protein
-	I-Protein
17	I-Protein
was	O
already	O
known	O
from	O
earlier	O
reports	O
to	O
be	O
produced	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
different	O
concentrations	O
of	O
anti	O
-	O
CD3	O
(	O
1	O
,	O
5	O
and	O
10	O
mug	O
/	O
ml	O
)	O
as	O
a	O
T	O
cell	O
activation	O
,	O
which	O
showed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

On	O
the	O
basis	O
of	O
this	O
,	O
we	O
chose	O
10	O
mug	O
/	O
ml	O
as	O
a	O
stimulation	O
concentration	O
for	O
anti	O
-	O
CD3	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
anti	O
-	O
CD3	O
significantly	O
upregulated	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
up	O
to	O
3	O
.	O
7	O
-	O
fold	O
,	O
and	O
the	O
combination	O
of	O
anti	O
-	O
CD28	B-Protein
and	O
anti	O
-	O
CD3	O
produced	O
more	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
approximately	O
1	O
.	O
3	O
-	O
1	O
.	O
5	O
-	O
fold	O
)	O
than	O
anti	O
-	O
CD3	O
alone	O
.	O

Furthermore	O
,	O
when	O
incubated	O
with	O
T	O
cell	O
mitogens	O
such	O
as	O
PHA	B-Protein
,	O
increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
more	O
pronounced	O
than	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
588	O
+	O
/	O
-	O
85	O
versus	O
211	O
+	O
/	O
-	O
1	O
pg	O
/	O
ml	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Regulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
by	O
inflammatory	O
cytokines	O
and	O
chemokines	O

Because	O
RA	O
PBMC	O
include	O
several	O
cell	O
types	O
in	O
addition	O
to	O
T	O
cells	O
,	O
some	O
inflammatory	O
cytokines	O
released	O
from	O
macrophages	O
and	O
other	O
lymphocytes	O
might	O
have	O
affected	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
from	O
T	O
cells	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
inflammatory	O
cytokines	O
released	O
by	O
activated	O
PBMC	O
,	O
we	O
tested	O
the	O
effects	O
of	O
several	O
cytokines	O
and	O
chemokines	O
on	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
.	O

We	O
detected	O
an	O
increase	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
level	O
after	O
stimulation	O
with	O
IL	B-Protein
-	I-Protein
15	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
whereas	O
with	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
or	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
the	O
levels	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
were	O
unchanged	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

When	O
treated	O
with	O
MCP	B-Protein
-	I-Protein
1	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
or	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
significant	O
upregulations	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
proteins	O
were	O
observed	O
(	O
62	O
+	O
/	O
-	O
42	O
and	O
50	O
+	O
/	O
-	O
10	O
versus	O
31	O
+	O
/	O
-	O
11	O
pg	O
/	O
ml	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
none	O
was	O
observed	O
with	O
IL	B-Protein
-	I-Protein
8	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
or	O
MIP	B-Protein
-	I-Protein
1beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

Inhibition	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
signal	O
transduction	O
inhibitors	O
and	O
anti	O
-	O
rheumatic	O
drugs	O

Having	O
observed	O
the	O
increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
,	O
it	O
was	O
important	O
to	O
know	O
which	O
signal	O
transduction	O
pathways	O
were	O
involved	O
.	O

As	O
illustrated	O
in	O
Fig	O
.	O

3	O
,	O
an	O
significant	O
decrease	O
in	O
anti	O
-	O
CD3	O
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
observed	O
when	O
co	O
-	O
incubated	O
with	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
PDTC	O
and	O
dexamethasone	O
in	O
comparison	O
with	O
anti	O
-	O
CD3	O
alone	O
(	O
38	O
+	O
/	O
-	O
5	O
and	O
54	O
+	O
/	O
-	O
11	O
versus	O
98	O
+	O
/	O
-	O
19	O
pg	O
/	O
ml	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

LY294002	O
and	O
wortmannin	O
,	O
as	O
an	O
inhibitor	O
of	O
PI3K	O
,	O
also	O
markedly	O
inhibited	O
the	O
anti	O
-	O
CD3	O
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
(	O
98	O
+	O
/	O
-	O
19	O
versus	O
38	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
005	O
]	O
and	O
48	O
+	O
/	O
-	O
4	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
05	O
]	O
,	O
respectively	O
)	O
.	O

The	O
calcineurin	B-Protein
inhibitors	O
cyclosporin	O
A	O
and	O
FK506	O
also	O
downregulated	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
secretion	O
as	O
well	O
as	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
p38	O
inhibitor	O
SB203580	O
did	O
,	O
whereas	O
rapamycin	O
and	O
PD98059	O
had	O
no	O
effect	O
on	O
IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
(	O
Fig	O
.	O
3	O
)	O
.	O

To	O
evaluate	O
the	O
possibility	O
of	O
non	O
-	O
specific	O
inhibition	O
by	O
the	O
drug	O
at	O
high	O
concentrations	O
,	O
we	O
observed	O
the	O
dose	O
response	O
of	O
PDTC	O
and	O
LY294002	O
for	O
the	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
.	O

There	O
were	O
dose	O
-	O
dependent	O
inhibitions	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
with	O
chemical	O
inhibitors	O
(	O
Fig	O
.	O
4a	O
)	O
.	O

The	O
other	O
inhibitors	O
in	O
addition	O
to	O
PDTC	O
and	O
LY294002	O
showed	O
the	O
same	O
pattern	O
of	O
inhibition	O
.	O

Cytotoxic	O
effects	O
on	O
PBMC	O
by	O
the	O
chemical	O
inhibitors	O
at	O
experimental	O
concentrations	O
were	O
not	O
observed	O
(	O
Fig	O
.	O
4b	O
)	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
mRNA	O
expression	O
in	O
RA	O
PBMC	O

To	O
see	O
whether	O
enhanced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
could	O
be	O
regulated	O
at	O
a	O
transcriptional	O
level	O
,	O
semi	O
-	O
quantatitive	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
was	O
performed	O
.	O

We	O
observed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
mRNA	O
transcripts	O
after	O
stimulation	O
with	O
anti	O
-	O
CD3	O
;	O
this	O
was	O
inhibited	O
by	O
the	O
PI3K	O
inhibitor	O
LY294002	O
and	O
by	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
PDTC	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Activation	O
of	O
PI3K	O
/	O
Akt	B-Protein
signal	O
transduction	O
pathway	O
on	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
anti	O
-	O
CD3	O

To	O
determine	O
downstream	O
effector	O
molecules	O
of	O
the	O
PI3K	O
pathway	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
Akt	B-Protein
by	O
western	O
blotting	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

6	O
,	O
at	O
10	O
min	O
of	O
incubation	O
with	O
anti	O
-	O
CD3	O
(	O
10	O
mug	O
/	O
ml	O
)	O
or	O
LY294002	O
(	O
20	O
muM	O
)	O
,	O
no	O
difference	O
in	O
the	O
amounts	O
of	O
phosphorylated	O
Akt	B-Protein
was	O
observed	O
.	O

However	O
,	O
after	O
30	O
min	O
of	O
incubation	O
,	O
phosphorylated	O
Akt	B-Protein
increased	O
(	O
lane	O
2	O
)	O
,	O
and	O
the	O
effect	O
of	O
inhibition	O
by	O
LY294002	O
(	O
lane	O
3	O
)	O
reached	O
a	O
peak	O
at	O
60	O
min	O
,	O
lasting	O
to	O
120	O
-	O
240	O
min	O
.	O

In	O
contrast	O
,	O
non	O
-	O
phosphorylated	O
Akt	B-Protein
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
remained	O
unchanged	O
regardless	O
of	O
incubation	O
time	O
.	O

PHA	B-Protein
,	O
concanavalin	O
A	O
and	O
IL	B-Protein
-	I-Protein
15	I-Protein
also	O
demonstrated	O
the	O
same	O
effect	O
on	O
phosphorylated	O
Akt	B-Protein
as	O
shown	O
with	O
anti	O
-	O
CD3	O
,	O
which	O
was	O
an	O
inhibition	O
by	O
wortmannin	O
and	O
PDTC	O
as	O
well	O
as	O
by	O
LY294002	O
(	O
data	O
not	O
shown	O
)	O
.	O

Activation	O
of	O
the	O
NF	O
-	O
kappaB	O
and	O
activator	B-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
AP	B-Protein
-	I-Protein
1	I-Protein
)	O
pathway	O
in	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
region	O

To	O
investigate	O
further	O
the	O
intracellular	O
signaling	O
pathway	O
activated	O
by	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
,	O
concanavalin	O
A	O
,	O
PHA	B-Protein
and	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
and	O
responsible	O
for	O
inducing	O
IL	B-Protein
-	I-Protein
17	I-Protein
expression	O
,	O
we	O
performed	O
an	O
electrophoretic	O
mobility	O
-	O
shift	O
assay	O
(	O
EMSA	O
)	O
of	O
NF	O
-	O
kappaB	O
recognition	O
sites	O
in	O
the	O
promoters	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
.	O

As	O
shown	O
in	O
Fig	O
.	O

7a	O
,	O
nuclear	O
extracts	O
from	O
RA	O
PBMC	O
stimulated	O
with	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
(	O
lane	O
2	O
)	O
demonstrated	O
increased	O
binding	O
of	O
NF	O
-	O
kappaB	O
to	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoters	O
in	O
comparison	O
with	O
that	O
of	O
controls	O
(	O
lane	O
1	O
)	O
.	O

A	O
supershift	O
assay	O
demonstrated	O
shifted	O
bands	O
in	O
p65	B-Protein
and	O
p50	B-Protein
(	O
lanes	O
3	O
and	O
4	O
)	O
not	O
in	O
c	B-Protein
-	I-Protein
Rel	I-Protein
(	O
lane	O
5	O
)	O
.	O

In	O
normal	O
PBMC	O
the	O
same	O
pattern	O
was	O
observed	O
,	O
but	O
the	O
degree	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
was	O
less	O
intense	O
than	O
that	O
in	O
RA	O
PBMC	O
(	O
Fig	O
.	O
7b	O
)	O
.	O

To	O
confirm	O
the	O
link	O
between	O
PI3K	O
activity	O
and	O
NF	O
-	O
kappaB	O
,	O
we	O
performed	O
EMSA	O
to	O
determine	O
the	O
NF	O
-	O
kappaB	O
binding	O
activity	O
after	O
treatment	O
with	O
both	O
LY294002	O
and	O
PDTC	O
.	O

Both	O
agents	O
block	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

Western	O
blotting	O
for	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
showed	O
inhibition	O
of	O
degradation	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
by	O
LY294002	O
and	O
PDTC	O
at	O
the	O
same	O
time	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

In	O
contrast	O
,	O
the	O
AP	B-Protein
-	I-Protein
1	I-Protein
pathway	O
was	O
not	O
activated	O
by	O
stimulation	O
with	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
(	O
data	O
not	O
shown	O
)	O
,	O
demonstrating	O
that	O
NF	O
-	O
kappaB	O
is	O
the	O
main	O
intracellular	O
signaling	O
pathway	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
activated	O
PBMC	O
from	O
patients	O
with	O
RA	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
was	O
first	O
described	O
as	O
a	O
T	O
cell	O
product	O
with	O
proinflammatory	O
properties	O
[	O
5	O
,	O
22	O
]	O
.	O

RA	O
is	O
characterized	O
by	O
hyperplasia	O
of	O
synovial	O
lining	O
cells	O
and	O
an	O
intense	O
infiltration	O
by	O
mononuclear	O
cells	O
[	O
23	O
]	O
.	O

Proinflammatory	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
are	O
abundant	O
in	O
rheumatoid	O
synovium	O
,	O
whereas	O
the	O
T	O
cell	O
-	O
derived	O
cytokines	O
,	O
especially	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
,	O
have	O
often	O
proved	O
difficult	O
to	O
detect	O
in	O
RA	O
synovium	O
[	O
24	O
]	O
.	O

Although	O
T	O
cells	O
may	O
have	O
a	O
role	O
in	O
the	O
augmentation	O
of	O
rheumatoid	O
synovial	O
inflammation	O
,	O
the	O
lack	O
of	O
T	O
cell	O
-	O
derived	O
cytokines	O
has	O
limited	O
its	O
importance	O
.	O

In	O
this	O
respect	O
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
is	O
appealing	O
because	O
it	O
has	O
been	O
described	O
as	O
a	O
T	O
cell	O
-	O
derived	O
cytokine	O
with	O
proinflammatory	O
properties	O
.	O

In	O
our	O
studies	O
,	O
we	O
tried	O
to	O
evaluate	O
how	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
is	O
regulated	O
in	O
RA	O
PBMC	O
,	O
and	O
which	O
signaling	O
pathway	O
it	O
used	O
.	O

Levels	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
were	O
found	O
to	O
be	O
higher	O
in	O
RA	O
synovial	O
fluid	O
than	O
in	O
OA	O
synovial	O
fluid	O
[	O
15	O
]	O
.	O

However	O
,	O
there	O
are	O
few	O
data	O
available	O
on	O
the	O
agents	O
that	O
stimulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
,	O
although	O
the	O
highest	O
level	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
can	O
be	O
achieved	O
by	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
stimulation	O
in	O
healthy	O
individuals	O
[	O
25	O
]	O
.	O

In	O
our	O
experiments	O
,	O
PHA	B-Protein
as	O
mitogens	O
,	O
as	O
well	O
as	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
for	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
,	O
increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
from	O
RA	O
PBMC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
found	O
,	O
by	O
a	O
cell	O
proliferation	O
assay	O
(	O
data	O
not	O
shown	O
)	O
,	O
that	O
this	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
might	O
be	O
due	O
to	O
increased	O
cellular	O
activity	O
rather	O
than	O
to	O
cellular	O
proliferation	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
is	O
produced	O
mainly	O
by	O
activated	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
especially	O
for	O
Th1	O
/	O
Th0	O
cells	O
,	O
not	O
the	O
Th2	O
phenotype	O
[	O
26	O
]	O
.	O

However	O
,	O
it	O
can	O
also	O
be	O
produced	O
by	O
CD8	B-Protein
+	O
T	O
cells	O
via	O
an	O
IL	B-Protein
-	I-Protein
23	I-Protein
triggering	O
mechanism	O
in	O
Gram	O
-	O
negative	O
pulmonary	O
infection	O
[	O
14	O
]	O
.	O

In	O
addition	O
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
significantly	O
augmented	O
by	O
T	O
cells	O
recognizing	O
type	O
II	O
collagen	O
in	O
a	O
collagen	O
-	O
induced	O
arthritis	O
model	O
[	O
27	O
]	O
.	O

A	O
complex	O
interaction	O
between	O
cells	O
in	O
inflamed	O
RA	O
joints	O
might	O
produce	O
a	O
variety	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
also	O
activate	O
other	O
cells	O
in	O
the	O
joints	O
.	O

For	O
example	O
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
stimulates	O
rheumatoid	O
synoviocytes	O
to	O
secrete	O
several	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
stimulated	I-Protein
gene	I-Protein
6	I-Protein
as	O
well	O
as	O
prostaglandin	O
E2	O
in	O
vitro	O
[	O
12	O
,	O
28	O
,	O
29	O
]	O
.	O

There	O
are	O
as	O
yet	O
few	O
data	O
available	O
on	O
the	O
agents	O
that	O
stimulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
,	O
although	O
some	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
IL	B-Protein
-	I-Protein
23	I-Protein
)	O
have	O
been	O
known	O
to	O
regulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
[	O
13	O
,	O
14	O
]	O
.	O

We	O
therefore	O
investigated	O
the	O
in	O
vitro	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
responding	O
to	O
a	O
variety	O
of	O
cytokines	O
/	O
chemokines	O
and	O
mitogens	O
as	O
well	O
as	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
ligation	O
using	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
.	O

Our	O
studies	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
as	O
well	O
as	O
TCR	O
ligation	O
significantly	O
increased	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
.	O

Adding	O
IL	B-Protein
-	I-Protein
15	I-Protein
or	O
MCP	B-Protein
-	I-Protein
1	I-Protein
to	O
TCR	O
ligation	O
augmented	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
more	O
markedly	O
.	O

In	O
contrast	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
which	O
are	O
known	O
to	O
have	O
proinflammatory	O
properties	O
and	O
to	O
be	O
increased	O
in	O
RA	O
joints	O
,	O
did	O
not	O
affect	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
.	O

Our	O
data	O
were	O
consistent	O
with	O
a	O
recent	O
report	O
that	O
IL	B-Protein
-	I-Protein
15	I-Protein
triggered	O
in	O
vitro	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
,	O
but	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
did	O
not	O
do	O
so	O
[	O
13	O
]	O
.	O

Although	O
there	O
were	O
no	O
data	O
that	O
MCP	B-Protein
-	I-Protein
1	I-Protein
directly	O
induces	O
T	O
cell	O
activation	O
,	O
it	O
might	O
exert	O
effects	O
indirectly	O
on	O
T	O
cells	O
through	O
the	O
activation	O
of	O
monocytes	O
/	O
macrophages	O
in	O
PBMC	O
cultures	O
.	O

As	O
reported	O
for	O
normal	O
individuals	O
[	O
25	O
]	O
,	O
T	O
cell	O
activation	O
through	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
also	O
increases	O
IL	B-Protein
-	I-Protein
17	I-Protein
induction	O
in	O
RA	O
PBMC	O
.	O

Although	O
the	O
signaling	O
pathway	O
for	O
the	O
induction	O
of	O
cytokines	O
/	O
chemokines	O
by	O
IL	B-Protein
-	I-Protein
17	I-Protein
has	O
been	O
documented	O
widely	O
[	O
8	O
,	O
30	O
,	O
31	O
]	O
,	O
no	O
data	O
have	O
been	O
available	O
on	O
how	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
can	O
be	O
regulated	O
by	O
certain	O
signaling	O
pathways	O
.	O

By	O
using	O
signal	O
transduction	O
inhibitors	O
,	O
we	O
therefore	O
examined	O
which	O
signaling	O
pathway	O
was	O
mainly	O
involved	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
.	O

We	O
identified	O
that	O
anti	O
-	O
CD3	B-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
was	O
significantly	O
hampered	O
by	O
the	O
PI3K	O
inhibitor	O
LY294002	O
and	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
PDTC	O
to	O
comparable	O
levels	O
of	O
basal	O
production	O
without	O
stimulation	O
.	O

We	O
also	O
found	O
that	O
anti	O
-	O
CD3	O
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
downregulated	O
by	O
the	O
addition	O
of	O
SB203580	O
,	O
a	O
p38	O
MAPK	O
inhibitor	O
.	O

It	O
is	O
interesting	O
that	O
a	O
series	O
of	O
evidence	O
supports	O
crosstalk	O
between	O
NF	O
-	O
kappaB	O
and	O
p38	O
.	O

In	O
myocytes	O
,	O
IkappaB	B-Protein
kinase	I-Protein
-	I-Protein
beta	I-Protein
is	O
activated	O
by	O
p38	O
[	O
32	O
]	O
,	O
and	O
the	O
activated	O
p38	O
can	O
stimulate	O
NF	O
-	O
kappaB	O
by	O
a	O
mechanism	O
involving	O
histone	O
acetylase	O
p300	B-Protein
/	O
CREB	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
[	O
33	O
]	O
.	O

Our	O
results	O
revealed	O
that	O
p38	O
MAPK	O
activation	O
was	O
not	O
affected	O
by	O
LY294002	O
,	O
whereas	O
NF	O
-	O
kappaB	O
binding	O
activity	O
was	O
decreased	O
by	O
LY294002	O
,	O
which	O
provided	O
the	O
evidence	O
for	O
a	O
p38	O
MAPK	O
pathway	O
independent	O
of	O
PI3K	O
activation	O
.	O

The	O
direct	O
relationship	O
between	O
p38	O
and	O
NF	O
-	O
kappaB	O
for	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
needs	O
to	O
be	O
studied	O
in	O
future	O
experiments	O
.	O

The	O
search	O
for	O
a	O
downstream	O
pathway	O
of	O
PI3K	O
seemed	O
to	O
have	O
a	O
maximal	O
response	O
of	O
Akt	B-Protein
activation	O
at	O
1	O
hour	O
and	O
a	O
gradual	O
loss	O
of	O
activity	O
at	O
2	O
hours	O
.	O

The	O
fact	O
that	O
Akt	B-Protein
is	O
phosphorylated	O
upon	O
anti	O
-	O
CD3	O
stimulation	O
suggests	O
the	O
possible	O
involvement	O
of	O
PI3K	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
.	O

In	O
view	O
of	O
the	O
fact	O
that	O
NF	O
-	O
kappaB	O
was	O
also	O
activated	O
by	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
or	O
mitogens	O
in	O
our	O
experiments	O
,	O
it	O
is	O
most	O
likely	O
that	O
the	O
NF	O
-	O
kappaB	O
pathway	O
is	O
also	O
actively	O
involved	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
.	O

In	O
contrast	O
,	O
the	O
AP	B-Protein
-	I-Protein
1	I-Protein
signal	O
transduction	O
pathway	O
,	O
another	O
important	O
signaling	O
pathway	O
for	O
cytokines	O
/	O
chemokines	O
,	O
was	O
not	O
activated	O
in	O
our	O
experiments	O
(	O
data	O
not	O
shown	O
)	O
.	O

Although	O
PI3K	O
and	O
its	O
downstream	O
kinase	O
Akt	B-Protein
in	O
association	O
with	O
NF	O
-	O
kappaB	O
have	O
been	O
reported	O
to	O
deliver	O
activating	O
signals	O
in	O
many	O
cell	O
types	O
,	O
the	O
data	O
on	O
the	O
signal	O
inducing	O
IL	B-Protein
-	I-Protein
17	I-Protein
are	O
lacking	O
.	O

Our	O
data	O
clearly	O
demonstrated	O
that	O
PI3K	O
/	O
Akt	B-Protein
and	O
resultant	O
NF	O
-	O
kappaB	O
activation	O
could	O
be	O
an	O
important	O
arbitrator	O
of	O
the	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
,	O
on	O
the	O
basis	O
of	O
our	O
experiments	O
showing	O
simultaneous	O
blocking	O
of	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
by	O
PDTC	O
and	O
LY294002	O
.	O

Considering	O
its	O
proinflammatory	O
activities	O
and	O
successful	O
induction	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
17	I-Protein
for	O
ameliorating	O
arthritis	O
in	O
animal	O
models	O
[	O
2	O
,	O
6	O
,	O
34	O
-	O
36	O
]	O
,	O
understanding	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
signaling	O
pathway	O
is	O
an	O
important	O
element	O
of	O
developing	O
new	O
targeted	O
therapies	O
in	O
RA	O
.	O

We	O
have	O
detected	O
a	O
more	O
pronounced	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
from	O
RA	O
PBMC	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
as	O
well	O
as	O
stimulation	O
by	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
.	O

We	O
have	O
also	O
shown	O
that	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
by	O
activated	O
T	O
cells	O
in	O
patients	O
with	O
RA	O
could	O
be	O
the	O
result	O
of	O
activation	O
via	O
the	O
PI3K	O
/	O
Akt	B-Protein
pathway	O
with	O
resultant	O
NF	O
-	O
kappaB	O
activation	O
.	O

Our	O
data	O
provide	O
insights	O
into	O
cellular	O
mechanisms	O
of	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
,	O
and	O
highlight	O
the	O
role	O
of	O
T	O
cells	O
,	O
which	O
has	O
hitherto	O
been	O
neglected	O
in	O
RA	O
pathogenesis	O
.	O

Together	O
with	O
recent	O
data	O
on	O
the	O
successful	O
introduction	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
,	O
our	O
results	O
have	O
added	O
information	O
for	O
the	O
future	O
molecular	O
targeting	O
of	O
new	O
therapeutic	O
applications	O
in	O
RA	O
.	O

Sox6	B-Protein
Directly	O
Silences	O
Epsilon	B-Protein
Globin	I-Protein
Expression	O
in	O
Definitive	O
Erythropoiesis	O

Sox6	B-Protein
is	O
a	O
member	O
of	O
the	O
Sox	O
transcription	O
factor	O
family	O
that	O
is	O
defined	O
by	O
the	O
conserved	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
DNA	O
binding	O
domain	O
,	O
first	O
described	O
in	O
the	O
testis	O
determining	O
gene	O
,	O
Sry	B-Protein
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
Sox6	B-Protein
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
,	O
cartilage	O
,	O
and	O
muscle	O
.	O

In	O
the	O
Sox6	B-Protein
-	O
deficient	O
mouse	O
,	O
p100H	O
,	O
epsilony	B-Protein
globin	I-Protein
is	O
persistently	O
expressed	O
,	O
and	O
increased	O
numbers	O
of	O
nucleated	O
red	O
cells	O
are	O
present	O
in	O
the	O
fetal	O
circulation	O
.	O

Transfection	O
assays	O
in	O
GM979	O
(	O
erythroleukemic	O
)	O
cells	O
define	O
a	O
36	O
-	O
base	O
pair	O
region	O
of	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
that	O
is	O
critical	O
for	O
Sox6	B-Protein
mediated	O
repression	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
demonstrate	O
that	O
Sox6	B-Protein
acts	O
as	O
a	O
repressor	O
by	O
directly	O
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
.	O

The	O
normal	O
expression	O
of	O
Sox6	B-Protein
in	O
wild	O
-	O
type	O
fetal	O
liver	O
and	O
the	O
ectopic	O
expression	O
of	O
epsilony	B-Protein
in	O
p100H	O
homozygous	O
fetal	O
liver	O
demonstrate	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
.	O

The	O
present	O
study	O
shows	O
that	O
Sox6	B-Protein
is	O
required	O
for	O
silencing	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
definitive	O
erythropoiesis	O
and	O
suggests	O
a	O
role	O
for	O
Sox6	B-Protein
in	O
erythroid	O
cell	O
maturation	O
.	O

Thus	O
,	O
Sox6	B-Protein
regulation	O
of	O
epsilony	B-Protein
globin	I-Protein
might	O
provide	O
a	O
novel	O
therapeutical	O
target	O
in	O
the	O
treatment	O
of	O
hemoglobinopathies	O
such	O
as	O
sickle	O
cell	O
anemia	O
and	O
thalassemia	O
.	O

Sry	B-Protein
type	O
HMG	O
box	O
(	O
Sox6	B-Protein
)	O
is	O
a	O
member	O
of	O
the	O
Sox	O
transcription	O
factor	O
family	O
characterized	O
by	O
the	O
conserved	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
domain	O
,	O
consisting	O
of	O
79	O
amino	O
acids	O
involved	O
in	O
DNA	O
recognition	O
and	O
binding	O
[	O
1	O
]	O
.	O

Sox	O
transcription	O
factors	O
bind	O
to	O
the	O
minor	O
groove	O
of	O
DNA	O
and	O
cause	O
a	O
70degrees	O
-	O
85degrees	O
bend	O
of	O
the	O
DNA	O
that	O
leads	O
to	O
local	O
conformational	O
changes	O
[	O
2	O
,	O
3	O
]	O
,	O
while	O
most	O
other	O
transcription	O
factors	O
target	O
the	O
major	O
groove	O
of	O
DNA	O
[	O
4	O
]	O
.	O

Therefore	O
,	O
Sox	O
proteins	O
may	O
perform	O
part	O
of	O
their	O
function	O
as	O
architectural	O
proteins	O
by	O
organizing	O
local	O
chromatin	O
structure	O
and	O
assembling	O
other	O
DNA	O
-	O
bound	O
transcription	O
factors	O
into	O
biologically	O
active	O
,	O
sterically	O
defined	O
multiprotein	O
complexes	O
.	O

Sox6	B-Protein
has	O
been	O
reported	O
to	O
be	O
able	O
to	O
act	O
as	O
either	O
an	O
activator	O
or	O
a	O
repressor	O
,	O
depending	O
on	O
its	O
interactors	O
and	O
its	O
target	O
promoter	O
context	O
[	O
5	O
,	O
6	O
]	O
.	O

Intriguingly	O
,	O
Sox6	B-Protein
has	O
also	O
been	O
shown	O
to	O
act	O
as	O
a	O
general	O
splicing	O
factor	O
that	O
participates	O
in	O
pre	O
-	O
mRNA	O
splicing	O
[	O
7	O
]	O
.	O

Depletion	O
of	O
Sox6	B-Protein
in	O
HeLa	O
cell	O
extracts	O
blocked	O
splicing	O
of	O
multiple	O
substrates	O
,	O
and	O
expression	O
of	O
the	O
HMG	O
domain	O
of	O
either	O
Sox6	B-Protein
,	O
Sox9	B-Protein
,	O
or	O
Sry	B-Protein
in	O
the	O
extracts	O
restored	O
splicing	O
,	O
indicating	O
functional	O
overlap	O
of	O
these	O
proteins	O
[	O
7	O
]	O
.	O

Regardless	O
of	O
how	O
Sox6	B-Protein
functions	O
in	O
regulating	O
gene	O
expression	O
,	O
previous	O
studies	O
have	O
demonstrated	O
that	O
Sox6	B-Protein
is	O
an	O
important	O
regulatory	O
molecule	O
that	O
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
[	O
8	O
-	O
11	O
]	O
,	O
cartilage	O
[	O
6	O
,	O
12	O
,	O
13	O
]	O
,	O
and	O
muscle	O
[	O
14	O
,	O
15	O
]	O
.	O

A	O
Sox6	B-Protein
-	O
null	O
mutant	O
mouse	O
(	O
p100H	O
)	O
has	O
previously	O
been	O
identified	O
in	O
our	O
laboratory	O
[	O
14	O
]	O
.	O

Mice	O
homozygous	O
for	O
p100H	O
show	O
delayed	O
growth	O
,	O
develop	O
myopathy	O
and	O
arterioventricular	O
heart	O
block	O
,	O
and	O
die	O
within	O
2	O
wk	O
after	O
birth	O
[	O
14	O
]	O
.	O

The	O
p100H	O
mutant	O
allele	O
is	O
associated	O
with	O
a	O
Chromosome	O
7	O
inversion	O
that	O
disrupts	O
both	O
the	O
p	B-Protein
gene	O
and	O
the	O
Sox6	B-Protein
gene	O
(	O
and	O
no	O
other	O
gene	O
within	O
50	O
,	O
000	O
nucleotides	O
of	O
the	O
chromosomal	O
breakpoints	O
)	O
[	O
14	O
]	O
.	O

Because	O
the	O
p	B-Protein
gene	O
functions	O
solely	O
in	O
pigmentation	O
[	O
16	O
]	O
,	O
the	O
Sox6	B-Protein
transcription	O
factor	O
is	O
implicated	O
in	O
all	O
other	O
phenotypes	O
.	O

Among	O
the	O
HMG	O
box	O
proteins	O
distantly	O
related	O
to	O
Sry	B-Protein
(	O
the	O
first	O
member	O
identified	O
of	O
the	O
Sox	O
transcription	O
factor	O
family	O
)	O
that	O
similarly	O
bind	O
to	O
the	O
minor	O
groove	O
and	O
bend	O
DNA	O
,	O
but	O
without	O
sequence	O
specificity	O
,	O
are	O
the	O
ubiquitously	O
expressed	O
HMG1	B-Protein
and	O
HMG2	B-Protein
proteins	O
[	O
17	O
]	O
.	O

Modulation	O
of	O
DNA	O
structure	O
by	O
these	O
and	O
other	O
HMG	O
proteins	O
can	O
mediate	O
long	O
-	O
range	O
enhancer	O
function	O
on	O
both	O
DNA	O
and	O
chromatin	O
-	O
assembled	O
genes	O
by	O
bringing	O
together	O
distant	O
regions	O
of	O
DNA	O
and	O
associated	O
factors	O
.	O

Specifically	O
,	O
HMG	O
proteins	O
have	O
been	O
shown	O
to	O
modulate	O
beta	O
-	O
globin	O
genes	O
[	O
18	O
-	O
21	O
]	O
.	O

The	O
mouse	O
beta	O
-	O
globin	O
genes	O
{	O
epsilony	B-Protein
,	O
betah1	B-Protein
,	O
beta	B-Protein
-	I-Protein
major	I-Protein
,	O
and	O
beta	B-Protein
-	I-Protein
minor	I-Protein
}	O
are	O
clustered	O
on	O
Chromosome	O
7	O
and	O
they	O
are	O
highly	O
homologous	O
to	O
their	O
human	O
counterparts	O
in	O
organizational	O
structure	O
and	O
function	O
[	O
22	O
]	O
.	O

High	O
-	O
level	O
expression	O
of	O
these	O
genes	O
requires	O
a	O
regulatory	O
element	O
,	O
the	O
locus	O
control	O
region	O
that	O
is	O
characterized	O
by	O
a	O
set	O
of	O
nuclease	O
hypersensitive	O
sites	O
spread	O
over	O
25	O
kb	O
located	O
5	O
'	O
of	O
the	O
epsilony	B-Protein
gene	O
[	O
23	O
]	O
.	O

The	O
beta	O
-	O
globin	O
genes	O
are	O
expressed	O
in	O
a	O
tissue	O
-	O
and	O
development	O
-	O
specific	O
fashion	O
.	O

In	O
mice	O
,	O
erythropoiesis	O
originates	O
in	O
the	O
embryonic	O
yolk	O
sac	O
where	O
primitive	O
erythroid	O
cells	O
express	O
epsilony	B-Protein
and	O
betah	B-Protein
-	I-Protein
1	I-Protein
globins	I-Protein
[	O
22	O
]	O
.	O

At	O
11	O
.	O
5	O
d	O
post	O
coitus	O
(	O
dpc	O
)	O
,	O
erythropoiesis	O
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
definitive	O
erythroid	O
cells	O
express	O
adult	O
beta	O
globins	O
(	O
beta	B-Protein
major	I-Protein
and	O
minor	B-Protein
)	O
[	O
22	O
]	O
.	O

The	O
epsilony	B-Protein
gene	O
is	O
silenced	O
in	O
definitive	O
erythroid	O
cells	O
.	O

The	O
mechanism	O
of	O
silencing	O
of	O
its	O
human	O
counterpart	O
,	O
epsilon	B-Protein
globin	I-Protein
,	O
has	O
been	O
studied	O
extensively	O
.	O

In	O
definitive	O
erythropoiesis	O
,	O
epsilon	B-Protein
is	O
activated	O
and	O
silenced	O
autonomously	O
[	O
24	O
,	O
25	O
]	O
,	O
although	O
in	O
primitive	O
erythropoiesis	O
epsilon	B-Protein
also	O
appears	O
to	O
be	O
regulated	O
competitively	O
[	O
26	O
]	O
.	O

The	O
gamma	B-Protein
-	I-Protein
globin	I-Protein
to	O
adult	O
beta	B-Protein
-	I-Protein
globin	I-Protein
switch	O
is	O
controlled	O
by	O
promoter	O
competition	O
for	O
the	O
LCR	O
[	O
24	O
,	O
25	O
]	O
.	O

All	O
the	O
elements	O
responsible	O
for	O
silencing	O
the	O
epsilon	B-Protein
globin	I-Protein
gene	O
are	O
within	O
the	O
epsilon	B-Protein
gene	O
or	O
in	O
adjacent	O
sequences	O
[	O
27	O
]	O
,	O
suggesting	O
that	O
silencing	O
is	O
primarily	O
gene	O
autonomous	O
.	O

Using	O
promoter	O
deletion	O
analyses	O
in	O
transgenic	O
mouse	O
models	O
and	O
cell	O
transfection	O
assays	O
,	O
multiple	O
DNA	O
elements	O
important	O
to	O
the	O
silencing	O
process	O
have	O
been	O
previously	O
identified	O
in	O
both	O
the	O
proximal	O
and	O
the	O
distal	O
epsilon	B-Protein
gene	O
promoter	O
[	O
27	O
]	O
.	O

Their	O
corresponding	O
transcription	O
factors	O
,	O
such	O
as	O
GATA	B-Protein
-	I-Protein
1	I-Protein
,	O
YY	B-Protein
-	I-Protein
1	I-Protein
,	O
COUP	B-Protein
-	I-Protein
TF	I-Protein
,	O
and	O
DRED	B-Protein
have	O
been	O
identified	O
and	O
shown	O
to	O
directly	O
bind	O
to	O
these	O
DNA	O
elements	O
(	O
as	O
part	O
of	O
protein	O
complexes	O
)	O
to	O
regulate	O
epsilon	B-Protein
silencing	O
[	O
27	O
]	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
silencing	O
of	O
the	O
epsilon	B-Protein
gene	O
involves	O
a	O
complicated	O
network	O
of	O
multiple	O
cis	O
elements	O
and	O
transacting	O
proteins	O
.	O

In	O
addition	O
to	O
playing	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
[	O
8	O
-	O
11	O
]	O
,	O
cartilage	O
[	O
6	O
,	O
12	O
,	O
13	O
]	O
,	O
and	O
muscle	O
[	O
14	O
,	O
15	O
]	O
,	O
it	O
was	O
shown	O
that	O
Sox6	B-Protein
is	O
upregulated	O
in	O
long	O
-	O
term	O
hematopoiesis	O
stem	O
cells	O
(	O
LT	O
-	O
HSC	O
)	O
compared	O
with	O
multipotent	O
progenitors	O
of	O
adult	O
mouse	O
bone	O
marrow	O
lineage	O
[	O
28	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
that	O
Sox6	B-Protein
also	O
exerts	O
pleiotropic	O
effects	O
on	O
erythropoiesis	O
.	O

These	O
effects	O
include	O
delayed	O
maturation	O
of	O
erythrocytes	O
(	O
that	O
normally	O
enucleate	O
prior	O
to	O
entering	O
the	O
bloodstream	O
[	O
27	O
]	O
)	O
and	O
higher	O
expression	O
of	O
embryonic	O
globin	O
genes	O
.	O

The	O
most	O
extreme	O
effect	O
is	O
the	O
persistence	O
of	O
high	O
expression	O
of	O
the	O
embryonic	O
epsilony	B-Protein
globin	I-Protein
gene	O
.	O

Here	O
we	O
describe	O
and	O
characterize	O
the	O
effects	O
of	O
Sox6	B-Protein
on	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
.	O

We	O
show	O
that	O
Sox6	B-Protein
binds	O
to	O
the	O
proximal	O
promoter	O
of	O
epsilony	B-Protein
globin	I-Protein
and	O
represses	O
its	O
transcription	O
.	O

In	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
,	O
Sox6	B-Protein
is	O
not	O
expressed	O
in	O
yolk	O
sac	O
blood	O
islands	O
,	O
but	O
is	O
expressed	O
in	O
fetal	O
liver	O
,	O
the	O
opposite	O
expression	O
pattern	O
of	O
epsilony	B-Protein
globin	I-Protein
.	O

In	O
the	O
absence	O
of	O
Sox6	B-Protein
,	O
epsilony	B-Protein
globin	I-Protein
is	O
ectopically	O
expressed	O
in	O
the	O
fetal	O
liver	O
,	O
demonstrating	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
.	O

Persistent	O
Expression	O
of	O
the	O
Embryonic	O
Globin	B-Protein
,	O
epsilony	B-Protein
,	O
in	O
Sox6	B-Protein
-	O
Deficient	O
Mice	O

The	O
epsilony	B-Protein
globin	I-Protein
gene	O
was	O
initially	O
identified	O
as	O
an	O
upregulated	O
transcript	O
in	O
the	O
p100H	O
mouse	O
using	O
subtractive	O
hybridization	O
to	O
identify	O
Sox6	B-Protein
downstream	O
targets	O
.	O

This	O
initial	O
observation	O
was	O
confirmed	O
in	O
an	O
independent	O
knock	O
-	O
out	O
allele	O
of	O
Sox6	B-Protein
[	O
13	O
]	O
using	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
used	O
to	O
quantitate	O
the	O
expression	O
levels	O
of	O
other	O
globin	O
genes	O
in	O
p100H	O
mutant	O
and	O
WT	O
mouse	O
livers	O
at	O
two	O
developmental	O
stages	O
,	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
the	O
epsilony	B-Protein
gene	O
is	O
expressed	O
at	O
high	O
levels	O
at	O
both	O
time	O
points	O
in	O
mutant	O
mice	O
,	O
in	O
contrast	O
to	O
the	O
decline	O
in	O
expression	O
observed	O
in	O
WT	O
mice	O
.	O

No	O
difference	O
was	O
seen	O
between	O
WT	O
and	O
heterozygous	O
mice	O
(	O
unpublished	O
data	O
)	O
.	O

Interestingly	O
,	O
the	O
expression	O
levels	O
of	O
the	O
other	O
two	O
embryonic	O
globin	O
genes	O
(	O
zeta	B-Protein
and	O
betah1	B-Protein
)	O
are	O
also	O
higher	O
in	O
p100H	O
homozygous	O
mice	O
,	O
compared	O
with	O
WT	O
mice	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
seen	O
for	O
epsilony	B-Protein
globin	I-Protein
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
.	O

Moreover	O
,	O
the	O
expression	O
level	O
of	O
adult	O
beta	B-Protein
globin	I-Protein
is	O
also	O
somewhat	O
higher	O
in	O
p100H	O
homozygous	O
mice	O
than	O
in	O
WT	O
mice	O
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
.	O

Perinatal	O
lethality	O
of	O
mutant	O
mice	O
(	O
presumably	O
from	O
the	O
heart	O
defect	O
[	O
14	O
]	O
)	O
precludes	O
us	O
from	O
evaluating	O
postnatal	O
globin	O
expression	O
.	O

The	O
graphs	O
in	O
Figure	O
1	O
illustrate	O
real	O
time	O
PCR	O
results	O
that	O
were	O
performed	O
in	O
triplicate	O
(	O
standard	O
deviation	O
of	O
the	O
data	O
is	O
shown	O
by	O
error	O
bars	O
)	O
.	O

Because	O
all	O
of	O
the	O
assays	O
were	O
performed	O
at	O
the	O
same	O
time	O
with	O
the	O
same	O
internal	O
control	O
,	O
the	O
levels	O
shown	O
are	O
relative	O
levels	O
and	O
are	O
thus	O
comparable	O
across	O
all	O
samples	O
and	O
are	O
in	O
agreement	O
with	O
previously	O
published	O
results	O
for	O
WT	O
fetal	O
mice	O
[	O
29	O
]	O
.	O

We	O
note	O
that	O
the	O
level	O
of	O
epsilony	B-Protein
expression	O
in	O
the	O
livers	O
of	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
homozygous	O
mutant	O
mice	O
is	O
statistically	O
equivalent	O
to	O
the	O
level	O
of	O
betamaj	B-Protein
/	O
min	B-Protein
expression	O
in	O
the	O
livers	O
of	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
homozygous	O
WT	O
mice	O
.	O

Transfection	O
Studies	O
Using	O
GM979	O
Cells	O
Indicate	O
That	O
Sox6	B-Protein
Directly	O
Represses	O
the	O
epsilony	B-Protein
Gene	O
Promoter	O
at	O
the	O
Transcriptional	O
Level	O

Real	O
-	O
time	O
PCR	O
assays	O
(	O
Figure	O
1	O
)	O
measure	O
steady	O
-	O
state	O
levels	O
of	O
epsilony	B-Protein
mRNA	O
,	O
not	O
transcriptional	O
activity	O
of	O
the	O
epsilony	B-Protein
promoter	O
.	O

To	O
investigate	O
whether	O
Sox6	B-Protein
directly	O
acts	O
on	O
the	O
epsilony	B-Protein
gene	O
promoter	O
at	O
the	O
transcriptional	O
level	O
,	O
we	O
used	O
an	O
in	O
vitro	O
transient	O
transfection	O
assay	O
and	O
GM979	O
cells	O
,	O
a	O
murine	O
erythroleukemic	O
cell	O
line	O
that	O
expresses	O
both	O
epsilony	B-Protein
and	O
adult	O
beta	B-Protein
globins	I-Protein
[	O
30	O
]	O
.	O

We	O
generated	O
an	O
epsilony	B-Protein
promoter	O
reporter	O
construct	O
(	O
E	O
-	O
Luc	O
)	O
by	O
fusing	O
a	O
micro	O
-	O
LCR	O
(	O
muLCR	O
)	O
element	O
(	O
2	O
.	O
5	O
kb	O
)	O
[	O
31	O
]	O
to	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
(	O
2	O
.	O
2	O
kb	O
)	O
,	O
followed	O
by	O
the	O
luciferase	B-Protein
reporter	O
gene	O
,	O
as	O
shown	O
in	O
Figure	O
2A	O
(	O
detailed	O
in	O
Materials	O
and	O
Methods	O
)	O
.	O

Overexpression	O
of	O
Sox6	B-Protein
in	O
GM979	O
cells	O
by	O
transient	O
transfection	O
leads	O
to	O
a	O
dosage	O
-	O
dependent	O
repression	O
of	O
E	O
-	O
Luc	O
reporter	O
activity	O
(	O
Figure	O
2B	O
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
a	O
truncated	O
Sox6	B-Protein
protein	O
that	O
lacks	O
its	O
HMG	O
domain	O
[	O
32	O
]	O
(	O
similar	O
to	O
the	O
p100H	O
mouse	O
allele	O
)	O
fails	O
to	O
repress	O
E	O
-	O
Luc	O
activity	O
(	O
Figure	O
2B	O
)	O
.	O

These	O
data	O
indicate	O
that	O
Sox6	B-Protein
acts	O
to	O
repress	O
the	O
epsilony	B-Protein
promoter	O
at	O
the	O
transcriptional	O
level	O
.	O

Sox6	B-Protein
has	O
been	O
shown	O
to	O
act	O
as	O
a	O
repressor	O
and	O
to	O
interact	O
with	O
a	O
widely	O
expressed	O
co	O
-	O
repressor	O
,	O
CtBP2	B-Protein
,	O
on	O
the	O
fgf	B-Protein
-	I-Protein
3	I-Protein
promoter	O
[	O
5	O
]	O
.	O

CtBP2	B-Protein
is	O
expressed	O
in	O
GM979	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
interaction	O
with	O
CtBP2	B-Protein
is	O
required	O
for	O
Sox6	B-Protein
repression	O
of	O
the	O
epsilony	B-Protein
promoter	O
,	O
we	O
introduced	O
a	O
point	O
mutation	O
(	O
L386H	O
)	O
in	O
the	O
Sox6	B-Protein
protein	O
that	O
has	O
been	O
previously	O
reported	O
to	O
be	O
sufficient	O
to	O
abolish	O
Sox6	B-Protein
-	O
CtBP2	B-Protein
interaction	O
[	O
5	O
]	O
.	O

This	O
amino	O
acid	O
change	O
is	O
not	O
in	O
the	O
HMG	O
DNA	O
binding	O
domain	O
.	O

However	O
,	O
this	O
mutant	O
version	O
of	O
Sox6	B-Protein
retains	O
the	O
ability	O
to	O
repress	O
the	O
epsilony	B-Protein
promoter	O
in	O
the	O
transfection	O
assay	O
(	O
Figure	O
2B	O
)	O
,	O
indicating	O
that	O
Sox6	B-Protein
represses	O
the	O
epsilony	B-Protein
promoter	O
in	O
a	O
CtBP2	B-Protein
-	O
independent	O
manner	O
.	O

Deletion	O
analysis	O
of	O
the	O
epsilony	B-Protein
promoter	O
,	O
as	O
shown	O
in	O
Figure	O
2C	O
,	O
defined	O
a	O
region	O
(	O
-	O
63	O
to	O
-	O
37	O
)	O
within	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
that	O
is	O
critical	O
for	O
Sox6	B-Protein
repression	O
.	O

Analysis	O
of	O
this	O
short	O
region	O
reveals	O
two	O
Sox	O
/	O
Sox6	O
consensus	O
binding	O
sites	O
[	O
5	O
]	O
(	O
Figure	O
3A	O
)	O
.	O

EMSA	O
and	O
ChIP	O
Assays	O
Show	O
that	O
Sox6	B-Protein
Directly	O
Binds	O
to	O
the	O
epsilony	B-Protein
Promoter	O

Sox6	B-Protein
might	O
repress	O
the	O
epsilony	B-Protein
promoter	O
,	O
either	O
through	O
direct	O
physical	O
contact	O
with	O
the	O
promoter	O
or	O
by	O
regulating	O
intermediates	O
affecting	O
the	O
epsilony	B-Protein
promoter	O
.	O

To	O
investigate	O
whether	O
Sox6	B-Protein
is	O
directly	O
associated	O
with	O
the	O
epsilony	B-Protein
promoter	O
,	O
we	O
first	O
performed	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
using	O
a	O
c	B-Protein
-	I-Protein
Myc	I-Protein
-	O
tagged	O
Sox6	B-Protein
in	O
a	O
reticulocyte	O
lysate	O
-	O
based	O
transcription	O
/	O
translation	O
in	O
vitro	O
system	O
.	O

The	O
probes	O
used	O
are	O
listed	O
in	O
Figure	O
3A	O
.	O

The	O
36	O
-	O
base	O
pair	O
(	O
bp	O
)	O
WT	O
probe	O
corresponds	O
to	O
the	O
critical	O
region	O
of	O
the	O
epsilony	B-Protein
promoter	O
defined	O
in	O
our	O
promoter	O
deletion	O
analyses	O
.	O

This	O
probe	O
contains	O
two	O
consensus	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
.	O

Also	O
included	O
in	O
our	O
EMSA	O
are	O
three	O
mutated	O
probes	O
that	O
are	O
,	O
either	O
truncated	O
(	O
M1	O
)	O
,	O
or	O
mutated	O
(	O
M2	O
and	O
M3	O
)	O
in	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
(	O
Figure	O
3A	O
)	O
.	O

Sox6	B-Protein
is	O
able	O
to	O
physically	O
associate	O
with	O
the	O
36	O
-	O
bp	O
region	O
(	O
Figure	O
3B	O
)	O
within	O
the	O
epsilony	B-Protein
promoter	O
defined	O
by	O
the	O
deletion	O
analysis	O
experiments	O
(	O
Figure	O
2C	O
)	O
.	O

The	O
36	O
-	O
bp	O
probe	O
was	O
shifted	O
by	O
the	O
tagged	O
Sox6	B-Protein
protein	O
.	O

Moreover	O
,	O
both	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
Sox6	B-Protein
antibodies	O
supershift	O
the	O
band	O
,	O
indicating	O
that	O
the	O
binding	O
is	O
Sox6	B-Protein
-	O
specific	O
.	O

To	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
c	B-Protein
-	I-Protein
Myc	I-Protein
tag	O
itself	O
binds	O
to	O
the	O
probe	O
,	O
an	O
HA	B-Protein
-	O
tagged	O
Sox6	B-Protein
was	O
used	O
in	O
another	O
EMSA	O
that	O
confirmed	O
these	O
results	O
(	O
Figure	O
3C	O
)	O
.	O

Next	O
,	O
nuclear	O
extracts	O
from	O
MEL	O
cells	O
were	O
used	O
in	O
EMSA	O
employing	O
the	O
same	O
36	O
-	O
bp	O
probe	O
.	O

MEL	O
cells	O
,	O
a	O
murine	O
erythroleukemic	O
cell	O
line	O
,	O
express	O
adult	O
beta	B-Protein
globins	I-Protein
,	O
but	O
not	O
epsilony	B-Protein
[	O
33	O
]	O
.	O

Sox6	B-Protein
directly	O
binds	O
to	O
this	O
DNA	O
sequence	O
in	O
MEL	O
cells	O
(	O
Figure	O
3D	O
)	O
.	O

The	O
intact	O
consensus	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
of	O
the	O
DNA	O
probe	O
are	O
required	O
for	O
the	O
binding	O
,	O
as	O
shown	O
in	O
the	O
competition	O
assay	O
(	O
Figure	O
3E	O
)	O
.	O

Ablation	O
of	O
putative	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
(	O
M1	O
and	O
M3	O
)	O
abolish	O
their	O
ability	O
to	O
compete	O
in	O
EMSA	O
(	O
Figure	O
3E	O
)	O
.	O

The	O
M2	O
mutant	O
probe	O
may	O
compete	O
partially	O
with	O
WT	O
binding	O
.	O

To	O
investigate	O
the	O
functional	O
significance	O
of	O
the	O
intact	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
,	O
the	O
epsilony	B-Protein
promoter	O
reporter	O
constructs	O
with	O
mutagenized	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
were	O
co	O
-	O
transfected	O
with	O
the	O
Sox6	B-Protein
overexpression	O
vector	O
into	O
GM979	O
cells	O
.	O

Consistent	O
with	O
the	O
EMSA	O
results	O
,	O
the	O
mutant	O
epsilony	B-Protein
promoter	O
reporter	O
constructs	O
(	O
with	O
either	O
one	O
or	O
both	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
mutagenized	O
)	O
do	O
not	O
result	O
in	O
significant	O
promoter	O
repression	O
in	O
transfection	O
studies	O
(	O
Figure	O
3F	O
)	O
.	O

Thus	O
,	O
both	O
sites	O
are	O
required	O
for	O
maximal	O
repression	O
of	O
epsilony	B-Protein
by	O
Sox6	B-Protein
,	O
but	O
not	O
to	O
the	O
same	O
degree	O
.	O

We	O
also	O
tested	O
whether	O
Sox6	B-Protein
binds	O
to	O
the	O
epsilony	B-Protein
promoter	O
in	O
vivo	O
using	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
(	O
Figure	O
4	O
)	O
.	O

The	O
Sox6	B-Protein
-	O
containing	O
complex	O
was	O
immunoprecipitated	O
from	O
MEL	O
cells	O
or	O
from	O
liver	O
cells	O
of	O
15	O
.	O
5	O
dpc	O
WT	O
mice	O
using	O
Sox6	B-Protein
antibody	O
.	O

Figure	O
4	O
shows	O
that	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
is	O
readily	O
immunoprecipitated	O
with	O
Sox6	B-Protein
antibody	O
in	O
both	O
MEL	O
cells	O
and	O
liver	O
cells	O
.	O

Normal	O
IgG	O
was	O
used	O
as	O
a	O
negative	O
control	O
(	O
Figure	O
4A	O
)	O
.	O

The	O
above	O
data	O
(	O
Figures	O
3	O
and	O
4	O
)	O
clearly	O
indicate	O
that	O
Sox6	B-Protein
acts	O
as	O
a	O
repressor	O
of	O
the	O
epsilony	B-Protein
gene	O
by	O
directly	O
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
,	O
probably	O
as	O
a	O
dimer	O
.	O

The	O
Persistent	O
Expression	O
of	O
epsilony	B-Protein
Globin	I-Protein
in	O
Sox6	B-Protein
-	O
Deficient	O
Mice	O
Is	O
Due	O
to	O
a	O
Defect	O
in	O
the	O
epsilony	B-Protein
-	O
Gene	O
-	O
Silencing	O
Mechanism	O
in	O
Definitive	O
Erythroid	O
Cells	O

Normally	O
,	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
is	O
exclusively	O
expressed	O
in	O
primitive	O
erythrocytes	O
and	O
silenced	O
in	O
definitive	O
erythrocytes	O
.	O

To	O
determine	O
whether	O
the	O
persistent	O
expression	O
of	O
epsilony	B-Protein
globin	I-Protein
is	O
due	O
to	O
residual	O
primitive	O
erythrocytes	O
or	O
is	O
due	O
to	O
ectopic	O
expression	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
definitive	O
erythrocytes	O
,	O
we	O
examined	O
the	O
spatial	O
pattern	O
of	O
epsilony	B-Protein
globin	I-Protein
transcripts	O
in	O
mouse	O
embryos	O
by	O
in	O
situ	O
hybridization	O
(	O
Figure	O
5	O
)	O
.	O

As	O
expected	O
,	O
epsilony	B-Protein
globin	I-Protein
is	O
not	O
expressed	O
in	O
the	O
WT	O
14	O
.	O
5	O
-	O
dpc	O
liver	O
,	O
the	O
site	O
of	O
definitive	O
erythropoiesis	O
in	O
the	O
fetus	O
.	O

In	O
contrast	O
,	O
abundant	O
ectopic	O
epsilony	B-Protein
mRNA	O
expression	O
is	O
seen	O
in	O
the	O
liver	O
of	O
14	O
.	O
5	O
-	O
dpc	O
mutants	O
(	O
Figure	O
5	O
A	O
-	O
D	O
)	O
.	O

However	O
,	O
the	O
expression	O
of	O
betamaj	B-Protein
/	O
min	B-Protein
globin	I-Protein
is	O
equally	O
abundant	O
in	O
both	O
WT	O
and	O
p100H	O
mutant	O
mice	O
(	O
Figure	O
5	O
E	O
and	O
F	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
persistent	O
high	O
levels	O
of	O
epsilony	B-Protein
are	O
due	O
to	O
ectopic	O
expression	O
in	O
the	O
definitive	O
erythroid	O
cells	O
that	O
mature	O
in	O
the	O
fetal	O
liver	O
,	O
suggesting	O
that	O
there	O
is	O
an	O
intrinsic	O
defect	O
of	O
the	O
epsilony	B-Protein
silencing	O
mechanism	O
in	O
Sox6	B-Protein
-	O
null	O
mice	O
.	O

The	O
Expression	O
Pattern	O
of	O
Sox6	B-Protein
Suggests	O
a	O
Role	O
in	O
Definitive	O
Erythropoiesis	O

The	O
observation	O
that	O
Sox6	B-Protein
-	O
deficient	O
mice	O
ectopically	O
express	O
epsilony	B-Protein
globin	I-Protein
in	O
liver	O
,	O
where	O
definitive	O
erythroid	O
cells	O
mature	O
,	O
suggests	O
that	O
Sox6	B-Protein
is	O
an	O
important	O
regulator	O
in	O
definitive	O
erythropoiesis	O
.	O

To	O
determine	O
the	O
temporal	O
and	O
spatial	O
expression	O
pattern	O
of	O
Sox6	B-Protein
,	O
Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
assays	O
were	O
employed	O
.	O

As	O
shown	O
in	O
Figure	O
6A	O
,	O
Sox6	B-Protein
is	O
detectable	O
by	O
Northern	O
blot	O
beginning	O
at	O
10	O
.	O
5	O
dpc	O
,	O
coincident	O
with	O
the	O
temporal	O
onset	O
of	O
definitive	O
erythropoiesis	O
in	O
the	O
liver	O
.	O

Furthermore	O
,	O
in	O
situ	O
hybridization	O
shows	O
that	O
Sox6	B-Protein
is	O
highly	O
transcribed	O
in	O
12	O
.	O
5	O
-	O
dpc	O
liver	O
,	O
but	O
not	O
in	O
yolk	O
sac	O
blood	O
islands	O
at	O
7	O
.	O
5	O
dpc	O
(	O
Figure	O
6B	O
)	O
.	O

Therefore	O
,	O
Sox6	B-Protein
expression	O
is	O
temporally	O
and	O
spatially	O
coincident	O
with	O
definitive	O
,	O
but	O
not	O
primitive	O
,	O
erythropoiesis	O
.	O

These	O
data	O
,	O
taken	O
together	O
with	O
the	O
observation	O
that	O
epsilony	B-Protein
globin	I-Protein
is	O
highly	O
expressed	O
in	O
the	O
liver	O
cells	O
of	O
14	O
.	O
5	O
-	O
dpc	O
p100H	O
mutant	O
mice	O
(	O
Figure	O
5	O
)	O
,	O
demonstrate	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
.	O

Mutant	O
p100H	O
Mice	O
Have	O
Higher	O
Numbers	O
of	O
Nucleated	O
Red	O
Cells	O

Among	O
the	O
other	O
Sox6	B-Protein
effects	O
in	O
erythropoiesis	O
,	O
we	O
have	O
noticed	O
that	O
there	O
are	O
more	O
nucleated	O
red	O
blood	O
cells	O
circulating	O
in	O
p100H	O
mutant	O
mice	O
than	O
in	O
WT	O
mice	O
at	O
14	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
7A	O
)	O
.	O

However	O
,	O
at	O
postnatal	O
day	O
10	O
.	O
5	O
,	O
we	O
do	O
not	O
see	O
circulating	O
nucleated	O
red	O
cells	O
in	O
either	O
WT	O
or	O
mutant	O
mice	O
,	O
suggesting	O
that	O
this	O
may	O
be	O
a	O
transient	O
effect	O
.	O

In	O
addition	O
,	O
the	O
mutant	O
liver	O
shows	O
a	O
significant	O
increase	O
in	O
hematopoietic	O
precursor	O
cells	O
including	O
nucleated	O
erythrocytes	O
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
7B	O
)	O
.	O

This	O
alteration	O
is	O
noted	O
as	O
early	O
as	O
14	O
.	O
5	O
dpc	O
.	O

These	O
observations	O
suggest	O
that	O
besides	O
silencing	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
,	O
Sox6	B-Protein
may	O
affect	O
red	O
cell	O
maturation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Sox6	B-Protein
is	O
a	O
novel	O
factor	O
in	O
the	O
complicated	O
regulation	O
mechanism	O
of	O
globin	O
genes	O
.	O

In	O
the	O
Sox6	B-Protein
null	O
mouse	O
,	O
there	O
is	O
a	O
transient	O
effect	O
on	O
the	O
embryonic	O
globin	O
genes	O
,	O
zeta	B-Protein
and	O
betaH1	B-Protein
,	O
and	O
a	O
persistent	O
upregulation	O
of	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
.	O

Sox6	B-Protein
directly	O
regulates	O
and	O
binds	O
to	O
the	O
proximal	O
promoter	O
of	O
epsilony	B-Protein
gene	I-Protein
and	O
represses	O
the	O
epsilony	B-Protein
-	I-Protein
globin	I-Protein
gene	O
in	O
definitive	O
erythropoiesis	O
.	O

Sox6	B-Protein
belongs	O
to	O
group	O
D	O
of	O
the	O
Sox	O
family	O
of	O
proteins	O
that	O
includes	O
Sox5	B-Protein
,	O
12	B-Protein
,	O
13	B-Protein
,	O
and	O
23	B-Protein
[	O
34	O
]	O
.	O

Group	O
D	O
Sox	O
proteins	O
contain	O
a	O
coiled	O
-	O
coiled	O
domain	O
that	O
mediates	O
homo	O
-	O
and	O
heterodimerization	O
[	O
6	O
,	O
35	O
]	O
.	O

Functionally	O
,	O
dimerization	O
of	O
Sox5	B-Protein
and	O
Sox6	B-Protein
has	O
been	O
shown	O
to	O
greatly	O
increase	O
the	O
binding	O
efficiency	O
of	O
the	O
two	O
Sox	O
proteins	O
to	O
DNA	O
that	O
contains	O
adjacent	O
Sox	O
sites	O
[	O
6	O
]	O
.	O

In	O
addition	O
,	O
Sox6	B-Protein
binds	O
more	O
strongly	O
to	O
an	O
HMG	O
-	O
box	O
dimer	O
motif	O
than	O
to	O
a	O
single	O
HMG	O
-	O
box	O
motif	O
[	O
5	O
]	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
target	O
genes	O
for	O
group	O
D	O
Sox	O
proteins	O
,	O
such	O
as	O
Sox6	B-Protein
,	O
probably	O
harbor	O
pairs	O
of	O
HMG	O
binding	O
sites	O
with	O
a	O
configuration	O
compatible	O
with	O
binding	O
of	O
D	O
-	O
Sox	O
protein	O
dimers	O
.	O

Indeed	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
defined	O
Sox6	B-Protein
target	O
sequence	O
of	O
the	O
epsilony	B-Protein
promoter	O
contains	O
two	O
Sox	O
/	O
Sox6	O
consensus	O
sites	O
(	O
Figure	O
3A	O
)	O
.	O

Functionally	O
,	O
both	O
sites	O
are	O
essential	O
for	O
Sox6	B-Protein
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
and	O
repression	O
of	O
its	O
activity	O
(	O
Figure	O
3E	O
and	O
3F	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
Sox6	B-Protein
binds	O
to	O
this	O
sequence	O
of	O
the	O
epsilony	B-Protein
promoter	O
either	O
as	O
a	O
homodimer	O
or	O
as	O
a	O
heterodimer	O
with	O
other	O
Sox	O
proteins	O
.	O

Because	O
Sox	O
proteins	O
recognize	O
a	O
short	O
6	O
-	O
bp	O
core	O
-	O
binding	O
sequence	O
that	O
allows	O
for	O
considerable	O
degeneracy	O
,	O
the	O
specificity	O
of	O
their	O
actions	O
is	O
thought	O
to	O
rely	O
upon	O
interactions	O
with	O
other	O
transcription	O
factors	O
[	O
36	O
]	O
.	O

In	O
our	O
EMSAs	O
,	O
we	O
had	O
to	O
run	O
the	O
electrophoresis	O
on	O
a	O
4	O
%	O
-	O
6	O
%	O
gel	O
for	O
at	O
least	O
4	O
-	O
8	O
h	O
to	O
detect	O
the	O
Sox6	B-Protein
-	O
associated	O
band	O
,	O
suggesting	O
that	O
Sox6	B-Protein
is	O
part	O
of	O
a	O
high	O
molecular	O
weight	O
complex	O
.	O

A	O
few	O
other	O
epsilony	B-Protein
globin	I-Protein
repressors	O
have	O
been	O
reported	O
to	O
bind	O
to	O
DNA	O
sequences	O
near	O
the	O
Sox	O
/	O
Sox6	O
consensus	O
sites	O
,	O
including	O
the	O
DRED	B-Protein
complex	O
[	O
37	O
]	O
and	O
COUP	B-Protein
-	O
TF	B-Protein
[	O
38	O
]	O
.	O

Sox6	B-Protein
might	O
interact	O
with	O
these	O
factors	O
and	O
form	O
a	O
large	O
repression	O
complex	O
.	O

Identification	O
of	O
other	O
components	O
of	O
the	O
Sox6	B-Protein
-	O
containing	O
complex	O
associated	O
with	O
the	O
epsilony	B-Protein
promoter	O
will	O
shed	O
light	O
on	O
its	O
mechanism	O
of	O
repression	O
.	O

Sox	O
proteins	O
bind	O
and	O
bend	O
linear	O
DNA	O
by	O
partial	O
intercalation	O
in	O
the	O
minor	O
groove	O
,	O
and	O
can	O
also	O
bind	O
to	O
four	O
-	O
way	O
junctions	O
[	O
2	O
-	O
4	O
]	O
.	O

Therefore	O
,	O
one	O
attractive	O
model	O
to	O
explain	O
how	O
Sox6	B-Protein
proteins	O
control	O
gene	O
expression	O
is	O
that	O
they	O
function	O
as	O
architectural	O
factors	O
bound	O
to	O
DNA	O
,	O
influencing	O
local	O
chromatin	O
structure	O
by	O
bending	O
DNA	O
and	O
by	O
assembling	O
multiprotein	O
transcriptional	O
complexes	O
.	O

By	O
changing	O
the	O
local	O
chromatin	O
structure	O
,	O
Sox6	B-Protein
could	O
either	O
interfere	O
with	O
binding	O
of	O
other	O
activators	O
to	O
the	O
promoter	O
or	O
facilitate	O
binding	O
of	O
other	O
repressors	O
.	O

Another	O
example	O
of	O
a	O
repressor	O
that	O
interferes	O
with	O
an	O
activator	O
on	O
the	O
epsilony	B-Protein
promoter	O
is	O
DRED	B-Protein
.	O

DRED	B-Protein
interferes	O
with	O
EKLF	B-Protein
,	O
an	O
activator	O
,	O
in	O
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
[	O
39	O
]	O
.	O

Two	O
HMG	O
architectural	O
proteins	O
(	O
distantly	O
related	O
to	O
the	O
Sox	O
family	O
of	O
transcription	O
factors	O
)	O
,	O
HMG	B-Protein
-	I-Protein
I	I-Protein
and	O
HMG	B-Protein
-	I-Protein
Y	I-Protein
,	O
were	O
demonstrated	O
to	O
bind	O
to	O
the	O
human	O
adult	O
beta	O
globin	O
silencers	O
(	O
silencers	B-Protein
I	I-Protein
and	O
II	B-Protein
)	O
and	O
cause	O
bending	O
of	O
the	O
DNA	O
,	O
facilitating	O
the	O
binding	O
of	O
other	O
repressors	O
[	O
40	O
]	O
.	O

Sox6	B-Protein
expression	O
is	O
temporally	O
and	O
spatially	O
coincident	O
with	O
definitive	O
(	O
but	O
not	O
primitive	O
)	O
erythropoiesis	O
(	O
Figure	O
6	O
)	O
,	O
and	O
Sox6	B-Protein
represses	O
epsilony	B-Protein
globin	I-Protein
expression	O
both	O
in	O
vivo	O
(	O
Figure	O
1	O
)	O
and	O
in	O
vitro	O
(	O
Figure	O
2	O
)	O
.	O

Moreover	O
,	O
in	O
situ	O
hybridization	O
clearly	O
shows	O
that	O
the	O
persistent	O
expression	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
p100H	O
mutant	O
mice	O
is	O
due	O
to	O
defects	O
in	O
the	O
silencing	O
mechanism	O
of	O
definitive	O
erythropoiesis	O
that	O
takes	O
place	O
in	O
the	O
liver	O
(	O
Figure	O
5	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
to	O
silence	O
epsilony	B-Protein
globin	I-Protein
expression	O
.	O

The	O
expression	O
level	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
homozygous	O
Sox6	B-Protein
null	O
mice	O
at	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
is	O
statistically	O
equivalent	O
to	O
the	O
level	O
of	O
betamaj	B-Protein
/	O
min	B-Protein
expression	O
in	O
the	O
livers	O
of	O
15	O
.	O
5	O
-	O
dpc	O
and	O
18	O
.	O
5	O
-	O
dpc	O
homozygous	O
WT	O
mice	O
(	O
Figure	O
1	O
)	O
.	O

This	O
demonstrates	O
that	O
ectopic	O
expression	O
of	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
is	O
quite	O
robust	O
in	O
homozygous	O
mutant	O
mice	O
.	O

The	O
expression	O
levels	O
of	O
two	O
other	O
embryonic	O
globin	O
genes	O
(	O
zeta	B-Protein
and	O
betah1	B-Protein
)	O
are	O
also	O
higher	O
in	O
p100H	O
homozygotes	O
,	O
compared	O
with	O
WT	O
.	O

Like	O
epsilony	B-Protein
,	O
levels	O
of	O
zeta	B-Protein
and	O
betah1	B-Protein
are	O
dramatically	O
higher	O
in	O
mutant	O
mice	O
at	O
15	O
.	O
5	O
dpc	O
.	O

However	O
,	O
unlike	O
epsilony	B-Protein
globin	I-Protein
,	O
zeta	B-Protein
and	O
betah1	B-Protein
decline	O
in	O
expression	O
by	O
day	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
,	O
suggesting	O
that	O
epsilony	B-Protein
is	O
regulated	O
differently	O
than	O
zeta	B-Protein
and	O
betah1	B-Protein
.	O

It	O
is	O
possible	O
that	O
Sox6	B-Protein
has	O
a	O
general	O
effect	O
on	O
embryonic	O
globin	O
genes	O
(	O
and	O
erythrocyte	O
maturation	O
)	O
in	O
addition	O
to	O
a	O
specific	O
role	O
in	O
silencing	O
epsilony	B-Protein
.	O

Although	O
most	O
p100H	O
mutant	O
mice	O
die	O
just	O
after	O
being	O
born	O
,	O
a	O
rare	O
few	O
survive	O
longer	O
.	O

None	O
have	O
been	O
observed	O
to	O
live	O
longer	O
than	O
2	O
wk	O
after	O
birth	O
[	O
14	O
]	O
.	O

We	O
examined	O
a	O
single	O
archived	O
sample	O
of	O
liver	O
RNA	O
from	O
a	O
mutant	O
mouse	O
on	O
postnatal	O
day	O
13	O
.	O
5	O
for	O
globin	O
gene	O
expression	O
and	O
detected	O
high	O
levels	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
this	O
RNA	O
sample	O
,	O
compared	O
with	O
undetectable	O
epsilony	B-Protein
RNA	O
in	O
WT	O
control	O
mice	O
.	O

At	O
this	O
point	O
in	O
development	O
,	O
the	O
levels	O
of	O
zeta	B-Protein
and	O
betah1	B-Protein
RNA	O
were	O
undetectable	O
both	O
in	O
mutant	O
and	O
WT	O
;	O
however	O
,	O
adult	O
beta	B-Protein
-	I-Protein
like	I-Protein
globin	I-Protein
RNA	O
levels	O
were	O
moderately	O
elevated	O
in	O
the	O
mutant	O
RNA	O
compared	O
with	O
WT	O
(	O
unpublished	O
data	O
)	O
,	O
similar	O
to	O
what	O
we	O
observe	O
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
Sox6	B-Protein
continues	O
to	O
function	O
postnatally	O
to	O
silence	O
epsilony	B-Protein
globin	I-Protein
expression	O
and	O
has	O
a	O
unique	O
function	O
in	O
the	O
regulation	O
of	O
epsilony	B-Protein
-	I-Protein
globin	I-Protein
.	O

The	O
mechanism	O
by	O
which	O
Sox6	B-Protein
regulates	O
the	O
other	O
embryonic	O
globin	O
genes	O
remains	O
to	O
be	O
elucidated	O
.	O

Sox6	B-Protein
has	O
other	O
effects	O
in	O
erythropoiesis	O
,	O
including	O
a	O
delay	O
in	O
enucleation	O
/	O
maturation	O
in	O
p100H	O
mutant	O
mice	O
.	O

This	O
may	O
be	O
the	O
result	O
of	O
indirect	O
effects	O
,	O
such	O
as	O
stress	O
-	O
induced	O
proliferation	O
(	O
resulting	O
from	O
cardiac	O
defects	O
)	O
and	O
/	O
or	O
anemia	O
.	O

Severe	O
anemia	O
can	O
lead	O
to	O
rapid	O
premature	O
release	O
of	O
red	O
cells	O
,	O
prior	O
to	O
their	O
complete	O
maturation	O
.	O

However	O
,	O
the	O
hematocrit	O
of	O
18	O
.	O
5	O
-	O
dpc	O
mutant	O
mice	O
is	O
only	O
20	O
%	O
lower	O
than	O
that	O
of	O
WT	O
(	O
unpublished	O
data	O
)	O
,	O
and	O
this	O
mild	O
anemia	O
is	O
probably	O
not	O
sufficient	O
to	O
explain	O
the	O
extent	O
of	O
nucleated	O
red	O
cells	O
.	O

Alternatively	O
,	O
Sox6	B-Protein
itself	O
may	O
play	O
a	O
role	O
in	O
red	O
cell	O
terminal	O
differentiation	O
,	O
as	O
it	O
has	O
been	O
shown	O
to	O
be	O
an	O
important	O
factor	O
in	O
cardiac	O
[	O
15	O
]	O
,	O
neuronal	O
[	O
10	O
]	O
,	O
astrocytic	O
[	O
11	O
]	O
,	O
and	O
cartilage	O
differentiation	O
programs	O
[	O
32	O
,	O
41	O
-	O
44	O
]	O
.	O

The	O
restoration	O
of	O
normal	O
enucleation	O
of	O
red	O
cells	O
in	O
Sox6	B-Protein
-	O
deficient	O
mouse	O
by	O
postnatal	O
day	O
10	O
.	O
5	O
may	O
result	O
from	O
functional	O
compensation	O
of	O
other	O
Sox	O
proteins	O
(	O
expressed	O
at	O
later	O
developmental	O
stages	O
)	O
,	O
since	O
functional	O
redundancy	O
is	O
a	O
recurring	O
theme	O
with	O
Sox	O
proteins	O
[	O
13	O
,	O
45	O
,	O
46	O
]	O
.	O

Moreover	O
,	O
erythropoiesis	O
has	O
already	O
shifted	O
from	O
fetal	O
liver	O
to	O
bone	O
marrow	O
by	O
postnatal	O
day	O
10	O
.	O
5	O
.	O

The	O
accompanying	O
change	O
in	O
the	O
microenvironment	O
of	O
red	O
cell	O
production	O
may	O
permit	O
normal	O
enucleation	O
.	O

Identification	O
of	O
Sox6	B-Protein
downstream	O
target	O
genes	O
and	O
its	O
interacting	O
proteins	O
will	O
shed	O
light	O
on	O
the	O
role	O
of	O
Sox6	B-Protein
in	O
red	O
cell	O
terminal	O
differentiation	O
and	O
the	O
enucleation	O
process	O
.	O

Recently	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
analyses	O
suggest	O
that	O
reactivation	O
of	O
human	O
epsilon	B-Protein
-	I-Protein
globin	I-Protein
would	O
be	O
therapeutically	O
beneficial	O
to	O
adults	O
with	O
sickle	O
cell	O
disease	O
[	O
47	O
]	O
,	O
providing	O
a	O
rationale	O
for	O
detailed	O
investigations	O
into	O
the	O
molecular	O
basis	O
of	O
epsilon	B-Protein
-	I-Protein
globin	I-Protein
gene	O
silencing	O
.	O

The	O
present	O
study	O
identifies	O
a	O
novel	O
repressor	O
,	O
Sox6	B-Protein
,	O
which	O
binds	O
to	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
,	O
potentially	O
as	O
part	O
of	O
a	O
larger	O
repression	O
complex	O
.	O

Because	O
murine	O
Sox6	B-Protein
and	O
its	O
human	O
counterpart	O
are	O
94	O
%	O
identical	O
at	O
the	O
amino	O
acid	O
level	O
[	O
48	O
]	O
,	O
it	O
is	O
possible	O
that	O
human	O
Sox6	B-Protein
may	O
also	O
be	O
important	O
in	O
human	O
epsilon	B-Protein
globin	I-Protein
silencing	O
.	O

There	O
is	O
significant	O
sequence	O
homology	O
between	O
the	O
human	O
and	O
mouse	O
epsilon	B-Protein
promoter	O
regions	O
,	O
and	O
the	O
human	O
promoter	O
contains	O
at	O
least	O
two	O
potential	O
Sox6	O
binding	O
sites	O
.	O

Indeed	O
,	O
the	O
existence	O
of	O
a	O
silencer	O
of	O
the	O
human	O
epsilon	B-Protein
globin	I-Protein
gene	O
has	O
been	O
proposed	O
[	O
49	O
,	O
50	O
]	O
.	O

Thus	O
,	O
elucidation	O
of	O
the	O
Sox6	B-Protein
repression	O
mechanism	O
and	O
identification	O
of	O
other	O
components	O
of	O
the	O
Sox6	B-Protein
-	O
containing	O
complex	O
may	O
further	O
our	O
understanding	O
of	O
epsilon	B-Protein
globin	I-Protein
regulation	O
and	O
potentially	O
reveal	O
additional	O
molecular	O
targets	O
for	O
the	O
treatment	O
of	O
sickle	O
cell	O
anemia	O
and	O
beta	O
thalassemias	O
.	O

Plasmid	O
construction	O
.	O

The	O
epsilony	B-Protein
promoter	O
deletion	O
reporter	O
plasmid	O
(	O
E	O
-	O
luc	O
)	O
was	O
generated	O
by	O
PCR	O
amplification	O
of	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
.	O

A	O
2	O
.	O
2	O
-	O
kb	O
fragment	O
upstream	O
of	O
the	O
epsilony	B-Protein
globin	I-Protein
initiation	O
codon	O
(	O
ATG	O
)	O
was	O
used	O
,	O
because	O
it	O
has	O
been	O
shown	O
that	O
all	O
sequences	O
required	O
for	O
epsilon	B-Protein
gene	O
silencing	O
are	O
located	O
within	O
a	O
3	O
.	O
7	O
-	O
kb	O
EcoRI	O
fragment	O
containing	O
about	O
2	O
kb	O
of	O
sequence	O
upstream	O
of	O
the	O
epsilon	B-Protein
globin	I-Protein
gene	O
cap	O
site	O
[	O
50	O
]	O
.	O

Nucleotide	O
numbering	O
is	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

The	O
transcriptional	O
start	O
site	O
is	O
based	O
on	O
the	O
longest	O
cDNA	O
in	O
the	O
Fantom	O
(	O
Functional	O
Annotation	O
of	O
Mouse	O
)	O
database	O
.	O

The	O
PCR	O
primers	O
contained	O
XhoI	O
and	O
HindIII	O
sites	O
that	O
were	O
used	O
to	O
clone	O
the	O
epsilony	B-Protein
promoter	O
fragment	O
upstream	O
of	O
the	O
firefly	O
luciferase	B-Protein
gene	O
in	O
pGL3	O
Basic	O
(	O
Promega	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
United	O
States	O
)	O
.	O

A	O
2	O
.	O
5	O
-	O
kb	O
SstI	O
/	O
XhoI	O
fragment	O
of	O
muLCRbeta	O
9	O
.	O
3	O
(	O
micro	O
LCR	O
;	O
[	O
31	O
]	O
)	O
was	O
then	O
inserted	O
upstream	O
of	O
the	O
epsilony	B-Protein
promoter	O
in	O
the	O
above	O
pGL3	O
Basic	O
plasmid	O
,	O
resulting	O
in	O
a	O
reporter	O
construct	O
in	O
which	O
luciferase	B-Protein
expression	O
is	O
driven	O
by	O
the	O
epsilony	B-Protein
promoter	O
.	O

A	O
series	O
of	O
deletion	O
constructs	O
of	O
the	O
epsilony	B-Protein
promoter	O
were	O
generated	O
similarly	O
.	O

Forward	O
primers	O
with	O
an	O
XhoI	O
site	O
include	O
:	O
MHB1457	O
,	O
5	O
'	O
CCGCTCGAGTGCTAGGCAAACACTCA3	O
'	O
(	O
-	O
2077	O
to	O
-	O
2052	O
)	O
;	O
MHB1503	O
,	O
5	O
'	O
CCGCTCGAGTCTCTACACTGTCACTCCCTG3	O
'	O
(	O
-	O
634	O
to	O
-	O
605	O
)	O
;	O
MHB1505	O
,	O
5	O
'	O
CCGCTCGAGGGAGCCAAAAAAAGAATGC3	O
'	O
(	O
-	O
197	O
to	O
-	O
169	O
)	O
;	O
MHB1506	O
,	O
5	O
'	O
CCGCTCGAGCTGACCAATGGCTTCAAAG3	O
'	O
(	O
-	O
85	O
to	O
-	O
58	O
)	O
;	O
MHB1532	O
,	O
5	O
'	O
CCGCTCGAGAATGCAGAACAAAGGGTCAGA3	O
'	O
(	O
-	O
63	O
to	O
-	O
34	O
)	O
;	O
and	O
MHB1507	O
,	O
5	O
'	O
CCGCTCGAGGTCTGCGAAGAATAAAAGGC	O
3	O
'	O
(	O
-	O
37	O
to	O
-	O
9	O
)	O
.	O

All	O
forward	O
primers	O
were	O
used	O
in	O
combination	O
with	O
the	O
reverse	O
primer	O
HindIII	O
site	O
:	O
MHB1477	O
,	O
5	O
'	O
CGGAAGCTTGGGAGGTTGCTGGTGA3	O
'	O
(	O
+	O
45	O
to	O
+	O
20	O
)	O
.	O

Sox6	B-Protein
-	O
pcDNA3	O
.	O
1	O
[	O
15	O
]	O
was	O
used	O
to	O
overexpress	O
Sox6	B-Protein
.	O

A	O
truncated	O
version	O
of	O
the	O
Sox6	B-Protein
overexpression	O
construct	O
(	O
Sox6	B-Protein
-	O
deltaHMG	O
-	O
pcDNA3	O
.	O
1	O
)	O
that	O
lacks	O
the	O
HMG	O
domain	O
was	O
generated	O
,	O
as	O
described	O
by	O
others	O
[	O
32	O
]	O
.	O

Mutagenesis	O
of	O
Sox	O
/	O
Sox6	O
consensus	O
binding	O
sites	O
of	O
the	O
epsilony	B-Protein
promoter	O
were	O
done	O
by	O
PCR	O
.	O

Forward	O
primers	O
used	O
to	O
generate	O
these	O
mutagenized	O
epsilony	O
promoter	O
reporter	O
constructs	O
include	O
:	O
MHB1661	O
,	O
5	O
'	O
CCGCTCGAGAATGCAGTGCCAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
-	O
63	O
to	O
-	O
19	O
)	O
;	O
MHB1662	O
,	O
5	O
'	O
CCGCTCGAGAATGCAGAACAAAGGGTCAGATGAGTGTCTGCGAAGAA3	O
'	O
(	O
-	O
63	O
to	O
-	O
16	O
)	O
;	O
and	O
MHB1663	O
,	O
5	O
'	O
CCGCTCGAGAATGCATGCCAAGGGTCAGATGAGTGTCTGCGAAGAA	O
3	O
'	O
(	O
-	O
63	O
to	O
-	O
18	O
)	O
.	O

Quantitation	O
of	O
globin	O
mRNA	O
.	O

RNA	O
was	O
first	O
reverse	O
transcribed	O
to	O
cDNA	O
.	O

Primers	O
for	O
cDNA	O
PCR	O
amplification	O
of	O
globin	O
genes	O
were	O
obtained	O
from	O
Primerbank	O
[	O
51	O
]	O
.	O

All	O
primers	O
were	O
searched	O
against	O
the	O
NCBI	O
database	O
to	O
confirm	O
specificity	O
.	O

For	O
epsilony	B-Protein
globin	I-Protein
:	O
MHB1666	O
,	O
5	O
'	O
TGGCCTGTGGAGTAAGGTCAA3	O
'	O
;	O
and	O
MHB1667	O
,	O
5	O
'	O
GAAGCAGAGGACAAGTTCCCA3	O
'	O
.	O

For	O
zeta	B-Protein
globin	I-Protein
:	O
MHB1668	O
,	O
5	O
'	O
CTACCCCCAGACGAAGACCTA3	O
'	O
;	O
and	O
MHB1669	O
,	O
5	O
'	O
CTTAACCGCATCCCCTACGG3	O
'	O
.	O

For	O
betaH1	B-Protein
globin	I-Protein
:	O
MHB1672	O
,	O
5	O
'	O
TGGACAACCTCAAGGAGACC3	O
'	O
;	O
and	O
MHB1673	O
,	O
5	O
'	O
ACCTCTGGGGTGAATTCCTT3	O
'	O
.	O

For	O
betamaj	B-Protein
/	O
min	B-Protein
globin	I-Protein
:	O
MHB1674	O
:	O
5	O
'	O
ATGGCCTGAATCACTTGGAC3	O
'	O
;	O
and	O
MHB1675	O
,	O
5	O
'	O
ACGATCATATTGCCCAGGAG3	O
'	O
.	O

Using	O
the	O
SYBR	O
green	O
supermix	O
kit	O
with	O
ROX	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
PCR	O
amplification	O
was	O
run	O
on	O
an	O
ABI7000	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
the	O
University	O
of	O
Arizona	O
core	O
facility	O
.	O

All	O
PCR	O
was	O
performed	O
in	O
a	O
25	O
-	O
mul	O
reaction	O
with	O
12	O
.	O
5	O
mul	O
SYBR	O
green	O
supermix	O
.	O

GAPDH	B-Protein
mRNA	O
levels	O
were	O
used	O
as	O
control	O
for	O
input	O
RNA	O
.	O

Standard	O
curve	O
analyses	O
were	O
performed	O
to	O
test	O
the	O
efficiency	O
of	O
the	O
amplifications	O
.	O

Triplicates	O
were	O
done	O
for	O
each	O
PCR	O
reaction	O
.	O

Relative	O
quantitative	O
values	O
were	O
calculated	O
in	O
the	O
ABI	O
Prism	O
7000	O
SDS	O
Software	O
(	O
Applied	O
Biosystems	O
)	O
and	O
normalized	O
to	O
GAPDH	B-Protein
in	O
Microsoft	O
Excel	O
(	O
Redmond	O
,	O
Washington	O
,	O
United	O
States	O
)	O
.	O

In	O
situ	O
hybridization	O
.	O

Antisense	O
probes	O
were	O
designed	O
to	O
murine	O
epsilony	B-Protein
globin	I-Protein
nucleotides	O
509	O
-	O
584	O
;	O
betamaj	B-Protein
globin	I-Protein
nucleotides	O
458	O
-	O
549	O
;	O
and	O
mouse	O
Sox6	B-Protein
nucleotides	O
1353	O
-	O
1927	O
.	O

Embryos	O
were	O
fixed	O
overnight	O
by	O
immersion	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
embedded	O
in	O
paraffin	O
,	O
sectioned	O
at	O
5	O
mum	O
,	O
and	O
adhered	O
to	O
charge	O
modified	O
slides	O
(	O
VWR	O
,	O
West	O
Chester	O
,	O
Pennsylvania	O
,	O
United	O
States	O
)	O
.	O

Slides	O
were	O
processed	O
for	O
in	O
situ	O
hybridization	O
as	O
described	O
[	O
52	O
]	O
using	O
in	O
vitro	O
transcribed	O
RNA	O
probes	O
labeled	O
with	O
33P	O
.	O

Darkfield	O
and	O
brightfield	O
images	O
were	O
obtained	O
with	O
a	O
Nikon	O
Optiphot	O
microscope	O
(	O
Nikon	O
,	O
Melville	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
and	O
SPOT	O
RT	O
-	O
Slider	O
digital	O
camera	O
(	O
Diagnostic	O
Instruments	O
,	O
Sterling	O
Heights	O
,	O
Michigan	O
,	O
United	O
States	O
)	O
.	O

Objectives	O
used	O
were	O
1x	O
(	O
NA	O
=	O
0	O
.	O
04	O
)	O
and	O
10x	O
(	O
NA	O
=	O
0	O
.	O
5	O
)	O
.	O

Images	O
were	O
processed	O
,	O
pseudocolored	O
,	O
and	O
combined	O
using	O
Photoshop	O
(	O
Adobe	O
,	O
San	O
Jose	O
,	O
California	O
,	O
United	O
States	O
)	O
software	O
with	O
Fovea	O
Pro	O
(	O
Reindeer	O
Graphics	O
,	O
Asheville	O
,	O
North	O
Carolina	O
,	O
United	O
States	O
)	O
plugins	O
.	O

Original	O
images	O
are	O
available	O
.	O

Histology	O
.	O

18	O
.	O
5	O
-	O
dpc	O
embryos	O
were	O
exsanguinated	O
and	O
peripheral	O
blood	O
smears	O
were	O
prepared	O
from	O
both	O
mutant	O
and	O
WT	O
mice	O
.	O

The	O
slides	O
were	O
Wright	O
-	O
stained	O
and	O
read	O
by	O
DAF	O
.	O

For	O
whole	O
mount	O
analysis	O
,	O
14	O
.	O
5	O
-	O
dpc	O
WT	O
and	O
mutant	O
embryos	O
,	O
and	O
postnatal	O
day	O
-	O
10	O
.	O
5	O
mice	O
were	O
fixed	O
in	O
10	O
%	O
formalin	O
,	O
paraffin	O
-	O
embedded	O
,	O
sectioned	O
at	O
5	O
mum	O
,	O
and	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
.	O

Liver	O
samples	O
(	O
at	O
14	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
)	O
were	O
prepared	O
in	O
a	O
similar	O
manner	O
.	O

Images	O
were	O
obtained	O
with	O
Nikon	O
Labophot	O
-	O
2	O
microscope	O
.	O

Objectives	O
used	O
were	O
E	O
Plan	O
40	O
/	O
0	O
.	O
65	O
160	O
/	O
0	O
.	O
17	O
Nikon	O
(	O
40x	O
objective	O
)	O
,	O
E	O
Plan	O
100	O
/	O
1	O
.	O
25	O
oil	O
160	O
/	O
0	O
.	O
17	O
Nikon	O
(	O
100x	O
objective	O
)	O
.	O

The	O
camera	O
was	O
a	O
Nikon	O
Coolpix	O
4300	O
.	O

Original	O
images	O
are	O
available	O
.	O

Northern	O
blot	O
.	O

A	O
mouse	O
embryonic	O
tissue	O
Northern	O
blot	O
filter	O
(	O
Seegene	O
,	O
Rockville	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
was	O
hybridized	O
with	O
a	O
Sox6	B-Protein
probe	O
generated	O
by	O
RT	O
-	O
PCR	O
(	O
nucleotides	O
1353	O
-	O
1927	O
)	O
and	O
labeled	O
with	O
[	O
alpha	O
-	O
32P	O
]	O
dCTP	O
,	O
by	O
random	O
primer	O
labeling	O
(	O
RediprimeII	O
;	O
Amersham	O
Biosciences	O
,	O
Buckinghamshire	O
,	O
England	O
,	O
United	O
Kingdom	O
)	O
.	O

The	O
hybridization	O
was	O
performed	O
in	O
phosphate	O
buffered	O
7	O
%	O
SDS	O
hybridization	O
solution	O
.	O

Blots	O
were	O
washed	O
with	O
0	O
.	O
2x	O
SSC	O
,	O
1	O
%	O
SDS	O
at	O
60	O
degreesC	O
prior	O
to	O
exposure	O
to	O
X	O
-	O
ray	O
film	O
(	O
Kodak	O
,	O
Rochester	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
at	O
-	O
80	O
degreesC	O
for	O
6	O
d	O
.	O

Cell	O
culture	O
and	O
transfection	O
.	O

GM979	O
cells	O
(	O
Coriell	O
Cell	O
Repositories	O
,	O
Camden	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
were	O
cultured	O
in	O
Ham	O
'	O
s	O
F12	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
Ivitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
penicillin	O
(	O
100	O
units	O
/	O
ml	O
)	O
,	O
streptomycin	O
100	O
mug	O
/	O
ml	O
)	O
,	O
and	O
L	O
-	O
glutamine	O
(	O
2	O
mM	O
)	O
.	O

MEL	O
cells	O
were	O
cultured	O
in	O
DMEM	O
supplemented	O
as	O
above	O
(	O
without	O
heat	O
inactivating	O
the	O
serum	O
)	O
.	O

GM979	O
cells	O
(	O
4	O
x	O
105	O
)	O
in	O
log	O
phase	O
of	O
growth	O
were	O
transfected	O
with	O
plasmids	O
by	O
FuGENE6	O
(	O
Roche	O
,	O
Indianapolis	O
,	O
Indiana	O
,	O
United	O
States	O
)	O
.	O

Cells	O
were	O
transfected	O
with	O
epsilony	B-Protein
promoter	O
reporter	O
constructs	O
(	O
500	O
ng	O
)	O
along	O
with	O
either	O
empty	O
vector	O
or	O
Sox6	B-Protein
overexpression	O
vector	O
(	O
1000	O
ng	O
)	O
.	O

In	O
assays	O
of	O
dosage	O
effect	O
,	O
we	O
used	O
200	O
ng	O
,	O
500	O
ng	O
,	O
and	O
1000	O
ng	O
)	O
.	O

pRL	O
-	O
CMV	O
15ng	O
(	O
Promega	O
)	O
was	O
used	O
as	O
a	O
control	O
for	O
transfection	O
efficiency	O
.	O

Nuclear	O
protein	O
extract	O
and	O
in	O
vitro	O
translation	O
of	O
Sox6	B-Protein
.	O

Nuclear	O
extracts	O
were	O
prepared	O
from	O
MEL	O
cells	O
(	O
2	O
x	O
107	O
)	O
using	O
a	O
kit	O
(	O
Active	O
Motif	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

The	O
Sox6	B-Protein
in	O
vitro	O
translation	O
expression	O
vector	O
,	O
tagged	O
with	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
HA	B-Protein
,	O
was	O
described	O
before	O
[	O
15	O
]	O
.	O

The	O
translation	O
was	O
performed	O
in	O
a	O
reticulocyte	O
lysate	O
based	O
in	O
vitro	O
translational	O
system	O
(	O
TNT	O
(	O
R	O
)	O
Quick	O
Coupled	O
Transcription	O
/	O
Translation	O
Systems	O
,	O
Promega	O
)	O
.	O

A	O
vector	O
without	O
the	O
Sox6	B-Protein
coding	O
sequence	O
was	O
also	O
translated	O
as	O
a	O
negative	O
control	O
.	O

Antibodies	O
.	O

Sox6	B-Protein
antibodies	O
used	O
in	O
this	O
study	O
were	O
either	O
kindly	O
provided	O
by	O
Dr	O
.	O
Enzo	O
Lalli	O
(	O
Universite	O
Louis	O
Pasteur	O
,	O
France	O
[	O
7	O
]	O
)	O
or	O
commercially	O
obtained	O
(	O
Catalog	O
No	O
.	O
sc	O
-	O
17332	O
X	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

All	O
Sox6	B-Protein
antibodies	O
generated	O
similar	O
results	O
.	O

c	B-Protein
-	I-Protein
Myc	I-Protein
antibody	O
was	O
purchased	O
from	O
Invitrogen	O
.	O

Normal	O
rabbit	O
IgG	O
antibody	O
was	O
obtained	O
from	O
Upstate	O
Biotechnology	O
(	O
Lake	O
Placid	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
.	O

EMSA	O
.	O

Single	O
-	O
stranded	O
complementary	O
oligonucleotides	O
were	O
annealed	O
and	O
end	O
-	O
labeled	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
with	O
T4	B-Protein
polynucleotide	I-Protein
kinase	I-Protein
.	O

EMSA	O
was	O
performed	O
with	O
5	O
mug	O
of	O
nuclear	O
proteins	O
from	O
MEL	O
cells	O
or	O
3	O
mul	O
of	O
in	O
vitro	O
-	O
translated	O
Sox6	B-Protein
along	O
with	O
the	O
reticulocyte	O
lysate	O
in	O
binding	O
buffer	O
:	O
100	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
200	O
ng	O
/	O
mul	O
BSA	B-Protein
,	O
50	O
ng	O
/	O
mul	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
or	O
poly	O
(	O
dG	O
-	O
dC	O
)	O
,	O
10	O
mM	O
HEPES	O
(	O
pH	O
7	O
)	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
25	O
mM	O
DTT	O
,	O
0	O
.	O
6	O
mM	O
MgCl2	O
.	O

For	O
competition	O
or	O
supershift	O
assays	O
,	O
the	O
indicated	O
unlabelled	O
oligonucleotide	O
competitor	O
(	O
200	O
-	O
fold	O
molar	O
excess	O
)	O
or	O
antibody	O
(	O
3	O
mul	O
)	O
was	O
added	O
30	O
min	O
to	O
60	O
min	O
prior	O
to	O
addition	O
of	O
radiolabeled	O
probe	O
.	O

Following	O
addition	O
of	O
the	O
radiolabeled	O
probe	O
,	O
the	O
samples	O
were	O
incubated	O
for	O
30	O
min	O
or	O
60	O
min	O
at	O
room	O
temperature	O
and	O
loaded	O
on	O
a	O
4	O
%	O
or	O
6	O
%	O
(	O
w	O
/	O
v	O
)	O
polyacrylamide	O
gel	O
.	O

Electrophoresis	O
was	O
performed	O
at	O
a	O
constant	O
19	O
mAmp	O
for	O
4	O
-	O
8	O
h	O
at	O
room	O
temperature	O
,	O
and	O
the	O
gels	O
were	O
dried	O
prior	O
to	O
autoradiography	O
.	O

Antibodies	O
used	O
for	O
supershift	O
analyses	O
included	O
c	B-Protein
-	I-Protein
Myc	I-Protein
,	O
HA	B-Protein
,	O
and	O
Sox6	B-Protein
antibodies	O
(	O
described	O
as	O
above	O
)	O
.	O

The	O
DNA	O
sequences	O
of	O
the	O
oligonucleotides	O
are	O
as	O
follows	O
(	O
only	O
forward	O
oligos	O
are	O
listed	O
)	O
:	O
For	O
the	O
36	O
-	O
bp	O
WT	O
probe	O
:	O
5	O
'	O
AATGCAGAACAAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
MHB1556	O
)	O
;	O
for	O
mutant	O
probe	O
1	O
(	O
M1	O
)	O
:	O
5	O
'	O
AACAAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
MHB1644	O
)	O
;	O
for	O
mutant	O
probe	O
2	O
(	O
M2	O
)	O
:	O
5	O
'	O
AATGCAGAACAAAGGGTCAGAtgagTGTCTGCGAAG3	O
'	O
(	O
MHB1648	O
)	O
;	O
for	O
mutant	O
probe	O
3	O
(	O
M3	O
)	O
:	O
5	O
'	O
AATGCAGtgccAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
MHB1650	O
)	O
.	O

ChIP	O
assay	O
.	O

As	O
described	O
by	O
Nouzova	O
[	O
53	O
]	O
,	O
in	O
brief	O
:	O
Cells	O
from	O
MEL	O
cells	O
(	O
4	O
x	O
107	O
)	O
or	O
fetal	O
liver	O
cells	O
from	O
three	O
15	O
.	O
5	O
-	O
dpc	O
WT	O
mice	O
were	O
treated	O
with	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
at	O
37	O
degreesC	O
,	O
rinsed	O
in	O
ice	O
-	O
cold	O
1x	O
Hanks	O
'	O
balanced	O
salt	O
solution	O
with	O
0	O
.	O
1	O
%	O
EDTA	O
containing	O
protease	O
inhibitors	O
,	O
collected	O
by	O
centrifugation	O
at	O
4	O
degreesC	O
,	O
resuspended	O
in	O
a	O
SDS	O
lysis	O
buffer	O
containing	O
protease	O
inhibitors	O
,	O
and	O
incubated	O
on	O
ice	O
for	O
10	O
min	O
.	O

DNA	O
-	O
protein	O
complexes	O
were	O
sonicated	O
to	O
200	O
and	O
600	O
bp	O
.	O

One	O
-	O
tenth	O
of	O
the	O
sample	O
was	O
set	O
aside	O
for	O
input	O
control	O
,	O
and	O
the	O
remaining	O
sample	O
was	O
precleared	O
with	O
protein	B-Protein
A	I-Protein
-	O
Sepharose	O
(	O
Amersham	O
Biosciences	O
,	O
Piscataway	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
.	O

Following	O
preclearing	O
,	O
the	O
samples	O
were	O
split	O
into	O
thirds	O
:	O
one	O
sample	O
treated	O
with	O
anti	O
-	O
Sox6	B-Protein
,	O
a	O
second	O
treated	O
with	O
normal	O
rabbit	O
IgG	O
,	O
and	O
the	O
third	O
sample	O
without	O
Ab	O
.	O

The	O
last	O
two	O
were	O
used	O
as	O
negative	O
controls	O
.	O

The	O
chromatin	O
-	O
antibody	O
complexes	O
were	O
eluted	O
,	O
and	O
the	O
DNA	O
protein	O
cross	O
-	O
links	O
were	O
reversed	O
with	O
5	O
M	O
NaCl	O
at	O
65	O
degreesC	O
for	O
4	O
h	O
.	O

Input	O
DNA	O
or	O
immunoprecipitated	O
DNA	O
was	O
used	O
as	O
a	O
template	O
in	O
the	O
PCR	O
reaction	O
.	O

PCR	O
amplification	O
of	O
the	O
epsilony	B-Protein
promoter	O
was	O
performed	O
and	O
yielded	O
a	O
172	O
-	O
bp	O
amplicon	O
,	O
corresponding	O
to	O
nucleotides	O
-	O
31	O
to	O
+	O
140	O
of	O
the	O
epsilony	B-Protein
promoter	O
(	O
primers	O
MHB1688	O
,	O
5	O
'	O
CGAAGAATAAAAGGCCACCA3	O
'	O
;	O
and	O
MHB1689	O
,	O
5	O
'	O
GCTTCACCACCAACCTCTTC3	O
'	O
)	O
.	O

PCR	O
was	O
performed	O
under	O
the	O
following	O
conditions	O
:	O
95	O
degreesC	O
for	O
15	O
min	O
followed	O
by	O
30	O
cycles	O
at	O
95	O
degreesC	O
for	O
30	O
s	O
,	O
60	O
degreesC	O
for	O
30	O
s	O
,	O
and	O
72	O
degreesC	O
for	O
45	O
s	O
,	O
ending	O
with	O
a	O
final	O
extension	O
at	O
72	O
degreesC	O
for	O
5	O
min	O
.	O

beta	O
-	O
(	O
1	O
-	O
>	O
3	O
)	O
-	O
D	O
-	O
glucan	O
modulates	O
DNA	O
binding	O
of	O
nuclear	O
factors	O
kappaB	O
,	O
AT	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
leading	O
to	O
an	O
anti	O
-	O
inflammatory	O
shift	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
ratio	O

Background	O

beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
represent	O
a	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
and	O
are	O
able	O
to	O
modify	O
biological	O
responses	O
.	O

Employing	O
a	O
comprehensive	O
methodological	O
approach	O
,	O
the	O
aim	O
of	O
our	O
in	O
vitro	O
study	O
was	O
to	O
elucidate	O
novel	O
molecular	O
and	O
cellular	O
mechanisms	O
of	O
human	O
peripheral	O
blood	O
immune	O
cells	O
mediated	O
by	O
a	O
fungal	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
,	O
i	O
.	O
e	O
.	O
glucan	O
phosphate	O
,	O
in	O
the	O
presence	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
toxic	B-Protein
shock	I-Protein
syndrome	I-Protein
toxin	I-Protein
1	I-Protein
(	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
.	O

Results	O

Despite	O
an	O
activation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappaB	O
,	O
NFinterleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
similar	O
to	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
we	O
observed	O
no	O
significant	O
production	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
or	O
interferon	B-Protein
gamma	I-Protein
induced	O
by	O
glucan	O
phosphate	O
.	O

Glucan	O
phosphate	O
-	O
treated	O
leukocytes	O
induced	O
a	O
substantial	O
amount	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
(	O
peak	O
at	O
18	O
h	O
:	O
5000	O
pg	O
/	O
ml	O
)	O
,	O
likely	O
due	O
to	O
binding	O
of	O
NFkappaB	O
to	O
a	O
consensus	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
.	O

An	O
increase	O
in	O
IL	B-Protein
-	I-Protein
1receptor	I-Protein
antagonist	I-Protein
(	O
RA	B-Protein
)	O
production	O
(	O
peak	O
at	O
24	O
h	O
:	O
12000	O
pg	O
/	O
ml	O
)	O
by	O
glucan	O
phosphate	O
-	O
treated	O
cells	O
positively	O
correlated	O
with	O
IL	B-Protein
-	I-Protein
8	I-Protein
levels	O
.	O

Glucan	O
phosphate	O
induced	O
significant	O
binding	O
to	O
a	O
known	O
NFIL	O
-	O
6	O
site	O
and	O
a	O
new	O
NFAT	O
site	O
within	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
which	O
was	O
confirmed	O
by	O
inhibition	O
experiments	O
.	O

When	O
applied	O
in	O
combination	O
with	O
either	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
at	O
the	O
same	O
time	O
points	O
,	O
we	O
detected	O
that	O
glucan	O
phosphate	O
elevated	O
the	O
LPS	O
-	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
DNA	O
binding	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
,	O
leading	O
to	O
a	O
synergistic	O
increase	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
.	O

Further	O
,	O
glucan	O
phosphate	O
modulated	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
inflammatory	O
response	O
via	O
reduction	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

As	O
a	O
consequence	O
,	O
glucan	O
phosphate	O
shifted	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
towards	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O
.	O

Subsequently	O
,	O
glucan	O
phosphate	O
decreased	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
-	O
dependent	O
production	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Conclusion	O

Thus	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
may	O
induce	O
beneficial	O
effects	O
in	O
the	O
presence	O
of	O
pro	O
-	O
inflammatory	O
responses	O
,	O
downstream	O
of	O
receptor	O
binding	O
and	O
signaling	O
by	O
switching	O
a	O
pro	O
-	O
to	O
an	O
anti	O
-	O
inflammatory	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
-	O
mediated	O
reaction	O
.	O

Our	O
results	O
also	O
offer	O
new	O
insights	O
into	O
the	O
complex	O
regulation	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
gene	O
,	O
which	O
can	O
be	O
modulated	O
by	O
a	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
.	O

beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
occur	O
as	O
a	O
principal	O
component	O
of	O
microbial	O
cell	O
walls	O
or	O
can	O
be	O
secreted	O
from	O
both	O
,	O
non	O
-	O
pathogenic	O
and	O
pathogenic	O
fungi	O
such	O
as	O
S	O
.	O
cerevisae	O
and	O
C	O
.	O
albicans	O
[	O
1	O
]	O
.	O

These	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
linked	O
glucose	O
polymers	O
are	O
characterized	O
as	O
a	O
fungal	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
(	O
PAMP	O
)	O
[	O
2	O
]	O
.	O

The	O
primary	O
cellular	O
recognition	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
is	O
mediated	O
by	O
several	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
receptors	O
on	O
phagocytes	O
[	O
3	O
,	O
4	O
]	O
and	O
other	O
cells	O
[	O
5	O
,	O
6	O
]	O
.	O

Human	O
as	O
well	O
as	O
murine	O
Dectin	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
demonstrated	O
to	O
be	O
the	O
major	O
pattern	O
recognition	O
receptor	O
(	O
PRR	O
)	O
for	O
intact	O
yeast	O
and	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
-	O
containing	O
particles	O
(	O
i	O
.	O
e	O
.	O
zymosan	O
)	O
on	O
monocytes	O
/	O
macrophages	O
as	O
well	O
as	O
neutrophils	O
and	O
on	O
primary	O
cells	O
[	O
7	O
-	O
11	O
]	O
.	O

In	O
the	O
murine	O
system	O
,	O
binding	O
of	O
zymosan	O
to	O
Dectin	B-Protein
-	I-Protein
1	I-Protein
resulted	O
in	O
production	O
of	O
TNFalpha	B-Protein
through	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
and	O
the	O
adaptor	O
protein	O
MyD88	B-Protein
[	O
12	O
]	O
.	O

Another	O
water	O
-	O
soluble	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
(	O
PGG	O
-	O
glucan	O
)	O
has	O
been	O
described	O
to	O
activate	O
NFkappaB	O
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
in	O
murine	O
cell	O
lines	O
[	O
13	O
,	O
14	O
]	O
.	O

Similarly	O
,	O
it	O
has	O
been	O
shown	O
that	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
activate	O
NFkappaB	O
in	O
a	O
human	O
monocyte	O
-	O
like	O
cell	O
line	O
[	O
15	O
]	O
and	O
in	O
human	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
,	O
in	O
the	O
latter	O
case	O
without	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNFalpha	B-Protein
)	O
[	O
16	O
]	O
.	O

One	O
study	O
proposed	O
that	O
the	O
production	O
of	O
the	O
anti	O
-	O
inflammatory	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
1	I-Protein
by	O
human	O
monocytes	O
may	O
be	O
a	O
potentially	O
protective	O
mechanism	O
induced	O
by	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
[	O
17	O
]	O
.	O

Three	O
other	O
investigations	O
have	O
reported	O
that	O
human	O
leukocytes	O
and	O
human	O
vascular	O
endothelial	O
cells	O
produce	O
IL	B-Protein
-	I-Protein
8	I-Protein
in	O
response	O
to	O
zymosan	O
[	O
18	O
]	O
or	O
a	O
water	O
-	O
soluble	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
[	O
6	O
,	O
19	O
]	O
.	O

In	O
addition	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
seem	O
to	O
be	O
able	O
to	O
modify	O
the	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
or	O
even	O
sepsis	O
.	O

In	O
a	O
murine	O
polymicrobial	O
sepsis	O
model	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
[	O
20	O
]	O
treatment	O
resulted	O
in	O
decreased	O
septic	O
morbidity	O
and	O
mortality	O
mediated	O
via	O
inhibition	O
of	O
NFkappaB	O
and	O
stimulation	O
of	O
the	O
phosphoinositide	O
-	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
[	O
21	O
,	O
22	O
]	O
.	O

These	O
and	O
other	O
animal	O
studies	O
[	O
23	O
,	O
24	O
]	O
as	O
well	O
as	O
a	O
clinical	O
trial	O
[	O
25	O
]	O
support	O
a	O
protective	O
role	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
in	O
certain	O
pro	O
-	O
inflammatory	O
conditions	O
.	O

The	O
mechanisms	O
underlying	O
these	O
beneficial	O
effects	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
are	O
only	O
partially	O
resolved	O
,	O
especially	O
in	O
humans	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
molecular	O
and	O
cellular	O
mechanisms	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
on	O
human	O
leukocytes	O
in	O
pro	O
-	O
inflammatory	O
conditions	O
with	O
special	O
emphasis	O
on	O
the	O
cytokine	O
profile	O
and	O
its	O
transcriptional	O
regulation	O
.	O

For	O
this	O
purpose	O
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
exposed	O
to	O
a	O
well	O
-	O
defined	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
,	O
i	O
.	O
e	O
.	O
glucan	O
phosphate	O
(	O
GP	O
)	O
[	O
20	O
,	O
26	O
]	O
,	O
alone	O
or	O
simultaneously	O
with	O
LPS	O
from	O
gram	O
-	O
negative	O
bacteria	O
or	O
the	O
superantigen	O
TSST	B-Protein
-	I-Protein
1	I-Protein
from	O
gram	O
-	O
positive	O
bacteria	O
over	O
48	O
h	O
.	O

Because	O
of	O
the	O
potential	O
effect	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
on	O
cytokine	O
production	O
[	O
12	O
,	O
16	O
-	O
19	O
]	O
,	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
were	O
measured	O
as	O
well	O
as	O
IFNgamma	B-Protein
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
TGFbeta1	B-Protein
.	O

Correspondingly	O
,	O
four	O
NFkappaB	O
sites	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
(	O
kappa	O
consensus	O
,	O
kappa1	O
,	O
kappa2	O
,	O
kappa3	O
)	O
[	O
27	O
]	O
,	O
a	O
kappa	O
consensus	O
site	O
from	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
[	O
28	O
]	O
,	O
an	O
NFAT	O
site	O
from	O
the	O
IFNgamma	B-Protein
promoter	O
(	O
ATP2	O
)	O
[	O
29	O
]	O
and	O
a	O
consensus	O
NFIL	O
-	O
6	O
site	O
from	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
[	O
13	O
]	O
were	O
examined	O
.	O

Because	O
of	O
the	O
anti	O
-	O
inflammatory	O
role	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
,	O
we	O
focused	O
on	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

An	O
inhibitory	O
element	O
and	O
three	O
positive	O
-	O
acting	O
LPS	O
-	O
response	O
elements	O
(	O
LRE	O
-	O
1	O
,	O
LRE	O
-	O
2	O
and	O
LRE	O
-	O
3	O
)	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
including	O
NFkappaB	O
,	O
PU	O
.	O
1	O
and	O
NFIL	O
-	O
6	O
sites	O
,	O
have	O
been	O
characterized	O
previously	O
[	O
30	O
-	O
33	O
]	O
.	O

Using	O
computational	O
analysis	O
for	O
homology	O
search	O
[	O
34	O
]	O
,	O
we	O
looked	O
for	O
new	O
binding	O
motifs	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Binding	O
activities	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
from	O
human	O
PBMC	O
to	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNgamma	B-Protein
promoters	O
following	O
an	O
in	O
vitro	O
stimulation	O
(	O
1	O
h	O
)	O
with	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein

GP	O
induced	O
band	O
shifts	O
,	O
indicating	O
binding	O
of	O
NFkappaB	O
as	O
well	O
as	O
of	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
to	O
the	O
corresponding	O
DNA	O
oligonucleotides	O
(	O
kappa	O
consensus	O
,	O
kappa1	O
,	O
kappa2	O
,	O
kappa3	O
sites	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
;	O
kappa	O
consensus	O
from	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
;	O
NFIL	O
-	O
6consensus	O
from	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
;	O
Table	O
1	O
;	O
Fig	O
.	O
1A	O
)	O
.	O

The	O
extent	O
of	O
the	O
band	O
shifts	O
induced	O
by	O
GP	O
was	O
not	O
statistically	O
different	O
when	O
compared	O
to	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
Fig	O
.	O
1B	O
)	O
.	O

A	O
supershift	O
,	O
conducted	O
for	O
an	O
NFkappaB	O
consensus	O
site	O
from	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
,	O
demonstrated	O
a	O
GP	O
-	O
induced	O
predominant	O
binding	O
of	O
NFkappaB	O
p65	B-Protein
and	O
to	O
a	O
lesser	O
degree	O
of	O
p50	B-Protein
(	O
Fig	O
.	O
1A	O
)	O
.	O

Accordingly	O
,	O
an	O
immunoblot	O
of	O
nuclear	O
extracts	O
from	O
GP	O
-	O
treated	O
PBMC	O
showed	O
a	O
strong	O
binding	O
of	O
NFkappaB	O
p65	B-Protein
and	O
a	O
weaker	O
reaction	O
of	O
p50	B-Protein
,	O
whereas	O
p52	B-Protein
was	O
negative	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Simultaneous	O
co	O
-	O
treatment	O
of	O
PBMC	O
with	O
GP	O
did	O
not	O
change	O
the	O
LPS	O
-	O
induced	O
NFkappaB	O
binding	O
to	O
oligos	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
significantly	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
but	O
substantially	O
decreased	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
NFkappaB	O
binding	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
(	O
100	O
mug	O
)	O
and	O
thus	O
differed	O
completely	O
from	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
n	O
=	O
4	O
;	O
p	O
<	O
0	O
.	O
05	O
vs	O
.	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
and	O
p	O
=	O
0	O
.	O
07	O
vs	O
.	O
TSST	B-Protein
-	I-Protein
1	I-Protein
;	O
Fig	O
.	O
1B	O
)	O
.	O

GP	O
was	O
also	O
able	O
to	O
induce	O
band	O
shifts	O
indicative	O
of	O
binding	O
of	O
particular	O
variants	O
of	O
NFAT	B-Protein
to	O
an	O
oligo	O
from	O
the	O
IFNgamma	B-Protein
promoter	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

An	O
immunoblot	O
for	O
two	O
NFAT	B-Protein
subunits	O
demonstrated	O
a	O
GP	O
-	O
induced	O
binding	O
of	O
NFATc2	B-Protein
and	O
to	O
a	O
lesser	O
degree	O
of	O
NFATc1	B-Protein
(	O
Fig	O
.	O
2	O
)	O
.	O

Cytokine	O
profile	O
of	O
human	O
PBMC	O
following	O
a	O
48	O
h	O
in	O
vitro	O
stimulation	O
with	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein

Because	O
of	O
the	O
GP	O
-	O
induced	O
band	O
shifts	O
to	O
seven	O
sites	O
from	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNgamma	B-Protein
promoters	O
,	O
it	O
could	O
be	O
assumed	O
that	O
GP	O
treatment	O
of	O
human	O
PBMC	O
would	O
lead	O
to	O
production	O
of	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IFNgamma	B-Protein
and	O
other	O
pro	O
-	O
inflammatory	O
mediators	O
.	O

Previous	O
studies	O
reported	O
that	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
induced	O
only	O
a	O
limited	O
cytokine	O
secretion	O
of	O
human	O
blood	O
cells	O
[	O
15	O
-	O
18	O
]	O
.	O

Corroborating	O
and	O
extending	O
these	O
singular	O
findings	O
in	O
terms	O
of	O
examining	O
pro	O
-	O
(	O
eight	O
)	O
as	O
well	O
as	O
anti	O
-	O
(	O
three	O
)	O
inflammatory	O
cytokines	O
over	O
time	O
(	O
48	O
h	O
)	O
and	O
six	O
additional	O
transcription	O
factor	O
binding	O
sites	O
,	O
our	O
comprehensive	O
analysis	O
revealed	O
the	O
following	O
cytokine	O
profile	O
of	O
human	O
leukocytes	O
in	O
response	O
to	O
a	O
highly	O
purified	O
water	O
soluble	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
and	O
in	O
comparison	O
to	O
two	O
pro	O
-	O
inflammatory	O
mediators	O
(	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
:	O

(	O
i	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein

There	O
was	O
no	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
detectable	O
following	O
PBMC	O
treatment	O
with	O
1	O
nor	O
100	O
mug	O
GP	O
.	O

An	O
insignificant	O
up	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
for	O
GP	O
+	O
LPS	O
was	O
observed	O
in	O
comparison	O
with	O
LPS	O
.	O

For	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
we	O
found	O
a	O
significant	O
reduction	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
from	O
18	O
h	O
-	O
24	O
h	O
,	O
for	O
the	O
latter	O
by	O
about	O
40	O
%	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
n	O
=	O
6	O
;	O
both	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

On	O
the	O
whole	O
,	O
GP	O
mediated	O
a	O
reduction	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
amount	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
by	O
about	O
50	O
%	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

(	O
ii	O
)	O
IL	B-Protein
-	I-Protein
6	I-Protein

GP	O
induced	O
only	O
a	O
small	O
amount	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
there	O
was	O
no	O
significant	O
alteration	O
of	O
the	O
LPS	O
-	O
induced	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
by	O
GP	O
.	O

On	O
the	O
contrary	O
,	O
we	O
observed	O
a	O
decreased	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
for	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
,	O
especially	O
at	O
24	O
h	O
by	O
about	O
40	O
%	O
(	O
n	O
=	O
5	O
;	O
both	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
(	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

(	O
iii	O
)	O
IL	B-Protein
-	I-Protein
8	I-Protein

We	O
found	O
that	O
GP	O
induced	O
a	O
substantial	O
IL	B-Protein
-	I-Protein
8	I-Protein
production	O
,	O
in	O
comparison	O
with	O
medium	O
control	O
,	O
especially	O
at	O
24	O
h	O
(	O
n	O
=	O
13	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
combination	O
of	O
GP	O
and	O
LPS	O
resulted	O
in	O
a	O
non	O
-	O
significant	O
increase	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
production	O
when	O
compared	O
to	O
LPS	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O

There	O
was	O
no	O
significant	O
alteration	O
in	O
IL	B-Protein
-	I-Protein
8	I-Protein
production	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

(	O
iv	O
)	O
IL	B-Protein
-	I-Protein
1RA	I-Protein

Besides	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
was	O
the	O
only	O
mediator	O
which	O
was	O
produced	O
in	O
significant	O
quantities	O
following	O
GP	O
treatment	O
,	O
especially	O
at	O
24	O
h	O
(	O
n	O
=	O
14	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

When	O
compared	O
to	O
LPS	O
stimulation	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O
,	O
GP	O
+	O
LPS	O
did	O
not	O
alter	O
the	O
kinetic	O
course	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
.	O

However	O
,	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
we	O
found	O
a	O
synergistic	O
increase	O
in	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
from	O
18	O
h	O
to	O
48	O
h	O
,	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
for	O
instance	O
at	O
24	O
h	O
:	O
n	O
=	O
6	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
or	O
to	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
from	O
18	O
h	O
to	O
36	O
h	O
)	O
.	O

Over	O
the	O
time	O
course	O
of	O
48	O
h	O
,	O
GP	O
elevated	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
amount	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
approximately	O
200	O
%	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Positive	O
correlation	O
between	O
GP	O
-	O
induced	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
productions	O
.	O

Following	O
stimulation	O
with	O
GP	O
(	O
24	O
h	O
)	O
,	O
we	O
observed	O
a	O
positive	O
correlation	O
between	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
.	O

Moreover	O
,	O
we	O
found	O
this	O
correlation	O
to	O
be	O
dose	O
-	O
dependent	O
,	O
since	O
100	O
mug	O
of	O
GP	O
induced	O
larger	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
than	O
1	O
mug	O
GP	O
(	O
n	O
=	O
5	O
,	O
p	O
<	O
=	O
0	O
.	O
002	O
,	O
r	O
=	O
0	O
.	O
9	O
and	O
0	O
.	O
98	O
,	O
respectively	O
)	O
.	O

(	O
v	O
)	O
TNFalpha	B-Protein

With	O
respect	O
to	O
TNFalpha	B-Protein
production	O
,	O
100	O
mug	O
of	O
GP	O
yielded	O
minor	O
,	O
statistically	O
not	O
distinguishable	O
amounts	O
,	O
when	O
compared	O
to	O
medium	O
control	O
.	O

GP	O
+	O
LPS	O
did	O
not	O
change	O
the	O
TNFalpha	B-Protein
production	O
when	O
compared	O
to	O
LPS	O
supplementation	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O

When	O
combined	O
with	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
,	O
GP	O
seemed	O
to	O
exert	O
a	O
synergistic	O
effect	O
on	O
TNFalpha	B-Protein
secretion	O
after	O
36	O
h	O
(	O
n	O
=	O
3	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
overall	O
an	O
enhancement	O
of	O
only	O
10	O
%	O
was	O
observed	O
(	O
p	O
>	O
0	O
.	O
05	O
;	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

(	O
vi	O
)	O
IFNgamma	B-Protein

No	O
IFNgamma	B-Protein
production	O
was	O
detectable	O
following	O
treatment	O
of	O
PBMC	O
with	O
100	O
mug	O
GP	O
.	O

There	O
was	O
a	O
minor	O
increase	O
in	O
IFNgamma	B-Protein
production	O
following	O
GP	O
+	O
LPS	O
at	O
36	O
h	O
,	O
when	O
compared	O
to	O
LPS	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O
,	O
and	O
a	O
slight	O
down	O
-	O
regulation	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
at	O
24	O
h	O
and	O
36	O
h	O
,	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
data	O
not	O
shown	O
)	O
.	O

(	O
vii	O
)	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
TGFbeta1	B-Protein

The	O
production	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
TGFbeta	B-Protein
1	I-Protein
was	O
not	O
induced	O
by	O
GP	O
.	O

There	O
were	O
also	O
no	O
significant	O
differences	O
between	O
medium	O
control	O
,	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
LPS	O
,	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
over	O
48	O
h	O
(	O
data	O
not	O
shown	O
)	O
.	O

Role	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
binding	O
in	O
LPS	O
-	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
,	O
GP	O
-	O
,	O
GP	O
+	O
LPS	O
-	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
expression	O
by	O
human	O
PBMC	O

Because	O
GP	O
induced	O
band	O
shifts	O
to	O
NFkappaB	O
,	O
NFIL	O
-	O
6	O
and	O
NFAT	O
sites	O
,	O
but	O
no	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
or	O
IFNgamma	B-Protein
,	O
we	O
hypothesized	O
that	O
the	O
activated	O
transcription	O
factors	O
might	O
bind	O
to	O
sites	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

We	O
investigated	O
previoulsy	O
described	O
and	O
newly	O
discovered	O
transcription	O
factor	O
binding	O
sites	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
(	O
Table	O
1	O
)	O
using	O
the	O
program	O
OMIGA	O
(	O
v	O
.	O
1	O
.	O
1	O
.	O
3	O
,	O
Oxford	O
Molecular	O
,	O
Oxford	O
,	O
UK	O
)	O
.	O

The	O
LPS	O
responsive	O
kappaB	O
consensus	O
site	O
of	O
LRE	O
-	O
1	O
(	O
between	O
-	O
84	O
and	O
-	O
93	O
)	O
[	O
30	O
]	O
displayed	O
band	O
shifts	O
,	O
but	O
no	O
significant	O
alterations	O
of	O
its	O
binding	O
activity	O
,	O
irrespective	O
of	O
the	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

A	O
new	O
kappaB3	O
site	O
(	O
-	O
100	O
and	O
-	O
130	O
)	O
within	O
the	O
LRE	O
-	O
1	O
[	O
30	O
]	O
showed	O
increased	O
binding	O
induced	O
by	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
+	O
30	O
%	O
vs	O
.	O
control	O
)	O
,	O
but	O
GP	O
co	O
-	O
treatment	O
up	O
-	O
regulated	O
the	O
LPS	O
(	O
+	O
65	O
%	O
vs	O
.	O
control	O
)	O
-	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
+	O
110	O
%	O
vs	O
.	O
control	O
)	O
-	O
induced	O
binding	O
in	O
a	O
superadditive	O
synergistic	O
fashion	O
,	O
when	O
compared	O
to	O
medium	O
control	O
as	O
well	O
as	O
to	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
or	O
the	O
theoretical	O
values	O
of	O
GP	O
/	O
LPS	O
calc	O
.	O
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
all	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
4	O
)	O
.	O

Binding	O
to	O
a	O
new	O
kappaB	O
consensus	O
site	O
(	O
between	O
-	O
266	O
and	O
-	O
280	O
)	O
was	O
significantly	O
elevated	O
for	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
p	O
<	O
0	O
.	O
05	O
;	O
data	O
not	O
shown	O
)	O
.	O

The	O
LPS	O
-	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
and	O
GP	O
+	O
LPS	O
-	O
induced	O
binding	O
to	O
the	O
new	O
kappaB2	O
/	O
3	O
site	O
(	O
-	O
288	O
and	O
-	O
302	O
)	O
was	O
down	O
-	O
regulated	O
by	O
about	O
20	O
-	O
35	O
%	O
in	O
comparison	O
with	O
medium	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
data	O
not	O
shown	O
)	O
.	O

The	O
NFIL	O
-	O
6	O
site	O
(	O
-	O
147	O
and	O
-	O
170	O
)	O
close	O
to	O
LRE	O
-	O
2	O
[	O
31	O
,	O
32	O
]	O
showed	O
an	O
up	O
-	O
regulation	O
of	O
binding	O
for	O
all	O
compounds	O
and	O
combinations	O
vs	O
.	O
medium	O
control	O
,	O
ranging	O
from	O
25	O
-	O
110	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Further	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
induced	O
an	O
increased	O
binding	O
to	O
the	O
NFIL	O
-	O
6	O
site	O
in	O
comparison	O
with	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
1	O
.	O
3fold	O
)	O
or	O
GP	O
(	O
1	O
.	O
6fold	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
(	O
data	O
not	O
shown	O
)	O
.	O

A	O
new	O
binding	O
site	O
for	O
NFATP2	O
/	O
3	O
was	O
found	O
more	O
distal	O
of	O
the	O
transcription	O
start	O
site	O
,	O
between	O
-	O
471	O
and	O
-	O
490	O
,	O
displaying	O
again	O
a	O
substantial	O
increase	O
of	O
binding	O
for	O
all	O
compounds	O
and	O
combinations	O
,	O
when	O
compared	O
to	O
medium	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
binding	O
to	O
the	O
NFATP2	O
/	O
3	O
site	O
following	O
both	O
,	O
GP	O
+	O
LPS	O
(	O
1	O
.	O
4fold	O
of	O
GP	O
)	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
1	O
.	O
5fold	O
of	O
GP	O
,	O
1	O
.	O
25fold	O
of	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
was	O
elevated	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
5	O
)	O
,	O
but	O
only	O
in	O
an	O
additive	O
synergistic	O
manner	O
,	O
i	O
.	O
e	O
.	O
the	O
experimental	O
results	O
were	O
not	O
different	O
from	O
the	O
theoretical	O
values	O
(	O
calc	O
.	O
)	O
.	O

GP	O
modulated	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
towards	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O

In	O
a	O
simplified	O
approach	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
might	O
represent	O
two	O
sides	O
of	O
a	O
coin	O
,	O
i	O
.	O
e	O
.	O
pro	O
-	O
or	O
anti	O
-	O
inflammatory	O
action	O
.	O

Therefore	O
,	O
we	O
applied	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
as	O
an	O
indicator	O
of	O
the	O
degree	O
of	O
inflammation	O
.	O

Both	O
,	O
LPS	O
and	O
GP	O
+	O
LPS	O
treatments	O
resulted	O
in	O
generating	O
more	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
than	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
at	O
early	O
time	O
points	O
,	O
i	O
.	O
e	O
.	O
up	O
to	O
24	O
h	O
.	O

Comparing	O
LPS	O
vs	O
.	O
GP	O
+	O
LPS	O
,	O
we	O
did	O
not	O
find	O
substantial	O
alterations	O
over	O
a	O
time	O
course	O
of	O
48	O
h	O
in	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
,	O
only	O
a	O
-	O
non	O
-	O
significant	O
-	O
2	O
.	O
5fold	O
higher	O
ratio	O
at	O
6	O
h	O
.	O

With	O
respect	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

vs	O
.	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
we	O
observed	O
a	O
pronounced	O
anti	O
-	O
inflammatory	O
action	O
of	O
GP	O
,	O
as	O
demonstrated	O
by	O
an	O
about	O
10	O
-	O
100	O
fold	O
reduced	O
ratio	O
at	O
18	O
h	O
and	O
24	O
h	O
of	O
incubation	O
,	O
i	O
.	O
e	O
.	O
a	O
higher	O
production	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
than	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
n	O
=	O
3	O
;	O
both	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
6	O
)	O
.	O

A	O
biological	O
relevance	O
of	O
this	O
result	O
was	O
suggested	O
by	O
a	O
decrease	O
of	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
dependent	O
release	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
from	O
murine	O
EL	O
-	O
4	O
cells	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
data	O
not	O
shown	O
in	O
detail	O
,	O
n	O
=	O
4	O
;	O
p	O
<	O
0	O
.	O
07	O
)	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
led	O
to	O
reduced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
levels	O

Pharmacological	O
inhibitors	O
were	O
used	O
to	O
demonstrate	O
that	O
the	O
transcription	O
factor	O
sites	O
within	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
are	O
relevant	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
GP	O
.	O

As	O
expected	O
,	O
an	O
inhibition	O
of	O
NFkappaB	O
via	O
CAPE	O
[	O
35	O
]	O
and	O
CyA	O
,	O
NFAT	B-Protein
via	O
CyA	O
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
via	O
CHX	O
[	O
36	O
]	O
could	O
not	O
be	O
overruled	O
by	O
GP	O
,	O
leading	O
to	O
a	O
down	O
-	O
regulated	O
binding	O
activity	O
of	O
the	O
transcription	O
factors	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
sites	O
,	O
and	O
a	O
reduction	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
protein	O
levels	O
(	O
Fig	O
.	O
7	O
)	O
.	O

The	O
extent	O
of	O
reduction	O
in	O
NFATP2	O
/	O
3	O
binding	O
is	O
exemplarily	O
shown	O
in	O
an	O
autoradiogram	O
(	O
Fig	O
.	O
7A	O
,	O
left	O
side	O
)	O
and	O
graphically	O
summarized	O
(	O
n	O
=	O
4	O
,	O
Fig	O
.	O
7A	O
,	O
right	O
side	O
)	O
.	O

The	O
results	O
for	O
the	O
NFkappaB	O
and	O
NFIL	O
-	O
6	O
binding	O
sites	O
were	O
similar	O
(	O
data	O
not	O
shown	O
)	O
.	O

Because	O
the	O
highest	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
amount	O
was	O
found	O
at	O
24	O
h	O
,	O
mRNA	O
was	O
examined	O
following	O
1	O
h	O
inhibition	O
and	O
18	O
h	O
of	O
GP	O
.	O

A	O
representative	O
gel	O
demonstrating	O
a	O
decrease	O
in	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
after	O
inhibition	O
with	O
CAPE	O
,	O
CyA	O
and	O
CHX	O
is	O
displayed	O
in	O
Fig	O
.	O

7B	O
(	O
n	O
=	O
4	O
)	O
.	O

In	O
addition	O
,	O
corresponding	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
protein	O
levels	O
after	O
24	O
h	O
of	O
GP	O
are	O
shown	O
in	O
Fig	O
.	O

7C	O
(	O
n	O
=	O
3	O
)	O
.	O

Altogether	O
,	O
NFkappaB	O
inhibition	O
by	O
CAPE	O
was	O
more	O
pronounced	O
at	O
the	O
binding	O
activity	O
and	O
the	O
transcription	O
,	O
whereas	O
CyA	O
and	O
CHX	O
mainly	O
led	O
to	O
a	O
decreased	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
release	O
.	O

Animal	O
models	O
of	O
sepsis	O
and	O
myocardial	O
injury	O
suggest	O
that	O
a	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
like	O
GP	O
mediates	O
its	O
protective	O
mechanisms	O
,	O
in	O
part	O
,	O
via	O
a	O
rapid	O
shift	O
from	O
NFkappaB	O
-	O
to	O
PI3K	O
-	O
signaling	O
[	O
22	O
,	O
37	O
]	O
.	O

Our	O
study	O
provides	O
novel	O
evidence	O
that	O
downstream	O
of	O
recognition	O
and	O
signaling	O
pro	O
-	O
inflammatory	O
transcription	O
factor	O
binding	O
and	O
cytokine	O
expression	O
of	O
human	O
leukocytes	O
is	O
switched	O
to	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O
by	O
GP	O
.	O

We	O
confirmed	O
and	O
extended	O
previous	O
results	O
[	O
13	O
-	O
16	O
]	O
indicating	O
that	O
,	O
in	O
the	O
absence	O
of	O
other	O
stimuli	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
induced	O
binding	O
of	O
NFkappaB	O
-	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
-	O
and	O
NFAT	B-Protein
-	O
mers	O
to	O
cytokine	O
promoters	O
.	O

Because	O
of	O
the	O
multiple	O
band	O
shifts	O
observed	O
for	O
NFAT	B-Protein
binding	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
one	O
could	O
speculate	O
that	O
there	O
is	O
activation	O
of	O
several	O
different	O
NFAT	B-Protein
isoforms	O
,	O
probably	O
derived	O
from	O
alternative	O
splicing	O
[	O
38	O
]	O
.	O

Interestingly	O
,	O
the	O
GP	O
-	O
induced	O
transcription	O
factor	O
binding	O
transformed	O
only	O
into	O
a	O
very	O
limited	O
cytokine	O
response	O
,	O
namely	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
(	O
Fig	O
.	O
3B	O
)	O
.	O

Hence	O
,	O
our	O
data	O
are	O
in	O
aggreement	O
with	O
the	O
few	O
reports	O
describing	O
a	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
8	I-Protein
[	O
6	O
,	O
16	O
,	O
19	O
]	O
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
[	O
17	O
]	O
.	O

In	O
addition	O
,	O
our	O
EMSA	O
/	O
supershift	O
and	O
immunoblotting	O
results	O
demonstrated	O
a	O
GP	O
-	O
mediated	O
predominant	O
binding	O
of	O
NFkappaB	O
p65	B-Protein
and	O
to	O
a	O
lesser	O
extent	O
of	O
p50	B-Protein
to	O
a	O
kappaB	O
consensus	O
site	O
of	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
(	O
Figs	O
.	O
1A	O
,	O
2	O
)	O
.	O

Results	O
by	O
Schulte	O
and	O
colleagues	O
[	O
28	O
]	O
pointed	O
to	O
an	O
induction	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
transcription	O
depending	O
on	O
activation	O
via	O
an	O
NFkappaB	O
p65	B-Protein
/	O
65	B-Protein
homodimer	O
,	O
rather	O
than	O
via	O
p65	B-Protein
/	O
50	B-Protein
heterodimers	O
,	O
which	O
might	O
be	O
the	O
case	O
for	O
the	O
GP	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
8	I-Protein
transcription	O
.	O

A	O
GP	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
8	I-Protein
transcription	O
based	O
upon	O
a	O
cooperation	O
between	O
transactivated	O
NFkappaB	O
p65	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
[	O
13	O
,	O
39	O
]	O
or	O
NFATc2	B-Protein
dimer	O
binding	O
to	O
the	O
IL	B-Protein
-	I-Protein
8kappaB	I-Protein
site	O
[	O
38	O
]	O
seems	O
also	O
possible	O
.	O

The	O
IL	B-Protein
-	I-Protein
8kappaB	I-Protein
consensus	O
site	O
exhibits	O
a	O
preferentially	O
p65	B-Protein
binding	O
half	O
site	O
and	O
thus	O
differs	O
from	O
the	O
kappaB	O
half	O
site	O
described	O
for	O
TNFalpha	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
[	O
27	O
,	O
40	O
]	O
,	O
supporting	O
the	O
idea	O
of	O
regulating	O
NFkappaB	O
binding	O
through	O
combinatorial	O
associations	O
of	O
the	O
subunits	O
and	O
the	O
specific	O
sequence	O
of	O
the	O
decameric	O
kappaB	O
motif	O
[	O
41	O
,	O
42	O
]	O
.	O

Unlike	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
we	O
found	O
that	O
GP	O
did	O
not	O
induce	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
but	O
it	O
strongly	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
,	O
suggesting	O
an	O
immediate	O
anti	O
-	O
inflammatory	O
potential	O
of	O
GP	O
.	O

Analysing	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
[	O
34	O
]	O
,	O
we	O
discovered	O
four	O
new	O
binding	O
sites	O
(	O
Fig	O
.	O
8	O
)	O
:	O
an	O
NFkappaB3	O
site	O
(	O
between	O
-	O
100	O
and	O
-	O
130	O
)	O
,	O
an	O
NFkappaB	O
consensus	O
site	O
(	O
-	O
266	O
and	O
-	O
280	O
)	O
,	O
another	O
NFkappaB2	O
/	O
3	O
site	O
(	O
-	O
288	O
and	O
-	O
302	O
)	O
and	O
a	O
more	O
distal	O
NFATP2	O
/	O
3	O
site	O
(	O
-	O
471	O
and	O
-	O
490	O
)	O
.	O

Our	O
data	O
indicated	O
that	O
GP	O
leads	O
to	O
production	O
of	O
IL	O
-	O
1RA	O
primarily	O
via	O
induction	O
of	O
NFATP2	B-Protein
/	O
3	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
DNA	O
binding	O
,	O
which	O
might	O
be	O
due	O
to	O
differences	O
in	O
the	O
binding	O
motif	O
or	O
the	O
composition	O
of	O
the	O
activated	O
transcription	O
factors	O
(	O
NFAT	B-Protein
)	O
between	O
the	O
IFNgamma	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

The	O
differential	O
decrease	O
of	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
binding	O
to	O
sites	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
as	O
well	O
as	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
and	O
protein	O
induced	O
by	O
selective	O
inhibitors	O
prior	O
to	O
GP	O
treatment	O
might	O
suggest	O
that	O
these	O
steps	O
are	O
linked	O
to	O
each	O
other	O
and	O
necessary	O
for	O
induction	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
(	O
Fig	O
.	O
7	O
)	O
.	O

Regarding	O
cellular	O
sources	O
,	O
both	O
,	O
monocytes	O
as	O
well	O
as	O
neutrophils	O
have	O
been	O
reported	O
to	O
produce	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
[	O
32	O
]	O
.	O

Flow	O
cytometric	O
experiments	O
seemed	O
to	O
confirm	O
that	O
monocytes	O
and	O
neutrophils	O
were	O
able	O
to	O
produce	O
IL	B-Protein
-	I-Protein
8	I-Protein
just	O
as	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
in	O
response	O
to	O
GP	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
GP	O
-	O
induced	O
cytokine	O
profile	O
was	O
substantially	O
more	O
restricted	O
than	O
that	O
of	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
which	O
is	O
likely	O
due	O
to	O
differences	O
in	O
recognition	O
and	O
signaling	O
between	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
.	O

Recognition	O
of	O
LPS	O
is	O
mainly	O
mediated	O
through	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
and	O
subsequent	O
signaling	O
via	O
the	O
NFkappaB	O
pathway	O
,	O
leading	O
to	O
expression	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
like	O
TNFalpha	B-Protein
[	O
43	O
]	O
.	O

A	O
bacterial	O
superantigen	O
like	O
TSST	B-Protein
-	I-Protein
1	I-Protein
acts	O
through	O
binding	O
to	O
MHC	O
-	O
II	O
molecules	O
and	O
subsequently	O
the	O
T	O
cell	O
receptor	O
,	O
leading	O
to	O
release	O
of	O
mainly	O
IFNgamma	B-Protein
and	O
TNFalpha	B-Protein
,	O
the	O
latter	O
via	O
both	O
,	O
PI3K	O
and	O
p38	B-Protein
mitogen	I-Protein
-	I-Protein
activated	I-Protein
kinase	I-Protein
signaling	O
[	O
44	O
,	O
45	O
]	O
.	O

Altogether	O
,	O
the	O
induction	O
of	O
the	O
neutrophil	O
-	O
attracting	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
the	O
anti	O
-	O
inflammatory	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
fungal	O
carbohydrates	O
(	O
GP	O
)	O
may	O
well	O
fit	O
to	O
a	O
benign	O
PAMP	O
response	O
,	O
mounting	O
defensive	O
mechanisms	O
against	O
a	O
possible	O
microbial	O
attack	O
.	O

Potentially	O
even	O
more	O
relevant	O
than	O
the	O
specific	O
cytokine	O
panel	O
induced	O
by	O
GP	O
,	O
we	O
found	O
that	O
,	O
in	O
the	O
presence	O
of	O
other	O
stimuli	O
(	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
GP	O
ameliorated	O
their	O
pro	O
-	O
inflammatory	O
immune	O
reactions	O
,	O
similar	O
to	O
the	O
effects	O
in	O
murine	O
models	O
of	O
sepsis	O
and	O
inflammation	O
[	O
21	O
-	O
24	O
]	O
.	O

Mainly	O
,	O
GP	O
altered	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
from	O
a	O
pro	O
-	O
to	O
an	O
anti	O
-	O
inflammatory	O
profile	O
via	O
down	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
at	O
the	O
same	O
time	O
there	O
was	O
a	O
synergistic	O
up	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
.	O

In	O
part	O
,	O
this	O
change	O
may	O
be	O
caused	O
by	O
GP	O
-	O
mediated	O
modulations	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
induced	O
binding	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
to	O
known	O
and	O
up	O
to	O
now	O
unknown	O
sites	O
within	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
instead	O
of	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
or	O
IFNgamma	B-Protein
promoter	O
.	O

Accordingly	O
,	O
we	O
found	O
that	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
of	O
NFkappaB	O
to	O
sites	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
negatively	O
correlated	O
with	O
the	O
GP	O
-	O
mediated	O
enhancement	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
(	O
r	O
=	O
-	O
0	O
.	O
88	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

Of	O
the	O
four	O
examined	O
NFkappaB	O
sites	O
from	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
mostly	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
and	O
LPS	O
-	O
induced	O
binding	O
to	O
the	O
NFkappaB3	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
to	O
the	O
new	O
NFkappaB	O
consensus	O
site	O
seemed	O
to	O
be	O
increased	O
by	O
GP	O
.	O

So	O
,	O
while	O
we	O
observed	O
a	O
GP	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
the	O
LPS	O
-	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
NFkappaB	O
binding	O
to	O
sites	O
of	O
the	O
TNFalpha	B-Protein
promoter	O
,	O
there	O
was	O
an	O
up	O
-	O
regulation	O
to	O
NFkappaB3	O
and	O
NFkappaB	O
consensus	O
sites	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

These	O
seemingly	O
contradictory	O
data	O
could	O
be	O
explained	O
by	O
differences	O
in	O
either	O
NFkappaB	O
subunits	O
or	O
conserved	O
nucleotides	O
(	O
#	O
1	O
,	O
2	O
,	O
3	O
,	O
10	O
)	O
within	O
the	O
decameric	O
NFkappaB	O
binding	O
motif	O
between	O
the	O
TNFalpha	B-Protein
and	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
(	O
for	O
NFkappaB3	O
the	O
IL	O
-	O
1RA	O
motif	O
contains	O
a	O
T	O
on	O
position	O
10	O
instead	O
of	O
the	O
conserved	O
C	O
in	O
the	O
TNFalpha	O
motif	O
,	O
see	O
Table	O
1	O
)	O
,	O
probably	O
leading	O
to	O
differences	O
in	O
binding	O
[	O
41	O
,	O
42	O
]	O
.	O

Despite	O
the	O
location	O
of	O
the	O
new	O
NFkappaB	O
consensus	O
site	O
(	O
-	O
266	O
and	O
-	O
280	O
)	O
in	O
the	O
inhibitory	O
element	O
(	O
-	O
250	O
and	O
-	O
294	O
)	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
[	O
30	O
]	O
,	O
we	O
observed	O
no	O
inhibition	O
.	O

On	O
the	O
other	O
side	O
,	O
we	O
found	O
an	O
inhibitory	O
NFkappaB2	O
/	O
3	O
site	O
(	O
-	O
288	O
and	O
-	O
302	O
)	O
towards	O
the	O
end	O
of	O
the	O
inhibitory	O
element	O
,	O
demonstrating	O
down	O
-	O
regulations	O
of	O
the	O
LPS	O
-	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
,	O
which	O
could	O
not	O
be	O
altered	O
by	O
GP	O
.	O

In	O
our	O
opinion	O
,	O
this	O
site	O
may	O
therefore	O
represent	O
at	O
least	O
a	O
part	O
of	O
the	O
previoulsy	O
described	O
inhibitory	O
element	O
[	O
30	O
]	O
.	O

The	O
GP	O
-	O
modulated	O
increase	O
in	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
to	O
the	O
new	O
NFkappaB3	O
and	O
NFkappaB	O
consensus	O
site	O
,	O
the	O
NFIL	O
-	O
6	O
site	O
[	O
32	O
]	O
as	O
well	O
as	O
to	O
the	O
novel	O
NFATP2	O
/	O
3	O
site	O
may	O
explain	O
the	O
synergistic	O
up	O
-	O
regulation	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
.	O

We	O
think	O
that	O
this	O
GP	O
-	O
modulated	O
activation	O
of	O
transcription	O
was	O
reflected	O
by	O
the	O
decrease	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
Fig	O
.	O
6	O
)	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
postulated	O
that	O
in	O
vitro	O
a	O
100fold	O
excess	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
over	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
might	O
control	O
the	O
biological	O
effects	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
[	O
46	O
,	O
47	O
]	O
.	O

Since	O
,	O
in	O
fact	O
,	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
is	O
partially	O
less	O
than	O
0	O
.	O
01	O
,	O
it	O
is	O
not	O
unreasonable	O
to	O
assume	O
that	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
bioactivity	O
is	O
inactivated	O
in	O
our	O
system	O
.	O

Indeed	O
,	O
GP	O
reduced	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
-	O
dependent	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
of	O
murine	O
EL	O
-	O
4	O
cells	O
(	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

The	O
weaker	O
modulating	O
effects	O
of	O
GP	O
on	O
the	O
LPS	O
-	O
induced	O
immune	O
response	O
observed	O
in	O
this	O
study	O
,	O
may	O
be	O
attributed	O
to	O
delicately	O
balanced	O
differences	O
in	O
signaling	O
pathways	O
between	O
LPS	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
[	O
43	O
-	O
45	O
]	O
.	O

TSST	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
shown	O
to	O
use	O
the	O
PI3K	O
pathway	O
for	O
signaling	O
[	O
44	O
]	O
and	O
this	O
effect	O
may	O
be	O
sustained	O
by	O
GP	O
treatment	O
[	O
22	O
,	O
37	O
]	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
in	O
septic	O
/	O
LPS	O
-	O
adapted	O
leukocytes	O
the	O
PI3K	O
pathway	O
selectively	O
controls	O
sIL	B-Protein
-	I-Protein
1RA	I-Protein
but	O
not	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
[	O
48	O
]	O
.	O

Signaling	O
via	O
PI3K	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
activation	O
of	O
NFAT	B-Protein
in	O
T	O
cells	O
[	O
49	O
]	O
.	O

Activation	O
of	O
NFkappaB	O
can	O
also	O
take	O
place	O
via	O
PI3K	O
[	O
50	O
]	O
,	O
which	O
may	O
offer	O
an	O
explanation	O
for	O
a	O
difference	O
in	O
signaling	O
between	O
GP	O
(	O
PI3K	O
)	O
and	O
LPS	O
(	O
mitogen	O
-	O
activated	O
kinase	O
signaling	O
)	O
.	O

This	O
idea	O
may	O
be	O
supported	O
by	O
another	O
study	O
showing	O
that	O
despite	O
the	O
use	O
of	O
similar	O
PRR	O
,	O
LPS	O
and	O
peptidoglycan	O
activated	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
gene	O
through	O
different	O
mechanisms	O
/	O
DNA	O
-	O
binding	O
proteins	O
and	O
acted	O
synergistically	O
in	O
combination	O
,	O
suggestive	O
of	O
signals	O
which	O
are	O
not	O
equivalent	O
in	O
all	O
parts	O
[	O
51	O
]	O
.	O

In	O
summary	O
,	O
our	O
data	O
demonstrated	O
that	O
in	O
vitro	O
glucan	O
phosphate	O
induced	O
a	O
transcription	O
factor	O
binding	O
and	O
a	O
subsequent	O
cytokine	O
profile	O
different	O
from	O
LPS	O
and	O
also	O
from	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
,	O
moreover	O
,	O
switched	O
a	O
pro	O
-	O
inflammatory	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
response	O
to	O
an	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
-	O
mediated	O
anti	O
-	O
inflammatory	O
reaction	O
.	O

Our	O
results	O
also	O
generated	O
new	O
insights	O
into	O
a	O
very	O
complex	O
interplay	O
of	O
transcription	O
factor	O
binding	O
to	O
various	O
known	O
and	O
newly	O
identified	O
sites	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
(	O
Fig	O
.	O
8	O
)	O
,	O
which	O
can	O
be	O
regulated	O
differentially	O
by	O
a	O
fungal	O
carbohydrate	O
.	O

Together	O
with	O
the	O
in	O
vivo	O
studies	O
[	O
22	O
,	O
37	O
]	O
,	O
our	O
findings	O
might	O
support	O
the	O
concept	O
of	O
protective	O
effects	O
mediated	O
by	O
glucan	O
phosphate	O
in	O
pro	O
-	O
inflammatory	O
conditions	O
,	O
especially	O
with	O
a	O
dysregulated	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
[	O
52	O
,	O
53	O
]	O
.	O

Materials	O

Water	O
soluble	O
phosphorylated	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
(	O
GP	O
)	O
was	O
prepared	O
as	O
done	O
before	O
[	O
20	O
]	O
.	O

The	O
physicochemical	O
characteristics	O
of	O
GP	O
were	O
determined	O
as	O
reported	O
previously	O
[	O
20	O
,	O
26	O
]	O
.	O

GP	O
was	O
dissolved	O
in	O
aqueous	O
media	O
,	O
filter	O
-	O
sterilized	O
(	O
0	O
.	O
2	O
mum	O
)	O
and	O
screened	O
for	O
endotoxin	O
contamination	O
with	O
the	O
Endospecy	O
assay	O
(	O
Seigakaku	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
which	O
is	O
specific	O
for	O
endotoxin	O
but	O
does	O
not	O
respond	O
to	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
.	O

Isolation	O
of	O
human	O
PBMC	O

Buffy	O
coats	O
were	O
obtained	O
from	O
healthy	O
blood	O
donors	O
in	O
compliance	O
with	O
the	O
Helsinki	O
declaration	O
and	O
with	O
the	O
approval	O
of	O
the	O
ethics	O
committee	O
of	O
the	O
University	O
of	O
Luebeck	O
.	O

The	O
buffy	O
coats	O
were	O
separated	O
over	O
a	O
Ficoll	O
-	O
Hypaque	O
(	O
Biochrom	O
,	O
Berlin	O
,	O
Germany	O
)	O
gradient	O
[	O
54	O
,	O
55	O
]	O
.	O

Following	O
isolation	O
,	O
PBMC	O
were	O
cultured	O
at	O
a	O
final	O
concentration	O
of	O
3	O
x	O
106	O
cells	O
/	O
ml	O
(	O
for	O
ELISA	O
measurements	O
)	O
or	O
5	O
x	O
106	O
/	O
ml	O
(	O
for	O
gel	O
shifts	O
)	O
or	O
1	O
x	O
106	O
cells	O
/	O
ml	O
(	O
for	O
flow	O
cytometry	O
)	O
in	O
RPMI	O
1640	O
medium	O
(	O
BioWhittaker	O
,	O
Heidelberg	O
,	O
Germany	O
,	O
LPS	O
-	O
free	O
)	O
,	O
containing	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
(	O
FCS	O
,	O
low	O
-	O
LPS	O
,	O
Invitrogen	O
,	O
Karlsruhe	O
,	O
Germany	O
)	O
,	O
1	O
%	O
penicillin	O
(	O
10000	O
U	O
/	O
ml	O
)	O
,	O
1	O
%	O
streptomycin	O
(	O
10000	O
mug	O
/	O
ml	O
)	O
,	O
and	O
1	O
%	O
200	O
mM	O
L	O
-	O
glutamine	O
(	O
BioWhittaker	O
)	O
.	O

Stimulation	O
conditions	O

For	O
induction	O
of	O
transcription	O
factors	O
and	O
cytokines	O
,	O
PBMC	O
were	O
cultured	O
in	O
a	O
volume	O
of	O
4	O
ml	O
in	O
sterile	O
pyrogen	O
-	O
free	O
6	O
-	O
well	O
culture	O
plates	O
(	O
Falcon	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

Cultures	O
were	O
stimulated	O
for	O
1	O
h	O
(	O
EMSA	O
)	O
or	O
from	O
0	O
h	O
to	O
48	O
h	O
(	O
ELISA	O
)	O
with	O
1	O
or	O
100	O
mug	O
per	O
106	O
cells	O
of	O
GP	O
,	O
with	O
250	O
ng	O
/	O
106	O
cells	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
Toxin	O
Technologies	O
,	O
Sarasota	O
,	O
FL	O
,	O
USA	O
)	O
or	O
with	O
250	O
ng	O
/	O
106	O
cells	O
wild	O
-	O
type	O
LPS	O
from	O
Escherichia	O
coli	O
serotype	O
0111	O
:	O
B4	O
(	O
Sigma	O
,	O
Munich	O
,	O
Germany	O
)	O
.	O

In	O
costimulatory	O
experiments	O
,	O
PBMC	O
were	O
supplemented	O
simultaneously	O
with	O
a	O
combination	O
of	O
GP	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
with	O
a	O
combination	O
of	O
GP	O
and	O
LPS	O
.	O

Oligonucleotides	O
(	O
Oligos	O
)	O
and	O
5	O
'	O
-	O
32	O
-	O
P	O
-	O
Labeling	O

The	O
complementary	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
oligonucleotides	O
(	O
oligos	O
)	O
from	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IFNgamma	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoters	O
were	O
synthesised	O
from	O
single	O
stranded	O
(	O
ss	O
)	O
oligos	O
(	O
illustrated	O
in	O
Table	O
1	O
)	O
,	O
(	O
TIB	O
Molbiol	O
,	O
Berlin	O
,	O
Germany	O
)	O
and	O
32P	O
-	O
labeled	O
with	O
5	O
'	O
gamma	O
-	O
P	O
-	O
ATP	O
(	O
3	O
,	O
000	O
Ci	O
/	O
mmol	O
,	O
Amersham	O
,	O
Braunschweig	O
,	O
Germany	O
)	O
using	O
the	O
Ready	O
-	O
To	O
-	O
Go	O
-	O
Polynucleotide	O
-	O
Kinase	O
Kit	O
(	O
PNK	O
Kit	O
,	O
Pharmacia	O
LKB	O
,	O
Freiburg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

To	O
test	O
the	O
binding	O
specificity	O
of	O
the	O
oligos	O
,	O
mutated	O
oligos	O
were	O
used	O
as	O
an	O
additional	O
control	O
.	O

Mutations	O
in	O
the	O
P2	O
site	O
of	O
the	O
IFNgamma	B-Protein
promoter	O
[	O
29	O
]	O
and	O
in	O
the	O
kappa	O
consensus	O
sequence	O
of	O
the	O
TNFalpha	B-Protein
promoter	O
[	O
55	O
]	O
have	O
been	O
reported	O
to	O
interfere	O
with	O
sequences	O
,	O
which	O
seem	O
to	O
be	O
crucial	O
for	O
the	O
binding	O
of	O
NFAT	B-Protein
and	O
NFkappaB	O
proteins	O
,	O
respectively	O
.	O

Afterwards	O
,	O
the	O
ds	O
oligos	O
were	O
purified	O
via	O
gel	O
filtration	O
using	O
Probe	O
Quant	O
G	O
-	O
50	O
Micro	O
Columns	O
(	O
Pharmacia	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Preparation	O
of	O
nuclear	O
extracts	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O

Nuclear	O
extracts	O
of	O
purified	O
PBMCs	O
were	O
prepared	O
according	O
to	O
a	O
technique	O
described	O
by	O
Trede	O
et	O
al	O
.	O

[	O
27	O
]	O
and	O
modified	O
for	O
our	O
experimental	O
setup	O
[	O
56	O
]	O
.	O

The	O
intensity	O
of	O
shifted	O
bands	O
was	O
normalized	O
to	O
bands	O
of	O
unstimulated	O
controls	O
.	O

Competition	O
experiments	O
with	O
labeled	O
and	O
unlabeled	O
mutated	O
oligos	O
of	O
the	O
cytokine	O
promoter	O
binding	O
sites	O
(	O
see	O
above	O
)	O
were	O
carried	O
out	O
in	O
order	O
to	O
prevent	O
non	O
-	O
specific	O
binding	O
to	O
nuclear	O
proteins	O
.	O

For	O
such	O
experiments	O
,	O
an	O
excess	O
(	O
5	O
-	O
50x	O
)	O
of	O
unlabeled	O
oligos	O
was	O
added	O
to	O
the	O
nuclear	O
extracts	O
.	O

For	O
specificity	O
of	O
binding	O
,	O
supershift	O
assays	O
for	O
NFkappaB	O
with	O
a	O
combined	O
p65	B-Protein
/	O
50	B-Protein
antibody	O
were	O
performed	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
exclude	O
non	O
-	O
specific	O
reactions	O
,	O
a	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
Oct	B-Protein
-	I-Protein
1	I-Protein
DNA	O
(	O
unrelated	O
DNA	O
,	O
Table	O
1	O
)	O
was	O
used	O
,	O
which	O
did	O
not	O
compete	O
with	O
specific	O
binding	O
.	O

Immuno	O
(	O
Dot	O
)	O
blot	O

To	O
determine	O
whether	O
the	O
DNA	O
binding	O
proteins	O
were	O
related	O
to	O
NFkappaB	O
and	O
NFAT	B-Protein
,	O
dot	O
blots	O
using	O
a	O
SRC96D	O
SNS	O
minifold	O
I	O
dot	O
blotter	O
(	O
Schleicher	O
&	O
Schull	O
,	O
Dassel	O
,	O
Germany	O
)	O
were	O
performed	O
with	O
the	O
following	O
positive	O
controls	O
and	O
antibodies	O
(	O
all	O
from	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
:	O
positive	O
controls	O
(	O
10	O
ng	O
/	O
dot	O
)	O
:	O
NFkappaB	O
p52	B-Protein
(	O
80	O
kD	O
)	O
sc	O
-	O
4095WB	O
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
(	O
61	O
kD	O
)	O
sc	O
-	O
4030WB	O
;	O
Jurkat	O
nuclear	O
extract	O
,	O
PMA	O
-	O
stimulated	O
;	O
primary	O
antibodies	O
(	O
1	O
mug	O
/	O
dot	O
)	O
:	O
anti	O
-	O
NFkappaB	O
p50	B-Protein
(	O
NLS	O
)	O
sc	O
-	O
114	O
,	O
anti	O
-	O
NFkappaB	O
p65	B-Protein
(	O
A	O
)	O
sc	O
-	O
109	O
,	O
anti	O
-	O
NFkappaB	O
p52	B-Protein
(	O
447	O
)	O
sc	O
-	O
848	O
,	O
a	O
rabbit	O
polyclonal	O
IgG1	O
antiserum	O
,	O
anti	O
-	O
c	B-Protein
-	I-Protein
rel	I-Protein
(	O
N466	O
)	O
sc	O
-	O
272	O
,	O
anti	O
-	O
NFATc2	B-Protein
(	O
M	O
-	O
20	O
)	O
sc	O
-	O
1151	O
,	O
anti	O
-	O
NFATc1	B-Protein
(	O
K	O
-	O
18	O
)	O
sc	O
-	O
1149	O
,	O
two	O
goat	O
polyclonal	O
IgG1	O
antisera	O
;	O
secondary	O
antibodies	O
(	O
0	O
.	O
8	O
mug	O
/	O
dot	O
)	O
:	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
AP	O
-	O
conjugate	O
sc	O
-	O
2007	O
,	O
and	O
donkey	O
anti	O
-	O
goat	O
IgG	O
AP	O
-	O
conjugate	O
sc	O
-	O
2022	O
.	O

The	O
nuclear	O
proteins	O
were	O
blotted	O
onto	O
a	O
nitrocellulose	O
membrane	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

After	O
blocking	O
with	O
PBS	O
/	O
3	O
%	O
BSA	O
(	O
Fluka	O
,	O
Deisenhofen	O
,	O
Germany	O
)	O
,	O
the	O
blot	O
was	O
incubated	O
overnight	O
with	O
the	O
primary	O
antibodies	O
diluted	O
1	O
:	O
2000	O
in	O
PBS	O
/	O
1	O
%	O
BSA	O
,	O
washed	O
again	O
and	O
incubated	O
with	O
the	O
alkaline	O
phosphatase	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
1	O
:	O
500	O
in	O
PBS	O
/	O
1	O
%	O
BSA	O
)	O
.	O

The	O
blot	O
was	O
developed	O
using	O
the	O
Vectastain	O
(	O
R	O
)	O
staining	O
kit	O
(	O
Vector	O
Laboratories	O
Inc	O
.	O
Burlingame	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cytokine	O
measurements	O

Supernatants	O
of	O
cell	O
cultures	O
were	O
harvested	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
18	O
,	O
24	O
,	O
30	O
,	O
36	O
and	O
48	O
hours	O
after	O
stimulation	O
and	O
stored	O
at	O
-	O
80	O
degreesC	O
until	O
used	O
and	O
thawed	O
only	O
once	O
.	O

IFNgamma	B-Protein
,	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
determined	O
using	O
an	O
ELISA	O
from	O
Bender	O
Systems	O
(	O
Vienna	O
,	O
Austria	O
)	O
,	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
by	O
an	O
ELISA	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Wiesbaden	O
-	O
Nordenstadt	O
,	O
Germany	O
)	O
,	O
and	O
TGFbeta	B-Protein
1	I-Protein
using	O
an	O
ELISA	O
as	O
previously	O
described	O
[	O
57	O
]	O
.	O

Quantification	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
as	O
an	O
indicator	O
for	O
the	O
bioactivity	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
was	O
done	O
as	O
previously	O
described	O
[	O
46	O
]	O
.	O

Samples	O
were	O
diluted	O
in	O
the	O
same	O
buffer	O
as	O
that	O
used	O
for	O
the	O
standards	O
.	O

All	O
cytokines	O
were	O
quantified	O
using	O
an	O
ELISA	O
plate	O
reader	O
(	O
Anthos	O
Labotec	O
,	O
Salzburg	O
,	O
Austria	O
or	O
Microplate	O
Reader	O
,	O
BioRad	O
)	O
.	O

Cytokine	O
amounts	O
were	O
all	O
within	O
the	O
range	O
of	O
the	O
standard	O
curve	O
.	O

Only	O
stimulation	O
of	O
PBMC	O
observed	O
in	O
donors	O
showing	O
no	O
spontaneous	O
cytokine	O
release	O
was	O
included	O
in	O
the	O
statistics	O
.	O

Inhibition	O
of	O
transcription	O
factors	O

To	O
inhibit	O
translocation	O
and	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
PBMC	O
were	O
incubated	O
for	O
1	O
h	O
with	O
each	O
of	O
the	O
following	O
substances	O
(	O
concentrations	O
were	O
based	O
upon	O
50	O
%	O
inhibition	O
)	O
:	O
50	O
mug	O
/	O
ml	O
of	O
CAPE	O
(	O
caffeic	O
-	O
3	O
,	O
4	O
-	O
dihydroxycinnamic	O
-	O
acid	O
-	O
phenyl	O
-	O
ester	O
)	O
,	O
(	O
Biomol	O
,	O
Hamburg	O
,	O
Germany	O
)	O
;	O
400	O
ng	O
/	O
ml	O
cyclosporin	O
A	O
(	O
Calbiochem	O
-	O
Merck	O
Biosciences	O
,	O
Bad	O
Soden	O
,	O
Germany	O
)	O
;	O
10	O
mug	O
/	O
ml	O
cycloheximide	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
prior	O
to	O
incubation	O
with	O
GP	O
.	O

Band	O
shifts	O
were	O
determined	O
after	O
1	O
h	O
incubation	O
with	O
GP	O
as	O
described	O
before	O
,	O
including	O
mutated	O
oligos	O
for	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
(	O
TTA	O
CAA	O
CAG	O
TGG	O
ATT	O
GCG	O
ACA	O
CTT	O
AGT	O
GGG	O
)	O
and	O
NFATP2	B-Protein
/	O
3	B-Protein
(	O
GGC	O
GCA	O
GAA	O
AAG	O
GTA	O
AAA	O
TAT	O
TTA	O
CTA	O
TCT	O
)	O
binding	O
sites	O
within	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

PBMC	O
RNA	O
was	O
isolated	O
with	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
,	O
Germany	O
)	O
and	O
messenger	O
RNA	O
was	O
transcribed	O
into	O
cDNA	O
with	O
Reactin	O
Ready	O
First	O
Strand	O
kit	O
(	O
Biomol	O
)	O
and	O
analysed	O
for	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
and	O
GAPDH	B-Protein
transcripts	O
by	O
PCR	O
with	O
a	O
HotStart	O
"	O
sweet	O
"	O
PCR	O
mastermix	O
(	O
Biomol	O
)	O
(	O
95degreesC	O
,	O
30	O
sec	O
,	O
55degreesC	O
,	O
30	O
sec	O
,	O
72degreesC	O
,	O
30	O
sec	O
,	O
25	O
cycles	O
for	O
IL	O
-	O
1RA	O
and	O
94degreesC	O
for	O
30	O
sec	O
,	O
50degreesC	O
for	O
30	O
sec	O
and	O
72degreesC	O
for	O
45	O
sec	O
,	O
25	O
cycles	O
for	O
GAPDH	O
)	O
following	O
18	O
h	O
incubation	O
with	O
GP	O
.	O

IL	B-Protein
-	I-Protein
1RA	I-Protein
protein	O
was	O
measured	O
in	O
the	O
supernatant	O
by	O
ELISA	O
after	O
24	O
h	O
incubation	O
with	O
GP	O
.	O

Statistical	O
analysis	O

The	O
Kolmogorow	O
-	O
Smirnov	O
test	O
was	O
used	O
to	O
evaluate	O
,	O
whether	O
cytokine	O
amounts	O
and	O
binding	O
activities	O
to	O
transcription	O
factors	O
were	O
normally	O
distributed	O
.	O

Correlation	O
coefficients	O
and	O
corresponding	O
significances	O
were	O
analyzed	O
by	O
the	O
Pearson	O
test	O
(	O
normal	O
distribution	O
)	O
or	O
the	O
Spearman	O
test	O
(	O
non	O
-	O
normal	O
distribution	O
)	O
.	O

To	O
compare	O
experimental	O
data	O
to	O
a	O
theoretical	O
value	O
(	O
for	O
example	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
vs	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
)	O
we	O
calculated	O
the	O
sum	O
of	O
the	O
individual	O
effects	O
and	O
added	O
these	O
values	O
into	O
Fig	O
.	O

1B	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
.	O

Significances	O
of	O
differences	O
between	O
experimental	O
data	O
(	O
for	O
example	O
GP	O
vs	O
LPS	O
)	O
as	O
well	O
as	O
between	O
experimental	O
data	O
and	O
theoretical	O
values	O
(	O
for	O
example	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
vs	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
)	O
were	O
analysed	O
using	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
normal	O
distribution	O
)	O
or	O
the	O
Wilcoxon	O
Signed	O
-	O
Rank	O
test	O
(	O
non	O
-	O
normal	O
distribution	O
)	O
,	O
(	O
SPSS	O
for	O
Windows	O
;	O
SPSS	O
Science	O
Software	O
,	O
Erkrath	O
,	O
Germany	O
)	O
.	O

A	O
,	O
GP	O
led	O
to	O
DNA	O
binding	O
of	O
NFAT	B-Protein
,	O
NFkappaB	O
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
.	O

Human	O
PBMC	O
were	O
incubated	O
with	O
medium	O
control	O
or	O
GP	O
(	O
1	O
and	O
100	O
mug	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
.	O

Nuclear	O
extracts	O
were	O
incubated	O
with	O
a	O
32P	O
-	O
labeled	O
NFAT	B-Protein
,	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
or	O
NFkappaB	O
-	O
IL	B-Protein
-	I-Protein
8	I-Protein
oligonucleotide	O
probe	O
corresponding	O
to	O
the	O
IFNgamma	B-Protein
,	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
gene	O
promoters	O
(	O
Table	O
1	O
)	O
.	O

Arrows	O
with	O
the	O
black	O
head	O
indicate	O
migrational	O
location	O
of	O
the	O
NFAT	B-Protein
-	O
DNA	O
,	O
NFkappaB	O
-	O
DNA	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
-	O
DNA	O
or	O
NFkappaB	O
-	O
IL	B-Protein
-	I-Protein
8	I-Protein
-	O
DNA	O
complex	O
compared	O
to	O
free	O
probe	O
(	O
no	O
shift	O
)	O
.	O

Arrow	O
with	O
the	O
open	O
head	O
indicates	O
a	O
supershift	O
of	O
NFkappaB	O
-	O
IL	B-Protein
-	I-Protein
8	I-Protein
-	O
DNA	O
-	O
anti	O
-	O
p65	B-Protein
and	O
-	O
p50	B-Protein
,	O
respectively	O
.	O

An	O
autoradiogram	O
from	O
a	O
representative	O
experiment	O
is	O
shown	O
(	O
n	O
=	O
7	O
)	O
.	O

B	O
,	O
Decreased	O
DNA	O
binding	O
of	O
NFkappaB	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
/	O
GP	O
.	O

Human	O
PBMC	O
were	O
incubated	O
with	O
medium	O
control	O
,	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
(	O
100	O
mug	O
)	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
+	O
LPS	O
for	O
1	O
h	O
at	O
37degreesC	O
.	O

An	O
autoradiogram	O
from	O
a	O
representative	O
experiment	O
is	O
shown	O
.	O

Schematic	O
representation	O
of	O
NFkappaB	O
-	O
DNA	O
binding	O
activity	O
following	O
GP	O
(	O
1	O
and	O
100	O
mug	O
)	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
treatment	O
(	O
250	O
ng	O
)	O
as	O
well	O
as	O
simultaneous	O
administration	O
of	O
both	O
compounds	O
and	O
the	O
theoretical	O
value	O
(	O
GP	O
/	O
TSST	O
-	O
1	O
calc	O
.	O
)	O
.	O

Medium	O
control	O
levels	O
were	O
set	O
equal	O
to	O
1	O
+	O
/	O
-	O
SEM	O
and	O
significances	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
are	O
shown	O
with	O
respect	O
to	O
medium	O
control	O
(	O
n	O
=	O
4	O
)	O
.	O

NFkappaB	O
p65	B-Protein
/	O
p50	B-Protein
and	O
NFATc2	B-Protein
/	O
c1	B-Protein
were	O
involved	O
in	O
GP	O
-	O
induced	O
DNA	O
binding	O
.	O

In	O
order	O
to	O
determine	O
whether	O
the	O
DNA	O
binding	O
proteins	O
activated	O
by	O
GP	O
were	O
related	O
to	O
NFkappaB	O
and	O
NFAT	B-Protein
,	O
an	O
immuno	O
(	O
dot	O
)	O
blot	O
was	O
performed	O
.	O

A	O
representative	O
dot	O
blot	O
showing	O
staining	O
of	O
negative	O
and	O
positive	O
controls	O
(	O
recombinant	O
proteins	O
NFkappaB	O
p52	B-Protein
,	O
c	B-Protein
-	I-Protein
rel	I-Protein
;	O
nuclear	O
extracts	O
of	O
PMA	O
-	O
treated	O
Jurkat	O
cells	O
positive	O
for	O
NFkappaB	O
p50	B-Protein
,	O
p65	B-Protein
and	O
for	O
NFATc1	B-Protein
,	O
c2	B-Protein
)	O
in	O
the	O
upper	O
panel	O
and	O
staining	O
of	O
nuclear	O
extracts	O
of	O
GP	O
-	O
treated	O
PBMC	O
(	O
positive	O
for	O
NFkappaB	O
p65	B-Protein
,	O
p50	B-Protein
and	O
NFAT	B-Protein
c2	I-Protein
,	O
c1	B-Protein
)	O
in	O
the	O
lower	O
panel	O
is	O
shown	O
(	O
n	O
=	O
3	O
)	O
.	O

A	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
was	O
down	O
-	O
regulated	O
(	O
12	O
h	O
-	O
24	O
h	O
)	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
.	O

Time	O
course	O
(	O
48	O
h	O
)	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
(	O
pg	O
/	O
ml	O
)	O
by	O
human	O
PBMC	O
incubated	O
with	O
medium	O
control	O
,	O
100	O
mug	O
GP	O
,	O
250	O
ng	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
250	O
ng	O
LPS	O
and	O
GP	O
+	O
LPS	O
.	O

At	O
18	O
h	O
and	O
24	O
h	O
there	O
was	O
a	O
marked	O
reduction	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Graphs	O
depicting	O
the	O
theoretical	O
values	O
for	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
are	O
also	O
shown	O
.	O

IL	B-Protein
-	I-Protein
1beta	I-Protein
levels	O
in	O
the	O
supernatnant	O
were	O
obtained	O
by	O
Elisa	O
and	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

B	O
,	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
was	O
exaggerated	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
12	O
h	O
-	O
48	O
h	O
)	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
.	O

Time	O
course	O
(	O
48	O
h	O
)	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
(	O
pg	O
/	O
ml	O
)	O
by	O
human	O
PBMC	O
incubated	O
with	O
medium	O
control	O
,	O
100	O
mug	O
GP	O
,	O
250	O
ng	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
250	O
ng	O
LPS	O
and	O
GP	O
+	O
LPS	O
.	O

Between	O
18	O
h	O
and	O
48	O
h	O
a	O
simultaneous	O
treatment	O
of	O
PBMC	O
with	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
led	O
to	O
a	O
synergistic	O
effect	O
,	O
i	O
.	O
e	O
.	O
a	O
higher	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
when	O
compared	O
to	O
an	O
addition	O
of	O
the	O
single	O
values	O
for	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Graphs	O
depicting	O
the	O
theoretical	O
values	O
for	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
are	O
included	O
.	O

IL	B-Protein
-	I-Protein
1RA	I-Protein
levels	O
in	O
the	O
supernatnant	O
were	O
obtained	O
by	O
Elisa	O
and	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

GP	O
modulated	O
LPS	O
-	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
to	O
a	O
new	O
NFkappaB3	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Binding	O
was	O
enhanced	O
for	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
when	O
compared	O
to	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
/	O
LPS	O
calc	O
.	O
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
,	O
respectively	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
=	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Medium	O
control	O
levels	O
were	O
set	O
equal	O
to	O
1	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
6	O
)	O
.	O

DNA	O
binding	O
was	O
assessed	O
by	O
EMSA	O
(	O
see	O
methods	O
)	O
.	O

GP	O
modulated	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
DNA	O
binding	O
to	O
a	O
new	O
NFATP2	O
/	O
3	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Binding	O
was	O
up	O
-	O
regulated	O
for	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
when	O
compared	O
to	O
GP	O
and	O
,	O
in	O
the	O
latter	O
case	O
,	O
to	O
both	O
GP	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Human	O
PBMC	O
were	O
incubated	O
with	O
medium	O
control	O
,	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
+	O
LPS	O
for	O
1	O
h	O
at	O
37degreesC	O
.	O

Schematic	O
representation	O
of	O
the	O
elevated	O
NFAT	B-Protein
-	O
DNA	O
binding	O
activity	O
to	O
the	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Bars	O
depicting	O
the	O
theoretical	O
values	O
for	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
are	O
added	O
.	O

Medium	O
control	O
levels	O
were	O
set	O
equal	O
to	O
1	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
6	O
)	O
.	O

An	O
autoradiogram	O
of	O
a	O
representative	O
experiment	O
is	O
shown	O
in	O
the	O
lower	O
panel	O
(	O
lane	O
1	O
:	O
water	O
;	O
lane	O
2	O
:	O
medium	O
control	O
;	O
lane	O
3	O
:	O
GP	O
;	O
lane	O
4	O
:	O
LPS	O
;	O
lane	O
5	O
:	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
lane	O
6	O
:	O
GP	O
+	O
LPS	O
;	O
lane	O
7	O
:	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
.	O

Decreased	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
.	O

Time	O
course	O
(	O
48	O
h	O
)	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
incubation	O
of	O
human	O
PBMC	O
with	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
+	O
LPS	O
,	O
GP	O
/	O
LPS	O
calc	O
.	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

LPS	O
and	O
GP	O
+	O
LPS	O
treatments	O
resulted	O
in	O
generating	O
more	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
than	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
up	O
to	O
24	O
h	O
.	O

When	O
comparing	O
LPS	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O

vs	O
GP	O
+	O
LPS	O
we	O
did	O
not	O
find	O
significant	O
alterations	O
in	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
over	O
48	O
h	O
.	O

With	O
respect	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

vs	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
we	O
observed	O
a	O
pronounced	O
anti	O
-	O
inflammatory	O
action	O
of	O
GP	O
,	O
as	O
demonstrated	O
by	O
an	O
about	O
10	O
-	O
100	O
fold	O
reduced	O
ratio	O
at	O
18	O
h	O
and	O
24	O
h	O
,	O
i	O
.	O
e	O
.	O
a	O
higher	O
production	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
than	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Data	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

Inhibition	O
of	O
GP	O
-	O
induced	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
DNA	O
binding	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

A	O
,	O
A	O
representative	O
autoradiogram	O
(	O
lane	O
1	O
:	O
control	O
,	O
lane	O
2	O
:	O
GP	O
,	O
lane	O
3	O
:	O
GP	O
+	O
unlabeled	O
mutated	O
NFATP2	O
/	O
3	O
oligo	O
,	O
lane	O
4	O
:	O
GP	O
+	O
CAPE	O
,	O
lane	O
5	O
:	O
GP	O
+	O
CyA	O
,	O
lane	O
6	O
:	O
GP	O
+	O
CHX	O
,	O
lane	O
7	O
:	O
GP	O
+	O
unlabeled	O
NFATP2	O
/	O
3	O
oligo	O
,	O
lane	O
8	O
:	O
water	O
)	O
as	O
well	O
as	O
a	O
graphical	O
summary	O
for	O
the	O
NFATP2	O
/	O
3	O
site	O
,	O
depicting	O
a	O
decrease	O
in	O
binding	O
following	O
inhibition	O
when	O
compared	O
to	O
GP	O
is	O
displayed	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Data	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
4	O
)	O
.	O

B	O
,	O
Inhibition	O
of	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
resulted	O
in	O
decreased	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
following	O
CHX	O
,	O
CAPE	O
or	O
CyA	O
compared	O
to	O
GP	O
.	O

GAPDH	B-Protein
is	O
used	O
as	O
housekeeping	O
control	O
(	O
representative	O
gel	O
,	O
n	O
=	O
4	O
)	O
.	O

C	O
,	O
Inhibition	O
of	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
significantly	O
reduced	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
human	O
PBMC	O
following	O
treatment	O
with	O
CHX	O
,	O
CAPE	O
or	O
CyA	O
when	O
compared	O
to	O
GP	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
=	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Data	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

Sense	O
strand	O
of	O
oligonucleotides	O
used	O
in	O
EMSAs	O
.	O

Cartoon	O
of	O
the	O
sense	O
strand	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Relative	O
locations	O
of	O
previously	O
(	O
LRE	O
-	O
1	O
)	O
[	O
30	O
-	O
33	O
]	O
and	O
newly	O
described	O
(	O
boxed	O
)	O
,	O
positively	O
(	O
black	O
)	O
and	O
negatively	O
(	O
gray	O
)	O
regulatory	O
transcription	O
factor	O
binding	O
sites	O
are	O
depicted	O
.	O

Activation	O
of	O
TLR4	B-Protein
-	O
Mediated	O
NFkappaB	O
Signaling	O
in	O
Hemorrhagic	O
Brain	O
in	O
Rats	O

Inflammation	O
and	O
immunity	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
Intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
.	O

Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
-	O
(	O
TLR4	B-Protein
-	O
)	O
mediated	O
nuclear	O
factor	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
signaling	O
plays	O
critical	O
roles	O
in	O
the	O
activation	O
and	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
injured	O
brain	O
.	O

However	O
,	O
the	O
involvement	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
remains	O
unknown	O
.	O

The	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
temporal	O
profile	O
of	O
the	O
expression	O
of	O
TLR4	B-Protein
and	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
in	O
brain	O
tissues	O
of	O
Wistar	O
rats	O
after	O
ICH	O
.	O

TLR4	B-Protein
mRNA	O
and	O
protein	O
,	O
the	O
phosphorylation	O
of	O
inhibitors	B-Protein
of	I-Protein
kappa	I-Protein
B	I-Protein
(	O
p	O
-	O
IkappaBalpha	B-Protein
)	O
,	O
and	O
the	O
activity	O
of	O
NFkappaB	O
were	O
examined	O
in	O
hemorrhagic	O
cerebral	O
tissue	O
by	O
Rt	O
-	O
PCR	O
,	O
Western	O
blots	O
,	O
immunohistochemistry	O
staining	O
,	O
and	O
EMSA	O
.	O

Compared	O
with	O
saline	O
control	O
,	O
the	O
TLR4	B-Protein
mRNA	O
and	O
protein	O
significantly	O
increased	O
starting	O
at	O
6	O
hours	O
after	O
ICH	O
,	O
peaked	O
on	O
the	O
3rd	O
day	O
after	O
ICH	O
,	O
and	O
then	O
decreased	O
but	O
still	O
maintained	O
at	O
a	O
higher	O
level	O
on	O
the	O
7th	O
day	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

The	O
level	O
of	O
p	O
-	O
IkappaBalpha	B-Protein
and	O
the	O
activity	O
of	O
NFkappaB	O
also	O
increased	O
in	O
the	O
brain	O
after	O
ICH	O
compared	O
with	O
saline	O
control	O
.	O

The	O
present	O
study	O
firstly	O
suggests	O
that	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
participates	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
,	O
which	O
may	O
become	O
a	O
therapeutic	O
target	O
for	O
ICH	O
-	O
induced	O
brain	O
damage	O
.	O

Intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
represents	O
10	O
%	O
-	O
15	O
%	O
of	O
all	O
strokes	O
and	O
occurs	O
with	O
increasing	O
frequency	O
as	O
a	O
complication	O
of	O
the	O
thrombolytic	O
treatment	O
of	O
ischemic	O
stroke	O
,	O
which	O
is	O
associated	O
with	O
high	O
mortality	O
and	O
severe	O
disability	O
in	O
survivors	O
[	O
1	O
,	O
2	O
]	O
.	O

Local	O
brain	O
tissue	O
deformation	O
induces	O
primary	O
brain	O
damage	O
after	O
ICH	O
;	O
more	O
importantly	O
,	O
the	O
excitotoxicity	O
and	O
inflammatory	O
responses	O
in	O
the	O
brain	O
tissue	O
induced	O
by	O
ICH	O
result	O
in	O
further	O
brain	O
damage	O
following	O
ICH	O
[	O
3	O
]	O
.	O

Both	O
innate	O
and	O
adaptive	O
immunological	O
/	O
inflammatory	O
mechanisms	O
have	O
been	O
clearly	O
shown	O
to	O
participate	O
in	O
the	O
progression	O
of	O
brain	O
injury	O
after	O
ischemic	O
stroke	O
.	O

Nevertheless	O
,	O
how	O
the	O
inflammatory	O
responses	O
in	O
ICH	O
are	O
triggered	O
and	O
regulated	O
remains	O
to	O
be	O
elucidated	O
.	O

TLRs	O
are	O
a	O
family	O
of	O
transmembrane	O
proteins	O
and	O
act	O
as	O
signal	O
transduction	O
molecules	O
[	O
4	O
]	O
.	O

Activation	O
of	O
TLRs	O
recruits	O
downstream	O
signaling	O
proteins	O
and	O
results	O
in	O
transcription	O
of	O
genes	O
encoding	O
inflammation	O
-	O
associated	O
molecules	O
and	O
cytokines	O
[	O
5	O
,	O
6	O
]	O
.	O

For	O
example	O
,	O
combined	O
with	O
specific	O
ligand	O
,	O
the	O
activation	O
of	O
TLR4	B-Protein
induces	O
the	O
phosphorylation	O
of	O
inhibitor	O
of	O
kappa	O
-	O
B	O
(	O
IkappaB	O
)	O
and	O
dissociates	O
IkappaB	O
from	O
NF	O
-	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
.	O

Then	O
,	O
NFkappaB	O
trans	O
-	O
locates	O
into	O
the	O
nucleus	O
and	O
activates	O
and	O
regulates	O
the	O
transcription	O
of	O
genes	O
related	O
to	O
inflammatory	O
responses	O
[	O
5	O
,	O
6	O
]	O
.	O

TLRs	O
play	O
a	O
critical	O
role	O
in	O
the	O
induction	O
of	O
immunological	O
/	O
inflammatory	O
responses	O
and	O
are	O
implicated	O
in	O
several	O
CNS	O
diseases	O
,	O
such	O
as	O
infectious	O
disease	O
,	O
autoimmune	O
disease	O
,	O
and	O
ischemic	O
brain	O
injury	O
[	O
7	O
,	O
8	O
]	O
.	O

Accumulating	O
evidences	O
demonstrate	O
that	O
TLR4	B-Protein
,	O
the	O
first	O
mammalian	O
TLR	O
recognized	O
,	O
contributes	O
to	O
the	O
neuronal	O
death	O
,	O
blood	O
brain	O
barrier	O
damage	O
,	O
brain	O
edema	O
,	O
and	O
inflammatory	O
responses	O
in	O
the	O
brain	O
injury	O
induced	O
by	O
ischemia	O
[	O
8	O
,	O
9	O
]	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
TLR4	B-Protein
in	O
the	O
brain	O
after	O
ICH	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
detected	O
the	O
transcription	O
of	O
TLR4	B-Protein
gene	O
and	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
in	O
the	O
rat	O
brains	O
subjected	O
to	O
experimental	O
ICH	O
.	O

Our	O
data	O
firstly	O
provided	O
the	O
knowledge	O
about	O
the	O
distribution	O
of	O
TLR4	B-Protein
and	O
the	O
temporal	O
profile	O
of	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
in	O
rat	O
brain	O
tissue	O
after	O
ICH	O
.	O

2	O
.	O
1	O
.	O

Animals	O

Ninety	O
Wister	O
rats	O
(	O
male	O
,	O
body	O
weight	O
:	O
250	O
g	O
to	O
300	O
g	O
)	O
were	O
provided	O
by	O
Experimental	O
Animal	O
Center	O
,	O
China	O
Medical	O
University	O
.	O

The	O
rats	O
were	O
assigned	O
randomly	O
to	O
three	O
groups	O
:	O
normal	O
group	O
(	O
N	O
,	O
n	O
=	O
10	O
,	O
without	O
any	O
treatment	O
)	O
,	O
normal	O
saline	O
control	O
(	O
S	O
,	O
n	O
=	O
40	O
,	O
intra	O
-	O
cerebral	O
injection	O
of	O
normal	O
saline	O
as	O
control	O
)	O
and	O
intra	O
-	O
cerebral	O
hemorrhage	O
group	O
(	O
ICH	O
,	O
n	O
=	O
40	O
)	O
.	O

The	O
experimental	O
protocol	O
used	O
for	O
animals	O
was	O
approved	O
by	O
the	O
Animal	O
Care	O
and	O
Use	O
Committee	O
,	O
China	O
Medical	O
University	O
.	O

The	O
rats	O
were	O
subjected	O
to	O
intra	O
-	O
cerebral	O
injection	O
of	O
normal	O
saline	O
or	O
autologous	O
whole	O
blood	O
and	O
were	O
sacrificed	O
on	O
6	O
hours	O
,	O
1	O
day	O
,	O
3	O
days	O
and	O
7	O
days	O
after	O
the	O
injection	O
,	O
respectively	O
.	O

Five	O
rats	O
in	O
each	O
group	O
at	O
each	O
time	O
point	O
were	O
sacrificed	O
by	O
transcardially	O
perfusion	O
of	O
normal	O
saline	O
followed	O
by	O
4	O
%	O
buffered	O
Para	O
formaldehyde	O
(	O
pH	O
=	O
7	O
.	O
4	O
)	O
.	O

The	O
brains	O
were	O
removed	O
,	O
postfixed	O
,	O
embedded	O
in	O
paraffin	O
,	O
and	O
cut	O
into	O
sections	O
(	O
7	O
mum	O
)	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O

Five	O
rats	O
in	O
each	O
group	O
at	O
each	O
time	O
point	O
were	O
sacrificed	O
by	O
over	O
dose	O
injection	O
of	O
Ketamine	O
.	O

The	O
brains	O
were	O
removed	O
and	O
stored	O
at	O
minus	O
80degreesC	O
for	O
RT	O
-	O
PCR	O
and	O
Western	O
Blots	O
.	O

2	O
.	O
2	O
.	O

Induction	O
of	O
Intracerebral	O
Hemorrhage	O

Since	O
most	O
intracerebral	O
hemorrhages	O
occur	O
in	O
the	O
basal	O
ganglia	O
clinically	O
,	O
in	O
the	O
present	O
study	O
,	O
rat	O
model	O
of	O
ICH	O
was	O
induced	O
in	O
left	O
basal	O
ganglia	O
.	O

Rats	O
were	O
anesthetized	O
with	O
intra	O
-	O
peritoneal	O
sodium	O
pentobarbital	O
(	O
60	O
mg	O
/	O
kg	O
)	O
.	O

The	O
body	O
(	O
rectal	O
)	O
temperature	O
was	O
maintained	O
at	O
37degreesC	O
during	O
the	O
surgery	O
using	O
a	O
feedback	O
-	O
controlled	O
heating	O
system	O
.	O

The	O
rats	O
were	O
positioned	O
in	O
a	O
stereotactic	O
frame	O
,	O
and	O
the	O
scalp	O
was	O
incised	O
along	O
the	O
midline	O
.	O

Using	O
a	O
sterile	O
technique	O
,	O
a	O
1	O
mm	O
burr	O
hole	O
was	O
opened	O
in	O
the	O
skull	O
on	O
the	O
left	O
coronal	O
suture	O
3	O
mm	O
lateral	O
to	O
the	O
midline	O
.	O

A	O
blunt	O
26	O
-	O
gauge	O
needle	O
was	O
inserted	O
into	O
the	O
left	O
basal	O
ganglia	O
under	O
stereotactic	O
guidance	O
(	O
coordinates	O
:	O
0	O
.	O
2	O
mm	O
anterior	O
,	O
6	O
.	O
0	O
mm	O
ventral	O
,	O
and	O
3	O
.	O
0	O
mm	O
lateral	O
to	O
the	O
midline	O
)	O
.	O

Then	O
,	O
a	O
75	O
muL	O
of	O
autologous	O
whole	O
blood	O
was	O
infused	O
at	O
a	O
rate	O
of	O
20	O
muL	O
/	O
min	O
with	O
the	O
use	O
of	O
a	O
microinfusion	O
pump	O
.	O

After	O
the	O
completion	O
of	O
the	O
infusion	O
,	O
the	O
needle	O
was	O
withdrawn	O
quickly	O
,	O
cyanoacrylate	O
glue	O
was	O
placed	O
around	O
the	O
burr	O
hole	O
,	O
and	O
the	O
skin	O
incision	O
was	O
closed	O
with	O
sutures	O
.	O

For	O
the	O
normal	O
saline	O
control	O
rats	O
,	O
only	O
75	O
muL	O
normal	O
saline	O
was	O
injected	O
.	O

2	O
.	O
3	O
.	O

Detection	O
of	O
TLR4	B-Protein
mRNA	O
by	O
the	O
Method	O
of	O
RT	O
-	O
PCR	O

Briefly	O
,	O
total	O
RNA	O
samples	O
were	O
isolated	O
from	O
peri	O
-	O
hemorrhage	O
regions	O
in	O
left	O
basal	O
ganglia	O
using	O
Simply	O
P	O
Total	O
RNA	O
isolation	O
Kit	O
(	O
BioFlux	O
,	O
HZ	O
,	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
quantity	O
of	O
total	O
RNA	O
was	O
determined	O
on	O
a	O
Nanodrop	O
(	O
ND	O
-	O
1000	O
Spectrophotometer	O
)	O
by	O
measuring	O
optical	O
density	O
at	O
A260	O
and	O
A280	O
nm	O
wavelength	O
.	O

Then	O
,	O
the	O
concentrations	O
of	O
mRNA	O
were	O
adjusted	O
to	O
1	O
.	O
0	O
g	O
/	O
mL	O
.	O

RNA	O
was	O
reverse	O
-	O
transcribed	O
into	O
cDNA	O
in	O
20	O
muL	O
reaction	O
system	O
using	O
Superscript	O
First	O
-	O
Strand	O
Synthesis	O
Kit	O
for	O
RT	O
-	O
PCR	O
(	O
promega	O
Inc	O
)	O
under	O
conditions	O
described	O
by	O
the	O
supplier	O
.	O

One	O
microliter	O
of	O
cDNA	O
was	O
used	O
to	O
amplify	O
the	O
TLR4	B-Protein
gene	O
fragment	O
with	O
1x	O
PCR	O
buffer	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
200	O
muM	O
of	O
each	O
dNTP	O
,	O
200	O
muM	O
of	O
primers	O
,	O
and	O
2u	O
Taq	B-Protein
DNA	I-Protein
polymerase	I-Protein
.	O

The	B-Protein
house	I-Protein
keep	I-Protein
gene	I-Protein
(	O
beta	B-Protein
-	I-Protein
actin	I-Protein
)	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

The	O
PCR	O
primer	O
sequences	O
were	O
designed	O
according	O
to	O
the	O
TLR4	B-Protein
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
gene	O
sequences	O
reported	O
in	O
GenBank	O
.	O

TLR4	B-Protein
(	O
145	O
bp	O
)	O
:	O
forward	O
:	O
5	O
'	O
-	O
AGCTTTGGTCAGTTGGCTCT	O
-	O
3	O
'	O
;	O
reverse	O
:	O
5	O
'	O
-	O
CAGGATGACACCATTGAAGC	O
-	O
3	O
'	O
;	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
701	O
bp	O
)	O
:	O
forward	O
:	O
5	O
'	O
-	O
GCCAACCGTGAAAAAGATG	O
-	O
3	O
'	O
;	O
reverse	O
:	O
5	O
'	O
-	O
CCAGGATAGAGCCACCAAT	O
-	O
3	O
'	O
.	O

Reaction	O
cycles	O
were	O
performed	O
at	O
the	O
following	O
condition	O
:	O
94degreesC	O
2	O
min	O
,	O
94degreesC	O
40	O
s	O
,	O
55degreesC	O
40	O
s	O
,	O
and	O
72degreesC	O
60	O
s	O
.	O

The	O
reaction	O
was	O
stopped	O
after	O
31	O
cycles	O
.	O

PCR	O
products	O
were	O
electrophoresed	O
through	O
agarose	O
gel	O
.	O

Image	O
Acquisition	O
and	O
Analysis	O
software	O
were	O
used	O
to	O
determine	O
band	O
densities	O
.	O

The	O
abundance	O
of	O
TLR4	B-Protein
mRNA	O
was	O
expressed	O
as	O
the	O
ratio	O
of	O
TLR4	B-Protein
mRNA	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
mRNA	O
.	O

2	O
.	O
4	O
.	O

Immunohistochemistry	O
(	O
IHC	O
)	O

The	O
IHC	O
staining	O
for	O
TLR4	B-Protein
was	O
performed	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O

The	O
primary	O
antibody	O
employed	O
was	O
rabbit	O
anti	O
-	O
TLR4	O
(	O
WuHan	O
,	O
BA1717	O
)	O
.	O

The	O
biotinylated	O
secondary	O
antibody	O
and	O
antibody	O
-	O
biotin	O
-	O
avidin	B-Protein
-	O
peroxidase	O
complexes	O
(	O
ABC	O
reagent	O
,	O
SC	O
-	O
2018	O
)	O
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.	O

(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Slides	O
processed	O
without	O
primary	O
antibodies	O
served	O
as	O
negative	O
controls	O
.	O

2	O
.	O
5	O
.	O

Western	O
Blots	O

Cellular	O
proteins	O
were	O
prepared	O
from	O
ICH	O
cerebral	O
hemispheres	O
,	O
electrophoresed	O
with	O
SDS	O
-	O
polyacrylamide	O
gel	O
and	O
transferred	O
onto	O
Hybond	O
ECL	O
membranes	O
(	O
Amersham	O
Pharmacia	O
,	O
Piscataway	O
,	O
NJ	O
)	O
.	O

The	O
ECL	O
membranes	O
were	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibody	O
(	O
WuHan	O
,	O
BA1717	O
)	O
followed	O
by	O
incubation	O
with	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibodies	O
(	O
Golden	O
Bridge	O
,	O
PV	O
-	O
6001	O
)	O
.	O

The	O
signals	O
were	O
detected	O
with	O
the	O
ECL	O
system	O
(	O
Amersham	O
Pharmacia	O
)	O
.	O

The	O
same	O
membranes	O
were	O
probed	O
with	O
anti	O
-	O
GAPDH	B-Protein
(	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
,	O
Biodesign	O
,	O
Saco	O
,	O
Maine	O
)	O
after	O
being	O
washed	O
with	O
stripping	O
buffer	O
.	O

The	O
signals	O
were	O
quantified	O
by	O
scanning	O
densitometry	O
and	O
computer	O
-	O
assisted	O
image	O
analysis	O
.	O

2	O
.	O
6	O
.	O

Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O

Nuclear	O
proteins	O
were	O
isolated	O
from	O
brain	O
tissue	O
.	O

Briefly	O
,	O
after	O
removal	O
of	O
supernatant	O
(	O
cytoplasmic	O
extract	O
)	O
,	O
the	O
pellets	O
were	O
resuspended	O
in	O
nuclear	O
extraction	O
reagent	O
.	O

The	O
tubes	O
containing	O
pellets	O
were	O
put	O
on	O
vortex	O
for	O
15	O
seconds	O
every	O
10	O
minutes	O
,	O
for	O
a	O
total	O
of	O
40	O
minutes	O
.	O

The	O
tubes	O
were	O
centrifuged	O
at	O
maximum	O
speed	O
(	O
~	O
16	O
,	O
000	O
x	O
g	O
)	O
in	O
a	O
micro	O
centrifuge	O
for	O
10	O
minutes	O
.	O

The	O
supernatants	O
(	O
nuclear	O
extract	O
)	O
were	O
transferred	O
to	O
a	O
clean	O
prechilled	O
tube	O
and	O
stored	O
at	O
-	O
80degreesC	O
until	O
use	O
.	O

EMSA	O
was	O
performed	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O

NFkappaB	O
binding	O
activity	O
was	O
examined	O
in	O
a	O
15	O
muL	O
binding	O
reaction	O
mixture	O
containing	O
15	O
mug	O
of	O
nuclear	O
proteins	O
and	O
35	O
fmol	O
[	O
gamma	O
-	O
32P	O
]	O
labeled	O
double	O
-	O
stranded	O
NFkappaB	O
consensus	O
oligonucleotide	O
.	O

A	O
super	O
shift	O
assay	O
using	O
antibodies	O
to	O
P65	B-Protein
and	O
P50	B-Protein
was	O
performed	O
to	O
confirm	O
NFkappaB	O
binding	O
specificity	O
as	O
previously	O
described	O
.	O

2	O
.	O
7	O
.	O

Statistical	O
Analysis	O

All	O
data	O
were	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

The	O
measurements	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
or	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

The	O
P	O
<	O
.	O
05	O
level	O
of	O
probability	O
was	O
used	O
as	O
the	O
criteria	O
of	O
significance	O
.	O

3	O
.	O
1	O
.	O

TLR4	B-Protein
mRNA	O
Increased	O
in	O
Brain	O
Tissue	O
after	O
ICH	O

TLR4	B-Protein
mRNA	O
levels	O
were	O
detected	O
by	O
Rt	O
-	O
PCR	O
.	O

The	O
low	O
level	O
of	O
TLR4	B-Protein
mRNA	O
was	O
observed	O
in	O
normal	O
rat	O
brain	O
tissue	O
.	O

In	O
the	O
saline	O
control	O
group	O
,	O
the	O
TLR4	B-Protein
mRNA	O
slightly	O
increased	O
,	O
but	O
was	O
not	O
significantly	O
different	O
from	O
normal	O
group	O
.	O

However	O
,	O
the	O
TLR4	B-Protein
mRNA	O
after	O
ICH	O
significantly	O
increased	O
starting	O
from	O
6	O
hours	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
peaked	O
on	O
the	O
3rd	O
day	O
after	O
ICH	O
,	O
and	O
then	O
decreased	O
on	O
the	O
7th	O
day	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
but	O
still	O
maintained	O
a	O
higher	O
level	O
compared	O
with	O
saline	O
control	O
(	O
P	O
<	O
.	O
05	O
,	O
Figure	O
1	O
)	O
.	O

3	O
.	O
2	O
.	O

Expression	O
of	O
TLR4	B-Protein
Protein	O
Increased	O
in	O
Brain	O
Tissue	O
after	O
ICH	O

To	O
investigate	O
the	O
increased	O
TLR4	B-Protein
at	O
the	O
protein	O
level	O
,	O
the	O
expression	O
of	O
TLR4	B-Protein
protein	O
was	O
measured	O
in	O
brain	O
tissue	O
by	O
the	O
method	O
of	O
Western	O
Blots	O
using	O
specific	O
antibodies	O
for	O
TLR4	B-Protein
.	O

Our	O
results	O
showed	O
that	O
a	O
low	O
level	O
of	O
TLR4	B-Protein
protein	O
was	O
detectable	O
in	O
the	O
saline	O
control	O
group	O
.	O

The	O
expression	O
of	O
TLR4	B-Protein
significantly	O
increased	O
starting	O
from	O
6	O
hours	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
peaked	O
on	O
the	O
3rd	O
day	O
after	O
ICH	O
,	O
and	O
then	O
decreased	O
but	O
still	O
maintained	O
at	O
a	O
high	O
level	O
on	O
the	O
7th	O
day	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
,	O
Figure	O
2	O
)	O
.	O

This	O
observation	O
of	O
TLR4	B-Protein
protein	O
was	O
consistent	O
with	O
the	O
temporal	O
profile	O
of	O
the	O
TLR4	B-Protein
mRNA	O
after	O
ICH	O
.	O

3	O
.	O
3	O
.	O

Distribution	O
of	O
TLR4	B-Protein
in	O
Brain	O
Subjected	O
to	O
ICH	O

To	O
explore	O
the	O
distribution	O
of	O
TLR4	B-Protein
protein	O
,	O
the	O
TLR4	B-Protein
was	O
detected	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

Results	O
showed	O
that	O
TLR4	B-Protein
immunoreactivity	O
was	O
not	O
detectable	O
in	O
brain	O
tissue	O
from	O
normal	O
and	O
sham	O
control	O
.	O

However	O
,	O
immunoreactivity	O
for	O
TLR4	B-Protein
was	O
consistently	O
demonstrated	O
in	O
peri	O
-	O
hemorrhage	O
areas	O
,	O
the	O
hippocampus	O
,	O
cortex	O
,	O
thalamic	O
nuclei	O
,	O
and	O
some	O
white	O
matter	O
tracts	O
(	O
Figure	O
3	O
)	O
.	O

3	O
.	O
4	O
.	O

Activation	O
of	O
TLR4	B-Protein
-	O
Mediated	O
NF	O
-	O
Kappa	O
-	O
B	O
Signaling	O

Activation	O
of	O
TLR4	B-Protein
induces	O
the	O
phosphorylation	O
of	O
inhibitor	O
of	O
kappa	O
-	O
B	O
(	O
IkappaB	O
)	O
,	O
which	O
dissociates	O
IkappaB	O
with	O
NF	O
-	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
.	O

Then	O
,	O
NFkappaB	O
translocates	O
into	O
the	O
nucleus	O
and	O
activates	O
and	O
regulates	O
the	O
transcription	O
of	O
genes	O
related	O
to	O
inflammatory	O
responses	O
.	O

To	O
detectd	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
,	O
the	O
phosphorylation	O
of	O
inhibitor	O
of	O
kappa	O
-	O
B	O
(	O
p	O
-	O
IkappaB	O
)	O
and	O
activity	O
of	O
NFkappaB	O
were	O
measured	O
by	O
methods	O
of	O
Western	O
Blots	O
and	O
EMSA	O
.	O

Results	O
showed	O
that	O
the	O
p	O
-	O
IkappaB	O
increased	O
at	O
6	O
hours	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
peaked	O
on	O
3	O
days	O
after	O
ICH	O
,	O
and	O
maintained	O
a	O
high	O
level	O
on	O
7	O
days	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
,	O
Figure	O
5	O
)	O
.	O

As	O
expected	O
,	O
the	O
activity	O
of	O
NFkappaB	O
was	O
also	O
increased	O
in	O
the	O
same	O
manner	O
as	O
that	O
of	O
the	O
p	O
-	O
IkappaB	O
(	O
Figure	O
4	O
)	O
.	O

Intra	O
-	O
cerebral	O
hemorrhage	O
(	O
ICH	O
)	O
represents	O
10	O
-	O
15	O
%	O
of	O
all	O
strokes	O
,	O
and	O
occurs	O
with	O
increasing	O
frequency	O
as	O
a	O
complication	O
of	O
the	O
thrombolytic	O
treatment	O
of	O
ischemic	O
stroke	O
[	O
1	O
]	O
.	O

The	O
mortality	O
of	O
ICH	O
is	O
higher	O
than	O
that	O
of	O
ischemic	O
stroke	O
.	O

Only	O
31	O
%	O
are	O
functionally	O
independent	O
at	O
3	O
months	O
.	O

Only	O
38	O
%	O
of	O
the	O
patients	O
survive	O
the	O
1st	O
year	O
[	O
10	O
]	O
.	O

Unfortunately	O
,	O
the	O
method	O
for	O
treatment	O
of	O
this	O
disease	O
and	O
protection	O
of	O
the	O
brain	O
tissue	O
after	O
ICH	O
are	O
not	O
effective	O
.	O

Mass	O
effect	O
,	O
ischemia	O
,	O
and	O
toxicity	O
of	O
blood	O
components	O
after	O
ICH	O
induce	O
brain	O
tissue	O
damage	O
.	O

In	O
addition	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
inflammatory	O
processes	O
are	O
involved	O
in	O
cerebrovascular	O
events	O
.	O

After	O
ICH	O
,	O
inflammatory	O
mediators	O
from	O
the	O
blood	O
might	O
enter	O
to	O
the	O
brain	O
and	O
induce	O
an	O
inflammatory	O
reaction	O
and	O
the	O
brain	O
cells	O
itself	O
are	O
also	O
capable	O
of	O
producing	O
many	O
of	O
these	O
agents	O
[	O
11	O
]	O
.	O

The	O
inflammatory	O
responses	O
are	O
responsible	O
for	O
the	O
ICH	O
induced	O
brain	O
injury	O
,	O
which	O
could	O
provide	O
new	O
therapeutic	O
targets	O
for	O
ICH	O
.	O

Various	O
constituents	O
of	O
the	O
inflammatory	O
response	O
,	O
including	O
adhesion	O
molecules	O
,	O
cytokines	O
,	O
leukocytes	O
,	O
immunoglobulins	O
,	O
and	O
complement	O
,	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
.	O

However	O
,	O
how	O
the	O
inflammatory	O
responses	O
is	O
activated	O
and	O
regulated	O
in	O
the	O
brain	O
tissue	O
after	O
ICH	O
is	O
unclear	O
.	O

Transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
is	O
an	O
important	O
nuclear	O
transcription	O
factor	O
,	O
which	O
initiates	O
transcription	O
of	O
genes	O
associated	O
with	O
immune	O
responses	O
and	O
inflammation	O
[	O
12	O
,	O
13	O
]	O
and	O
also	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
inflammation	O
in	O
brain	O
pathologies	O
.	O

It	O
has	O
been	O
reported	O
that	O
NFkappaB	O
increased	O
in	O
the	O
region	O
of	O
perihematoma	O
after	O
ICH	O
[	O
14	O
]	O
.	O

NFkappaB	O
activation	O
occurs	O
within	O
minutes	O
and	O
persists	O
for	O
at	O
least	O
a	O
week	O
in	O
response	O
to	O
ICH	O
,	O
which	O
is	O
associated	O
with	O
the	O
expression	O
of	O
selected	O
target	O
genes	O
[	O
15	O
]	O
.	O

Activation	O
of	O
NFkappaB	O
initiates	O
inflammatory	O
responses	O
and	O
contributes	O
to	O
the	O
pathobiology	O
of	O
perilesional	O
cell	O
death	O
after	O
ICH	O
[	O
16	O
]	O
.	O

Inhibition	O
of	O
NFkappaB	O
activity	O
has	O
been	O
shown	O
to	O
have	O
a	O
therapeutic	O
effect	O
on	O
experimental	O
ICH	O
,	O
such	O
as	O
reduce	O
inflammation	O
,	O
behavioral	O
dysfunction	O
,	O
and	O
neuronal	O
damage	O
produced	O
by	O
ICH	O
[	O
17	O
]	O
.	O

The	O
knowledge	O
about	O
how	O
NFkappaB	O
is	O
activated	O
in	O
the	O
brain	O
subjected	O
to	O
ICH	O
is	O
critical	O
for	O
seeking	O
a	O
new	O
neuroprotective	O
method	O
for	O
ICH	O
.	O

Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
are	O
a	O
family	O
of	O
signal	O
transduction	O
molecules	O
and	O
play	O
a	O
critical	O
role	O
in	O
the	O
induction	O
of	O
innate	O
and	O
adaptive	O
immunity	O
[	O
4	O
]	O
.	O

TLR	O
-	O
mediated	O
signaling	O
pathways	O
mainly	O
stimulate	O
the	O
activation	O
of	O
NFkappaB	O
[	O
12	O
,	O
13	O
]	O
.	O

TLR4	B-Protein
,	O
the	O
first	O
mammalian	O
TLR	O
recognized	O
,	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
several	O
central	O
nervous	O
(	O
CNS	O
)	O
system	O
diseases	O
,	O
such	O
as	O
inflammatory	O
or	O
autoimmune	O
CNS	O
diseases	O
and	O
cerebral	O
ischemic	O
injury	O
[	O
7	O
,	O
8	O
]	O
.	O

Although	O
previous	O
reports	O
indicated	O
that	O
the	O
activation	O
of	O
NFkappaB	O
was	O
attributed	O
to	O
the	O
oxidative	O
stress	O
or	O
glutamate	O
receptor	O
activation	O
induced	O
by	O
red	O
blood	O
cells	O
and	O
/	O
or	O
plasma	O
constituents	O
[	O
17	O
]	O
,	O
very	O
few	O
studies	O
have	O
been	O
directed	O
to	O
investigate	O
the	O
role	O
and	O
the	O
relationship	O
between	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
and	O
ICH	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
established	O
the	O
rat	O
model	O
of	O
experimental	O
ICH	O
and	O
detected	O
the	O
TLR4	B-Protein
mRNA	O
and	O
protein	O
.	O

Our	O
data	O
showed	O
that	O
transcription	O
of	O
TLR4	B-Protein
as	O
well	O
as	O
the	O
expression	O
of	O
TLR4	B-Protein
protein	O
after	O
ICH	O
significantly	O
elevated	O
in	O
brain	O
tissue	O
.	O

These	O
changes	O
started	O
as	O
early	O
as	O
6	O
hours	O
after	O
the	O
ICH	O
insult	O
and	O
maintained	O
at	O
a	O
high	O
level	O
for	O
7	O
days	O
afterward	O
.	O

The	O
TLR4	B-Protein
protein	O
,	O
detected	O
by	O
immunohistochemistry	O
,	O
was	O
consistently	O
distributed	O
in	O
peri	O
-	O
hemorrhage	O
areas	O
,	O
the	O
hippocampus	O
,	O
cortex	O
,	O
thalamic	O
nuclei	O
,	O
and	O
some	O
white	O
matter	O
tracts	O
.	O

These	O
data	O
indicated	O
that	O
increased	O
expression	O
of	O
TLR4	B-Protein
may	O
be	O
related	O
to	O
the	O
triggering	O
of	O
the	O
inflammatory	O
responses	O
in	O
the	O
brain	O
tissue	O
after	O
ICH	O
.	O

Recent	O
studies	O
demonstrated	O
that	O
ICH	O
initiates	O
inflammatory	O
responses	O
,	O
which	O
are	O
associated	O
with	O
secondary	O
growth	O
of	O
hemorrhage	O
and	O
cell	O
death	O
[	O
18	O
]	O
.	O

It	O
is	O
now	O
believed	O
that	O
TLR4	B-Protein
-	O
mediated	O
-	O
NFkappaB	O
pathway	O
activates	O
and	O
regulates	O
immunological	O
and	O
inflammatory	O
responses	O
.	O

To	O
investigate	O
the	O
mechanisms	O
underlying	O
the	O
increased	O
inflammatory	O
responses	O
in	O
the	O
brain	O
after	O
ICH	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
by	O
detecting	O
the	O
p	O
-	O
IkappaB	O
and	O
the	O
activity	O
of	O
NFkappaB	O
in	O
hemorrhagic	O
brains	O
.	O

NFkappaB	O
is	O
an	O
important	O
transcription	O
factor	O
downstream	O
in	O
the	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
pathway	O
.	O

Activation	O
of	O
TLR4	B-Protein
stimulates	O
IkappaBalpha	B-Protein
phosphorylation	O
and	O
degradation	O
,	O
resulting	O
in	O
nuclear	O
translocation	O
of	O
NFkappaB	O
,	O
which	O
initiates	O
transcription	O
of	O
genes	O
associated	O
with	O
innate	O
immune	O
responses	O
and	O
inflammation	O
[	O
5	O
,	O
6	O
]	O
.	O

We	O
observed	O
that	O
the	O
levels	O
of	O
phosphorylation	O
of	O
IkappaB	O
and	O
the	O
activity	O
of	O
NFkappaB	O
were	O
significantly	O
increased	O
in	O
brain	O
tissue	O
after	O
ICH	O
.	O

The	O
temporal	O
profile	O
of	O
the	O
expression	O
of	O
p	O
-	O
IkappaB	O
and	O
the	O
activation	O
of	O
NFkappaB	O
was	O
similar	O
to	O
that	O
of	O
the	O
expression	O
of	O
TLR4	B-Protein
.	O

Our	O
data	O
suggest	O
that	O
ICH	O
stimulates	O
activation	O
of	O
the	O
TLR4	B-Protein
/	O
NFkappaB	O
signaling	O
pathway	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
that	O
activation	O
of	O
NFkappaB	O
is	O
regulated	O
through	O
the	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
pathway	O
.	O

TLR4	B-Protein
plays	O
an	O
important	O
role	O
in	O
the	O
recognition	O
of	O
microbial	O
components	O
[	O
19	O
,	O
20	O
]	O
and	O
can	O
also	O
recognize	O
endogenous	O
molecules	O
such	O
as	O
the	O
degradation	O
products	O
of	O
macromolecules	O
,	O
products	O
of	O
proteolytic	O
cascades	O
,	O
intracellular	O
components	O
of	O
ruptured	O
cells	O
,	O
and	O
products	O
of	O
genes	O
that	O
are	O
activated	O
by	O
inflammation	O
.	O

For	O
instance	O
,	O
HSP70	B-Protein
,	O
HSP32	B-Protein
,	O
HSP27	B-Protein
,	O
and	O
enzymes	O
involved	O
in	O
oxidative	O
stress	O
are	O
found	O
to	O
be	O
upregulated	O
in	O
the	O
brain	O
after	O
ICH	O
,	O
which	O
may	O
be	O
produced	O
by	O
injured	O
neuronal	O
cells	O
or	O
blood	O
cells	O
[	O
21	O
]	O
.	O

It	O
may	O
be	O
speculated	O
that	O
these	O
molecules	O
produced	O
in	O
damaged	O
brain	O
or	O
came	O
from	O
blood	O
cells	O
and	O
constituents	O
of	O
plasma	O
server	O
as	O
endogenous	O
TLR4	B-Protein
ligands	O
,	O
activate	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
,	O
and	O
initiate	O
the	O
inflammatory	O
responses	O
in	O
IHC	O
brain	O
.	O

However	O
,	O
the	O
specific	O
endogenous	O
ligands	O
for	O
TLR4	B-Protein
in	O
hemorrhagic	O
brain	O
have	O
not	O
been	O
determined	O
and	O
need	O
to	O
be	O
identified	O
through	O
further	O
research	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrated	O
the	O
temporal	O
profile	O
of	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
in	O
brain	O
tissue	O
in	O
a	O
rat	O
model	O
of	O
experimental	O
ICH	O
,	O
which	O
suggests	O
that	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
participates	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
,	O
which	O
may	O
be	O
a	O
therapeutic	O
target	O
for	O
the	O
prevention	O
of	O
ICH	O
-	O
induced	O
brain	O
damage	O
.	O

Negative	O
regulation	O
of	O
NF	O
-	O
kappaB	O
and	O
its	O
involvement	O
in	O
rheumatoid	O
arthritis	O

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
plays	O
crucial	O
roles	O
in	O
the	O
regulation	O
of	O
inflammation	O
and	O
mmune	O
responses	O
,	O
and	O
inappropriate	O
NF	O
-	O
kappaB	O
activity	O
has	O
been	O
linked	O
with	O
many	O
autoimmune	O
and	O
inflammatory	O
diseases	O
,	O
including	O
rheumatoid	O
arthritis	O
.	O

Cells	O
employ	O
a	O
multilayered	O
control	O
system	O
to	O
keep	O
NF	O
-	O
kappaB	O
signalling	O
in	O
check	O
,	O
including	O
a	O
repertoire	O
of	O
negative	O
feedback	O
regulators	O
ensuring	O
termination	O
of	O
NF	O
-	O
kappaB	O
responses	O
.	O

Here	O
we	O
will	O
review	O
various	O
negative	O
regulatory	O
mechanisms	O
that	O
have	O
evolved	O
to	O
control	O
NF	O
-	O
kappaB	O
signalling	O
and	O
which	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
the	O
most	O
common	O
inflammatory	O
arthritis	O
,	O
affecting	O
up	O
to	O
1	O
%	O
of	O
the	O
adult	O
population	O
.	O

RA	O
is	O
characterised	O
by	O
a	O
symmetrical	O
polyarthritis	O
in	O
which	O
chronic	O
inflammation	O
of	O
joints	O
is	O
associated	O
with	O
a	O
progressive	O
destruction	O
of	O
cartilage	O
and	O
bone	O
,	O
leading	O
to	O
functional	O
decline	O
and	O
disability	O
.	O

Infiltration	O
of	O
cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
into	O
the	O
joint	O
space	O
drives	O
the	O
local	O
production	O
of	O
proinflammatory	O
T	O
-	O
helper	O
type	O
1	O
and	O
T	O
-	O
helper	O
type	O
17	O
cytokines	O
,	O
chemokines	O
,	O
and	O
matrix	O
metalloproteinases	O
by	O
infiltrating	O
monocytes	O
and	O
synovial	O
cells	O
.	O

Proliferation	O
of	O
synovial	O
fibroblasts	O
leads	O
to	O
the	O
formation	O
of	O
pannus	O
tissue	O
,	O
which	O
invades	O
and	O
degrades	O
articular	O
cartilage	O
and	O
subchondral	O
bone	O
.	O

The	O
aetiology	O
of	O
RA	O
is	O
still	O
not	O
understood	O
,	O
but	O
it	O
is	O
well	O
accepted	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
RA	O
and	O
many	O
other	O
autoimmune	O
diseases	O
.	O

NF	O
-	O
kappaB	O
represents	O
a	O
family	O
of	O
structurally	O
related	O
and	O
evolutionarily	O
conserved	O
proteins	O
(	O
p100	B-Protein
or	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
,	O
p105	B-Protein
or	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
,	O
p65	B-Protein
or	O
RelA	B-Protein
,	O
RelB	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
)	O
that	O
function	O
as	O
homodimers	O
or	O
heterodimers	O
[	O
1	O
]	O
,	O
and	O
that	O
regulate	O
the	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
-	O
such	O
as	O
TNF	B-Protein
,	O
IL	O
-	O
1	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
cyclo	B-Protein
-	I-Protein
oxygenase	I-Protein
-	I-Protein
2	I-Protein
,	O
chemokines	O
,	O
inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
,	O
and	O
matrix	O
metalloproteinases	O
-	O
that	O
are	O
involved	O
in	O
RA	O
.	O

In	O
addition	O
,	O
TNF	B-Protein
and	O
IL	O
-	O
1	O
are	O
themselves	O
very	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
(	O
reviewed	O
in	O
[	O
2	O
,	O
3	O
]	O
)	O
.	O

NF	O
-	O
kappaB	O
activation	O
can	O
be	O
detected	O
in	O
cultured	O
synovial	O
fibroblasts	O
and	O
synovial	O
tissue	O
from	O
RA	O
patients	O
,	O
and	O
animal	O
models	O
of	O
inflammatory	O
arthritis	O
also	O
demonstrate	O
the	O
active	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
development	O
and	O
progression	O
of	O
RA	O
(	O
reviewed	O
in	O
[	O
4	O
]	O
)	O
.	O

The	O
time	O
course	O
of	O
NF	O
-	O
kappaB	O
activation	O
appears	O
to	O
precede	O
the	O
onset	O
of	O
disease	O
,	O
and	O
blockade	O
of	O
NF	O
-	O
kappaB	O
by	O
different	O
means	O
decreases	O
disease	O
severity	O
[	O
5	O
,	O
6	O
]	O
.	O

Next	O
to	O
its	O
role	O
in	O
proinflammatory	O
gene	O
expression	O
,	O
NF	O
-	O
kappaB	O
is	O
also	O
essential	O
for	O
osteoclastogenesis	O
,	O
mainly	O
by	O
mediating	O
the	O
effects	O
of	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
ligand	I-Protein
(	O
RANKL	B-Protein
)	O
.	O

Defects	O
in	O
the	O
regulation	O
of	O
osteoclastogenesis	O
are	O
the	O
major	O
cause	O
of	O
bone	O
erosion	O
in	O
osteolytic	O
diseases	O
such	O
as	O
RA	O
[	O
7	O
]	O
.	O

Finally	O
,	O
recent	O
discoveries	O
revealing	O
a	O
genetic	O
association	O
with	O
several	O
genes	O
relevant	O
to	O
NF	O
-	O
kappaB	O
signalling	O
,	O
including	O
CD40	B-Protein
,	O
TRAF1	B-Protein
,	O
TNFAIP3	B-Protein
,	O
and	O
c	B-Protein
-	I-Protein
REL	I-Protein
,	O
further	O
highlight	O
the	O
importance	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
RA	O
pathogenesis	O
[	O
8	O
]	O
.	O

Since	O
NF	O
-	O
kappaB	O
is	O
central	O
to	O
the	O
process	O
of	O
inflammation	O
in	O
RA	O
,	O
much	O
research	O
deals	O
with	O
the	O
identification	O
of	O
the	O
molecular	O
triggers	O
that	O
activate	O
NF	O
-	O
kappaB	O
in	O
RA	O
.	O

It	O
is	O
well	O
accepted	O
that	O
proinflammatory	O
cytokines	O
such	O
as	O
TNF	B-Protein
and	O
IL	O
-	O
1	O
play	O
an	O
important	O
role	O
,	O
and	O
administration	O
of	O
TNF	B-Protein
antagonists	O
is	O
an	O
effective	O
treatment	O
for	O
severe	O
RA	O
(	O
reviewed	O
in	O
[	O
9	O
]	O
)	O
.	O

TNF	B-Protein
and	O
IL	O
-	O
1	O
are	O
both	O
very	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
and	O
it	O
can	O
be	O
expected	O
that	O
NF	O
-	O
kappaB	O
activation	O
by	O
these	O
cytokines	O
mediates	O
most	O
of	O
their	O
pro	O
-	O
inflammatory	O
activities	O
in	O
RA	O
(	O
reviewed	O
in	O
[	O
3	O
]	O
)	O
.	O

NF	O
-	O
kappaB	O
activation	O
by	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
(	O
RANK	B-Protein
)	O
,	O
a	O
TNF	O
receptor	O
family	O
member	O
,	O
is	O
important	O
for	O
osteoclastogenesis	O
,	O
and	O
defects	O
in	O
proper	O
RANK	B-Protein
-	O
NF	O
-	O
kappaB	O
signalling	O
are	O
likely	O
to	O
be	O
involved	O
in	O
RA	O
pathology	O
and	O
other	O
diseases	O
associated	O
with	O
bone	O
loss	O
[	O
7	O
]	O
.	O

CD40	B-Protein
is	O
another	O
TNF	B-Protein
receptor	I-Protein
family	I-Protein
member	I-Protein
that	O
is	O
functionally	O
expressed	O
on	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
smooth	O
muscle	O
fibroblasts	O
from	O
normal	O
and	O
RA	O
patients	O
and	O
RA	O
synovial	O
cells	O
,	O
B	O
cells	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
,	O
and	O
can	O
be	O
upregulated	O
by	O
proinflammatory	O
cytokines	O
including	O
TNF	B-Protein
[	O
10	O
]	O
.	O

Binding	O
of	O
the	O
CD40	B-Protein
ligand	I-Protein
(	O
CD154	B-Protein
)	O
,	O
which	O
is	O
transiently	O
expressed	O
on	O
the	O
surface	O
of	O
activated	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
triggers	O
NF	O
-	O
kappaB	O
activation	O
resulting	O
in	O
fibroblast	O
proliferation	O
and	O
secretion	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
contributes	O
to	O
joint	O
destruction	O
.	O

However	O
,	O
studies	O
with	O
antagonistic	O
anti	O
-	O
CD40	O
or	O
anti	O
-	O
CD154	O
antibodies	O
led	O
to	O
the	O
conclusion	O
that	O
CD40	B-Protein
signals	O
may	O
be	O
important	O
at	O
the	O
initial	O
stages	O
of	O
arthritis	O
induction	O
,	O
but	O
are	O
not	O
required	O
once	O
disease	O
is	O
established	O
and	O
pathogenic	O
antibodies	O
are	O
already	O
present	O
[	O
11	O
,	O
12	O
]	O
.	O

Enhanced	O
expression	O
of	O
the	O
TNF	O
receptor	O
family	O
member	O
B	B-Protein
-	I-Protein
cell	I-Protein
activating	I-Protein
factor	I-Protein
(	O
BAFF	B-Protein
)	O
,	O
allowing	O
the	O
survival	O
of	O
autoantibody	O
-	O
producing	O
B	O
lymphocytes	O
,	O
is	O
also	O
characteristic	O
for	O
RA	O
,	O
and	O
antagonists	O
of	O
BAFF	B-Protein
have	O
been	O
developed	O
to	O
counter	O
RA	O
[	O
13	O
]	O
.	O

Finally	O
,	O
lymphotoxin	B-Protein
beta	I-Protein
receptor	I-Protein
signalling	O
has	O
been	O
implicated	O
in	O
tertiary	O
lymphoid	O
organ	O
formation	O
at	O
sites	O
of	O
chronic	O
inflammation	O
including	O
RA	O
[	O
13	O
]	O
.	O

Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
have	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
autoimmune	O
diseases	O
and	O
are	O
potential	O
candidates	O
for	O
inducing	O
NF	O
-	O
kappaB	O
-	O
dependent	O
inflammation	O
in	O
RA	O
.	O

In	O
addition	O
to	O
microbial	O
ligands	O
,	O
an	O
increasing	O
number	O
of	O
endogenous	O
ligands	O
-	O
a	O
group	O
of	O
proteins	O
derived	O
from	O
host	O
tissues	O
and	O
cells	O
-	O
have	O
been	O
reported	O
as	O
candidate	O
activators	O
of	O
TLRs	O
inducing	O
so	O
-	O
called	O
sterile	O
inflammation	O
(	O
reviewed	O
in	O
[	O
14	O
,	O
15	O
]	O
)	O
.	O

TLRs	O
are	O
expressed	O
in	O
RA	O
synovial	O
tissues	O
and	O
various	O
endogenous	O
ligands	O
are	O
present	O
within	O
the	O
inflamed	O
joints	O
of	O
RA	O
patients	O
.	O

Moreover	O
,	O
animal	O
models	O
using	O
TLR	O
knockout	O
mice	O
or	O
strategies	O
to	O
block	O
TLR	O
signalling	O
clearly	O
identify	O
TLR	O
-	O
dependent	O
inflammation	O
as	O
being	O
important	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

High	B-Protein
mobility	I-Protein
group	I-Protein
box	I-Protein
chromosomal	I-Protein
protein	I-Protein
1	I-Protein
(	O
HMGB1	B-Protein
)	O
,	O
a	O
highly	O
conserved	O
chromatin	B-Protein
component	I-Protein
that	O
can	O
be	O
actively	O
secreted	O
by	O
macrophages	O
or	O
passively	O
released	O
by	O
necrotic	O
cells	O
,	O
is	O
one	O
of	O
the	O
most	O
putative	O
endogenous	O
TLR4	B-Protein
ligands	I-Protein
involved	O
in	O
RA	O
pathology	O
.	O

HMGB1	B-Protein
is	O
increased	O
in	O
RA	O
synovial	O
tissue	O
and	O
HMGB1	B-Protein
neutralising	O
antibodies	O
or	O
the	O
antagonistic	O
BoxA	O
domain	O
of	O
HMGB1	B-Protein
protect	O
against	O
collagen	O
-	O
induced	O
arthritis	O
in	O
mice	O
[	O
16	O
]	O
.	O

Myeloid	B-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
8	I-Protein
and	O
myeloid	B-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
14	I-Protein
,	O
damage	O
-	O
associated	O
molecular	O
pattern	O
molecules	O
belonging	O
to	O
the	O
S100	O
family	O
of	O
calcium	O
-	O
binding	O
proteins	O
,	O
are	O
also	O
abundantly	O
present	O
in	O
RA	O
synovial	O
fluid	O
,	O
and	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
TLR4	B-Protein
-	O
induced	O
chronic	O
inflammation	O
in	O
RA	O
[	O
17	O
,	O
18	O
]	O
.	O

Other	O
endogenous	O
TLR	O
ligands	O
that	O
may	O
be	O
involved	O
in	O
RA	O
pathology	O
are	O
extracellular	O
matrix	O
components	O
such	O
as	O
fibrinogen	O
,	O
fibronectin	B-Protein
,	O
biglycan	B-Protein
,	O
tenascin	B-Protein
C	I-Protein
,	O
and	O
hyal	O
-	O
uronic	O
acid	O
fragments	O
(	O
reviewed	O
in	O
[	O
14	O
,	O
15	O
]	O
)	O
.	O

Together	O
,	O
these	O
studies	O
suggest	O
that	O
several	O
TLR	O
ligands	O
in	O
the	O
inflamed	O
joint	O
tissue	O
may	O
contribute	O
to	O
NF	O
-	O
kappaB	O
activation	O
and	O
inflammatory	O
gene	O
expression	O
in	O
RA	O
.	O

NF	O
-	O
kappaB	O
proteins	O
are	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
latent	O
complexes	O
by	O
inhibitory	O
proteins	O
referred	O
to	O
as	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
(	O
IkappaB	O
)	O
proteins	O
,	O
which	O
prevent	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
[	O
19	O
]	O
.	O

Whereas	O
the	O
majority	O
of	O
IkappaBs	O
(	O
IkappaBalpha	B-Protein
,	O
IkappaBbeta	B-Protein
,	O
IkappaBepsilon	B-Protein
,	O
p105	B-Protein
(	O
also	O
known	O
as	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
)	O
,	O
p100	B-Protein
(	O
also	O
known	O
as	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
)	O
)	O
serve	O
as	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
,	O
IkappaBxi	B-Protein
and	O
Bcl	B-Protein
-	I-Protein
3	I-Protein
instead	O
potentiate	O
NF	O
-	O
kappaB	O
transactivation	O
in	O
the	O
nucleus	O
.	O

p100	B-Protein
and	O
p105	B-Protein
are	O
precursors	O
of	O
the	O
p52	B-Protein
and	O
p50	B-Protein
NF	O
-	O
kappaB	O
subunits	O
,	O
respectively	O
.	O

There	O
are	O
two	O
unique	O
NF	O
-	O
kappaB	O
signalling	O
pathways	O
,	O
termed	O
canonical	O
(	O
or	O
classical	O
)	O
and	O
noncanonical	O
(	O
or	O
alternative	O
)	O
NF	O
-	O
kappaB	O
pathways	O
.	O

The	O
canonical	O
NF	O
-	O
kappaB	O
pathway	O
plays	O
a	O
major	O
role	O
in	O
innate	O
and	O
adaptive	O
immunity	O
,	O
and	O
is	O
triggered	O
by	O
many	O
stimuli	O
including	O
proinflammatory	O
cytokines	O
(	O
for	O
example	O
,	O
TNF	B-Protein
,	O
IL	O
-	O
1	O
)	O
,	O
antigens	O
,	O
RANKL	B-Protein
,	O
and	O
TLR	O
ligands	O
.	O

NF	O
-	O
kappaB	O
signalling	O
initiated	O
by	O
different	O
receptors	O
requires	O
the	O
formation	O
of	O
proximal	O
protein	O
-	O
protein	O
interactions	O
that	O
are	O
often	O
receptor	O
specific	O
,	O
but	O
ultimately	O
converge	O
in	O
the	O
activation	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
,	O
which	O
mediates	O
phosphorylation	O
of	O
the	O
inhibitory	O
IkappaB	O
protein	O
leading	O
to	O
its	O
K48	O
-	O
polyubiquitination	O
and	O
degradation	O
by	O
the	O
proteasome	O
[	O
20	O
]	O
.	O

The	O
IKK	O
complex	O
is	O
comprised	O
of	O
the	O
two	O
catalytic	O
subunits	O
IKK1	B-Protein
and	O
IKK2	B-Protein
(	O
also	O
known	O
as	O
IKKalpha	B-Protein
and	O
IKKbeta	B-Protein
)	O
and	O
the	O
regulatory	O
subunit	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
essential	I-Protein
modulator	I-Protein
(	O
NEMO	B-Protein
-	O
also	O
known	O
as	O
IKKgamma	B-Protein
)	O
(	O
Figure	O
1	O
)	O
.	O

Gene	O
targeting	O
experiments	O
showed	O
that	O
IKK2	B-Protein
and	O
NEMO	B-Protein
,	O
but	O
not	O
IKK1	B-Protein
,	O
are	O
required	O
for	O
canonical	O
NF	O
-	O
kappaB	O
activation	O
[	O
21	O
]	O
.	O

One	O
of	O
the	O
best	O
studied	O
NF	O
-	O
kappaB	O
signalling	O
pathways	O
is	O
the	O
TNF	B-Protein
pathway	O
.	O

TNF	B-Protein
stimulation	O
results	O
in	O
the	O
recruitment	O
of	O
TNF	B-Protein
receptor	I-Protein
-	I-Protein
1	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
(	O
TRADD	B-Protein
)	O
protein	O
and	O
of	O
receptor	B-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
(	O
RIP1	B-Protein
)	O
,	O
which	O
function	O
as	O
adaptor	O
proteins	O
for	O
the	O
E3	O
ubiquitin	O
ligases	O
TNF	B-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
(	I-Protein
TRAF	I-Protein
)	I-Protein
2	I-Protein
and	O
TRAF5	B-Protein
,	O
which	O
in	O
turn	O
bind	O
the	O
E3	O
ubiquitin	O
ligases	O
cellular	B-Protein
inhibitor	I-Protein
of	I-Protein
apoptosis	I-Protein
(	I-Protein
cIAP	I-Protein
)	I-Protein
1	I-Protein
and	O
cIAP2	B-Protein
(	O
Figure	O
1	O
)	O
.	O

On	O
TNF	B-Protein
stimulation	O
,	O
TNF	O
-	O
receptor	O
bound	O
RIP1	B-Protein
is	O
rapidly	O
modified	O
by	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
.	O

TRAF2	B-Protein
/	O
5	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
are	O
good	O
candidates	O
for	O
RIP1	B-Protein
ubiquitination	O
,	O
but	O
the	O
specific	O
role	O
of	O
each	O
is	O
still	O
unclear	O
.	O

The	O
polyubiquitin	O
chains	O
on	O
RIP1	B-Protein
are	O
believed	O
to	O
create	O
a	O
scaffold	O
to	O
recruit	O
the	O
IKK	O
and	O
TAK1	B-Protein
complex	O
via	O
the	O
ubiquitin	O
-	O
binding	O
proteins	O
NEMO	B-Protein
and	O
TAB1	B-Protein
/	O
2	B-Protein
,	O
respectively	O
.	O

The	O
recent	O
identification	O
of	O
a	O
distinct	O
E2	O
/	O
E3	O
enzyme	O
complex	O
that	O
modifies	O
NEMO	B-Protein
with	O
linear	O
polyubiquitin	O
chains	O
and	O
is	O
essential	O
for	O
TNF	B-Protein
-	O
activated	O
NF	O
-	O
kappaB	O
signalling	O
adds	O
further	O
complexity	O
[	O
22	O
]	O
.	O

The	O
exact	O
role	O
of	O
protein	O
-	O
anchored	O
polyubiquitin	O
chains	O
remains	O
unclear	O
,	O
as	O
it	O
was	O
recently	O
suggested	O
that	O
unanchored	O
polyubiquitin	O
chains	O
can	O
directly	O
activate	O
the	O
TAK1	B-Protein
complex	O
[	O
23	O
]	O
.	O

Similar	O
signalling	O
principles	O
apply	O
to	O
other	O
receptors	O
.	O

For	O
example	O
,	O
TLR4	B-Protein
stimulation	O
by	O
lipopolysaccharide	O
induces	O
the	O
recruitment	O
of	O
Toll	B-Protein
/	I-Protein
IL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
adaptor	I-Protein
protein	I-Protein
(	O
also	O
referred	O
to	O
as	O
Mal	B-Protein
)	O
and	O
TRIF	B-Protein
-	I-Protein
related	I-Protein
adaptor	I-Protein
molecule	I-Protein
(	O
TRAM	B-Protein
)	O
,	O
which	O
most	O
probably	O
serve	O
as	O
bridging	O
factors	O
to	O
recruit	O
myeloid	B-Protein
differentiation	I-Protein
primary	I-Protein
response	I-Protein
gene	I-Protein
88	I-Protein
(	O
MyD88	B-Protein
)	O
and	O
TIR	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
adaptor	I-Protein
-	I-Protein
inducing	I-Protein
IFNbeta	I-Protein
(	O
TRIF	B-Protein
)	O
,	O
respectively	O
.	O

MyD88	B-Protein
in	O
turn	O
recruits	O
members	O
of	O
the	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
family	O
and	O
TRAF6	B-Protein
,	O
leading	O
to	O
oligomerisation	O
and	O
selfubiquitination	O
of	O
TRAF6	B-Protein
[	O
24	O
]	O
.	O

TRIF	B-Protein
also	O
recruits	O
TRAF6	B-Protein
[	O
25	O
]	O
and	O
RIP1	B-Protein
[	O
26	O
]	O
via	O
a	O
direct	O
interaction	O
.	O

Both	O
pathways	O
then	O
activate	O
TAK1	B-Protein
and	O
IKK	O
in	O
a	O
ubiquitination	O
-	O
dependent	O
manner	O
similar	O
to	O
the	O
TNF	B-Protein
pathway	O
(	O
Figure	O
1	O
)	O
.	O

The	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
can	O
be	O
activated	O
by	O
the	O
lymphotoxin	B-Protein
beta	I-Protein
receptor	I-Protein
,	O
BAFF	B-Protein
receptor	I-Protein
,	O
CD40	B-Protein
,	O
and	O
RANK	B-Protein
(	O
Figure	O
2	O
)	O
.	O

In	O
this	O
pathway	O
,	O
p100	B-Protein
is	O
processed	O
by	O
the	O
proteasome	O
to	O
p52	B-Protein
,	O
which	O
together	O
with	O
the	O
RelB	B-Protein
NF	O
-	O
kappaB	O
subunit	O
regulates	O
a	O
distinct	O
set	O
of	O
target	O
genes	O
that	O
control	O
B	O
-	O
cell	O
development	O
,	O
secondary	O
lymphoid	O
organ	O
development	O
,	O
and	O
osteoclastogenesis	O
[	O
27	O
]	O
The	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
is	O
strictly	O
dependent	O
on	O
IKK1	B-Protein
,	O
which	O
is	O
activated	O
upon	O
phosphorylation	O
by	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
inducing	I-Protein
kinase	I-Protein
(	O
NIK	B-Protein
)	O
.	O

NIK	B-Protein
is	O
predominantly	O
regulated	O
at	O
the	O
post	O
-	O
translational	O
level	O
and	O
is	O
present	O
at	O
extremely	O
low	O
levels	O
in	O
most	O
cell	O
types	O
.	O

In	O
unstimulated	O
cells	O
,	O
NIK	B-Protein
occurs	O
in	O
a	O
cytoplasmic	O
complex	O
with	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
which	O
K48	O
-	O
polyubiquitinates	O
NIK	B-Protein
,	O
leading	O
to	O
its	O
continuous	O
degradation	O
by	O
the	O
proteasome	O
.	O

Receptor	O
ligation	O
has	O
been	O
shown	O
not	O
only	O
to	O
remove	O
TRAF3	B-Protein
from	O
this	O
complex	O
by	O
recruiting	O
it	O
to	O
the	O
receptor	O
,	O
but	O
also	O
to	O
attract	O
TRAF2	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
which	O
are	O
essential	O
for	O
subsequent	O
TRAF3	B-Protein
degradation	O
.	O

All	O
this	O
contributes	O
to	O
releasing	O
NIK	B-Protein
from	O
its	O
constitutive	O
degradation	O
,	O
resulting	O
in	O
NIK	B-Protein
accumulation	O
and	O
IKK1	B-Protein
phosphorylation	O
[	O
28	O
,	O
29	O
]	O
(	O
Figure	O
2	O
)	O
.	O

It	O
should	O
be	O
mentioned	O
that	O
CD40	B-Protein
,	O
lymphotoxin	B-Protein
beta	I-Protein
receptor	I-Protein
and	O
RANK	B-Protein
mediate	O
the	O
activation	O
of	O
both	O
canonical	O
and	O
noncanonical	O
NF	O
-	O
kappaB	O
signalling	O
pathways	O
.	O

Upon	O
binding	O
of	O
their	O
ligand	O
,	O
CD40	B-Protein
and	O
RANK	B-Protein
interact	O
with	O
several	O
TRAF	O
members	O
,	O
including	O
TRAF1	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
TRAF5	B-Protein
,	O
and	O
TRAF6	B-Protein
,	O
and	O
this	O
leads	O
to	O
the	O
proteolysis	O
of	O
both	O
TRAF2	B-Protein
and	O
TRAF3	B-Protein
,	O
which	O
represents	O
an	O
important	O
step	O
in	O
the	O
activation	O
of	O
the	O
noncanonical	O
pathway	O
as	O
described	O
above	O
.	O

Specific	O
TRAF	O
molecules	O
are	O
associated	O
with	O
overlapping	O
and	O
distinct	O
CD40	B-Protein
-	O
mediated	O
functions	O
.	O

For	O
example	O
,	O
in	O
B	O
cells	O
TRAF6	B-Protein
is	O
required	O
for	O
CD40	B-Protein
-	O
mediated	O
JNK	O
activation	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
,	O
while	O
TRAF2	B-Protein
is	O
required	O
for	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
and	O
TRAF3	B-Protein
serves	O
as	O
a	O
negative	O
regulator	O
of	O
CD40	B-Protein
signalling	O
[	O
30	O
,	O
31	O
]	O
.	O

Since	O
NF	O
-	O
kappaB	O
activation	O
is	O
so	O
crucial	O
to	O
many	O
cellular	O
processes	O
,	O
a	O
tight	O
regulation	O
of	O
the	O
NF	O
-	O
kappaB	O
signalling	O
pathway	O
and	O
the	O
genes	O
it	O
induces	O
is	O
an	O
absolute	O
requirement	O
to	O
fine	O
-	O
tune	O
the	O
inflammatory	O
response	O
.	O

Moreover	O
,	O
terminating	O
an	O
NF	O
-	O
kappaB	O
response	O
is	O
essential	O
to	O
prevent	O
persistent	O
NF	O
-	O
kappaB	O
activation	O
that	O
may	O
lead	O
to	O
chronic	O
inflammation	O
and	O
/	O
or	O
tumorigenesis	O
.	O

To	O
achieve	O
this	O
,	O
cells	O
employ	O
different	O
mechanisms	O
,	O
including	O
the	O
expression	O
of	O
inhibitory	O
proteins	O
that	O
downregulate	O
NF	O
-	O
kappaB	O
signalling	O
[	O
32	O
]	O
.	O

Below	O
we	O
give	O
an	O
overview	O
of	O
a	O
number	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
dampening	O
or	O
termination	O
of	O
the	O
NF	O
-	O
kappaB	O
response	O
,	O
some	O
of	O
them	O
under	O
the	O
control	O
of	O
NF	O
-	O
kappaB	O
itself	O
and	O
thus	O
acting	O
in	O
a	O
negative	O
feedback	O
loop	O
.	O

In	O
addition	O
,	O
we	O
discuss	O
the	O
potential	O
role	O
of	O
these	O
NF	O
-	O
kappaB	O
inhibitory	O
factors	O
in	O
the	O
immunopathology	O
of	O
RA	O
.	O

Several	O
other	O
proteins	O
involved	O
in	O
the	O
negative	O
regulation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
inflammatory	O
responses	O
,	O
such	O
as	O
MyD88s	B-Protein
,	O
IRAK	B-Protein
-	I-Protein
M	I-Protein
,	O
and	O
TOLLIP	B-Protein
,	O
have	O
been	O
described	O
(	O
reviewed	O
in	O
[	O
33	O
]	O
)	O
.	O

These	O
proteins	O
are	O
not	O
discussed	O
here	O
,	O
since	O
a	O
link	O
with	O
RA	O
pathology	O
has	O
not	O
yet	O
been	O
reported	O
.	O
Although	O
IKK1	B-Protein
is	O
a	O
critical	O
component	O
of	O
the	O
non	O
-	O
canonical	O
NF	O
-	O
kappaB	O
pathway	O
,	O
it	O
should	O
be	O
mentioned	O
that	O
this	O
kinase	O
also	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
both	O
canonical	O
and	O
noncanonical	O
NF	O
-	O
kappaB	O
pathways	O
.	O

Macrophages	O
from	O
IKK1	B-Protein
-	O
deficient	O
mice	O
or	O
knockin	O
mice	O
expressing	O
inactive	O
IKK1	B-Protein
show	O
increased	O
production	O
of	O
proinflammatory	O
cytokines	O
as	O
a	O
result	O
of	O
enhanced	O
IKK2	B-Protein
activation	O
and	O
IkappaBalpha	B-Protein
degradation	O
[	O
34	O
]	O
.	O

IKK1	B-Protein
has	O
also	O
been	O
shown	O
to	O
inhibit	O
nuclear	O
NF	O
-	O
kappaB	O
and	O
to	O
downregulate	O
proinflammatory	O
signalling	O
by	O
phosphorylating	O
STAT1	B-Protein
[	O
35	O
]	O
.	O

Interestingly	O
,	O
a	O
recent	O
study	O
has	O
demonstrated	O
that	O
IKK1	B-Protein
phosphorylates	O
NIK	B-Protein
in	O
negative	O
feedback	O
regulation	O
of	O
the	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
[	O
36	O
]	O
,	O
supporting	O
the	O
idea	O
that	O
IKK1	B-Protein
plays	O
important	O
roles	O
in	O
terminating	O
both	O
canonical	O
and	O
noncanonical	O
NF	O
-	O
kappaB	O
pathways	O
with	O
possible	O
implications	O
for	O
chronic	O
inflammatory	O
diseases	O
like	O
RA	O
.	O

A20	B-Protein
protein	O

A20	B-Protein
(	O
also	O
known	O
as	O
TNFAIP3	B-Protein
)	O
is	O
a	O
ubiquitin	B-Protein
-	I-Protein
editing	I-Protein
protein	I-Protein
that	O
negatively	O
regulates	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
-	O
dependent	O
gene	O
expression	O
in	O
response	O
to	O
different	O
immune	O
-	O
activating	O
stimuli	O
,	O
including	O
TNF	B-Protein
,	O
IL	O
-	O
1	O
and	O
antigens	O
,	O
and	O
the	O
triggering	O
of	O
TLRs	O
and	O
the	O
nucleotide	O
-	O
binding	O
oligomerisation	O
domain	O
-	O
containing	O
2	O
receptor	O
(	O
reviewed	O
in	O
[	O
37	O
]	O
)	O
.	O

A20	B-Protein
is	O
believed	O
to	O
inhibit	O
NF	O
-	O
kappaB	O
function	O
by	O
deubiquitinating	O
specific	O
NF	O
-	O
kappaB	O
signalling	O
molecules	O
,	O
such	O
as	O
RIP1	B-Protein
,	O
RIP2	B-Protein
,	O
TRAF6	B-Protein
and	O
MALT1	B-Protein
,	O
which	O
disrupts	O
specific	O
protein	O
-	O
protein	O
interactions	O
[	O
38	O
-	O
41	O
]	O
(	O
Figure	O
1	O
)	O
.	O

Recently	O
,	O
the	O
disruption	O
of	O
interactions	O
between	O
E2	O
ubiquitin	O
conjugating	O
enzymes	O
(	O
Ubc13	B-Protein
and	O
Ubc5hc	B-Protein
)	O
and	O
E3	O
ubiquitin	O
ligases	O
(	O
TRAF6	B-Protein
,	O
TRAF2	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
)	O
were	O
described	O
as	O
another	O
important	O
mechanism	O
used	O
by	O
A20	B-Protein
to	O
downregulate	O
NF	O
-	O
kappaB	O
signalling	O
[	O
42	O
]	O
.	O

The	O
association	O
of	O
A20	B-Protein
with	O
its	O
targets	O
requires	O
specific	O
ubiquitin	O
-	O
binding	O
adaptor	O
proteins	O
,	O
including	O
A20	B-Protein
-	I-Protein
binding	I-Protein
inhibitor	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
(	I-Protein
ABIN	I-Protein
)	I-Protein
1	I-Protein
and	O
Tax1	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
[	O
43	O
-	O
46	O
]	O
.	O

Next	O
to	O
its	O
role	O
in	O
suppressing	O
NF	O
-	O
kappaB	O
activation	O
,	O
A20	B-Protein
is	O
also	O
a	O
strong	O
inhibitor	O
of	O
apoptosis	O
,	O
at	O
least	O
in	O
some	O
cell	O
types	O
.	O

The	O
mechanisms	O
by	O
which	O
A20	B-Protein
regulates	O
apoptotic	O
signalling	O
,	O
however	O
,	O
are	O
still	O
elusive	O
.	O

A20	B-Protein
-	O
deficient	O
mice	O
spontaneously	O
develop	O
multiorgan	O
inflammation	O
and	O
cachexia	O
and	O
die	O
within	O
2	O
weeks	O
of	O
birth	O
,	O
illustrating	O
the	O
potent	O
anti	O
-	O
inflammatory	O
function	O
of	O
this	O
molecule	O
[	O
46	O
]	O
.	O

A20	B-Protein
-	O
deficient	O
cells	O
are	O
also	O
more	O
susceptible	O
to	O
TNF	B-Protein
-	O
mediated	O
apoptosis	O
,	O
confirming	O
its	O
role	O
as	O
an	O
antiapoptotic	O
protein	O
.	O

We	O
recently	O
showed	O
that	O
mice	O
specifically	O
lacking	O
A20	B-Protein
in	O
intestinal	O
epithelial	O
cells	O
exhibit	O
increased	O
susceptibility	O
to	O
experimental	O
colitis	O
due	O
to	O
the	O
hypersensitivity	O
of	O
their	O
intestinal	O
epithelial	O
cells	O
to	O
TNF	B-Protein
-	O
induced	O
apoptosis	O
,	O
confirming	O
A20	B-Protein
as	O
a	O
major	O
antiapoptotic	O
protein	O
in	O
the	O
intestinal	O
epithelium	O
[	O
47	O
]	O
.	O

Two	O
independent	O
studies	O
showed	O
that	O
mice	O
lacking	O
A20	B-Protein
in	O
B	O
cells	O
develop	O
autoimmunity	O
due	O
to	O
hyperactive	O
NF	O
-	O
kappaB	O
responses	O
in	O
B	O
cells	O
leading	O
to	O
unrestricted	O
B	O
-	O
cell	O
survival	O
[	O
48	O
,	O
49	O
]	O
.	O

A20	B-Protein
expression	O
has	O
been	O
observed	O
in	O
several	O
cell	O
types	O
that	O
play	O
important	O
roles	O
in	O
the	O
pathophysiology	O
of	O
RA	O
,	O
such	O
as	O
fibroblasts	O
,	O
synoviocytes	O
and	O
lymphocytes	O
.	O

Interestingly	O
,	O
A20	B-Protein
expression	O
is	O
itself	O
regulated	O
by	O
NF	O
-	O
kappaB	O
[	O
50	O
]	O
,	O
implicating	O
A20	B-Protein
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
signalling	O
.	O

Recently	O
,	O
intra	O
-	O
articular	O
injection	O
of	O
an	O
A20	B-Protein
-	O
expressing	O
adenovirus	O
was	O
shown	O
to	O
reduce	O
the	O
severity	O
of	O
synovial	O
inflammation	O
and	O
joint	O
destruction	O
in	O
a	O
mouse	O
model	O
of	O
collagen	O
-	O
induced	O
arthritis	O
,	O
even	O
in	O
untreated	O
joints	O
,	O
in	O
both	O
a	O
prophylactic	O
and	O
therapeutic	O
setting	O
.	O

A20	B-Protein
expression	O
in	O
synovial	O
tissue	O
was	O
associated	O
with	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
decreased	O
levels	O
of	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
soluble	O
RANKL	B-Protein
,	O
monocyte	B-Protein
chemo	I-Protein
-	I-Protein
attractant	I-Protein
protein	I-Protein
1	I-Protein
,	O
and	O
IL	O
-	O
17	O
,	O
suggesting	O
that	O
A20	B-Protein
induces	O
a	O
protective	O
effect	O
in	O
collagen	O
-	O
induced	O
arthritis	O
mice	O
through	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
[	O
51	O
]	O
.	O

Because	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
are	O
known	O
to	O
mediate	O
synovitis	O
,	O
pannus	O
formation	O
,	O
and	O
erosion	O
of	O
cartilage	O
and	O
bone	O
in	O
RA	O
,	O
the	O
decreased	O
serum	O
levels	O
of	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
A20	B-Protein
-	O
transduced	O
mice	O
might	O
explain	O
the	O
beneficial	O
effects	O
in	O
the	O
clinical	O
,	O
pathological	O
,	O
and	O
radiological	O
findings	O
.	O

This	O
study	O
also	O
demonstrated	O
that	O
A20	B-Protein
overexpression	O
leads	O
to	O
a	O
decrease	O
in	O
the	O
number	O
of	O
activated	O
osteoclasts	O
in	O
joint	O
tissue	O
.	O

A20	B-Protein
might	O
therefore	O
minimise	O
joint	O
destruction	O
through	O
decreasing	O
the	O
osteoclast	O
number	O
and	O
activity	O
.	O

It	O
will	O
be	O
interesting	O
to	O
analyse	O
in	O
future	O
the	O
susceptibility	O
of	O
conditional	O
knockout	O
mice	O
that	O
lack	O
A20	B-Protein
in	O
specific	O
cell	O
types	O
such	O
as	O
synovial	O
fibroblasts	O
,	O
macrophages	O
,	O
dendritic	O
cells	O
,	O
B	O
cells	O
or	O
T	O
cells	O
.	O

Importantly	O
,	O
several	O
SNPs	O
in	O
the	O
human	O
A20	B-Protein
locus	O
have	O
been	O
associated	O
with	O
increased	O
susceptibility	O
to	O
development	O
of	O
autoimmune	O
pathologies	O
(	O
reviewed	O
in	O
[	O
52	O
]	O
)	O
.	O

Several	O
genome	O
-	O
wide	O
association	O
studies	O
also	O
revealed	O
a	O
clear	O
association	O
between	O
mutations	O
in	O
the	O
A20	B-Protein
locus	O
in	O
the	O
6q23	O
chromosome	O
and	O
susceptibility	O
to	O
RA	O
[	O
52	O
]	O
.	O

Although	O
the	O
identified	O
variants	O
are	O
not	O
located	O
in	O
a	O
gene	O
,	O
they	O
are	O
thought	O
to	O
influence	O
A20	B-Protein
as	O
its	O
nearest	O
gene	O
(	O
~	O
150	O
kb	O
downstream	O
of	O
A20	B-Protein
)	O
,	O
probably	O
by	O
the	O
presence	O
of	O
potential	O
regulatory	O
DNA	O
elements	O
in	O
this	O
region	O
.	O

As	O
A20	B-Protein
is	O
required	O
for	O
termination	O
of	O
TNF	B-Protein
-	O
induced	O
signals	O
,	O
and	O
TNF	B-Protein
is	O
the	O
primary	O
inflammatory	O
cytokine	B-Protein
in	O
RA	O
,	O
these	O
findings	O
reveal	O
A20	B-Protein
as	O
a	O
candidate	O
susceptibility	O
locus	O
for	O
RA	O
.	O

How	O
these	O
variants	O
affect	O
normal	O
A20	B-Protein
activity	O
and	O
how	O
they	O
cause	O
RA	O
,	O
however	O
,	O
remain	O
unclear	O
.	O

Recently	O
,	O
Elsby	O
and	O
colleagues	O
functionally	O
evaluated	O
in	O
vitro	O
the	O
regulatory	O
ability	O
of	O
RA	O
-	O
associated	O
SNP	O
variants	O
on	O
A20	B-Protein
promoter	O
activity	O
,	O
and	O
could	O
show	O
repressed	O
A20	B-Protein
transcription	O
for	O
some	O
of	O
the	O
SNPs	O
investigated	O
[	O
53	O
]	O
.	O

It	O
will	O
be	O
of	O
interest	O
to	O
identify	O
the	O
actual	O
causal	O
variants	O
and	O
to	O
elucidate	O
the	O
functional	O
consequences	O
of	O
these	O
variants	O
.	O

In	O
this	O
context	O
,	O
knockin	O
mice	O
for	O
the	O
corresponding	O
A20	B-Protein
SNPs	O
,	O
combined	O
with	O
mouse	O
models	O
for	O
RA	O
,	O
will	O
be	O
very	O
valuable	O
tools	O
.	O

A20	B-Protein
-	O
binding	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O

ABIN	B-Protein
-	I-Protein
1	I-Protein
,	O
ABIN	B-Protein
-	I-Protein
2	I-Protein
and	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
(	O
also	O
known	O
as	O
TNIP	B-Protein
-	I-Protein
1	I-Protein
,	O
TNIP	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
TNIP	B-Protein
-	I-Protein
3	I-Protein
)	O
were	O
identified	O
as	O
ubiquitously	O
expressed	O
A20	B-Protein
interacting	O
proteins	O
and	O
were	O
shown	O
to	O
inhibit	O
NF	O
-	O
kappaB	O
activation	O
by	O
TNF	B-Protein
and	O
several	O
other	O
inflammatory	O
stimuli	O
upon	O
overexpression	O
.	O

Because	O
ABINs	O
contain	O
a	O
specific	O
ubiquitin	O
-	O
binding	O
motif	O
,	O
they	O
have	O
been	O
proposed	O
to	O
target	O
A20	B-Protein
to	O
polyubiquitinated	O
substrates	O
[	O
43	O
,	O
44	O
]	O
.	O

Similar	O
to	O
A20	B-Protein
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
and	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
expression	O
is	O
NF	O
-	O
kappaB	O
dependent	O
,	O
implicating	O
a	O
potential	O
role	O
for	O
the	O
A20	B-Protein
/	O
ABIN	O
complex	O
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
(	O
reviewed	O
in	O
[	O
54	O
]	O
)	O
.	O

Unexpectedly	O
,	O
both	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
-	O
deficient	O
and	O
ABIN	B-Protein
-	I-Protein
2	I-Protein
-	O
deficient	O
mice	O
exhibit	O
only	O
slightly	O
increased	O
or	O
normal	O
NF	O
-	O
kappaB	O
responses	O
,	O
respectively	O
,	O
possibly	O
reflecting	O
redundant	O
NF	O
-	O
kappaB	O
inhibitory	O
activities	O
of	O
multiple	O
ABINs	O
[	O
55	O
,	O
56	O
]	O
.	O

Functional	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
is	O
expressed	O
in	O
humans	O
,	O
but	O
mice	O
only	O
express	O
a	O
truncated	B-Protein
and	I-Protein
inactive	I-Protein
form	I-Protein
lacking	O
the	O
crucial	O
ubiquitin	O
-	O
binding	O
domain	O
[	O
57	O
]	O
.	O

As	O
for	O
A20	B-Protein
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
also	O
strongly	O
inhibits	O
TNF	B-Protein
-	O
induced	O
apoptosis	O
[	O
58	O
]	O
,	O
and	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
deficient	O
mice	O
die	O
embryonically	O
due	O
to	O
TNF	B-Protein
-	O
dependent	O
foetal	O
liver	O
apoptosis	O
[	O
56	O
]	O
.	O

Using	O
oligonucleotide	O
microarray	O
analysis	O
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
was	O
identified	O
among	O
TNF	B-Protein
-	O
induced	O
genes	O
in	O
human	O
synoviocytes	O
,	O
and	O
high	O
levels	O
of	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
were	O
detected	O
in	O
RA	O
tissue	O
biopsies	O
,	O
indicating	O
a	O
potential	O
role	O
for	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
,	O
together	O
with	O
A20	B-Protein
,	O
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
signalling	O
and	O
the	O
pathogenesis	O
of	O
RA	O
[	O
59	O
]	O
.	O

In	O
a	O
recent	O
study	O
,	O
inhibition	O
of	O
TLR	O
responses	O
by	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
(	O
ITAM	O
)	O
-	O
coupled	O
receptors	O
was	O
shown	O
to	O
depend	O
on	O
the	O
expression	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
proteins	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
and	O
A20	B-Protein
.	O

Moreover	O
,	O
this	O
protective	O
effect	O
of	O
the	O
ITAM	O
was	O
strongly	O
suppressed	O
in	O
inflammatory	O
arthritis	O
synovial	O
macrophages	O
[	O
60	O
]	O
.	O

Interestingly	O
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
polymorphisms	O
have	O
been	O
associated	O
with	O
psoriasis	O
and	O
systemic	O
lupus	O
erythematosus	O
in	O
humans	O
[	O
61	O
,	O
62	O
]	O
.	O

A	O
high	O
degree	O
of	O
overlap	O
between	O
systemic	O
lupus	O
erythematosus	O
and	O
RA	O
susceptibility	O
loci	O
might	O
be	O
expected	O
as	O
the	O
two	O
diseases	O
show	O
some	O
clinical	O
overlap	O
in	O
joint	O
involvement	O
,	O
autoantibody	O
production	O
,	O
systemic	O
features	O
and	O
response	O
to	O
treatments	O
such	O
as	O
B	O
-	O
cell	O
depletion	O
(	O
rituximab	O
)	O
.	O

It	O
will	O
therefore	O
be	O
interesting	O
to	O
investigate	O
whether	O
SNPs	O
that	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
systemic	O
lupus	O
erythematosus	O
are	O
also	O
associated	O
with	O
RA	O
.	O

Cylindromatosis	B-Protein
protein	O

Cylindromatosis	B-Protein
(	O
CYLD	B-Protein
)	O
protein	O
was	O
originally	O
identified	O
as	O
a	O
tumour	O
suppressor	O
involved	O
in	O
familial	O
cylindromatosis	O
[	O
63	O
]	O
.	O

CYLD	B-Protein
is	O
also	O
involved	O
,	O
however	O
,	O
in	O
diverse	O
physiological	O
processes	O
ranging	O
from	O
immunity	O
and	O
inflammation	O
to	O
cell	O
cycle	O
progression	O
,	O
spermatogenesis	O
,	O
and	O
osteoclastogenesis	O
(	O
reviewed	O
in	O
[	O
64	O
]	O
)	O
.	O

CYLD	B-Protein
is	O
a	O
deubiquitinating	B-Protein
enzyme	I-Protein
that	O
negatively	O
regulates	O
NF	O
-	O
kappaB	O
signalling	O
initiated	O
by	O
TNFR	O
,	O
RANK	B-Protein
and	O
T	O
-	O
cell	O
receptor	O
stimulation	O
(	O
reviewed	O
in	O
[	O
64	O
]	O
)	O
(	O
Figure	O
1	O
)	O
,	O
by	O
deubiquitina	O
-	O
ting	O
several	O
NF	O
-	O
kappaB	O
signalling	O
proteins	O
including	O
NEMO	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF6	B-Protein
,	O
TRAF7	B-Protein
,	O
RIP1	B-Protein
and	O
TAK1	B-Protein
.	O

Many	O
of	O
these	O
are	O
also	O
targeted	O
by	O
A20	B-Protein
and	O
it	O
is	O
still	O
not	O
clear	O
why	O
the	O
cell	O
needs	O
A20	B-Protein
as	O
well	O
as	O
CYLD	B-Protein
to	O
control	O
NF	O
-	O
kappaB	O
activation	O
.	O

As	O
A20	B-Protein
is	O
only	O
expressed	O
in	O
many	O
cell	O
types	O
upon	O
stimulation	O
,	O
it	O
has	O
been	O
suggested	O
that	O
this	O
protein	O
mainly	O
regulates	O
later	O
phases	O
of	O
NF	O
-	O
kappaB	O
signalling	O
,	O
whereas	O
CYLD	B-Protein
would	O
regulate	O
constitutive	O
and	O
early	O
signalling	O
.	O

In	O
addition	O
,	O
their	O
relative	O
activity	O
might	O
also	O
be	O
cell	O
-	O
type	O
dependent	O
[	O
64	O
]	O
.	O

Interestingly	O
,	O
CYLD	B-Protein
has	O
been	O
shown	O
to	O
negatively	O
regulate	O
RANK	B-Protein
signalling	O
and	O
osteoclastogenesis	O
in	O
mice	O
[	O
65	O
]	O
.	O

Mice	O
with	O
a	O
genetic	O
deficiency	O
of	O
CYLD	B-Protein
have	O
aberrant	O
osteoclast	O
differentiation	O
and	O
develop	O
severe	O
osteoporosis	O
.	O

Osteoclast	O
precursors	O
of	O
these	O
mice	O
are	O
hyper	O
-	O
responsive	O
to	O
RANKL	B-Protein
-	O
induced	O
differentiation	O
and	O
produce	O
more	O
and	O
larger	O
osteoclasts	O
.	O

CYLD	B-Protein
expression	O
is	O
markedly	O
upregulated	O
under	O
conditions	O
of	O
RANKL	B-Protein
-	O
induced	O
osteoclastogenesis	O
and	O
is	O
recruited	O
to	O
ubiquitinated	O
TRAF6	B-Protein
via	O
the	O
ubiquitin	B-Protein
-	O
binding	O
adaptor	O
protein	O
p62	B-Protein
(	O
also	O
known	O
as	O
sequestosome	B-Protein
1	I-Protein
)	O
[	O
65	O
]	O
,	O
followed	O
by	O
the	O
CYLD	B-Protein
-	O
mediated	O
deubiquitination	O
of	O
TRAF6	B-Protein
.	O

In	O
this	O
context	O
,	O
it	O
is	O
worth	O
mentioning	O
that	O
transgenic	O
mice	O
expressing	O
a	O
mutated	O
form	O
of	O
p62	B-Protein
also	O
display	O
abnormal	O
osteoclastogenesis	O
and	O
develop	O
progressive	O
bone	O
loss	O
[	O
66	O
]	O
.	O

These	O
findings	O
suggest	O
that	O
CYLD	B-Protein
-	O
mediated	O
inhibi	O
-	O
tion	O
of	O
RANK	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
signalling	O
plays	O
a	O
key	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
osteoclastogenesis	O
and	O
indicate	O
CYLD	B-Protein
as	O
a	O
potential	O
genetic	O
factor	O
involved	O
in	O
the	O
pathology	O
of	O
bone	O
disorders	O
such	O
as	O
RA	O
.	O

Single	B-Protein
-	I-Protein
immunoglobulin	I-Protein
IL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
protein	O

Single	B-Protein
-	I-Protein
immunoglobulin	I-Protein
IL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
(	O
SIGIRR	B-Protein
)	O
protein	O
,	O
also	O
known	O
as	O
TIR	B-Protein
-	I-Protein
8	I-Protein
,	O
is	O
a	O
member	O
of	O
the	O
TLR	O
/	O
IL	O
-	O
1R	O
family	O
that	O
has	O
been	O
extensively	O
characterised	O
as	O
an	O
inhibitor	O
of	O
IL	B-Protein
-	I-Protein
1R	I-Protein
and	O
TLR	O
signalling	O
,	O
probably	O
through	O
direct	O
interaction	O
with	O
these	O
receptors	O
,	O
MyD88	B-Protein
,	O
IRAK1	B-Protein
or	O
TRAF6	B-Protein
[	O
67	O
]	O
(	O
Figure	O
1	O
)	O
.	O

Given	O
the	O
important	O
role	O
of	O
IL	B-Protein
-	I-Protein
1R	I-Protein
and	O
TLR	O
signalling	O
in	O
the	O
chronic	O
inflammation	O
observed	O
in	O
RA	O
[	O
68	O
]	O
,	O
a	O
regulatory	O
role	O
for	O
SIGIRR	B-Protein
in	O
RA	O
is	O
not	O
unlikely	O
.	O

SIGIRR	B-Protein
has	O
a	O
very	O
restricted	O
expression	O
pattern	O
,	O
being	O
expressed	O
in	O
epithelial	O
cells	O
,	O
monocytes	O
and	O
immature	O
dendritic	O
cells	O
,	O
but	O
not	O
in	O
mature	O
macro	O
-	O
phages	O
[	O
69	O
,	O
70	O
]	O
.	O

Recently	O
,	O
SIGIRR	B-Protein
overexpression	O
was	O
shown	O
to	O
inhibit	O
the	O
spontaneous	O
release	O
of	O
inflammatory	O
cytokines	O
by	O
human	O
RA	O
synovial	O
cells	O
.	O

This	O
inhibitory	O
function	O
of	O
SIGIRR	B-Protein
was	O
further	O
confirmed	O
in	O
vivo	O
,	O
since	O
SIGIRR	B-Protein
-	O
deficient	O
mice	O
developed	O
a	O
more	O
severe	O
disease	O
in	O
zymosan	O
-	O
induced	O
arthritis	O
,	O
as	O
well	O
as	O
collagen	O
-	O
induced	O
arthritis	O
mouse	O
models	O
[	O
70	O
]	O
.	O

It	O
will	O
be	O
interesting	O
to	O
compare	O
the	O
expression	O
of	O
SIGIRR	B-Protein
in	O
RA	O
patients	O
with	O
its	O
expression	O
in	O
control	O
patients	O
,	O
or	O
to	O
investigate	O
whether	O
the	O
function	O
of	O
SIGIRR	B-Protein
is	O
compromised	O
in	O
RA	O
patients	O
.	O

Because	O
of	O
its	O
restricted	O
expression	O
pattern	O
,	O
SIGIRR	B-Protein
may	O
also	O
be	O
an	O
interesting	O
therapeutic	O
target	O
in	O
RA	O
.	O

TNF	B-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
1	I-Protein

TRAF1	B-Protein
is	O
a	O
unique	O
member	O
of	O
the	O
TRAF	O
protein	O
family	O
because	O
it	O
lacks	O
a	O
RING	O
finger	O
domain	O
and	O
therefore	O
lacks	O
ubiquitin	B-Protein
ligase	O
activity	O
.	O

Accumulating	O
data	O
support	O
a	O
role	O
for	O
TRAF1	B-Protein
as	O
both	O
a	O
negative	O
and	O
a	O
positive	O
modulator	O
of	O
NF	O
-	O
kappaB	O
signalling	O
by	O
certain	O
TNF	O
family	O
receptors	O
,	O
possibly	O
in	O
a	O
cell	O
-	O
type	O
-	O
dependent	O
manner	O
[	O
71	O
,	O
72	O
]	O
.	O

Expression	O
of	O
TRAF1	B-Protein
is	O
inducible	O
by	O
TNF	B-Protein
and	O
overexpression	O
of	O
TRAF1	B-Protein
inhibits	O
TNF	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

TRAF1	B-Protein
-	O
deficient	O
T	O
cells	O
are	O
hyper	O
-	O
responsive	O
to	O
TNF	B-Protein
,	O
with	O
enhanced	O
proliferation	O
and	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
signalling	O
pathway	O
.	O

TRAF1	B-Protein
also	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
CD40	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

TRAF1	B-Protein
-	O
deficient	O
dendritic	O
cells	O
,	O
however	O
,	O
show	O
attenuated	O
responses	O
to	O
secondary	O
stimulation	O
by	O
TRAF2	B-Protein
-	O
dependent	O
factors	O
,	O
suggesting	O
a	O
positive	O
regulatory	O
role	O
in	O
these	O
cells	O
.	O

The	O
mechanism	O
by	O
which	O
TRAF1	B-Protein
modulates	O
NF	O
-	O
kappaB	O
activation	O
is	O
still	O
unclear	O
.	O

Most	O
probably	O
,	O
TRAF1	B-Protein
competes	O
with	O
TRAF	O
family	O
members	O
for	O
binding	O
to	O
the	O
receptor	O
or	O
other	O
signalling	O
proteins	O
.	O

Alternatively	O
,	O
TRAF1	B-Protein
might	O
recruit	O
A20	B-Protein
with	O
which	O
it	O
can	O
physically	O
interact	O
[	O
73	O
]	O
.	O

A	O
genome	O
-	O
wide	O
association	O
study	O
examining	O
more	O
than	O
300	O
,	O
000	O
SNPs	O
among	O
approximately	O
1	O
,	O
500	O
autoantibody	O
-	O
positive	O
RA	O
cases	O
and	O
1	O
,	O
800	O
controls	O
identified	O
a	O
genetic	O
variation	O
at	O
the	O
TRAF1	B-Protein
-	O
complement	O
component	O
5	O
locus	O
as	O
an	O
important	O
RA	O
risk	O
locus	O
[	O
74	O
]	O
.	O

Subsequent	O
work	O
indicates	O
that	O
TRAF1	B-Protein
is	O
more	O
likely	O
to	O
be	O
the	O
causative	O
locus	O
[	O
75	O
]	O
.	O

Recent	O
work	O
in	O
a	O
Korean	O
population	O
also	O
demonstrates	O
genetic	O
association	O
of	O
the	O
TRAF1	B-Protein
region	O
with	O
RA	O
[	O
76	O
]	O
.	O

microRNAs	O

miRNAs	O
are	O
recently	O
discovered	O
regulators	O
of	O
gene	O
expression	O
and	O
represent	O
a	O
class	O
of	O
noncoding	O
RNA	O
molecules	O
essential	O
in	O
many	O
cellular	O
and	O
developmental	O
processes	O
,	O
including	O
immune	O
responses	O
and	O
inflammation	O
.	O

They	O
bind	O
the	O
3	O
'	O
-	O
UTR	O
of	O
target	O
mRNAs	O
leading	O
to	O
the	O
repression	O
of	O
protein	O
expression	O
and	O
the	O
promotion	O
of	O
target	O
mRNA	O
degradation	O
[	O
77	O
]	O
.	O

miR	B-Protein
-	I-Protein
146a	I-Protein
/	O
b	B-Protein
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
are	O
of	O
particular	O
interest	O
for	O
inflammatory	O
signalling	O
to	O
NF	O
-	O
kappaB	O
,	O
since	O
these	O
miRNAs	O
can	O
be	O
induced	O
by	O
inflammatory	O
stimuli	O
such	O
as	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
TNF	B-Protein
and	O
TLRs	O
[	O
78	O
,	O
79	O
]	O
.	O

In	O
addition	O
,	O
miR	B-Protein
-	I-Protein
146a	I-Protein
is	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
,	O
and	O
the	O
NF	O
-	O
kappaB	O
signalling	O
molecules	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
were	O
identified	O
as	O
target	O
genes	O
of	O
miR	B-Protein
-	I-Protein
146a	I-Protein
[	O
78	O
]	O
(	O
Figure	O
1	O
)	O
.	O

Similarly	O
,	O
miR	B-Protein
-	I-Protein
155	I-Protein
was	O
shown	O
to	O
target	O
transcripts	O
for	O
the	O
NF	O
-	O
kappaB	O
signalling	O
molecules	O
IKKepsilon	B-Protein
and	O
RIP1	B-Protein
[	O
79	O
,	O
80	O
]	O
.	O

Notably	O
,	O
both	O
miR	O
-	O
146	O
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
are	O
expressed	O
at	O
higher	O
levels	O
in	O
RA	O
synovial	O
fibroblasts	O
and	O
synovial	O
tissue	O
[	O
81	O
,	O
82	O
]	O
,	O
as	O
well	O
as	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
RA	O
patients	O
[	O
83	O
]	O
.	O

miR	B-Protein
-	I-Protein
146a	I-Protein
is	O
also	O
overexpressed	O
in	O
CD4	B-Protein
+	O
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
-	O
producing	O
T	O
cells	O
from	O
RA	O
patients	O
[	O
84	O
,	O
85	O
]	O
.	O

Interestingly	O
,	O
a	O
polymorphism	O
in	O
the	O
3	O
'	O
-	O
UTR	O
of	O
the	O
miR	B-Protein
-	I-Protein
146a	I-Protein
target	O
gene	O
was	O
recently	O
shown	O
to	O
be	O
associated	O
with	O
RA	O
susceptibility	O
[	O
86	O
]	O
.	O

miR	B-Protein
-	I-Protein
155	I-Protein
overexpression	O
in	O
synovial	O
fibroblasts	O
was	O
able	O
to	O
prevent	O
the	O
TLR	O
and	O
cytokine	O
-	O
inducible	O
expression	O
of	O
specific	O
matrix	O
metalloproteinases	O
that	O
mediate	O
tissue	O
destruction	O
in	O
RA	O
[	O
81	O
]	O
.	O

Moreover	O
,	O
miR	B-Protein
-	I-Protein
155	I-Protein
was	O
shown	O
to	O
promote	O
TNF	B-Protein
production	O
,	O
a	O
key	O
process	O
in	O
the	O
pathogenesis	O
of	O
RA	O
[	O
87	O
]	O
.	O

miR	O
-	O
146	O
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
may	O
therefore	O
be	O
important	O
negative	O
regulators	O
of	O
inflammation	O
in	O
RA	O
and	O
their	O
potential	O
for	O
the	O
development	O
of	O
new	O
treatments	O
is	O
substantial	O
.	O

In	O
addition	O
,	O
their	O
increased	O
expression	O
in	O
RA	O
patients	O
is	O
potentially	O
useful	O
as	O
a	O
marker	O
for	O
disease	O
diagnosis	O
,	O
progression	O
,	O
or	O
treatment	O
efficacy	O
[	O
88	O
]	O
,	O
but	O
this	O
will	O
require	O
confirmation	O
using	O
a	O
large	O
and	O
well	O
-	O
defined	O
cohort	O
.	O

Besides	O
miR	O
-	O
146	O
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
,	O
a	O
number	O
of	O
other	O
miRNAs	O
with	O
a	O
potential	O
role	O
in	O
the	O
control	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
inflammatory	O
responses	O
in	O
RA	O
pathology	O
were	O
recently	O
identified	O
.	O

In	O
this	O
context	O
,	O
miR	B-Protein
-	I-Protein
124a	I-Protein
-	O
a	O
key	O
regulator	O
of	O
the	O
chemokine	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
1	I-Protein
-	O
was	O
shown	O
to	O
be	O
decreased	O
in	O
synoviocytes	O
from	O
RA	O
patients	O
[	O
89	O
]	O
.	O

Similarly	O
,	O
elevated	O
levels	O
of	O
miR	B-Protein
-	I-Protein
203	I-Protein
-	O
leading	O
to	O
increased	O
secretion	O
of	O
matrix	B-Protein
metalloproteinase	I-Protein
-	I-Protein
1	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
were	O
detected	O
in	O
RA	O
synovial	O
fibroblasts	O
[	O
90	O
]	O
.	O

Finally	O
,	O
miR	B-Protein
-	I-Protein
16	I-Protein
,	O
miR	B-Protein
-	I-Protein
132	I-Protein
,	O
and	O
miR	B-Protein
-	I-Protein
223	I-Protein
were	O
also	O
shown	O
to	O
have	O
an	O
altered	O
expression	O
in	O
RA	O
patients	O
,	O
indicating	O
their	O
potential	O
as	O
diagnostic	O
biomarkers	O
for	O
pathogenesis	O
[	O
83	O
,	O
88	O
,	O
91	O
]	O
.	O

The	O
NF	O
-	O
kappaB	O
family	O
of	O
transcription	O
factors	O
plays	O
crucial	O
roles	O
in	O
the	O
inflammatory	O
processes	O
in	O
RA	O
leading	O
to	O
cartilage	O
and	O
bone	O
destruction	O
.	O

Keeping	O
NF	O
-	O
kappaB	O
activation	O
under	O
control	O
can	O
thus	O
be	O
very	O
important	O
for	O
the	O
design	O
of	O
specific	O
therapeutics	O
.	O

The	O
existence	O
of	O
multiple	O
negative	O
regulators	O
ensuring	O
a	O
tight	O
regulation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
however	O
,	O
raises	O
the	O
question	O
of	O
the	O
specific	O
role	O
of	O
each	O
of	O
these	O
regulators	O
and	O
the	O
relationship	O
between	O
them	O
.	O

In	O
addition	O
,	O
given	O
the	O
number	O
of	O
miRNAs	O
in	O
humans	O
and	O
the	O
multiple	O
mRNAs	O
they	O
target	O
,	O
intense	O
complexity	O
can	O
be	O
expected	O
.	O

How	O
all	O
these	O
regulatory	O
signals	O
are	O
themselves	O
regulated	O
will	O
be	O
an	O
important	O
question	O
in	O
order	O
to	O
clarify	O
how	O
NF	O
-	O
kappaB	O
signalling	O
is	O
organised	O
,	O
and	O
,	O
more	O
importantly	O
,	O
how	O
this	O
knowledge	O
may	O
lead	O
to	O
new	O
treatments	O
for	O
inflammatory	O
diseases	O
such	O
as	O
RA	O
.	O

Canonical	O
NF	O
-	O
kappaB	O
signalling	O
and	O
negative	O
regulators	O
.	O

Ligand	O
engagement	O
of	O
specific	O
membrane	O
receptors	O
such	O
as	O
TNFR1	B-Protein
,	O
CD40	B-Protein
,	O
RANK	B-Protein
,	O
and	O
TLR4	B-Protein
trigger	O
the	O
recruitment	O
of	O
specific	O
adaptor	O
proteins	O
(	O
TNF	B-Protein
receptor	I-Protein
1	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
protein	I-Protein
(	O
TRADD	B-Protein
)	O
,	O
MyD88	B-Protein
,	O
MAL	B-Protein
,	O
TIR	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
adaptor	I-Protein
-	I-Protein
inducing	I-Protein
IFNbeta	I-Protein
(	O
TRIF	B-Protein
)	O
)	O
,	O
kinases	O
(	O
RIP1	B-Protein
,	O
IRAK1	B-Protein
,	O
IRAK4	B-Protein
)	O
,	O
and	O
ubiquitin	O
ligases	O
(	O
TRAF2	B-Protein
,	O
TRAF6	B-Protein
,	O
cIAP1	B-Protein
,	O
cIAP2	B-Protein
)	O
to	O
the	O
receptor	O
.	O

K63	O
-	O
linked	O
polyubiquitination	O
of	O
TRAFs	O
,	O
RIP1	B-Protein
and	O
IRAK1	B-Protein
,	O
is	O
recognised	O
by	O
NEMO	B-Protein
and	O
TAB	O
proteins	O
,	O
resulting	O
in	O
the	O
recruitment	O
and	O
activation	O
of	O
respectively	O
IKK2	B-Protein
and	O
TAK1	B-Protein
.	O

TAK1	B-Protein
then	O
phosphorylates	O
and	O
activates	O
IKK2	B-Protein
,	O
which	O
in	O
turn	O
phosphorylates	O
IkappaBalpha	B-Protein
,	O
triggering	O
its	O
K48	O
-	O
linked	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

This	O
allows	O
NF	O
-	O
kappaB	O
(	O
here	O
shown	O
as	O
a	O
heterodimer	O
of	O
p65	B-Protein
and	O
p50	B-Protein
)	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
promote	O
target	O
gene	O
expression	O
.	O

TRAF1	B-Protein
,	O
which	O
has	O
no	O
ubiquitin	O
ligase	O
activity	O
,	O
can	O
negatively	O
regulate	O
NF	O
-	O
kappaB	O
activation	O
,	O
most	O
probably	O
by	O
competing	O
with	O
other	O
TRAFs	O
.	O

A20	B-Protein
and	O
CYLD	B-Protein
are	O
deubiquitinating	O
enzymes	O
that	O
control	O
NF	O
-	O
kappaB	O
activation	O
by	O
targeting	O
specific	O
signalling	O
proteins	O
including	O
RIP1	B-Protein
and	O
TRAF6	B-Protein
,	O
to	O
which	O
they	O
are	O
recruited	O
using	O
specific	O
ubiquitin	O
-	O
binding	O
adaptor	O
proteins	O
such	O
as	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
and	O
p62	B-Protein
.	O

miR	O
-	O
146	O
is	O
thought	O
to	O
negatively	O
regulate	O
TLR	O
signalling	O
by	O
inhibiting	O
expression	O
of	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
.	O

Finally	O
,	O
TLR	O
signalling	O
can	O
also	O
be	O
inhibited	O
by	O
the	O
transmembrane	O
protein	O
SIGIRR	B-Protein
,	O
which	O
has	O
been	O
proposed	O
to	O
compete	O
with	O
TLR4	B-Protein
for	O
binding	O
to	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
.	O

The	O
expression	O
of	O
many	O
of	O
these	O
negative	O
regulatory	O
molecules	O
is	O
NF	O
-	O
kappaB	O
dependent	O
,	O
implicating	O
them	O
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

ABIN	B-Protein
,	O
A20	B-Protein
-	I-Protein
binding	I-Protein
inhibitor	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
;	O
cIAP	O
,	O
cellular	O
inhibitor	O
of	O
apoptosis	O
;	O
CYLD	B-Protein
,	O
cylindromatosis	B-Protein
;	O
IKK	O
,	O
IkappaB	O
kinase	O
;	O
IkappaB	O
,	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
;	O
IRAK	O
,	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
;	O
MyD88	B-Protein
,	O
myeloid	B-Protein
differentiation	I-Protein
primary	I-Protein
response	I-Protein
gene	I-Protein
88	I-Protein
;	O
NEMO	B-Protein
,	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
essential	I-Protein
modulator	I-Protein
;	O
NF	O
,	O
nuclear	O
factor	O
;	O
RANK	B-Protein
,	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
;	O
RIP1	B-Protein
,	O
receptor	B-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
;	O
SIGIRR	B-Protein
,	O
single	B-Protein
-	I-Protein
immunoglobulinIL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
;	O
TIR	O
,	O
Toll	O
-	O
like	O
receptor	O
/	O
IL	O
-	O
1R	O
;	O
TRAF	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
;	O
TLR	O
,	O
Toll	O
-	O
like	O
receptor	O
;	O
TNF	B-Protein
,	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
.	O

Noncanonical	O
NF	O
-	O
kappaB	O
signalling	O
.	O

CD40	B-Protein
and	O
RANK	B-Protein
can	O
activate	O
the	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
that	O
is	O
dependent	O
on	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
inducing	I-Protein
kinase	I-Protein
(	O
NIK	B-Protein
)	O
expression	O
levels	O
.	O

In	O
unstimulated	O
cells	O
NIK	B-Protein
forms	O
a	O
cytosolic	O
complex	O
with	O
the	O
ubiquitin	O
ligases	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
which	O
facilitates	O
the	O
K48	O
-	O
linked	O
polyubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
NIK	B-Protein
,	O
keeping	O
NIK	B-Protein
levels	O
low	O
.	O

Upon	O
ligand	O
binding	O
,	O
TRAF3	B-Protein
is	O
recruited	O
to	O
the	O
receptor	O
,	O
where	O
TRAF2	B-Protein
directs	O
nondegradative	O
K63	O
-	O
linked	O
polyubiquitination	O
of	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
resulting	O
in	O
their	O
activation	O
.	O

Subsequently	O
cIAP1	B-Protein
/	O
2	B-Protein
directs	O
its	O
K48	O
-	O
linked	O
polyubiquitination	O
to	O
TRAF3	B-Protein
,	O
rather	O
than	O
NIK	B-Protein
.	O

As	O
a	O
result	O
,	O
TRAF3	B-Protein
is	O
degraded	O
and	O
NIK	B-Protein
is	O
stabilised	O
,	O
resulting	O
in	O
increased	O
NIK	B-Protein
levels	O
in	O
the	O
cell	O
.	O

NIK	B-Protein
then	O
phosphorylates	O
and	O
activates	O
IKK1	B-Protein
,	O
which	O
mediates	O
NF	O
-	O
kappaB	O
p100	B-Protein
phosphorylation	O
.	O

This	O
is	O
followed	O
by	O
K48	O
-	O
linked	O
polyubiquitination	O
and	O
partial	O
proteasomal	O
degradation	O
of	O
p100	B-Protein
to	O
p52	B-Protein
,	O
which	O
forms	O
a	O
heterodimer	O
with	O
RelB	B-Protein
to	O
activate	O
transcription	O
.	O

Next	O
to	O
TRAF3	B-Protein
,	O
TRAF1	B-Protein
has	O
also	O
been	O
identified	O
as	O
a	O
negative	O
regulator	O
of	O
this	O
pathway	O
,	O
most	O
probably	O
by	O
competing	O
with	O
other	O
TNF	O
receptor	O
-	O
associated	O
factors	O
.	O

cIAP	O
,	O
cellular	O
inhibitor	O
of	O
apoptosis	O
;	O
IKK	O
,	O
IkappaB	O
kinase	O
;	O
NF	O
,	O
nuclear	O
factor	O
;	O
RANK	B-Protein
,	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
;	O
TRAF	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
;	O
TNF	B-Protein
,	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
.	O

A20	O
(	O
Tnfaip3	B-Protein
)	O
Deficiency	O
in	O
Myeloid	O
Cells	O
Protects	O
against	O
Influenza	O
A	O
Virus	O
Infection	O

The	O
innate	O
immune	O
response	O
provides	O
the	O
first	O
line	O
of	O
defense	O
against	O
viruses	O
and	O
other	O
pathogens	O
by	O
responding	O
to	O
specific	O
microbial	O
molecules	O
.	O

Influenza	O
A	O
virus	O
(	O
IAV	O
)	O
produces	O
double	O
-	O
stranded	O
RNA	O
as	O
an	O
intermediate	O
during	O
the	O
replication	O
life	O
cycle	O
,	O
which	O
activates	O
the	O
intracellular	O
pathogen	B-Protein
recognition	I-Protein
receptor	I-Protein
RIG	B-Protein
-	I-Protein
I	I-Protein
and	O
induces	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
and	O
antiviral	O
interferon	O
.	O

Understanding	O
the	O
mechanisms	O
that	O
regulate	O
innate	O
immune	O
responses	O
to	O
IAV	O
and	O
other	O
viruses	O
is	O
of	O
key	O
importance	O
to	O
develop	O
novel	O
therapeutic	O
strategies	O
.	O

Here	O
we	O
used	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
to	O
examine	O
the	O
role	O
of	O
the	O
ubiquitin	O
-	O
editing	O
protein	O
A20	O
in	O
the	O
response	O
of	O
myeloid	O
cells	O
to	O
IAV	O
infection	O
.	O

A20	O
deficient	O
macrophages	O
were	O
hyperresponsive	O
to	O
double	O
stranded	O
RNA	O
and	O
IAV	O
infection	O
,	O
as	O
illustrated	O
by	O
enhanced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
,	O
concomitant	O
with	O
increased	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
chemokines	O
and	O
type	O
I	O
interferon	O
.	O

In	O
vivo	O
this	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
alveolar	O
macrophages	O
and	O
neutrophils	O
in	O
the	O
lungs	O
of	O
IAV	O
infected	O
mice	O
.	O

Surprisingly	O
,	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
are	O
protected	O
against	O
lethal	O
IAV	O
infection	O
.	O

These	O
results	O
challenge	O
the	O
general	O
belief	O
that	O
an	O
excessive	O
host	O
proinflammatory	O
response	O
is	O
associated	O
with	O
IAV	O
-	O
induced	O
lethality	O
,	O
and	O
suggest	O
that	O
under	O
certain	O
conditions	O
inhibition	O
of	O
A20	O
might	O
be	O
of	O
interest	O
in	O
the	O
management	O
of	O
IAV	O
infections	O
.	O

Viruses	O
are	O
a	O
class	O
of	O
highly	O
diverse	O
pathogens	O
which	O
depend	O
on	O
the	O
host	O
cell	O
for	O
their	O
replication	O
.	O

The	O
initiation	O
of	O
a	O
protective	O
innate	O
antiviral	O
immune	O
response	O
involves	O
the	O
action	O
of	O
specialized	O
pattern	O
recognition	O
receptors	O
(	O
PRR	O
)	O
,	O
which	O
detect	O
conserved	O
molecular	O
structures	O
of	O
the	O
invading	O
pathogen	O
.	O

Triggering	O
of	O
PRRs	O
induces	O
the	O
production	O
of	O
host	O
proinflammatory	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
type	O
I	O
interferons	O
(	O
interferon	B-Protein
-	I-Protein
alpha	I-Protein
(	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
)	O
through	O
activation	O
of	O
downstream	O
signaling	O
pathways	O
that	O
control	O
various	O
transcription	O
factors	O
such	O
as	O
NF	O
-	O
kappaB	O
,	O
AP	O
-	O
1	O
,	O
IRF3	B-Protein
and	O
IRF7	B-Protein
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

The	O
presence	O
of	O
viral	O
nucleic	O
acids	O
,	O
such	O
as	O
viral	O
RNA	O
and	O
DNA	O
,	O
viral	O
replication	O
intermediates	O
and	O
viral	O
transcription	O
products	O
,	O
can	O
be	O
sensed	O
by	O
specific	O
intracellular	O
PRRs	O
[	O
3	O
]	O
.	O

Endosomal	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
and	O
cytoplasmic	O
RNA	O
helicase	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
)	O
or	O
Nod	O
-	O
like	O
receptors	O
(	O
NLRs	O
)	O
detect	O
the	O
presence	O
of	O
viral	O
single	O
stranded	O
(	O
TLR7	B-Protein
,	O
TLR8	B-Protein
,	O
Nod2	B-Protein
)	O
or	O
double	O
stranded	O
RNA	O
(	O
TLR3	B-Protein
,	O
RIG	B-Protein
-	I-Protein
I	I-Protein
,	O
MDA5	B-Protein
)	O
.	O

Intracellular	O
DNA	O
sensors	O
that	O
mediate	O
antiviral	O
immune	O
responses	O
to	O
DNA	O
viruses	O
include	O
TLR9	B-Protein
,	O
DAI	B-Protein
[	O
4	O
]	O
and	O
the	O
PYHIN	O
domain	O
containing	O
proteins	O
AIM2	B-Protein
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
and	O
IFI16	B-Protein
[	O
8	O
]	O
.	O

TLR	O
mediated	O
antiviral	O
responses	O
are	O
restricted	O
to	O
specialized	O
type	O
I	O
IFN	O
producing	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	O
)	O
,	O
while	O
most	O
other	O
cell	O
types	O
,	O
including	O
conventional	O
DC	O
(	O
cDC	O
)	O
,	O
macrophages	O
and	O
fibroblasts	O
,	O
depend	O
on	O
the	O
cytosolic	O
RNA	O
and	O
DNA	O
sensors	O
for	O
the	O
production	O
of	O
antiviral	O
proteins	O
[	O
9	O
]	O
.	O

Influenza	O
A	O
virus	O
(	O
IAV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
a	O
contagious	O
acute	O
respiratory	O
disease	O
that	O
causes	O
considerable	O
mortality	O
,	O
which	O
is	O
generally	O
believed	O
to	O
be	O
due	O
to	O
an	O
excessive	O
host	O
inflammatory	O
response	O
.	O

Emergence	O
of	O
drug	O
-	O
resistant	O
strains	O
of	O
influenza	O
viruses	O
with	O
pandemic	O
potential	O
underscores	O
the	O
importance	O
of	O
developing	O
novel	O
antiviral	O
strategies	O
.	O

In	O
this	O
context	O
,	O
understanding	O
of	O
the	O
mechanisms	O
that	O
regulate	O
IAV	O
-	O
induced	O
immune	O
responses	O
is	O
critical	O
.	O

IAV	O
infection	O
leads	O
to	O
the	O
exposure	O
in	O
the	O
host	O
cell	O
of	O
single	O
-	O
stranded	O
genomic	O
RNA	O
and	O
double	O
stranded	O
RNA	O
,	O
the	O
latter	O
being	O
an	O
intermediate	O
of	O
viral	O
replication	O
.	O

TLR3	B-Protein
and	O
RIG	B-Protein
-	I-Protein
I	I-Protein
have	O
been	O
implicated	O
as	O
sensors	O
of	O
IAV	O
infection	O
[	O
10	O
]	O
-	O
[	O
12	O
]	O
.	O

Both	O
receptors	O
contribute	O
to	O
the	O
proinflammatory	O
response	O
to	O
IAV	O
,	O
but	O
the	O
initiation	O
of	O
the	O
innate	O
antiviral	O
immune	O
response	O
largely	O
depends	O
on	O
RIG	B-Protein
-	I-Protein
I	I-Protein
mediated	O
signaling	O
[	O
13	O
]	O
.	O

Interestingly	O
,	O
RIG	B-Protein
-	I-Protein
I	I-Protein
deficient	O
mice	O
are	O
highly	O
susceptible	O
to	O
IAV	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
whereas	O
TLR3	B-Protein
deficient	O
mice	O
have	O
a	O
survival	O
advantage	O
to	O
acute	O
infection	O
[	O
16	O
]	O
.	O

These	O
results	O
indicate	O
that	O
an	O
imbalance	O
between	O
the	O
beneficial	O
and	O
harmful	O
effects	O
of	O
mediators	O
released	O
by	O
immune	O
cells	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
influenza	O
.	O

RIG	B-Protein
-	I-Protein
I	I-Protein
contains	O
a	O
C	O
-	O
terminal	O
DExD	O
/	O
H	O
box	O
helicase	O
domain	O
,	O
which	O
is	O
required	O
for	O
ligand	O
recognition	O
,	O
and	O
two	O
N	O
-	O
terminal	O
CARD	O
domains	O
.	O

Upon	O
ligand	O
binding	O
,	O
the	O
CARD	O
domains	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
associate	O
with	O
the	O
CARD	O
domain	O
of	O
the	O
MAVS	B-Protein
(	O
also	O
termed	O
IPS	B-Protein
-	I-Protein
1	I-Protein
,	O
VISA	B-Protein
,	O
Cardif	B-Protein
)	O
adaptor	O
protein	O
,	O
which	O
subsequently	O
translocates	O
to	O
and	O
inserts	O
in	O
the	O
outer	O
mitochondrial	O
membrane	O
via	O
its	O
C	O
-	O
terminal	O
transmembrane	O
domain	O
[	O
17	O
]	O
-	O
[	O
20	O
]	O
.	O

Signaling	O
downstream	O
of	O
MAVS	B-Protein
requires	O
the	O
action	O
of	O
various	O
ubiquitin	O
modifying	O
enzymes	O
,	O
which	O
both	O
positively	O
and	O
negatively	O
regulate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
mediated	O
signal	O
transduction	O
[	O
21	O
]	O
.	O

K63	O
-	O
specific	O
ubiquitin	O
ligases	O
(	O
E3s	O
)	O
,	O
such	O
as	O
TRIM25	B-Protein
[	O
22	O
]	O
and	O
Riplet	B-Protein
[	O
23	O
]	O
,	O
[	O
24	O
]	O
,	O
have	O
been	O
shown	O
to	O
directly	O
promote	O
RIG	B-Protein
-	I-Protein
I	I-Protein
activation	O
.	O

In	O
addition	O
,	O
well	O
characterized	O
ubiquitin	O
ligases	O
such	O
as	O
TRAF6	B-Protein
[	O
25	O
]	O
,	O
[	O
26	O
]	O
and	O
TRAF3	B-Protein
[	O
27	O
]	O
mediate	O
respectively	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
upon	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
.	O

On	O
the	O
other	O
hand	O
,	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
,	O
such	O
as	O
DUBA	B-Protein
[	O
28	O
]	O
,	O
CYLD	B-Protein
[	O
29	O
]	O
,	O
[	O
30	O
]	O
and	O
OTUB1	O
/	O
2	O
[	O
31	O
]	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
RLR	B-Protein
signaling	O
by	O
specifically	O
removing	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
from	O
several	O
signaling	O
molecules	O
.	O

Furthermore	O
,	O
various	O
K48	O
-	O
specific	O
ubiquitin	O
ligases	O
,	O
such	O
as	O
AIP4	B-Protein
[	O
32	O
]	O
and	O
TRIAD3A	B-Protein
[	O
33	O
]	O
mark	O
respectively	O
MAVS	B-Protein
and	O
TRAF3	B-Protein
for	O
proteasome	O
mediated	O
degradation	O
,	O
thus	O
inhibiting	O
further	O
downstream	O
signaling	O
.	O

Additionally	O
,	O
the	O
attachment	O
of	O
K48	O
-	O
specific	O
polyubiquitin	O
chains	O
to	O
the	O
IRF3	B-Protein
and	O
IRF7	B-Protein
transcription	O
factors	O
by	O
E3s	O
such	O
as	O
RAUL	B-Protein
[	O
34	O
]	O
,	O
TRIM21	B-Protein
[	O
35	O
]	O
and	O
RBCK1	B-Protein
[	O
36	O
]	O
further	O
dampens	O
antiviral	O
signal	O
transduction	O
.	O

A20	O
is	O
an	O
ubiquitin	O
-	O
editing	O
enzyme	O
belonging	O
to	O
the	O
OTU	O
-	O
domain	O
family	O
of	O
DUBs	O
.	O

Interestingly	O
,	O
A20	O
also	O
harbors	O
atypical	O
zinc	O
finger	O
dependent	O
K48	O
-	O
specific	O
E3	O
ubiquitin	O
ligase	O
activity	O
.	O

Both	O
catalytic	O
and	O
noncatalytic	O
mechanisms	O
were	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
the	O
negative	O
regulation	O
of	O
proinflammatory	O
signaling	O
by	O
A20	O
in	O
response	O
to	O
multiple	O
receptors	O
such	O
as	O
TNF	B-Protein
receptor	I-Protein
I	I-Protein
[	O
37	O
]	O
-	O
[	O
39	O
]	O
,	O
TLR4	B-Protein
[	O
40	O
]	O
,	O
and	O
IL	B-Protein
-	I-Protein
1R	I-Protein
[	O
41	O
]	O
.	O

The	O
anti	O
-	O
inflammatory	O
role	O
of	O
A20	O
is	O
clearly	O
demonstrated	O
by	O
the	O
fact	O
that	O
A20	O
deficient	O
mice	O
die	O
early	O
after	O
birth	O
due	O
to	O
severe	O
multi	O
-	O
organ	O
inflammation	O
and	O
cachexia	O
[	O
37	O
]	O
.	O

More	O
recently	O
,	O
gene	O
targeting	O
of	O
A20	O
in	O
specific	O
cell	O
types	O
was	O
shown	O
to	O
be	O
associated	O
with	O
autoimmunity	O
and	O
chronic	O
inflammation	O
[	O
42	O
]	O
-	O
[	O
48	O
]	O
,	O
further	O
illustrating	O
that	O
A20	O
is	O
an	O
important	O
brake	O
on	O
the	O
inflammatory	O
response	O
.	O

The	O
relevance	O
of	O
these	O
findings	O
for	O
human	O
disease	O
has	O
recently	O
been	O
illustrated	O
through	O
the	O
identification	O
of	O
polymorphisms	O
in	O
the	O
A20	O
locus	O
that	O
are	O
associated	O
with	O
several	O
autoimmune	O
diseases	O
and	O
chronic	O
inflammation	O
[	O
45	O
]	O
.	O

In	O
contrast	O
to	O
its	O
well	O
established	O
function	O
in	O
the	O
regulation	O
of	O
proinflammatory	O
responses	O
,	O
the	O
role	O
of	O
A20	O
in	O
the	O
regulation	O
of	O
antiviral	O
immune	O
responses	O
is	O
less	O
well	O
described	O
and	O
limited	O
to	O
a	O
number	O
of	O
in	O
vitro	O
studies	O
using	O
overexpression	O
or	O
silencing	O
in	O
specific	O
cell	O
lines	O
,	O
indicating	O
that	O
A20	O
may	O
regulate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
and	O
TLR3	B-Protein
-	O
induced	O
signaling	O
to	O
NF	O
-	O
kappaB	O
and	O
IRF	B-Protein
-	I-Protein
3	I-Protein
[	O
49	O
]	O
-	O
[	O
52	O
]	O
.	O

However	O
,	O
the	O
precise	O
in	O
vivo	O
role	O
of	O
A20	O
in	O
the	O
response	O
to	O
viral	O
infection	O
remains	O
to	O
be	O
clarified	O
.	O

Using	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
(	O
A20myel	O
-	O
KO	O
)	O
that	O
were	O
recently	O
generated	O
in	O
our	O
lab	O
and	O
primary	O
cells	O
derived	O
of	O
these	O
mice	O
,	O
we	O
here	O
provide	O
evidence	O
that	O
A20	O
is	O
a	O
crucial	O
negative	O
regulator	O
of	O
IAV	O
-	O
induced	O
proinflammatory	O
and	O
antiviral	O
signaling	O
in	O
macrophages	O
.	O

Interestingly	O
,	O
A20myel	O
-	O
KO	O
mice	O
show	O
enhanced	O
survival	O
and	O
reduced	O
morbidity	O
in	O
response	O
to	O
IAV	O
lung	O
infection	O
compared	O
to	O
wild	O
type	O
mice	O
.	O

Protection	O
against	O
IAV	O
in	O
A20myel	O
-	O
KO	O
mice	O
is	O
associated	O
with	O
increased	O
cytokine	O
and	O
chemokine	O
production	O
,	O
augmented	O
recruitment	O
of	O
innate	O
immune	O
cells	O
such	O
as	O
neutophils	O
and	O
alveolar	O
macrophages	O
,	O
and	O
enhanced	O
viral	O
clearance	O
.	O

These	O
results	O
suggest	O
that	O
boosting	O
the	O
innate	O
immune	O
response	O
to	O
IAV	O
by	O
targeting	O
A20	O
activity	O
in	O
myeloid	O
cells	O
might	O
have	O
therapeutic	O
potential	O
.	O

A20	O
inhibits	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O

RIG	B-Protein
-	I-Protein
I	I-Protein
signaling	O
induces	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
IRF3	B-Protein
and	O
IRF7	B-Protein
transcription	O
factors	O
,	O
which	O
promote	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
and	O
type	O
I	O
IFNs	O
that	O
restrict	O
further	O
viral	O
propagation	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
ectopically	O
expressed	O
A20	O
negatively	O
regulates	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
upon	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
[	O
50	O
]	O
-	O
[	O
52	O
]	O
.	O

Similarly	O
,	O
we	O
show	O
that	O
A20	O
overexpression	O
in	O
HEK293T	O
cells	O
prevents	O
NF	O
-	O
kappaB	O
-	O
and	O
IRF3	B-Protein
-	O
dependent	O
luciferase	B-Protein
reporter	O
gene	O
activation	O
induced	O
by	O
transfection	O
of	O
a	O
truncated	B-Protein
constitutive	I-Protein
active	I-Protein
form	I-Protein
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
[	O
53	O
]	O
,	O
corresponding	O
to	O
only	O
the	O
two	O
N	O
-	O
terminal	O
CARD	O
domains	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
[	O
RIG	O
-	O
I	O
(	O
2CARD	O
)	O
]	O
(	O
figure	O
1A	O
,	O
left	O
and	O
middle	O
graph	O
)	O
.	O

We	O
next	O
investigated	O
whether	O
A20	O
also	O
inhibits	O
IRF7	B-Protein
activation	O
.	O

Unlike	O
IRF3	B-Protein
,	O
IRF7	B-Protein
is	O
not	O
or	O
weakly	O
expressed	O
under	O
naive	O
conditions	O
and	O
IRF7	B-Protein
protein	O
levels	O
are	O
rapidly	O
upregulated	O
upon	O
virus	O
-	O
induced	O
IRF3	B-Protein
activation	O
[	O
54	O
]	O
,	O
[	O
55	O
]	O
.	O

To	O
determine	O
the	O
effect	O
of	O
A20	O
on	O
IRF7	B-Protein
activation	O
,	O
we	O
therefore	O
transfected	O
minor	O
amounts	O
of	O
an	O
IRF7	B-Protein
expression	O
plasmid	O
together	O
with	O
plasmids	O
encoding	O
RIG	O
-	O
I	O
(	O
2CARD	O
)	O
,	O
A20	O
and	O
an	O
IRF7	B-Protein
-	O
specific	O
IFNalpha4	O
luciferase	B-Protein
reporter	O
construct	O
.	O

RIG	O
-	O
I	O
(	O
2CARD	O
)	O
expression	O
in	O
the	O
absence	O
of	O
IRF7	B-Protein
co	O
-	O
expression	O
showed	O
negligible	O
IFNalpha4	O
promoter	O
activation	O
(	O
grey	O
bar	O
,	O
figure	O
1A	O
,	O
right	O
graph	O
)	O
,	O
whereas	O
significant	O
reporter	O
gene	O
expression	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IRF7	B-Protein
.	O

Similar	O
to	O
its	O
inhibitory	O
effect	O
on	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
,	O
A20	O
also	O
prevented	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
IRF7	B-Protein
activation	O
(	O
figure	O
1A	O
,	O
right	O
graph	O
)	O
.	O

These	O
results	O
demonstrate	O
the	O
potential	O
of	O
A20	O
to	O
inhibit	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
/	O
7	B-Protein
activation	O
.	O

To	O
study	O
the	O
effect	O
of	O
endogenously	O
expressed	O
A20	O
on	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
signaling	O
in	O
a	O
more	O
immunological	O
relevant	O
context	O
,	O
we	O
performed	O
further	O
experiments	O
in	O
A20	O
deficient	O
primary	O
macrophages	O
.	O

Since	O
A20	O
full	O
knockout	O
mice	O
die	O
prematurely	O
as	O
a	O
result	O
of	O
severe	O
multi	O
-	O
organ	O
inflammation	O
[	O
37	O
]	O
,	O
we	O
generated	O
mice	O
carrying	O
a	O
conditional	O
A20	O
allele	O
in	O
which	O
exon	O
IV	O
and	O
exon	O
V	O
were	O
flanked	O
by	O
two	O
loxP	O
sites	O
[	O
56	O
]	O
.	O

Crossing	O
these	O
mice	O
with	O
transgenic	O
mice	O
expressing	O
Cre	O
recombinase	O
under	O
control	O
of	O
the	O
lysozyme	O
M	O
promoter	O
leads	O
to	O
specific	O
deletion	O
in	O
myeloid	O
cells	O
and	O
allowed	O
us	O
to	O
generate	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
[	O
48	O
]	O
.	O

To	O
stimulate	O
the	O
RIG	B-Protein
-	I-Protein
I	I-Protein
receptor	O
,	O
we	O
transfected	O
A20myel	O
-	O
KO	O
BMDM	O
and	O
wild	O
type	O
control	O
cells	O
with	O
minimal	O
amounts	O
of	O
low	O
molecular	O
weight	O
(	O
LMW	O
)	O
poly	O
(	O
I	O
:	O
C	O
)	O
,	O
which	O
is	O
known	O
to	O
preferentially	O
bind	O
and	O
activate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
rather	O
than	O
MDA5	B-Protein
[	O
57	O
]	O
.	O

Of	O
note	O
,	O
this	O
concentration	O
of	O
poly	O
(	O
I	O
:	O
C	O
)	O
was	O
unable	O
to	O
induce	O
significant	O
TLR3	B-Protein
dependent	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
or	O
cytokine	O
production	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
expected	O
,	O
poly	O
(	O
I	O
:	O
C	O
)	O
transfection	O
induced	O
the	O
rapid	O
expression	O
of	O
A20	O
in	O
wild	O
type	O
,	O
but	O
not	O
in	O
A20myel	O
-	O
KO	O
BMDM	O
(	O
figure	O
1B	O
,	O
upper	O
panel	O
)	O
.	O

At	O
early	O
time	O
points	O
,	O
slightly	O
slower	O
migrating	O
forms	O
of	O
A20	O
were	O
observed	O
,	O
indicating	O
that	O
A20	O
undergoes	O
a	O
yet	O
unknown	O
modification	O
upon	O
poly	O
(	O
I	O
:	O
C	O
)	O
transfection	O
.	O

Compared	O
to	O
wild	O
type	O
BMBM	O
,	O
A20	O
deficient	O
cells	O
showed	O
enhanced	O
NF	O
-	O
kappaB	O
activation	O
as	O
indicated	O
by	O
increased	O
phosphorylation	O
and	O
sustained	O
degradation	O
of	O
IkappaBalpha	B-Protein
(	O
figure	O
1B	O
)	O
.	O

Furthermore	O
,	O
nuclear	O
translocation	O
of	O
the	O
p65	B-Protein
NF	O
-	O
kappaB	O
subunit	O
was	O
enhanced	O
in	O
poly	O
(	O
I	O
:	O
C	O
)	O
transfected	O
A20myel	O
-	O
KO	O
BMDM	O
,	O
reaching	O
a	O
maximum	O
at	O
earlier	O
time	O
points	O
compared	O
to	O
wild	O
type	O
cells	O
(	O
figure	O
1C	O
)	O
.	O

IRF3	B-Protein
is	O
known	O
to	O
be	O
activated	O
upon	O
phosphorylation	O
of	O
a	O
series	O
of	O
carboxyl	O
terminal	O
serine	O
residues	O
by	O
the	O
IKK	O
-	O
like	O
kinases	O
TBK1	B-Protein
and	O
IKKepsilon	B-Protein
[	O
58	O
]	O
,	O
leading	O
to	O
its	O
dimerization	O
and	O
subsequent	O
translocation	O
to	O
the	O
nucleus	O
[	O
59	O
]	O
.	O

Using	O
immunoblotting	O
with	O
an	O
antibody	O
directed	O
against	O
phosphorylated	O
Ser396	O
,	O
maximum	O
IRF3	B-Protein
phosphorylation	O
was	O
detected	O
at	O
earlier	O
time	O
points	O
in	O
A20myel	O
-	O
KO	O
BMDM	O
compared	O
to	O
wild	O
type	O
BMDM	O
(	O
figure	O
1B	O
)	O
.	O

Similar	O
to	O
p65	B-Protein
,	O
IRF3	B-Protein
nuclear	O
translocation	O
reached	O
its	O
maximum	O
at	O
an	O
earlier	O
time	O
point	O
in	O
A20	O
deficient	O
BMDM	O
compared	O
to	O
wild	O
type	O
cells	O
(	O
figure	O
1C	O
)	O
.	O

NF	O
-	O
kappaB	O
controls	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	B-Protein
,	O
and	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
control	O
the	O
expression	O
of	O
IFNbeta	B-Protein
.	O

In	O
line	O
with	O
the	O
enhanced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
as	O
described	O
above	O
,	O
A20myel	O
-	O
KO	O
BMDM	O
secreted	O
increased	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
(	O
figure	O
1D	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
peritoneal	O
macrophages	O
(	O
data	O
not	O
shown	O
)	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
A20	O
plays	O
an	O
important	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
primary	O
macrophages	O
.	O

A20	O
negatively	O
regulates	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
BMDM	O

To	O
investigate	O
the	O
role	O
of	O
A20	O
in	O
the	O
IAV	O
-	O
induced	O
proinflammatory	O
and	O
antiviral	O
innate	O
immune	O
responses	O
,	O
we	O
infected	O
A20	O
deficient	O
and	O
control	O
BMDM	O
with	O
IAV	O
X	O
-	O
47	O
(	O
H3N2	O
)	O
.	O

A20	O
mRNA	O
levels	O
were	O
rapidly	O
induced	O
in	O
wild	O
type	O
BMDM	O
,	O
but	O
not	O
in	O
A20	O
deficient	O
BMDM	O
,	O
upon	O
viral	O
infection	O
(	O
figure	O
2A	O
)	O
.	O

Furthermore	O
,	O
A20myel	O
-	O
KO	O
BMDM	O
show	O
enhanced	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNbeta	B-Protein
mRNA	O
after	O
IAV	O
infection	O
compared	O
to	O
control	O
cells	O
(	O
figure	O
2A	O
)	O
.	O

In	O
accordance	O
with	O
these	O
data	O
,	O
cell	O
culture	O
supernatant	O
collected	O
from	O
these	O
cells	O
contained	O
higher	O
levels	O
of	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
(	O
figure	O
2B	O
)	O
.	O

Upon	O
host	O
infection	O
with	O
IAV	O
,	O
alveolar	O
macrophages	O
are	O
an	O
important	O
source	O
of	O
cytokines	O
and	O
chemokines	O
,	O
attracting	O
innate	O
immune	O
cells	O
to	O
the	O
lung	O
during	O
the	O
primary	O
phase	O
of	O
infection	O
.	O

To	O
test	O
whether	O
A20	O
directly	O
controls	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
alveolar	O
macrophages	O
,	O
we	O
isolated	O
these	O
cells	O
from	O
lungs	O
of	O
A20myel	O
-	O
KO	O
and	O
control	O
littermates	O
and	O
infected	O
them	O
in	O
vitro	O
with	O
IAV	O
X	O
-	O
47	O
.	O

Expression	O
and	O
secretion	O
of	O
the	O
proinflammatory	O
cytokines	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	B-Protein
,	O
the	O
type	O
-	O
I	O
IFN	O
IFNbeta	B-Protein
and	O
IFNalpha4	B-Protein
and	O
the	O
chemokines	O
MCP	B-Protein
-	I-Protein
1	I-Protein
(	O
ccl2	B-Protein
)	O
and	O
KC	B-Protein
(	O
cxcl1	B-Protein
)	O
was	O
significantly	O
higher	O
in	O
IAV	O
infected	O
cells	O
lacking	O
A20	O
compared	O
to	O
infected	O
wild	O
type	O
cells	O
(	O
figure	O
2C	O
and	O
figure	O
S1	O
)	O
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
A20	O
negatively	O
regulates	O
IAV	O
-	O
induced	O
proinflammatory	O
and	O
antiviral	O
gene	O
expression	O
in	O
alveolar	O
macrophages	O
,	O
consistent	O
with	O
the	O
inhibitory	O
effect	O
of	O
A20	O
seen	O
on	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
.	O

A20	O
deficiency	O
in	O
myeloid	O
cells	O
protects	O
against	O
IAV	O
lung	O
infection	O

To	O
determine	O
the	O
role	O
of	O
A20	O
expression	O
in	O
myeloid	O
cells	O
during	O
an	O
IAV	O
infection	O
in	O
vivo	O
,	O
we	O
intranasally	O
inoculated	O
both	O
A20myel	O
-	O
KO	O
mice	O
and	O
control	O
littermates	O
with	O
a	O
sublethal	O
dose	O
of	O
the	O
mouse	O
adapted	O
IAV	O
X	O
-	O
47	O
(	O
H3N2	O
)	O
strain	O
and	O
monitored	O
morbidity	O
in	O
terms	O
of	O
weight	O
loss	O
.	O

A20myel	O
-	O
KO	O
mice	O
showed	O
reduced	O
weight	O
loss	O
compared	O
to	O
wild	O
type	O
control	O
littermates	O
and	O
recovered	O
faster	O
from	O
the	O
viral	O
challenge	O
(	O
figure	O
3A	O
)	O
.	O

Also	O
,	O
total	O
protein	O
concentration	O
in	O
BAL	O
fluid	O
,	O
which	O
reflects	O
lung	O
damage	O
and	O
vascular	O
leakage	O
,	O
was	O
increased	O
significantly	O
at	O
7	O
and	O
10	O
days	O
post	O
infection	O
in	O
both	O
wild	O
type	O
and	O
A20myel	O
-	O
KO	O
mice	O
,	O
and	O
was	O
slightly	O
lower	O
in	O
A20myel	O
-	O
KO	O
mice	O
(	O
data	O
not	O
shown	O
)	O
.	O

Next	O
,	O
we	O
measured	O
pulmonary	O
viral	O
titers	O
at	O
4	O
,	O
7	O
and	O
10	O
days	O
post	O
infection	O
.	O

No	O
differences	O
in	O
viral	O
titers	O
were	O
observed	O
in	O
A20myel	O
-	O
KO	O
mice	O
versus	O
wild	O
type	O
mice	O
at	O
day	O
4	O
and	O
7	O
post	O
infection	O
.	O

However	O
,	O
after	O
10	O
days	O
,	O
almost	O
no	O
virus	O
could	O
be	O
detected	O
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
mice	O
while	O
abundant	O
infectious	O
viral	O
particles	O
could	O
still	O
be	O
isolated	O
from	O
lungs	O
of	O
all	O
wild	O
type	O
mice	O
(	O
figure	O
3B	O
)	O
.	O

This	O
indicates	O
that	O
loss	O
of	O
A20	O
in	O
myeloid	O
cells	O
does	O
not	O
affect	O
early	O
viral	O
replication	O
but	O
contributes	O
to	O
viral	O
clearance	O
at	O
later	O
stages	O
during	O
infection	O
.	O

To	O
verify	O
if	O
A20	O
deficiency	O
in	O
myeloid	O
cells	O
affects	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
the	O
lung	O
,	O
we	O
analyzed	O
the	O
levels	O
of	O
several	O
chemokines	O
and	O
cytokines	O
in	O
the	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
at	O
day	O
4	O
,	O
7	O
and	O
day	O
10	O
following	O
infection	O
.	O

Levels	O
of	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
chemokines	O
,	O
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
significantly	O
higher	O
at	O
day	O
7	O
p	O
.	O
i	O
.	O
in	O
BAL	O
from	O
IAV	O
infected	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
IAV	O
infected	O
wild	O
type	O
mice	O
(	O
figure	O
3C	O
)	O
.	O

Unlike	O
our	O
observations	O
with	O
in	O
vitro	O
stimulated	O
primary	O
macrophages	O
we	O
could	O
not	O
detect	O
a	O
significant	O
increase	O
in	O
MCP	B-Protein
-	I-Protein
1	I-Protein
or	O
IFNalpha	O
production	O
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
animals	O
(	O
figure	O
3C	O
)	O
.	O

KC	B-Protein
is	O
the	O
murine	O
orthologue	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
serves	O
together	O
with	O
MIP	B-Protein
-	I-Protein
2	I-Protein
as	O
a	O
chemoattractant	O
for	O
neutrophils	O
,	O
while	O
MCP	B-Protein
-	I-Protein
1	I-Protein
is	O
mainly	O
known	O
as	O
a	O
chemoattractant	O
for	O
monocytes	O
,	O
which	O
eventually	O
develop	O
into	O
macrophages	O
upon	O
entering	O
the	O
alveolar	O
lumen	O
[	O
60	O
]	O
.	O

Consistent	O
with	O
the	O
higher	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
levels	O
in	O
A20myel	O
-	O
KO	O
mice	O
,	O
the	O
number	O
of	O
neutrophils	O
(	O
CD11b	O
+	O
Ly6C	O
+	O
Ly6G	O
+	O
F4	B-Protein
/	I-Protein
80	I-Protein
-	O
)	O
that	O
were	O
recruited	O
in	O
the	O
bronchoalveolar	O
spaces	O
upon	O
IAV	O
infection	O
was	O
clearly	O
higher	O
throughout	O
infection	O
in	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
control	O
animals	O
(	O
figure	O
3D	O
)	O
.	O

Although	O
we	O
could	O
detect	O
a	O
significant	O
increase	O
in	O
monocyte	O
(	O
CD11b	O
+	O
Ly6C	O
+	O
)	O
recruitment	O
at	O
day	O
4	O
post	O
infection	O
,	O
this	O
was	O
not	O
evident	O
at	O
later	O
time	O
points	O
after	O
infection	O
(	O
figure	O
3D	O
)	O
,	O
which	O
is	O
consistent	O
with	O
the	O
equal	O
expression	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
in	O
both	O
groups	O
of	O
mice	O
.	O

The	O
number	O
of	O
resident	O
alveolar	O
macrophages	O
(	O
autofluorescent	O
+	O
CD11c	O
+	O
F4	B-Protein
/	I-Protein
80	I-Protein
+	O
CD11b	O
-	O
)	O
was	O
also	O
elevated	O
in	O
A20myel	O
-	O
KO	O
mice	O
but	O
did	O
not	O
differ	O
significantly	O
between	O
IAV	O
infected	O
or	O
mock	O
infected	O
mice	O
(	O
figure	O
3D	O
)	O
.	O

Elimination	O
of	O
IAV	O
infected	O
cells	O
depends	O
on	O
the	O
clonal	O
expansion	O
of	O
virus	O
specific	O
cytotoxic	O
CD8	O
+	O
T	O
cells	O
(	O
CTL	O
)	O
[	O
61	O
]	O
,	O
[	O
62	O
]	O
,	O
[	O
63	O
]	O
.	O

To	O
test	O
whether	O
A20	O
expression	O
in	O
myeloid	O
cells	O
regulates	O
the	O
antiviral	O
CTL	O
response	O
,	O
total	O
CD8	O
+	O
T	O
cells	O
and	O
virus	O
specific	O
Granzyme	B-Protein
B	I-Protein
(	O
GrB	B-Protein
)	O
and	O
IFNgamma	O
expressing	O
CD8	O
+	O
T	O
cells	O
were	O
measured	O
in	O
BAL	O
and	O
lung	O
parenchyma	O
of	O
wild	O
type	O
and	O
A20myel	O
-	O
KO	O
mice	O
.	O

A	O
clear	O
increase	O
in	O
CD8	O
+	O
T	O
cells	O
could	O
be	O
detected	O
at	O
day	O
7	O
and	O
10	O
post	O
infection	O
,	O
but	O
no	O
differences	O
were	O
observed	O
between	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
mice	O
(	O
figure	O
S2A	O
and	O
figure	O
S2C	O
)	O
.	O

Also	O
,	O
the	O
number	O
of	O
GrB	B-Protein
and	O
IFNgamma	O
CD8	O
+	O
T	O
cells	O
as	O
well	O
as	O
IFNgamma	O
expression	O
levels	O
in	O
the	O
lungs	O
were	O
not	O
altered	O
by	O
the	O
absence	O
of	O
A20	O
in	O
myeloid	O
cells	O
(	O
figure	O
S2A	O
-	O
C	O
)	O
.	O

Protection	O
against	O
IAV	O
infection	O
is	O
also	O
provided	O
by	O
the	O
humoral	O
immune	O
response	O
.	O

To	O
test	O
whether	O
loss	O
of	O
A20	O
in	O
myeloid	O
cells	O
affects	O
B	O
cell	O
mediated	O
immunity	O
,	O
we	O
determined	O
hemagglutinin	O
(	O
HA	O
)	O
antibody	O
titers	O
in	O
the	O
serum	O
of	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
littermates	O
.	O

However	O
,	O
no	O
differences	O
could	O
be	O
detected	O
between	O
wild	O
type	O
and	O
A20myel	O
-	O
KO	O
animals	O
(	O
figure	O
S2D	O
)	O
,	O
indicating	O
that	O
humoral	O
immunity	O
is	O
not	O
affected	O
by	O
A20	O
expression	O
in	O
myeloid	O
cells	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
mechanisms	O
other	O
than	O
adaptive	O
immunity	O
,	O
such	O
as	O
an	O
increased	O
innate	O
immune	O
response	O
,	O
characterized	O
by	O
an	O
increased	O
influx	O
of	O
neutrophils	O
and	O
increased	O
numbers	O
of	O
alveolar	O
macrophages	O
,	O
contribute	O
to	O
the	O
better	O
viral	O
clearance	O
in	O
A20myel	O
-	O
KO	O
mice	O
.	O

It	O
is	O
generally	O
believed	O
that	O
IAV	O
-	O
induced	O
mortality	O
is	O
due	O
to	O
an	O
excessive	O
proinflammatory	O
response	O
in	O
the	O
lung	O
.	O

We	O
therefore	O
analyzed	O
whether	O
the	O
increased	O
proinflammatory	O
cytokine	O
production	O
and	O
infiltration	O
of	O
proinflammatory	O
cells	O
in	O
A20myel	O
-	O
KO	O
mice	O
affects	O
mortality	O
induced	O
by	O
intranasal	O
infection	O
with	O
a	O
lethal	O
dose	O
of	O
IAV	O
X	O
-	O
47	O
.	O

Surprisingly	O
,	O
almost	O
all	O
A20myel	O
-	O
KO	O
mice	O
survived	O
(	O
10	O
/	O
11	O
)	O
,	O
while	O
all	O
control	O
mice	O
succumbed	O
(	O
0	O
/	O
11	O
)	O
within	O
16	O
days	O
after	O
infection	O
(	O
figure	O
4A	O
)	O
.	O

A20myel	O
-	O
KO	O
mice	O
still	O
showed	O
significant	O
weight	O
loss	O
and	O
lung	O
damage	O
(	O
as	O
reflected	O
by	O
increased	O
total	O
protein	O
concentration	O
in	O
the	O
BAL	O
;	O
data	O
not	O
shown	O
)	O
during	O
the	O
course	O
of	O
infection	O
but	O
were	O
able	O
to	O
recover	O
,	O
in	O
contrast	O
to	O
wild	O
type	O
mice	O
that	O
succumbed	O
(	O
figure	O
4B	O
)	O
.	O

Similar	O
to	O
our	O
observations	O
with	O
sublethal	O
IAV	O
infection	O
,	O
pulmonary	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
production	O
was	O
stronger	O
in	O
A20myel	O
-	O
KO	O
animals	O
compared	O
to	O
wild	O
type	O
mice	O
following	O
lethal	O
IAV	O
infection	O
(	O
figure	O
4C	O
)	O
,	O
which	O
correlates	O
with	O
the	O
increased	O
numbers	O
of	O
neutrophils	O
in	O
the	O
lungs	O
of	O
these	O
mice	O
(	O
figure	O
4C	O
)	O
.	O

Also	O
levels	O
of	O
the	O
proinflammatory	O
cytokines	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
which	O
are	O
often	O
associated	O
with	O
immunopathogenesis	O
in	O
humans	O
[	O
64	O
]	O
,	O
were	O
increased	O
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
control	O
animals	O
(	O
figure	O
4C	O
and	O
figure	O
S3A	O
)	O
.	O

Again	O
,	O
MCP	B-Protein
-	I-Protein
1	I-Protein
production	O
was	O
not	O
increased	O
and	O
even	O
lower	O
in	O
A20myel	O
-	O
KO	O
mice	O
(	O
figure	O
4C	O
)	O
,	O
and	O
also	O
monocyte	O
recruitment	O
was	O
not	O
different	O
between	O
both	O
groups	O
of	O
mice	O
.	O

We	O
could	O
also	O
not	O
detect	O
any	O
differences	O
in	O
viral	O
clearance	O
or	O
antiviral	O
adaptive	O
immunity	O
at	O
6	O
h	O
post	O
infection	O
(	O
figure	O
S3B	O
-	O
F	O
)	O
.	O

Collectively	O
these	O
data	O
indicate	O
that	O
A20	O
deficiency	O
in	O
myeloid	O
cells	O
is	O
associated	O
with	O
an	O
increased	O
innate	O
immune	O
response	O
and	O
protection	O
against	O
a	O
lethal	O
IAV	O
infection	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
investigated	O
the	O
contribution	O
of	O
A20	O
expression	O
in	O
myeloid	O
cells	O
in	O
the	O
innate	O
immune	O
response	O
to	O
IAV	O
lung	O
infection	O
.	O

In	O
the	O
pulmonary	O
environment	O
,	O
macrophages	O
populate	O
both	O
lung	O
parenchyma	O
and	O
the	O
alveolar	O
lumen	O
where	O
they	O
are	O
referred	O
to	O
as	O
alveolar	O
macrophages	O
.	O

Under	O
naive	O
conditions	O
,	O
alveolar	O
macrophages	O
exert	O
important	O
immunomodulatory	O
functions	O
[	O
65	O
]	O
,	O
[	O
66	O
]	O
.	O

However	O
,	O
alveolar	O
macrophages	O
are	O
also	O
crucial	O
in	O
the	O
innate	O
immune	O
response	O
against	O
IAV	O
as	O
they	O
are	O
one	O
of	O
the	O
first	O
cells	O
that	O
encounter	O
infectious	O
IAV	O
particles	O
[	O
67	O
]	O
,	O
[	O
68	O
]	O
.	O

They	O
are	O
an	O
important	O
source	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
that	O
attract	O
innate	O
immune	O
cells	O
to	O
the	O
lung	O
during	O
the	O
primary	O
phase	O
of	O
infection	O
[	O
69	O
]	O
,	O
and	O
they	O
are	O
the	O
primary	O
producers	O
of	O
type	O
I	O
IFNs	O
[	O
70	O
]	O
.	O

Alveolar	O
macrophages	O
are	O
also	O
known	O
to	O
phagocytose	O
virus	O
infected	O
apoptotic	O
cells	O
and	O
antibody	O
coated	O
viral	O
particles	O
,	O
further	O
contributing	O
to	O
viral	O
clearance	O
.	O

We	O
could	O
show	O
that	O
BMDM	O
or	O
alveolar	O
macrophages	O
derived	O
from	O
A20myel	O
-	O
KO	O
mice	O
express	O
higher	O
amounts	O
of	O
chemokines	O
,	O
cytokines	O
and	O
type	O
I	O
IFNs	O
compared	O
to	O
wild	O
type	O
mice	O
in	O
response	O
to	O
in	O
vitro	O
infection	O
.	O

Similarly	O
,	O
in	O
vivo	O
infection	O
with	O
IAV	O
resulted	O
in	O
higher	O
levels	O
of	O
primarily	O
neutrophil	O
attracting	O
chemokines	O
such	O
as	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
and	O
several	O
proinflammatory	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
wild	O
type	O
mice	O
.	O

This	O
was	O
associated	O
with	O
a	O
selective	O
enhancement	O
of	O
neutrophil	O
recruitment	O
to	O
the	O
bronchoalveolar	O
compartment	O
,	O
and	O
resulted	O
in	O
improved	O
viral	O
clearance	O
later	O
on	O
during	O
infection	O
.	O

Although	O
the	O
role	O
of	O
neutrophils	O
during	O
viral	O
infection	O
is	O
still	O
under	O
debate	O
,	O
recent	O
evidence	O
supports	O
a	O
protective	O
function	O
of	O
these	O
cells	O
during	O
IAV	O
infection	O
[	O
71	O
]	O
,	O
[	O
72	O
]	O
.	O

MCP	B-Protein
-	I-Protein
1	I-Protein
levels	O
were	O
not	O
affected	O
by	O
the	O
absence	O
of	O
A20	O
in	O
myeloid	O
cells	O
,	O
which	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
airway	O
epithelial	O
cells	O
are	O
the	O
primary	O
source	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
production	O
during	O
IAV	O
infection	O
[	O
73	O
]	O
.	O

Mice	O
deficient	O
for	O
the	O
MCP	O
-	O
1	O
receptor	O
CCR2	O
,	O
which	O
is	O
expressed	O
on	O
a	O
subset	O
of	O
circulating	O
monocytes	O
,	O
are	O
protected	O
against	O
IAV	O
infection	O
and	O
display	O
reduced	O
signs	O
of	O
immunopathology	O
[	O
74	O
]	O
-	O
[	O
76	O
]	O
.	O

During	O
IAV	O
infection	O
these	O
monocytes	O
develop	O
into	O
inflammatory	O
dendritic	O
cells	O
or	O
proinflammatory	O
macrophages	O
[	O
77	O
]	O
and	O
are	O
considered	O
major	O
contributors	O
to	O
IAV	O
-	O
induced	O
immunopathology	O
[	O
78	O
]	O
.	O

A20myel	O
-	O
KO	O
mice	O
were	O
protected	O
against	O
a	O
lethal	O
IAV	O
infection	O
,	O
which	O
is	O
rather	O
surprising	O
since	O
an	O
excessive	O
proinflammatory	O
cytokine	O
response	O
and	O
an	O
excessive	O
influx	O
of	O
inflammatory	O
cells	O
is	O
generally	O
believed	O
to	O
be	O
associated	O
with	O
increased	O
lethality	O
[	O
64	O
]	O
,	O
[	O
79	O
]	O
.	O

However	O
,	O
the	O
selective	O
effect	O
of	O
A20	O
deficiency	O
on	O
neutrophil	O
recruitment	O
,	O
without	O
altering	O
inflammatory	O
monocyte	O
(	O
Ly6C	O
+	O
CD11b	O
+	O
)	O
recruitment	O
,	O
further	O
support	O
the	O
idea	O
that	O
monocytes	O
and	O
not	O
neutrophils	O
are	O
major	O
contributors	O
to	O
IAV	O
-	O
associated	O
immunopathology	O
and	O
lethality	O
[	O
78	O
]	O
.	O

We	O
show	O
that	O
A20	O
deficient	O
BMDM	O
display	O
enhanced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
response	O
to	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
by	O
synthetic	O
LMW	O
double	O
stranded	O
RNA	O
.	O

RIG	B-Protein
-	I-Protein
I	I-Protein
has	O
previously	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
innate	O
immune	O
response	O
to	O
IAV	O
[	O
13	O
]	O
,	O
suggesting	O
that	O
the	O
increased	O
immune	O
response	O
of	O
A20myel	O
-	O
KO	O
mice	O
to	O
IAV	O
lung	O
infection	O
reflects	O
enhanced	O
RIG	B-Protein
-	I-Protein
I	I-Protein
signaling	O
.	O

We	O
propose	O
that	O
A20	O
inhibits	O
IAV	O
-	O
induced	O
proinflammatory	O
gene	O
expression	O
(	O
as	O
shown	O
in	O
our	O
manuscript	O
for	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
KC	B-Protein
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
IFNbeta	B-Protein
)	O
by	O
negatively	O
regulating	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
,	O
which	O
are	O
the	O
major	O
pathways	O
controlling	O
these	O
genes	O
.	O

However	O
,	O
this	O
does	O
not	O
exclude	O
an	O
additional	O
effect	O
of	O
A20	O
on	O
other	O
signaling	O
pathways	O
that	O
may	O
contribute	O
to	O
proinflammatory	O
gene	O
expression	O
.	O

A20	O
is	O
believed	O
to	O
exert	O
its	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
inhibitory	O
functions	O
by	O
modulating	O
the	O
ubiquitination	O
status	O
of	O
different	O
signaling	O
proteins	O
[	O
80	O
]	O
.	O

In	O
this	O
context	O
,	O
it	O
was	O
recently	O
shown	O
that	O
A20	O
cooperates	O
with	O
the	O
ubiquitin	O
-	O
binding	O
proteins	O
TAX1BP1	O
and	O
ABIN1	B-Protein
to	O
to	O
disrupt	O
the	O
TRAF3	O
-	O
TBK1	O
-	O
IKKepsilon	O
complex	O
,	O
thereby	O
negatively	O
affecting	O
K63	O
-	O
polyubiquitination	O
of	O
TBK1	B-Protein
and	O
IKKepsilon	B-Protein
,	O
and	O
their	O
ability	O
to	O
activity	O
IRF3	B-Protein
[	O
81	O
]	O
,	O
[	O
82	O
]	O
.	O

Whether	O
similar	O
mechanisms	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
induced	O
NF	O
-	O
kappaB	O
activation	O
is	O
still	O
unclear	O
.	O

So	O
far	O
we	O
were	O
unable	O
to	O
clearly	O
detect	O
ubiquitination	O
of	O
TBK1	B-Protein
and	O
IKKepsilon	B-Protein
in	O
primary	O
macrophages	O
,	O
preventing	O
us	O
from	O
studying	O
the	O
effect	O
of	O
A20	O
deficiency	O
on	O
their	O
ubiquitination	O
status	O
.	O

It	O
cannot	O
be	O
excluded	O
however	O
that	O
A20	O
also	O
targets	O
other	O
substrates	O
that	O
mediate	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
myeloid	O
cells	O
.	O

The	O
identification	O
of	O
these	O
substrates	O
will	O
be	O
the	O
topic	O
of	O
future	O
investigations	O
in	O
our	O
laboratory	O
.	O

Multiple	O
other	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
,	O
such	O
as	O
DUBA	O
[	O
28	O
]	O
,	O
CYLD	B-Protein
[	O
29	O
]	O
,	O
[	O
30	O
]	O
,	O
OTUB1	O
/	O
2	O
[	O
31	O
]	O
,	O
and	O
A20	O
[	O
49	O
]	O
-	O
[	O
52	O
]	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
signaling	O
to	O
NF	O
-	O
kappaB	O
and	O
IRF	B-Protein
-	I-Protein
3	I-Protein
,	O
implicating	O
possible	O
redundancy	O
.	O

However	O
,	O
evidence	O
so	O
far	O
was	O
limited	O
to	O
in	O
vitro	O
data	O
and	O
was	O
obtained	O
under	O
non	O
-	O
physiological	O
conditions	O
.	O

The	O
clear	O
protective	O
phenotype	O
of	O
A20myel	O
-	O
KO	O
mice	O
that	O
we	O
here	O
describe	O
indicates	O
that	O
A20	O
expression	O
in	O
myeloid	O
cells	O
is	O
a	O
central	O
gatekeeper	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
induced	O
signaling	O
in	O
response	O
to	O
IAV	O
infection	O
and	O
that	O
other	O
DUBs	O
cannot	O
substitute	O
for	O
A20	O
deficiency	O
under	O
physiological	O
conditions	O
.	O

If	O
A20	O
has	O
a	O
similar	O
non	O
-	O
redundant	O
role	O
in	O
other	O
cell	O
types	O
that	O
are	O
implicated	O
in	O
the	O
response	O
to	O
IAV	O
,	O
such	O
as	O
lung	O
epithelial	O
cells	O
,	O
remains	O
to	O
be	O
investigated	O
.	O

Understanding	O
and	O
controlling	O
the	O
activation	O
of	O
innate	O
antiviral	O
immune	O
responses	O
is	O
an	O
important	O
step	O
toward	O
novel	O
therapies	O
.	O

About	O
a	O
fifth	O
of	O
world	O
'	O
s	O
population	O
is	O
infected	O
by	O
IAV	O
annually	O
,	O
leading	O
to	O
high	O
morbidity	O
and	O
mortality	O
,	O
particularly	O
in	O
infants	O
,	O
the	O
elderly	O
and	O
the	O
immunocompromised	O
.	O

The	O
high	O
mutation	O
rate	O
of	O
IAV	O
turns	O
all	O
attempts	O
of	O
vaccine	O
and	O
antiviral	O
design	O
into	O
a	O
never	O
ending	O
battle	O
.	O

In	O
recent	O
years	O
,	O
RNA	O
interference	O
,	O
triggered	O
by	O
synthetic	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
has	O
rapidly	O
evolved	O
as	O
a	O
potent	O
antiviral	O
regimen	O
.	O

Properly	O
designed	O
siRNAs	O
have	O
been	O
shown	O
to	O
function	O
as	O
potent	O
inhibitors	O
of	O
influenza	O
virus	O
replication	O
.	O

Although	O
specificity	O
and	O
tissue	O
delivery	O
remain	O
major	O
bottlenecks	O
in	O
the	O
clinical	O
applications	O
of	O
RNAi	O
in	O
general	O
,	O
intranasal	O
application	O
of	O
siRNA	O
against	O
respiratory	O
viruses	O
including	O
,	O
but	O
not	O
limited	O
to	O
influenza	O
virus	O
,	O
has	O
experienced	O
significant	O
success	O
and	O
optimism	O
[	O
83	O
]	O
.	O

Our	O
results	O
suggest	O
that	O
not	O
only	O
siRNA	O
targeting	O
IAV	O
components	O
,	O
but	O
boosting	O
the	O
antiviral	O
immune	O
response	O
by	O
intranasal	O
administration	O
of	O
siRNA	O
against	O
A20	O
might	O
be	O
a	O
valid	O
therapeutic	O
approach	O
.	O

Also	O
small	O
compound	O
inhibitors	O
of	O
A20	O
might	O
be	O
an	O
interesting	O
alternative	O
.	O

Finally	O
,	O
similar	O
targeting	O
of	O
A20	O
might	O
be	O
of	O
interest	O
in	O
the	O
battle	O
against	O
other	O
viral	O
infections	O
including	O
RSV	O
and	O
SARS	O
coronavirus	O
.	O

Ethics	O
statement	O

All	O
experiments	O
on	O
mice	O
were	O
conducted	O
according	O
to	O
the	O
national	O
(	O
Belgian	O
Law	O
14	O
/	O
08	O
/	O
1986	O
and	O
22	O
/	O
12	O
/	O
2003	O
,	O
Belgian	O
Royal	O
Decree	O
06	O
/	O
04	O
/	O
2010	O
)	O
and	O
European	O
(	O
EU	O
Directives	O
2010	O
/	O
63	O
/	O
EU	O
,	O
86	O
/	O
609	O
/	O
EEG	O
)	O
animal	O
regulations	O
.	O

Animal	O
protocols	O
were	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
Ghent	O
University	O
(	O
permit	O
number	O
LA1400091	O
,	O
approval	O
ID	O
2010	O
/	O
001	O
)	O
.	O

All	O
efforts	O
were	O
made	O
to	O
ameliorate	O
suffering	O
of	O
animals	O
.	O

Mice	O
were	O
anesthetized	O
by	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
injection	O
of	O
a	O
mixture	O
of	O
ketamine	O
(	O
12	O
mg	O
/	O
kg	O
)	O
and	O
xylazine	O
(	O
60	O
mg	O
/	O
kg	O
)	O
.	O

Mice	O

A20fl	O
/	O
fl	O
mice	O
were	O
generated	O
as	O
previously	O
described	O
[	O
56	O
]	O
.	O

A20fl	O
/	O
fl	O
mice	O
were	O
crossed	O
with	O
LysM	O
-	O
Cre	O
mice	O
[	O
84	O
]	O
(	O
provided	O
by	O
I	O
.	O
Forster	O
,	O
Institute	O
of	O
Genetics	O
,	O
University	O
of	O
Cologne	O
,	O
Germany	O
)	O
to	O
generate	O
A20fl	O
/	O
fl	O
LysMCre	O
transgenes	O
and	O
are	O
described	O
in	O
detail	O
elsewhere	O
[	O
48	O
]	O
.	O

Mice	O
were	O
housed	O
in	O
individually	O
ventilated	O
cages	O
at	O
the	O
VIB	O
Department	O
of	O
Molecular	O
Biomedical	O
Research	O
in	O
specific	O
pathogen	O
-	O
free	O
animal	O
facilities	O
.	O

Influenza	O
infections	O
were	O
performed	O
on	O
age	O
-	O
(	O
between	O
7	O
and	O
9	O
weeks	O
old	O
)	O
and	O
sex	O
-	O
matched	O
littermates	O
.	O

A20fl	O
/	O
fl	O
LysM	O
-	O
Cre	O
animals	O
were	O
backcrossed	O
three	O
times	O
to	O
the	O
C57Bl	O
/	O
6	O
background	O
.	O

A20fl	O
/	O
fl	O
mice	O
expressing	O
or	O
lacking	O
the	O
LysM	O
-	O
Cre	O
transgene	O
were	O
termed	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
(	O
A20myel	O
-	O
WT	O
)	O
respectively	O
.	O

Viral	O
infection	O
and	O
determination	O
of	O
viral	O
titers	O

Mouse	O
adapted	O
IAV	O
X	O
-	O
47	O
(	O
H3N2	O
;	O
PR8xA	O
/	O
Victoria	O
/	O
3	O
/	O
75	O
)	O
was	O
propagated	O
in	O
MDCK	O
cells	O
.	O

For	O
viral	O
inoculation	O
,	O
mice	O
were	O
anesthetized	O
by	O
i	O
.	O
p	O
.	O
injection	O
with	O
ketamine	O
(	O
12	O
mg	O
/	O
kg	O
)	O
and	O
xylazine	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
50	O
microl	O
X	O
-	O
47	O
diluted	O
in	O
PBS	O
was	O
administered	O
intranasally	O
.	O

For	O
lethal	O
and	O
sublethal	O
infection	O
,	O
mice	O
received	O
respectively	O
2	O
-	O
LD50	O
or	O
0	O
.	O
05	O
-	O
LD50	O
X	O
-	O
47	O
.	O

To	O
determine	O
pulmonary	O
viral	O
titers	O
,	O
median	O
tissue	O
culture	O
infectious	O
dose	O
(	O
TCID50	O
)	O
was	O
measured	O
as	O
follows	O
:	O
lungs	O
were	O
homogenized	O
with	O
a	O
Polytron	O
homogenizer	O
(	O
Kinematica	O
)	O
in	O
PBS	O
.	O

Eight	O
-	O
fold	O
serial	O
dilutions	O
of	O
lung	O
homogenates	O
were	O
incubated	O
on	O
MDCK	O
cells	O
for	O
5	O
days	O
in	O
DMEM	O
supplemented	O
with	O
trypsin	O
(	O
1	O
microg	O
/	O
ml	O
)	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
and	O
antibiotics	O
.	O

For	O
read	O
-	O
out	O
,	O
0	O
.	O
5	O
%	O
chicken	O
red	O
blood	O
cells	O
(	O
RBC	O
)	O
were	O
added	O
and	O
end	O
-	O
point	O
dilution	O
of	O
hemagglutination	O
was	O
monitored	O
.	O

TCID50	O
titers	O
were	O
then	O
calculated	O
according	O
to	O
the	O
method	O
of	O
Reed	O
and	O
Muench	O
[	O
85	O
]	O
.	O

Determination	O
of	O
HAI	O
(	O
hemagglutination	O
inhibition	O
)	O
titers	O

To	O
determine	O
the	O
HAI	O
titers	O
in	O
infected	O
mice	O
,	O
sera	O
of	O
these	O
were	O
treated	O
with	O
receptor	O
-	O
destroying	O
enzyme	O
(	O
RDE	O
/	O
Cholera	O
filtrate	O
;	O
Sigma	O
)	O
to	O
remove	O
sialic	O
acids	O
from	O
serum	O
proteins	O
capable	O
of	O
aspecific	O
inhibition	O
of	O
agglutination	O
.	O

After	O
incubation	O
overnight	O
at	O
37degreesC	O
,	O
the	O
RDE	O
was	O
inactivated	O
by	O
addition	O
of	O
0	O
.	O
75	O
%	O
sodium	O
citrate	O
in	O
PBS	O
and	O
heating	O
to	O
56degreesC	O
for	O
30	O
min	O
.	O

To	O
remove	O
sialic	O
acid	O
binding	O
proteins	O
,	O
sera	O
were	O
cleared	O
with	O
1	O
/	O
10	O
volume	O
50	O
%	O
chicken	O
RBC	O
.	O

Titration	O
was	O
done	O
by	O
incubating	O
a	O
two	O
-	O
fold	O
dilution	O
series	O
of	O
sera	O
with	O
4	O
HA	O
units	O
of	O
X	O
-	O
47	O
virus	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
in	O
96	O
-	O
well	O
U	O
-	O
bottom	O
plates	O
.	O

Finally	O
,	O
an	O
equal	O
volume	O
of	O
0	O
.	O
5	O
%	O
chicken	O
RBC	O
was	O
added	O
and	O
titers	O
were	O
read	O
30	O
min	O
later	O
.	O

Negative	O
controls	O
included	O
PBS	O
instead	O
of	O
immune	O
serum	O
(	O
agglutination	O
control	O
)	O
or	O
PR8	O
instead	O
of	O
X	O
-	O
47	O
virus	O
(	O
control	O
for	O
agglutination	O
effect	O
of	O
sera	O
)	O
;	O
as	O
positive	O
control	O
,	O
serum	O
from	O
a	O
mouse	O
infected	O
twice	O
with	O
a	O
sublethal	O
dose	O
of	O
X	O
-	O
47	O
was	O
used	O
.	O

In	O
vivo	O
intracellular	O
GrB	B-Protein
and	O
IFNgamma	O
staining	O
of	O
activated	O
CD8	B-Protein
+	O
T	O
cells	O

Granzyme	B-Protein
B	I-Protein
(	O
GrB	B-Protein
)	O
and	O
IFNgamma	O
expressing	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
determined	O
by	O
treating	O
the	O
mice	O
intranasally	O
with	O
50	O
microg	O
Brefeldin	O
A	O
(	O
Sigma	O
)	O
as	O
previously	O
described	O
[	O
86	O
]	O
.	O

6	O
h	O
later	O
,	O
BAL	O
and	O
lungs	O
were	O
isolated	O
and	O
single	O
cell	O
suspensions	O
were	O
prepared	O
from	O
the	O
lung	O
in	O
the	O
presence	O
of	O
3	O
microg	O
/	O
ml	O
Brefeldin	O
A	O
.	O
Cells	O
were	O
stained	O
,	O
fixed	O
and	O
permeabilized	O
(	O
Cytofix	O
/	O
Cytoperm	O
,	O
BD	O
Biosciences	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Activated	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
based	O
on	O
CD62lo	O
CD3	B-Protein
+	O
and	O
CD8	B-Protein
+	O
expression	O
.	O

Live	O
/	O
Dead	O
fixable	O
aqua	O
dead	O
cell	O
stain	O
kit	O
(	O
Molecular	O
Probes	O
)	O
was	O
used	O
to	O
discriminate	O
live	O
from	O
dead	O
cells	O
.	O

Cells	O
and	O
transfection	O

HEK293T	O
and	O
MDCK	O
cells	O
were	O
grown	O
in	O
DMEM	O
(	O
Gibco	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
and	O
antibiotics	O
.	O

HEK293T	O
cells	O
were	O
transfected	O
using	O
the	O
calcium	O
phosphate	O
precipitate	O
transfection	O
method	O
with	O
specific	O
expression	O
vectors	O
(	O
pCAGGS	O
-	O
E	O
-	O
hA20	O
(	O
LMBP	O
3778	O
)	O
,	O
pCAGGS	O
-	O
E	O
-	O
RIG	O
-	O
I	O
-	O
CARD	O
(	O
LMBP	O
6517	O
)	O
,	O
pEF	O
-	O
HA	O
-	O
IRF	O
-	O
7	O
(	O
kindly	O
provided	O
by	O
T	O
.	O
Taniguchi	O
,	O
Graduate	O
School	O
of	O
Medicine	O
and	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
)	O
)	O
,	O
NF	O
-	O
kappaB	O
,	O
IRF3	B-Protein
,	O
IRF7	B-Protein
reporter	O
plasmids	O
(	O
respectively	O
pConLuc	O
(	O
LMBP3248	O
)	O
,	O
pISRE	O
-	O
luc	O
(	O
LMBP4011	O
)	O
,	O
pGL3	O
-	O
IFNalpha4	O
-	O
luc	O
(	O
kindly	O
provided	O
by	O
J	O
.	O
Hiscott	O
,	O
McGill	O
University	O
,	O
Montreal	O
,	O
Quebec	O
,	O
Canada	O
)	O
,	O
and	O
pACTbetagal	O
(	O
LMBP4341	O
)	O
for	O
transfection	O
efficiency	O
normalization	O
.	O

Details	O
of	O
plasmids	O
are	O
presented	O
along	O
with	O
detailed	O
sequence	O
maps	O
at	O
the	O
BCCM	O
-	O
LMBP	O
plasmid	O
databank	O
http	O
:	O
/	O
/	O
bccm	O
.	O
belspo	O
.	O
be	O
/	O
index	O
.	O
php	O
.	O

For	O
the	O
generation	O
of	O
BMDM	O
,	O
bone	O
marrow	O
cells	O
were	O
cultured	O
7	O
days	O
in	O
RPMI	O
1640	O
(	O
Gibco	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
,	O
antibiotics	O
and	O
40	O
ng	O
/	O
ml	O
recombinant	O
M	O
-	O
CSF	O
.	O

BMDM	O
were	O
of	O
>	O
=	O
95	O
%	O
purity	O
as	O
measured	O
by	O
flow	O
cytometry	O
using	O
F4	O
/	O
80	O
and	O
CD11b	O
specific	O
antibodies	O
.	O

For	O
the	O
isolation	O
of	O
alveolar	O
macrophages	O
,	O
the	O
trachea	O
was	O
canulated	O
and	O
the	O
lung	O
was	O
flushed	O
4	O
times	O
with	O
HBSS	O
containing	O
1	O
mM	O
EDTA	O
.	O

Alveolar	O
macrophages	O
were	O
cultured	O
in	O
RPMI	O
1640	O
(	O
Gibco	O
)	O
supplemented	O
with	O
1	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
and	O
antibiotics	O
.	O

Western	O
blotting	O

For	O
total	O
lysates	O
,	O
cells	O
were	O
lysed	O
at	O
4degreesC	O
for	O
15	O
min	O
in	O
lysis	O
buffer	O
(	O
200	O
mM	O
NaCl	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7	O
.	O
5	O
,	O
5	O
mM	O
EDTA	O
,	O
2	O
mM	O
DTT	O
)	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitors	O
.	O

Nuclear	O
and	O
cytoplasmic	O
lysates	O
were	O
prepared	O
by	O
resuspending	O
cells	O
in	O
B1	O
(	O
10	O
mM	O
Hepes	O
pH	O
7	O
.	O
5	O
,	O
10	O
mM	O
KCl	O
,	O
1	O
mM	O
MgCl2	O
,	O
5	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
and	O
0	O
.	O
1	O
mM	O
EGTA	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

Next	O
,	O
NP	O
-	O
40	O
detergent	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
0	O
.	O
65	O
%	O
and	O
cells	O
were	O
centrifuged	O
at	O
500	O
g	O
for	O
5	O
min	O
.	O

The	O
nuclear	O
fraction	O
containing	O
pellet	O
was	O
lyzed	O
in	O
B2	O
(	O
20	O
mM	O
Hepes	O
pH	O
7	O
.	O
5	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
400	O
mM	O
NaCl	O
,	O
10	O
mM	O
KCl	O
,	O
1	O
mM	O
MgCl2	O
,	O
20	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
and	O
0	O
.	O
1	O
mM	O
EGTA	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

The	O
lysates	O
were	O
subsequently	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
analyzed	O
by	O
western	O
blotting	O
and	O
ECL	O
detection	O
(	O
Perkin	O
Elmer	O
Life	O
Sciences	O
)	O
.	O

Immunoblots	O
were	O
revealed	O
with	O
anti	O
-	O
A20	O
,	O
anti	O
-	O
IkappaBalpha	O
,	O
anti	O
-	O
p65	O
,	O
and	O
anti	O
-	O
histon	O
H1	O
(	O
Santa	O
Cruz	O
)	O
,	O
anti	O
-	O
IRF3	O
(	O
Invitrogen	O
)	O
,	O
anti	O
-	O
phospho	O
-	O
IRF3	O
and	O
anti	O
-	O
phospho	O
-	O
IkappaBalpha	O
(	O
Cell	O
Signaling	O
)	O
and	O
anti	O
-	O
actin	O
(	O
MP	O
Biomedicals	O
)	O
.	O

The	O
density	O
of	O
the	O
bands	O
was	O
quantified	O
(	O
fold	O
induction	O
)	O
with	O
the	O
ImageJ	O
(	O
http	O
:	O
/	O
/	O
rsbweb	O
.	O
nih	O
.	O
gov	O
/	O
ij	O
)	O
Gel	O
analyzer	O
tool	O
.	O

All	O
intensities	O
were	O
calculated	O
relative	O
to	O
the	O
first	O
lane	O
(	O
=	O
time	O
0	O
)	O
.	O

Flow	O
cytometry	O

Lungs	O
were	O
dissected	O
and	O
incubated	O
with	O
collagenase	B-Protein
type	I-Protein
IV	I-Protein
(	O
1	O
mg	O
/	O
ml	O
;	O
Sigma	O
)	O
and	O
DNAse	O
(	O
100	O
U	O
/	O
ml	O
;	O
Roche	O
)	O
at	O
37degreesC	O
for	O
30	O
min	O
.	O

Subsequently	O
,	O
samples	O
were	O
filtered	O
through	O
a	O
70	O
microm	O
and	O
40	O
microm	O
nylon	O
mesh	O
.	O

For	O
the	O
preparation	O
of	O
BAL	O
,	O
trachea	O
were	O
canulated	O
and	O
airway	O
lumen	O
was	O
flushed	O
4	O
times	O
with	O
HBSS	O
with	O
1	O
mM	O
EDTA	O
.	O

Cells	O
were	O
stained	O
with	O
monoclonal	O
antibodies	O
directed	O
against	O
MHC	O
-	O
II	O
(	O
I	O
-	O
A	O
/	O
I	O
-	O
E	O
)	O
FITC	O
(	O
M5	O
/	O
114	O
.	O
15	O
.	O
2	O
)	O
,	O
CD11c	O
PerCP	O
-	O
Cy5	O
.	O
5	O
(	O
N418	O
)	O
,	O
F4	O
/	O
80	O
APC	O
(	O
BM8	O
)	O
,	O
CD62L	B-Protein
PE	O
(	O
MEL	O
-	O
14	O
)	O
,	O
Granzyme	B-Protein
B	I-Protein
FITC	O
(	O
NGZB	O
)	O
from	O
eBiosciences	O
and	O
CD3	B-Protein
Molecular	O
Complex	O
Horizon	O
v450	O
(	O
17A2	O
)	O
,	O
Ly6C	O
Horizon	O
v450	O
(	O
AL	O
-	O
21	O
)	O
,	O
Ly6G	B-Protein
PE	O
(	O
1A8	O
)	O
,	O
CD11b	O
APC	O
-	O
Cy7	O
(	O
M1	O
/	O
70	O
)	O
,	O
CD8alpha	B-Protein
PerCP	O
(	O
53	O
-	O
6	O
.	O
7	O
)	O
,	O
IFNgamma	B-Protein
Alexa	O
647	O
(	O
XMG1	O
.	O
2	O
)	O
and	O
CD16	B-Protein
/	O
32	O
(	O
2	O
.	O
4G2	O
)	O
from	O
BD	O
Pharmingen	O
.	O

Samples	O
were	O
acquired	O
on	O
a	O
LSRII	O
Cytometer	O
and	O
analyzed	O
using	O
FACSDiva	O
software	O
(	O
BD	O
Biosciences	O
)	O
.	O

Propidium	O
iodide	O
was	O
used	O
to	O
discriminate	O
between	O
live	O
and	O
dead	O
cells	O
.	O

Cytokine	O
quantification	O

For	O
TNF	B-Protein
ELISA	O
,	O
96	O
-	O
well	O
plates	O
were	O
coated	O
with	O
TNF	B-Protein
coating	O
(	O
TN3	O
-	O
19	O
,	O
eBioscience	O
)	O
and	O
detection	O
(	O
R4	O
-	O
6A2	O
,	O
eBioscience	O
)	O
antibodies	O
.	O

IFNalpha	O
and	O
IFNbeta	B-Protein
protein	O
levels	O
were	O
determined	O
with	O
an	O
ELISA	O
kit	O
(	O
PBL	O
Biomedical	O
Laboratories	O
)	O
.	O

For	O
IFNgamma	O
ELISA	O
,	O
96	O
-	O
well	O
plates	O
were	O
coated	O
with	O
IFNgamma	O
coating	O
(	O
XMG1	O
.	O
2	O
)	O
and	O
detection	O
(	O
R4	O
-	O
6A2	O
)	O
antibodies	O
(	O
eBiosciences	O
)	O
.	O

Detection	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
KC	B-Protein
,	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
BAL	O
fluid	O
was	O
performed	O
using	O
Bioplex	O
(	O
BioRad	O
)	O
technology	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Milliplex	O
technology	O
(	O
Millipore	O
)	O
was	O
used	O
for	O
the	O
detection	O
of	O
MIP	O
-	O
2	O
in	O
BAL	O
fluid	O
.	O

RNA	O
isolation	O
,	O
cDNA	O
synthesis	O
and	O
qPCR	O

Total	O
RNA	O
was	O
extracted	O
using	O
Aurum	O
Total	O
RNA	O
mini	O
kit	O
(	O
BioRad	O
)	O
and	O
reverse	O
transcribed	O
into	O
cDNA	O
with	O
iScript	O
cDNA	O
synthesis	O
kit	O
(	O
BioRad	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

qPCR	O
was	O
performed	O
by	O
using	O
SYBR	O
Green	O
I	O
master	O
mix	O
I	O
(	O
Roche	O
)	O
in	O
the	O
Lightcycler	O
480	O
detection	O
system	O
(	O
Roche	O
)	O
with	O
the	O
following	O
primers	O
:	O
HPRT	O
:	O
5	O
'	O
-	O
AGTGTTGGATACAGGCCAGAC	O
-	O
3	O
'	O
and	O
5	O
'	O
CGTGATTCAAATCCCTGAAGT	O
-	O
3	O
'	O
;	O
IL	B-Protein
-	I-Protein
6	I-Protein
:	O
5	O
'	O
-	O
GAGGATACCACTCCCAACAGACC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
AAGTGCATCATCGTTGTTCATACA	O
-	O
3	O
'	O
;	O
IFNbeta	B-Protein
:	O
5	O
'	O
-	O
TCAGAATGAGTGGTGGTTGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GACCTTTCAAATGCAGTAGATTCA	O
-	O
3	O
'	O
;	O
A20	B-Protein
:	O
5	O
'	O
-	O
AAACCAATGGTGATGGAAACTG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GTTGTCCCATTCGTCATTCC	O
-	O
3	O
'	O
;	O
CCL2	B-Protein
:	O
5	O
'	O
-	O
TTAAAAACCTGGATCGGAACCAA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCATTAGCTTCAGATTTACGGGT	O
-	O
3	O
'	O
;	O
CXCL1	B-Protein
:	O
5	O
'	O
-	O
GAGCCTCTAACCAGTTCCAG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TGAGTGTGGCTATGACTTCG	O
-	O
3	O
'	O
and	O
IFNalpha4	B-Protein
:	O
5	O
'	O
-	O
TGATGAGCTACTACTGGTCAGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GATCTCTTAGCACAAGGATGGC	O
-	O
3	O
'	O
.	O

Primers	O
were	O
designed	O
with	O
PerlPrimer	O
(	O
http	O
:	O
/	O
/	O
perlprimer	O
.	O
sourceforge	O
.	O
net	O
)	O
.	O

Quantification	O
was	O
performed	O
using	O
the	O
comparative	O
CT	O
method	O
(	O
deltadeltaCT	O
)	O
.	O

Results	O
are	O
expressed	O
relative	O
to	O
HPRT	O
values	O
.	O

Statistics	O

Results	O
are	O
expressed	O
as	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Statistical	O
significance	O
between	O
groups	O
was	O
assessed	O
using	O
two	O
-	O
way	O
ANOVA	O
.	O

The	O
differences	O
for	O
in	O
vivo	O
experiments	O
(	O
at	O
least	O
5	O
mice	O
per	O
group	O
)	O
were	O
calculated	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
for	O
unpaired	O
data	O
.	O

Statistical	O
significance	O
of	O
differences	O
between	O
survival	O
rates	O
was	O
analyzed	O
by	O
comparing	O
Kaplan	O
-	O
Meier	O
curves	O
using	O
the	O
log	O
-	O
rank	O
test	O
(	O
GraphPad	O
Prism	O
version	O
5	O
,	O
GraphPad	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

A20	O
inhibits	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
response	O
to	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
.	O

(	O
A	O
)	O
HEK293T	O
cells	O
were	O
transfected	O
with	O
NF	O
-	O
kappaB	O
(	O
left	O
)	O
,	O
IRF3	B-Protein
(	O
middle	O
)	O
or	O
IRF7	B-Protein
dependent	O
luciferase	B-Protein
reporter	O
(	O
right	O
)	O
plasmids	O
,	O
together	O
with	O
plasmids	O
expressing	O
RIG	O
-	O
I	O
(	O
2CARD	O
)	O
,	O
IRF7	B-Protein
(	O
right	O
)	O
and	O
increasing	O
amounts	O
of	O
A20	O
.	O

Luciferase	O
activity	O
in	O
cell	O
extracts	O
was	O
analyzed	O
in	O
a	O
luminometer	O
.	O

Numbers	O
are	O
averages	O
+	O
/	O
-	O
SD	O
of	O
3	O
samples	O
per	O
set	O
-	O
up	O
.	O

(	O
B	O
-	O
D	O
)	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
(	O
A20myel	O
-	O
WT	O
)	O
BMDM	O
were	O
transfected	O
with	O
LMW	O
poly	O
(	O
I	O
:	O
C	O
)	O
and	O
analyzed	O
at	O
different	O
time	O
points	O
(	O
minutes	O
)	O
after	O
the	O
start	O
of	O
transfection	O
for	O
IkappaBalpha	B-Protein
phosphorylation	O
and	O
degradation	O
,	O
and	O
IRF3	B-Protein
phosphorylation	O
by	O
immunoblotting	O
of	O
total	O
cell	O
extracts	O
(	O
B	O
)	O
.	O

The	O
band	O
that	O
is	O
non	O
-	O
specifically	O
recognized	O
by	O
the	O
anti	O
-	O
IkappaBalpha	O
antibody	O
(	O
indicated	O
by	O
an	O
asterisk	O
)	O
can	O
be	O
used	O
as	O
a	O
loading	O
control	O
.	O

Nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
(	O
p65	B-Protein
)	O
and	O
IRF3	B-Protein
was	O
analyzed	O
by	O
immunoblotting	O
of	O
cytoplasmic	O
or	O
nuclear	O
fractions	O
(	O
C	O
)	O
.	O

Quantification	O
of	O
band	O
density	O
for	O
nuclear	O
p65	B-Protein
and	O
IRF3	B-Protein
is	O
shown	O
in	O
bar	O
graphs	O
(	O
expressed	O
as	O
relative	O
density	O
compared	O
to	O
the	O
first	O
lane	O
;	O
=	O
time	O
0	O
)	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
levels	O
in	O
the	O
supernatant	O
of	O
cells	O
used	O
in	O
(	O
B	O
)	O
were	O
determined	O
by	O
bioassay	O
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
and	O
ELISA	O
(	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
)	O
as	O
described	O
in	O
the	O
'	O
materials	O
and	O
methods	O
'	O
section	O
(	O
D	O
)	O
.	O

Data	O
are	O
representative	O
of	O
2	O
independent	O
experiments	O
.	O

A20	O
negatively	O
regulates	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
BMDM	O
and	O
alveolar	O
macrophages	O
.	O

(	O
A	O
-	O
B	O
)	O
BMDM	O
isolated	O
from	O
A20myel	O
-	O
WT	O
and	O
A20myel	O
-	O
KO	O
animals	O
were	O
infected	O
with	O
IAV	O
(	O
moi	O
1	O
)	O
.	O

At	O
different	O
hours	O
post	O
infection	O
(	O
hours	O
p	O
.	O
i	O
.	O
)	O
cells	O
were	O
lysed	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IFNbeta	B-Protein
and	O
A20	O
mRNA	O
expression	O
was	O
analyzed	O
by	O
qPCR	O
(	O
A	O
)	O
.	O

18	O
hours	O
post	O
infection	O
cell	O
culture	O
supernatant	O
was	O
analyzed	O
for	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
protein	O
levels	O
by	O
ELISA	O
and	O
multiplexing	O
technologies	O
(	O
B	O
)	O
.	O

(	O
C	O
-	O
D	O
)	O
Alveolar	O
macrophages	O
were	O
mock	O
treated	O
or	O
infected	O
with	O
IAV	O
(	O
moi	O
1	O
)	O
for	O
18	O
hours	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNbeta	B-Protein
mRNA	O
expression	O
was	O
determined	O
by	O
qPCR	O
(	O
C	O
)	O
.	O

Cell	O
culture	O
supernatant	O
was	O
analyzed	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNbeta	B-Protein
protein	O
levels	O
by	O
ELISA	O
and	O
multiplexing	O
technologies	O
(	O
D	O
)	O
.	O

Error	O
bars	O
represent	O
mean	O
values	O
(	O
+	O
/	O
-	O
SEM	O
)	O
of	O
2	O
-	O
3	O
samples	O
.	O

Results	O
are	O
representative	O
for	O
2	O
independent	O
experiments	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
,	O
001	O
.	O

A20	O
deficiency	O
in	O
myeloid	O
cells	O
protects	O
against	O
IAV	O
lung	O
infection	O
.	O

A20myel	O
-	O
WT	O
and	O
A20myel	O
-	O
KO	O
mice	O
were	O
infected	O
intranasally	O
with	O
a	O
sublethal	O
dose	O
of	O
IAV	O
and	O
weight	O
loss	O
was	O
monitored	O
(	O
A	O
)	O
.	O

At	O
day	O
4	O
,	O
7	O
and	O
10	O
post	O
infection	O
(	O
p	O
.	O
i	O
.	O
)	O
viral	O
titers	O
in	O
the	O
lung	O
were	O
measured	O
and	O
expressed	O
as	O
mean	O
TCID50	O
(	O
B	O
)	O
.	O

The	O
dashed	O
line	O
represents	O
the	O
detection	O
limit	O
.	O

ND	O
,	O
not	O
detectable	O
.	O

BAL	O
was	O
isolated	O
from	O
IAV	O
infected	O
mice	O
at	O
4	O
,	O
7	O
and	O
10	O
days	O
p	O
.	O
i	O
.	O
and	O
KC	B-Protein
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
,	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNalpha	O
protein	O
levels	O
were	O
analyzed	O
by	O
ELISA	O
and	O
multiplexing	O
technologies	O
(	O
C	O
)	O
.	O

Absolute	O
numbers	O
of	O
resident	O
alveolar	O
macrophages	O
,	O
neutrophils	O
and	O
monocytes	O
in	O
BAL	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
at	O
4	O
,	O
7	O
and	O
10	O
days	O
p	O
.	O
i	O
.	O

(	O
D	O
)	O
.	O

Numbers	O
are	O
averages	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
5	O
mice	O
per	O
group	O
and	O
are	O
representative	O
of	O
2	O
independent	O
experiments	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
.	O

A20	O
deficiency	O
in	O
myeloid	O
cells	O
protects	O
against	O
lethal	O
IAV	O
infection	O
.	O

A20myel	O
-	O
WT	O
(	O
n	O
=	O
11	O
)	O
and	O
A20myel	O
-	O
KO	O
(	O
n	O
=	O
11	O
)	O
mice	O
were	O
intranasally	O
infected	O
with	O
a	O
lethal	O
dose	O
of	O
IAV	O
and	O
survival	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
A	O
)	O
and	O
weight	O
loss	O
+	O
/	O
-	O
SEM	O
(	O
B	O
)	O
was	O
monitored	O
for	O
respectively	O
21	O
and	O
15	O
days	O
p	O
.	O
i	O
.	O

BAL	O
fluid	O
was	O
collected	O
from	O
wild	O
type	O
(	O
A20myel	O
-	O
WT	O
)	O
and	O
A20myel	O
-	O
KO	O
mice	O
6	O
days	O
following	O
infection	O
with	O
a	O
lethal	O
dose	O
IAV	O
and	O
KC	B-Protein
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
,	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNalpha	B-Protein
protein	O
levels	O
were	O
determined	O
(	O
C	O
)	O
.	O

Absolute	O
numbers	O
of	O
alveolar	O
macrophages	O
,	O
neutrophils	O
and	O
monocytes	O
in	O
BAL	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
at	O
6	O
days	O
p	O
.	O
i	O
.	O

(	O
D	O
)	O
.	O

Numbers	O
are	O
averages	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
5	O
mice	O
per	O
group	O
.	O

Data	O
are	O
representative	O
of	O
2	O
independent	O
experiments	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
.	O

Tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
threonine	O
435	O
phosphorylation	O
of	O
p65	B-Protein
nuclear	O
factor	O
-	O
kappaB	O
subunit	O
in	O
endothelial	O
cells	O
induces	O
vasogenic	O
edema	O
and	O
neutrophil	O
infiltration	O
in	O
the	O
rat	O
piriform	O
cortex	O
following	O
status	O
epilepticus	O

Background	O

Status	O
epilepticus	O
(	O
SE	O
)	O
induces	O
severe	O
vasogenic	O
edema	O
in	O
the	O
piriform	O
cortex	O
(	O
PC	O
)	O
accompanied	O
by	O
neuronal	O
and	O
astroglial	O
damages	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
(	I-Protein
TNF	I-Protein
)	I-Protein
-	I-Protein
alpha	I-Protein
in	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
disruption	O
during	O
vasogenic	O
edema	O
and	O
its	O
related	O
events	O
in	O
rat	O
epilepsy	O
models	O
provoked	O
by	O
pilocarpine	O
-	O
induced	O
SE	O
.	O

Methods	O

SE	O
was	O
induced	O
by	O
pilocarpine	O
in	O
rats	O
that	O
were	O
intracerebroventricularly	O
infused	O
with	O
saline	O
-	O
,	O
and	O
soluble	O
TNF	B-Protein
p55	I-Protein
receptor	I-Protein
(	O
sTNFp55R	B-Protein
)	O
prior	O
to	O
SE	O
induction	O
.	O

Thereafter	O
,	O
we	O
performed	O
Fluoro	O
-	O
Jade	O
B	O
staining	O
and	O
immunohistochemical	O
studies	O
for	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
NF	O
-	O
kappaB	O
subunits	O
.	O

Results	O

Following	O
SE	O
,	O
most	O
activated	O
microglia	O
showed	O
strong	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
.	O

In	O
addition	O
,	O
TNF	B-Protein
p75	I-Protein
receptor	I-Protein
expression	O
was	O
detected	O
in	O
endothelial	O
cells	O
as	O
well	O
as	O
astrocytes	O
.	O

In	O
addition	O
,	O
only	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
was	O
increased	O
in	O
endothelial	O
cells	O
accompanied	O
by	O
SMI	O
-	O
71	O
expression	O
(	O
an	O
endothelial	O
barrier	O
antigen	O
)	O
.	O

Neutralization	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
by	O
soluble	O
TNF	B-Protein
p55	I-Protein
receptor	I-Protein
(	O
sTNFp55R	B-Protein
)	O
infusion	O
attenuated	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damages	O
via	O
inhibition	O
of	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
sTNFp55R	B-Protein
infusion	O
reduced	O
SE	O
-	O
induced	O
neutrophil	O
infiltration	O
in	O
the	O
PC	O
.	O

Conclusion	O

These	O
findings	O
suggest	O
that	O
impairments	O
of	O
endothelial	O
cell	O
functions	O
via	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
p65	B-Protein
-	O
Thr	O
485	O
NF	O
-	O
kappaB	O
phosphorylation	O
may	O
be	O
involved	O
in	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
.	O

Subsequently	O
,	O
vasogenic	O
edema	O
results	O
in	O
extensive	O
neutrophil	O
infiltration	O
and	O
neuronal	O
-	O
astroglial	O
loss	O
.	O

Status	O
epilepticus	O
(	O
SE	O
)	O
is	O
a	O
medical	O
emergency	O
with	O
significant	O
mortality	O
[	O
1	O
]	O
.	O

SE	O
has	O
been	O
defined	O
as	O
continuous	O
seizure	O
activity	O
,	O
which	O
causes	O
neuronal	O
cell	O
death	O
,	O
epileptogenesis	O
and	O
learning	O
impairment	O
[	O
2	O
,	O
3	O
]	O
.	O

Some	O
brain	O
regions	O
vulnerable	O
to	O
SE	O
play	O
a	O
role	O
in	O
the	O
generation	O
and	O
propagation	O
of	O
paroxysmal	O
activity	O
in	O
experimental	O
epilepsy	O
models	O
.	O

The	O
piriform	O
cortex	O
(	O
PC	O
)	O
is	O
one	O
of	O
the	O
most	O
susceptible	O
brain	O
regions	O
to	O
seizure	O
-	O
induced	O
damage	O
in	O
the	O
kainate	O
,	O
pilocarpine	O
and	O
other	O
models	O
of	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
[	O
4	O
-	O
6	O
]	O
.	O

Pilocarpine	O
,	O
a	O
cholinergic	O
agonist	O
,	O
induces	O
SE	O
in	O
rodents	O
.	O

This	O
pilocarpine	O
-	O
induced	O
SE	O
,	O
similar	O
to	O
human	O
TLE	O
,	O
shows	O
massive	O
neuronal	O
loss	O
in	O
the	O
hippocampus	O
followed	O
by	O
glial	O
proliferation	O
.	O

This	O
neuronal	O
damage	O
in	O
the	O
pilocarpine	O
model	O
is	O
not	O
restricted	O
to	O
the	O
hippocampus	O
,	O
but	O
often	O
extends	O
to	O
extrahippocampal	O
limbic	O
structures	O
.	O

Indeed	O
,	O
pilocarpine	O
-	O
induced	O
SE	O
results	O
in	O
acute	O
neuronal	O
damages	O
within	O
layers	O
II	O
and	O
III	O
of	O
the	O
PC	O
[	O
5	O
,	O
6	O
]	O
.	O

SE	O
also	O
induces	O
severe	O
vasogenic	O
edema	O
in	O
the	O
PC	O
accompanied	O
by	O
neuronal	O
and	O
astroglial	O
damages	O
[	O
5	O
-	O
8	O
]	O
.	O

Brain	O
edema	O
proceeds	O
in	O
two	O
phases	O
,	O
early	O
cytotoxic	O
edema	O
phase	O
and	O
late	O
vasogenic	O
edema	O
phase	O
.	O

Early	O
cytotoxic	O
osmotic	O
edema	O
is	O
due	O
to	O
excess	O
stimulation	O
of	O
glutamatergic	O
pathways	O
during	O
SE	O
,	O
which	O
increases	O
intracellular	O
Na	O
+	O
and	O
Ca2	O
+	O
concentrations	O
.	O

The	O
vasogenic	O
edema	O
results	O
from	O
dysfunction	O
of	O
endothelial	O
cells	O
and	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

Many	O
studies	O
have	O
reported	O
increased	O
permeability	O
of	O
the	O
BBB	O
during	O
epileptic	O
activity	O
[	O
9	O
-	O
13	O
]	O
.	O

A	O
fast	O
and	O
significant	O
increase	O
in	O
systemic	O
blood	O
pressure	O
,	O
particularly	O
shown	O
during	O
tonic	O
epileptic	O
seizures	O
,	O
induces	O
a	O
marked	O
vasodilation	O
of	O
the	O
large	O
cerebral	O
arteries	O
and	O
an	O
increase	O
in	O
blood	O
pressure	O
in	O
capillaries	O
,	O
small	O
arteries	O
,	O
and	O
veins	O
leading	O
to	O
leakage	O
of	O
the	O
BBB	O
[	O
9	O
]	O
.	O

Loss	O
of	O
BBB	O
integrity	O
is	O
not	O
only	O
due	O
to	O
an	O
abrupt	O
increase	O
in	O
the	O
intraluminal	O
pressure	O
but	O
also	O
influenced	O
by	O
the	O
properties	O
of	O
cerebral	O
tissue	O
.	O

Indeed	O
,	O
an	O
acute	O
increase	O
in	O
blood	O
pressure	O
or	O
epileptic	O
activity	O
causes	O
an	O
increase	O
in	O
pinocytosis	O
at	O
the	O
level	O
of	O
the	O
cerebral	O
endothelium	O
[	O
11	O
-	O
13	O
]	O
.	O

Recently	O
,	O
reports	O
have	O
also	O
emphasized	O
that	O
seizure	O
or	O
epilepsy	O
is	O
a	O
prolonged	O
inflammatory	O
condition	O
,	O
and	O
that	O
seizure	O
activity	O
rapidly	O
increases	O
the	O
synthesis	O
and	O
release	O
of	O
various	O
interleukins	O
in	O
rodent	O
brain	O
areas	O
involved	O
in	O
seizure	O
onset	O
and	O
their	O
generalization	O
.	O

Cytokines	O
act	O
on	O
endothelial	O
cells	O
and	O
change	O
the	O
permeability	O
of	O
the	O
BBB	O
,	O
which	O
exerts	O
significant	O
effects	O
on	O
neuronal	O
viability	O
and	O
excitability	O
[	O
14	O
,	O
15	O
]	O
.	O

Indeed	O
,	O
Sztriha	O
[	O
16	O
]	O
reported	O
that	O
dexamethasone	O
pretreatment	O
reduces	O
vasogenic	O
edema	O
in	O
thalamus	O
following	O
kainic	O
acid	O
-	O
induced	O
seizure	O
.	O

Among	O
cytokines	O
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
is	O
a	O
17	O
kDa	O
protein	O
that	O
is	O
produced	O
mainly	O
by	O
activated	O
macrophages	O
and	O
T	O
cells	O
in	O
the	O
immune	O
system	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
expressed	O
at	O
low	O
levels	O
in	O
normal	O
brain	O
and	O
is	O
rapidly	O
upregulated	O
in	O
glia	O
,	O
neurons	O
and	O
endothelial	O
cells	O
in	O
various	O
pathophysiological	O
conditions	O
,	O
including	O
SE	O
[	O
17	O
,	O
18	O
]	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
shows	O
various	O
effects	O
on	O
brain	O
function	O
depending	O
on	O
its	O
local	O
tissue	O
concentration	O
,	O
the	O
type	O
of	O
target	O
cells	O
,	O
and	O
especially	O
the	O
specific	O
receptor	O
subtype	O
:	O
TNF	B-Protein
receptor	I-Protein
I	I-Protein
,	O
or	O
p55	B-Protein
receptor	I-Protein
(	O
TNFp55R	B-Protein
)	O
;	O
and	O
TNF	B-Protein
receptor	I-Protein
II	I-Protein
,	O
or	O
p75	B-Protein
receptor	I-Protein
(	O
TNFp75R	B-Protein
)	O
[	O
19	O
]	O
.	O

Furthermore	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
induces	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
(	O
MIP	B-Protein
-	I-Protein
2	I-Protein
)	O
that	O
recruits	O
neutrophils	O
under	O
pathological	O
conditions	O
,	O
including	O
SE	O
[	O
14	O
,	O
20	O
]	O
.	O

Neurons	O
,	O
microglia	O
,	O
and	O
astrocytes	O
produce	O
MIP	B-Protein
-	I-Protein
2	I-Protein
when	O
incubated	O
with	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
/	O
or	O
interleukin	B-Protein
-	I-Protein
1beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
or	O
after	O
injury	O
[	O
21	O
-	O
23	O
]	O
.	O

Indeed	O
,	O
we	O
have	O
recently	O
reported	O
that	O
SE	O
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
is	O
relevant	O
to	O
leukocyte	O
infiltrations	O
following	O
SE	O
in	O
an	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
-	O
independent	O
manner	O
[	O
20	O
]	O
.	O

However	O
,	O
the	O
relationship	O
between	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
system	O
and	O
BBB	O
disruption	O
/	O
neutrophil	O
infiltration	O
during	O
vasogenic	O
edema	O
formation	O
induced	O
by	O
epileptogenic	O
insults	O
has	O
not	O
been	O
fully	O
clarified	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
vasogenic	O
edema	O
and	O
its	O
related	O
events	O
in	O
rat	O
epilepsy	O
models	O
provoked	O
by	O
pilocarpine	O
-	O
induced	O
SE	O
.	O

Experimental	O
animals	O

This	O
study	O
utilized	O
progeny	O
of	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
(	O
male	O
,	O
9	O
-	O
11	O
weeks	O
old	O
)	O
obtained	O
from	O
Experimental	O
Animal	O
Center	O
,	O
Hallym	O
University	O
,	O
Chunchon	O
,	O
South	O
Korea	O
.	O

The	O
animals	O
were	O
provided	O
with	O
a	O
commercial	O
diet	O
and	O
water	O
ad	O
libitum	O
under	O
controlled	O
temperature	O
,	O
humidity	O
and	O
lighting	O
conditions	O
(	O
22	O
+	O
/	O
-	O
2degreesC	O
,	O
55	O
+	O
/	O
-	O
5	O
%	O
and	O
a	O
12	O
:	O
12	O
light	O
/	O
dark	O
cycle	O
with	O
lights	O
)	O
.	O

Animal	O
protocols	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Hallym	O
University	O
.	O

Procedures	O
involving	O
animals	O
and	O
their	O
care	O
were	O
conducted	O
in	O
accord	O
with	O
our	O
institutional	O
guidelines	O
that	O
comply	O
with	O
NIH	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
(	O
NIH	O
Publications	O
No	O
.	O
80	O
-	O
23	O
,	O
1996	O
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
made	O
all	O
efforts	O
to	O
minimize	O
the	O
number	O
of	O
animals	O
used	O
and	O
their	O
suffering	O
.	O

Intracerebroventricular	O
drug	O
infusion	O

Rats	O
were	O
divided	O
into	O
two	O
groups	O
:	O
vehicle	O
(	O
saline	O
)	O
-	O
treated	O
and	O
soluble	O
TNFp55	B-Protein
receptor	I-Protein
(	O
sTNFp55R	B-Protein
,	O
50	O
mug	O
/	O
ml	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
-	O
treated	O
groups	O
.	O

The	O
dosage	O
of	O
sTNFp55R	B-Protein
was	O
determined	O
as	O
the	O
highest	O
dose	O
that	O
induced	O
SE	O
of	O
comparable	O
severity	O
in	O
100	O
%	O
of	O
animals	O
with	O
5	O
%	O
mortality	O
in	O
the	O
preliminary	O
study	O
.	O

Animals	O
were	O
anesthetized	O
(	O
Zolretil	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
m	O
.	O
;	O
Virbac	O
Laboratories	O
,	O
France	O
)	O
and	O
placed	O
in	O
a	O
stereotaxic	O
frames	O
.	O

For	O
the	O
osmotic	O
pump	O
implantation	O
,	O
holes	O
were	O
drilled	O
through	O
the	O
skull	O
to	O
introduce	O
a	O
brain	O
infusion	O
kit	O
1	O
(	O
Alzet	O
,	O
Cupertino	O
,	O
CA	O
)	O
into	O
the	O
right	O
lateral	O
ventricle	O
(	O
1	O
mm	O
posterior	O
;	O
1	O
.	O
5	O
mm	O
lateral	O
;	O
-	O
3	O
.	O
5	O
mm	O
depth	O
;	O
flat	O
skull	O
position	O
with	O
bregma	O
as	O
reference	O
)	O
,	O
according	O
to	O
the	O
atlas	O
of	O
Paxinos	O
and	O
Watson	O
[	O
24	O
]	O
.	O

The	O
infusion	O
kit	O
was	O
sealed	O
with	O
dental	O
cement	O
and	O
connected	O
to	O
an	O
osmotic	O
pump	O
(	O
1007D	O
,	O
Alzet	O
,	O
Cupertino	O
,	O
CA	O
)	O
.	O

The	O
pump	O
was	O
placed	O
in	O
a	O
subcutaneous	O
pocket	O
in	O
the	O
dorsal	O
region	O
.	O

Animals	O
received	O
0	O
.	O
5	O
mul	O
/	O
hr	O
of	O
vehicle	O
or	O
compound	O
for	O
1	O
week	O
.	O

Therefore	O
,	O
the	O
dose	O
of	O
sTNFp55R	B-Protein
was	O
0	O
.	O
6	O
mug	O
/	O
day	O
per	O
each	O
animal	O
.	O

The	O
compounds	O
began	O
to	O
be	O
immediately	O
infused	O
after	O
surgery	O
.	O

Since	O
the	O
volume	O
of	O
vasogenic	O
edema	O
peaked	O
at	O
2	O
-	O
3	O
days	O
after	O
SE	O
in	O
our	O
previous	O
studies	O
[	O
5	O
-	O
8	O
,	O
20	O
]	O
,	O
we	O
chose	O
this	O
time	O
point	O
.	O

Thus	O
,	O
our	O
experimental	O
schedules	O
at	O
least	O
inhibit	O
the	O
function	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
from	O
3	O
days	O
prior	O
to	O
SE	O
to	O
4	O
days	O
after	O
SE	O
when	O
the	O
volume	O
of	O
vasogenic	O
edema	O
peaked	O
.	O

Seizure	O
induction	O

Three	O
days	O
after	O
surgery	O
,	O
rats	O
were	O
treated	O
with	O
pilocarpine	O
(	O
380	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
at	O
20	O
min	O
after	O
methylscopolamine	O
(	O
5	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

Using	O
this	O
treatment	O
paradigm	O
,	O
behavioral	O
seizures	O
typically	O
began	O
within	O
20	O
-	O
40	O
min	O
.	O

Approximately	O
80	O
%	O
of	O
pilocarpine	O
treated	O
rats	O
showed	O
acute	O
behavioral	O
features	O
of	O
SE	O
(	O
including	O
akinesia	O
,	O
facial	O
automatisms	O
,	O
limbic	O
seizures	O
consisting	O
of	O
forelimb	O
clonus	O
with	O
rearing	O
,	O
salivation	O
,	O
masticatory	O
jaw	O
movements	O
,	O
and	O
falling	O
)	O
.	O

We	O
applied	O
the	O
2	O
hr	O
-	O
SE	O
rat	O
model	O
,	O
because	O
>	O
90	O
%	O
of	O
the	O
rats	O
that	O
we	O
monitored	O
in	O
our	O
previous	O
studies	O
[	O
25	O
]	O
displayed	O
spontaneous	O
,	O
recurrent	O
seizures	O
within	O
1	O
-	O
3	O
months	O
after	O
pilocarpine	O
-	O
induced	O
status	O
epilepticus	O
.	O

Diazepam	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Hoffman	O
Ia	O
Roche	O
,	O
Neuilly	O
sur	O
-	O
Seine	O
)	O
was	O
administered	O
2	O
hours	O
after	O
onset	O
of	O
SE	O
and	O
repeated	O
,	O
as	O
needed	O
.	O

The	O
rats	O
were	O
then	O
observed	O
3	O
-	O
4	O
hours	O
a	O
day	O
in	O
the	O
vivarium	O
for	O
general	O
behavior	O
and	O
occurrence	O
of	O
spontaneous	O
seizures	O
.	O

Non	O
-	O
experienced	O
SE	O
(	O
non	O
-	O
SE	O
)	O
rats	O
(	O
showing	O
only	O
acute	O
seizure	O
behaviors	O
during	O
10	O
-	O
30	O
min	O
,	O
n	O
=	O
8	O
)	O
and	O
age	O
-	O
matched	O
normal	O
rats	O
were	O
used	O
as	O
controls	O
(	O
n	O
=	O
7	O
)	O
.	O

Tissue	O
processing	O

At	O
designated	O
time	O
points	O
(	O
non	O
-	O
SE	O
:	O
12	O
hr	O
,	O
1	O
day	O
,	O
2	O
days	O
,	O
3	O
days	O
,	O
4	O
days	O
and	O
1	O
week	O
after	O
SE	O
;	O
n	O
=	O
5	O
,	O
for	O
each	O
time	O
point	O
)	O
,	O
animals	O
were	O
perfused	O
transcardially	O
with	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
followed	O
by	O
4	O
%	O
paraformaldehyde	O
in	O
0	O
.	O
1	O
M	O
phosphate	O
buffer	O
(	O
PB	O
,	O
pH	O
7	O
.	O
4	O
)	O
under	O
urethane	O
anesthesia	O
(	O
1	O
.	O
5	O
g	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

The	O
brains	O
were	O
removed	O
,	O
and	O
postfixed	O
in	O
the	O
same	O
fixative	O
for	O
4	O
hr	O
.	O

The	O
brain	O
tissues	O
were	O
cryoprotected	O
by	O
infiltration	O
with	O
30	O
%	O
sucrose	O
overnight	O
.	O

Thereafter	O
,	O
the	O
entire	O
hippocampus	O
was	O
frozen	O
and	O
sectioned	O
with	O
a	O
cryostat	O
at	O
30	O
mum	O
and	O
consecutive	O
sections	O
were	O
contained	O
in	O
six	O
-	O
well	O
plates	O
containing	O
PBS	O
.	O

For	O
stereological	O
study	O
,	O
every	O
sixth	O
section	O
in	O
the	O
series	O
throughout	O
the	O
entire	O
hippocampus	O
was	O
used	O
in	O
some	O
animals	O
.	O

Immunohistochemistry	O

Free	O
-	O
floating	O
sections	O
were	O
first	O
incubated	O
with	O
10	O
%	O
normal	O
goat	O
serum	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

They	O
were	O
then	O
incubated	O
in	O
rabbit	O
anti	O
-	O
MPO	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Thermo	O
fisher	O
scientific	O
)	O
or	O
rabbit	O
anti	O
-	O
MIP	O
-	O
2	O
IgG	O
(	O
1	O
:	O
200	O
,	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
in	O
PBS	O
containing	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
(	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
and	O
2	O
%	O
normal	O
goat	O
serum	O
(	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
three	O
times	O
for	O
10	O
min	O
with	O
PBS	O
,	O
the	O
sections	O
were	O
incubated	O
sequentially	O
,	O
in	O
goat	O
anti	O
-	O
rabbit	O
or	O
horse	O
anti	O
-	O
mouse	O
IgG	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
and	O
ABC	O
complex	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
,	O
diluted	O
1	O
:	O
200	O
in	O
the	O
same	O
solution	O
as	O
the	O
primary	O
antiserum	O
.	O

Between	O
the	O
incubations	O
,	O
the	O
tissues	O
were	O
washed	O
with	O
PBS	O
three	O
times	O
for	O
10	O
min	O
each	O
.	O

To	O
confirm	O
vasogenic	O
edema	O
,	O
some	O
tissue	O
sections	O
were	O
reacted	O
for	O
serum	O
-	O
proteins	O
using	O
horse	O
anti	O
-	O
rat	O
IgG	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
as	O
a	O
primary	O
antibody	O
.	O

The	O
sections	O
were	O
visualized	O
with	O
3	O
,	O
3	O
'	O
-	O
diaminobenzidine	O
(	O
DAB	O
,	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
in	O
0	O
.	O
1	O
M	O
Tris	O
buffer	O
and	O
mounted	O
on	O
the	O
gelatin	O
-	O
coated	O
slides	O
.	O

The	O
immunoreactions	O
were	O
observed	O
under	O
the	O
Axioscope	O
microscope	O
(	O
Carl	O
Zeiss	O
,	O
Munchen	O
-	O
Hallbergmoos	O
)	O
.	O

For	O
negative	O
controls	O
,	O
rat	O
hippocampal	O
tissues	O
were	O
incubated	O
with	O
1	O
mug	O
of	O
the	O
antibody	O
that	O
was	O
preincubated	O
with	O
1	O
mug	O
of	O
purified	O
peptide	O
for	O
1	O
hr	O
at	O
room	O
temperature	O
or	O
incubated	O
with	O
pre	O
-	O
immune	O
serum	O
instead	O
of	O
the	O
primary	O
antibody	O
.	O

For	O
negative	O
controls	O
,	O
tissues	O
were	O
incubated	O
with	O
pre	O
-	O
immune	O
serum	O
instead	O
of	O
primary	O
antibody	O
.	O

Double	O
immunofluorescence	O
study	O

Sections	O
were	O
incubated	O
with	O
3	O
%	O
bovine	O
serum	B-Protein
albumin	I-Protein
in	O
PBS	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Sections	O
were	O
then	O
incubated	O
in	O
a	O
mixture	O
of	O
goat	O
anti	O
-	O
TNF	O
-	O
alpha	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
R	O
&	O
D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
/	O
mouse	O
anti	O
-	O
OX	O
-	O
42	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Serotec	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
an	O
astroglial	O
marker	O
,	O
Millipore	O
Corporation	O
,	O
Billerica	O
,	O
MA	O
)	O
/	O
rabbit	O
anti	O
-	O
TNFp55R	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
/	O
rabbit	O
anti	O
-	O
TNFp75R	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
SMI	O
-	O
71	O
IgM	O
(	O
1	O
:	O
1000	O
,	O
Covance	O
,	O
Berkeley	O
,	O
CA	O
)	O
/	O
rabbit	O
anti	O
-	O
TNFp75R	O
IgG	O
,	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
/	O
rabbit	O
anti	O
-	O
NF	O
-	O
kappaB	O
(	O
p65	O
-	O
Ser276	O
,	O
p65	O
-	O
Ser311	O
,	O
p65	O
-	O
Ser529	O
,	O
and	O
p65	O
-	O
Thr435	O
)	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
SMI	O
-	O
71	O
IgM	O
/	O
rabbit	O
anti	O
-	O
p65	O
-	O
Thr435	O
NF	O
-	O
kappaB	O
IgG	O
,	O
mouse	O
anti	O
-	O
SMI	O
-	O
71	O
IgM	O
/	O
rabbit	O
anti	O
-	O
GLUT	O
-	O
1	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
or	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
/	O
rabbit	O
anti	O
-	O
MIP	O
-	O
2	O
IgG	O
(	O
1	O
:	O
100	O
)	O
in	O
PBS	O
containing	O
0	O
.	O
3	O
%	O
triton	O
X	O
-	O
100	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
three	O
times	O
for	O
10	O
minutes	O
with	O
PBS	O
,	O
sections	O
were	O
also	O
incubated	O
in	O
a	O
mixture	O
of	O
FITC	O
-	O
and	O
Cy3	O
-	O
conjugated	O
secondary	O
antisera	O
(	O
Amersham	O
,	O
San	O
Francisco	O
,	O
CA	O
)	O
,	O
diluted	O
1	O
:	O
200	O
,	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
.	O

The	O
sections	O
were	O
washed	O
three	O
times	O
for	O
10	O
min	O
with	O
PBS	O
,	O
and	O
mounted	O
on	O
gelatin	O
-	O
coated	O
slides	O
.	O

For	O
nuclei	O
counterstaining	O
,	O
we	O
used	O
Vectashield	O
mounting	O
medium	O
with	O
DAPI	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
.	O

All	O
images	O
were	O
captured	O
using	O
an	O
AxioImage	O
M2	O
microscope	O
and	O
AxioVision	O
Rel	O
.	O

4	O
.	O
8	O
software	O
.	O

Fluoro	O
-	O
Jade	O
B	O
staining	O

Fluoro	O
-	O
Jade	O
B	O
(	O
FJB	O
)	O
staining	O
was	O
used	O
to	O
identify	O
degenerating	O
neurons	O
in	O
tissues	O
obtained	O
from	O
non	O
-	O
SE	O
and	O
3	O
days	O
post	O
-	O
SE	O
animals	O
in	O
every	O
group	O
.	O

In	O
our	O
previous	O
[	O
18	O
,	O
25	O
]	O
and	O
preliminary	O
data	O
,	O
neuronal	O
damage	O
was	O
first	O
detectable	O
at	O
3	O
days	O
after	O
SE	O
.	O

Therefore	O
,	O
we	O
determined	O
3	O
days	O
after	O
SE	O
as	O
the	O
best	O
time	O
point	O
to	O
look	O
FJB	O
.	O

Briefly	O
,	O
sections	O
were	O
rinsed	O
in	O
distilled	O
water	O
,	O
and	O
mounted	O
onto	O
gelatin	O
-	O
coated	O
slides	O
and	O
then	O
dried	O
on	O
a	O
slide	O
warmer	O
.	O

The	O
slides	O
were	O
immersed	O
in	O
100	O
%	O
ethanol	O
for	O
3	O
min	O
,	O
followed	O
by	O
70	O
%	O
ethanol	O
for	O
2	O
min	O
and	O
distilled	O
water	O
for	O
2	O
min	O
.	O

The	O
slides	O
were	O
then	O
transferred	O
to	O
0	O
.	O
06	O
%	O
potassium	O
permanganate	O
for	O
15	O
min	O
and	O
gently	O
agitated	O
.	O

After	O
rinsing	O
in	O
distilled	O
water	O
for	O
2	O
min	O
,	O
the	O
slides	O
were	O
incubated	O
for	O
30	O
min	O
in	O
0	O
.	O
001	O
%	O
FJB	O
(	O
Histo	O
-	O
Chem	O
Inc	O
.	O
,	O
Jefferson	O
,	O
AR	O
)	O
,	O
freshly	O
prepared	O
by	O
adding	O
20	O
ml	O
of	O
a	O
0	O
.	O
01	O
%	O
stock	O
FJB	O
solution	O
to	O
180	O
ml	O
of	O
0	O
.	O
1	O
%	O
acetic	O
acid	O
,	O
with	O
gentle	O
shaking	O
in	O
the	O
dark	O
.	O

After	O
rinsing	O
for	O
1	O
min	O
in	O
each	O
of	O
three	O
changes	O
of	O
distilled	O
water	O
,	O
the	O
slides	O
were	O
dried	O
,	O
dehydrated	O
in	O
xylene	O
and	O
coverslipped	O
with	O
DPX	O
(	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

For	O
stereological	O
study	O
,	O
every	O
sixth	O
section	O
in	O
the	O
series	O
throughout	O
the	O
entire	O
PC	O
was	O
used	O
(	O
see	O
below	O
)	O
.	O

Volumetric	O
analysis	O
and	O
cell	O
counts	O

To	O
measure	O
vasogenic	O
edema	O
,	O
the	O
volume	O
of	O
anti	O
-	O
rat	O
IgG	O
positive	O
region	O
in	O
PC	O
was	O
estimated	O
according	O
to	O
the	O
formula	O
based	O
on	O
the	O
modified	O
Cavalieri	O
method	O
:	O
V	O
=	O
sigmaa	O
x	O
tnom	O
x	O
1	O
/	O
ssf	O
,	O
where	O
a	O
is	O
area	O
of	O
the	O
region	O
of	O
the	O
delineated	O
subfield	O
measured	O
by	O
AxioVision	O
Rel	O
.	O

4	O
.	O
8	O
software	O
,	O
tnom	O
is	O
the	O
nominal	O
section	O
thickness	O
(	O
of	O
30	O
mum	O
in	O
this	O
study	O
)	O
,	O
and	O
ssf	O
is	O
the	O
fraction	O
of	O
the	O
sections	O
sampled	O
or	O
section	O
sampling	O
fraction	O
(	O
of	O
1	O
/	O
6	O
in	O
this	O
study	O
)	O
.	O

The	O
subfield	O
areas	O
were	O
delineated	O
with	O
a	O
2	O
.	O
5	O
x	O
objective	O
lens	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
18	O
,	O
25	O
]	O
.	O

The	O
volumes	O
are	O
reported	O
as	O
mm3	O
.	O

An	O
optical	O
fractionator	O
was	O
used	O
to	O
estimate	O
cell	O
numbers	O
.	O

The	O
optical	O
fractionator	O
(	O
a	O
combination	O
of	O
performing	O
counting	O
with	O
the	O
optical	O
dissector	O
,	O
with	O
fractionator	O
sampling	O
)	O
is	O
a	O
stereological	O
method	O
based	O
on	O
a	O
properly	O
designed	O
systematic	O
random	O
sampling	O
method	O
that	O
by	O
definition	O
yields	O
unbiased	O
estimates	O
of	O
population	O
number	O
.	O

The	O
sampling	O
procedure	O
is	O
accomplished	O
by	O
focusing	O
through	O
the	O
depth	O
of	O
the	O
tissue	O
(	O
the	O
optical	O
dissector	O
height	O
,	O
h	O
;	O
15	O
mum	O
in	O
all	O
cases	O
for	O
this	O
study	O
)	O
.	O

The	O
number	O
of	O
each	O
cell	O
type	O
(	O
C	O
)	O
in	O
each	O
of	O
the	O
subregions	O
is	O
estimated	O
as	O
:	O
C	O
=	O
sigmaQ	O
-	O
x	O
t	O
/	O
h	O
x	O
1	O
/	O
asf	O
x	O
1	O
/	O
ssf	O
,	O
where	O
Q	O
-	O
is	O
the	O
number	O
of	O
cells	O
actually	O
counted	O
in	O
the	O
dissectors	O
that	O
fell	O
within	O
the	O
sectional	O
profiles	O
of	O
the	O
subregion	O
seen	O
on	O
the	O
sampled	O
sections	O
,	O
and	O
Asf	O
is	O
the	O
areal	O
sampling	O
fraction	O
calculated	O
by	O
the	O
area	O
of	O
the	O
counting	O
frame	O
of	O
the	O
dissector	O
,	O
a	O
(	O
frame	O
)	O
(	O
of	O
50	O
x	O
50	O
mum2	O
in	O
this	O
study	O
)	O
and	O
the	O
area	O
associated	O
with	O
each	O
x	O
,	O
y	O
movement	O
,	O
grid	O
(	O
x	O
,	O
y	O
step	O
)	O
(	O
of	O
250	O
x	O
250	O
mum2	O
in	O
this	O
study	O
)	O
{	O
asf	O
=	O
(	O
a	O
(	O
frame	O
)	O
/	O
a	O
(	O
x	O
,	O
y	O
step	O
)	O
)	O
}	O
.	O

The	O
immunoreactive	O
cells	O
were	O
counted	O
with	O
a	O
40x	O
objective	O
lens	O
.	O

The	O
immunoreactive	O
cells	O
were	O
counted	O
with	O
a	O
40x	O
objective	O
lens	O
.	O

All	O
immunoreactive	O
cells	O
were	O
counted	O
regardless	O
the	O
intensity	O
of	O
labeling	O
.	O

Cell	O
counts	O
were	O
performed	O
by	O
two	O
different	O
investigators	O
who	O
were	O
blind	O
to	O
the	O
classification	O
of	O
tissues	O
.	O

SE	O
-	O
induced	O
PC	O
atrophy	O
is	O
evident	O
[	O
8	O
]	O
,	O
so	O
changes	O
in	O
cell	O
number	O
may	O
be	O
caused	O
by	O
an	O
alterations	O
in	O
the	O
volume	O
of	O
the	O
PC	O
.	O

Therefore	O
,	O
the	O
total	O
number	O
of	O
cells	O
was	O
corrected	O
by	O
multiplying	O
with	O
appropriate	O
correction	O
factors	O
(	O
CF	O
)	O
representing	O
the	O
degree	O
of	O
shrinkage	O
(	O
or	O
swelling	O
)	O
compared	O
with	O
the	O
Non	O
-	O
SE	O
.	O

Quantification	O
of	O
data	O

The	O
fluorescence	O
intensities	O
of	O
SMI	O
-	O
71	O
/	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
or	O
GFPA	O
/	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
were	O
measured	O
using	O
a	O
computer	O
-	O
assisted	O
image	O
analysis	O
program	O
(	O
The	O
University	O
of	O
Texas	O
ImageTool	O
program	O
V	O
.	O
3	O
.	O
0	O
and	O
AxioVision	O
Rel	O
.	O
4	O
.	O
8	O
software	O
)	O
.	O

After	O
regions	O
were	O
outlined	O
,	O
30	O
areas	O
/	O
rat	O
(	O
300	O
mum2	O
/	O
area	O
)	O
were	O
randomly	O
selected	O
within	O
the	O
PC	O
,	O
and	O
double	O
immunofluorescent	O
merge	O
images	O
were	O
captured	O
from	O
the	O
PC	O
(	O
15	O
sections	O
from	O
each	O
animal	O
)	O
.	O

Merge	O
images	O
were	O
digitally	O
separated	O
to	O
red	O
or	O
green	O
image	O
,	O
and	O
converted	O
to	O
grayscale	O
images	O
,	O
respectively	O
(	O
n	O
=	O
36	O
per	O
region	O
examined	O
,	O
in	O
non	O
-	O
SE	O
,	O
12	O
hr	O
post	O
-	O
SE	O
and	O
1	O
day	O
post	O
-	O
SE	O
)	O
.	O

The	O
range	O
of	O
intensity	O
values	O
was	O
obtained	O
from	O
the	O
selected	O
images	O
.	O

Based	O
on	O
the	O
mean	O
range	O
of	O
intensity	O
values	O
,	O
each	O
image	O
was	O
normalized	O
by	O
adjusting	O
the	O
black	O
and	O
white	O
range	O
of	O
the	O
image	O
.	O

Manipulation	O
of	O
the	O
images	O
was	O
restricted	O
to	O
threshold	O
and	O
brightness	O
adjustments	O
to	O
the	O
whole	O
image	O
.	O

Intensity	O
measurements	O
are	O
represented	O
as	O
the	O
mean	O
number	O
of	O
a	O
256	O
gray	O
scale	O
(	O
NIH	O
Image	O
1	O
.	O
59	O
software	O
and	O
AxioVision	O
Rel	O
.	O
4	O
.	O
8	O
software	O
)	O
.	O

Values	O
for	O
background	O
staining	O
were	O
obtained	O
from	O
the	O
corpus	O
callosum	O
.	O

Optical	O
density	O
values	O
were	O
then	O
corrected	O
by	O
subtracting	O
the	O
average	O
values	O
of	O
background	O
noise	O
obtained	O
from	O
15	O
image	O
inputs	O
.	O

Data	O
analysis	O

Data	O
obtained	O
from	O
volumetric	O
analysis	O
,	O
cell	O
counts	O
,	O
and	O
quantitative	O
measurements	O
were	O
analyzed	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
to	O
determine	O
statistical	O
significance	O
.	O

Linear	O
regression	O
analysis	O
was	O
also	O
performed	O
to	O
determine	O
correlations	O
with	O
SMI	O
-	O
71	O
/	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
,	O
and	O
the	O
number	O
of	O
MPO	O
cells	O
/	O
vasogenic	O
edema	O
areas	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
and	O
TNF	O
receptor	O
expression	O

In	O
non	O
-	O
SE	O
induced	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
groups	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
was	O
weakly	O
detected	O
in	O
PC	O
neurons	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
,	O
most	O
of	O
the	O
activated	O
microglia	O
showed	O
strong	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
(	O
Figure	O
1A	O
)	O
.	O

This	O
expression	O
pattern	O
was	O
maintained	O
up	O
to	O
1	O
week	O
after	O
SE	O
.	O

In	O
non	O
-	O
SE	O
-	O
induced	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
groups	O
,	O
TNFp55R	B-Protein
and	O
TNFp75R	B-Protein
immunoreactivities	O
were	O
also	O
weakly	O
observed	O
in	O
astrocytes	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
,	O
TNFp55R	B-Protein
immunoreactivity	O
was	O
observed	O
in	O
astrocytes	O
(	O
Figure	O
1B	O
)	O
.	O

Unlike	O
TNFp55R	B-Protein
,	O
TNFp75R	B-Protein
immunoreactivity	O
was	O
detected	O
in	O
endothelial	O
cells	O
as	O
well	O
as	O
astrocytes	O
(	O
Figures	O
1C	O
-	O
E	O
)	O
.	O

One	O
day	O
to	O
1	O
week	O
after	O
SE	O
,	O
both	O
TNFp55R	B-Protein
and	O
TNFp75R	B-Protein
immunoreactivities	O
were	O
significantly	O
reduced	O
in	O
astrocytes	O
,	O
not	O
in	O
endothelial	O
cells	O
,	O
due	O
to	O
massive	O
astroglial	O
loss	O
(	O
data	O
not	O
shown	O
)	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
20	O
]	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
SE	O
-	O
induced	O
serum	O
-	O
protein	O
extravasation	O
and	O
neuronal	O
damage	O

In	O
our	O
previous	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
20	O
]	O
and	O
preliminary	O
data	O
,	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
were	O
noticeable	O
at	O
1	O
day	O
and	O
3	O
days	O
after	O
SE	O
,	O
respectively	O
.	O

Therefore	O
,	O
we	O
determined	O
that	O
3	O
days	O
after	O
SE	O
was	O
the	O
best	O
time	O
point	O
to	O
evaluate	O
the	O
effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
both	O
vasogenic	O
edema	O
and	O
neuronal	O
damages	O
induced	O
by	O
SE	O
.	O

In	O
saline	O
-	O
treated	O
animals	O
,	O
the	O
PC	O
was	O
stained	O
diffusely	O
with	O
anti	O
-	O
rat	O
IgG	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
volume	O
of	O
vasogenic	O
edema	O
was	O
17	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm3	O
(	O
Figure	O
2E	O
)	O
.	O

The	O
number	O
of	O
FJB	O
-	O
positive	O
neurons	O
in	O
the	O
PC	O
was	O
236	O
,	O
145	O
+	O
/	O
-	O
49	O
,	O
469	O
(	O
Figure	O
2B	O
)	O
.	O

In	O
sTNFp55R	B-Protein
-	O
treated	O
animals	O
,	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
was	O
attenuated	O
to	O
9	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
7	O
mm3	O
(	O
Figures	O
2C	O
and	O
2E	O
)	O
.	O

In	O
addition	O
,	O
the	O
number	O
of	O
FJB	O
-	O
positive	O
neurons	O
in	O
the	O
PC	O
was	O
89	O
,	O
138	O
+	O
/	O
-	O
5	O
,	O
698	O
(	O
Figures	O
2D	O
-	O
E	O
)	O
.	O

Thus	O
,	O
sTNFp55R	B-Protein
infusion	O
attenuated	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
compared	O
to	O
saline	O
-	O
infused	O
animals	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

NF	O
-	O
kappaB	O
phosphorylation	O

It	O
is	O
well	O
established	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
one	O
of	O
the	O
major	O
stimuli	O
toward	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
.	O

To	O
confirm	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
signaling	O
following	O
SE	O
,	O
we	O
performed	O
an	O
immunohistochemical	O
study	O
using	O
five	O
phospho	O
-	O
NF	O
-	O
kappaB	O
antibodies	O
.	O

Compared	O
to	O
non	O
-	O
SE	O
animals	O
(	O
data	O
not	O
shown	O
)	O
,	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
showed	O
p65	B-Protein
-	O
Ser276	O
,	O
p65	B-Protein
-	O
Ser311	O
,	O
p65	B-Protein
-	O
Ser529	O
,	O
and	O
p65	B-Protein
-	O
Ser536	O
phosphorylation	O
in	O
astrocytes	O
(	O
not	O
endothelial	O
cells	O
)	O
.	O

sTNFp55R	B-Protein
infusion	O
effectively	O
reduced	O
p65	B-Protein
-	O
Ser276	O
and	O
p65	B-Protein
-	O
Ser311	O
phosphorylation	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
,	O
while	O
it	O
could	O
not	O
affect	O
p65	B-Protein
-	O
Ser529	O
or	O
p65	B-Protein
-	O
Ser536	O
phosphorylation	O
(	O
Figures	O
3	O
and	O
4A	O
)	O
.	O

In	O
contrast	O
,	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
was	O
increased	O
in	O
endothelial	O
cells	O
(	O
not	O
astrocytes	O
)	O
within	O
the	O
PC	O
of	O
saline	O
-	O
infused	O
animals	O
12	O
hr	O
after	O
SE	O
(	O
Figure	O
5A	O
)	O
.	O

In	O
addition	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
alleviated	O
SE	O
-	O
induced	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
,	O
compared	O
to	O
saline	O
infusion	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Figure	O
5B	O
)	O
.	O

SMI	O
-	O
71	O
expression	O

Previously	O
,	O
we	O
reported	O
that	O
SMI	O
-	O
71	O
(	O
an	O
endothelial	O
barrier	O
antigen	O
)	O
immunoreactivity	O
decreased	O
in	O
the	O
PC	O
1	O
day	O
after	O
SE	O
[	O
5	O
]	O
.	O

Similarly	O
,	O
in	O
1	O
day	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
,	O
loss	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
was	O
detected	O
in	O
layer	O
III	O
/	O
IV	O
of	O
the	O
PC	O
as	O
compared	O
to	O
non	O
-	O
SE	O
animals	O
(	O
Figures	O
4B	O
and	O
5C	O
-	O
E	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Thus	O
,	O
loss	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
correlated	O
with	O
volume	O
of	O
vasogenic	O
edema	O
following	O
SE	O
.	O

This	O
reduction	O
in	O
SMI	O
-	O
71	O
was	O
accompanied	O
by	O
increased	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
(	O
Figures	O
5C	O
-	O
D	O
)	O
.	O

Therefore	O
,	O
the	O
degree	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
was	O
inversely	O
correlated	O
to	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
with	O
a	O
linear	O
coefficient	O
of	O
correlation	O
of	O
-	O
0	O
.	O
6324	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
4C	O
)	O
.	O

In	O
addition	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
alleviated	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
and	O
preserved	O
SMI	O
-	O
71	O
immunoreactivity	O
in	O
endothelial	O
cells	O
following	O
SE	O
,	O
as	O
compared	O
to	O
saline	O
infusion	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Figures	O
4A	O
-	O
B	O
,	O
5D	O
and	O
5F	O
)	O
.	O

Neutrophil	O
infiltration	O

Recent	O
studies	O
have	O
reported	O
that	O
neutrophils	O
infiltrate	O
the	O
brain	O
under	O
certain	O
pathological	O
conditions	O
[	O
26	O
]	O
.	O

Indeed	O
,	O
we	O
have	O
reported	O
massive	O
neutrophil	O
infiltration	O
in	O
layer	O
III	O
/	O
IV	O
of	O
the	O
PC	O
1	O
day	O
after	O
SE	O
[	O
20	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
1	O
day	O
-	O
post	O
-	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
showed	O
infiltration	O
of	O
MPO	O
-	O
positive	O
neutrophils	O
into	O
the	O
PC	O
.	O

Similarly	O
,	O
1	O
day	O
-	O
post	O
-	O
SE	O
animals	O
of	O
the	O
sTNFp55R	B-Protein
-	O
infused	O
group	O
showed	O
neutrophil	O
infiltration	O
into	O
the	O
PC	O
1	O
day	O
after	O
SE	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
number	O
of	O
neutrophils	O
/	O
area	O
in	O
the	O
PC	O
region	O
(	O
including	O
the	O
vasogenic	O
edema	O
region	O
and	O
the	O
non	O
-	O
vasogenic	O
edema	O
region	O
)	O
of	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
saline	O
-	O
infused	O
group	O
(	O
Figure	O
6D	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
neutrophil	O
infiltration	O
per	O
unit	O
area	O
of	O
vasogenic	O
edema	O
between	O
the	O
saline	O
-	O
and	O
sTNFp55R	B-Protein
-	O
infused	O
groups	O
(	O
Figure	O
6D	O
)	O
.	O

Furthermore	O
,	O
neutrophil	O
infiltration	O
showed	O
a	O
direct	O
proportion	O
to	O
the	O
area	O
of	O
vasogenic	O
edema	O
,	O
with	O
a	O
linear	O
coefficient	O
of	O
correlation	O
of	O
0	O
.	O
8631	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Figure	O
6E	O
)	O
.	O

Therefore	O
,	O
our	O
findings	O
indicate	O
that	O
SE	O
-	O
induced	O
neutrophil	O
infiltration	O
into	O
the	O
PC	O
may	O
be	O
correlated	O
to	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
vasogenic	O
edema	O
formation	O
.	O

MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O

MIP	B-Protein
-	I-Protein
2	I-Protein
is	O
a	O
powerful	O
chemokine	B-Protein
that	O
contributes	O
to	O
recruitment	O
of	O
neutrophils	O
[	O
27	O
]	O
.	O

MIP	B-Protein
-	I-Protein
2	I-Protein
is	O
undetectable	O
or	O
present	O
at	O
low	O
levels	O
under	O
physiological	O
conditions	O
,	O
and	O
shows	O
transient	O
increases	O
under	O
pathological	O
conditions	O
via	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
/	O
or	O
interleukin	B-Protein
-	I-Protein
1beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
-	O
dependent	O
mechanisms	O
[	O
14	O
]	O
.	O

Thus	O
,	O
it	O
would	O
be	O
plausible	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
may	O
provoke	O
SE	O
-	O
induced	O
neutrophil	O
infiltrations	O
.	O

To	O
confirm	O
this	O
hypothesis	O
,	O
we	O
investigated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
the	O
PC	O
.	O

Consistent	O
with	O
our	O
previous	O
study	O
[	O
20	O
]	O
,	O
some	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
positive	O
astrocytes	O
were	O
observed	O
in	O
the	O
core	O
and	O
periphery	O
of	O
the	O
vasogenic	O
edema	O
lesions	O
,	O
but	O
not	O
in	O
the	O
non	O
-	O
vasogenic	O
edema	O
region	O
(	O
Figure	O
6B	O
and	O
6C	O
)	O
.	O

Although	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
unit	O
area	O
in	O
the	O
PC	O
region	O
of	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
saline	O
-	O
infused	O
group	O
due	O
to	O
reduction	O
of	O
the	O
area	O
of	O
vasogenic	O
edema	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
unit	O
area	O
of	O
vasogenic	O
edema	O
between	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
and	O
saline	O
-	O
infused	O
animals	O
(	O
Figure	O
6F	O
)	O
.	O

Furthermore	O
,	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
positive	O
cells	O
showed	O
a	O
direct	O
proportion	O
to	O
the	O
unit	O
area	O
of	O
vasogenic	O
edema	O
with	O
a	O
linear	O
coefficient	O
of	O
correlation	O
of	O
0	O
.	O
682	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Figure	O
6G	O
)	O
.	O

Therefore	O
,	O
together	O
with	O
reduction	O
in	O
neutrophil	O
infiltration	O
in	O
the	O
PC	O
region	O
of	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
,	O
our	O
findings	O
provide	O
evidence	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
may	O
regulate	O
SE	O
-	O
induced	O
neutrophil	O
infiltration	O
at	O
least	O
in	O
the	O
PC	O
via	O
vasogenic	O
edema	O
formation	O
and	O
not	O
via	O
direct	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
astrocytes	O
.	O

The	O
major	O
findings	O
in	O
the	O
present	O
study	O
are	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
showed	O
cellular	O
specific	O
responses	O
of	O
NF	O
-	O
kappaB	O
phosphorylation	O
in	O
the	O
PC	O
following	O
SE	O
,	O
which	O
may	O
be	O
related	O
to	O
vasogenic	O
edema	O
formation	O
followed	O
by	O
neutrophil	O
infiltration	O
.	O

BBB	O
disruption	O
has	O
been	O
reported	O
in	O
experimental	O
and	O
human	O
epilepsy	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
16	O
,	O
28	O
]	O
.	O

Leakage	O
of	O
serum	O
-	O
derived	O
components	O
into	O
the	O
extracellular	O
space	O
is	O
associated	O
with	O
hyperexcitability	O
and	O
seizure	O
onset	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
16	O
,	O
28	O
]	O
.	O

Furthermore	O
,	O
dysfunction	O
of	O
the	O
BBB	O
leads	O
to	O
epileptogenesis	O
and	O
contributes	O
to	O
progression	O
of	O
epilepsy	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
16	O
,	O
28	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
was	O
obviously	O
observed	O
in	O
microglia	O
in	O
the	O
PC	O
following	O
SE	O
.	O

TNF	O
receptor	O
expressions	O
were	O
also	O
up	O
-	O
regulated	O
in	O
astrocytes	O
(	O
TNFp55R	B-Protein
and	O
TNFp75R	B-Protein
)	O
and	O
endothelial	O
cells	O
(	O
TNFp75R	B-Protein
)	O
.	O

Furthermore	O
,	O
blockade	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
by	O
sTNFp55	B-Protein
infusion	O
effectively	O
(	O
but	O
not	O
completely	O
)	O
reduced	O
volumes	O
of	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
in	O
the	O
PC	O
.	O

These	O
findings	O
indicate	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
may	O
participate	O
in	O
astroglial	O
and	O
endothelial	O
responses	O
to	O
SE	O
,	O
which	O
are	O
relevant	O
to	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
formation	O
[	O
5	O
-	O
8	O
]	O
.	O

Indeed	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
increases	O
BBB	O
permeability	O
in	O
various	O
experimental	O
disease	O
models	O
[	O
29	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
sTNFp55	B-Protein
infusion	O
could	O
not	O
completely	O
prevent	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
in	O
the	O
PC	O
.	O

Therefore	O
,	O
our	O
findings	O
suggest	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
may	O
not	O
be	O
a	O
unique	O
upstream	O
event	O
in	O
vasogenic	O
edema	O
development	O
.	O

p65	B-Protein
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
enhances	O
its	O
transactivation	O
potential	O
,	O
and	O
p65	B-Protein
phosphorylation	O
occurs	O
in	O
either	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
[	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
p65	B-Protein
-	O
Thr435	O
immunoreactivity	O
was	O
detected	O
in	O
endothelial	O
cells	O
,	O
and	O
its	O
immunoreactivity	O
showed	O
an	O
inverse	O
correlation	O
to	O
the	O
degree	O
of	O
SMI	O
-	O
71	O
expression	O
.	O

SMI	O
-	O
71	O
,	O
an	O
endothelial	O
barrier	O
antigen	O
,	O
is	O
a	O
protein	O
expressed	O
by	O
endothelial	O
cells	O
of	O
rat	O
BBB	O
[	O
31	O
]	O
.	O

Under	O
pathological	O
conditions	O
,	O
SMI	O
-	O
71	O
expression	O
is	O
lost	O
in	O
endothelial	O
cells	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
30	O
,	O
32	O
]	O
.	O

Acute	O
phases	O
of	O
the	O
above	O
pathological	O
conditions	O
are	O
accompanied	O
by	O
opening	O
of	O
the	O
BBB	O
and	O
development	O
of	O
vasogenic	O
edema	O
[	O
33	O
]	O
.	O

Indeed	O
,	O
neutralization	O
of	O
SMI	O
-	O
71	O
in	O
vivo	O
leads	O
to	O
widening	O
of	O
intercellular	O
junctions	O
between	O
endothelial	O
cells	O
and	O
swelling	O
of	O
perivascular	O
astrocytic	O
processes	O
[	O
34	O
]	O
,	O
although	O
SMI	O
-	O
71	O
is	O
not	O
localized	O
at	O
endothelial	O
cell	O
junctions	O
[	O
35	O
-	O
38	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
SMI	O
-	O
71	O
immunoreactivity	O
was	O
significantly	O
reduced	O
in	O
blood	O
vessels	O
1	O
day	O
after	O
SE	O
when	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
were	O
observed	O
.	O

Furthermore	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
prevented	O
SE	O
-	O
induced	O
SMI	O
-	O
71	O
down	O
-	O
regulation	O
.	O

With	O
respect	O
to	O
the	O
phosphorylation	O
of	O
p65	B-Protein
-	O
Thr435	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
[	O
39	O
]	O
,	O
our	O
findings	O
indicate	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
vasogenic	O
edema	O
induction	O
via	O
SMI	O
-	O
71	O
degradation	O
or	O
its	O
posttranslational	O
dysfunction	O
influencing	O
BBB	O
permeability	O
.	O

In	O
our	O
previous	O
studies	O
[	O
5	O
,	O
8	O
]	O
,	O
dystrophin	B-Protein
(	O
an	O
actin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
[	O
40	O
]	O
)	O
immunoreactivity	O
was	O
detected	O
in	O
blood	O
vessels	O
and	O
in	O
astrocytic	O
perivascular	O
end	O
-	O
feet	O
,	O
and	O
was	O
down	O
-	O
regulated	O
12	O
hrs	O
after	O
SE	O
prior	O
to	O
the	O
appearance	O
of	O
vasogenic	O
edema	O
and	O
down	O
-	O
regulation	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
.	O

With	O
respect	O
to	O
this	O
previous	O
report	O
,	O
changes	O
in	O
SMI	O
immunoreactivity	O
would	O
be	O
causes	O
/	O
results	O
of	O
interaction	O
between	O
endothelial	O
cells	O
and	O
perivascular	O
astrocytes	O
.	O

In	O
the	O
present	O
study	O
,	O
p65	B-Protein
-	O
Ser276	O
,	O
p65	B-Protein
-	O
Ser311	O
,	O
p65	B-Protein
-	O
Ser529	O
,	O
and	O
p65	B-Protein
-	O
Ser536	O
phosphorylation	O
was	O
observed	O
in	O
astrocytes	O
following	O
SE	O
.	O

Furthermore	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
inhibited	O
p65	B-Protein
-	O
Ser276	O
and	O
p65	B-Protein
-	O
Ser311phosphorylation	O
in	O
astrocytes	O
following	O
SE	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
enhanced	O
p65	B-Protein
-	O
Ser276	O
and	O
p65	B-Protein
-	O
Ser311	O
phosphorylation	O
may	O
be	O
involved	O
in	O
TNF	B-Protein
-	O
alpha	O
-	O
mediated	O
BBB	O
disruption	O
.	O

However	O
,	O
sTNFp55R	B-Protein
infusion	O
could	O
not	O
prevent	O
p65	B-Protein
-	O
Ser529	O
and	O
p65	B-Protein
-	O
Ser536	O
phosphorylations	O
from	O
SE	O
insults	O
.	O

Since	O
p65	B-Protein
-	O
Ser529	O
and	O
p65	B-Protein
-	O
Ser536	O
are	O
phosphorylated	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
[	O
41	O
]	O
,	O
it	O
is	O
likely	O
that	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
-	O
mediated	O
p65	B-Protein
-	O
Ser529	O
/	O
Ser536	O
phosphorylation	O
may	O
also	O
play	O
a	O
role	O
in	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
.	O

Therefore	O
,	O
our	O
findings	O
indicate	O
that	O
both	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
may	O
be	O
synergists	O
to	O
play	O
either	O
a	O
direct	O
(	O
by	O
endothelial	O
cells	O
)	O
or	O
indirect	O
(	O
by	O
astrocytes	O
)	O
role	O
in	O
the	O
maintenance	O
of	O
BBB	O
permeability	O
.	O

Neutrophil	O
infiltration	O
into	O
brain	O
parenchyma	O
is	O
transiently	O
observed	O
during	O
the	O
acute	O
phase	O
of	O
SE	O
(	O
4	O
-	O
36	O
hr	O
after	O
SE	O
)	O
and	O
disappears	O
thereafter	O
[	O
20	O
]	O
.	O

SE	O
rapidly	O
increases	O
synthesis	O
and	O
release	O
of	O
chemokines	O
in	O
various	O
areas	O
of	O
the	O
rodent	O
brain	O
[	O
42	O
]	O
.	O

Among	O
them	O
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
is	O
required	O
for	O
efficient	O
neutrophil	O
or	O
lymphocyte	O
recruitment	O
to	O
brain	O
parenchyma	O
[	O
43	O
]	O
.	O

In	O
our	O
previous	O
study	O
[	O
20	O
]	O
,	O
neutrophil	O
infiltration	O
in	O
the	O
frontoparietal	O
cortex	O
was	O
regulated	O
by	O
P2X7	B-Protein
receptor	I-Protein
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
.	O

In	O
the	O
PC	O
,	O
however	O
,	O
neither	O
a	O
P2X7	O
receptor	O
agonist	O
/	O
antagonist	O
nor	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
(	O
an	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
antagonist	I-Protein
)	O
infusion	O
could	O
not	O
affect	O
leukocyte	O
infiltration	O
.	O

In	O
the	O
present	O
study	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
inhibited	O
neutrophil	O
infiltration	O
in	O
the	O
PC	O
by	O
reducing	O
vasogenic	O
edema	O
formation	O
in	O
a	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
manner	O
.	O

With	O
respect	O
to	O
the	O
present	O
and	O
our	O
previous	O
reports	O
,	O
it	O
is	O
therefore	O
likely	O
that	O
vasogenic	O
edema	O
induced	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
can	O
induce	O
neutrophil	O
infiltration	O
and	O
press	O
injury	O
to	O
evoke	O
neuronal	O
-	O
astroglial	O
loss	O
in	O
the	O
PC	O
,	O
unlike	O
other	O
brain	O
regions	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
reveal	O
that	O
impairments	O
of	O
endothelial	O
cell	O
function	O
via	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
mediated	O
p65	B-Protein
-	O
Thr	O
435	O
NF	O
-	O
kappaB	O
phosphorylation	O
may	O
be	O
involved	O
in	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
,	O
which	O
is	O
relevant	O
to	O
neutrophil	O
infiltration	O
and	O
neuronal	O
-	O
astroglial	O
loss	O
.	O

Expression	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
TNF	O
receptor	O
in	O
the	O
PC	O
12	O
hr	O
-	O
post	O
SE	O
.	O

(	O
A	O
)	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
in	O
Ox	O
-	O
42	O
-	O
positive	O
microglia	O
(	O
arrows	O
)	O
.	O

(	O
B	O
)	O
TNFp55R	B-Protein
expression	O
in	O
astrocytes	O
(	O
arrows	O
)	O
.	O

(	O
C	O
-	O
D	O
)	O
TNFp75R	B-Protein
expression	O
in	O
astrocytes	O
as	O
well	O
as	O
endothelial	O
cells	O
(	O
arrows	O
)	O
.	O

Bar	O
=	O
25	O
(	O
A	O
-	O
D	O
)	O
mum	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
SE	O
-	O
induced	O
serum	O
-	O
protein	O
extravasation	O
and	O
neuronal	O
damage	O
.	O

(	O
A	O
-	O
D	O
)	O
Serum	O
-	O
protein	O
extravasation	O
and	O
FJB	O
-	O
positive	O
neuronal	O
damages	O
in	O
the	O
PC	O
3	O
days	O
after	O
SE	O
.	O

Compared	O
to	O
saline	O
-	O
infused	O
animals	O
,	O
serum	O
-	O
protein	O
extravasation	O
and	O
FJB	O
-	O
positive	O
neuronal	O
damage	O
is	O
markedly	O
ameliorated	O
in	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
.	O

Bars	O
=	O
400	O
(	O
A	O
and	O
C	O
)	O
and	O
50	O
(	O
B	O
and	O
D	O
)	O
mum	O
.	O

(	O
E	O
)	O
Quantitative	O
analyses	O
of	O
serum	O
-	O
protein	O
extravasation	O
and	O
FJB	O
-	O
positive	O
neuronal	O
damage	O
in	O
the	O
PC	O
3	O
days	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
treated	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
NF	O
-	O
kappaB	O
phosphorylation	O
in	O
astrocytes	O
12	O
hr	O
after	O
SE	O
.	O

In	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
(	O
A	O
,	O
C	O
,	O
E	O
and	O
G	O
)	O
,	O
astrocytes	O
show	O
p65	B-Protein
-	O
Ser276	O
(	O
A	O
)	O
,	O
p65	B-Protein
-	O
Ser311	O
(	O
C	O
)	O
,	O
p65	B-Protein
-	O
Ser529	O
(	O
E	O
)	O
,	O
and	O
p65	B-Protein
-	O
Ser536	O
(	O
G	O
)	O
phosphorylation	O
(	O
arrows	O
)	O
.	O

sTNFp55R	B-Protein
infusion	O
(	O
B	O
,	O
D	O
,	O
F	O
and	O
H	O
)	O
effectively	O
reduces	O
p65	B-Protein
-	O
Ser276	O
(	O
B	O
)	O
and	O
p65	B-Protein
-	O
Ser311	O
(	O
D	O
)	O
phosphorylation	O
,	O
while	O
it	O
does	O
not	O
affect	O
p65	B-Protein
-	O
Ser529	O
(	O
F	O
)	O
and	O
p65	B-Protein
-	O
Ser536	O
(	O
H	O
)	O
phosphorylation	O
(	O
arrows	O
)	O
.	O

Bar	O
=	O
12	O
.	O
5	O
mum	O
.	O

Quantitative	O
analyses	O
of	O
the	O
effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
NF	O
-	O
kappaB	O
phosphorylation	O
and	O
SMI	O
-	O
71	O
expression	O
.	O

(	O
A	O
)	O
Quantitative	O
analysis	O
of	O
NF	O
-	O
kappaB	O
phosphorylation	O
12	O
hr	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
infused	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
B	O
)	O
Quantitative	O
analysis	O
of	O
SMI	O
-	O
71	O
expression	O
1	O
day	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
infused	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
C	O
)	O
Linear	O
regression	O
analysis	O
between	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
and	O
SMI	O
-	O
71	O
in	O
the	O
PC	O
following	O
SE	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
following	O
SE	O
.	O

(	O
A	O
-	O
B	O
)	O
Inhibition	O
of	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
by	O
sTNFp55R	B-Protein
infusion	O
12	O
hr	O
after	O
SE	O
.	O

p65	B-Protein
-	O
Thr435	O
phosphorylation	O
is	O
rarely	O
observed	O
in	O
astrocytes	O
(	O
arrows	O
)	O
.	O

(	O
C	O
)	O
Endothelial	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
non	O
-	O
SE	O
animals	O
.	O

(	O
D	O
-	O
E	O
)	O
Endothelial	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
saline	O
-	O
infused	O
animals	O
1	O
day	O
after	O
SE	O
.	O

p65	B-Protein
-	O
Thr435	O
phosphorylation	O
is	O
enhanced	O
,	O
while	O
SMI	O
-	O
71	O
expression	O
is	O
reduced	O
in	O
GLUT	B-Protein
-	I-Protein
1	I-Protein
-	O
positive	O
endothelial	O
cells	O
(	O
arrows	O
)	O
.	O

(	O
F	O
-	O
G	O
)	O
Endothelial	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
sTNFp55R	B-Protein
-	O
infused	O
animal	O
1	O
day	O
after	O
SE	O
.	O

sTNFp55R	B-Protein
infusion	O
effectively	O
reduces	O
p65	B-Protein
-	O
Thr435	O
and	O
preserves	O
SMI	O
-	O
71	O
expression	O
in	O
GLUT	B-Protein
-	I-Protein
1	I-Protein
-	O
positive	O
endothelial	O
cells	O
(	O
arrows	O
)	O
.	O

Bars	O
=	O
12	O
.	O
5	O
(	O
A	O
-	O
D	O
)	O
and	O
25	O
(	O
E	O
-	O
G	O
)	O
mum	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
neutrophil	O
infiltration	O
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
following	O
SE	O
.	O

(	O
A	O
)	O
Neutrophil	O
infiltration	O
in	O
vasogenic	O
edema	O
lesion	O
1	O
day	O
after	O
SE	O
.	O

(	O
B	O
)	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
the	O
PC	O
1	O
day	O
after	O
SE	O
.	O

(	O
C	O
)	O
Astroglial	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
(	O
arrows	O
)	O
.	O

Bars	O
=	O
12	O
.	O
5	O
(	O
A	O
and	O
C	O
)	O
and	O
150	O
(	O
B	O
)	O
mum	O
.	O

(	O
D	O
)	O
Quantitative	O
analysis	O
of	O
neutrophil	O
infiltration	O
1	O
day	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
infused	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
E	O
)	O
Linear	O
regression	O
analysis	O
between	O
the	O
number	O
of	O
infiltrated	O
neutrophils	O
/	O
area	O
in	O
the	O
vasogenic	O
edema	O
region	O
and	O
the	O
area	O
of	O
vasogenic	O
edema	O
in	O
the	O
PC	O
.	O

(	O
F	O
)	O
Quantitative	O
analysis	O
of	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
the	O
unit	O
area	O
of	O
vasogenic	O
edema	O
1	O
day	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

There	O
is	O
no	O
difference	O
in	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
positive	O
cells	O
per	O
unit	O
area	O
of	O
vasogenic	O
edema	O
between	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
and	O
saline	O
-	O
infused	O
animals	O
.	O

(	O
G	O
)	O
Linear	O
regression	O
analysis	O
between	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
unit	O
area	O
in	O
vasogenic	O
edema	O
region	O
and	O
the	O
area	O
of	O
vasogenic	O
edema	O
in	O
the	O
PC	O
.	O

The	O
Absence	O
of	O
Nrf2	O
Enhances	O
NF	O
-	O
kappaB	O
-	O
Dependent	O
Inflammation	O
following	O
Scratch	O
Injury	O
in	O
Mouse	O
Primary	O
Cultured	O
Astrocytes	O

It	O
has	O
been	O
proved	O
that	O
Nrf2	O
depletion	O
enhances	O
inflammatory	O
process	O
through	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
brain	O
after	O
TBI	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
relationship	O
between	O
Nrf2	O
and	O
NF	O
-	O
kappaB	O
in	O
astrocytes	O
after	O
TBI	O
.	O

Hence	O
,	O
we	O
used	O
primary	O
cultured	O
astrocytes	O
from	O
either	O
Nrf2	O
wildtype	O
or	O
knockout	O
mice	O
to	O
study	O
the	O
influence	O
of	O
Nrf2	O
on	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
a	O
model	O
of	O
TBI	O
in	O
vitro	O
.	O

Primary	O
cultured	O
astrocytes	O
were	O
scratched	O
to	O
mimic	O
the	O
traumatic	O
injury	O
in	O
vitro	O
.	O

Then	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
was	O
evaluated	O
by	O
EMSA	O
.	O

The	O
mRNA	O
and	O
protein	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
were	O
also	O
evaluated	O
.	O

Gelatin	O
zymography	O
was	O
performed	O
to	O
detect	O
the	O
activity	O
of	O
MMP9	B-Protein
.	O

The	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
expression	O
of	O
proinflammatory	O
cytokines	O
mentioned	O
above	O
were	O
upregulated	O
at	O
24	O
h	O
after	O
scratch	O
.	O

The	O
expression	O
and	O
activity	O
of	O
MMP9	B-Protein
were	O
also	O
elevated	O
.	O

And	O
such	O
tendency	O
was	O
much	O
more	O
prominent	O
in	O
Nrf2	O
KO	O
astrocytes	O
than	O
that	O
in	O
WT	O
astrocytes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
absence	O
of	O
Nrf2	O
may	O
induce	O
more	O
aggressive	O
inflammation	O
through	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
downstream	O
proinflammatory	O
cytokines	O
in	O
astrocytes	O
.	O

Brain	O
damage	O
following	O
traumatic	O
injury	O
is	O
a	O
result	O
of	O
direct	O
(	O
primary	O
injury	O
)	O
and	O
indirect	O
(	O
secondary	O
or	O
delayed	O
injury	O
)	O
mechanisms	O
.	O

The	O
secondary	O
injury	O
mechanism	O
involves	O
the	O
initiation	O
of	O
an	O
acute	O
inflammatory	O
response	O
,	O
including	O
breakdown	O
of	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
,	O
brain	O
edema	O
,	O
infiltration	O
of	O
peripheral	O
blood	O
cells	O
,	O
and	O
activation	O
of	O
resident	O
immunocompetent	O
cells	O
,	O
as	O
well	O
as	O
the	O
release	O
of	O
numerous	O
immune	O
mediators	O
such	O
as	O
interleukins	O
and	O
chemotactic	O
factors	O
[	O
1	O
]	O
.	O

And	O
the	O
subsequent	O
inflammation	O
leads	O
to	O
secondary	O
damage	O
not	O
only	O
in	O
brain	O
but	O
also	O
in	O
other	O
organs	O
[	O
2	O
-	O
4	O
]	O
.	O

Nuclear	O
factor	O
erythroid	O
2	O
-	O
related	O
factor2	O
(	O
Nrf2	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
regulates	O
many	O
kinds	O
of	O
antioxidant	O
genes	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
Nrf2	O
regulates	O
the	O
inflammation	O
in	O
the	O
brain	O
after	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
.	O

It	O
was	O
also	O
showed	O
that	O
TBI	O
could	O
induce	O
more	O
aggravated	O
damage	O
in	O
Nrf2	O
knockout	O
mice	O
than	O
in	O
wildtype	O
mice	O
[	O
5	O
]	O
.	O

On	O
the	O
contrary	O
,	O
such	O
inflammation	O
can	O
be	O
extenuated	O
through	O
elevating	O
the	O
level	O
of	O
Nrf2	O
by	O
its	O
inducers	O
,	O
such	O
as	O
sulforaphane	O
(	O
SFN	O
)	O
[	O
6	O
]	O
.	O

It	O
is	O
well	O
documented	O
that	O
astrocytes	O
play	O
a	O
critical	O
role	O
in	O
maintaining	O
normal	O
brain	O
physiology	O
and	O
responding	O
to	O
injury	O
or	O
disease	O
.	O

In	O
fact	O
,	O
all	O
the	O
aforementioned	O
studies	O
are	O
performed	O
in	O
vivo	O
.	O

Little	O
is	O
known	O
about	O
the	O
relationship	O
between	O
Nrf2	O
and	O
inflammation	O
in	O
astrocytes	O
after	O
TBI	O
.	O

Therefore	O
,	O
here	O
we	O
analysed	O
the	O
influence	O
of	O
Nrf2	O
on	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
primary	O
cultured	O
astrocytes	O
from	O
transgenic	O
mice	O
after	O
scratch	O
injury	O
.	O

2	O
.	O
1	O
.	O

Primary	O
Culture	O
and	O
Identification	O
of	O
Mouse	O
Astrocytes	O

Nrf2	O
knockout	O
ICR	O
mice	O
were	O
kindly	O
provided	O
by	O
Dr	O
.	O
Thomas	O
W	O
.	O
Kensler	O
(	O
Johns	O
Hopkins	O
University	O
,	O
Baltimore	O
,	O
MD	O
,	O
USA	O
)	O
.	O

Primary	O
astrocytes	O
were	O
obtained	O
from	O
postnatal	O
2	O
-	O
day	O
-	O
old	O
Nrf2	O
wide	O
type	O
(	O
WT	O
)	O
and	O
knockout	O
(	O
KO	O
)	O
mice	O
(	O
6	O
mice	O
for	O
each	O
genotype	O
)	O
.	O

Following	O
decapitation	O
,	O
the	O
cortices	O
were	O
dissected	O
out	O
,	O
and	O
the	O
meninges	O
and	O
associated	O
blood	O
vessels	O
were	O
removed	O
.	O

The	O
tissue	O
was	O
roughly	O
chopped	O
with	O
a	O
scalpel	O
blade	O
,	O
incubated	O
in	O
0	O
.	O
5	O
%	O
trypsin	O
for	O
10	O
minutes	O
at	O
37degreesC	O
,	O
and	O
agitated	O
every	O
few	O
minutes	O
.	O

After	O
digestion	O
,	O
the	O
tissue	O
was	O
rinsed	O
twice	O
in	O
DMEM	O
with	O
10	O
%	O
FBS	O
,	O
followed	O
by	O
a	O
mechanical	O
dissociation	O
in	O
DMEM	O
with	O
20	O
%	O
FBS	O
and	O
5	O
units	O
/	O
mL	O
penicillin	O
,	O
5	O
mug	O
/	O
mL	O
streptomycin	O
(	O
complete	O
culture	O
medium	O
)	O
.	O

After	O
incubation	O
for	O
1	O
h	O
,	O
the	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
flask	O
or	O
dish	O
(	O
Costar	O
,	O
USA	O
)	O
for	O
depleting	O
the	O
residual	O
epithelial	O
cells	O
.	O

Then	O
the	O
cells	O
were	O
cultivated	O
at	O
37degreesC	O
with	O
5	O
%	O
CO2	O
.	O

And	O
the	O
complete	O
culture	O
medium	O
was	O
half	O
-	O
changed	O
twice	O
a	O
week	O
.	O

Astrocytes	O
expanded	O
for	O
about	O
7	O
days	O
to	O
reach	O
confluence	O
.	O

Then	O
the	O
flasks	O
or	O
dishes	O
were	O
shaken	O
at	O
150	O
rpm	O
for	O
4	O
h	O
to	O
deplete	O
the	O
microglia	O
and	O
less	O
adherent	O
cells	O
from	O
the	O
cultures	O
.	O

After	O
shaking	O
,	O
the	O
resulting	O
cultures	O
were	O
mainly	O
astrocytes	O
,	O
which	O
were	O
determined	O
by	O
immunoreactivity	O
for	O
GFAP	O
(	O
sc	O
-	O
166481	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cells	O
passaged	O
for	O
2	O
-	O
3	O
generations	O
were	O
used	O
in	O
the	O
following	O
studies	O
.	O

2	O
.	O
2	O
.	O

In	O
Vitro	O
Model	O
of	O
TBI	O
Established	O
by	O
Scratch	O
Injury	O

Astrocyte	O
scratch	O
injury	O
was	O
performed	O
as	O
in	O
a	O
previous	O
report	O
[	O
7	O
]	O
.	O

Astrocytes	O
were	O
planted	O
in	O
6	O
-	O
well	O
plates	O
and	O
grown	O
to	O
confluence	O
.	O

The	O
cell	O
monolayer	O
was	O
scratched	O
with	O
a	O
sterile	O
26G	O
syringe	O
needle	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
a	O
0	O
.	O
5	O
mm	O
wide	O
gap	O
.	O

Immediately	O
after	O
scratch	O
,	O
cells	O
were	O
washed	O
twice	O
with	O
sterile	O
PBS	O
,	O
cultured	O
with	O
complete	O
culture	O
medium	O
,	O
and	O
named	O
as	O
TBI	O
group	O
.	O

Cells	O
,	O
which	O
did	O
not	O
received	O
scratch	O
,	O
were	O
used	O
as	O
blank	O
control	O
and	O
named	O
as	O
sham	O
group	O
.	O

2	O
.	O
3	O
.	O

Cell	O
Death	O
Measurement	O
by	O
CCK	O
-	O
8	O
Assay	O

1	O
x	O
103	O
/	O
well	O
cells	O
were	O
seeded	O
to	O
96	O
-	O
well	O
culture	O
plates	O
and	O
cultivated	O
for	O
24	O
h	O
to	O
adhere	O
.	O

Then	O
the	O
cell	O
was	O
scrated	O
as	O
mentioned	O
above	O
.	O

Astrocyte	O
cell	O
death	O
was	O
assessed	O
by	O
cell	O
counting	O
kit	O
-	O
8	O
(	O
CCK	O
-	O
8	O
)	O
(	O
Dojindo	O
,	O
Japan	O
)	O
assay	O
24	O
h	O
after	O
scratch	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Briefly	O
,	O
10	O
muL	O
CCK	O
-	O
8	O
was	O
added	O
into	O
every	O
well	O
and	O
incubated	O
for	O
1	O
h	O
.	O

Then	O
OD	O
value	O
was	O
read	O
at	O
450	O
nm	O
using	O
a	O
Bio	O
-	O
Rad	O
ELISA	O
microplate	O
reader	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
CA	O
,	O
USA	O
)	O
.	O

All	O
measurements	O
were	O
performed	O
in	O
sextuplicate	O
.	O

Results	O
were	O
expressed	O
as	O
mean	O
of	O
OD	O
value	O
at	O
450	O
nm	O
+	O
/	O
-	O
SD	O
.	O

2	O
.	O
4	O
.	O

Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O

Monolayers	O
of	O
astrocytes	O
were	O
washed	O
with	O
PBS	O
and	O
harvested	O
by	O
scraping	O
into	O
cold	O
PBS	O
.	O

The	O
cell	O
pellet	O
obtained	O
by	O
centrifugation	O
was	O
resuspended	O
in	O
buffer	O
containing	O
10	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
9	O
)	O
,	O
10	O
mM	O
KCl	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
1	O
mM	O
EGTA	O
,	O
1	O
.	O
0	O
mM	O
DTT	O
,	O
and	O
0	O
.	O
5	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
.	O

Then	O
10	O
%	O
Nonidet	O
P	O
-	O
40	O
was	O
added	O
and	O
vortexed	O
briefly	O
,	O
and	O
the	O
nuclei	O
were	O
pelleted	O
by	O
centrifugation	O
.	O

The	O
nuclear	O
proteins	O
were	O
extracted	O
with	O
buffer	O
containing	O
20	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
9	O
)	O
,	O
0	O
.	O
4	O
mM	O
NaCl	O
,	O
1	O
.	O
0	O
mM	O
EDTA	O
,	O
1	O
.	O
0	O
mM	O
EGTA	O
,	O
1	O
.	O
0	O
mM	O
DTT	O
,	O
and	O
1	O
.	O
0	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
at	O
14000	O
rpm	O
,	O
and	O
the	O
supernatant	O
containing	O
the	O
nuclear	O
proteins	O
was	O
stored	O
at	O
-	O
80degreesC	O
until	O
use	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
a	O
bicinchoninic	O
acid	O
assay	O
kit	O
with	O
bovine	O
serum	O
albumin	O
as	O
the	O
standard	O
(	O
Pierce	O
Biochemicals	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
.	O

EMSA	O
was	O
performed	O
using	O
gel	O
shift	O
assay	O
system	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Consensus	O
oligonucleotide	O
probe	O
(	O
5	O
'	O
-	O
AGTTGAGGGGACTTTCCCAGGG	O
-	O
3	O
'	O
)	O
was	O
end	O
-	O
labeled	O
by	O
T4	O
-	O
polynucleotide	O
kinase	O
using	O
[	O
gamma	O
-	O
32P	O
]	O
-	O
ATP	O
(	O
Free	O
Biotech	O
.	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

Nuclear	O
protein	O
(	O
20	O
mug	O
)	O
was	O
preincubated	O
in	O
20	O
muL	O
binding	O
buffer	O
containing	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
PH	O
7	O
.	O
5	O
)	O
,	O
1	O
mM	O
MgCl2	O
,	O
0	O
.	O
5	O
mM	O
NaCl	O
,	O
4	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
and	O
2	O
mug	O
poly	O
dI	O
-	O
dC	O
for	O
20	O
minutes	O
on	O
ice	O
.	O

After	O
addition	O
of	O
the	O
1	O
muL	O
32P	O
-	O
labled	O
oligonucleotide	O
probe	O
,	O
the	O
incubation	O
was	O
continued	O
for	O
20	O
minutes	O
on	O
ice	O
.	O

The	O
DNA	O
-	O
protein	O
complexes	O
were	O
separated	O
by	O
electrophoresis	O
on	O
4	O
%	O
nondenaturing	O
polyacrylamide	O
gel	O
in	O
0	O
.	O
5	O
x	O
TBE	O
buffer	O
(	O
tris	O
-	O
borate	O
-	O
EDTA	O
)	O
at	O
390	O
V	O
for	O
1	O
hour	O
at	O
4degreesC	O
.	O

After	O
electrophoresis	O
,	O
the	O
gel	O
was	O
dried	O
and	O
exposed	O
to	O
X	O
-	O
ray	O
film	O
(	O
Fuji	O
Hyperfilm	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Levels	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
were	O
quantified	O
by	O
software	O
ImageJ	O
.	O

2	O
.	O
5	O
.	O

RT	O
-	O
PCR	O

Total	O
RNA	O
was	O
isolated	O
with	O
Trizol	O
(	O
Invitrogen	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
single	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
2	O
mug	O
of	O
total	O
RNA	O
with	O
BU	O
-	O
Script	O
RT	O
-	O
Kit	O
(	O
Biunique	O
,	O
Jiangsu	O
,	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
cDNA	O
was	O
stored	O
in	O
-	O
20degreesC	O
.	O

Reverse	O
transcription	O
was	O
conducted	O
with	O
GoTaq	O
Green	O
Master	O
Mix	O
(	O
Promega	O
,	O
WI	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Table	O
1	O
shows	O
the	O
primers	O
and	O
PCR	O
parameters	O
.	O

PCR	O
products	O
were	O
detected	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

The	O
intensity	O
of	O
the	O
bands	O
was	O
analyzed	O
by	O
ImageJ	O
program	O
.	O

The	O
level	O
of	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
used	O
as	O
an	O
internal	O
standard	O
.	O

2	O
.	O
6	O
.	O

Western	O
Blot	O

To	O
obtain	O
total	O
protein	O
lysates	O
,	O
cells	O
were	O
homogenized	O
in	O
RIPA	O
buffer	O
(	O
1	O
%	O
NP40	O
,	O
0	O
.	O
5	O
%	O
sodium	O
deoxycholate	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
EGTA	O
,	O
1	O
mM	O
Na3VO4	O
,	O
20	O
mM	O
NaF	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
,	O
and	O
protease	O
inhibitor	O
cocktail	O
in	O
PBS	O
pH	O
7	O
.	O
4	O
)	O
and	O
centrifuged	O
at	O
12	O
,	O
000	O
g	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

Protein	O
concentrations	O
were	O
estimated	O
by	O
Coomassie	O
Plus	O
Protein	O
Assay	O
Reagent	O
(	O
Pierce	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Fifty	O
micrograms	O
of	O
the	O
resulting	O
cytosolic	O
protein	O
extracts	O
were	O
heat	O
-	O
denatured	O
in	O
Laemmli	O
sample	O
loading	O
buffer	O
,	O
separated	O
by	O
10	O
%	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
,	O
and	O
electroblotted	O
onto	O
a	O
nitrocellulose	O
membrane	O
.	O

For	O
immunoblotting	O
,	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
nonfat	O
dry	O
milk	O
in	O
saline	O
buffer	O
overnight	O
at	O
4degreesC	O
,	O
and	O
the	O
following	O
antibodies	O
were	O
used	O
:	O
anti	O
-	O
beta	O
-	O
actin	O
(	O
sc	O
-	O
130657	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
,	O
USA	O
,	O
43	O
kDa	O
)	O
and	O
anti	O
-	O
matrix	O
metallopeptidase	O
9	O
(	O
MMP9	B-Protein
)	O
(	O
sc	O
-	O
6841	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
,	O
USA	O
,	O
92	O
kDa	O
)	O
.	O

Each	O
primary	O
antibody	O
was	O
diluted	O
appropriately	O
in	O
blocking	O
buffer	O
and	O
then	O
added	O
to	O
the	O
blots	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

The	O
blots	O
were	O
washed	O
three	O
times	O
in	O
the	O
washing	O
buffer	O
and	O
covered	O
with	O
the	O
horseradish	O
peroxidase	O
-	O
linked	O
secondary	O
antibody	O
at	O
a	O
1	O
:	O
2000	O
dilution	O
for	O
1	O
h	O
.	O

Blots	O
were	O
incubated	O
with	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
)	O
detection	O
system	O
(	O
Amersham	O
Biosciences	O
,	O
Bucks	O
,	O
UK	O
)	O
and	O
exposed	O
to	O
radiographic	O
film	O
(	O
Fuji	O
Hyperfilm	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

ImageJ	O
was	O
used	O
to	O
analyze	O
the	O
intensity	O
of	O
the	O
blots	O
.	O

The	O
level	O
of	O
beta	O
-	O
actin	O
was	O
used	O
as	O
internal	O
standard	O
.	O

2	O
.	O
7	O
.	O

Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
)	O

Cells	O
of	O
four	O
groups	O
were	O
homogenized	O
as	O
mentioned	O
above	O
.	O

The	O
supernatant	O
was	O
collected	O
,	O
and	O
total	O
protein	O
was	O
determined	O
by	O
Coomassie	O
Plus	O
Protein	O
Assay	O
Reagent	O
(	O
Pierce	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Levels	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
interleukin	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
,	O
and	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
protein	O
were	O
quantified	O
using	O
ELISA	O
kits	O
specific	O
for	O
mouse	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Bender	O
MedSystems	O
Inc	O
.	O
CA	O
,	O
USA	O
)	O
.	O

Briefly	O
,	O
prepared	O
the	O
standard	O
and	O
created	O
the	O
standard	O
dilution	O
for	O
building	O
standard	O
curve	O
.	O

Then	O
samples	O
and	O
biotinconjugate	O
were	O
added	O
to	O
microwell	O
strips	O
.	O

After	O
incubated	O
for	O
2	O
h	O
at	O
room	O
temperature	O
,	O
the	O
microwell	O
strips	O
were	O
washed	O
3	O
times	O
with	O
wash	O
buffer	O
,	O
and	O
streptavidin	O
-	O
HRP	O
were	O
added	O
to	O
all	O
wells	O
.	O

After	O
incubated	O
for	O
1	O
h	O
,	O
microwell	O
strips	O
were	O
washed	O
3	O
times	O
followed	O
by	O
adding	O
TMB	O
substrate	O
.	O

After	O
incubated	O
for	O
about	O
10	O
-	O
30	O
min	O
,	O
the	O
stop	O
solution	O
was	O
added	O
.	O

The	O
colour	O
intensity	O
was	O
measured	O
at	O
450	O
nm	O
using	O
a	O
Bio	O
-	O
Rad	O
ELISA	O
microplate	O
reader	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
concentration	O
of	O
protein	O
was	O
determined	O
according	O
to	O
the	O
standard	O
curve	O
and	O
expressed	O
as	O
pg	O
/	O
mg	O
of	O
total	O
protein	O
.	O

2	O
.	O
8	O
.	O

Gelatine	O
Zymography	O

Cells	O
of	O
four	O
groups	O
were	O
homogenized	O
in	O
lysis	O
buffer	O
containing	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
CaCl2	O
,	O
0	O
.	O
2	O
mM	O
NaN3	O
,	O
and	O
0	O
.	O
01	O
%	O
Triton	O
.	O

Soluble	O
extracts	O
were	O
separated	O
by	O
centrifugation	O
and	O
stored	O
at	O
-	O
20degreesC	O
.	O

Gelatin	O
zymography	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Genmed	O
Scientifics	O
Inc	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Briefly	O
,	O
40	O
mug	O
cytosolic	O
protein	O
extracts	O
were	O
separated	O
by	O
electrophoresis	O
.	O

Then	O
the	O
proteins	O
were	O
renatured	O
by	O
incubation	O
in	O
2	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
and	O
then	O
incubated	O
in	O
substrate	O
buffer	O
for	O
40	O
h	O
at	O
37degreesC	O
to	O
enable	O
the	O
MMP9	B-Protein
to	O
cleave	O
the	O
gelatin	O
.	O

After	O
rinsing	O
in	O
water	O
,	O
each	O
gel	O
was	O
stained	O
with	O
Coomassie	O
blue	O
for	O
1	O
h	O
and	O
destained	O
in	O
50	O
%	O
methanol	O
.	O

Proteolytic	O
activities	O
were	O
showed	O
by	O
clear	O
bands	O
in	O
blue	O
gel	O
which	O
indicates	O
the	O
lysis	O
of	O
the	O
substrate	O
.	O

Quantification	O
of	O
MMP9	B-Protein
band	O
density	O
was	O
performed	O
with	O
image	O
analysis	O
program	O
ImageJ	O
.	O

2	O
.	O
9	O
.	O

Statistical	O
Analysis	O

Data	O
were	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
and	O
evaluated	O
by	O
ANOVA	O
and	O
LSD	O
multiple	O
comparison	O
test	O
.	O

P	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
to	O
be	O
significant	O
.	O

All	O
analyses	O
were	O
performed	O
by	O
using	O
SPSS	O
18	O
.	O
0	O
software	O
.	O

3	O
.	O
1	O
.	O

Depletion	O
of	O
Nrf2	O
Aggravated	O
the	O
Cell	O
Death	O
in	O
Astrocytes	O
after	O
Scratch	O
Injury	O

Cell	O
death	O
was	O
detected	O
by	O
microscope	O
and	O
CCK	O
-	O
8	O
analysis	O
at	O
24	O
h	O
after	O
scratch	O
.	O

The	O
detachment	O
from	O
culture	O
plate	O
,	O
cell	O
lost	O
,	O
and	O
cytoplasmic	O
process	O
distortion	O
were	O
mostly	O
observed	O
in	O
both	O
sides	O
of	O
scratch	O
line	O
in	O
group	O
KO	O
TBI	O
.	O

CCK	O
-	O
8	O
assay	O
also	O
showed	O
lower	O
OD	O
value	O
of	O
group	O
KO	O
TBI	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
064	O
)	O
than	O
that	O
of	O
group	O
WT	O
TBI	O
(	O
0	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
098	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
which	O
also	O
suggested	O
more	O
cell	O
death	O
in	O
group	O
KO	O
TBI	O
(	O
Figure	O
1	O
)	O
.	O

There	O
was	O
no	O
difference	O
between	O
two	O
sham	O
-	O
operated	O
groups	O
.	O

3	O
.	O
2	O
.	O

Disruption	O
of	O
Nrf2	O
Enhanced	O
Upregulation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
-	O
Binding	O
Activity	O
after	O
Scratch	O
Injury	O

It	O
has	O
been	O
reported	O
that	O
NF	O
-	O
kappaB	O
is	O
activated	O
in	O
brain	O
after	O
TBI	O
[	O
2	O
]	O
.	O

Here	O
,	O
we	O
studied	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
of	O
astrocytes	O
from	O
Nrf2	O
WT	O
or	O
KO	O
mice	O
by	O
EMSA	O
at	O
24	O
h	O
after	O
scratch	O
injury	O
.	O

Scratch	O
injury	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
astrocytes	O
of	O
both	O
genotypes	O
,	O
while	O
higher	O
NF	O
-	O
kappaB	O
activity	O
was	O
observed	O
in	O
group	O
KO	O
TBI	O
than	O
in	O
group	O
WT	O
TBI	O
(	O
2	O
.	O
67	O
+	O
/	O
-	O
0	O
.	O
173	O
versus	O
2	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
072	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
2	O
)	O
.	O

3	O
.	O
3	O
.	O

Expression	O
of	O
Proinflammatory	O
Cytokines	O
Was	O
Elevated	O
in	O
Nrf2	O
Knockout	O
Astrocytes	O
after	O
Scratch	O
Injury	O

As	O
we	O
all	O
know	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
are	O
regulated	O
by	O
NF	O
-	O
kappaB	O
and	O
reflect	O
the	O
endogenous	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

It	O
has	O
been	O
revealed	O
that	O
these	O
proinflammatory	O
cytokines	O
are	O
increased	O
after	O
TBI	O
in	O
animals	O
[	O
2	O
,	O
8	O
]	O
.	O

And	O
our	O
previous	O
study	O
has	O
proved	O
that	O
higher	O
levels	O
of	O
such	O
proinflammatory	O
cytokines	O
were	O
observed	O
in	O
the	O
brain	O
of	O
Nrf2	O
-	O
deficient	O
mice	O
after	O
TBI	O
[	O
5	O
]	O
.	O

But	O
it	O
is	O
still	O
ambiguous	O
about	O
the	O
relationship	O
between	O
these	O
cytokines	O
and	O
Nrf2	O
in	O
astrocytes	O
after	O
TBI	O
.	O

Here	O
,	O
we	O
tested	O
the	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
cultured	O
astrocytes	O
at	O
24	O
h	O
after	O
scratch	O
injury	O
by	O
RT	O
-	O
PCR	O
and	O
ELISA	O
.	O

It	O
was	O
shown	O
that	O
the	O
mRNA	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
increased	O
after	O
scratch	O
in	O
both	O
WT	O
and	O
KO	O
astrocytes	O
when	O
compared	O
with	O
their	O
sham	O
counterparts	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
mRNA	O
levels	O
of	O
these	O
cytokines	O
in	O
group	O
KO	O
TBI	O
were	O
much	O
higher	O
than	O
those	O
in	O
group	O
WT	O
TBI	O
(	O
1	O
.	O
66	O
+	O
/	O
-	O
0	O
.	O
085	O
versus	O
1	O
.	O
39	O
+	O
/	O
-	O
0	O
.	O
110	O
for	O
TNF	O
-	O
alpha	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
064	O
versus	O
0	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
088	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
1	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
102	O
versus	O
0	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
073	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figures	O
3	O
(	O
a	O
)	O
-	O
3	O
(	O
d	O
)	O
)	O
.	O

The	O
results	O
of	O
ELISA	O
revealed	O
that	O
the	O
protein	O
level	O
of	O
TNF	O
-	O
alpha	O
was	O
upregulated	O
after	O
scratch	O
injury	O
in	O
WT	O
and	O
KO	O
astrocytes	O
when	O
compared	O
with	O
their	O
sham	O
counterparts	O
.	O

And	O
it	O
was	O
also	O
higher	O
in	O
group	O
KO	O
TBI	O
than	O
in	O
group	O
WT	O
TBI	O
(	O
3	O
.	O
67	O
+	O
/	O
-	O
0	O
.	O
156	O
versus	O
2	O
.	O
31	O
+	O
/	O
-	O
0	O
.	O
087	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
4	O
(	O
a	O
)	O
)	O
.	O

Similar	O
tendency	O
was	O
observed	O
in	O
protein	O
level	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O

For	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
it	O
was	O
36	O
.	O
07	O
+	O
/	O
-	O
0	O
.	O
786	O
for	O
group	O
KO	O
TBI	O
while	O
25	O
.	O
76	O
+	O
/	O
-	O
0	O
.	O
536	O
for	O
group	O
WT	O
TBI	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
4	O
(	O
b	O
)	O
)	O
.	O

For	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
it	O
was	O
190	O
.	O
75	O
+	O
/	O
-	O
6	O
.	O
339	O
for	O
group	O
KO	O
TBI	O
while	O
154	O
.	O
50	O
+	O
/	O
-	O
5	O
.	O
348	O
for	O
group	O
WT	O
TBI	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

3	O
.	O
4	O
.	O

Expression	O
and	O
Activity	O
of	O
MMP9	B-Protein
Were	O
Greatly	O
Enhanced	O
in	O
Nrf2	O
Knockout	O
Astrocytes	O
after	O
Scratch	O
Injury	O

MMP9	B-Protein
is	O
an	O
important	O
gelatinase	O
to	O
induce	O
or	O
aggravate	O
the	O
inflammation	O
process	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
elevated	O
the	O
mRNA	O
,	O
protein	O
levels	O
,	O
and	O
activity	O
of	O
MMP9	B-Protein
in	O
astrocytes	O
at	O
24	O
h	O
after	O
scratch	O
injury	O
by	O
RT	O
-	O
PCR	O
,	O
western	O
blot	O
,	O
and	O
gelatine	O
zymography	O
.	O

Expression	O
of	O
MMP9	B-Protein
was	O
elevated	O
after	O
scratch	O
injury	O
in	O
WT	O
and	O
KO	O
astrocytes	O
as	O
compared	O
with	O
their	O
sham	O
counterparts	O
.	O

The	O
mRNA	O
level	O
of	O
MMP9	B-Protein
was	O
higher	O
in	O
group	O
KO	O
TBI	O
than	O
in	O
group	O
WT	O
TBI	O
(	O
1	O
.	O
36	O
+	O
/	O
-	O
0	O
.	O
090	O
versus	O
1	O
.	O
01	O
+	O
/	O
-	O
0	O
.	O
068	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figures	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
e	O
)	O
)	O
.	O

Significant	O
difference	O
was	O
also	O
discovered	O
in	O
MMP9	B-Protein
protein	O
level	O
by	O
western	O
blot	O
,	O
as	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
076	O
for	O
group	O
KO	O
TBI	O
and	O
1	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
048	O
for	O
group	O
WT	O
TBI	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Gelatine	O
zymography	O
revealed	O
higher	O
MMP9	B-Protein
activity	O
in	O
group	O
KO	O
TBI	O
than	O
that	O
in	O
group	O
WT	O
TBI	O
too	O
(	O
101	O
.	O
76	O
+	O
/	O
-	O
6	O
.	O
343	O
versus	O
76	O
.	O
32	O
+	O
/	O
-	O
3	O
.	O
388	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
6	O
)	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
scratch	O
injury	O
induced	O
the	O
upregulation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
overexpression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
in	O
cultured	O
astrocytes	O
.	O

Also	O
we	O
revealed	O
that	O
scratch	O
injury	O
induced	O
higher	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
enhanced	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
Nrf2	O
knockout	O
cultured	O
astrocytes	O
than	O
those	O
in	O
wildtype	O
astrocytes	O
for	O
the	O
first	O
time	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
NF	O
-	O
kappaB	O
is	O
activated	O
in	O
brain	O
and	O
spinal	O
cord	O
after	O
traumatic	O
injury	O
[	O
2	O
,	O
9	O
]	O
.	O

As	O
a	O
transcript	O
factor	O
,	O
NF	O
-	O
kappaB	O
binds	O
with	O
DNA	O
once	O
it	O
was	O
activated	O
and	O
induces	O
transcription	O
of	O
MMP9	B-Protein
and	O
a	O
battery	O
of	O
proinflammatory	O
cytokines	O
,	O
including	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
in	O
brain	O
tissues	O
after	O
TBI	O
[	O
3	O
,	O
10	O
,	O
11	O
]	O
.	O

Our	O
results	O
also	O
revealed	O
that	O
scratch	O
injury	O
induced	O
elevation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
,	O
overexpression	O
of	O
MMP9	B-Protein
,	O
and	O
proinflammatory	O
mediators	O
mentioned	O
above	O
in	O
cultured	O
astrocytes	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
there	O
is	O
an	O
autoregulatory	O
loop	O
among	O
these	O
proinflammatory	O
mediators	O
.	O

For	O
example	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
are	O
potent	O
stimulators	O
for	O
MMP9	B-Protein
in	O
astrocytes	O
[	O
12	O
,	O
13	O
]	O
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
induces	O
overexpression	O
of	O
MMP9	B-Protein
in	O
human	O
colon	O
carcinoma	O
cells	O
[	O
14	O
]	O
,	O
and	O
TNF	O
-	O
alpha	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
also	O
can	O
induce	O
activation	O
of	O
NF	O
-	O
kappaB	O
[	O
15	O
,	O
16	O
]	O
.	O

This	O
autoregulatory	O
loop	O
extremely	O
aggravates	O
the	O
damaging	O
effect	O
of	O
inflammation	O
and	O
induces	O
secondary	O
injury	O
to	O
brain	O
.	O

It	O
is	O
a	O
good	O
choice	O
for	O
targeting	O
on	O
an	O
upstream	O
factor	O
to	O
prevent	O
such	O
autoregulatory	O
loop	O
after	O
TBI	O
.	O

Nrf2	O
-	O
ARE	O
pathway	O
has	O
been	O
proved	O
to	O
be	O
the	O
key	O
regulator	O
in	O
reducing	O
oxidative	O
stress	O
,	O
inflammatory	O
damage	O
,	O
and	O
accumulation	O
of	O
toxic	O
metabolites	O
,	O
which	O
are	O
all	O
involved	O
in	O
TBI	O
.	O

Our	O
previous	O
study	O
has	O
proved	O
the	O
augmentation	O
of	O
Nrf2	O
in	O
brain	O
tissue	O
after	O
TBI	O
[	O
17	O
]	O
.	O

Enhanced	O
level	O
of	O
Nrf2	O
activates	O
transcription	O
of	O
a	O
group	O
of	O
antioxidant	O
genes	O
,	O
such	O
as	O
heme	B-Protein
oxygenase	I-Protein
-	I-Protein
1	I-Protein
(	O
HO	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
-	O
1	O
(	O
NQO1	O
)	O
,	O
which	O
would	O
subsequently	O
reduce	O
the	O
damage	O
in	O
brain	O
[	O
18	O
]	O
.	O

Postinjury	O
administration	O
of	O
SFN	O
,	O
an	O
inducer	O
of	O
Nrf2	O
,	O
significantly	O
improves	O
spatial	O
memory	O
of	O
rat	O
and	O
decreases	O
the	O
immunoreactivity	O
for	O
4	O
-	O
Hydroxynonenal	O
(	O
4	O
-	O
HNE	O
)	O
,	O
a	O
marker	O
of	O
lipid	O
peroxidation	O
,	O
in	O
the	O
cortex	O
and	O
the	O
CA3	O
subfield	O
of	O
hippocampus	O
after	O
TBI	O
[	O
19	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
Nrf2	O
-	O
deficient	O
mice	O
appear	O
more	O
susceptible	O
to	O
TBI	O
.	O

Depletion	O
of	O
Nrf2	O
induces	O
higher	O
expression	O
of	O
proinflammatory	O
mediators	O
in	O
brain	O
after	O
TBI	O
[	O
20	O
]	O
.	O

Here	O
,	O
our	O
results	O
revealed	O
that	O
overexpression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
after	O
scratch	O
injury	O
was	O
more	O
aggravated	O
in	O
cultured	O
Nrf2	O
knockout	O
astrocytes	O
than	O
in	O
wildtype	O
astrocyetes	O
for	O
the	O
first	O
time	O
,	O
and	O
overexpression	O
of	O
these	O
proinflammatory	O
mediators	O
led	O
to	O
more	O
astrocytes	O
deaths	O
.	O

Data	O
obtained	O
from	O
animal	O
studies	O
suggest	O
the	O
possibility	O
that	O
antioxidant	O
effect	O
of	O
Nrf2	O
may	O
be	O
achieved	O
by	O
suppression	O
of	O
proinflammatory	O
pathways	O
which	O
are	O
mediated	O
by	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Administration	O
of	O
SFN	O
is	O
found	O
to	O
be	O
able	O
to	O
inhibit	O
IKK	O
/	O
IkappaB	O
phosphorylation	O
and	O
p65	B-Protein
NF	O
-	O
kappaB	O
subunit	O
nuclear	O
translocation	O
,	O
consequently	O
alleviating	O
NF	O
-	O
kappaB	O
signaling	O
[	O
21	O
]	O
.	O

And	O
NF	O
-	O
kappaB	O
activation	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
could	O
be	O
attenuated	O
by	O
diverse	O
Nrf2	O
activators	O
,	O
such	O
as	O
SFN	O
and	O
curcumin	O
(	O
CUR	O
)	O
[	O
22	O
]	O
.	O

Furthermore	O
,	O
our	O
previous	O
studies	O
indicate	O
that	O
depletion	O
of	O
Nrf2	O
induces	O
augmentation	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
inflammatory	O
response	O
in	O
lung	O
,	O
brain	O
,	O
and	O
intestine	O
after	O
TBI	O
[	O
4	O
,	O
5	O
,	O
23	O
]	O
.	O

Results	O
from	O
this	O
study	O
further	O
confirmed	O
such	O
relationship	O
existed	O
in	O
cultured	O
astrocytes	O
after	O
scratch	O
injury	O
.	O

Enhanced	O
activation	O
of	O
NF	O
-	O
kappaB	O
is	O
also	O
discovered	O
in	O
lung	O
,	O
macrophages	O
,	O
and	O
mouse	O
embryonic	O
fibroblasts	O
of	O
Nrf2	O
-	O
deficient	O
mice	O
after	O
experimental	O
sepsis	O
[	O
24	O
]	O
.	O

Interestingly	O
,	O
it	O
is	O
reported	O
that	O
NF	O
-	O
kappaB	O
can	O
inhibit	O
Nrf2	O
at	O
transcriptional	O
level	O
.	O

NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
repressed	O
the	O
Nrf2	O
-	O
ARE	O
pathway	O
at	O
transcriptional	O
level	O
by	O
competitive	O
interaction	O
with	O
the	O
CH1	O
-	O
KIX	O
domain	O
of	O
CBP	O
or	O
local	O
histone	O
hypoacetylation	O
[	O
25	O
]	O
.	O

All	O
these	O
findings	O
indicate	O
the	O
potential	O
complicate	O
crosstalk	O
between	O
NF	O
-	O
kappaB	O
and	O
Nrf2	O
,	O
which	O
may	O
be	O
regulated	O
by	O
the	O
upstream	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPKs	O
)	O
pathway	O
[	O
26	O
]	O
.	O

It	O
has	O
been	O
confirmed	O
that	O
Nrf2	O
is	O
mainly	O
detected	O
in	O
nucleus	O
of	O
astrocytes	O
after	O
TBI	O
[	O
18	O
]	O
.	O

In	O
view	O
of	O
the	O
fact	O
that	O
Nrf2	O
is	O
a	O
transcription	O
factor	O
which	O
should	O
take	O
function	O
mainly	O
in	O
nucleus	O
,	O
it	O
can	O
be	O
reasoned	O
that	O
astrocytes	O
may	O
be	O
one	O
kind	O
of	O
respondent	O
cells	O
in	O
activation	O
of	O
Nrf2	O
-	O
ARE	O
pathway	O
after	O
TBI	O
.	O

Previous	O
study	O
identified	O
the	O
expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
cultured	O
astrocytes	O
after	O
treatment	O
with	O
LPS	O
or	O
oxyhemoglobin	O
[	O
27	O
,	O
28	O
]	O
.	O

Another	O
study	O
revealed	O
that	O
after	O
middle	O
cerebral	O
artery	O
occlusion	O
,	O
MMP9	B-Protein
-	O
positive	O
astrocytes	O
were	O
observed	O
in	O
brain	O
tissues	O
by	O
immunohistochemistry	O
[	O
29	O
]	O
.	O

Those	O
results	O
indicate	O
the	O
role	O
of	O
astrocytes	O
in	O
inflammatory	O
process	O
after	O
brain	O
injury	O
.	O

But	O
till	O
now	O
,	O
there	O
is	O
no	O
study	O
focused	O
on	O
the	O
relationship	O
among	O
astrocytes	O
,	O
Nrf2	O
,	O
and	O
proinflammatory	O
mediators	O
after	O
TBI	O
.	O

Our	O
results	O
demonstrated	O
the	O
upregulated	O
expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
in	O
Nrf2	O
knockout	O
astrocytes	O
after	O
scratch	O
injury	O
for	O
the	O
first	O
time	O
.	O

In	O
conclusion	O
,	O
depletion	O
of	O
Nrf2	O
induced	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
resulting	O
in	O
more	O
cell	O
deaths	O
in	O
astrocytes	O
after	O
scratch	O
injury	O
.	O

These	O
results	O
suggest	O
that	O
Nrf2	O
may	O
be	O
an	O
important	O
target	O
for	O
anti	O
-	O
inflammatory	O
therapy	O
after	O
TBI	O
.	O

Regulation	O
ofMycobacterium	O
tuberculosis	O
-	O
Dependent	O
HIV	O
-	O
1	O
Transcription	O
Reveals	O
a	O
New	O
Role	O
for	O
NFAT5	B-Protein
in	O
the	O
Toll	O
-	O
Like	O
Receptor	O
Pathway	O

Tuberculosis	O
(	O
TB	O
)	O
disease	O
in	O
HIV	O
co	O
-	O
infected	O
patients	O
contributes	O
to	O
increased	O
mortality	O
by	O
activating	O
innate	O
and	O
adaptive	O
immune	O
signaling	O
cascades	O
that	O
stimulate	O
HIV	O
-	O
1	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
viral	O
load	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
silencing	O
of	O
the	O
expression	O
of	O
the	O
transcription	O
factor	O
nuclear	B-Protein
factor	I-Protein
of	I-Protein
activated	I-Protein
T	I-Protein
cells	I-Protein
5	I-Protein
(	O
NFAT5	B-Protein
)	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
inhibits	O
Mycobacterium	O
tuberculosis	O
(	O
MTb	O
)	O
-	O
stimulated	O
HIV	O
-	O
1	O
replication	O
in	O
co	O
-	O
infected	O
macrophages	O
.	O

We	O
show	O
that	O
NFAT5	B-Protein
gene	O
and	O
protein	O
expression	O
are	O
strongly	O
induced	O
by	O
MTb	O
,	O
which	O
is	O
a	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
ligand	O
,	O
and	O
that	O
an	O
intact	O
NFAT5	O
binding	O
site	O
in	O
the	O
viral	O
promoter	O
of	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
subtype	O
B	O
and	O
subtype	O
C	O
molecular	O
clones	O
is	O
required	O
for	O
efficent	O
induction	O
of	O
HIV	O
-	O
1	O
replication	O
by	O
MTb	O
.	O

Furthermore	O
,	O
silencing	O
by	O
RNAi	O
of	O
key	O
components	O
of	O
the	O
TLR	O
pathway	O
in	O
human	O
monocytes	O
,	O
including	O
the	O
downstream	O
signaling	O
molecules	O
MyD88	B-Protein
,	O
IRAK1	B-Protein
,	O
and	O
TRAF6	B-Protein
,	O
significantly	O
inhibits	O
MTb	O
-	O
induced	O
NFAT5	B-Protein
gene	O
expression	O
.	O

Thus	O
,	O
the	O
innate	O
immune	O
response	O
to	O
MTb	O
infection	O
induces	O
NFAT5	B-Protein
gene	O
and	O
protein	O
expression	O
,	O
and	O
NFAT5	B-Protein
plays	O
a	O
crucial	O
role	O
in	O
MTb	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
via	O
a	O
direct	O
interaction	O
with	O
the	O
viral	O
promoter	O
.	O

These	O
findings	O
also	O
demonstrate	O
a	O
general	O
role	O
for	O
NFAT5	B-Protein
in	O
TLR	O
-	O
and	O
MTb	O
-	O
mediated	O
control	O
of	O
gene	O
expression	O
.	O

Mycobacterium	O
tuberculosis	O
(	O
MTb	O
)	O
,	O
the	O
causative	O
agent	O
of	O
tuberculosis	O
(	O
TB	O
)	O
,	O
is	O
the	O
most	O
common	O
co	O
-	O
infection	O
and	O
cause	O
of	O
death	O
in	O
patients	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Direct	O
engagement	O
of	O
pathogen	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
by	O
MTb	O
on	O
mononuclear	O
phagocytes	O
activates	O
signaling	O
cascades	O
that	O
directly	O
induce	O
transcription	O
from	O
the	O
proviral	O
LTR	O
(	O
reviewed	O
in	O
[	O
3	O
]	O
)	O
.	O

Furthermore	O
,	O
inflammatory	O
cytokines	O
and	O
chemokines	O
produced	O
by	O
the	O
human	O
host	O
in	O
response	O
to	O
MTb	O
infection	O
activate	O
signal	O
transduction	O
pathways	O
in	O
CD4	B-Protein
T	O
cells	O
and	O
monocytic	O
cells	O
that	O
also	O
result	O
in	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
[	O
4	O
]	O
-	O
[	O
6	O
]	O
.	O

Activation	O
of	O
HIV	O
-	O
1	O
replication	O
via	O
these	O
MTb	O
-	O
induced	O
pathways	O
ultimately	O
leads	O
to	O
higher	O
viral	O
loads	O
and	O
,	O
in	O
turn	O
,	O
expedited	O
CD4	B-Protein
T	O
cell	O
loss	O
and	O
progression	O
to	O
AIDS	O
(	O
[	O
7	O
]	O
,	O
reviewed	O
in	O
[	O
8	O
]	O
-	O
[	O
10	O
]	O
)	O
.	O

Furthermore	O
,	O
the	O
progressive	O
immune	O
compromise	O
associated	O
with	O
HIV	O
-	O
1	O
infection	O
itself	O
is	O
a	O
major	O
cause	O
of	O
latent	O
MTb	O
reactivation	O
,	O
as	O
well	O
as	O
increased	O
susceptibility	O
to	O
primary	O
TB	O
infection	O
(	O
[	O
11	O
]	O
-	O
[	O
15	O
]	O
,	O
reviewed	O
in	O
[	O
8	O
]	O
)	O
.	O

The	O
primary	O
PRR	O
on	O
monocytic	O
cells	O
triggered	O
by	O
MTb	O
infection	O
is	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
(	I-Protein
TLR	I-Protein
)	I-Protein
2	I-Protein
[	O
16	O
]	O
-	O
[	O
20	O
]	O
.	O

Engagement	O
of	O
TLR2	B-Protein
results	O
in	O
engagement	O
of	O
the	O
adaptor	O
protein	O
MyD88	B-Protein
and	O
the	O
subsequent	O
recruitment	O
of	O
several	O
kinases	O
,	O
including	O
IRAK1	B-Protein
and	O
IRAK4	B-Protein
,	O
and	O
the	O
ubiquitin	O
ligase	O
TRAF6	B-Protein
(	O
[	O
21	O
]	O
-	O
[	O
23	O
]	O
,	O
reviewed	O
in	O
[	O
10	O
]	O
,	O
[	O
24	O
]	O
)	O
.	O

TRAF6	B-Protein
activates	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
that	O
,	O
in	O
turn	O
,	O
ultimately	O
induce	O
activation	O
of	O
specific	O
transcription	O
factor	O
families	O
,	O
including	O
the	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
families	O
,	O
which	O
have	O
been	O
shown	O
to	O
associate	O
with	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
to	O
drive	O
its	O
transcription	O
(	O
[	O
22	O
]	O
,	O
[	O
25	O
]	O
-	O
[	O
27	O
]	O
,	O
reviewed	O
in	O
[	O
10	O
]	O
)	O
.	O

Notably	O
,	O
HIV	O
-	O
1	O
comprises	O
several	O
subtypes	O
,	O
and	O
the	O
LTR	O
of	O
each	O
subtype	O
is	O
unique	O
with	O
respect	O
to	O
the	O
number	O
and	O
organization	O
of	O
activator	O
binding	O
sites	O
.	O

For	O
example	O
,	O
HIV	O
-	O
1	O
subtype	O
B	O
,	O
the	O
most	O
highly	O
characterized	O
viral	O
subtype	O
and	O
the	O
primary	O
cause	O
of	O
infection	O
in	O
the	O
Americas	O
,	O
Europe	O
,	O
Japan	O
,	O
and	O
Australia	O
,	O
has	O
two	O
tandem	O
NF	O
-	O
kappaB	O
motifs	O
in	O
its	O
LTR	O
.	O

By	O
contrast	O
,	O
HIV	O
-	O
1	O
subtypes	O
C	O
and	O
E	O
,	O
which	O
have	O
spread	O
disproportionately	O
in	O
TB	O
-	O
burdened	O
sub	O
-	O
Saharan	O
Africa	O
and	O
southeast	O
Asia	O
,	O
have	O
three	O
and	O
one	O
NF	O
-	O
kappaB	O
binding	O
sites	O
,	O
respectively	O
[	O
1	O
]	O
,	O
[	O
28	O
]	O
-	O
[	O
30	O
]	O
.	O

We	O
previously	O
showed	O
that	O
the	O
most	O
primordial	O
member	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
,	O
NFAT5	B-Protein
(	O
also	O
known	O
as	O
TonEBP	B-Protein
)	O
,	O
binds	O
to	O
a	O
site	O
within	O
the	O
HIV	O
-	O
1	O
LTR	O
that	O
is	O
highly	O
conserved	O
across	O
all	O
HIV	O
-	O
1	O
subtypes	O
,	O
and	O
is	O
also	O
conserved	O
in	O
HIV	O
-	O
2	O
and	O
SIV	O
LTRs	O
.	O

This	O
NFAT5	O
site	O
overlaps	O
the	O
core	O
NF	O
-	O
kappaB	O
binding	O
motifs	O
in	O
the	O
LTR	O
and	O
is	O
required	O
for	O
constitutive	O
replication	O
of	O
representative	O
HIV	O
-	O
1	O
subtype	O
B	O
,	O
C	O
,	O
and	O
E	O
isolates	O
in	O
human	O
primary	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDM	O
)	O
[	O
31	O
]	O
.	O

Given	O
that	O
NFAT5	B-Protein
has	O
previously	O
been	O
shown	O
to	O
be	O
transcriptionally	O
activated	O
by	O
the	O
MAP	O
kinase	O
p38	O
,	O
which	O
is	O
downstream	O
of	O
MyD88	B-Protein
signaling	O
,	O
[	O
32	O
]	O
,	O
we	O
speculated	O
that	O
NFAT5	B-Protein
may	O
also	O
be	O
involved	O
in	O
MTb	O
-	O
induced	O
activation	O
of	O
HIV	O
-	O
1	O
replication	O
via	O
a	O
TLR	O
-	O
mediated	O
pathway	O
in	O
monocytes	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
NFAT5	B-Protein
and	O
its	O
cognate	O
binding	O
site	O
are	O
of	O
crucial	O
importance	O
for	O
efficient	O
MTb	O
-	O
induced	O
stimulation	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
human	O
MDM	O
and	O
PBMC	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
MTb	O
infection	O
increases	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
in	O
a	O
MyD88	B-Protein
-	O
dependent	O
manner	O
.	O

Thus	O
,	O
these	O
results	O
expand	O
the	O
known	O
stimuli	O
of	O
NFAT5	B-Protein
expression	O
to	O
the	O
PRR	O
-	O
mediated	O
innate	O
immune	O
response	O
,	O
and	O
demonstrate	O
that	O
NFAT5	B-Protein
is	O
a	O
critical	O
modulator	O
of	O
MTb	O
-	O
induced	O
enhancement	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Ethics	O
statement	O

In	O
our	O
studies	O
we	O
used	O
unidentified	O
human	O
discarded	O
blood	O
cells	O
(	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
PBMC	O
)	O
,	O
which	O
we	O
obtained	O
from	O
the	O
Blood	O
Bank	O
of	O
Children	O
'	O
s	O
Hospital	O
in	O
Boston	O
.	O

Cell	O
culture	O

PBMC	O
from	O
normal	O
unidentified	O
donors	O
were	O
isolated	O
by	O
Ficoll	O
-	O
Hypaque	O
(	O
Pharmacia	O
Corporation	O
,	O
Peapack	O
,	O
NJ	O
)	O
density	O
gradient	O
centrifugation	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
(	O
BioWhittaker	O
,	O
Inc	O
.	O
,	O
Walkersville	O
,	O
MD	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
(	O
Gemini	O
Bio	O
-	O
Products	O
,	O
www	O
.	O
gembio	O
.	O
com	O
)	O
.	O

Human	O
monocytes	O
were	O
isolated	O
from	O
PBMC	O
preparations	O
by	O
positive	O
selection	O
with	O
CD14	B-Protein
microbeads	O
from	O
Miltenyi	O
Biotec	O
(	O
www	O
.	O
miltenyibiotec	O
.	O
com	O
)	O
as	O
described	O
by	O
the	O
manufacturer	O
,	O
and	O
were	O
cultured	O
at	O
1x106	O
cells	O
per	O
well	O
in	O
6	O
-	O
well	O
plates	O
in	O
Macrophage	O
-	O
SFM	O
medium	O
(	O
Gibco	O
,	O
www	O
.	O
invitrogen	O
.	O
com	O
)	O
supplemented	O
with	O
15	O
ng	O
/	O
ml	O
recombinant	O
human	O
MCSF	B-Protein
(	O
R	O
&	O
D	O
,	O
www	O
.	O
rndsystems	O
.	O
com	O
)	O
and	O
5	O
%	O
heat	O
-	O
inactivated	O
human	O
AB	O
serum	O
(	O
Nabi	O
,	O
Boca	O
Raton	O
,	O
FL	O
)	O
.	O

The	O
cell	O
cultures	O
were	O
incubated	O
at	O
37degreesC	O
and	O
5	O
%	O
CO2	O
for	O
5	O
days	O
,	O
after	O
which	O
supernatant	O
was	O
replaced	O
with	O
fresh	O
medium	O
lacking	O
MCSF	B-Protein
before	O
manipulation	O
.	O

More	O
than	O
95	O
%	O
of	O
the	O
adherent	O
cells	O
obtained	O
with	O
this	O
technique	O
were	O
CD14	B-Protein
+	O
macrophages	O
as	O
verified	O
by	O
flow	O
cytometry	O
.	O

THP	O
-	O
1	O
cells	O
were	O
obtained	O
from	O
ATCC	O
(	O
www	O
.	O
atcc	O
.	O
org	O
)	O
and	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
FCS	O
(	O
BioWhittaker	O
,	O
www	O
.	O
lonzabio	O
.	O
com	O
)	O
.	O

293T	O
cells	O
were	O
obtained	O
from	O
ATCC	O
(	O
www	O
.	O
atcc	O
.	O
org	O
)	O
and	O
were	O
maintained	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
(	O
Gibco	O
,	O
www	O
.	O
invitrogen	O
.	O
com	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
.	O

Viruses	O

HIV	O
-	O
1Bal	O
,	O
HIV	O
-	O
1Lai	O
,	O
HIV	O
-	O
193TH64	O
,	O
HIV	O
-	O
192TH51	O
,	O
HIV	O
-	O
192TH53	O
,	O
HIV	O
-	O
198CH01	O
,	O
and	O
HIV	O
-	O
198IN22	O
were	O
obtained	O
from	O
The	O
Centralized	O
Facility	O
for	O
AIDS	O
Reagents	O
,	O
National	O
Institute	O
for	O
Biological	O
Standard	O
and	O
Control	O
(	O
NIBSC	O
)	O
,	O
United	O
Kingdom	O
.	O

HIV	O
-	O
1KR25	O
was	O
isolated	O
in	O
our	O
laboratory	O
as	O
described	O
before	O
[	O
33	O
]	O
.	O

LTR	O
plasmid	O
construction	O
and	O
reporter	O
assay	O

LTR	O
reporter	O
plasmids	O
were	O
constructed	O
by	O
inserting	O
nucleotides	O
-	O
208	O
to	O
+	O
64	O
relative	O
to	O
the	O
transcriptional	O
initiation	O
site	O
of	O
HIV	O
-	O
1Lai	O
,	O
HIV	O
-	O
1Bal	O
(	O
B	O
subtype	O
)	O
,	O
HIV	O
-	O
198IN17	O
,	O
HIV	O
-	O
198IN22	O
,	O
HIV	O
-	O
198CH01	O
,	O
HIV	O
-	O
1CM9	O
(	O
C	O
subtype	O
)	O
,	O
HIV	O
-	O
193TH64	O
,	O
HIV	O
-	O
192TH53	O
,	O
HIV	O
-	O
192TH51	O
,	O
and	O
HIV	O
-	O
1KR25	O
(	O
E	O
subtype	O
)	O
into	O
the	O
reporter	O
vector	O
pGL3	O
(	O
Promega	O
BioSciences	O
,	O
www	O
.	O
promega	O
.	O
com	O
)	O
using	O
Xho	O
I	O
and	O
Hind	O
III	O
restriction	O
enzyme	O
sites	O
.	O

Sequences	O
were	O
aligned	O
and	O
analyzed	O
with	O
CLUSTAL	O
W	O
(	O
www	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
/	O
clustalw	O
/	O
)	O
.	O

The	O
HIV	O
-	O
1Lai	O
NFAT5	O
binding	O
site	O
-	O
mutant	O
(	O
N5	O
-	O
Mut	O
)	O
reporter	O
plasmid	O
was	O
created	O
by	O
standard	O
PCR	O
-	O
based	O
mutagenesis	O
methods	O
[	O
34	O
]	O
.	O

THP	O
-	O
1	O
cells	O
(	O
0	O
.	O
8x106	O
/	O
ml	O
)	O
were	O
transfected	O
with	O
0	O
.	O
3	O
microg	O
/	O
ml	O
LTR	O
wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
mutated	O
reporter	O
plasmids	O
in	O
combination	O
with	O
0	O
.	O
03	O
microg	O
/	O
ml	O
Renilla	O
luciferase	B-Protein
(	O
pRL	O
-	O
TK	O
)	O
control	O
vector	O
using	O
Effectene	O
transfection	O
reagent	O
(	O
Qiagen	O
;	O
www	O
.	O
qiagen	O
.	O
com	O
)	O
.	O

Cells	O
were	O
incubated	O
at	O
37degreesC	O
for	O
16	O
hours	O
after	O
which	O
they	O
were	O
stimulated	O
with	O
10	O
microg	O
/	O
ml	O
MTb	O
CDC1551	O
lysate	O
or	O
left	O
unstimulated	O
for	O
8	O
hours	O
.	O

Reporter	B-Protein
gene	I-Protein
expression	O
was	O
quantitated	O
by	O
dual	O
-	O
luciferase	B-Protein
reporter	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Promega	O
;	O
www	O
.	O
promega	O
.	O
com	O
)	O
.	O

Quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O

Recombinant	O
NFAT5	B-Protein
(	O
amino	O
acids	O
175	O
-	O
471	O
)	O
with	O
an	O
N	O
-	O
terminal	O
6x	O
His	O
tag	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
cells	O
(	O
Stratagene	O
;	O
www	O
.	O
stratagene	O
.	O
com	O
)	O
and	O
purified	O
under	O
native	O
conditions	O
using	O
Ni	O
-	O
NTA	O
agarose	O
(	O
Qiagen	O
)	O
.	O

Recombinant	O
p50	B-Protein
and	O
p65	B-Protein
were	O
purchased	O
(	O
Active	O
Motif	O
,	O
www	O
.	O
activemotif	O
.	O
com	O
)	O
.	O

Quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O
was	O
performed	O
as	O
previously	O
described	O
[	O
31	O
]	O
.	O

HIV	O
-	O
1	O
infectious	O
molecular	O
clones	O

The	O
plasmid	O
encoding	O
the	O
full	O
-	O
length	O
infectious	O
molecular	O
clone	O
of	O
HIV	O
-	O
1Lai	O
was	O
obtained	O
from	O
the	O
NIH	O
AIDS	O
Reagent	O
and	O
Reference	O
Program	O
.	O

The	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
infectious	O
molecular	O
clone	O
was	O
constructed	O
by	O
replacing	O
the	O
envelope	O
(	O
env	O
)	O
gp160	B-Protein
amino	O
acids	O
103	O
-	O
717	O
of	O
the	O
HIV	O
-	O
1Lai	O
(	O
B	O
subtype	O
that	O
utilizes	O
CXCR4	B-Protein
)	O
molecular	O
clone	O
with	O
the	O
corresponding	O
region	O
of	O
HIV	O
-	O
1Bal	O
(	O
B	O
subtype	O
that	O
utilizes	O
CCR5	B-Protein
)	O
.	O

The	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
chimeric	O
virus	O
uses	O
CCR5	O
as	O
a	O
secondary	O
receptor	O
.	O

The	O
infectious	O
molecular	O
clone	O
of	O
HIV	O
-	O
198IN22	O
was	O
constructed	O
using	O
DNA	O
extracted	O
from	O
PBMC	O
that	O
were	O
infected	O
with	O
a	O
primary	O
isolate	O
of	O
HIV	O
-	O
198IN22	O
.	O

HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
and	O
HIV	O
-	O
198IN22	O
mutant	O
viruses	O
were	O
constructed	O
by	O
introducing	O
point	O
mutations	O
using	O
standard	O
PCR	O
-	O
based	O
mutagenesis	O
methods	O
.	O

siRNA	O
transfection	O
of	O
MDM	O

An	O
siRNA	O
was	O
constructed	O
(	O
Ambion	O
Inc	O
.	O
,	O
www	O
.	O
ambion	O
.	O
com	O
)	O
to	O
target	O
a	O
sequence	O
unique	O
to	O
the	O
NFAT5	B-Protein
transcript	O
:	O
5	O
'	O
-	O
CAACATGCCTGGAATTCAA	O
-	O
3	O
'	O
(	O
nt	O
335	O
to	O
353	O
)	O
[	O
31	O
]	O
.	O

As	O
described	O
,	O
a	O
control	O
for	O
non	O
-	O
specific	O
siRNA	O
effects	O
,	O
we	O
used	O
an	O
siRNA	O
targeting	O
the	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
,	O
5	O
'	O
-	O
GGCTACGTCCAGGAGCGCACC	O
-	O
3	O
'	O
.	O

MDM	O
were	O
transfected	O
in	O
6	O
-	O
well	O
plates	O
using	O
1	O
microM	O
of	O
the	O
indicated	O
siRNA	O
in	O
siPORT	O
NeoFX	O
transfection	O
reagent	O
(	O
Ambion	O
Inc	O
.	O
,	O
www	O
.	O
ambion	O
.	O
com	O
)	O
,	O
prepared	O
as	O
recommended	O
by	O
the	O
manufacturer	O
,	O
in	O
a	O
final	O
volume	O
of	O
750	O
microl	O
in	O
Macrophage	O
-	O
SFM	O
medium	O
plus	O
5	O
%	O
heat	O
-	O
inactivated	O
human	O
AB	O
serum	O
.	O

The	O
cultures	O
were	O
left	O
at	O
37degreesC	O
overnight	O
after	O
which	O
cells	O
were	O
washed	O
and	O
incubated	O
in	O
fresh	O
medium	O
.	O

MDM	O
were	O
transfected	O
two	O
times	O
for	O
efficient	O
knock	O
down	O
of	O
NFAT5	B-Protein
expression	O
before	O
infection	O
experiments	O
were	O
performed	O
[	O
31	O
]	O
.	O

Stable	O
THP	O
-	O
1	O
cells	O
expressing	O
shRNA	B-Protein

The	O
lentiviral	O
plasmid	O
pLKO	O
.	O
1	O
expressing	O
shRNA	B-Protein
targeting	O
human	O
MyD88	B-Protein
was	O
purchased	O
from	O
Open	O
Biosystems	O
(	O
www	O
.	O
openbiosystems	O
.	O
com	O
)	O
and	O
was	O
validated	O
in	O
our	O
laboratory	O
.	O

shRNA	O
targeting	O
human	O
IRAK1	B-Protein
(	O
forward	O
primer	O
5	O
'	O
-	O
CCGGAGCAGCTGTCCAGGTTTCGTCTCATAAAACCTGGACAGCTGCTCCTTTTTG	O
-	O
3	O
'	O
,	O
reverse	O
primer	O
5	O
'	O
-	O
AATTCAAAAAGGAGCAGCTGTCCAGGTTTTATGAGACGAAACCTGGACAGCTGCT	O
-	O
3	O
'	O
mRNA	O
(	O
IRAK1	B-Protein
mRNA	O
target	O
sequence	O
is	O
underlined	O
)	O
and	O
human	O
TRAF6	B-Protein
(	O
forward	O
primer	O
5	O
'	O
-	O
CCGGAGAAACCTGTTGTGATTCGTCTCATAAATCACAACAGGTTTCTCCTTTTTG	O
-	O
3	O
'	O
,	O
reverse	O
primer	O
5	O
'	O
-	O
AATTCAAAAAGGAGAAACCTGTTGTGATTTATGAGACGAATCACAACAGGTTTCT	O
-	O
3	O
'	O
(	O
TRAF6	B-Protein
mRNA	O
target	O
sequence	O
is	O
underlined	O
)	O
were	O
designed	O
in	O
our	O
laboratory	O
and	O
were	O
cloned	O
into	O
the	O
pLKO	O
.	O
1	O
plasmid	O
.	O

Lentiviruses	O
encoding	O
shRNA	O
sequences	O
were	O
generated	O
by	O
transfecting	O
the	O
packaging	O
cell	O
line	O
HEK	O
-	O
293T	O
with	O
the	O
shRNA	O
-	O
encoding	O
pLKO	O
.	O
1	O
plasmids	O
in	O
combination	O
with	O
the	O
packaging	O
plasmid	O
psPAX2	O
and	O
the	O
envelope	O
plasmid	O
pMD2	O
.	O
G	O
using	O
Effectene	O
transfection	O
reagent	O
(	O
Qiagen	O
,	O
www	O
.	O
qiagen	O
.	O
com	O
)	O
.	O

Supernatants	O
were	O
collected	O
48	O
hours	O
post	O
-	O
transfection	O
,	O
clarified	O
by	O
centrifugation	O
,	O
and	O
stored	O
at	O
-	O
80degreesC	O
.	O

THP	O
-	O
1	O
cells	O
were	O
transduced	O
with	O
the	O
lentiviral	O
particles	O
by	O
culturing	O
the	O
cells	O
with	O
supernatants	O
from	O
the	O
virus	O
-	O
producing	O
cells	O
in	O
the	O
presence	O
of	O
8	O
microg	O
/	O
ml	O
polybrene	O
(	O
Millipore	O
,	O
www	O
.	O
millipore	O
.	O
com	O
)	O
and	O
spinoculation	O
for	O
two	O
hours	O
at	O
2000	O
RPM	O
.	O

Successfully	O
transduced	O
cells	O
were	O
selected	O
and	O
expanded	O
by	O
treatment	O
with	O
0	O
.	O
8	O
microg	O
/	O
ml	O
puromycin	O
.	O

MTb	O
culture	O

The	O
MTb	O
clinical	O
strain	O
CDC1551	O
was	O
prepared	O
by	O
adding	O
100	O
microl	O
of	O
frozen	O
bacteria	O
stock	O
into	O
10	O
ml	O
of	O
Middlebrook	O
7H9	O
medium	O
(	O
Difco	O
BD	O
,	O
www	O
.	O
bd	O
.	O
com	O
)	O
supplemented	O
with	O
albumin	O
dextrose	O
complex	O
(	O
ADC	O
)	O
and	O
0	O
.	O
05	O
%	O
Tween	O
80	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
www	O
.	O
sigmaaldrich	O
.	O
com	O
)	O
.	O

The	O
cultures	O
were	O
grown	O
to	O
an	O
OD650	O
of	O
0	O
.	O
4	O
at	O
37degreesC	O
to	O
ensure	O
that	O
they	O
were	O
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O

Bacteria	O
were	O
then	O
plated	O
,	O
washed	O
with	O
PBS	O
,	O
resuspended	O
in	O
PBS	O
,	O
and	O
passed	O
through	O
a	O
5	O
microm	O
filter	O
to	O
ensure	O
that	O
the	O
bacteria	O
were	O
in	O
a	O
single	O
cell	O
suspension	O
.	O

Bacterial	O
cell	O
numbers	O
were	O
determined	O
by	O
measurement	O
of	O
OD650	O
before	O
further	O
dilution	O
with	O
RPMI	O
1640	O
medium	O
for	O
cell	O
infection	O
studies	O
at	O
10	O
:	O
1	O
PBMC	O
:	O
bacilli	O
or	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
and	O
THP	O
-	O
1	O
:	O
bacilli	O
.	O

Colony	O
-	O
forming	O
unit	O
(	O
CFU	O
)	O
analysis	O
was	O
performed	O
and	O
on	O
days	O
4	O
and	O
7	O
the	O
average	O
CFU	O
counts	O
were	O
6x103	O
and	O
5x104	O
,	O
respectively	O
,	O
confirming	O
that	O
mycobacteria	O
levels	O
increased	O
over	O
the	O
course	O
of	O
infection	O
of	O
primary	O
MDM	O
.	O

Western	O
blot	O

Whole	O
cell	O
extracts	O
were	O
collected	O
with	O
lysis	O
buffer	O
containing	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
,	O
1	O
%	O
Triton	O
,	O
10	O
%	O
glycerol	O
,	O
and	O
1	O
tablet	O
of	O
Complete	O
EDTA	O
-	O
free	O
Protease	O
Inhibitor	O
Cocktail	O
(	O
Roche	O
)	O
per	O
25	O
ml	O
of	O
buffer	O
.	O

Extracts	O
were	O
boiled	O
for	O
5	O
min	O
in	O
1x	O
Laemmli	O
sample	O
buffer	O
with	O
5	O
%	O
v	O
/	O
v	O
2	O
-	O
mercaptoethanol	O
and	O
proteins	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
.	O

The	O
gel	O
was	O
transferred	O
to	O
a	O
nitrocellulose	O
Trans	O
-	O
Blot	O
Transfer	O
Membrane	O
(	O
BioRad	O
)	O
.	O

The	O
blot	O
was	O
then	O
blocked	O
for	O
1	O
h	O
at	O
37degreesC	O
in	O
a	O
solution	O
of	O
4	O
%	O
BSA	B-Protein
(	O
Sigma	O
)	O
and	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
(	O
BioRad	O
)	O
in	O
a	O
buffer	O
containing	O
50	O
mM	O
Tris	O
and	O
150	O
mM	O
NaCl	O
at	O
pH	O
7	O
.	O
6	O
(	O
BSA	O
/	O
TBST	O
)	O
.	O

Primary	O
incubation	O
was	O
carried	O
out	O
with	O
a1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
NFAT5	O
antibody	O
(	O
H	O
-	O
300	O
)	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
and	O
a	O
1	O
:	O
500	O
dilution	O
of	O
goat	O
anti	O
-	O
Lamin	O
-	O
B1	O
antibody	O
(	O
sc	O
-	O
6217	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
in	O
BSA	B-Protein
/	O
TBST	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

The	O
blot	O
was	O
washed	O
3x5	O
min	O
in	O
TBST	O
and	O
incubated	O
in	O
1	O
:	O
6000	O
donkey	O
anti	O
-	O
goat	O
-	O
HRP	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
or	O
goat	O
anti	O
-	O
rabbit	O
-	O
HRP	O
(	O
BioRad	O
)	O
as	O
appropriate	O
for	O
1	O
h	O
.	O

The	O
blot	O
was	O
again	O
washed	O
3x5	O
min	O
in	O
TBST	O
and	O
developed	O
with	O
SuperSignal	O
West	O
Pico	O
Chemiluminescent	O
Reagent	O
(	O
Pierce	O
)	O
.	O

Quantitative	O
PCR	O

The	O
mRNA	O
expression	O
levels	O
were	O
determined	O
by	O
SYBR	O
Green	O
-	O
based	O
real	O
-	O
time	O
PCR	O
(	O
Applied	O
Biosystems	O
,	O
www	O
.	O
appliedbiosystems	O
.	O
com	O
)	O
.	O

The	O
reaction	O
conditions	O
were	O
95degreesC	O
for	O
10	O
min	O
followed	O
by	O
40	O
cycles	O
of	O
95degreesC	O
for	O
15	O
sec	O
and	O
60degreesC	O
for	O
1	O
min	O
.	O

The	O
results	O
were	O
normalized	O
using	O
beta	B-Protein
-	I-Protein
actin	I-Protein
mRNA	O
as	O
an	O
internal	O
control	O
and	O
expressed	O
as	O
relative	O
values	O
.	O

Statistical	O
analysis	O

Where	O
applicable	O
,	O
results	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Comparison	O
between	O
two	O
groups	O
was	O
performed	O
using	O
the	O
paired	O
Student	O
t	O
-	O
Test	O
with	O
the	O
aid	O
of	O
Microsoft	O
Excel	O
software	O
.	O

p	O
<	O
=	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

MTb	O
increases	O
HIV	O
-	O
1	O
LTR	O
activity	O
of	O
HIV	O
-	O
1	O
subtypes	O
B	O
,	O
C	O
,	O
and	O
E	O

To	O
compare	O
the	O
functional	O
impact	O
of	O
MTb	O
stimulation	O
on	O
subtype	O
-	O
specific	O
HIV	O
-	O
1	O
LTR	O
activity	O
,	O
we	O
first	O
constructed	O
reporter	O
plasmids	O
containing	O
viral	O
subtype	O
B	O
,	O
C	O
,	O
and	O
E	O
LTRs	O
(	O
-	O
208	O
to	O
+	O
64	O
nt	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
linked	O
to	O
the	O
firefly	O
luciferase	B-Protein
reporter	O
gene	O
.	O

After	O
transfection	O
of	O
the	O
monocytic	O
THP	O
-	O
1	O
cell	O
line	O
with	O
these	O
plasmids	O
,	O
cells	O
were	O
stimulated	O
with	O
an	O
irradiated	O
whole	O
cell	O
lysate	O
of	O
MTb	O
(	O
H37Rv	O
)	O
.	O

We	O
note	O
that	O
MTb	O
lysate	O
induces	O
inflammatory	O
responses	O
in	O
monocytes	O
that	O
resemble	O
those	O
induced	O
in	O
response	O
to	O
live	O
MTb	O
(	O
see	O
for	O
example	O
,	O
[	O
35	O
]	O
-	O
[	O
37	O
]	O
)	O
.	O

Upon	O
stimulation	O
,	O
the	O
B	O
,	O
C	O
,	O
and	O
E	O
LTR	O
-	O
driven	O
reporters	O
demonstrated	O
a	O
significant	O
enhancement	O
in	O
luciferase	B-Protein
activity	O
(	O
Figure	O
1A	O
)	O
and	O
the	O
magnitude	O
of	O
this	O
effect	O
was	O
subtype	O
-	O
specific	O
.	O

Subtype	O
C	O
LTRs	O
displayed	O
the	O
strongest	O
activity	O
,	O
while	O
the	O
LTRs	O
from	O
subtype	O
E	O
isolates	O
consistently	O
showed	O
the	O
weakest	O
activity	O
(	O
Figure	O
1A	O
)	O
,	O
consistent	O
with	O
previous	O
studies	O
demonstrating	O
subtype	O
-	O
specific	O
LTR	O
activity	O
that	O
used	O
TNF	B-Protein
as	O
a	O
stimulus	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
.	O

Specific	O
disruption	O
of	O
NFAT5	B-Protein
binding	O
impairs	O
LTR	O
-	O
driven	O
transcription	O
in	O
THP	O
-	O
1	O
cells	O
in	O
response	O
to	O
MTb	O
stimulation	O

Although	O
the	O
transcription	O
factor	O
NFAT5	B-Protein
binds	O
to	O
a	O
core	O
NF	O
-	O
kappaB	O
binding	O
motif	O
in	O
the	O
HIV	O
-	O
1	O
LTR	O
enhancer	O
region	O
of	O
subtype	O
B	O
,	O
when	O
two	O
thymines	O
(	O
TT	O
)	O
are	O
changed	O
to	O
cytosines	O
(	O
CC	O
)	O
in	O
the	O
proximal	O
NF	O
-	O
kappaB	O
binding	O
motif	O
(	O
named	O
N5	O
-	O
Mut	O
)	O
(	O
bottom	O
of	O
Figure	O
1B	O
)	O
,	O
the	O
binding	O
of	O
NFAT5	B-Protein
can	O
be	O
disrupted	O
while	O
leaving	O
binding	O
of	O
NF	O
-	O
kappaB	O
unperturbed	O
[	O
31	O
]	O
.	O

We	O
examined	O
the	O
requirement	O
of	O
NFAT5	B-Protein
for	O
MTb	O
-	O
induced	O
LTR	O
activity	O
by	O
transfecting	O
a	O
wild	O
-	O
type	O
and	O
NFAT5	O
mutant	O
LTR	O
reporter	O
construct	O
into	O
THP	O
-	O
1	O
cells	O
,	O
followed	O
by	O
stimulation	O
with	O
an	O
MTb	O
lysate	O
.	O

As	O
shown	O
in	O
Figure	O
1B	O
,	O
in	O
the	O
absence	O
of	O
MTb	O
lysate	O
stimulation	O
the	O
activity	O
of	O
the	O
NFAT5	O
binding	O
site	O
-	O
mutant	O
LTR	O
was	O
significantly	O
reduced	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
LTR	O
.	O

When	O
the	O
NFAT5	O
binding	O
site	O
-	O
mutant	O
LTR	O
was	O
examined	O
in	O
THP	O
-	O
1	O
cells	O
stimulated	O
with	O
the	O
MTb	O
lysate	O
,	O
its	O
activity	O
was	O
reduced	O
to	O
an	O
even	O
more	O
significant	O
extent	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

To	O
determine	O
whether	O
MTb	O
lysate	O
stimulation	O
directly	O
enhances	O
NFAT5	B-Protein
expression	O
in	O
THP	O
-	O
1	O
cells	O
,	O
we	O
stimulated	O
cells	O
for	O
8	O
or	O
24	O
hours	O
or	O
left	O
them	O
unstimulated	O
and	O
examined	O
NFAT5	B-Protein
protein	O
levels	O
by	O
western	O
blot	O
.	O

As	O
shown	O
in	O
Figure	O
1C	O
,	O
we	O
found	O
that	O
NFAT5	B-Protein
protein	O
levels	O
steadily	O
increased	O
in	O
response	O
to	O
MTb	O
lysate	O
stimulation	O
,	O
revealing	O
that	O
TLR	O
engagement	O
by	O
MTb	O
results	O
in	O
enhanced	O
levels	O
of	O
NFAT5	B-Protein
,	O
consistent	O
with	O
its	O
playing	O
a	O
role	O
in	O
MTb	O
-	O
induced	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

MTb	O
increases	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
human	O
MDM	O

Given	O
that	O
macrophages	O
,	O
which	O
are	O
the	O
primary	O
target	O
of	O
MTb	O
infection	O
,	O
are	O
also	O
a	O
major	O
reservoir	O
of	O
HIV	O
-	O
1	O
as	O
infection	O
progresses	O
[	O
40	O
]	O
,	O
we	O
next	O
investigated	O
whether	O
MTb	O
is	O
able	O
to	O
directly	O
enhance	O
NFAT5	B-Protein
mRNA	O
expression	O
in	O
primary	O
human	O
MDM	O
.	O

We	O
prepared	O
MDM	O
from	O
five	O
normal	O
donors	O
,	O
stimulated	O
the	O
cells	O
with	O
the	O
MTb	O
lysate	O
or	O
left	O
them	O
unstimulated	O
,	O
and	O
measured	O
NFAT5	B-Protein
gene	O
expression	O
levels	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
at	O
24	O
and	O
48	O
hours	O
.	O

We	O
also	O
investigated	O
whether	O
HIV	O
-	O
1	O
infection	O
is	O
capable	O
of	O
inducing	O
NFAT5	B-Protein
mRNA	O
synthesis	O
by	O
infecting	O
MDM	O
with	O
live	O
or	O
heat	O
-	O
inactivated	O
R5	O
-	O
tropic	O
representatives	O
of	O
subtype	O
B	O
(	O
HIV	O
-	O
1Bal	O
)	O
,	O
C	O
(	O
HIV	O
-	O
198IN22	O
)	O
,	O
or	O
E	O
(	O
HIV	O
-	O
192TH64	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
2A	O
,	O
stimulation	O
with	O
MTb	O
lysate	O
significantly	O
increased	O
NFAT5	B-Protein
mRNA	O
levels	O
at	O
24	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
48	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
hours	O
,	O
whereas	O
infection	O
with	O
viable	O
or	O
heat	O
-	O
inactivated	O
HIV	O
-	O
1	O
isolates	O
did	O
not	O
increase	O
NFAT5	B-Protein
mRNA	O
levels	O
(	O
Figure	O
2A	O
)	O
.	O

Thus	O
,	O
MTb	O
specifically	O
enhances	O
NFAT5	B-Protein
mRNA	O
expression	O
in	O
human	O
MDM	O
,	O
and	O
this	O
response	O
continues	O
to	O
increase	O
for	O
at	O
least	O
48	O
hours	O
post	O
-	O
stimulation	O
(	O
Figure	O
2A	O
)	O
.	O

RNAi	O
directed	O
against	O
NFAT5	B-Protein
inhibits	O
replication	O
of	O
subtype	O
B	O
HIV	O
-	O
1	O

To	O
extend	O
the	O
results	O
we	O
obtained	O
in	O
the	O
reporter	O
assays	O
to	O
a	O
physiological	O
TB	O
/	O
HIV	O
co	O
-	O
infection	O
model	O
,	O
we	O
next	O
tested	O
the	O
effect	O
of	O
siRNA	O
-	O
mediated	O
ablation	O
of	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
MDM	O
co	O
-	O
infected	O
with	O
a	O
subtype	O
B	O
HIV	O
-	O
1Lai	O
infectious	O
molecular	O
clone	O
and	O
a	O
clinical	O
isolate	O
of	O
MTb	O
.	O

To	O
perform	O
this	O
experiment	O
,	O
we	O
first	O
constructed	O
an	O
HIV	O
-	O
1Lai	O
clone	O
bearing	O
the	O
CCR5	B-Protein
-	O
tropic	O
envelope	O
region	O
of	O
HIV	O
-	O
1Bal	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
)	O
so	O
that	O
it	O
would	O
efficiently	O
infect	O
primary	O
MDM	O
.	O

We	O
used	O
this	O
approach	O
to	O
ensure	O
that	O
our	O
analysis	O
of	O
the	O
roles	O
of	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
in	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
could	O
be	O
interpreted	O
in	O
the	O
proper	O
context	O
of	O
previous	O
research	O
findings	O
that	O
examined	O
LTR	O
regulation	O
in	O
the	O
context	O
of	O
full	O
-	O
length	O
viral	O
replication	O
[	O
41	O
]	O
-	O
[	O
46	O
]	O
.	O

The	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	B-Protein
infectious	O
clone	O
is	O
isogenic	O
for	O
the	O
entire	O
sequence	O
of	O
the	O
parental	O
HIV	O
-	O
1Lai	O
infectious	O
clone	O
except	O
for	O
the	O
substitution	O
of	O
the	O
HIV	O
-	O
1Bal	O
envelope	B-Protein
co	O
-	O
receptor	O
binding	O
region	O
in	O
place	O
of	O
the	O
HIV	O
-	O
1Lai	O
envelope	B-Protein
co	O
-	O
receptor	O
binding	O
region	O
.	O

We	O
note	O
that	O
we	O
confirmed	O
that	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	B-Protein
grew	O
in	O
PBMC	O
at	O
a	O
similar	O
rate	O
to	O
wild	O
-	O
type	O
HIV	O
-	O
1Bal	O
,	O
indicating	O
proper	O
co	O
-	O
receptor	O
engagement	O
and	O
internalization	O
of	O
this	O
infectious	O
clone	O
(	O
data	O
not	O
shown	O
)	O
.	O

Next	O
,	O
we	O
knocked	O
down	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
MDM	O
using	O
an	O
siRNA	O
that	O
suppresses	O
both	O
NFAT5	B-Protein
mRNA	O
and	O
NFAT5	B-Protein
protein	O
levels	O
[	O
31	O
]	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
transfection	O
of	O
the	O
siRNA	O
specific	O
for	O
NFAT5	B-Protein
reduces	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
both	O
MTb	O
-	O
uninfected	O
(	O
p	O
=	O
0	O
.	O
048	O
)	O
and	O
MTb	O
-	O
infected	O
(	O
p	O
=	O
0	O
.	O
021	O
)	O
MDM	O
as	O
compared	O
to	O
transfection	O
of	O
control	O
GFP	B-Protein
siRNA	O
into	O
MTb	O
-	O
uninfected	O
or	O
-	O
infected	O
MDM	O
(	O
Figure	O
2B	O
)	O
.	O

We	O
note	O
that	O
although	O
siRNA	O
normally	O
is	O
effective	O
for	O
48	O
-	O
72	O
hours	O
in	O
cell	O
lines	O
that	O
divide	O
rapidly	O
,	O
in	O
human	O
MDM	O
,	O
which	O
are	O
non	O
-	O
dividing	O
cells	O
,	O
siRNA	O
to	O
host	O
factors	O
remains	O
detectable	O
and	O
functional	O
up	O
to	O
at	O
least	O
15	O
days	O
post	O
-	O
transfection	O
[	O
47	O
]	O
.	O

MDM	O
in	O
which	O
NFAT5	B-Protein
expression	O
had	O
been	O
inhibited	O
with	O
NFAT5	B-Protein
siRNA	O
or	O
that	O
were	O
transfected	O
with	O
control	O
GFP	B-Protein
siRNA	O
were	O
then	O
infected	O
with	O
1000	O
TCID50	O
of	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
.	O

After	O
overnight	O
virus	O
infection	O
,	O
the	O
cells	O
were	O
then	O
co	O
-	O
infected	O
with	O
the	O
MTb	O
clinical	O
strain	O
CDC1551	O
.	O

Free	O
virus	O
levels	O
were	O
then	O
measured	O
in	O
culture	O
supernatants	O
from	O
MDM	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
or	O
GFP	B-Protein
control	O
siRNA	O
at	O
days	O
6	O
,	O
9	O
and	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
to	O
measure	O
the	O
impact	O
of	O
NFAT5	B-Protein
inhibition	O
on	O
MTb	O
-	O
induced	O
HIV	O
replication	O
.	O

As	O
shown	O
in	O
Figure	O
2C	O
,	O
HIV	O
-	O
1	O
replication	O
was	O
suppressed	O
at	O
days	O
6	O
and	O
9	O
post	O
-	O
infection	O
in	O
the	O
NFAT5	B-Protein
siRNA	O
-	O
treated	O
cells	O
as	O
compared	O
to	O
cells	O
treated	O
with	O
control	O
siRNA	O
,	O
and	O
it	O
was	O
significantly	O
inhibited	O
by	O
day	O
12	O
post	O
-	O
infection	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
Figure	O
2C	O
)	O
.	O

Thus	O
,	O
knock	O
down	O
of	O
NFAT5	B-Protein
expression	O
significantly	O
impairs	O
HIV	O
-	O
1	O
subtype	O
B	O
replication	O
in	O
MDM	O
co	O
-	O
infected	O
with	O
MTb	O
.	O

NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
binding	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
can	O
be	O
specifically	O
disrupted	O

To	O
demonstrate	O
that	O
the	O
impact	O
of	O
NFAT5	B-Protein
silencing	O
on	O
MTb	O
-	O
induced	O
viral	O
replication	O
was	O
a	O
direct	O
effect	O
due	O
to	O
modulation	O
of	O
recruitment	O
of	O
NFAT5	B-Protein
to	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
not	O
due	O
to	O
secondary	O
,	O
NFAT5	B-Protein
-	O
regulated	O
effects	O
,	O
we	O
set	O
out	O
to	O
disrupt	O
NFAT5	B-Protein
binding	O
to	O
the	O
viral	O
LTR	O
in	O
the	O
context	O
of	O
HIV	O
-	O
1	O
/	O
MTb	O
co	O
-	O
infection	O
.	O

This	O
series	O
of	O
experiments	O
also	O
allowed	O
us	O
to	O
dissect	O
the	O
relative	O
importance	O
of	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
MTb	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

To	O
perform	O
these	O
experiments	O
,	O
we	O
constructed	O
a	O
panel	O
of	O
infectious	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
molecular	O
clones	O
where	O
either	O
the	O
NFAT5	O
site	O
was	O
specifically	O
disrupted	O
or	O
the	O
two	O
NF	O
-	O
kappaB	O
binding	O
sites	O
were	O
either	O
individually	O
or	O
dually	O
disrupted	O
(	O
Figure	O
3A	O
)	O
.	O

Specifically	O
,	O
we	O
constructed	O
a	O
clone	O
in	O
which	O
the	O
NFAT5	O
binding	O
site	O
was	O
mutated	O
(	O
named	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
)	O
by	O
changing	O
the	O
CC	O
dinucleotide	O
to	O
TT	O
in	O
the	O
core	O
NFAT5	O
binding	O
site	O
and	O
introduced	O
substitution	O
mutations	O
into	O
the	O
NF	O
-	O
kappaB	O
/	O
NFAT5	O
shared	O
binding	O
element	O
that	O
we	O
predicted	O
would	O
disrupt	O
NF	O
-	O
kappaB	O
binding	O
but	O
preserve	O
NFAT5	B-Protein
binding	O
.	O

Specifically	O
,	O
we	O
mutated	O
two	O
guanines	O
(	O
GG	O
)	O
in	O
the	O
kappaB	O
I	O
site	O
and	O
changed	O
them	O
to	O
thymine	O
and	O
adenine	O
(	O
TA	O
)	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
mut	O
)	O
and	O
also	O
introduced	O
the	O
same	O
GG	O
to	O
TA	O
change	O
in	O
the	O
second	O
,	O
more	O
distal	O
NF	O
-	O
kappaB	O
site	O
(	O
kappaB	O
II	O
)	O
in	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
)	O
.	O

We	O
also	O
created	O
a	O
double	O
NF	O
-	O
kappaB	O
site	O
mutant	O
virus	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
)	O
in	O
order	O
to	O
test	O
the	O
impact	O
of	O
complete	O
disruption	O
of	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
on	O
MTb	O
regulation	O
.	O

To	O
determine	O
the	O
specificity	O
of	O
these	O
substitutions	O
upon	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
to	O
the	O
LTR	O
,	O
we	O
performed	O
a	O
quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O
analysis	O
using	O
the	O
wild	O
-	O
type	O
LTR	O
or	O
mutant	O
LTRs	O
in	O
combination	O
with	O
increasing	O
concentrations	O
of	O
recombinant	O
NFAT5	B-Protein
or	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
proteins	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
the	O
N5	O
-	O
Mut	O
LTR	O
could	O
not	O
bind	O
NFAT5	B-Protein
(	O
compare	O
lanes	O
12	O
-	O
15	O
and	O
lanes	O
17	O
-	O
20	O
)	O
,	O
but	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
was	O
not	O
impaired	O
(	O
compare	O
lanes	O
2	O
-	O
5	O
with	O
lanes	O
7	O
-	O
10	O
)	O
.	O

By	O
contrast	O
,	O
changing	O
the	O
GG	O
dinucleotide	O
to	O
TA	O
in	O
either	O
NF	O
-	O
kappaB	O
binding	O
motif	O
,	O
as	O
predicted	O
,	O
inhibited	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
at	O
each	O
site	O
(	O
compare	O
lanes	O
2	O
-	O
5	O
with	O
lanes	O
7	O
-	O
10	O
and	O
lanes	O
12	O
-	O
15	O
of	O
Figure	O
3C	O
)	O
.	O

As	O
expected	O
,	O
mutation	O
of	O
both	O
NF	O
-	O
kappaB	O
sites	O
(	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
)	O
resulted	O
in	O
abrogation	O
of	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
to	O
the	O
LTR	O
.	O

However	O
,	O
recombinant	O
NFAT5	B-Protein
binding	O
to	O
the	O
single	O
and	O
the	O
double	O
NF	O
-	O
kappaB	O
mutant	O
LTRs	O
was	O
not	O
impaired	O
and	O
indeed	O
appeared	O
enhanced	O
(	O
compare	O
lanes	O
2	O
-	O
5	O
to	O
lanes	O
7	O
-	O
20	O
of	O
Figure	O
3D	O
)	O
.	O

Thus	O
,	O
binding	O
of	O
NFAT5	B-Protein
or	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
to	O
their	O
respective	O
motifs	O
can	O
be	O
specifically	O
disrupted	O
within	O
an	O
overlapping	O
or	O
shared	O
binding	O
site	O
.	O

NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
binding	O
play	O
independent	O
activating	O
roles	O
in	O
MTb	O
-	O
mediated	O
induction	O
of	O
HIV	O
-	O
1	O
replication	O

We	O
next	O
examined	O
the	O
functional	O
impact	O
of	O
specifically	O
disrupting	O
NF	O
-	O
kappaB	O
or	O
NFAT5	B-Protein
binding	O
on	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
by	O
infecting	O
bulk	O
PBMC	O
from	O
four	O
normal	O
donors	O
with	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
molecular	O
clones	O
.	O

After	O
overnight	O
infection	O
,	O
cells	O
were	O
co	O
-	O
infected	O
with	O
MTb	O
(	O
CDC1551	O
)	O
or	O
mock	O
-	O
infected	O
and	O
free	O
virus	O
levels	O
were	O
detected	O
by	O
measuring	O
p24	B-Protein
levels	O
in	O
culture	O
supernatants	O
at	O
days	O
4	O
,	O
7	O
,	O
and	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
.	O

Replication	O
of	O
each	O
mutant	O
virus	O
was	O
reduced	O
in	O
comparison	O
to	O
wild	O
-	O
type	O
virus	O
in	O
mock	O
-	O
and	O
MTb	O
-	O
co	O
-	O
infected	O
cells	O
at	O
all	O
timepoints	O
examined	O
(	O
Figures	O
4A	O
-	O
4B	O
)	O
.	O

As	O
depicted	O
in	O
the	O
histograms	O
displayed	O
in	O
Figure	O
4C	O
,	O
at	O
day	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
in	O
MTb	O
-	O
co	O
-	O
infected	O
cells	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
levels	O
of	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
in	O
comparison	O
to	O
wild	O
-	O
type	O
virus	O
(	O
Figure	O
4C	O
)	O
.	O

In	O
the	O
absence	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
p24	B-Protein
levels	O
were	O
also	O
significantly	O
lower	O
in	O
the	O
PBMC	O
cultures	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
,	O
but	O
not	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
in	O
comparison	O
to	O
wild	O
-	O
type	O
virus	O
(	O
Figure	O
4C	O
)	O
.	O

None	O
of	O
the	O
mutations	O
completely	O
abolished	O
viral	O
induction	O
by	O
MTb	O
co	O
-	O
infection	O
.	O

However	O
,	O
the	O
replication	O
of	O
each	O
mutant	O
virus	O
was	O
impaired	O
to	O
a	O
more	O
significant	O
extent	O
in	O
the	O
context	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
consistent	O
with	O
important	O
roles	O
for	O
both	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
in	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
.	O

To	O
specifically	O
examine	O
the	O
functional	O
impact	O
of	O
NF	O
-	O
kappaB	O
and	O
NFAT5	O
binding	O
site	O
usage	O
in	O
MDM	O
,	O
which	O
are	O
efficiently	O
infected	O
by	O
both	O
pathogens	O
,	O
we	O
next	O
isolated	O
MDM	O
from	O
four	O
normal	O
donors	O
and	O
infected	O
these	O
cells	O
with	O
1000	O
TCID50	O
of	O
wild	O
-	O
type	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
or	O
with	O
the	O
mutant	O
viral	O
clones	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
or	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
.	O

After	O
overnight	O
incubation	O
,	O
cell	O
cultures	O
were	O
co	O
-	O
infected	O
with	O
MTb	O
(	O
CDC1551	O
)	O
or	O
left	O
infected	O
with	O
virus	O
alone	O
.	O

Supernatants	O
were	O
collected	O
at	O
days	O
4	O
,	O
7	O
,	O
and	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
and	O
virus	O
replication	O
was	O
measured	O
.	O

As	O
shown	O
in	O
Figures	O
5A	O
and	O
5C	O
,	O
in	O
the	O
absence	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
replication	O
of	O
mutant	O
viral	O
molecular	O
clones	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
as	O
well	O
as	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
significantly	O
reduced	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
virus	O
(	O
Figures	O
5A	O
-	O
5C	O
)	O
.	O

When	O
the	O
cultures	O
were	O
co	O
-	O
infected	O
with	O
MTb	O
,	O
p24	B-Protein
levels	O
increased	O
when	O
the	O
cells	O
were	O
infected	O
with	O
either	O
the	O
wild	O
-	O
type	O
or	O
,	O
to	O
lower	O
levels	O
,	O
with	O
the	O
kappaB	O
-	O
I	O
mutant	O
virus	O
(	O
Figure	O
5B	O
)	O
.	O

However	O
,	O
p24	B-Protein
levels	O
were	O
significantly	O
inhibited	O
in	O
cells	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
5D	O
)	O
.	O

Moreover	O
,	O
p24	B-Protein
levels	O
were	O
significantly	O
lower	O
at	O
day	O
12	O
in	O
cultures	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
as	O
compared	O
to	O
infection	O
of	O
cells	O
with	O
wild	O
-	O
type	O
virus	O
(	O
Figure	O
5D	O
)	O
.	O

Notably	O
,	O
although	O
replication	O
of	O
the	O
mutant	O
virus	O
with	O
the	O
single	O
,	O
proximal	O
NF	O
-	O
kappaB	O
binding	O
site	O
mutation	O
in	O
the	O
shared	O
NFAT5	O
/	O
NF	O
-	O
kappaB	O
element	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
)	O
was	O
diminished	O
,	O
this	O
was	O
not	O
significant	O
at	O
day	O
12	O
(	O
Figures	O
5B	O
-	O
5D	O
)	O
.	O

We	O
note	O
that	O
overall	O
p24	B-Protein
levels	O
were	O
noticeably	O
lower	O
in	O
the	O
cultures	O
co	O
-	O
infected	O
with	O
MTb	O
compared	O
with	O
those	O
infected	O
with	O
HIV	O
-	O
1	O
alone	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
observations	O
showing	O
that	O
MTb	O
infection	O
of	O
human	O
primary	O
macrophage	O
cultures	O
ex	O
vivo	O
suppresses	O
HIV	O
-	O
1	O
infection	O
due	O
to	O
chemokine	O
synthesis	O
and	O
the	O
enhanced	O
expression	O
of	O
cellular	O
inhibitory	O
factors	O
[	O
48	O
]	O
-	O
[	O
50	O
]	O
.	O

Given	O
that	O
NF	O
-	O
kappaB	O
is	O
efficiently	O
activated	O
in	O
primary	O
MDM	O
in	O
response	O
to	O
TLR	O
agonists	O
[	O
51	O
]	O
and	O
as	O
we	O
have	O
shown	O
in	O
Figure	O
2	O
,	O
NFAT5	B-Protein
gene	O
expression	O
is	O
also	O
induced	O
by	O
TLR	O
agonists	O
,	O
MDM	O
are	O
a	O
suitable	O
experimental	O
system	O
to	O
analyze	O
the	O
effect	O
of	O
NF	O
-	O
kappaB	O
versus	O
NFAT5	O
binding	O
site	O
mutations	O
on	O
virus	O
replication	O
in	O
isolated	O
MDM	O
in	O
the	O
absence	O
or	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

Taken	O
together	O
,	O
the	O
results	O
from	O
PBMC	O
and	O
MDM	O
co	O
-	O
infection	O
experiments	O
demonstrate	O
that	O
the	O
conserved	O
NFAT5	O
binding	O
site	O
plays	O
as	O
important	O
a	O
transcriptional	O
role	O
in	O
LTR	O
regulation	O
by	O
MTb	O
as	O
do	O
the	O
NF	O
-	O
kappaB	O
sites	O
.	O

NFAT5	B-Protein
is	O
important	O
for	O
enhancement	O
of	O
HIV	O
-	O
1	O
subtype	O
C	O
replication	O
in	O
response	O
to	O
MTb	O
infection	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
the	O
subtype	O
C	O
LTR	O
was	O
the	O
most	O
active	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
subtypes	O
in	O
the	O
reporter	O
assays	O
.	O

Subtype	O
C	O
LTRs	O
generally	O
have	O
three	O
functional	O
NF	O
-	O
kappaB	O
sites	O
in	O
their	O
LTRs	O
,	O
and	O
subtype	O
C	O
is	O
the	O
predominant	O
viral	O
subtype	O
in	O
the	O
African	O
and	O
Asian	O
HIV	O
-	O
1	O
epidemics	O
where	O
MTb	O
co	O
-	O
infection	O
is	O
extremely	O
common	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
28	O
]	O
,	O
[	O
52	O
]	O
.	O

We	O
thus	O
next	O
extended	O
our	O
analysis	O
of	O
the	O
role	O
of	O
NFAT5	B-Protein
in	O
MTb	O
/	O
HIV	O
-	O
1	O
co	O
-	O
infection	O
to	O
a	O
subtype	O
C	O
isolate	O
.	O

We	O
first	O
constructed	O
an	O
infectious	O
molecular	O
clone	O
of	O
the	O
HIV	O
-	O
1	O
subtype	O
C	O
primary	O
isolate	O
HIV	O
-	O
198IN22	O
,	O
which	O
has	O
two	O
NFAT5	O
binding	O
sites	O
in	O
its	O
LTR	O
and	O
three	O
NF	O
-	O
kappaB	O
sites	O
(	O
Figure	O
6A	O
)	O
.	O

We	O
disrupted	O
the	O
two	O
NFAT5	O
binding	O
sites	O
by	O
changing	O
the	O
TT	O
of	O
each	O
site	O
to	O
CC	O
to	O
create	O
a	O
mutant	O
virus	O
that	O
we	O
named	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
.	O

Bulk	O
PBMC	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
overnight	O
with	O
1000	O
TCID50	O
of	O
wild	O
-	O
type	O
HIV	O
-	O
198IN22	O
or	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
and	O
the	O
cultures	O
were	O
then	O
co	O
-	O
infected	O
with	O
MTb	O
CDC1551	O
or	O
left	O
infected	O
with	O
virus	O
alone	O
.	O

At	O
day	O
11	O
post	O
-	O
viral	O
infection	O
,	O
wild	O
-	O
type	O
HIV	O
-	O
198IN22	O
replication	O
was	O
greater	O
,	O
but	O
not	O
significantly	O
so	O
,	O
as	O
compared	O
to	O
replication	O
of	O
HIV	O
-	O
198IN22	O
NFAT5	O
-	O
Mut	O
(	O
Figure	O
6B	O
)	O
.	O

However	O
,	O
in	O
the	O
context	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
wild	O
-	O
type	O
HIV	O
-	O
198IN22	O
replication	O
was	O
significantly	O
increased	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
at	O
day	O
11	O
over	O
HIV	O
-	O
198IN22	O
NFAT5	O
-	O
Mut	O
replication	O
(	O
Figure	O
6C	O
)	O
,	O
indicating	O
that	O
the	O
absence	O
of	O
NFAT5	O
binding	O
sites	O
was	O
particularly	O
detrimental	O
to	O
virus	O
replication	O
in	O
the	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

Thus	O
,	O
even	O
when	O
three	O
functional	O
NF	O
-	O
kappaB	O
binding	O
sites	O
are	O
present	O
in	O
the	O
LTR	O
,	O
as	O
in	O
the	O
HIV	O
-	O
1	O
subtype	O
C	O
infectious	O
clone	O
studied	O
here	O
,	O
disruption	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
LTR	O
impairs	O
virus	O
replication	O
in	O
response	O
to	O
MTb	O
co	O
-	O
infection	O
.	O

MTb	O
induces	O
NFAT5	B-Protein
gene	O
expression	O
via	O
the	O
MyD88	B-Protein
-	O
dependent	O
signaling	O
cascade	O

To	O
begin	O
to	O
decipher	O
the	O
cellular	O
mechanisms	O
underlying	O
NFAT5	B-Protein
-	O
dependent	O
,	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
,	O
we	O
next	O
investigated	O
the	O
requirement	O
for	O
specific	O
signaling	O
molecules	O
in	O
the	O
TLR	O
pathway	O
that	O
are	O
required	O
for	O
MTb	O
stimulation	O
of	O
NFAT5	B-Protein
gene	O
expression	O
.	O

We	O
began	O
by	O
examining	O
the	O
requirement	O
of	O
TLR2	B-Protein
ligation	O
in	O
enhancing	O
NFAT5	B-Protein
mRNA	O
levels	O
.	O

When	O
THP	O
-	O
1	O
cells	O
were	O
treated	O
with	O
the	O
TLR2	B-Protein
-	O
specific	O
agonist	O
Pam3Cys	O
for	O
16	O
hours	O
,	O
NFAT5	B-Protein
mRNA	O
levels	O
were	O
significantly	O
increased	O
in	O
Pam3Cys	O
-	O
stimulated	O
cells	O
as	O
compared	O
to	O
mock	O
-	O
stimulated	O
control	O
cells	O
(	O
Figure	O
7A	O
)	O
.	O

As	O
a	O
positive	O
control	O
for	O
this	O
experiment	O
we	O
also	O
infected	O
THP	O
-	O
1	O
cells	O
with	O
CDC1551	O
(	O
Figure	O
7A	O
)	O
.	O

Notably	O
,	O
MTb	O
infection	O
enhanced	O
NFAT5	B-Protein
mRNA	O
levels	O
to	O
a	O
greater	O
extent	O
than	O
Pam3Cys	O
stimulation	O
,	O
suggesting	O
that	O
additional	O
PRRs	O
may	O
be	O
triggered	O
during	O
actual	O
MTb	O
infection	O
,	O
augmenting	O
its	O
stimulatory	O
effect	O
on	O
NFAT5	B-Protein
gene	O
expression	O
(	O
Figure	O
7A	O
)	O
.	O

The	O
adaptor	O
molecule	O
MyD88	B-Protein
transmits	O
signals	O
upon	O
TLR2	B-Protein
ligation	O
(	O
reviewed	O
in	O
[	O
53	O
]	O
)	O
.	O

To	O
confirm	O
that	O
this	O
protein	O
and	O
,	O
therefore	O
,	O
that	O
this	O
TLR	O
-	O
dependent	O
pathway	O
is	O
important	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
gene	O
expression	O
,	O
we	O
constructed	O
a	O
THP	O
-	O
1	O
cell	O
line	O
that	O
constitutively	O
expresses	O
a	O
lentivirally	O
-	O
delivered	O
short	B-Protein
hairpin	I-Protein
(	I-Protein
sh	I-Protein
)	I-Protein
RNA	I-Protein
targeting	O
MyD88	B-Protein
.	O

Real	O
-	O
time	O
PCR	O
analysis	O
demonstrated	O
that	O
MyD88	B-Protein
mRNA	O
levels	O
in	O
these	O
cells	O
were	O
constitutively	O
and	O
significantly	O
reduced	O
in	O
comparison	O
to	O
control	O
THP	O
-	O
1	O
cells	O
transduced	O
with	O
a	O
lentivirus	O
expressing	O
control	O
GFP	B-Protein
shRNA	I-Protein
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
MyD88	B-Protein
knockdown	O
THP	O
-	O
1	O
cells	O
were	O
then	O
infected	O
with	O
MTb	O
(	O
CDC1551	O
)	O
and	O
NFAT5	B-Protein
mRNA	O
levels	O
were	O
examined	O
.	O

Since	O
TNF	B-Protein
is	O
a	O
MyD88	B-Protein
-	O
dependent	O
gene	O
[	O
21	O
]	O
,	O
[	O
54	O
]	O
,	O
[	O
55	O
]	O
,	O
as	O
a	O
positive	O
control	O
we	O
measured	O
TNF	B-Protein
mRNA	O
levels	O
.	O

For	O
a	O
negative	O
control	O
,	O
we	O
measured	O
mRNA	O
levels	O
of	O
the	O
MyD88	B-Protein
-	O
independent	O
gene	O
CD86	B-Protein
[	O
55	O
]	O
,	O
[	O
56	O
]	O
.	O

As	O
shown	O
in	O
Figure	O
7B	O
,	O
knockdown	O
of	O
MyD88	B-Protein
specifically	O
inhibited	O
MTb	O
-	O
induced	O
NFAT5	B-Protein
and	O
TNF	B-Protein
mRNA	O
levels	O
and	O
had	O
no	O
impact	O
on	O
CD86	B-Protein
mRNA	O
levels	O
.	O

Thus	O
,	O
MTb	O
regulation	O
of	O
NFAT5	B-Protein
is	O
dependent	O
upon	O
MyD88	B-Protein
.	O

To	O
futher	O
dissect	O
the	O
pathway	O
mediating	O
MTb	O
upregulation	O
of	O
NFAT5	B-Protein
transcription	O
,	O
we	O
also	O
constructed	O
THP	O
-	O
1	O
cells	O
transduced	O
with	O
lentivirally	O
-	O
delivered	O
shRNAs	O
targeting	O
IRAK1	B-Protein
or	O
TRAF6	B-Protein
,	O
two	O
signaling	O
molecules	O
downstream	O
of	O
MyD88	B-Protein
.	O

As	O
shown	O
in	O
Figures	O
7C	O
and	O
7D	O
,	O
knockdown	O
of	O
both	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
significantly	O
inhibited	O
MTb	O
induced	O
NFAT5	B-Protein
mRNA	O
levels	O
.	O

As	O
expected	O
,	O
MTb	O
-	O
induced	O
TNF	B-Protein
gene	O
expression	O
was	O
also	O
significantly	O
reduced	O
(	O
Figures	O
7C	O
-	O
7D	O
)	O
,	O
consistent	O
with	O
a	O
role	O
for	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
in	O
TNF	B-Protein
gene	O
expression	O
secondary	O
to	O
MTb	O
infection	O
as	O
previously	O
reported	O
.	O

Although	O
CD86	B-Protein
gene	O
expression	O
did	O
not	O
depend	O
on	O
MyD88	B-Protein
(	O
Figure	O
7B	O
)	O
,	O
abrogation	O
of	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
gene	O
expression	O
significantly	O
reduced	O
CD86	B-Protein
mRNA	O
levels	O
,	O
indicating	O
that	O
CD86	B-Protein
expression	O
is	O
IRAK1	B-Protein
-	O
and	O
TRAF6	B-Protein
-	O
dependent	O
,	O
but	O
MyD88	B-Protein
-	O
independent	O
in	O
MTb	O
-	O
infected	O
monocytes	O
(	O
Figures	O
7C	O
-	O
7D	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
clearly	O
demonstrate	O
that	O
MTb	O
upregulation	O
of	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	O
of	O
MyD88	B-Protein
and	O
the	O
MyD88	B-Protein
-	O
associated	O
adaptor	O
molecules	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
.	O

The	O
transcription	O
factor	O
NFAT5	B-Protein
is	O
the	O
most	O
evolutionarily	O
divergent	O
member	O
of	O
the	O
Rel	O
family	O
of	O
NFAT	O
proteins	O
[	O
57	O
]	O
.	O

Unlike	O
the	O
other	O
NFAT	O
proteins	O
(	O
NFATp	B-Protein
,	O
NFATc	B-Protein
,	O
NFAT3	B-Protein
,	O
and	O
NFAT4	B-Protein
)	O
,	O
NFAT5	B-Protein
binds	O
DNA	O
as	O
an	O
obligate	O
dimer	O
in	O
a	O
fashion	O
resembling	O
NF	O
-	O
kappaB	O
proteins	O
[	O
58	O
]	O
,	O
is	O
calcineurin	B-Protein
independent	O
,	O
and	O
does	O
not	O
cooperate	O
with	O
the	O
basic	O
region	O
-	O
leucine	O
zipper	O
proteins	O
Fos	B-Protein
and	O
Jun	B-Protein
in	O
gene	O
activation	O
(	O
[	O
59	O
]	O
,	O
[	O
60	O
]	O
,	O
reviewed	O
in	O
[	O
61	O
]	O
-	O
[	O
63	O
]	O
)	O
.	O

To	O
date	O
,	O
osmotic	O
stress	O
,	O
integrin	O
activation	O
,	O
and	O
T	O
cell	O
-	O
stimulation	O
have	O
been	O
shown	O
to	O
regulate	O
NFAT5	B-Protein
activity	O
[	O
59	O
]	O
,	O
[	O
64	O
]	O
,	O
[	O
65	O
]	O
.	O

Based	O
on	O
our	O
demonstration	O
here	O
that	O
the	O
host	O
innate	O
immune	O
response	O
to	O
MTb	O
infection	O
induces	O
MyD88	B-Protein
-	O
dependent	O
upregulation	O
of	O
NFAT5	B-Protein
gene	O
expression	O
,	O
we	O
have	O
expanded	O
this	O
list	O
to	O
include	O
MTb	O
as	O
an	O
additional	O
stimulus	O
.	O

We	O
have	O
linked	O
this	O
observation	O
to	O
MTb	O
-	O
stimulated	O
HIV	O
-	O
1	O
gene	O
expression	O
by	O
showing	O
that	O
MTb	O
enhances	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
subtypes	O
B	O
and	O
C	O
via	O
a	O
direct	O
interaction	O
between	O
NFAT5	B-Protein
and	O
the	O
viral	O
promoter	O
.	O

Thus	O
,	O
HIV	O
-	O
1	O
has	O
co	O
-	O
opted	O
NFAT5	B-Protein
,	O
which	O
is	O
induced	O
as	O
part	O
of	O
the	O
innate	O
immune	O
response	O
to	O
TB	O
,	O
for	O
enhanced	O
viral	O
transcription	O
/	O
replication	O
.	O

NF	O
-	O
kappaB	O
is	O
activated	O
after	O
MTb	O
engagement	O
of	O
PRRs	O
[	O
20	O
]	O
,	O
[	O
66	O
]	O
.	O

Multiple	O
studies	O
of	O
HIV	O
-	O
1	O
activation	O
have	O
shown	O
that	O
initial	O
recruitment	O
of	O
the	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
heterodimer	O
to	O
the	O
HIV	O
-	O
1	O
proviral	O
enhancer	O
region	O
is	O
crucial	O
for	O
HIV	O
gene	O
transcription	O
(	O
reviewed	O
in	O
[	O
67	O
]	O
,	O
[	O
68	O
]	O
)	O
.	O

Upon	O
interaction	O
with	O
the	O
viral	O
LTR	O
,	O
NF	O
-	O
kappaB	O
rapidly	O
induces	O
hyperacetylation	O
of	O
histones	O
associated	O
with	O
nucleosome	O
1	O
(	O
nuc	O
-	O
1	O
)	O
at	O
the	O
HIV	O
-	O
1	O
transcription	O
start	O
site	O
,	O
resulting	O
in	O
recruitment	O
of	O
the	O
pTEFb	O
complex	O
,	O
which	O
is	O
required	O
for	O
RNA	O
pol	O
II	O
processivity	O
(	O
[	O
69	O
]	O
,	O
reviewed	O
in	O
[	O
68	O
]	O
,	O
[	O
70	O
]	O
)	O
.	O

In	O
this	O
report	O
we	O
directly	O
examined	O
the	O
relative	O
roles	O
of	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
in	O
HIV	O
-	O
1	O
replication	O
under	O
conditions	O
of	O
activation	O
by	O
MTb	O
co	O
-	O
infection	O
,	O
when	O
NF	O
-	O
kappaB	O
levels	O
in	O
the	O
nucleus	O
are	O
elevated	O
.	O

We	O
found	O
that	O
specific	O
disruption	O
of	O
the	O
NFAT5	O
binding	O
site	O
(	O
s	O
)	O
in	O
R5	O
-	O
tropic	O
subtype	O
B	O
or	O
subtype	O
C	O
infectious	O
molecular	O
clones	O
significantly	O
reduced	O
virus	O
replication	O
in	O
PBMC	O
or	O
MDM	O
co	O
-	O
infected	O
with	O
a	O
clinical	O
isolate	O
of	O
MTb	O
.	O

Thus	O
,	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
viral	O
LTR	O
is	O
not	O
sufficient	O
to	O
compensate	O
for	O
the	O
loss	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
LTR	O
under	O
conditions	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

Reciprocally	O
,	O
an	O
intact	O
NFAT5	O
site	O
could	O
not	O
compensate	O
for	O
disruption	O
of	O
the	O
two	O
NF	O
-	O
kappaB	O
sites	O
.	O

Thus	O
,	O
both	O
factors	O
are	O
required	O
for	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
.	O

Intriguingly	O
,	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
disruption	O
of	O
NF	O
-	O
kappaB	O
site	O
II	O
consistently	O
resulted	O
in	O
greater	O
suppression	O
of	O
virus	O
replication	O
than	O
disruption	O
of	O
NF	O
-	O
kappaB	O
site	O
I	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
synthetic	O
reporter	O
assays	O
have	O
previously	O
shown	O
that	O
these	O
two	O
sites	O
have	O
distinct	O
roles	O
in	O
driving	O
transcription	O
.	O

The	O
downstream	O
NF	O
-	O
kappaB	O
site	O
I	O
binding	O
site	O
,	O
which	O
is	O
directly	O
upstream	O
of	O
three	O
highly	O
conserved	O
Sp	O
binding	O
sites	O
,	O
appears	O
to	O
enhance	O
Sp	O
protein	O
recruitment	O
to	O
the	O
LTR	O
[	O
71	O
]	O
-	O
[	O
73	O
]	O
.	O

Because	O
NF	O
-	O
kappaB	O
site	O
I	O
overlaps	O
the	O
NFAT5	O
binding	O
site	O
,	O
it	O
is	O
possible	O
that	O
loss	O
of	O
NF	O
-	O
kappaB	O
binding	O
to	O
this	O
site	O
is	O
mitigated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
increased	O
NFAT5	B-Protein
binding	O
to	O
the	O
mutated	O
site	O
.	O

This	O
hypothesis	O
is	O
consistent	O
with	O
our	O
quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O
analysis	O
that	O
shows	O
that	O
specific	O
disruption	O
of	O
NF	O
-	O
kappaB	O
site	O
I	O
results	O
in	O
enhanced	O
binding	O
of	O
NFAT5	B-Protein
to	O
the	O
LTR	O
.	O

HIV	O
-	O
1	O
subtype	O
C	O
now	O
makes	O
up	O
greater	O
than	O
50	O
%	O
of	O
all	O
HIV	O
-	O
1	O
infections	O
worldwide	O
,	O
and	O
its	O
prevalence	O
is	O
especially	O
high	O
in	O
regions	O
of	O
endemic	O
TB	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
28	O
]	O
,	O
[	O
52	O
]	O
,	O
Most	O
HIV	O
-	O
1	O
subtype	O
C	O
isolates	O
possess	O
three	O
NF	O
-	O
kappaB	O
binding	O
sites	O
in	O
the	O
LTR	O
[	O
30	O
]	O
.	O

Our	O
analysis	O
of	O
MTb	O
whole	O
lysate	O
-	O
stimulated	O
,	O
LTR	O
-	O
driven	O
reporter	O
gene	O
expression	O
from	O
representative	O
B	O
,	O
C	O
,	O
and	O
E	O
LTRs	O
showed	O
that	O
LTRs	O
derived	O
from	O
subtype	O
C	O
isolates	O
were	O
superior	O
in	O
driving	O
reporter	O
gene	O
expression	O
as	O
compared	O
to	O
LTRs	O
derived	O
from	O
subtype	O
B	O
or	O
E	O
isolates	O
.	O

Other	O
studies	O
have	O
found	O
that	O
,	O
in	O
response	O
to	O
TNF	B-Protein
,	O
subtype	O
C	O
LTRs	O
drive	O
reporter	O
gene	O
transcription	O
more	O
strongly	O
than	O
other	O
subtype	O
LTRs	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
.	O

In	O
the	O
co	O
-	O
infection	O
model	O
utilized	O
in	O
this	O
report	O
,	O
in	O
which	O
clinical	O
isolates	O
of	O
both	O
MTb	O
and	O
HIV	O
-	O
1	O
subtype	O
C	O
were	O
used	O
to	O
infect	O
freshly	O
prepared	O
human	O
peripheral	O
blood	O
cells	O
,	O
we	O
found	O
that	O
specific	O
disruption	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
LTR	O
significantly	O
impaired	O
viral	O
replication	O
during	O
MTb	O
co	O
-	O
infection	O
,	O
indicating	O
that	O
even	O
the	O
presence	O
of	O
three	O
intact	O
NF	O
-	O
kappaB	O
binding	O
sites	O
,	O
which	O
is	O
typical	O
for	O
HIV	O
-	O
1	O
subtype	O
C	O
isolates	O
[	O
30	O
]	O
,	O
cannot	O
compensate	O
for	O
loss	O
of	O
NFAT5	B-Protein
recruitment	O
to	O
the	O
viral	O
LTR	O
in	O
the	O
context	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

Given	O
that	O
the	O
NF	O
-	O
kappaB	O
and	O
NFAT5	O
binding	O
motifs	O
overlap	O
,	O
how	O
do	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
function	O
at	O
this	O
overlapping	O
or	O
shared	O
site	O
in	O
the	O
LTR	O
to	O
drive	O
viral	O
transcription	O
in	O
response	O
to	O
MTb	O
infection	O
?	O

Because	O
NFAT5	B-Protein
expression	O
continues	O
to	O
rise	O
for	O
at	O
least	O
48	O
hours	O
post	O
-	O
MTb	O
infection	O
(	O
Figure	O
2A	O
)	O
,	O
one	O
possibility	O
is	O
that	O
the	O
host	O
factors	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
associate	O
with	O
the	O
LTR	O
at	O
different	O
stages	O
after	O
viral	O
activation	O
.	O

While	O
NF	O
-	O
kappaB	O
presence	O
in	O
the	O
nucleus	O
declines	O
in	O
the	O
hours	O
post	O
MTb	O
infection	O
[	O
74	O
]	O
,	O
[	O
75	O
]	O
,	O
NFAT5	B-Protein
levels	O
escalate	O
.	O

Thus	O
,	O
NFAT5	B-Protein
,	O
which	O
is	O
pivotal	O
for	O
HIV	O
-	O
1	O
transcription	O
in	O
unstimulated	O
cells	O
[	O
31	O
]	O
,	O
may	O
,	O
after	O
Mtb	O
infection	O
,	O
perpetuate	O
viral	O
transcriptional	O
initiation	O
begun	O
by	O
NF	O
-	O
kappaB	O
and	O
,	O
with	O
Tat	B-Protein
levels	O
also	O
elevated	O
,	O
promote	O
high	O
levels	O
of	O
sustained	O
HIV	O
-	O
1	O
transcription	O
.	O

Indeed	O
,	O
in	O
response	O
to	O
hypertonic	O
stress	O
,	O
NFAT5	B-Protein
binds	O
to	O
the	O
aldose	B-Protein
reductase	I-Protein
(	O
AR	B-Protein
)	O
promoter	O
and	O
induces	O
rapid	O
hyperacetylation	O
of	O
histones	O
H3	O
and	O
H4	O
[	O
76	O
]	O
.	O

Furthermore	O
,	O
hypertonic	O
stress	O
of	O
mouse	O
renal	O
collecting	O
duct	O
epithelial	O
cells	O
results	O
in	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
complex	O
formation	O
at	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
promoters	O
[	O
77	O
]	O
.	O

Thus	O
,	O
there	O
are	O
precedents	O
for	O
imagining	O
that	O
NFAT5	B-Protein
could	O
function	O
at	O
the	O
HIV	O
-	O
1	O
LTR	O
by	O
inducing	O
histone	O
remodeling	O
in	O
a	O
manner	O
similar	O
to	O
NF	O
-	O
kappaB	O
(	O
[	O
69	O
]	O
,	O
reviewed	O
in	O
[	O
68	O
]	O
,	O
[	O
70	O
]	O
)	O
or	O
by	O
directly	O
interacting	O
with	O
NF	O
-	O
kappaB	O
in	O
a	O
cooperative	O
manner	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
demonstrated	O
that	O
NFAT5	B-Protein
is	O
required	O
for	O
the	O
replication	O
of	O
R5	O
-	O
tropic	O
subtype	O
B	O
and	O
subtype	O
C	O
HIV	O
-	O
1	O
isolates	O
in	O
response	O
to	O
MTb	O
-	O
co	O
-	O
infection	O
of	O
human	O
PBMC	O
and	O
MDM	O
.	O

Functional	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
interaction	O
with	O
the	O
viral	O
LTR	O
is	O
also	O
required	O
,	O
but	O
fully	O
intact	O
NF	O
-	O
kappaB	O
binding	O
elements	O
are	O
unable	O
to	O
compensate	O
for	O
the	O
loss	O
of	O
NFAT5	B-Protein
recruitment	O
to	O
the	O
viral	O
promoter	O
.	O

In	O
addition	O
,	O
we	O
have	O
demonstrated	O
that	O
MTb	O
infection	O
or	O
stimulation	O
with	O
the	O
TLR2	B-Protein
ligand	O
PAM3Cys	O
,	O
induces	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
MTb	O
stimulation	O
of	O
NFAT5	B-Protein
depends	O
on	O
TLR	O
pathway	O
signaling	O
molecules	O
,	O
including	O
MyD88	B-Protein
,	O
IRAK1	B-Protein
,	O
and	O
TRAF6	B-Protein
.	O

Taken	O
together	O
,	O
the	O
findings	O
presented	O
here	O
enhance	O
the	O
general	O
understanding	O
of	O
the	O
innate	O
immune	O
response	O
to	O
MTb	O
infection	O
by	O
showing	O
that	O
NFAT5	B-Protein
is	O
a	O
major	O
mediator	O
of	O
TLR	O
-	O
dependent	O
gene	O
expression	O
;	O
its	O
importance	O
for	O
gene	O
regulation	O
is	O
likely	O
applicable	O
to	O
other	O
MTb	O
-	O
and	O
TLR	O
-	O
regulated	O
genes	O
.	O

Moreover	O
,	O
these	O
data	O
provide	O
molecular	O
insights	O
into	O
MTb	O
regulation	O
of	O
HIV	O
-	O
1	O
transcription	O
,	O
thereby	O
elucidating	O
several	O
new	O
targets	O
for	O
therapeutic	O
interventions	O
aimed	O
at	O
controlling	O
TB	O
/	O
HIV	O
-	O
1	O
co	O
-	O
infection	O
.	O

NFAT5	B-Protein
interaction	O
with	O
the	O
LTR	O
is	O
important	O
for	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
transcription	O
.	O

(	O
A	O
)	O
MTb	O
stimulation	O
increases	O
activity	O
of	O
LTRs	O
derived	O
from	O
HIV	O
-	O
1	O
subtypes	O
B	O
,	O
C	O
,	O
and	O
E	O
.	O

HIV	O
-	O
1	O
LTRs	O
(	O
-	O
208	O
to	O
+	O
64	O
nt	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
from	O
representative	O
subtype	O
B	O
,	O
C	O
,	O
and	O
E	O
viral	O
isolates	O
were	O
cloned	O
into	O
plasmid	O
pGL3	O
.	O

THP	O
-	O
1	O
cells	O
(	O
0	O
.	O
8x106	O
/	O
ml	O
)	O
were	O
transfected	O
with	O
each	O
reporter	O
plasmid	O
(	O
0	O
.	O
3	O
microg	O
/	O
ml	O
)	O
plus	O
the	O
Renilla	O
luciferase	B-Protein
control	O
plasmid	O
pRL	O
-	O
TK	O
(	O
0	O
.	O
03	O
microg	O
/	O
ml	O
)	O
and	O
incubated	O
at	O
37degreesC	O
for	O
16	O
hours	O
.	O

Cells	O
were	O
then	O
either	O
left	O
untreated	O
or	O
treated	O
with	O
10	O
microg	O
/	O
ml	O
MTb	O
lysate	O
for	O
8	O
hours	O
before	O
termination	O
of	O
the	O
cultures	O
.	O

In	O
the	O
histogram	O
,	O
open	O
bars	O
represent	O
individual	O
LTR	O
activities	O
in	O
untreated	O
cells	O
.	O

Light	O
grey	O
bars	O
represent	O
mean	O
values	O
of	O
LTR	O
activities	O
from	O
each	O
subtype	O
in	O
untreated	O
cells	O
.	O

Black	O
bars	O
represent	O
individual	O
LTR	O
activities	O
in	O
MTb	O
lysate	O
-	O
treated	O
cells	O
,	O
and	O
dark	O
grey	O
bars	O
represent	O
mean	O
values	O
of	O
LTR	O
activities	O
from	O
each	O
subtype	O
in	O
cells	O
treated	O
with	O
MTb	O
lysate	O
.	O

LTR	O
transcriptional	O
activity	O
for	O
all	O
of	O
the	O
representative	O
LTRs	O
tested	O
was	O
significantly	O
increased	O
in	O
cultures	O
treated	O
with	O
MTb	O
lysate	O
in	O
comparison	O
to	O
untreated	O
cultures	O
.	O

Results	O
are	O
from	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
as	O
compared	O
to	O
unstimulated	O
cultures	O
)	O
.	O

(	O
B	O
)	O
Specific	O
disruption	O
of	O
the	O
NFAT5	O
binding	O
site	O
significantly	O
reduces	O
LTR	O
-	O
reporter	O
gene	O
activity	O
in	O
monocytic	O
cells	O
in	O
response	O
to	O
MTb	O
lysate	O
treatment	O
.	O

THP	O
-	O
1	O
cells	O
were	O
transfected	O
with	O
luciferase	B-Protein
expression	O
vectors	O
encoding	O
nucleotides	O
208	O
to	O
+	O
64	O
of	O
the	O
wild	O
-	O
type	O
HIV	O
-	O
1Lai	O
LTR	O
and	O
an	O
HIV	O
-	O
1Lai	O
LTR	O
containing	O
the	O
NFAT5	O
binding	O
site	O
mutations	O
(	O
N5	O
-	O
Mut	O
)	O
.	O

After	O
16	O
hours	O
,	O
the	O
cells	O
were	O
left	O
untreated	O
or	O
exposed	O
to	O
10	O
microg	O
/	O
ml	O
MTb	O
lysate	O
for	O
8	O
hours	O
at	O
37degreesC	O
.	O

Disruption	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
enhancer	O
region	O
significantly	O
suppressed	O
LTR	O
-	O
driven	O
reporter	O
gene	O
expression	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
LTR	O
when	O
cells	O
were	O
treated	O
with	O
MTb	O
lysate	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

LTR	O
activity	O
was	O
also	O
suppressed	O
in	O
the	O
untreated	O
cells	O
but	O
to	O
a	O
lesser	O
extent	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Results	O
are	O
from	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
and	O
adjusted	O
to	O
Renilla	O
luciferase	B-Protein
control	O
expression	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Nucleotide	O
sequences	O
representing	O
the	O
wild	O
-	O
type	O
and	O
NFAT5	O
binding	O
site	O
-	O
mutated	O
HIV	O
-	O
1Lai	O
LTRs	O
are	O
shown	O
at	O
the	O
bottom	O
of	O
the	O
figure	O
.	O

(	O
C	O
)	O
MTb	O
lysate	O
increases	O
NFAT5	B-Protein
protein	O
levels	O
in	O
monocytic	O
cells	O
.	O

THP	O
-	O
1	O
cells	O
were	O
left	O
untreated	O
(	O
control	O
)	O
or	O
exposed	O
to	O
10	O
microg	O
/	O
ml	O
MTb	O
lysate	O
for	O
8	O
or	O
24	O
hours	O
at	O
37degreesC	O
.	O

Whole	O
cell	O
extracts	O
were	O
collected	O
and	O
analyzed	O
by	O
western	O
blot	O
with	O
anti	O
-	O
NFAT5	O
antibody	O
.	O

An	O
antibody	O
directed	O
against	O
Lamin	B-Protein
-	I-Protein
B1	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

The	O
histogram	O
shows	O
densitometric	O
analysis	O
of	O
the	O
NFAT5	B-Protein
bands	O
from	O
the	O
western	O
blot	O
autoradiograph	O
displayed	O
and	O
values	O
represent	O
mean	O
band	O
intensities	O
at	O
0	O
,	O
8	O
,	O
and	O
24	O
hours	O
post	O
-	O
stimulation	O
with	O
MTb	O
lysate	O
.	O

MTb	O
induces	O
NFAT5	B-Protein
gene	O
expression	O
and	O
knockdown	O
of	O
NFAT5	B-Protein
impairs	O
HIV	O
-	O
1	O
replication	O
during	O
MTb	O
co	O
-	O
infection	O
.	O

(	O
A	O
)	O
MTb	O
but	O
not	O
HIV	O
-	O
1	O
increases	O
NFAT5	B-Protein
mRNA	O
synthesis	O
in	O
human	O
macrophages	O
.	O

MDM	O
were	O
isolated	O
from	O
PBMC	O
obtained	O
from	O
four	O
normal	O
donors	O
.	O

The	O
cells	O
were	O
incubated	O
for	O
24	O
or	O
48	O
hours	O
with	O
heat	O
-	O
inactivated	O
or	O
live	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
subtype	O
B	O
,	O
C	O
,	O
or	O
E	O
isolates	O
,	O
live	O
MTb	O
strain	O
CDC1551	O
(	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
)	O
,	O
or	O
left	O
untreated	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
of	O
NFAT5	B-Protein
mRNA	O
expression	O
levels	O
revealed	O
that	O
the	O
low	O
,	O
constitutively	O
present	O
level	O
of	O
NFAT5	B-Protein
mRNA	O
expressed	O
in	O
untreated	O
cells	O
was	O
not	O
affected	O
by	O
exposure	O
to	O
live	O
or	O
inactivated	O
HIV	O
-	O
1	O
,	O
but	O
was	O
significantly	O
increased	O
at	O
both	O
24	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
48	O
(	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
hours	O
following	O
infection	O
with	O
MTb	O
.	O

(	O
B	O
)	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
effectively	O
suppresses	O
NFAT5	B-Protein
expression	O
in	O
MDM	O
in	O
both	O
the	O
absence	O
and	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

MDM	O
(	O
1x106	O
cells	O
/	O
well	O
in	O
a	O
6	O
-	O
well	O
plate	O
)	O
from	O
four	O
normal	O
donors	O
were	O
transfected	O
with	O
siRNA	O
specific	O
for	O
NFAT5	B-Protein
or	O
,	O
as	O
a	O
control	O
,	O
GFP	B-Protein
,	O
and	O
were	O
then	O
infected	O
with	O
MTb	O
(	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
)	O
or	O
left	O
uninfected	O
.	O

In	O
the	O
cells	O
transfected	O
with	O
control	O
siRNA	O
,	O
MTb	O
infection	O
significantly	O
increased	O
NFAT5	B-Protein
expression	O
in	O
comparison	O
to	O
uninfected	O
cells	O
(	O
open	O
bars	O
)	O
.	O

When	O
MDM	O
were	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
,	O
both	O
constitutively	O
expressed	O
(	O
p	O
=	O
0	O
.	O
048	O
)	O
and	O
MTb	O
-	O
induced	O
(	O
p	O
=	O
0	O
.	O
021	O
)	O
NFAT5	B-Protein
mRNA	O
were	O
significantly	O
suppressed	O
(	O
grey	O
bars	O
)	O
.	O

(	O
C	O
)	O
HIV	O
-	O
1	O
subtype	O
B	O
replication	O
is	O
significantly	O
suppressed	O
in	O
the	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
when	O
NFAT5	B-Protein
expression	O
is	O
abrogated	O
in	O
human	O
MDM	O
.	O

MDM	O
from	O
four	O
normal	O
donors	O
were	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
and	O
control	O
siRNAs	O
as	O
described	O
in	O
2B	O
.	O

Cells	O
were	O
then	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
followed	O
by	O
co	O
-	O
infection	O
with	O
MTb	O
CDC1551	O
.	O

Virus	O
replication	O
was	O
measured	O
at	O
days	O
6	O
,	O
9	O
,	O
and	O
12	O
post	O
-	O
infection	O
.	O

At	O
day	O
12	O
,	O
virus	O
replication	O
was	O
significantly	O
reduced	O
in	O
cells	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
in	O
comparison	O
to	O
cells	O
transfected	O
with	O
control	O
siRNA	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

We	O
monitored	O
the	O
morphology	O
of	O
cells	O
within	O
the	O
infected	O
cultures	O
and	O
did	O
not	O
observe	O
noticeable	O
macrophage	O
necrosis	O
even	O
at	O
the	O
final	O
timepoint	O
of	O
viral	O
harvest	O
.	O

Specific	O
disruption	O
of	O
NFAT5	O
or	O
NF	O
-	O
kappaB	O
binding	O
sites	O
in	O
the	O
LTR	O
of	O
HIV	O
-	O
1	O
subtype	O
B	O
.	O

(	O
A	O
)	O
Mutations	O
introduced	O
into	O
a	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
infectious	O
molecular	O
clone	O
.	O

NF	O
-	O
kappaB	O
and	O
NFAT5	O
binding	O
site	O
mutations	O
were	O
introduced	O
into	O
the	O
LTR	O
of	O
the	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
wild	O
type	O
(	O
WT	O
)	O
infectious	O
molecular	O
clone	O
.	O

The	O
NF	O
-	O
kappaB	O
binding	O
site	O
mutants	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
)	O
,	O
and	O
NFAT5	O
binding	O
site	O
mutant	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
)	O
are	O
shown	O
along	O
with	O
the	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
sequence	O
.	O

Mutations	O
were	O
introduced	O
into	O
the	O
3	O
'	O
LTR	O
of	O
the	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
proviral	O
sequence	O
.	O

(	O
B	O
)	O
Specific	O
mutation	O
of	O
the	O
NFAT5	O
binding	O
site	O
abolishes	O
NFAT5	B-Protein
binding	O
to	O
the	O
viral	O
LTR	O
but	O
does	O
not	O
affect	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
to	O
the	O
overlapping	O
NF	O
-	O
kappaB	O
binding	O
site	O
.	O

Quantitative	O
DNaseI	B-Protein
footprinting	O
analysis	O
is	O
shown	O
using	O
HIV	O
-	O
1	O
LTR	O
fragments	O
(	O
-	O
262	O
to	O
+	O
4	O
nt	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
from	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
and	O
increasing	O
concentrations	O
of	O
recombinant	O
NF	O
-	O
kappaB	O
(	O
p50	B-Protein
/	O
p65	B-Protein
)	O
(	O
25	O
ng	O
,	O
100	O
ng	O
,	O
and	O
500	O
ng	O
)	O
,	O
or	O
NFAT5	B-Protein
(	O
10	O
ng	O
,	O
50	O
ng	O
,	O
and	O
250	O
ng	O
)	O
.	O

The	O
regions	O
that	O
are	O
protected	O
from	O
DNase	B-Protein
I	I-Protein
cleavage	O
by	O
the	O
binding	O
of	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
are	O
indicated	O
with	O
a	O
bars	O
.	O

(	O
C	O
)	O
Specific	O
disruption	O
of	O
the	O
HIV	O
-	O
1	O
subtype	O
B	O
NF	O
-	O
kappaB	O
binding	O
sites	O
effectively	O
abrogates	O
recombinant	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
.	O

Quantitative	O
DNaseI	B-Protein
footprinting	O
analysis	O
is	O
shown	O
of	O
nucleotides	O
-	O
262	O
to	O
+	O
4	O
from	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
and	O
increasing	O
concentrations	O
of	O
recombinant	O
NF	O
-	O
kappaB	O
(	O
p50	B-Protein
/	O
p65	B-Protein
)	O
(	O
25	O
ng	O
,	O
100	O
ng	O
,	O
and	O
500	O
ng	O
)	O
.	O

The	O
regions	O
that	O
are	O
protected	O
from	O
DNase	B-Protein
I	I-Protein
cleavage	O
by	O
the	O
binding	O
of	O
recombinant	O
NF	O
-	O
kappaB	O
are	O
indicated	O
with	O
a	O
bars	O
.	O

(	O
D	O
)	O
Specific	O
disruption	O
of	O
the	O
HIV	O
-	O
1	O
subtype	O
B	O
NF	O
-	O
kappaB	O
binding	O
site	O
does	O
not	O
inhibit	O
but	O
enhances	O
NFAT5	B-Protein
binding	O
to	O
this	O
region	O
.	O

Quantitative	O
DNaseI	B-Protein
footprinting	O
analysis	O
is	O
shown	O
of	O
nucleotides	O
-	O
262	O
to	O
+	O
4	O
from	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
and	O
increasing	O
concentrations	O
of	O
recombinant	O
NFAT5	B-Protein
(	O
10	O
ng	O
,	O
50	O
ng	O
,	O
and	O
250	O
ng	O
)	O
.	O

The	O
regions	O
that	O
are	O
protected	O
from	O
DNase	B-Protein
I	I-Protein
cleavage	O
by	O
the	O
binding	O
of	O
recombinant	O
NFAT5	B-Protein
are	O
indicated	O
with	O
a	O
bars	O
.	O

MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
PBMC	O
depends	O
on	O
binding	O
of	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
to	O
the	O
LTR	O
.	O

Specific	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
or	O
NFAT5	O
binding	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
subtype	O
B	O
LTR	O
inhibits	O
R5	O
-	O
tropic	O
virus	O
replication	O
in	O
human	O
PBMC	O
after	O
co	O
-	O
infection	O
with	O
MTb	O
.	O

PBMC	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
with	O
1000	O
TCID50	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
or	O
the	O
mutants	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
or	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
and	O
either	O
;	O
(	O
A	O
)	O
left	O
untreated	O
,	O
or	O
(	O
B	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
isolate	O
CDC1551	O
(	O
10	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
.	O

Viral	O
p24	B-Protein
levels	O
in	O
culture	O
supernatants	O
were	O
measured	O
at	O
days	O
4	O
,	O
7	O
and	O
12	O
post	O
-	O
infection	O
.	O

(	O
C	O
)	O
Histograms	O
show	O
viral	O
p24	B-Protein
levels	O
at	O
day	O
12	O
in	O
the	O
MTb	O
uninfected	O
(	O
grey	O
bars	O
)	O
and	O
MTb	O
co	O
-	O
infected	O
(	O
black	O
bars	O
)	O
PBMC	O
cultures	O
.	O

Replication	O
of	O
the	O
mutant	O
viruses	O
was	O
compared	O
to	O
wild	O
-	O
type	O
virus	O
replication	O
under	O
the	O
same	O
experimental	O
conditions	O
(	O
without	O
and	O
with	O
MTb	O
co	O
-	O
infection	O
,	O
respectively	O
)	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
as	O
compared	O
to	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
-	O
WT	O
.	O

Disruption	O
of	O
NF	O
-	O
kappaB	O
or	O
NFAT5	O
sites	O
in	O
the	O
LTR	O
inhibits	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
MDM	O
.	O

MDM	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
with	O
1000	O
TCID50	O
of	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
or	O
the	O
mutants	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
or	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
,	O
and	O
were	O
either	O
(	O
A	O
)	O
left	O
infected	O
with	O
virus	O
alone	O
or	O
(	O
B	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
CDC1551	O
(	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
)	O
.	O

Viral	O
p24	B-Protein
levels	O
in	O
the	O
culture	O
supernatants	O
were	O
measured	O
at	O
days	O
4	O
,	O
7	O
and	O
12	O
post	O
-	O
infection	O
.	O

Presentation	O
of	O
viral	O
p24	B-Protein
levels	O
at	O
day	O
12	O
in	O
cultures	O
infected	O
with	O
(	O
C	O
)	O
HIV	O
-	O
1	O
alone	O
or	O
(	O
D	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
are	O
shown	O
as	O
histograms	O
.	O

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
as	O
compared	O
to	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
)	O
.	O

Disruption	O
of	O
the	O
NFAT5	O
site	O
in	O
HIV	O
-	O
1	O
subtype	O
C	O
significantly	O
impairs	O
MTb	O
-	O
induced	O
viral	O
replication	O
.	O

(	O
A	O
)	O
Mutation	O
of	O
the	O
NFAT5	O
binding	O
site	O
in	O
an	O
HIV	O
-	O
1	O
subtype	O
C	O
infectious	O
molecular	O
clone	O
.	O

NFAT5	O
binding	O
site	O
mutations	O
were	O
introduced	O
into	O
the	O
LTR	O
of	O
subtype	O
C	O
HIV	O
-	O
198IN22	O
-	O
WT	O
.	O

The	O
NFAT5	O
binding	O
site	O
mutant	O
(	O
HIV	O
-	O
198IN22	O
N5	O
-	O
Mut	O
)	O
LTR	O
sequence	O
is	O
shown	O
alongside	O
that	O
of	O
HIV	O
-	O
198IN22	O
-	O
WT	O
.	O

The	O
HIV	O
-	O
198IN22	O
isolate	O
analyzed	O
here	O
contains	O
three	O
NF	O
-	O
kappaB	O
and	O
two	O
NFAT5	O
binding	O
sites	O
.	O

The	O
unique	O
3	O
'	O
terminal	O
adenine	O
,	O
which	O
is	O
important	O
for	O
NFAT5	B-Protein
binding	O
to	O
its	O
site	O
,	O
is	O
shown	O
in	O
blocks	O
.	O

Mutations	O
were	O
introduced	O
into	O
the	O
3	O
'	O
LTR	O
of	O
the	O
HIV	O
-	O
198IN22	O
-	O
WT	O
proviral	O
sequence	O
.	O

PBMC	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
with	O
1000	O
TCID50	O
of	O
HIV	O
-	O
198IN22	O
-	O
WT	O
or	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
.	O

Cells	O
were	O
then	O
(	O
B	O
)	O
left	O
infected	O
with	O
virus	O
alone	O
or	O
(	O
C	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
(	O
10	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
.	O

Culture	O
supernatants	O
were	O
collected	O
at	O
days	O
3	O
,	O
7	O
and	O
11	O
post	O
-	O
infection	O
and	O
viral	O
p24	B-Protein
levels	O
were	O
measured	O
.	O

Replication	O
of	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
was	O
significantly	O
reduced	O
at	O
day	O
11	O
post	O
-	O
infection	O
in	O
comparison	O
to	O
HIV	O
-	O
198IN22	O
-	O
WT	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

The	O
MyD88	B-Protein
-	O
mediated	O
signaling	O
cascade	O
is	O
important	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
expression	O
in	O
human	O
monocytes	O
.	O

(	O
A	O
)	O
Engagement	O
of	O
TLR2	B-Protein
significantly	O
enhances	O
NFAT5	B-Protein
mRNA	O
synthesis	O
in	O
monocytes	O
.	O

THP	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
the	O
TLR2	B-Protein
-	O
specific	O
ligand	O
Pam3Cys	O
(	O
5	O
microg	O
/	O
ml	O
)	O
,	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
(	O
1	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
,	O
or	O
left	O
untreated	O
.	O

After	O
16	O
hours	O
,	O
NFAT5	B-Protein
mRNA	O
levels	O
were	O
measured	O
.	O

NFAT5	B-Protein
mRNA	O
expression	O
was	O
significantly	O
increased	O
when	O
the	O
cells	O
were	O
incubated	O
with	O
Pam3Cys	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
or	O
infected	O
with	O
MTb	O
(	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

(	O
B	O
)	O
MyD88	B-Protein
is	O
important	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

THP	O
-	O
1	O
cells	O
that	O
constitutively	O
express	O
lentivirally	O
-	O
delivered	O
shRNA	O
targeting	O
MyD88	B-Protein
or	O
control	O
shRNA	O
targeting	O
GFP	B-Protein
were	O
constructed	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Cells	O
were	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
(	O
1	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
or	O
left	O
uninfected	O
for	O
16	O
hours	O
at	O
37degreesC	O
,	O
and	O
RNA	O
was	O
analyzed	O
.	O

NFAT5	B-Protein
mRNA	O
levels	O
were	O
significantly	O
inhibited	O
in	O
the	O
cells	O
transduced	O
with	O
MyD88	B-Protein
-	O
specific	O
shRNA	O
(	O
black	O
bars	O
)	O
compared	O
with	O
the	O
cells	O
transduced	O
with	O
control	O
shRNA	O
(	O
open	O
bars	O
)	O
in	O
both	O
,	O
the	O
absence	O
or	O
presence	O
of	O
MTb	O
infection	O
.	O

TNF	B-Protein
and	O
CD86	B-Protein
mRNAs	O
,	O
the	O
expression	O
of	O
which	O
are	O
MyD88	B-Protein
-	O
dependent	O
and	O
-	O
independent	O
,	O
respectively	O
,	O
during	O
MTb	O
infection	O
,	O
were	O
measured	O
as	O
controls	O
.	O

(	O
C	O
,	O
D	O
)	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
are	O
required	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

THP	O
-	O
1	O
cells	O
that	O
constitutively	O
express	O
lentivirally	O
-	O
delivered	O
IRAK1	B-Protein
-	O
or	O
TRAF6	B-Protein
-	O
specific	O
shRNA	O
were	O
constructed	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

THP	O
-	O
1	O
cells	O
expressing	O
control	O
shRNA	B-Protein
were	O
used	O
as	O
described	O
in	O
7B	O
.	O

Cells	O
were	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
or	O
left	O
uninfected	O
for	O
16	O
hours	O
at	O
37degreesC	O
,	O
and	O
RNA	O
was	O
analyzed	O
.	O

NFAT5	B-Protein
expression	O
was	O
significantly	O
inhibited	O
in	O
the	O
MTb	O
-	O
infected	O
cells	O
expressing	O
either	O
IRAK1	B-Protein
(	O
C	O
)	O
or	O
TRAF6	B-Protein
(	O
D	O
)	O
shRNA	O
(	O
black	O
bars	O
)	O
compared	O
to	O
cells	O
expressing	O
control	O
shRNA	B-Protein
(	O
open	O
bars	O
)	O
.	O

TNF	B-Protein
and	O
CD86	B-Protein
mRNAs	O
,	O
both	O
of	O
which	O
require	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
to	O
be	O
induced	O
by	O
PRR	O
activation	O
,	O
were	O
measured	O
as	O
controls	O
.	O

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Deficiency	O
of	O
C	B-Protein
-	I-Protein
C	I-Protein
Chemokine	I-Protein
Receptor	I-Protein
5	I-Protein
Suppresses	O
Tumor	O
DevelopmentviaInactivation	O
of	O
NF	O
-	O
?	O
B	O
and	O
Upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
Melanoma	O
Model	O

To	O
evaluate	O
the	O
relevance	O
of	O
C	B-Protein
-	I-Protein
C	I-Protein
chemokine	I-Protein
receptor	I-Protein
type	I-Protein
5	I-Protein
(	O
CCR5	B-Protein
)	O
expression	O
and	O
tumor	O
development	O
,	O
we	O
compared	O
melanoma	O
growth	O
in	O
CCR5	B-Protein
knockout	O
(	O
CCR5	B-Protein
-	O
/	O
-	O
)	O
mice	O
and	O
wild	O
type	O
(	O
CCR5	B-Protein
+	O
/	O
+	O
)	O
mice	O
.	O

CCR5	B-Protein
-	O
/	O
-	O
mice	O
showed	O
reduced	O
tumor	O
volume	O
,	O
tumor	O
weight	O
,	O
and	O
increased	O
survival	O
rate	O
when	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

We	O
investigated	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
since	O
it	O
is	O
an	O
implicated	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
genes	O
involving	O
cell	O
growth	O
,	O
apoptosis	O
,	O
and	O
tumor	O
growth	O
.	O

Significant	O
inhibition	O
of	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
,	O
and	O
translocation	O
of	O
p50	B-Protein
and	O
p65	B-Protein
into	O
the	O
nucleus	O
through	O
the	O
inhibition	O
of	O
phosphorylation	O
of	O
IkappaB	O
was	O
found	O
in	O
the	O
melanoma	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
melanoma	O
tissues	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

NF	O
-	O
kappaB	O
target	O
apoptotic	O
protein	O
expression	O
,	O
such	O
as	O
cleaved	O
caspase	O
-	O
3	O
,	O
cleaved	O
PARP	O
,	O
and	O
Bax	O
,	O
was	O
elevated	O
,	O
whereas	O
the	O
survival	O
protein	O
expression	O
levels	O
,	O
such	O
as	O
Bcl	O
-	O
2	O
,	O
C	B-Protein
-	I-Protein
IAP1	I-Protein
,	O
was	O
decreased	O
in	O
the	O
melanoma	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
the	O
level	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
a	O
tumor	O
growth	O
suppressive	O
cytokine	O
,	O
was	O
significantly	O
elevated	O
in	O
tumor	O
tissue	O
and	O
spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
the	O
level	O
in	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Moreover	O
,	O
infiltration	O
of	O
CD8	O
+	O
cytotoxic	O
T	O
cell	O
and	O
CD57	O
+	O
natural	O
killer	O
cells	O
was	O
significantly	O
increased	O
in	O
melanoma	O
tumor	O
and	O
spleen	O
tissue	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
that	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Therefore	O
,	O
these	O
results	O
showed	O
that	O
CCR5	B-Protein
deficiency	O
caused	O
apoptotic	O
cell	O
death	O
of	O
melanoma	O
through	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
and	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
.	O

Chemokines	O
are	O
small	O
soluble	O
molecules	O
that	O
are	O
best	O
known	O
for	O
their	O
potent	O
ability	O
to	O
induce	O
cancer	O
cell	O
growth	O
by	O
inflammation	O
.	O

Many	O
types	O
of	O
cancer	O
cells	O
express	O
chemokines	O
and	O
chemokine	O
receptors	O
[	O
1	O
]	O
.	O

The	O
accumulated	O
evidence	O
indicates	O
that	O
the	O
chemokine	B-Protein
(	I-Protein
C	I-Protein
-	I-Protein
C	I-Protein
motif	I-Protein
)	I-Protein
ligand	I-Protein
5	I-Protein
(	O
CCL5	B-Protein
)	O
and	O
C	B-Protein
-	I-Protein
C	I-Protein
chemokine	I-Protein
receptor	I-Protein
(	O
CCR5	B-Protein
)	O
,	O
which	O
are	O
potent	O
chemotactic	O
factors	O
for	O
inflammatory	O
cells	O
,	O
may	O
be	O
significantly	O
involved	O
in	O
the	O
proliferation	O
and	O
metastasis	O
of	O
several	O
cancers	O
.	O

Intermediate	O
and	O
strong	O
CCR5	B-Protein
expression	O
is	O
significantly	O
associated	O
with	O
nonmetastatic	O
development	O
of	O
colorectal	O
cancer	O
[	O
2	O
]	O
,	O
melanoma	O
[	O
3	O
]	O
,	O
hepatoma	O
[	O
4	O
]	O
,	O
glioblastoma	O
,	O
Hodgkin	O
lymphoma	O
[	O
5	O
]	O
,	O
as	O
well	O
as	O
oral	O
and	O
prostate	O
cancer	O
cells	O
[	O
6	O
]	O
.	O

Local	O
production	O
of	O
the	O
CCL5	B-Protein
is	O
also	O
important	O
in	O
the	O
progression	O
of	O
breast	O
cancer	O
[	O
7	O
]	O
,	O
and	O
also	O
correlates	O
with	O
poor	O
prognosis	O
[	O
8	O
]	O
.	O

Meanwhile	O
,	O
CCR5	B-Protein
disruption	O
has	O
been	O
demonstrated	O
to	O
inhibit	O
experimental	O
tumor	O
growth	O
and	O
metastasis	O
of	O
pancreatic	O
cancer	O
[	O
9	O
]	O
.	O

In	O
addition	O
,	O
host	O
absence	O
of	O
CCR5	B-Protein
potentiates	O
the	O
delay	O
of	O
tumor	O
growth	O
[	O
10	O
]	O
,	O
and	O
CCR5	B-Protein
inhibitors	O
prevented	O
cancer	O
cell	O
growth	O
,	O
such	O
as	O
prostate	O
cancer	O
[	O
11	O
]	O
,	O
breast	O
cancer	O
,	O
hepatoma	O
cells	O
[	O
4	O
]	O
,	O
and	O
lung	O
cancer	O
[	O
12	O
]	O
.	O

These	O
data	O
suggest	O
that	O
the	O
deficiency	O
of	O
inflammatory	O
chemokine	O
receptor	O
CCR5	B-Protein
may	O
function	O
as	O
a	O
suppressive	O
receptor	O
in	O
cancer	O
progression	O
.	O

However	O
,	O
more	O
studies	O
are	O
required	O
to	O
describe	O
how	O
CCR5	B-Protein
deficiency	O
acts	O
in	O
the	O
inhibition	O
of	O
tumor	O
development	O
.	O

Interleukin	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
(	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
)	O
,	O
a	O
member	O
of	O
the	O
IL	O
-	O
1	O
family	O
,	O
is	O
a	O
naturally	O
occurring	O
cytokine	B-Protein
that	O
competitively	O
blocks	O
the	O
IL	O
-	O
1	O
receptor	O
[	O
13	O
]	O
.	O

Because	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
has	O
been	O
shown	O
to	O
inhibit	O
tumor	O
progression	O
by	O
promoting	O
antitumor	O
immune	O
responses	O
and	O
by	O
enhancing	O
the	O
activity	O
of	O
chemotherapy	O
,	O
numerous	O
studies	O
have	O
examined	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
to	O
block	O
tumor	O
progression	O
.	O

IL	B-Protein
-	I-Protein
1Ra	I-Protein
expression	O
was	O
reduced	O
in	O
prostate	O
[	O
14	O
]	O
,	O
breast	O
[	O
15	O
]	O
,	O
and	O
skin	O
cancer	O
[	O
16	O
]	O
.	O

It	O
was	O
also	O
reported	O
that	O
endogenous	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
deficient	O
mice	O
developed	O
aggressive	O
tumors	O
following	O
exposure	O
to	O
carcinogens	O
[	O
17	O
]	O
.	O

Meanwhile	O
,	O
proliferation	O
of	O
the	O
melanoma	O
cells	O
that	O
were	O
transduced	O
with	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
gene	O
was	O
reduced	O
and	O
inhibited	O
melanoma	O
development	O
[	O
18	O
]	O
.	O

IL	O
-	O
1R	O
blockade	O
also	O
reduced	O
hepatic	O
tumor	O
growth	O
[	O
19	O
]	O
.	O

Moreover	O
,	O
it	O
has	O
also	O
been	O
reported	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
reduces	O
fibrosarcoma	O
development	O
[	O
20	O
]	O
,	O
B16	O
melanoma	O
growth	O
and	O
metastasis	O
[	O
21	O
]	O
,	O
colon	O
adenocarcinoma	O
growth	O
[	O
22	O
]	O
,	O
and	O
skin	O
cancer	O
development	O
[	O
23	O
]	O
.	O

IL	O
-	O
1	O
knockout	O
mice	O
injected	O
with	O
melanoma	O
failed	O
to	O
develop	O
solid	O
tumors	O
[	O
24	O
]	O
.	O

It	O
was	O
also	O
found	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
combined	O
with	O
temozolomide	O
and	O
docetaxel	O
chemotherapy	O
,	O
demonstrated	O
more	O
significant	O
antitumor	O
activity	O
against	O
B16	O
melanoma	O
cells	O
in	O
vivo	O
[	O
25	O
]	O
.	O

These	O
data	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
is	O
important	O
as	O
a	O
tumor	O
growth	O
suppressing	O
cytokine	B-Protein
.	O

NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
suppression	O
of	O
apoptosis	O
,	O
as	O
well	O
as	O
the	O
induction	O
of	O
cell	O
proliferation	O
and	O
inflammation	O
,	O
and	O
is	O
closely	O
associated	O
with	O
cancer	O
development	O
[	O
26	O
]	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
has	O
been	O
described	O
in	O
a	O
great	O
number	O
of	O
cancers	O
including	O
colon	O
cancers	O
,	O
prostate	O
cancers	O
and	O
melanoma	O
[	O
27	O
]	O
,	O
and	O
was	O
found	O
to	O
up	O
-	O
regulate	O
anti	O
-	O
apoptotic	O
genes	O
and	O
/	O
or	O
down	O
regulate	O
apoptotic	O
gene	O
expression	O
[	O
28	O
]	O
.	O

Although	O
NF	O
-	O
kappaB	O
promotes	O
tumor	O
growth	O
,	O
it	O
is	O
required	O
for	O
the	O
immune	O
system	O
to	O
function	O
normally	O
[	O
29	O
]	O
.	O

Studies	O
on	O
c	B-Protein
-	I-Protein
Rel	I-Protein
-	O
deficient	O
mice	O
demonstrated	O
that	O
c	B-Protein
-	I-Protein
Rel	I-Protein
is	O
essential	O
for	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
3	I-Protein
,	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
,	O
and	O
IFNgamma	O
expression	O
in	O
T	O
lymphocytes	O
[	O
30	O
]	O
.	O

C	O
-	O
Rel	O
-	O
deficient	O
mice	O
also	O
have	O
a	O
tissue	O
-	O
specific	O
deficiency	O
of	O
various	O
cytokines	O
and	O
growth	O
factors	O
in	O
T	O
cells	O
and	O
macrophages	O
affecting	O
both	O
innate	O
and	O
humoral	O
immune	O
responses	O
in	O
the	O
host	O
[	O
31	O
]	O
.	O

Therefore	O
,	O
NF	O
-	O
kappaB	O
can	O
be	O
specially	O
targeted	O
to	O
prevent	O
cancer	O
cell	O
growth	O
by	O
(	O
1	O
)	O
directly	O
affecting	O
apoptotic	O
cancer	O
cell	O
death	O
,	O
(	O
2	O
)	O
stimulating	O
tumor	O
killing	O
lymphocytes	O
infiltration	O
or	O
(	O
3	O
)	O
increasing	O
the	O
production	O
of	O
tumor	O
killing	O
lymphokines	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
is	O
important	O
in	O
the	O
regulation	O
of	O
CCR	O
-	O
mediated	O
tumor	O
growth	O
and	O
metastasis	O
.	O

It	O
was	O
reported	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
by	O
dehydroxymethyl	O
-	O
epoxyquinomicin	O
(	O
DHMEQ	O
)	O
induces	O
cell	O
death	O
of	O
primary	O
effusion	O
lymphoma	O
by	O
inhibition	O
of	O
CCR5	B-Protein
expression	O
[	O
32	O
]	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
also	O
increases	O
CCL5	B-Protein
-	O
mediated	O
oral	O
cancer	O
motility	O
(	O
5	O
)	O
and	O
lung	O
metastasis	O
[	O
33	O
]	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
could	O
be	O
involved	O
in	O
CCR5	B-Protein
mediated	O
tumor	O
development	O
.	O

NF	O
-	O
kappaB	O
transcription	O
factor	O
binding	O
sites	O
are	O
present	O
in	O
the	O
promoter	O
region	O
of	O
proinflammatory	O
cytokine	O
genes	O
,	O
such	O
as	O
IL	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
,	O
and	O
KC	B-Protein
[	O
34	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
is	O
a	O
negative	O
regulator	O
of	O
the	O
inflammatory	O
response	O
.	O

Several	O
studies	O
have	O
demonstrated	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
to	O
abrogate	O
the	O
proinflammatory	O
effects	O
of	O
IL	O
-	O
1	O
.	O

Smith	O
et	O
al	O
.	O
suggested	O
that	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
gene	O
expression	O
is	O
a	O
complex	O
event	O
involving	O
the	O
interactions	O
of	O
three	O
different	O
transcription	O
factors	O
;	O
NF	O
-	O
kappaB	O
/	O
PU	B-Protein
.	I-Protein
1	I-Protein
/	O
GA	O
-	O
binding	O
protein	O
binding	O
site	O
[	O
35	O
]	O
.	O

Nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
(	O
p65	B-Protein
)	O
was	O
significantly	O
enhanced	O
and	O
prolonged	O
in	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
-	O
deficient	O
mice	O
,	O
compared	O
to	O
that	O
in	O
wild	O
type	O
mice	O
[	O
36	O
]	O
.	O

Intracellular	B-Protein
IL	I-Protein
-	I-Protein
1Ra	I-Protein
(	O
icIL	B-Protein
-	I-Protein
1Ra	I-Protein
)	O
was	O
found	O
to	O
inhibit	O
IL	O
-	O
1	O
by	O
blocking	O
NF	O
-	O
kappaB	O
signal	O
transduction	O
pathways	O
in	O
inflammatory	O
responses	O
[	O
37	O
]	O
.	O

Because	O
IL	O
-	O
1	O
has	O
been	O
shown	O
to	O
be	O
an	O
inducer	O
of	O
NF	O
-	O
kappaB	O
activation	O
[	O
38	O
]	O
,	O
we	O
hypothesized	O
that	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
play	O
an	O
important	O
role	O
in	O
the	O
autocrine	O
activation	O
of	O
transcription	O
factors	O
NF	O
-	O
kappaB	O
or	O
vice	O
versa	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
roles	O
of	O
NF	O
-	O
kappaB	O
and	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
chemokine	B-Protein
receptor	I-Protein
CCR5	B-Protein
-	O
mediated	O
suppression	O
of	O
tumor	O
development	O
.	O

Inhibition	O
of	O
Tumor	O
Development	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O

The	O
effect	O
of	O
CCR5	B-Protein
in	O
tumor	O
development	O
was	O
investigated	O
using	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

B16	O
-	O
F0	O
melanoma	O
cells	O
were	O
inoculated	O
subcutaneously	O
into	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
n	O
=	O
20	O
)	O
.	O

Tumor	O
growth	O
was	O
monitored	O
for	O
31	O
days	O
.	O

Tumor	O
growth	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

The	O
tumor	O
growth	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
was	O
reduced	O
to	O
19	O
.	O
1	O
%	O
,	O
whereas	O
the	O
tumor	O
growth	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
was	O
only	O
reduced	O
to	O
24	O
.	O
3	O
%	O
,	O
in	O
both	O
tumor	O
weight	O
(	O
Figure	O
1A	O
and	O
1B	O
)	O
and	O
tumor	O
volume	O
,	O
respectively	O
(	O
Figure	O
1A	O
and	O
1C	O
)	O
.	O

These	O
results	O
correlated	O
with	O
mice	O
survival	O
rates	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
survival	O
rates	O
between	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
75	O
%	O
of	O
starting	O
time	O
)	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
15	O
%	O
)	O
at	O
the	O
end	O
of	O
the	O
experiment	O
(	O
Figure	O
1D	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
survival	O
rates	O
between	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
75	O
%	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
survived	O
while	O
only	O
15	O
%	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
survived	O
.	O

Subcutaneous	O
tumors	O
were	O
harvested	O
from	O
the	O
sacrificed	O
mice	O
31	O
days	O
after	O
inoculation	O
.	O

The	O
immunohistochemical	O
analysis	O
of	O
tumor	O
sections	O
,	O
stained	O
with	O
H	O
&	O
E	O
and	O
for	O
proliferation	O
antigen	O
PCNA	O
,	O
revealed	O
greater	O
inhibition	O
of	O
tumor	O
cell	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

The	O
histologic	O
findings	O
after	O
H	O
&	O
E	O
staining	O
indicated	O
that	O
the	O
tumor	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
but	O
not	O
those	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
,	O
contained	O
large	O
areas	O
of	O
necrosis	O
.	O

PCNA	O
reactive	O
cells	O
were	O
significantly	O
reduced	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
1E	O
)	O
.	O

Decrease	O
of	O
NF	O
-	O
kappaB	O
Activity	O
in	O
Tumor	O
Tissue	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
critical	O
role	O
in	O
cancer	O
cell	O
survival	O
,	O
especially	O
melanoma	O
cancer	O
cells	O
and	O
in	O
CCR5	B-Protein
expression	O
.	O

To	O
evaluate	O
whether	O
the	O
tumor	O
inhibition	O
was	O
related	O
with	O
the	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
in	O
melanoma	O
,	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
was	O
determined	O
by	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
in	O
melanoma	O
tissue	O
.	O

The	O
constitutively	O
activated	O
DNA	O
binding	O
activity	O
was	O
reduced	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
tumor	O
tissue	O
(	O
Figure	O
2A	O
)	O
.	O

Moreover	O
,	O
the	O
translocation	O
of	O
p50	B-Protein
and	O
p	O
-	O
p65	B-Protein
into	O
the	O
nucleus	O
through	O
the	O
inhibition	O
of	O
phosphorylation	O
of	O
IkappaB	O
was	O
also	O
prevented	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
2B	O
)	O
.	O

Immunofluorescence	O
analysis	O
also	O
confirmed	O
that	O
the	O
intensity	O
of	O
nuclear	O
staining	O
for	O
p50	B-Protein
had	O
decreased	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
2C	O
)	O
.	O

Induction	O
of	O
Apoptotic	O
Cell	O
Death	O
and	O
Inhibition	O
of	O
the	O
Expression	O
of	O
Anti	O
-	O
apoptotic	O
Proteins	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O

To	O
see	O
whether	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
results	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
and	O
expression	O
of	O
NF	O
-	O
kappaB	O
target	O
apoptotic	O
cell	O
death	O
regulatory	O
protein	O
,	O
the	O
levels	O
of	O
apoptotic	O
cell	O
death	O
and	O
expression	O
of	O
apoptotic	O
cell	O
death	O
regulatory	O
proteins	O
were	O
assessed	O
.	O

Apoptotic	O
cell	O
death	O
in	O
the	O
tumor	O
sections	O
were	O
evaluated	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
that	O
were	O
inoculated	O
with	O
melanoma	O
cells	O
.	O

TUNEL	O
staining	O
revealed	O
a	O
higher	O
frequency	O
of	O
apoptotic	O
cell	O
death	O
in	O
the	O
tumor	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
than	O
that	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
3A	O
)	O
.	O

Immunohistochemical	O
and	O
immunofluorescence	O
showed	O
that	O
high	O
levels	O
of	O
cleaved	O
caspase	O
-	O
3	O
and	O
Bax	O
were	O
found	O
more	O
frequently	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
than	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
3B	O
and	O
3C	O
)	O
.	O

Consistent	O
with	O
the	O
immunohistochemical	O
data	O
,	O
Western	O
blot	O
analysis	O
of	O
tumor	O
proteins	O
showed	O
greater	O
increased	O
levels	O
of	O
cleaved	O
caspase	O
-	O
3	O
,	O
cleaved	O
caspase	O
-	O
9	O
,	O
cleaved	O
PARP	O
and	O
Bax	O
,	O
whereas	O
the	O
levels	O
of	O
Bcl	O
-	O
2	O
and	O
C	B-Protein
-	I-Protein
IAP1	I-Protein
were	O
significantly	O
decreased	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
tissues	O
(	O
Figure	O
3D	O
)	O
.	O

Upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
Tumor	O
and	O
Spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O

To	O
investigate	O
the	O
difference	O
in	O
the	O
cytokine	O
levels	O
between	O
the	O
tumor	O
and	O
spleen	O
tissues	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
we	O
conducted	O
a	O
cytokine	O
array	O
assay	O
using	O
a	O
Mouse	O
Proteome	O
Array	O
(	O
Figure	O
4A	O
)	O
.	O

Among	O
40	O
tested	O
cytokines	O
,	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
MIG	B-Protein
,	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
increased	O
about	O
686	O
,	O
9	O
and	O
25	O
-	O
fold	O
respectively	O
,	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Using	O
this	O
technique	O
,	O
no	O
other	O
cytokines	O
were	O
found	O
to	O
be	O
different	O
between	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
4B	O
)	O
.	O

Similar	O
altered	O
cytokine	O
levels	O
were	O
found	O
in	O
the	O
spleens	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
4C	O
)	O
.	O

Since	O
the	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
level	O
was	O
the	O
most	O
significantly	O
elevated	O
,	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
tumor	O
and	O
spleen	O
tissues	O
was	O
analyzed	O
by	O
immunofluorescence	O
and	O
western	O
blotting	O
.	O

The	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
was	O
upregulated	O
in	O
tumor	O
and	O
spleen	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
4D	O
-	O
G	O
)	O
.	O

Induction	O
of	O
CD8	O
T	O
cells	O
and	O
NK	O
Cell	O
Infiltration	O
into	O
Tumor	O
and	O
Spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O

To	O
investigate	O
whether	O
the	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
is	O
related	O
to	O
tumor	O
-	O
specific	O
immune	O
responses	O
,	O
we	O
analyzed	O
the	O
distribution	O
patterns	O
of	O
CD8	O
+	O
cytotoxic	O
T	O
cell	O
and	O
CD57	O
+	O
Natural	O
Killer	O
cells	O
in	O
tumor	O
and	O
spleen	O
tissues	O
.	O

By	O
staining	O
the	O
tumor	O
sections	O
from	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
we	O
found	O
that	O
there	O
was	O
a	O
significant	O
influx	O
of	O
CD8	O
+	O
cells	O
into	O
the	O
tumor	O
,	O
as	O
well	O
as	O
an	O
increase	O
in	O
the	O
number	O
of	O
infiltrating	O
NK	O
cells	O
(	O
Figure	O
5A	O
)	O
.	O

CD8	O
+	O
T	O
cells	O
and	O
CD57	O
+	O
NK	O
cells	O
were	O
spread	O
diffusely	O
throughout	O
the	O
entire	O
sections	O
.	O

To	O
further	O
investigate	O
the	O
differences	O
in	O
the	O
numbers	O
of	O
CD8	O
+	O
T	O
cells	O
and	O
CD57	O
+	O
NK	O
cells	O
between	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
in	O
immunity	O
-	O
related	O
organ	O
,	O
we	O
also	O
analyzed	O
the	O
CD8	O
and	O
CD57	O
reactive	O
cell	O
number	O
in	O
spleen	O
tissues	O
.	O

The	O
number	O
of	O
CD8	O
+	O
T	O
cells	O
and	O
CD57	O
+	O
NK	O
cells	O
were	O
higher	O
in	O
the	O
spleen	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
than	O
in	O
the	O
spleen	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
5B	O
)	O
.	O

These	O
data	O
suggest	O
that	O
by	O
promoting	O
the	O
infiltration	O
of	O
CD8	O
T	O
cells	O
and	O
NK	O
cells	O
,	O
which	O
are	O
potent	O
cytotoxic	O
effectors	O
for	O
tumors	O
,	O
could	O
play	O
a	O
role	O
in	O
an	O
anti	O
-	O
tumor	O
effect	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

To	O
analyze	O
the	O
cell	O
phenotype	O
change	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
by	O
inoculation	O
of	O
the	O
melanoma	O
cell	O
,	O
lymphocytes	O
were	O
isolated	O
from	O
the	O
tumor	O
and	O
spleen	O
tissues	O
.	O

The	O
B	O
,	O
CD3	O
T	O
,	O
CD4	B-Protein
T	O
,	O
CD	O
8	O
T	O
and	O
NK	O
cell	O
portion	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
tumor	O
tissue	O
were	O
7	O
.	O
2	O
%	O
,	O
48	O
.	O
2	O
%	O
,	O
16	O
.	O
9	O
%	O
,	O
32	O
.	O
1	O
%	O
and	O
7	O
.	O
8	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
2	O
.	O
9	O
%	O
,	O
11	O
.	O
1	O
%	O
,	O
2	O
.	O
3	O
%	O
,	O
0	O
.	O
6	O
%	O
and	O
3	O
.	O
1	O
%	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
5C	O
)	O
.	O

The	O
lymphocytes	O
that	O
infiltrated	O
the	O
tumor	O
tissue	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
also	O
had	O
higher	O
levels	O
of	O
CD19	B-Protein
,	O
CD3	O
,	O
CD4	B-Protein
,	O
CD8	O
and	O
CD57	O
when	O
compared	O
to	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

The	O
B	O
,	O
CD3	O
T	O
,	O
CD4	B-Protein
T	O
,	O
CD	O
8	O
T	O
and	O
NK	O
cell	O
portion	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
spleen	O
were	O
61	O
.	O
3	O
%	O
,	O
33	O
.	O
4	O
%	O
,	O
17	O
.	O
6	O
%	O
,	O
9	O
.	O
2	O
%	O
and	O
0	O
.	O
6	O
%	O
,	O
respectively	O
compared	O
to	O
38	O
.	O
3	O
%	O
,	O
5	O
.	O
9	O
%	O
,	O
4	O
.	O
0	O
%	O
,	O
1	O
.	O
0	O
%	O
and	O
3	O
.	O
9	O
%	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
5D	O
)	O
.	O

These	O
data	O
suggest	O
that	O
by	O
promoting	O
the	O
infiltration	O
of	O
CD8	O
T	O
cells	O
and	O
NK	O
cells	O
,	O
which	O
are	O
potent	O
cytotoxic	O
effectors	O
for	O
tumors	O
,	O
could	O
play	O
a	O
role	O
in	O
the	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
tumor	O
weight	O
and	O
volume	O
were	O
much	O
smaller	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
inoculated	O
with	O
B16	O
melanoma	O
cells	O
(	O
Figure	O
1A	O
and	O
1B	O
)	O
.	O

The	O
tumor	O
growth	O
inhibition	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
was	O
associated	O
with	O
the	O
inhibition	O
of	O
constitutively	O
activated	O
NF	O
-	O
kappaB	O
and	O
elevation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
tumor	O
tissue	O
.	O

This	O
anti	O
-	O
tumor	O
activity	O
was	O
also	O
associated	O
with	O
decreased	O
expression	O
of	O
NF	O
-	O
kappaB	O
target	O
anti	O
-	O
apoptotic	O
,	O
cell	O
proliferative	O
,	O
and	O
tumor	O
promoting	O
genes	O
(	O
Bcl	O
-	O
2	O
and	O
C	B-Protein
-	I-Protein
IAP1	I-Protein
)	O
but	O
with	O
increased	O
expression	O
of	O
their	O
target	O
apoptotic	O
genes	O
;	O
cleaved	O
caspase	O
-	O
3	O
and	O
9	O
,	O
and	O
Bax	O
(	O
Figure	O
3A	O
-	O
D	O
)	O
.	O

In	O
the	O
tumor	O
and	O
the	O
spleen	O
,	O
the	O
number	O
of	O
cytotoxic	O
CD8	O
+	O
T	O
cells	O
,	O
CD57	O
+	O
natural	O
killer	O
cells	O
,	O
and	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
were	O
increased	O
(	O
Figure	O
4	O
and	O
5	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
melanoma	O
growth	O
was	O
inhibited	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
and	O
that	O
the	O
elevation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
accompanied	O
with	O
decreased	O
NF	O
-	O
kappaB	O
,	O
is	O
significant	O
in	O
the	O
inhibition	O
of	O
melanoma	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

NF	O
-	O
kappaB	O
regulates	O
the	O
expression	O
of	O
over	O
200	O
genes	O
that	O
control	O
the	O
immune	O
system	O
,	O
cancer	O
cell	O
growth	O
and	O
inflammation	O
[	O
39	O
]	O
.	O

Because	O
of	O
its	O
abilities	O
to	O
induce	O
the	O
expression	O
of	O
a	O
large	O
array	O
of	O
inflammatory	O
mediators	O
and	O
its	O
roles	O
as	O
core	O
transcription	O
factors	O
in	O
diverse	O
immune	O
responses	O
,	O
NF	O
-	O
kappaB	O
has	O
been	O
recognized	O
as	O
a	O
major	O
factor	O
responsible	O
for	O
cytokine	O
-	O
associated	O
cancer	O
development	O
or	O
anti	O
-	O
tumor	O
immunity	O
.	O

In	O
the	O
melanoma	O
tumor	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
target	O
cell	O
death	O
genes	O
(	O
Bax	O
,	O
caspase	O
-	O
3	O
and	O
9	O
)	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
,	O
were	O
significantly	O
inhibited	O
,	O
but	O
the	O
expression	O
of	O
cell	O
death	O
inhibitory	O
NF	O
-	O
kappaB	O
target	O
genes	O
,	O
such	O
as	O
Bcl	O
-	O
2	O
and	O
cIAP	O
were	O
enhanced	O
.	O

In	O
addition	O
,	O
CCR5	B-Protein
-	O
/	O
-	O
prevented	O
the	O
phosphorylation	O
of	O
IkappaB	O
,	O
accompanied	O
with	O
the	O
inhibition	O
of	O
the	O
p50	B-Protein
and	O
p65	B-Protein
translocation	O
into	O
the	O
nucleus	O
(	O
Figure	O
2A	O
-	O
C	O
)	O
.	O

Many	O
tumors	O
,	O
including	O
melanoma	O
,	O
have	O
increased	O
levels	O
of	O
NF	O
-	O
kappaB	O
[	O
40	O
]	O
,	O
which	O
is	O
likely	O
acting	O
as	O
a	O
survival	O
factor	O
for	O
melanoma	O
growth	O
.	O

Thus	O
,	O
the	O
inhibitions	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
the	O
expression	O
of	O
target	O
genes	O
are	O
critical	O
in	O
the	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Although	O
the	O
mechanism	O
is	O
not	O
clear	O
as	O
to	O
how	O
CCR5	B-Protein
-	O
/	O
-	O
downregulates	O
NF	O
-	O
kappaB	O
,	O
it	O
is	O
noteworthy	O
that	O
NF	O
-	O
kappaB	O
is	O
activated	O
or	O
inactivated	O
by	O
many	O
cytokines	O
.	O

Numerous	O
studies	O
showed	O
that	O
cytokine	O
affect	O
tumor	O
growth	O
by	O
regulating	O
NF	O
-	O
kappaB	O
.	O

Inflammatory	O
cytokines	O
,	O
including	O
IL	O
-	O
1	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	O
-	O
8	O
,	O
activate	O
NF	O
-	O
kappaB	O
pathways	O
in	O
tumor	O
cells	O
[	O
41	O
]	O
.	O

The	O
interleukin	B-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
is	O
well	O
known	O
as	O
an	O
anti	O
-	O
tumor	O
factor	O
as	O
well	O
as	O
an	O
anti	O
-	O
inflammatory	O
factor	O
[	O
42	O
]	O
,	O
[	O
43	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
inhibits	O
constitutively	O
activated	O
NF	O
-	O
kappaB	O
both	O
in	O
vitro	O
[	O
44	O
]	O
and	O
in	O
vivo	O
[	O
45	O
]	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
by	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
contributes	O
to	O
the	O
anti	O
-	O
tumor	O
effects	O
through	O
the	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
apoptosis	O
in	O
Colon26	O
-	O
bearing	O
mice	O
[	O
43	O
]	O
.	O

Similarly	O
,	O
several	O
studies	O
have	O
demonstrated	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
to	O
abrogate	O
the	O
proinflammatory	O
effects	O
of	O
IL	O
-	O
1	O
[	O
46	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
IL	O
-	O
1	O
induces	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
several	O
cancers	O
,	O
and	O
increases	O
cell	O
cycle	O
progression	O
,	O
and	O
the	O
suppression	O
of	O
apoptotic	O
cell	O
death	O
leading	O
to	O
tumor	O
promotion	O
.	O

The	O
results	O
of	O
various	O
studies	O
over	O
the	O
past	O
10	O
years	O
indicate	O
that	O
the	O
major	O
function	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
is	O
to	O
regulate	O
the	O
pleiotropic	O
effects	O
of	O
IL	O
-	O
1	O
by	O
competitively	O
blocking	O
its	O
functions	O
[	O
47	O
]	O
.	O

The	O
ability	O
of	O
IL	O
-	O
1	O
to	O
induce	O
its	O
own	O
antagonist	O
is	O
of	O
interest	O
in	O
understanding	O
the	O
regulation	O
and	O
dysregulation	O
of	O
IL	O
-	O
1	O
signaling	O
in	O
normal	O
and	O
diseased	O
tissue	O
.	O

Up	O
-	O
regulation	O
of	O
the	O
receptor	O
antagonist	O
represents	O
a	O
mechanism	O
for	O
turning	O
off	O
IL	O
-	O
1	O
signaling	O
and	O
creating	O
a	O
temporary	O
state	O
of	O
refractoriness	O
.	O

The	O
elevated	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
without	O
any	O
change	O
of	O
IL	O
-	O
1	O
in	O
tumors	O
,	O
suggests	O
that	O
the	O
IL	O
-	O
1	O
-	O
signaling	O
system	O
may	O
be	O
dysregulated	O
by	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
tumors	O
.	O

IL	O
-	O
1Ra	O
has	O
been	O
shown	O
to	O
inhibit	O
tumor	O
progression	O
in	O
prostate	O
,	O
breast	O
,	O
and	O
skin	O
cancer	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

Intracellular	B-Protein
IL	I-Protein
-	I-Protein
1Ra	I-Protein
(	O
icIL	B-Protein
-	I-Protein
1Ra	I-Protein
)	O
inhibits	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	O
-	O
8	O
production	O
in	O
Caco	O
-	O
2	O
cells	O
by	O
blocking	O
NF	O
-	O
kappaB	O
pathways	O
[	O
37	O
]	O
.	O

We	O
found	O
that	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
were	O
significantly	O
elevated	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
inoculated	O
with	O
B16	O
melanoma	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
be	O
critically	O
involved	O
in	O
the	O
tumor	O
growth	O
inhibition	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
through	O
the	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
present	O
study	O
.	O

CCR5	B-Protein
increases	O
tumor	O
growth	O
in	O
a	O
local	O
model	O
and	O
inhibits	O
the	O
efficacy	O
of	O
a	O
dendrite	O
cell	O
vaccine	O
in	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
compared	O
with	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
[	O
10	O
]	O
.	O

Cheng	O
J	O
and	O
Sung	O
RS	O
examined	O
the	O
effect	O
of	O
CCR5	B-Protein
on	O
the	O
immune	O
response	O
to	O
adenovirus	O
vectors	O
and	O
graft	O
function	O
in	O
an	O
islet	O
transplant	O
model	O
.	O

They	O
found	O
that	O
CCR5	B-Protein
absence	O
does	O
not	O
prevent	O
the	O
local	O
immune	O
response	O
to	O
adenovirus	O
transduction	O
[	O
48	O
]	O
.	O

Additionally	O
,	O
Tan	O
MC	O
et	O
al	O
.	O
suggested	O
that	O
disruption	O
of	O
CCR5	B-Protein
/	O
CCL5	B-Protein
signaling	O
,	O
either	O
by	O
reducing	O
CCL5	B-Protein
production	O
by	O
tumor	O
cells	O
or	O
by	O
systemic	O
administration	O
of	O
a	O
CCR5	B-Protein
inhibitor	O
(	O
TAK	O
-	O
779	O
)	O
,	O
reduced	O
Treg	O
(	O
regulatory	O
T	O
cells	O
)	O
migration	O
to	O
tumors	O
so	O
that	O
tumors	O
are	O
smaller	O
in	O
control	O
mice	O
[	O
9	O
]	O
.	O

These	O
data	O
support	O
the	O
important	O
premise	O
that	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
could	O
be	O
related	O
with	O
the	O
inhibition	O
of	O
immune	O
escape	O
.	O

Similar	O
to	O
this	O
finding	O
,	O
we	O
found	O
that	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
injected	O
with	O
melanoma	O
cells	O
apparently	O
have	O
a	O
lower	O
number	O
of	O
cytotoxic	O
T	O
cells	O
(	O
CD8	O
+	O
positive	O
T	O
Lymphocytes	O
cells	O
)	O
and	O
natural	O
killer	O
cells	O
(	O
CD57	O
positive	O
NK	O
cells	O
)	O
,	O
as	O
well	O
as	O
dendrite	O
cells	O
,	O
in	O
spleen	O
tissues	O
compared	O
to	O
those	O
without	O
melanoma	O
cells	O
.	O

But	O
the	O
lymphocytes	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
did	O
not	O
decrease	O
when	O
injected	O
with	O
melanoma	O
cells	O
.	O

These	O
differences	O
of	O
the	O
immune	O
response	O
between	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
involving	O
tumor	O
immune	O
tolerance	O
,	O
may	O
be	O
connected	O
with	O
the	O
inhibition	O
of	O
cancer	O
progression	O
.	O

Taken	O
together	O
,	O
in	O
the	O
cytokine	O
array	O
experiment	O
,	O
the	O
level	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
(	O
which	O
has	O
a	O
potent	O
activity	O
of	O
T	O
cell	O
and	O
B	O
cell	O
migration	O
)	O
was	O
increased	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
with	O
those	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Thus	O
,	O
relatively	O
increased	O
tumor	O
associated	O
cytotoxic	O
lymphocytes	O
could	O
play	O
an	O
important	O
role	O
in	O
inhibiting	O
the	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
could	O
modulate	O
subcellular	O
localization	O
of	O
NK	O
cells	O
and	O
pathogenesis	O
[	O
49	O
]	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
prevented	O
NK	O
cell	O
depletion	O
,	O
and	O
thus	O
increased	O
anti	O
-	O
tumor	O
activity	O
by	O
decreasing	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
[	O
50	O
]	O
.	O

Thus	O
,	O
the	O
decreased	O
NF	O
-	O
kappaB	O
and	O
elevated	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
also	O
be	O
associated	O
in	O
the	O
infiltration	O
of	O
cytotoxic	O
lymphocytes	O
into	O
tumor	O
,	O
resulting	O
in	O
tumor	O
growth	O
inhibition	O
.	O

In	O
contrast	O
,	O
IL	O
-	O
23	O
,	O
a	O
tumor	O
growth	O
promoting	O
cytokine	O
,	O
increased	O
NF	O
-	O
kappaB	O
and	O
immune	O
cell	O
infiltration	O
in	O
oral	O
tumor	O
[	O
51	O
]	O
.	O

These	O
data	O
indicate	O
that	O
NF	O
-	O
kappaB	O
could	O
be	O
involved	O
in	O
the	O
cytokine	O
mediated	O
anti	O
-	O
tumor	O
activities	O
of	O
immune	O
cells	O
.	O

It	O
is	O
also	O
noteworthy	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
inhibited	O
melanoma	O
tumor	O
growth	O
by	O
increasing	O
the	O
number	O
of	O
myeloid	O
suppressor	O
cells	O
in	O
tumor	O
[	O
25	O
]	O
.	O

The	O
3	O
-	O
methylcholatrene	O
-	O
induced	O
tumor	O
incidence	O
was	O
reduced	O
in	O
IL	B-Protein
-	I-Protein
1alpha	I-Protein
knockout	O
mice	O
,	O
but	O
increased	O
in	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
mice	O
with	O
concomitant	O
maturation	O
of	O
NK	O
cells	O
and	O
anti	O
-	O
tumor	O
immunity	O
[	O
52	O
]	O
.	O

These	O
data	O
indicate	O
that	O
the	O
decrease	O
of	O
NF	O
-	O
kappaB	O
,	O
and	O
thus	O
increase	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
be	O
significant	O
in	O
tumor	O
growth	O
inhibition	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Our	O
data	O
thus	O
show	O
significant	O
clinical	O
implications	O
of	O
CCR5	B-Protein
,	O
because	O
CCR5	B-Protein
is	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
and	O
it	O
is	O
amenable	O
to	O
use	O
as	O
a	O
small	O
molecule	O
for	O
the	O
inhibition	O
of	O
CCR5	B-Protein
.	O

Several	O
such	O
compounds	O
have	O
already	O
been	O
shown	O
to	O
be	O
safe	O
in	O
clinical	O
trials	O
for	O
use	O
in	O
certain	O
diseases	O
such	O
as	O
HIV	O
[	O
53	O
]	O
.	O

Thus	O
,	O
we	O
believe	O
CCR5	B-Protein
is	O
a	O
cancer	O
target	O
that	O
warrants	O
continued	O
investigation	O
.	O

In	O
summary	O
,	O
this	O
study	O
showed	O
that	O
melanoma	O
cells	O
growth	O
was	O
inhibited	O
via	O
modulation	O
of	O
NF	O
-	O
kappaB	O
/	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
pathways	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Ethics	O
Statement	O

All	O
experiments	O
were	O
approved	O
and	O
carried	O
out	O
according	O
to	O
the	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Animals	O
[	O
Animal	O
Care	O
Committee	O
of	O
Chungbuk	O
National	O
University	O
,	O
Korea	O
(	O
CBNUA	O
-	O
045	O
-	O
0902	O
-	O
01	O
)	O
]	O
.	O

Animals	O

The	O
CCR5	B-Protein
wild	O
type	O
(	O
CCR5	B-Protein
+	O
/	O
+	O
)	O
and	O
CCR5	B-Protein
knockout	O
(	O
CCR5	B-Protein
-	O
/	O
-	O
)	O
mice	O
were	O
purchased	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
04609	O
USA	O
)	O
.	O

The	O
mice	O
were	O
housed	O
and	O
bred	O
under	O
specific	O
pathogen	O
free	O
conditions	O
at	O
the	O
Laboratory	O
Animal	O
Research	O
Center	O
of	O
Chungbuk	O
National	O
University	O
,	O
Korea	O
.	O

The	O
mice	O
(	O
n	O
=	O
4	O
/	O
cage	O
)	O
were	O
maintained	O
in	O
a	O
room	O
with	O
a	O
constant	O
temperature	O
of	O
22	O
+	O
/	O
-	O
1degreesC	O
,	O
relative	O
humidity	O
of	O
55	O
+	O
/	O
-	O
10	O
%	O
,	O
and	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
,	O
and	O
fed	O
standard	O
rodent	O
chow	O
(	O
Samyang	O
,	O
Korea	O
)	O
and	O
purified	O
tap	O
water	O
ad	O
libitum	O
.	O

The	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
n	O
=	O
20	O
)	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
n	O
=	O
20	O
)	O
,	O
that	O
were	O
used	O
,	O
had	O
matched	O
ages	O
(	O
10	O
-	O
11	O
weeks	O
old	O
)	O
and	O
weights	O
(	O
16	O
-	O
19	O
g	O
)	O
.	O

Control	O
mice	O
(	O
B6129PF2	O
/	O
J	O
)	O
were	O
F2	O
hybrid	O
mice	O
from	O
the	O
C57BL	O
/	O
6J	O
-	O
AW	O
-	O
J	O
and	O
129P3	O
/	O
J	O
parental	O
strains	O
.	O

CCR5	B-Protein
mice	O
(	O
B6	O
,	O
129P2	O
-	O
Ccr5tm1Kuz	O
/	O
J	O
)	O
have	O
the	O
entire	O
coding	O
region	O
of	O
the	O
CCR5	B-Protein
gene	O
deleted	O
from	O
the	O
parental	O
strains	O
,	O
B6	O
;	O
129P2	O
-	O
Ccr5tm1kuz	O
and	O
B6	O
;	O
129P2	O
-	O
Cmkbr5tm1Kuz	O
.	O

Tumor	O
Inoculation	O
and	O
Tumor	O
Monitoring	O

B16	O
melanoma	O
cells	O
were	O
injected	O
subcutaneously	O
[	O
5x105	O
tumor	O
cells	O
in	O
0	O
.	O
1	O
ml	O
Phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
/	O
animal	O
]	O
using	O
a	O
27	O
G	O
needle	O
into	O
the	O
right	O
-	O
lower	O
flanks	O
of	O
the	O
carrier	O
mice	O
as	O
previously	O
described	O
[	O
54	O
]	O
.	O

The	O
body	O
weights	O
and	O
tumor	O
volumes	O
of	O
the	O
animals	O
were	O
monitored	O
twice	O
weekly	O
.	O

The	O
tumor	O
volumes	O
were	O
measured	O
with	O
Vernier	O
calipers	O
and	O
calculated	O
using	O
the	O
following	O
formula	O
:	O
(	O
AxB2	O
)	O
/	O
2	O
,	O
where	O
A	O
is	O
the	O
larger	O
and	O
B	O
is	O
the	O
smaller	O
of	O
the	O
two	O
dimensions	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
the	O
animals	O
were	O
sacrificed	O
.	O

The	O
tumors	O
were	O
separated	O
from	O
the	O
surrounding	O
muscles	O
and	O
dermis	O
.	O

Western	O
Blotting	O

Tumor	O
tissues	O
were	O
homogenized	O
with	O
protein	O
extraction	O
solution	O
(	O
PRO	O
-	O
PREPTM	O
,	O
Intron	O
Biotechnology	O
,	O
Seoul	O
,	O
Korea	O
)	O
,	O
and	O
lysed	O
by	O
60	O
min	O
incubation	O
on	O
ice	O
.	O

The	O
tissue	O
lysate	O
centrifuged	O
at	O
15	O
,	O
000	O
rpm	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

Equal	O
amounts	O
of	O
proteins	O
(	O
40	O
microg	O
)	O
were	O
separated	O
on	O
a	O
SDS	O
/	O
12	O
%	O
-	O
polyacrylamide	O
gel	O
,	O
and	O
then	O
transferred	O
to	O
a	O
polyvinylidene	O
difluoride	O
(	O
PVDF	O
)	O
membrane	O
(	O
GE	O
Water	O
and	O
Process	O
technologies	O
,	O
Trevose	O
,	O
PA	O
,	O
USA	O
)	O
.	O

Blots	O
were	O
blocked	O
for	O
1	O
h	O
at	O
room	O
temperature	O
with	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
non	O
-	O
fat	O
dried	O
milk	O
in	O
Tris	O
-	O
Buffered	O
Saline	O
Tween	O
-	O
20	O
[	O
TBST	O
:	O
10	O
mM	O
Tris	O
(	O
pH	O
8	O
.	O
0	O
)	O
and	O
150	O
mM	O
NaCl	O
solution	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
]	O
.	O

After	O
a	O
short	O
washing	O
in	O
TBST	O
,	O
the	O
membranes	O
were	O
immunoblotted	O
with	O
the	O
following	O
primary	O
antibodies	O
:	O
mouse	O
monoclonal	O
antibodies	O
directed	O
against	O
p65	B-Protein
and	O
p50	B-Protein
(	O
1	O
:	O
500	O
dilutions	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
rabbit	O
polyclonal	O
antibodies	O
directed	O
against	O
Bax	O
and	O
PARP	O
(	O
1	O
:	O
500	O
dilutions	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
and	O
against	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
9	O
,	O
Bcl	O
-	O
2	O
and	O
c	B-Protein
-	I-Protein
IAP	I-Protein
-	I-Protein
1	I-Protein
(	O
1	O
:	O
1000	O
dilutions	O
;	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
MA	O
)	O
.	O

The	O
blots	O
were	O
incubated	O
with	O
the	O
respective	O
horseradish	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
rabbit	O
or	O
anti	O
-	O
mouse	O
IgG	O
(	O
1	O
:	O
4000	O
dilutions	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
.	O

Immunoreactive	O
proteins	O
were	O
detected	O
with	O
the	O
ECL	O
detection	O
system	O
.	O

Immunohistochemistry	O

All	O
specimens	O
were	O
fixed	O
in	O
formalin	O
and	O
embedded	O
in	O
paraffin	O
for	O
examination	O
.	O

Sections	O
(	O
4	O
microm	O
thick	O
)	O
were	O
stained	O
with	O
H	O
&	O
E	O
and	O
analyzed	O
by	O
immunohistochemistry	O
.	O

The	O
paraffin	O
-	O
embedded	O
sections	O
were	O
deparaffinized	O
and	O
rehydrated	O
,	O
washed	O
in	O
distilled	O
water	O
,	O
and	O
then	O
subjected	O
to	O
heat	O
-	O
mediated	O
antigen	O
retrieval	O
.	O

Endogenous	O
peroxidase	O
activity	O
was	O
quenched	O
by	O
incubation	O
in	O
3	O
%	O
hydrogen	O
peroxide	O
in	O
methanol	O
for	O
15	O
min	O
,	O
followed	O
by	O
clearing	O
in	O
PBS	O
for	O
5	O
min	O
.	O

The	O
sections	O
were	O
blocked	O
for	O
30	O
min	O
with	O
3	O
%	O
normal	O
horse	O
serum	O
diluted	O
in	O
PBS	O
,	O
blotted	O
,	O
and	O
incubated	O
with	O
primary	O
mouse	O
anti	O
-	O
mouse	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
,	O
1	O
:	O
200	O
dilution	O
)	O
monoclonal	O
antibodies	O
in	O
blocking	O
serum	O
for	O
4	O
h	O
at	O
room	O
temperature	O
.	O

Thereafter	O
,	O
the	O
slides	O
were	O
washed	O
three	O
times	O
for	O
5	O
min	O
each	O
in	O
PBS	O
and	O
incubated	O
with	O
biotinylated	O
anti	O
-	O
mouse	O
and	O
anti	O
-	O
rabbit	O
antibodies	O
for	O
2	O
h	O
.	O

The	O
slides	O
were	O
washed	O
in	O
PBS	O
,	O
followed	O
by	O
the	O
addition	O
of	O
the	O
avidin	O
biotin	O
peroxidase	O
complex	O
(	O
ABC	O
kit	O
;	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
slides	O
were	O
washed	O
and	O
the	O
peroxidase	O
reaction	O
was	O
developed	O
with	O
diaminobenzidine	O
(	O
DAB	O
)	O
and	O
peroxide	O
,	O
followed	O
by	O
counterstaining	O
with	O
hematoxylin	O
,	O
mounting	O
in	O
aqua	O
-	O
mount	O
,	O
and	O
evaluation	O
under	O
a	O
light	O
microscope	O
(	O
magnificationx200	O
;	O
Olympus	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

A	O
negative	O
control	O
was	O
included	O
in	O
all	O
experiments	O
by	O
omitting	O
the	O
primary	O
antibody	O
.	O

For	O
the	O
detection	O
of	O
apoptotic	O
cell	O
death	O
in	O
the	O
tumor	O
tissues	O
,	O
the	O
paraffin	O
-	O
embedded	O
sections	O
were	O
incubated	O
in	O
a	O
mixture	O
of	O
the	O
labeling	O
solution	O
(	O
540	O
microl	O
)	O
and	O
enzyme	O
solution	O
(	O
60	O
microl	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
,	O
and	O
then	O
washed	O
three	O
times	O
in	O
0	O
.	O
1	O
M	O
PBS	O
for	O
5	O
min	O
each	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Next	O
,	O
the	O
sections	O
were	O
incubated	O
with	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
for	O
15	O
min	O
at	O
37degreesC	O
.	O

Finally	O
,	O
the	O
sections	O
were	O
rinsed	O
,	O
mounted	O
on	O
slides	O
,	O
and	O
cover	O
-	O
slipped	O
for	O
fluorescence	O
microscopy	O
(	O
DAS	O
microscope	O
)	O
.	O

Immunofluorescence	O

Sections	O
were	O
treated	O
with	O
10	O
%	O
bovine	O
serum	O
albumin	O
in	O
PBS	O
for	O
1	O
h	O
at	O
room	O
temperature	O
,	O
incubated	O
overnight	O
at	O
4degreesC	O
with	O
p50	B-Protein
(	O
1	O
:	O
250	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
p65	B-Protein
(	O
1	O
:	O
250	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
Bax	O
(	O
1	O
:	O
200	O
dilution	O
)	O
,	O
cleaved	O
caspase	O
-	O
3	O
(	O
1	O
:	O
100	O
)	O
,	O
CD8	O
(	O
1	O
:	O
10	O
)	O
,	O
CD57	O
(	O
1	O
:	O
50	O
)	O
and	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
(	O
1	O
:	O
500	O
)	O
antibodies	O
,	O
followed	O
by	O
incubation	O
in	O
anti	O
-	O
mouse	O
IgG	O
conjugated	O
with	O
Alexa	O
488	O
(	O
1	O
:	O
100	O
dilution	O
,	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
and	O
anti	O
-	O
rabbit	O
IgG	O
conjugated	O
with	O
Alexa	O
568	O
(	O
1	O
:	O
100	O
dilution	O
,	O
Molecular	O
Probes	O
)	O
for	O
40	O
min	O
at	O
room	O
temperature	O
.	O

Finally	O
,	O
the	O
sections	O
were	O
rinsed	O
,	O
mounted	O
on	O
slides	O
,	O
and	O
cover	O
-	O
slipped	O
for	O
fluorescence	O
microscopy	O
and	O
photography	O
using	O
ApoTome	O
microscopy	O
(	O
Carl	O
Zeiss	O
,	O
Thornwood	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Gel	O
Electromobility	O
Shift	O
Assay	O

A	O
gel	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

The	O
tumor	O
tissues	O
were	O
briefly	O
homogenized	O
in	O
200	O
microl	O
of	O
solution	O
A	O
(	O
10	O
mM	O
HEPES	O
[	O
pH	O
7	O
.	O
9	O
]	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
10	O
mM	O
KCl	O
,	O
0	O
.	O
5	O
mM	O
dithiothreitol	O
,	O
0	O
.	O
2	O
mM	O
phenylmethylsulfonylfluoride	O
)	O
,	O
vortexed	O
vigorously	O
,	O
incubated	O
on	O
ice	O
for	O
10	O
min	O
,	O
and	O
then	O
centrifuged	O
at	O
15000	O
rpm	O
for	O
15	O
min	O
.	O

The	O
pelleted	O
nuclei	O
were	O
resuspended	O
in	O
solution	O
C	O
(	O
solution	O
A	O
supplemented	O
with	O
420	O
mM	O
NaCl	O
and	O
20	O
%	O
glycerol	O
)	O
,	O
and	O
incubated	O
on	O
ice	O
for	O
20	O
min	O
.	O

The	O
resuspended	O
pellet	O
was	O
centrifuged	O
at	O
15000	O
rpm	O
for	O
15	O
min	O
,	O
and	O
the	O
resulting	O
nuclear	O
extracts	O
supernatant	O
were	O
collected	O
in	O
a	O
chilled	O
Eppendorf	O
tube	O
.	O

Consensus	O
oligonucleotides	O
were	O
end	O
-	O
labeled	O
using	O
T4	O
polynucleotide	O
kinase	O
and	O
[	O
P32	O
]	O
-	O
ATP	O
for	O
10	O
min	O
at	O
37degreesC	O
.	O

The	O
gel	O
shift	O
reactions	O
were	O
assembled	O
and	O
incubated	O
at	O
room	O
temperature	O
.	O

Subsequently	O
,	O
1	O
ml	O
of	O
gel	O
loading	O
buffer	O
was	O
added	O
to	O
each	O
reaction	O
and	O
loaded	O
onto	O
a	O
6	O
%	O
non	O
-	O
denaturating	O
gel	O
.	O

The	O
gel	O
was	O
subjected	O
to	O
electrophoresis	O
until	O
the	O
dye	O
was	O
four	O
-	O
fifths	O
of	O
the	O
way	O
down	O
the	O
gel	O
.	O

The	O
gel	O
was	O
dried	O
for	O
1	O
h	O
at	O
80degreesC	O
and	O
exposed	O
to	O
film	O
overnight	O
at	O
-	O
70degreesC	O
.	O

Flow	O
Cytometric	O
Analysis	O

Lymphocytes	O
were	O
obtained	O
from	O
tumor	O
and	O
spleen	O
tissues	O
for	O
phenotype	O
analysis	O
.	O

Spleen	O
and	O
tumor	O
lymphocytes	O
were	O
isolated	O
from	O
fresh	O
spleen	O
and	O
tumor	O
biopsies	O
obtained	O
from	O
three	O
mice	O
per	O
group	O
.	O

Spleen	O
and	O
tumor	O
biopsies	O
were	O
briefly	O
homogenized	O
mechanically	O
in	O
PBS	O
,	O
filtered	O
(	O
100	O
microm	O
cell	O
strainer	O
;	O
BD	O
PharMingen	O
)	O
and	O
then	O
placed	O
in	O
lysis	O
buffer	O
(	O
ACK	O
lysing	O
buffer	O
,	O
LONZA	O
)	O
to	O
remove	O
red	O
blood	O
cells	O
.	O

One	O
million	O
splenocytes	O
were	O
washed	O
once	O
in	O
PBS	O
containing	O
1	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
and	O
re	O
-	O
suspended	O
in	O
100	O
microl	O
of	O
PBS	O
/	O
BSA	O
buffer	O
.	O

Meanwhile	O
,	O
one	O
million	O
cells	O
obtained	O
from	O
tumor	O
tissues	O
were	O
placed	O
in	O
RPMI	O
medium	O
,	O
incubated	O
to	O
obtain	O
suspension	O
cell	O
for	O
1hour	O
at	O
37degreesC	O
,	O
centrifuged	O
(	O
1200	O
rpm	O
,	O
3	O
min	O
)	O
and	O
then	O
washed	O
in	O
PBS	O
.	O

Next	O
,	O
the	O
lymphocytes	O
were	O
incubated	O
with	O
various	O
conjugated	O
monoclonal	O
antibodies	O
,	O
including	O
CD4	B-Protein
-	O
APC	O
,	O
CD8	O
-	O
FITC	O
and	O
CD19	B-Protein
-	O
PE	O
for	O
20min	O
at	O
4degreesC	O
,	O
washed	O
twice	O
in	O
PBS	O
,	O
and	O
re	O
-	O
suspended	O
in	O
400	O
microl	O
of	O
PBS	O
.	O

A	O
flow	O
cytometric	O
analysis	O
was	O
performed	O
on	O
a	O
FACSAria	O
flow	O
cytometry	O
(	O
BD	O
Biosciences	O
)	O
,	O
and	O
the	O
data	O
were	O
analyzed	O
using	O
the	O
WinMDI	O
statistical	O
software	O
(	O
Scripps	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Forward	O
and	O
side	O
scatter	O
parameters	O
were	O
used	O
to	O
gate	O
on	O
lymphocytes	O
.	O

Protein	O
Immuno	O
-	O
arrays	O

The	O
tumor	O
and	O
spleen	O
tissues	O
were	O
excised	O
and	O
homogenized	O
in	O
PBS	O
with	O
protease	O
inhibitor	O
cocktail	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
USA	O
)	O
and	O
Triton	O
X	O
-	O
100	O
(	O
final	O
concentration	O
1	O
%	O
)	O
.	O

The	O
samples	O
were	O
frozen	O
at	O
-	O
70degreesC	O
,	O
thawed	O
,	O
and	O
centrifuged	O
at	O
10	O
,	O
000xg	O
for	O
5	O
min	O
to	O
remove	O
cellular	O
debris	O
.	O

The	O
tissue	O
lysates	O
were	O
performed	O
protein	O
assay	O
in	O
the	O
same	O
way	O
as	O
for	O
western	O
blotting	O
.	O

4	O
.	O
5	O
mg	O
of	O
proteins	O
,	O
collected	O
from	O
three	O
samples	O
per	O
group	O
,	O
were	O
used	O
for	O
Mouse	O
cytokine	O
array	O
as	O
the	O
protocol	O
provided	O
by	O
supplier	O
(	O
Proteome	O
Profiler	O
(	O
TM	O
)	O
,	O
#	O
ARY006	O
,	O
R	O
&	O
D	O
Systems	O
,	O
USA	O
)	O
.	O

Statistical	O
Analysis	O

The	O
data	O
were	O
analyzed	O
using	O
the	O
GraphPad	O
Prism	O
4	O
ver	O
.	O

4	O
.	O
03	O
software	O
(	O
GraphPad	O
Software	O
,	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O

Difference	O
between	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
were	O
compared	O
using	O
t	O
test	O
.	O

A	O
value	O
of	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

Survival	O
data	O
were	O
presented	O
by	O
Kaplan	O
-	O
Meier	O
survival	O
estimates	O
and	O
compared	O
and	O
calculated	O
by	O
Log	O
-	O
rank	O
(	O
Mantel	O
-	O
Cox	O
)	O
Test	O
in	O
GraphPad	O
Prism	O
.	O

Inhibition	O
of	O
tumor	O
development	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

A	O
-	O
C	O
,	O
Tumor	O
images	O
,	O
volumes	O
,	O
and	O
weights	O
.	O

B16	O
melanoma	O
cells	O
(	O
5x105	O
cells	O
/	O
mouse	O
)	O
were	O
inoculated	O
s	O
.	O
c	O
.	O
into	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
n	O
=	O
20	O
)	O
.	O

Tumor	O
volumes	O
were	O
measured	O
every	O
day	O
and	O
tumor	O
weights	O
were	O
measured	O
at	O
study	O
termination	O
(	O
Day	O
31	O
)	O
.	O

The	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
had	O
a	O
significant	O
reduction	O
in	O
tumor	O
growth	O
and	O
volume	O
as	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

The	O
results	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

D	O
,	O
The	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
demonstrated	O
significantly	O
higher	O
survival	O
rates	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
by	O
Log	O
-	O
rank	O
Test	O
)	O
.	O

E	O
.	O

Tumor	O
sections	O
were	O
analyzed	O
by	O
H	O
&	O
E	O
stain	O
and	O
expression	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
by	O
immunohistochemistry	O
.	O

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Scale	O
bar	O
indicates	O
50	O
m	O
.	O

Decrease	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
tumor	O
tissue	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

A	O
,	O
The	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
was	O
determined	O
in	O
the	O
nuclear	O
extracts	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
tumor	O
tissues	O
by	O
EMSA	O
described	O
in	O
material	O
and	O
methods	O
.	O

B	O
,	O
Expression	O
of	O
p50	B-Protein
and	O
p65	B-Protein
phosphorylation	O
in	O
nuclear	O
extracts	O
(	O
NE	O
)	O
,	O
and	O
IkappaB	O
and	O
IkappaB	O
phosphorylation	O
in	O
the	O
cytosol	O
(	O
CE	O
)	O
determined	O
by	O
Western	O
blotting	O
.	O

C	O
,	O
Immunolfluorescence	O
analysis	O
of	O
p50	B-Protein
confirmed	O
that	O
the	O
intensities	O
of	O
nuclear	O
staining	O
for	O
p50	B-Protein
were	O
decreased	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

Induction	O
of	O
apoptotic	O
cell	O
death	O
in	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

A	O
,	O
Apoptotic	O
cells	O
in	O
tumor	O
sections	O
were	O
examined	O
by	O
fluorescence	O
microscopy	O
after	O
DAPI	O
and	O
TUNEL	O
staining	O
as	O
described	O
in	O
material	O
and	O
methods	O
.	O

The	O
apoptotic	O
index	O
was	O
determined	O
as	O
the	O
number	O
of	O
DAPI	O
-	O
stained	O
,	O
TUNEL	O
-	O
positive	O
cells	O
that	O
were	O
counted	O
.	O

Values	O
are	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
statistically	O
significant	O
differences	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

B	O
and	O
C	O
,	O
Apoptotic	O
protein	O
(	O
cleaved	O
caspase	O
-	O
3	O
and	O
Bax	O
)	O
in	O
tumor	O
sections	O
were	O
detected	O
by	O
immunofluorescence	O
assay	O
.	O

The	O
reactive	O
cell	O
number	O
was	O
determined	O
as	O
the	O
number	O
of	O
DAPI	O
-	O
stained	O
,	O
Specific	O
antibody	O
(	O
cleaved	O
caspase	O
-	O
3	O
and	O
Bax	O
)	O
-	O
positive	O
cells	O
that	O
were	O
counted	O
.	O

Values	O
are	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
statistically	O
significant	O
differences	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

D	O
,	O
The	O
expression	O
of	O
apoptotic	O
proteins	O
was	O
detected	O
by	O
Western	O
blotting	O
using	O
specific	O
antibodies	O
;	O
cleaved	O
caspase	O
-	O
3	O
,	O
cleaved	O
caspase	O
-	O
9	O
,	O
cleaved	O
PARP	O
,	O
Bax	O
,	O
Bcl	O
-	O
2	O
and	O
c	B-Protein
-	I-Protein
IAP1	I-Protein
in	O
the	O
tumor	O
tissues	O
.	O

The	O
beta	B-Protein
-	I-Protein
actin	I-Protein
protein	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

Each	O
band	O
is	O
representative	O
of	O
three	O
independent	O
experimental	O
results	O
.	O

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
three	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
tumor	O
and	O
spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

A	O
,	O
Figure	O
4A	O
indicates	O
mouse	O
cytokine	O
array	O
panel	O
coordinates	O
.	O

Nitrocellulose	O
membranes	O
contain	O
40	O
different	O
anti	O
-	O
cytokine	O
antibodies	O
printed	O
in	O
duplicate	O
.	O

B	O
,	O
Mouse	O
cytokine	O
array	O
panel	O
indicate	O
the	O
cytokine	O
expression	O
difference	O
in	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
especially	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
.	O

Representative	O
blot	O
from	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O

Positive	O
controls	O
show	O
the	O
manufacturer	O
'	O
s	O
internal	O
positive	O
control	O
samples	O
on	O
the	O
membrane	O
.	O

C	O
,	O
Protein	O
immune	O
-	O
arrays	O
were	O
performed	O
using	O
Mouse	O
cytokine	O
array	O
in	O
spleen	O
tissues	O
.	O

There	O
were	O
differences	O
in	O
cytokines	O
between	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
especially	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
.	O

Representative	O
blot	O
from	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O

Positive	O
controls	O
show	O
the	O
manufacturer	O
'	O
s	O
internal	O
positive	O
control	O
samples	O
on	O
the	O
membrane	O
.	O

D	O
and	O
E	O
,	O
Immunolfluorescence	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
expression	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
tumor	O
and	O
spleen	O
tissues	O
.	O

The	O
reactive	O
cell	O
number	O
was	O
determined	O
as	O
the	O
number	O
of	O
DAPI	O
-	O
stained	O
,	O
IL	O
-	O
1Ra	O
antibody	O
-	O
positive	O
cells	O
that	O
were	O
counted	O
.	O

Values	O
are	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
statistically	O
significant	O
differences	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

F	O
and	O
G	O
,	O
Expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
was	O
analyzed	O
by	O
western	O
blotting	O
in	O
tumor	O
and	O
spleen	O
tissues	O
.	O

Each	O
band	O
is	O
representative	O
of	O
three	O
independent	O
experimental	O
results	O
.	O

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
three	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Induction	O
of	O
the	O
infiltration	O
of	O
CD8	O
+	O
T	O
cells	O
and	O
NK	O
cells	O
into	O
tumor	O
,	O
and	O
increase	O
in	O
spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

A	O
and	O
B	O
,	O
Immunolfluorescence	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
expression	O
levels	O
of	O
CD8	O
(	O
CD8	O
+	O
cytotoxic	O
T	O
-	O
cell	O
surface	O
marker	O
)	O
and	O
CD57	O
(	O
NK	O
cell	O
marker	O
)	O
in	O
tumor	O
and	O
spleen	O
sections	O
.	O

The	O
images	O
shown	O
are	O
representative	O
of	O
three	O
separate	O
experiments	O
performed	O
in	O
triplicate	O
.	O

Scale	O
bars	O
indicate	O
50	O
microm	O
(	O
A	O
)	O
and	O
100	O
microm	O
(	O
B	O
)	O
.	O

C	O
and	O
D	O
,	O
Analysis	O
of	O
lymphocyte	O
phenotypes	O
.	O

The	O
tumor	O
and	O
spleen	O
tissues	O
were	O
separated	O
at	O
study	O
termination	O
(	O
Day	O
31	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
was	O
performed	O
using	O
FACSAria	O
flow	O
cytometry	O
,	O
and	O
represent	O
data	O
were	O
shown	O
.	O

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

Akt	O
Regulates	O
TNFalpha	B-Protein
Synthesis	O
Downstream	O
of	O
RIP1	B-Protein
Kinase	O
Activation	O
during	O
Necroptosis	O

Necroptosis	O
is	O
a	O
regulated	O
form	O
of	O
necrotic	O
cell	O
death	O
that	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
various	O
diseases	O
including	O
intestinal	O
inflammation	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
signaling	O
mechanisms	O
controlled	O
by	O
the	O
necroptosis	O
mediator	O
receptor	B-Protein
interacting	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
RIP1	B-Protein
)	O
kinase	O
.	O

We	O
show	O
that	O
Akt	O
kinase	O
activity	O
is	O
critical	O
for	O
necroptosis	O
in	O
L929	O
cells	O
and	O
plays	O
a	O
key	O
role	O
in	O
TNFalpha	B-Protein
production	O
.	O

During	O
necroptosis	O
,	O
Akt	O
is	O
activated	O
in	O
a	O
RIP1	B-Protein
dependent	O
fashion	O
through	O
its	O
phosphorylation	O
on	O
Thr308	O
.	O

In	O
L929	O
cells	O
,	O
this	O
activation	O
requires	O
independent	O
signaling	O
inputs	O
from	O
both	O
growth	O
factors	O
and	O
RIP1	B-Protein
.	O

Akt	O
controls	O
necroptosis	O
through	O
downstream	O
targeting	O
of	O
mammalian	O
Target	O
of	O
Rapamycin	O
complex	O
1	O
(	O
mTORC1	O
)	O
.	O

Akt	O
activity	O
,	O
mediated	O
in	O
part	O
through	O
mTORC1	O
,	O
links	O
RIP1	B-Protein
to	O
JNK	O
activation	O
and	O
autocrine	O
production	O
of	O
TNFalpha	B-Protein
.	O

In	O
other	O
cell	O
types	O
,	O
such	O
as	O
mouse	O
lung	O
fibroblasts	O
and	O
macrophages	O
,	O
Akt	O
exhibited	O
control	O
over	O
necroptosis	O
-	O
associated	O
TNFalpha	B-Protein
production	O
without	O
contributing	O
to	O
cell	O
death	O
.	O

Overall	O
,	O
our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
mechanism	O
of	O
necroptosis	O
and	O
the	O
role	O
of	O
Akt	O
kinase	O
in	O
both	O
cell	O
death	O
and	O
inflammatory	O
regulation	O
.	O

Necroptosis	O
is	O
a	O
form	O
of	O
regulated	O
cell	O
death	O
that	O
displays	O
all	O
the	O
major	O
hallmarks	O
of	O
necrosis	O
[	O
1	O
]	O
.	O

A	O
growing	O
number	O
of	O
studies	O
have	O
implicated	O
necroptosis	O
in	O
a	O
wide	O
range	O
of	O
animal	O
models	O
of	O
human	O
disease	O
,	O
including	O
brain	O
,	O
heart	O
and	O
retinal	O
ischemia	O
-	O
reperfusion	O
injury	O
,	O
acute	O
pancreatitis	O
,	O
brain	O
trauma	O
,	O
retinal	O
detachment	O
,	O
and	O
Huntington	O
'	O
s	O
disease	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

Importantly	O
,	O
several	O
recent	O
studies	O
have	O
linked	O
necroptosis	O
to	O
models	O
of	O
inflammation	O
including	O
intestinal	O
inflammation	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
.	O

The	O
discovery	O
of	O
a	O
regulated	O
form	O
of	O
necrotic	O
death	O
could	O
uncover	O
molecular	O
targets	O
amenable	O
to	O
pharmacological	O
intervention	O
for	O
the	O
treatment	O
of	O
various	O
conditions	O
.	O

A	O
complex	O
consisting	O
of	O
two	O
related	O
Ser	O
/	O
Thr	O
kinases	O
,	O
RIP1	B-Protein
and	O
RIP3	B-Protein
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
initiation	O
of	O
necroptosis	O
in	O
multiple	O
systems	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

A	O
recent	O
genome	O
wide	O
siRNA	O
screen	O
for	O
mediators	O
of	O
necroptosis	O
induced	O
by	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
zVAD	O
.	O
fmk	O
in	O
mouse	O
fibrosarcoma	O
L929	O
cells	O
,	O
revealed	O
a	O
broad	O
and	O
diverse	O
cellular	O
network	O
of	O
432	O
genes	O
that	O
may	O
regulate	O
this	O
process	O
[	O
10	O
]	O
.	O

These	O
data	O
provided	O
important	O
confirmation	O
of	O
the	O
highly	O
regulated	O
nature	O
of	O
necroptosis	O
and	O
revealed	O
the	O
first	O
insight	O
into	O
the	O
full	O
repertoire	O
of	O
mediators	O
of	O
this	O
form	O
of	O
cell	O
death	O
.	O

However	O
,	O
the	O
specific	O
signaling	O
pathways	O
activated	O
during	O
necroptosis	O
and	O
their	O
connections	O
to	O
RIP1	B-Protein
and	O
RIP3	B-Protein
remain	O
poorly	O
understood	O
.	O

Several	O
recent	O
studies	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
,	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
have	O
suggested	O
that	O
JNK	O
kinase	O
activation	O
plays	O
an	O
important	O
role	O
during	O
necroptosis	O
in	O
L929	O
cells	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
.	O

For	O
example	O
,	O
the	O
transcription	O
factor	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
a	O
key	O
cellular	O
target	O
of	O
JNK	O
activity	O
,	O
was	O
one	O
of	O
the	O
hits	O
in	O
the	O
genome	O
wide	O
siRNA	O
screen	O
[	O
10	O
]	O
.	O

Activation	O
of	O
JNK	O
in	O
L929	O
cells	O
has	O
been	O
linked	O
to	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
,	O
activation	O
of	O
oxidative	O
stress	O
and	O
induction	O
of	O
autophagy	O
,	O
all	O
of	O
which	O
contribute	O
to	O
necroptosis	O
.	O

Importantly	O
,	O
RIP1	B-Protein
kinase	O
dependent	O
activation	O
of	O
JNK	O
and	O
TNFalpha	B-Protein
production	O
has	O
recently	O
been	O
described	O
to	O
be	O
independent	O
of	O
its	O
role	O
in	O
necroptosis	O
[	O
15	O
]	O
.	O

Curiously	O
,	O
Akt	O
kinase	O
,	O
a	O
key	O
pro	O
-	O
survival	O
molecule	O
and	O
a	O
well	O
-	O
established	O
inhibitor	O
of	O
apoptotic	O
cell	O
death	O
,	O
has	O
also	O
recently	O
been	O
linked	O
to	O
necroptosis	O
in	O
L929	O
cells	O
[	O
16	O
]	O
,	O
where	O
insulin	B-Protein
-	O
dependent	O
activation	O
of	O
Akt	O
was	O
suggested	O
to	O
promote	O
necroptosis	O
by	O
suppressing	O
autophagy	O
.	O

This	O
conclusion	O
was	O
unexpected	O
,	O
since	O
several	O
reports	O
from	O
different	O
groups	O
,	O
including	O
ours	O
,	O
have	O
established	O
that	O
autophagy	O
promotes	O
,	O
rather	O
than	O
suppresses	O
,	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
in	O
L929	O
cells	O
[	O
11	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
17	O
]	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
Akt	O
controls	O
more	O
general	O
mechanisms	O
that	O
contribute	O
to	O
the	O
execution	O
of	O
necroptosis	O
.	O

Furthermore	O
,	O
the	O
key	O
question	O
of	O
whether	O
insulin	B-Protein
-	O
dependent	O
Akt	O
activity	O
solely	O
provides	O
an	O
environment	O
conducive	O
for	O
necroptosis	O
or	O
if	O
Akt	O
activation	O
is	O
an	O
intrinsic	O
component	O
of	O
necroptosis	O
signaling	O
that	O
is	O
linked	O
to	O
RIP1	B-Protein
kinase	O
has	O
not	O
been	O
explored	O
.	O

In	O
this	O
study	O
,	O
we	O
expanded	O
these	O
observations	O
to	O
delineate	O
the	O
specific	O
contributions	O
and	O
molecular	O
ordering	O
of	O
the	O
Akt	O
and	O
JNK	O
pathways	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
during	O
necroptosis	O
.	O

Our	O
data	O
reveal	O
that	O
Akt	O
is	O
activated	O
through	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
Thr308	O
phosphorylation	O
during	O
necroptosis	O
in	O
multiple	O
cell	O
types	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
downstream	O
Akt	O
signaling	O
through	O
mTORC1	O
and	O
S6	B-Protein
contributes	O
to	O
the	O
activation	O
of	O
necroptosis	O
and	O
TNFalpha	B-Protein
production	O
.	O

We	O
found	O
that	O
the	O
Akt	O
pathway	O
serves	O
as	O
a	O
critical	O
link	O
between	O
RIP1	B-Protein
kinase	O
and	O
JNK	O
activation	O
in	O
L929	O
cells	O
.	O

Further	O
data	O
suggested	O
that	O
in	O
multiple	O
other	O
cell	O
types	O
including	O
FADD	B-Protein
deficient	O
Jurkat	O
cells	O
,	O
RAW	O
and	O
J774	O
.	O
1	O
macrophage	O
cell	O
lines	O
,	O
and	O
mouse	O
lung	O
fibroblasts	O
Akt	O
provides	O
a	O
key	O
link	O
to	O
TNFalpha	B-Protein
production	O
,	O
but	O
is	O
dispensible	O
for	O
cell	O
death	O
per	O
se	O
.	O

Overall	O
,	O
our	O
results	O
reveal	O
a	O
specific	O
and	O
novel	O
role	O
for	O
the	O
Akt	O
pathway	O
in	O
regulated	O
necrosis	O
and	O
necrosis	O
-	O
associated	O
inflammatory	O
signaling	O
.	O

Basic	B-Protein
Fibroblast	I-Protein
Growth	I-Protein
Factor	I-Protein
Promotes	O
Necroptosis	O
in	O
L929	O
Cells	O

It	O
has	O
been	O
established	O
that	O
mouse	O
fibrosarcoma	O
L929	O
cells	O
undergo	O
necroptotic	O
cell	O
death	O
following	O
stimulation	O
with	O
TNFalpha	B-Protein
[	O
10	O
]	O
,	O
[	O
17	O
]	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
caspase	B-Protein
-	I-Protein
8	I-Protein
activity	O
alone	O
,	O
either	O
through	O
siRNA	O
knockdown	O
or	O
by	O
using	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
,	O
zVAD	O
.	O
fmk	O
,	O
is	O
sufficient	O
to	O
trigger	O
necroptosis	O
in	O
these	O
cells	O
[	O
10	O
]	O
,	O
[	O
14	O
]	O
.	O

Interestingly	O
,	O
while	O
necroptosis	O
was	O
initially	O
identified	O
as	O
a	O
back	O
-	O
up	O
form	O
of	O
cell	O
death	O
triggered	O
by	O
pro	O
-	O
apoptotic	O
stimuli	O
in	O
the	O
presence	O
of	O
apoptosis	O
inhibitors	O
[	O
17	O
]	O
,	O
recent	O
analysis	O
of	O
physiological	O
cell	O
death	O
during	O
mouse	O
development	O
has	O
suggested	O
that	O
the	O
loss	O
of	O
apoptotic	O
regulators	O
,	O
such	O
as	O
caspase	B-Protein
-	I-Protein
8	I-Protein
and	O
FADD	B-Protein
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
,	O
leads	O
to	O
robust	O
induction	O
of	O
necroptosis	O
and	O
death	O
of	O
E10	O
.	O
5	O
embryos	O
even	O
though	O
apoptosis	O
is	O
not	O
normally	O
induced	O
in	O
wild	O
type	O
embryos	O
.	O

These	O
data	O
are	O
reminiscent	O
of	O
the	O
observations	O
in	O
L929	O
cells	O
where	O
the	O
loss	O
of	O
caspase	O
activity	O
in	O
healthy	O
cells	O
is	O
sufficient	O
to	O
trigger	O
necroptosis	O
and	O
prompted	O
us	O
to	O
explore	O
the	O
extrinsic	O
or	O
intrinsic	O
cellular	O
factors	O
that	O
promote	O
necroptosis	O
once	O
caspase	B-Protein
-	I-Protein
8	I-Protein
activity	O
,	O
which	O
cleaves	O
and	O
inactivates	O
RIP1	B-Protein
kinase	O
and	O
the	O
RIP1	B-Protein
deubiquitinase	I-Protein
CYLD	B-Protein
[	O
21	O
]	O
,	O
[	O
22	O
]	O
,	O
is	O
removed	O
in	O
L929	O
cells	O
.	O

Consistent	O
with	O
a	O
previous	O
report	O
[	O
16	O
]	O
,	O
we	O
found	O
that	O
serum	O
starvation	O
of	O
L929	O
cells	O
prevented	O
necroptosis	O
in	O
response	O
to	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

The	O
addition	O
of	O
growth	O
factors	O
,	O
such	O
as	O
bFGF	B-Protein
,	O
restored	O
zVAD	O
.	O
fmk	O
induced	O
death	O
under	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Interestingly	O
,	O
this	O
does	O
not	O
reflect	O
a	O
generic	O
requirement	O
for	O
growth	O
factor	O
signaling	O
,	O
as	O
only	O
some	O
growth	O
factors	O
(	O
bFGF	B-Protein
and	O
IGF	B-Protein
-	I-Protein
1	I-Protein
,	O
but	O
not	O
EGF	B-Protein
and	O
PDGF	O
)	O
promoted	O
death	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Furthermore	O
,	O
growth	O
factor	O
-	O
dependent	O
necroptosis	O
required	O
the	O
inhibition	O
of	O
caspase	O
activity	O
,	O
as	O
bFGF	B-Protein
alone	O
did	O
not	O
induce	O
cell	O
death	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

In	O
contrast	O
,	O
TNFalpha	B-Protein
triggered	O
necroptosis	O
equally	O
efficiently	O
in	O
the	O
absence	O
of	O
serum	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
suggesting	O
that	O
either	O
growth	O
factors	O
and	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
are	O
required	O
for	O
necroptotic	O
death	O
in	O
L929	O
cells	O
.	O

Previously	O
we	O
described	O
the	O
development	O
of	O
7	O
-	O
Cl	O
-	O
O	O
-	O
Nec	O
-	O
1	O
(	O
Nec	O
-	O
1	O
)	O
as	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
RIP1	B-Protein
kinase	O
and	O
necroptosis	O
(	O
Fig	O
.	O
S1A	O
)	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

Recently	O
,	O
its	O
selectivity	O
has	O
been	O
further	O
validated	O
against	O
a	O
panel	O
of	O
more	O
than	O
400	O
human	O
kinases	O
[	O
15	O
]	O
.	O

This	O
inhibitor	O
efficiently	O
blocked	O
growth	O
factor	O
/	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
under	O
serum	O
free	O
conditions	O
in	O
L929	O
cells	O
and	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
-	O
induced	O
necroptosis	O
under	O
full	O
serum	O
conditions	O
(	O
Fig	O
.	O
1B	O
,	O
S1B	O
)	O
.	O

To	O
further	O
validate	O
the	O
role	O
of	O
RIP1	B-Protein
,	O
we	O
used	O
an	O
inactive	O
analog	O
,	O
7	O
-	O
Cl	O
-	O
O	O
-	O
Nec	O
-	O
1i	O
(	O
Nec	O
-	O
1i	O
)	O
(	O
Fig	O
.	O
S1A	O
)	O
,	O
which	O
contains	O
an	O
extra	O
N	O
-	O
methyl	O
group	O
that	O
leads	O
to	O
almost	O
complete	O
loss	O
of	O
RIP1	B-Protein
kinase	O
inhibitory	O
activity	O
in	O
vitro	O
[	O
23	O
]	O
.	O

Nec	O
-	O
1i	O
was	O
unable	O
to	O
protect	O
L929	O
cell	O
death	O
under	O
serum	O
condtions	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
(	O
Fig	O
.	O
S1B	O
)	O
or	O
serum	O
free	O
conditions	O
treated	O
with	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
S1C	O
)	O
.	O

This	O
confirms	O
that	O
RIP1	B-Protein
kinase	O
is	O
responsible	O
for	O
necroptosis	O
in	O
L929	O
cells	O
under	O
both	O
serum	O
and	O
serum	O
free	O
conditions	O
.	O

We	O
next	O
examined	O
whether	O
bFGF	B-Protein
contributes	O
to	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
under	O
normal	O
serum	O
conditions	O
(	O
10	O
%	O
FBS	O
)	O
.	O

We	O
used	O
two	O
bFGF	B-Protein
receptor	I-Protein
tyrosine	I-Protein
kinase	I-Protein
inhibitors	O
(	O
PD173074	O
and	O
PD166866	O
)	O
,	O
and	O
determined	O
that	O
inhibition	O
of	O
bFGF	B-Protein
signaling	O
strongly	O
inhibited	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
under	O
normal	O
serum	O
conditions	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

In	O
contrast	O
,	O
neither	O
bFGF	B-Protein
receptor	I-Protein
inhibitor	O
was	O
able	O
to	O
attenuate	O
TNFalpha	B-Protein
-	O
induced	O
necroptosis	O
(	O
Fig	O
.	O
1D	O
)	O
,	O
consistent	O
with	O
growth	O
factors	O
being	O
dispensable	O
for	O
this	O
pathway	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Overall	O
,	O
these	O
data	O
suggest	O
that	O
the	O
induction	O
of	O
necroptosis	O
by	O
zVAD	O
.	O
fmk	O
is	O
promoted	O
by	O
bFGF	B-Protein
under	O
both	O
serum	O
and	O
serum	O
free	O
conditions	O
.	O

The	O
induction	O
of	O
necroptosis	O
,	O
however	O
,	O
is	O
not	O
a	O
simple	O
consequence	O
of	O
growth	O
factor	O
signaling	O
since	O
not	O
all	O
growth	O
factors	O
allowed	O
death	O
to	O
occur	O
.	O

Instead	O
,	O
specific	O
signaling	O
events	O
mediated	O
by	O
particular	O
growth	O
factors	O
appear	O
to	O
contribute	O
to	O
necroptotic	O
death	O
.	O

RIP1	B-Protein
Kinase	O
-	O
dependent	O
Activation	O
of	O
Akt	O
Contributes	O
to	O
Necroptosis	O

Given	O
our	O
observation	O
that	O
growth	O
factors	O
are	O
important	O
for	O
zVAD	O
.	O
fmk	O
induced	O
death	O
,	O
we	O
examined	O
the	O
contribution	O
of	O
several	O
pathways	O
,	O
including	O
MAPK	O
pathways	O
and	O
Akt	O
,	O
which	O
are	O
known	O
to	O
be	O
activated	O
following	O
growth	O
factor	O
receptor	O
activation	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Inhibition	O
of	O
Akt	O
(	O
Akt	O
inhibitor	O
VIII	O
)	O
strongly	O
protected	O
the	O
cells	O
from	O
growth	O
factor	O
-	O
sensitive	O
necroptosis	O
induced	O
by	O
zVAD	O
.	O
fmk	O
[	O
16	O
]	O
as	O
well	O
as	O
cell	O
death	O
triggered	O
by	O
bFGF	B-Protein
or	O
IGF	B-Protein
-	I-Protein
1	I-Protein
/	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Inhibition	O
of	O
Akt	O
also	O
protected	O
the	O
cells	O
from	O
growth	O
-	O
factor	O
insensitive	O
death	O
by	O
caused	O
by	O
TNFalpha	B-Protein
(	O
Fig	O
.	O
2A	O
)	O
.	O

Consistent	O
with	O
previous	O
reports	O
,	O
the	O
JNK	O
inhibitor	O
SP600125	O
protected	O
the	O
cells	O
from	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
induced	O
death	O
(	O
Fig	O
.	O
2A	O
,	O
B	O
and	O
Fig	O
.	O
S2A	O
)	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
two	O
other	O
MAPKs	O
,	O
p38	O
and	O
ERK	O
,	O
previously	O
reported	O
not	O
to	O
be	O
activated	O
during	O
necroptosis	O
[	O
14	O
]	O
,	O
did	O
not	O
protect	O
from	O
either	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
induced	O
death	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Next	O
,	O
we	O
used	O
two	O
approaches	O
to	O
further	O
validate	O
the	O
role	O
of	O
Akt	O
in	O
necroptotic	O
cell	O
death	O
.	O

First	O
,	O
two	O
additional	O
Akt	O
inhibitors	O
,	O
a	O
highly	O
specific	O
,	O
allosteric	O
kinase	O
inhibitor	O
MK	O
-	O
2206	O
[	O
25	O
]	O
and	O
triciribine	O
(	O
TCN	O
)	O
[	O
26	O
]	O
,	O
which	O
blocks	O
membrane	O
translocation	O
of	O
Akt	O
,	O
both	O
attenuated	O
cell	O
death	O
(	O
Fig	O
.	O
S2B	O
)	O
.	O

Secondly	O
,	O
simultaneous	O
knockdown	O
of	O
Akt	O
isoforms	O
Akt1	B-Protein
and	O
Akt2	B-Protein
using	O
siRNAs	O
protected	O
cells	O
from	O
necroptosis	O
induced	O
by	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
(	O
Fig	O
.	O
2C	O
)	O
.	O

No	O
expression	O
of	O
Akt3	B-Protein
was	O
seen	O
in	O
L929	O
cells	O
(	O
Fig	O
.	O
S2C	O
)	O
and	O
,	O
consistently	O
,	O
Akt3	B-Protein
siRNA	I-Protein
had	O
no	O
additional	O
effect	O
on	O
necroptosis	O
.	O

Our	O
results	O
confirmed	O
that	O
Akt	O
plays	O
a	O
key	O
role	O
in	O
necroptosis	O
induced	O
by	O
multiple	O
stimuli	O
in	O
L929	O
cells	O
.	O

To	O
understand	O
the	O
activation	O
of	O
Akt	O
and	O
JNK	O
under	O
necroptotic	O
conditions	O
,	O
we	O
examined	O
the	O
changes	O
in	O
Akt	O
and	O
JNK	O
phosphorylation	O
at	O
9	O
hrs	O
post	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
stimulation	O
.	O

This	O
time	O
point	O
was	O
chosen	O
because	O
it	O
reflects	O
the	O
early	O
stage	O
of	O
cell	O
death	O
in	O
our	O
system	O
(	O
Fig	O
.	O
S3A	O
,	O
B	O
)	O
.	O

Following	O
stimulation	O
with	O
either	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
we	O
observed	O
a	O
robust	O
increase	O
in	O
Akt	O
phosphorylation	O
at	O
a	O
known	O
major	O
activation	O
site	O
,	O
Thr308	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

Interestingly	O
,	O
we	O
did	O
not	O
observe	O
concomitant	O
phosphorylation	O
changes	O
in	O
the	O
second	O
major	O
activation	O
site	O
of	O
Akt	O
,	O
Ser473	O
.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
the	O
phosphorylation	O
of	O
both	O
the	O
p46	B-Protein
and	O
p54	B-Protein
isoforms	O
of	O
JNK	O
and	O
its	O
major	O
substrate	O
c	B-Protein
-	I-Protein
Jun	I-Protein
(	O
Fig	O
.	O
3A	O
)	O
.	O

These	O
data	O
indicate	O
that	O
both	O
Akt	O
and	O
JNK	O
are	O
activated	O
under	O
necroptotic	O
conditions	O
.	O

The	O
RIP1	B-Protein
kinase	O
inhibitor	O
,	O
Nec	O
-	O
1	O
,	O
completely	O
prevented	O
the	O
increase	O
in	O
Thr308	O
Akt	B-Protein
phosphorylation	O
,	O
while	O
Nec	O
-	O
1i	O
did	O
not	O
(	O
Fig	O
.	O
3A	O
,	O
Fig	O
.	O
S1D	O
)	O
.	O

Similarly	O
,	O
Nec	O
-	O
1	O
prevented	O
the	O
induction	O
of	O
JNK	O
phosphorylation	O
in	O
response	O
to	O
zVAD	O
.	O
fmk	O
and	O
substantially	O
reduced	O
this	O
change	O
after	O
TNFalpha	B-Protein
addition	O
.	O

We	O
observed	O
some	O
changes	O
in	O
total	O
protein	O
levels	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
following	O
necroptotic	O
stimulation	O
.	O

Some	O
of	O
these	O
changes	O
,	O
e	O
.	O
g	O
.	O
zVAD	O
.	O
fmk	O
-	O
induced	O
increase	O
in	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
were	O
also	O
attenuated	O
by	O
Nec	O
-	O
1	O
.	O

Importantly	O
,	O
Nec	O
-	O
1	O
did	O
not	O
alter	O
the	O
basal	O
phosphorylation	O
levels	O
of	O
either	O
Akt	O
or	O
JNK	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

This	O
established	O
that	O
Akt	O
Thr308	O
and	O
JNK	O
phosphorylation	O
during	O
necroptosis	O
is	O
RIP1	B-Protein
dependent	O
.	O

Interestingly	O
,	O
we	O
discovered	O
that	O
the	O
phosphorylation	O
of	O
Akt	O
Thr308	O
,	O
JNK	O
and	O
Jun	O
are	O
late	O
events	O
following	O
zVAD	O
.	O
fmk	O
stimulation	O
(	O
Fig	O
.	O
3B	O
)	O
that	O
coincide	O
with	O
the	O
onset	O
of	O
necroptosis	O
at	O
6	O
hr	O
post	O
-	O
stimulation	O
(	O
Fig	O
.	O
S3A	O
)	O
.	O

To	O
better	O
understand	O
the	O
contributions	O
of	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
to	O
necroptotic	O
regulation	O
of	O
Akt	O
,	O
we	O
next	O
analyzed	O
the	O
time	O
course	O
of	O
these	O
phosphorylation	O
changes	O
under	O
serum	O
free	O
conditions	O
.	O

We	O
found	O
that	O
the	O
addition	O
of	O
bFGF	B-Protein
alone	O
or	O
in	O
combination	O
with	O
zVAD	O
.	O
fmk	O
led	O
to	O
a	O
substantial	O
rapid	O
and	O
transient	O
increase	O
in	O
both	O
Thr308	O
and	O
Ser473	O
phosphorylation	O
of	O
Akt	O
as	O
well	O
as	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
at	O
15	O
minutes	O
,	O
reflecting	O
the	O
expected	O
response	O
to	O
growth	O
factor	O
stimulation	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

Significantly	O
,	O
the	O
combination	O
of	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
,	O
but	O
not	O
bFGF	B-Protein
alone	O
,	O
also	O
caused	O
a	O
robust	O
,	O
second	O
,	O
delayed	O
increase	O
in	O
the	O
phosphorylation	O
of	O
Thr308	O
,	O
but	O
not	O
Ser473	O
,	O
of	O
Akt	O
as	O
well	O
as	O
a	O
delayed	O
increase	O
in	O
the	O
phosphorylation	O
of	O
JNK	O
and	O
Jun	O
.	O

Furthermore	O
,	O
Nec	O
-	O
1	O
had	O
no	O
significant	O
effect	O
on	O
the	O
early	O
increase	O
in	O
both	O
Akt	O
and	O
JNK	O
/	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
triggered	O
by	O
both	O
bFGF	B-Protein
and	O
bFGF	B-Protein
/	O
zVAD	O
,	O
while	O
Nec	O
-	O
1	O
,	O
but	O
not	O
its	O
inactive	O
analog	O
Nec	O
-	O
1i	O
(	O
Fig	O
.	O
S1E	O
)	O
,	O
efficiently	O
blocked	O
the	O
bFGF	B-Protein
/	O
zVAD	O
increase	O
at	O
6	O
-	O
9	O
hr	O
(	O
Fig	O
.	O
3D	O
)	O
,	O
suggesting	O
that	O
only	O
the	O
delayed	O
activation	O
of	O
Akt	O
and	O
JNK	O
is	O
specific	O
for	O
necroptosis	O
and	O
dependent	O
on	O
RIP1	B-Protein
kinase	O
activity	O
.	O

Similarly	O
,	O
IGF	O
/	O
zVAD	O
,	O
which	O
also	O
promoted	O
cell	O
death	O
under	O
serum	O
free	O
conditions	O
,	O
produced	O
a	O
delayed	O
increase	O
in	O
Thr308	O
phosphorylation	O
on	O
Akt	O
,	O
while	O
IGF	O
alone	O
caused	O
solely	O
an	O
early	O
,	O
transient	O
increase	O
in	O
phosphorylation	O
(	O
Fig	O
.	O
S3C	O
)	O
.	O

We	O
confirmed	O
the	O
kinetics	O
of	O
the	O
Akt	O
Thr308	O
and	O
Ser473	O
phosphorylation	O
changes	O
using	O
a	O
quantitative	O
ELISA	O
assay	O
,	O
which	O
also	O
showed	O
a	O
robust	O
delayed	O
necroptosis	O
-	O
specific	O
RIP1	B-Protein
-	O
dependent	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
S3D	O
,	O
E	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
observed	O
delayed	O
increases	O
in	O
Akt	O
and	O
JNK	O
phosphorylation	O
,	O
preceding	O
the	O
onset	O
of	O
cell	O
death	O
,	O
represent	O
specific	O
consequences	O
of	O
necroptotic	O
signaling	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
.	O

TNFalpha	B-Protein
Induces	O
Delayed	O
Akt	O
Thr308	O
Phosphorylation	O
and	O
Necroptosis	O
Independent	O
of	O
Growth	O
Factor	O
Stimulation	O

Consistent	O
with	O
TNFalpha	B-Protein
inducing	O
necroptosis	O
independently	O
of	O
growth	O
factors	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
FGFR	O
inhibitors	O
did	O
not	O
attenuate	O
TNFalpha	B-Protein
-	O
induced	O
changes	O
in	O
Akt	O
or	O
JNK	O
phosphorylation	O
,	O
while	O
efficiently	O
preventing	O
these	O
changes	O
in	O
response	O
to	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
S4A	O
)	O
.	O

Furthermore	O
,	O
addition	O
of	O
TNFalpha	B-Protein
led	O
to	O
comparable	O
late	O
activation	O
of	O
Akt	O
p308	O
signal	O
under	O
both	O
normal	O
and	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
S4B	O
,	O
C	O
)	O
,	O
indicating	O
that	O
TNFalpha	B-Protein
signaling	O
to	O
Akt	O
Thr308	O
is	O
growth	O
factor	O
-	O
independent	O
.	O

In	O
contrast	O
,	O
activation	O
of	O
JNK	O
by	O
TNFalpha	B-Protein
followed	O
different	O
kinetics	O
from	O
zVAD	O
.	O
fmk	O
-	O
induced	O
changes	O
.	O

TNFalpha	B-Protein
treatment	O
caused	O
an	O
early	O
and	O
robust	O
increase	O
in	O
the	O
phosphorylation	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
.	O

Nec	O
-	O
1	O
did	O
not	O
affect	O
this	O
early	O
increase	O
,	O
however	O
,	O
it	O
reduced	O
levels	O
of	O
pJNK	O
/	O
Jun	O
at	O
the	O
late	O
,	O
9	O
hr	O
time	O
point	O
(	O
Fig	O
.	O
S4B	O
,	O
C	O
)	O
.	O

This	O
again	O
separated	O
early	O
RIP1	B-Protein
-	O
independent	O
changes	O
,	O
which	O
likely	O
reflect	O
the	O
ability	O
of	O
additional	O
upstream	O
kinases	O
,	O
such	O
as	O
Ask1	B-Protein
to	O
activate	O
JNK	O
[	O
27	O
]	O
,	O
from	O
the	O
late	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
necroptotic	O
signaling	O
.	O

Late	O
Increase	O
in	O
Akt	O
Thr308	O
Phosphorylation	O
Contributes	O
to	O
the	O
Induction	O
of	O
Necroptotic	O
Cell	O
Death	O

We	O
next	O
investigated	O
if	O
the	O
delayed	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
functionally	O
contributes	O
to	O
the	O
execution	O
of	O
necroptotic	O
cell	O
death	O
.	O

Firstly	O
,	O
PDGF	O
/	O
zVAD	O
.	O
fmk	O
,	O
which	O
cannot	O
induce	O
necroptosis	O
(	O
Fig	O
.	O
2A	O
)	O
,	O
triggered	O
only	O
the	O
initial	O
,	O
rapid	O
Akt	O
and	O
JNK	O
phosphorylation	O
changes	O
and	O
not	O
the	O
delayed	O
activation	O
(	O
Fig	O
.	O
4A	O
)	O
,	O
indicating	O
that	O
late	O
,	O
rather	O
than	O
early	O
Akt	O
phosphorylation	O
correlates	O
with	O
necroptosis	O
.	O

Secondly	O
,	O
we	O
saw	O
that	O
the	O
ability	O
of	O
the	O
Akt	O
inhibitor	O
to	O
protect	O
cells	O
from	O
necroptosis	O
rapidly	O
declined	O
after	O
6	O
hrs	O
of	O
stimulation	O
with	O
zVAD	O
.	O
fmk	O
,	O
TNFalpha	B-Protein
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
and	O
no	O
protection	O
was	O
observed	O
when	O
the	O
inhibitor	O
was	O
added	O
at	O
9	O
hrs	O
(	O
Fig	O
.	O
4B	O
,	O
C	O
)	O
.	O

This	O
time	O
frame	O
coincides	O
with	O
the	O
timing	O
of	O
the	O
secondary	O
Akt	O
Thr308	O
phosphorylation	O
.	O

Finally	O
,	O
we	O
terminated	O
the	O
bFGF	B-Protein
signal	O
one	O
hour	O
after	O
addition	O
of	O
bFGF	B-Protein
by	O
the	O
addition	O
of	O
PD173074	O
.	O

This	O
allowed	O
us	O
to	O
retain	O
early	O
Akt	O
activation	O
,	O
but	O
to	O
suppress	O
the	O
secondary	O
increase	O
(	O
Fig	O
.	O
4D	O
)	O
.	O

Both	O
pre	O
-	O
addition	O
and	O
delayed	O
addition	O
of	O
PD173074	O
fully	O
prevented	O
necroptosis	O
(	O
Fig	O
.	O
4E	O
)	O
.	O

Overall	O
,	O
these	O
data	O
,	O
while	O
correlative	O
,	O
indicate	O
that	O
early	O
Akt	O
activation	O
is	O
insufficient	O
to	O
promote	O
necroptosis	O
and	O
are	O
strongly	O
supportive	O
of	O
an	O
important	O
role	O
for	O
the	O
delayed	O
activation	O
of	O
Akt	O
in	O
the	O
induction	O
of	O
necroptotic	O
cell	O
death	O
.	O

The	O
Akt	O
Signaling	O
Pathway	O
Contributes	O
to	O
the	O
Regulation	O
of	O
Necroptosis	O

We	O
next	O
determined	O
whether	O
the	O
necroptosis	O
-	O
associated	O
increase	O
in	O
Thr308	O
phosphorylation	O
results	O
in	O
an	O
increase	O
in	O
Akt	O
kinase	O
activity	O
.	O

Under	O
necroptotic	O
conditions	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
phosphorylation	O
of	O
multiple	O
known	O
Akt	O
substrates	O
(	O
Forkhead	O
box	O
class	O
O	O
(	O
FoxO	O
)	O
proteins	O
,	O
GSK	O
-	O
3	O
kinases	O
and	O
mouse	O
double	B-Protein
minute	I-Protein
2	I-Protein
(	O
MDM2	B-Protein
)	O
)	O
as	O
well	O
as	O
downstream	O
molecules	O
(	O
p70	B-Protein
ribosomal	I-Protein
protein	I-Protein
S6	I-Protein
Kinase	I-Protein
(	O
p70S6K	B-Protein
)	O
,	O
S6	B-Protein
)	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

In	O
some	O
cases	O
(	O
FoxO1	B-Protein
,	O
FoxO4	B-Protein
,	O
MDM2	B-Protein
)	O
,	O
a	O
robust	O
increase	O
was	O
observed	O
.	O

In	O
other	O
cases	O
(	O
FoxO3a	B-Protein
,	O
GSK	B-Protein
-	I-Protein
3alpha	I-Protein
/	O
beta	B-Protein
,	O
p70S6K	B-Protein
and	O
its	O
substrate	O
S6	B-Protein
)	O
,	O
the	O
changes	O
were	O
less	O
pronounced	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

The	O
timing	O
of	O
the	O
phosphorylation	O
changes	O
paralleled	O
the	O
increase	O
in	O
Akt	O
phosphorylation	O
(	O
Fig	O
.	O
5B	O
,	O
S5A	O
,	O
B	O
)	O
.	O

In	O
the	O
case	O
of	O
pFoxO1	B-Protein
we	O
occasionally	O
observed	O
a	O
shift	O
in	O
migration	O
rather	O
than	O
an	O
increase	O
in	O
band	O
intensity	O
(	O
e	O
.	O
g	O
.	O
comparing	O
Fig	O
.	O
5A	O
and	O
B	O
)	O
,	O
suggesting	O
that	O
phosphorylation	O
events	O
in	O
addition	O
to	O
Thr24	O
take	O
place	O
during	O
necroptosis	O
.	O

Notably	O
,	O
in	O
all	O
cases	O
the	O
necroptosis	O
-	O
associated	O
increases	O
in	O
Akt	O
substrates	O
were	O
abrogated	O
by	O
Nec	O
-	O
1	O
(	O
Fig	O
.	O
5A	O
,	O
Fig	O
.	O
S5A	O
,	O
B	O
)	O
.	O

Overall	O
,	O
these	O
data	O
suggested	O
that	O
a	O
significant	O
part	O
of	O
the	O
"	O
canonical	O
"	O
Akt	O
signaling	O
network	O
is	O
activated	O
at	O
the	O
onset	O
of	O
necroptotic	O
cell	O
death	O
in	O
a	O
RIP1	B-Protein
dependent	O
fashion	O
.	O

Akt	O
kinase	O
is	O
considered	O
to	O
be	O
a	O
pro	O
-	O
survival	O
protein	O
that	O
inhibits	O
apoptosis	O
through	O
the	O
control	O
of	O
multiple	O
effectors	O
including	O
mTORC1	O
,	O
GSK	O
-	O
3	O
and	O
others	O
[	O
28	O
]	O
.	O

An	O
important	O
question	O
is	O
whether	O
these	O
same	O
molecules	O
reverse	O
their	O
pro	O
-	O
survival	O
roles	O
during	O
necroptosis	O
.	O

We	O
found	O
that	O
inhibition	O
of	O
mTORC1	O
by	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
the	O
mTOR	O
co	O
-	O
factor	O
Raptor	B-Protein
[	O
29	O
]	O
,	O
protected	O
cells	O
from	O
necroptosis	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

Similarly	O
,	O
the	O
direct	O
mTOR	O
kinase	O
inhibitor	O
Torin1	O
[	O
30	O
]	O
and	O
the	O
dual	O
PI3K	O
/	O
mTOR	O
inhibitor	O
PI	O
-	O
103	O
[	O
31	O
]	O
also	O
efficiently	O
inhibited	O
necroptosis	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

Knockdown	O
of	O
mTOR	O
using	O
siRNA	O
further	O
validated	O
the	O
small	O
-	O
molecule	O
inhibitor	O
data	O
indicating	O
a	O
role	O
for	O
mTOR	O
in	O
necroptosis	O
by	O
protecting	O
cells	O
from	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
induced	O
death	O
(	O
Fig	O
.	O
5D	O
)	O
.	O

mTORC1	O
regulates	O
translation	O
through	O
activation	O
of	O
p70S6	B-Protein
kinase	I-Protein
and	O
,	O
subsequently	O
,	O
ribosomal	O
protein	O
S6	B-Protein
[	O
32	O
]	O
.	O

Notably	O
,	O
a	O
genome	O
-	O
wide	O
siRNA	O
screen	O
[	O
10	O
]	O
suggested	O
an	O
important	O
role	O
for	O
protein	O
translation	O
in	O
necroptosis	O
.	O

Consistently	O
,	O
we	O
found	O
that	O
the	O
small	O
molecule	O
inhibitor	O
of	O
p70S6K	B-Protein
PF	O
-	O
4708671	O
[	O
33	O
]	O
attenuated	O
necroptosis	O
at	O
the	O
concentrations	O
required	O
to	O
block	O
S6	B-Protein
phosphorylation	O
(	O
Fig	O
.	O
S5C	O
,	O
D	O
)	O
.	O

Partial	O
siRNA	O
knockdown	O
of	O
S6	B-Protein
protein	O
attenuated	O
necroptosis	O
as	O
well	O
(	O
Fig	O
.	O
S5E	O
)	O
,	O
suggesting	O
that	O
translational	O
control	O
by	O
p70S6K	B-Protein
/	O
S6	B-Protein
may	O
play	O
a	O
role	O
in	O
necroptosis	O
.	O

Overall	O
,	O
while	O
the	O
full	O
repertoire	O
of	O
Akt	O
targets	O
during	O
necroptosis	O
remains	O
to	O
be	O
fully	O
explored	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
the	O
activity	O
of	O
an	O
anti	O
-	O
apoptotic	O
branch	O
of	O
Akt	O
signaling	O
can	O
promote	O
necroptosis	O
.	O

RIP1	B-Protein
kinase	O
,	O
Akt	O
,	O
mTORC1	O
and	O
JNK	O
control	O
the	O
upregulation	O
of	O
TNFalpha	B-Protein
accompanying	O
necroptosis	O
.	O

Hitomi	O
et	O
al	O
.	O

[	O
10	O
]	O
have	O
recently	O
reported	O
that	O
the	O
induction	O
of	O
necroptosis	O
by	O
zVAD	O
.	O
fmk	O
in	O
L929	O
cells	O
is	O
associated	O
with	O
increased	O
synthesis	O
of	O
TNFalpha	B-Protein
,	O
which	O
potentiates	O
cell	O
death	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
Akt	O
and	O
its	O
effectors	O
contribute	O
to	O
TNFalpha	B-Protein
synthesis	O
.	O

Consistent	O
with	O
a	O
RIP1	B-Protein
-	O
dependent	O
increase	O
in	O
TNFalpha	B-Protein
protein	O
(	O
Fig	O
.	O
S6A	O
,	O
B	O
)	O
,	O
we	O
found	O
that	O
TNFalpha	B-Protein
mRNA	O
levels	O
increased	O
during	O
necroptosis	O
in	O
L929	O
cells	O
in	O
a	O
RIP1	B-Protein
(	O
Fig	O
.	O

S6C	O
.	O

Under	O
serum	O
free	O
conditions	O
,	O
bFGF	B-Protein
alone	O
triggered	O
some	O
induction	O
of	O
TNFalpha	B-Protein
mRNA	O
,	O
while	O
its	O
combination	O
with	O
zVAD	O
.	O
fmk	O
(	O
but	O
not	O
zVAD	O
.	O
fmk	O
alone	O
)	O
caused	O
a	O
pronounced	O
further	O
increase	O
(	O
Fig	O
.	O
6A	O
)	O
.	O

Conversely	O
,	O
PDGF	O
caused	O
a	O
modest	O
upregulation	O
of	O
TNFalpha	B-Protein
mRNA	O
,	O
which	O
was	O
not	O
further	O
increased	O
in	O
the	O
presence	O
of	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
6A	O
)	O
,	O
demonstrating	O
that	O
activation	O
of	O
necroptosis	O
is	O
specifically	O
accompanied	O
by	O
a	O
marked	O
increase	O
in	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
.	O

Further	O
analysis	O
suggested	O
that	O
both	O
Akt	O
and	O
mTORC1	O
contribute	O
to	O
the	O
upregulation	O
of	O
TNFalpha	B-Protein
mRNA	O
during	O
necroptosis	O
as	O
both	O
small	O
-	O
molecule	O
inhibition	O
and	O
siRNA	O
knockdown	O
of	O
Akt	O
and	O
mTOR	O
reduced	O
TNFalpha	B-Protein
mRNA	O
levels	O
in	O
necroptotic	O
cells	O
(	O
Fig	O
.	O
6B	O
,	O
C	O
,	O
D	O
)	O
.	O

Notably	O
,	O
RIP1	B-Protein
and	O
Akt	O
inhibitors	O
had	O
no	O
effect	O
on	O
the	O
levels	O
of	O
TNFalpha	B-Protein
mRNA	O
in	O
control	O
cells	O
or	O
in	O
the	O
cells	O
stimulated	O
with	O
bFGF	B-Protein
alone	O
(	O
Fig	O
.	O
6A	O
,	O
B	O
,	O
Fig	O
.	O
S6C	O
)	O
,	O
suggesting	O
that	O
these	O
kinases	O
specifically	O
mediate	O
necroptosis	O
-	O
dependent	O
increase	O
in	O
TNFalpha	B-Protein
synthesis	O
.	O

Akt	O
and	O
mTORC1	O
Control	O
the	O
Activation	O
of	O
JNK	O
during	O
Necroptosis	O

JNK	O
is	O
a	O
well	O
-	O
established	O
regulator	O
of	O
TNFalpha	B-Protein
synthesis	O
in	O
a	O
variety	O
of	O
systems	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
34	O
]	O
.	O

Therefore	O
,	O
the	O
ability	O
of	O
Akt	O
and	O
mTORC1	O
inhibitors	O
to	O
block	O
the	O
increase	O
in	O
TNFalpha	B-Protein
mRNA	O
lead	O
us	O
to	O
examine	O
their	O
role	O
in	O
the	O
activation	O
of	O
JNK	O
during	O
necroptosis	O
.	O

Knockdown	O
of	O
Akt	O
isoforms	O
Akt1	B-Protein
and	O
Akt2	B-Protein
or	O
inhibition	O
of	O
Akt	O
prominently	O
suppressed	O
the	O
necroptosis	O
dependent	O
increase	O
in	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
6E	O
,	O
S6D	O
,	O
E	O
)	O
suggesting	O
that	O
Akt	O
may	O
provide	O
a	O
link	O
between	O
RIP1	B-Protein
and	O
JNK	O
activation	O
.	O

Importantly	O
,	O
inhibition	O
of	O
Akt	O
only	O
inhibited	O
the	O
delayed	O
,	O
but	O
not	O
the	O
early	O
,	O
increase	O
in	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
induced	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
S6F	O
)	O
.	O

Knockdown	O
of	O
mTOR	O
,	O
rapamycin	O
and	O
the	O
p70S6K	B-Protein
inhibitor	O
PF	O
-	O
4708671	O
also	O
attenuated	O
the	O
necroptosis	O
-	O
associated	O
increase	O
in	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
6F	O
,	O
S6E	O
,	O
G	O
,	O
Fig	O
.	O
S5D	O
)	O
.	O

Overall	O
,	O
these	O
data	O
suggested	O
that	O
the	O
Akt	O
-	O
mTORC1	O
-	O
S6K	B-Protein
axis	O
,	O
acting	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
,	O
is	O
required	O
for	O
the	O
increase	O
in	O
JNK	O
activity	O
during	O
necroptosis	O
in	O
L929	O
cells	O
.	O

PI3	O
-	O
kinase	O
and	O
PDK1	B-Protein
Mediate	O
the	O
Increase	O
in	O
Akt	O
Thr308	O
Phosphorylation	O
Under	O
Necroptotic	O
Conditions	O

Typical	O
regulation	O
of	O
Akt	O
by	O
growth	O
factors	O
involves	O
its	O
recruitment	O
to	O
the	O
plasma	O
membrane	O
,	O
which	O
is	O
mediated	O
by	O
the	O
binding	O
of	O
the	O
pleckstrin	O
homology	O
(	O
PH	O
)	O
domain	O
of	O
Akt	O
to	O
the	O
product	O
of	O
PI3K	O
,	O
phosphatidylinositol	O
-	O
3	O
,	O
4	O
,	O
5	O
-	O
triphosphate	O
(	O
PIP3	O
)	O
.	O

In	O
the	O
membrane	O
,	O
Akt	O
is	O
phosphorylated	O
on	O
Thr308	O
and	O
Ser473	O
by	O
3	B-Protein
-	I-Protein
phosphoinositide	I-Protein
dependent	I-Protein
protein	I-Protein
kinase	I-Protein
-	I-Protein
1	I-Protein
(	O
PDK1	B-Protein
)	O
and	O
mTORC2	O
(	O
or	O
DNA	O
-	O
PK	O
)	O
,	O
respectively	O
[	O
35	O
]	O
.	O

Since	O
our	O
results	O
showed	O
that	O
only	O
Thr308	O
Akt	O
phosphorylation	O
is	O
increased	O
during	O
necroptosis	O
,	O
we	O
next	O
examined	O
whether	O
it	O
is	O
still	O
dependent	O
on	O
PI3K	O
and	O
PDK1	B-Protein
.	O

Inhibition	O
of	O
PI3K	O
and	O
PDK1	B-Protein
using	O
the	O
specific	O
inhibitors	O
LY249002	O
and	O
BX912	O
[	O
36	O
]	O
resulted	O
in	O
the	O
efficient	O
inhibition	O
of	O
cell	O
death	O
and	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
S7A	O
-	O
D	O
)	O
.	O

Likewise	O
,	O
siRNA	O
knockdown	O
of	O
PDK1	B-Protein
protected	O
cells	O
from	O
death	O
and	O
inhibited	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
S7E	O
,	O
F	O
)	O
Therefore	O
,	O
PI3K	O
and	O
PDK1	B-Protein
activity	O
is	O
still	O
required	O
for	O
non	O
-	O
canonical	O
Akt	O
activation	O
during	O
necroptosis	O
.	O

Expression	O
of	O
Constitutively	O
Active	O
Akt	O
,	O
Rescues	O
Necroptosis	O
Under	O
Serum	O
Free	O
Conditions	O

We	O
used	O
L929	O
cells	O
stably	O
expressing	O
constitutively	O
active	O
wild	O
type	O
Akt1	B-Protein
(	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
)	O
or	O
the	O
catalytically	O
inactive	O
mutant	O
K179M	B-Protein
in	O
order	O
to	O
further	O
understand	O
the	O
contribution	O
of	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
to	O
Akt	O
activation	O
during	O
necroptosis	O
.	O

Constitutively	O
active	O
Akt1	B-Protein
(	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
)	O
was	O
generated	O
as	O
previously	O
described	O
[	O
37	O
]	O
by	O
the	O
addition	O
of	O
a	O
myristoylation	O
signal	O
which	O
provides	O
constitutive	O
localization	O
to	O
the	O
plasma	O
membrane	O
and	O
by	O
the	O
deletion	O
of	O
the	O
auto	O
-	O
inhibitory	O
PH	O
domain	O
(	O
Fig	O
.	O
7A	O
)	O
resulting	O
in	O
an	O
Akt	O
that	O
is	O
active	O
under	O
serum	O
free	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
cells	O
expressing	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
were	O
viable	O
,	O
grew	O
in	O
a	O
manner	O
indistinguishable	O
from	O
the	O
empty	O
vector	O
control	O
cells	O
,	O
and	O
were	O
not	O
triggered	O
to	O
induce	O
necroptosis	O
by	O
serum	O
starvation	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

This	O
indicates	O
that	O
active	O
Akt	O
alone	O
is	O
not	O
sufficient	O
to	O
induce	O
necroptotic	O
cell	O
death	O
.	O

Under	O
serum	O
free	O
conditions	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
,	O
but	O
not	O
the	O
K179M	B-Protein
mutant	O
,	O
fully	O
restored	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
(	O
Fig	O
.	O
7A	O
,	O
B	O
)	O
.	O

Nec	O
-	O
1	O
prevented	O
both	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
dependent	O
cell	O
death	O
and	O
the	O
necroptosis	O
-	O
specific	O
delayed	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
7B	O
,	O
C	O
)	O
.	O

Myr	O
-	O
Akt	O
also	O
allowed	O
other	O
zVAD	O
.	O
fmk	O
-	O
dependent	O
events	O
,	O
including	O
activation	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
7C	O
)	O
and	O
upregulation	O
of	O
TNFalpha	B-Protein
mRNA	O
(	O
Fig	O
.	O
7D	O
)	O
to	O
occur	O
under	O
serum	O
free	O
conditions	O
,	O
confirming	O
an	O
important	O
role	O
for	O
Akt	O
at	O
the	O
apex	O
of	O
necroptotic	O
signaling	O
.	O

These	O
data	O
demonstrated	O
that	O
the	O
presence	O
of	O
active	O
and	O
membrane	O
localized	O
Akt	O
is	O
sufficient	O
to	O
uncouple	O
Akt	O
activation	O
during	O
necroptosis	O
from	O
growth	O
factor	O
signaling	O
.	O

RIP1	B-Protein
kinase	O
was	O
still	O
able	O
to	O
regulate	O
Akt	O
activation	O
during	O
necroptosis	O
,	O
suggesting	O
that	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
provide	O
two	O
independent	O
inputs	O
required	O
for	O
Akt	O
changes	O
during	O
necroptosis	O
.	O

RIP1	B-Protein
kinase	O
-	O
dependent	O
Thr308	O
phosphorylation	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
during	O
necroptosis	O
increased	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
activity	O
as	O
it	O
did	O
with	O
endogenous	O
Akt	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Phosphorylation	O
of	O
many	O
previously	O
described	O
Akt	O
substrates	O
was	O
increased	O
upon	O
the	O
expression	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
,	O
but	O
not	O
the	O
K179M	B-Protein
mutant	O
,	O
confirming	O
that	O
these	O
molecules	O
are	O
Akt	O
substrates	O
in	O
L929	O
cells	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

The	O
effect	O
of	O
zVAD	O
.	O
fmk	O
on	O
their	O
phosphorylation	O
varied	O
,	O
likely	O
due	O
to	O
the	O
increased	O
basal	O
activity	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
.	O

Some	O
substrates	O
,	O
including	O
p70S6K	B-Protein
,	O
S6	B-Protein
,	O
GSK	O
-	O
3	O
and	O
FoxO4	B-Protein
,	O
were	O
fully	O
phosphorylated	O
even	O
in	O
the	O
absence	O
of	O
zVAD	O
.	O
fmk	O
.	O

On	O
the	O
other	O
hand	O
,	O
phosphorylation	O
of	O
FoxO1	B-Protein
and	O
MDM2	B-Protein
was	O
significantly	O
increased	O
in	O
the	O
presence	O
of	O
zVAD	O
.	O
fmk	O
,	O
indicating	O
that	O
necroptotic	O
Thr308	O
phosphorylation	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
still	O
promoted	O
its	O
activity	O
.	O

Under	O
serum	O
free	O
conditions	O
all	O
zVAD	O
.	O
fmk	O
-	O
induced	O
downstream	O
events	O
(	O
cell	O
death	O
,	O
JNK	O
activation	O
,	O
TNFalpha	B-Protein
production	O
)	O
were	O
dependent	O
on	O
the	O
over	O
expressed	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
.	O

This	O
allowed	O
us	O
to	O
examine	O
the	O
effects	O
of	O
other	O
Akt	O
mutations	O
on	O
necroptosis	O
.	O

First	O
,	O
we	O
found	O
that	O
membrane	O
localization	O
of	O
Akt	O
is	O
required	O
.	O

Full	O
length	O
Akt	O
or	O
a	O
mutant	O
lacking	O
both	O
the	O
PH	O
domain	O
and	O
the	O
Myr	O
tag	O
did	O
not	O
support	O
the	O
activation	O
of	O
cell	O
death	O
or	O
increased	O
Thr308	O
phosphorylation	O
following	O
zVAD	O
.	O
fmk	O
addition	O
under	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
S8A	O
,	O
B	O
)	O
.	O

Second	O
,	O
we	O
found	O
a	O
specific	O
and	O
critical	O
role	O
for	O
Thr308	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
the	O
necroptotic	O
functions	O
of	O
Akt	O
.	O

It	O
has	O
been	O
reported	O
that	O
Ala	O
mutations	O
at	O
Thr308	O
and	O
Ser473	O
cause	O
a	O
reduction	O
in	O
the	O
catalytic	O
activity	O
of	O
Akt	B-Protein
,	O
while	O
Asp	O
mutants	O
increase	O
activity	O
[	O
38	O
]	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Ala	O
and	O
Asp	O
mutants	O
at	O
both	O
sites	O
during	O
necroptosis	O
.	O

In	O
our	O
hands	O
,	O
both	O
Asp	O
mutants	O
displayed	O
activity	O
comparable	O
to	O
wild	O
type	O
Akt	O
,	O
while	O
both	O
Ala	O
mutants	O
displayed	O
comparable	O
decreases	O
in	O
activity	O
(	O
Fig	O
.	O
S8C	O
)	O
.	O

Despite	O
similar	O
catalytic	O
activities	O
,	O
Thr308	O
and	O
Ser473	O
mutants	O
displayed	O
major	O
differences	O
in	O
their	O
ability	O
to	O
promote	O
necroptotic	O
changes	O
(	O
Fig	O
.	O
7E	O
,	O
F	O
,	O
G	O
)	O
.	O

As	O
expected	O
,	O
the	O
S473D	B-Protein
mutant	I-Protein
,	O
which	O
was	O
phosphorylated	O
on	O
Thr308	O
after	O
the	O
addition	O
of	O
zVAD	O
,	O
displayed	O
only	O
slightly	O
reduced	O
activity	O
,	O
while	O
S473A	B-Protein
was	O
significantly	O
less	O
active	O
in	O
all	O
aspects	O
of	O
necroptosis	O
.	O

S473A	B-Protein
was	O
unable	O
to	O
be	O
efficiently	O
phosphorylated	O
on	O
Thr308	O
possibly	O
due	O
to	O
the	O
inability	O
of	O
the	O
Ala	O
mutated	O
473	O
site	O
to	O
be	O
phosphorylated	O
and	O
provide	O
a	O
docking	O
site	O
for	O
PDK1	B-Protein
to	O
phosphorylate	O
Thr308	O
[	O
39	O
]	O
.	O

Strikingly	O
,	O
both	O
Ala	O
and	O
Asp	O
mutants	O
of	O
Thr308	O
were	O
significantly	O
less	O
active	O
in	O
promoting	O
cell	O
death	O
,	O
phosphorylation	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
TNFalpha	B-Protein
mRNA	O
.	O

This	O
suggests	O
that	O
T308D	B-Protein
,	O
in	O
spite	O
of	O
being	O
an	O
active	O
Akt	O
construct	O
,	O
may	O
not	O
be	O
a	O
perfect	O
mimic	O
of	O
phosphorylation	O
and	O
this	O
mutant	O
form	O
of	O
the	O
kinase	O
may	O
not	O
have	O
sufficient	O
activity	O
to	O
phosphorylate	O
the	O
entire	O
repertoire	O
of	O
substrates	O
in	O
the	O
cells	O
.	O

When	O
tested	O
,	O
T308D	B-Protein
did	O
not	O
support	O
the	O
downstream	O
phosphorylation	O
of	O
several	O
substrates	O
that	O
were	O
phosphorylated	O
by	O
the	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
construct	O
in	O
the	O
presence	O
of	O
zVAD	O
including	O
FoxO1	B-Protein
,	O
Foxo4	B-Protein
,	O
MDM2	B-Protein
,	O
and	O
p70S6K	B-Protein
(	O
Fig	O
.	O
S8D	O
)	O
.	O

Our	O
model	O
,	O
based	O
on	O
these	O
results	O
,	O
is	O
that	O
necroptosis	O
-	O
specific	O
Thr308	O
phosphorylation	O
provides	O
a	O
critical	O
link	O
between	O
necroptotic	O
machinery	O
and	O
Akt	O
kinase	O
,	O
allowing	O
Akt	O
to	O
phosphorylate	O
substrates	O
during	O
necroptosis	O
,	O
promote	O
TNFalpha	B-Protein
synthesis	O
,	O
JNK	O
activation	O
and	O
eventual	O
cell	O
death	O
.	O

Akt	O
Controls	O
TNFalpha	B-Protein
Production	O
in	O
Other	O
Cell	O
Types	O

After	O
establishing	O
the	O
role	O
of	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
signaling	O
to	O
Akt	O
in	O
L929	O
cells	O
,	O
we	O
sought	O
to	O
expand	O
our	O
study	O
to	O
other	O
cell	O
types	O
that	O
are	O
known	O
to	O
undergo	O
necroptotic	O
cell	O
death	O
.	O

Fas	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
with	I-Protein
death	I-Protein
domain	I-Protein
(	O
FADD	B-Protein
)	O
-	O
deficient	O
Jurkat	O
T	O
lymphocytes	O
and	O
the	O
macrophage	O
cell	O
lines	O
(	O
J774A	O
.	O
1	O
and	O
RAW264	O
.	O
7	O
)	O
are	O
other	O
models	O
of	O
necroptosis	O
,	O
which	O
can	O
be	O
induced	O
by	O
stimulation	O
with	O
TNFalpha	B-Protein
or	O
zVAD	O
.	O
fmk	O
,	O
respectively	O
[	O
17	O
]	O
.	O

Similar	O
to	O
L929	O
cells	O
,	O
a	O
RIP1	B-Protein
kinase	O
dependent	O
increase	O
in	O
the	O
phosphorylation	O
of	O
Thr308	O
on	O
Akt	O
occurred	O
during	O
necroptosis	O
(	O
Fig	O
.	O
8B	O
,	O
D	O
,	O
F	O
)	O
in	O
these	O
cell	O
types	O
.	O

Furthermore	O
,	O
TNFalpha	B-Protein
mRNA	O
levels	O
were	O
increased	O
in	O
each	O
of	O
these	O
cell	O
types	O
during	O
necroptosis	O
and	O
efficiently	O
inhibited	O
by	O
both	O
RIP1	B-Protein
and	O
Akt	O
inhibitors	O
(	O
Fig	O
.	O
8A	O
,	O
C	O
,	O
E	O
)	O
.	O

However	O
,	O
inhibition	O
of	O
Akt	O
did	O
not	O
protect	O
these	O
cells	O
from	O
death	O
(	O
Fig	O
.	O
S9A	O
,	O
B	O
,	O
C	O
)	O
.	O

These	O
results	O
indicate	O
that	O
regulation	O
of	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
and	O
necroptosis	O
-	O
associated	O
inflammatory	O
signaling	O
may	O
be	O
a	O
more	O
important	O
function	O
of	O
Akt	O
pathway	O
activation	O
by	O
RIP1	B-Protein
kinase	O
in	O
multiple	O
cell	O
types	O
compared	O
to	O
its	O
contribution	O
to	O
cell	O
death	O
.	O

We	O
next	O
chose	O
to	O
look	O
at	O
the	O
role	O
of	O
Akt	O
in	O
necroptosis	O
in	O
mouse	O
lung	O
fibroblasts	O
.	O

Lung	O
fibroblasts	O
selected	O
to	O
survive	O
after	O
deletion	O
of	O
all	O
three	O
Akt	O
isoforms	O
[	O
40	O
]	O
were	O
resistant	O
to	O
cell	O
death	O
induced	O
by	O
the	O
addition	O
of	O
TNFalpha	B-Protein
and	O
zVAD	O
.	O
fmk	O
.	O

Expression	O
of	O
catalytically	O
active	O
Akt	O
(	O
Myr	O
-	O
Akt	O
)	O
in	O
these	O
cells	O
restored	O
TNFalpha	B-Protein
mRNA	O
production	O
in	O
response	O
to	O
TNFalpha	B-Protein
and	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
8G	O
)	O
without	O
re	O
-	O
establishing	O
cell	O
death	O
(	O
Fig	O
.	O
S9D	O
)	O
.	O

Consistent	O
with	O
our	O
earlier	O
Akt	O
knockdown	O
data	O
,	O
lung	O
fibroblasts	O
expressing	O
endogenous	O
Akt1	B-Protein
or	O
Akt2	B-Protein
were	O
phosphorylated	O
on	O
Thr308	O
in	O
response	O
to	O
TNFalpha	B-Protein
and	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
S9E	O
)	O
and	O
in	O
both	O
cases	O
robust	O
RIP1	B-Protein
-	O
dependent	O
TNFalpha	B-Protein
mRNA	O
upregulation	O
occurred	O
under	O
necroptotic	O
conditions	O
(	O
Fig	O
.	O
8H	O
)	O
.	O

These	O
data	O
further	O
support	O
the	O
notion	O
that	O
Akt	O
activity	O
is	O
critical	O
for	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
,	O
even	O
in	O
the	O
absence	O
of	O
necroptotic	O
cell	O
death	O
,	O
indicating	O
an	O
unexpected	O
differentiation	O
between	O
Akt	O
-	O
mediated	O
inflammatory	O
signaling	O
under	O
necroptotic	O
conditions	O
and	O
cell	O
death	O
per	O
se	O
.	O

Model	O
of	O
RIP1	B-Protein
,	O
Akt	O
and	O
JNK	O
Dependent	O
Signaling	O
in	O
Necroptotic	O
L929	O
Cells	O

In	O
this	O
study	O
we	O
investigated	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
signaling	O
pathways	O
using	O
mouse	O
fibrosarcoma	O
L929	O
cells	O
that	O
die	O
by	O
necroptosis	O
when	O
treated	O
with	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
zVAD	O
.	O
fmk	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
Akt	O
kinase	O
is	O
specifically	O
engaged	O
in	O
signaling	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
,	O
which	O
leads	O
to	O
a	O
selective	O
increase	O
in	O
its	O
phosphorylation	O
on	O
Thr308	O
,	O
but	O
not	O
Ser473	O
.	O

According	O
to	O
our	O
model	O
(	O
Fig	O
.	O
9	O
)	O
,	O
necroptosis	O
-	O
associated	O
phosphorylation	O
of	O
Akt	O
requires	O
two	O
distinct	O
signals	O
.	O

The	O
first	O
input	O
,	O
which	O
is	O
induced	O
by	O
growth	O
factors	O
,	O
leads	O
to	O
the	O
plasma	O
membrane	O
localization	O
of	O
Akt	O
.	O

Expression	O
of	O
a	O
constitutively	O
membrane	O
-	O
targeted	O
Akt	O
construct	O
,	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
,	O
overcomes	O
the	O
requirement	O
for	O
growth	O
factors	O
.	O

At	O
the	O
same	O
time	O
,	O
expression	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
alone	O
is	O
not	O
sufficient	O
for	O
the	O
induction	O
of	O
necroptosis	O
.	O

A	O
second	O
,	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
input	O
is	O
required	O
for	O
Thr308	O
phosphorylation	O
of	O
Akt	O
in	O
response	O
to	O
caspase	O
inhibition	O
and	O
is	O
essential	O
for	O
the	O
propagation	O
of	O
the	O
necroptotic	O
signal	O
.	O

Using	O
Akt	O
inhibitors	O
,	O
knockdown	O
of	O
Akt	O
isoforms	O
,	O
and	O
the	O
expression	O
of	O
Akt	O
mutants	O
,	O
we	O
showed	O
that	O
necroptotic	O
activation	O
of	O
Akt	O
is	O
indispensable	O
for	O
this	O
form	O
of	O
cell	O
death	O
in	O
L929	O
cells	O
.	O

We	O
also	O
investigated	O
downstream	O
Akt	O
-	O
dependent	O
pathways	O
that	O
contribute	O
to	O
necroptosis	O
.	O

First	O
,	O
we	O
demonstrated	O
that	O
selective	O
necroptotic	O
phosphorylation	O
of	O
Thr308	O
of	O
Akt	O
is	O
sufficient	O
to	O
increase	O
its	O
activity	O
towards	O
a	O
number	O
of	O
known	O
substrates	O
and	O
Akt	O
effector	O
pathways	O
such	O
as	O
the	O
mTORC1	O
pathway	O
,	O
which	O
,	O
in	O
turn	O
,	O
contributes	O
to	O
cell	O
death	O
.	O

Second	O
,	O
our	O
data	O
suggested	O
that	O
Akt	O
activation	O
provides	O
a	O
pivotal	O
link	O
connecting	O
RIP1	B-Protein
kinase	O
to	O
known	O
downstream	O
signaling	O
and	O
execution	O
events	O
in	O
necroptotic	O
L929	O
cells	O
,	O
namely	O
,	O
JNK	O
activation	O
and	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
,	O
a	O
critical	O
event	O
in	O
necroptosis	O
in	O
L929	O
cells	O
[	O
15	O
]	O
.	O

In	O
order	O
to	O
further	O
test	O
our	O
model	O
,	O
we	O
examined	O
Akt	O
phosphorylation	O
after	O
inhibition	O
of	O
a	O
downstream	O
kinase	O
in	O
the	O
pathway	O
,	O
JNK	O
.	O

However	O
,	O
we	O
found	O
that	O
SP600125	O
,	O
which	O
protected	O
L929	O
cells	O
from	O
death	O
and	O
inhibited	O
TNFalpha	B-Protein
production	O
(	O
Fig	O
.	O
2A	O
,	O
B	O
S2A	O
S10A	O
)	O
,	O
inhibited	O
both	O
basal	O
and	O
post	O
-	O
treatment	O
phosphorylation	O
levels	O
of	O
Akt	O
at	O
both	O
Ser473	O
and	O
Thr308	O
(	O
Fig	O
.	O
S10B	O
)	O
.	O

It	O
has	O
been	O
published	O
that	O
SP600125	O
is	O
a	O
somewhat	O
non	O
-	O
specific	O
inhibitor	O
that	O
may	O
inhibit	O
the	O
p110delta	B-Protein
subunit	I-Protein
of	O
PI3K	O
[	O
41	O
]	O
and	O
PDK1	B-Protein
[	O
42	O
]	O
.	O

Both	O
of	O
these	O
off	O
-	O
target	O
effects	O
could	O
inhibit	O
basal	O
Akt	O
phosphorylation	O
levels	O
,	O
precluding	O
the	O
use	O
of	O
SP600125	O
in	O
this	O
system	O
.	O

Therefore	O
,	O
to	O
examine	O
the	O
role	O
of	O
JNK	O
,	O
we	O
switched	O
to	O
a	O
more	O
specific	O
JNK	O
inhibitor	O
,	O
JNK	O
inhibitor	O
VIII	O
[	O
43	O
]	O
,	O
and	O
siRNAs	O
against	O
JNK1	B-Protein
and	O
JNK2	B-Protein
(	O
Fig	O
.	O
S10B	O
-	O
G	O
)	O
.	O

As	O
expected	O
,	O
specific	O
inhibition	O
or	O
knockdown	O
of	O
JNK1	B-Protein
/	O
2	B-Protein
allowed	O
phosphorylation	O
of	O
Akt	O
on	O
Thr308	O
while	O
inhibiting	O
the	O
phosphorylation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
at	O
Ser63	O
(	O
Fig	O
.	O
S10B	O
,	O
E	O
)	O
,	O
agreeing	O
with	O
our	O
model	O
.	O

It	O
did	O
not	O
,	O
however	O
,	O
lead	O
to	O
a	O
reduction	O
in	O
TNFalpha	B-Protein
production	O
or	O
cell	O
death	O
(	O
Fig	O
.	O
S10C	O
,	O
D	O
,	O
F	O
,	O
G	O
)	O
,	O
suggesting	O
that	O
earlier	O
data	O
with	O
SP600125	O
protection	O
(	O
Fig	O
.	O
2	O
)	O
could	O
reflect	O
off	O
-	O
target	O
effects	O
of	O
this	O
molecule	O
,	O
rather	O
than	O
JNK	O
inhibition	O
.	O

Previous	O
reports	O
also	O
suggested	O
a	O
critical	O
role	O
for	O
c	B-Protein
-	I-Protein
Jun	I-Protein
in	O
necroptosis	O
and	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
and	O
we	O
confirmed	O
these	O
conclusions	O
using	O
c	B-Protein
-	I-Protein
Jun	I-Protein
siRNA	O
knockdown	O
(	O
Fig	O
.	O
S10H	O
-	O
J	O
)	O
.	O

Notably	O
,	O
in	O
this	O
case	O
,	O
Thr308	O
phosphorylation	O
was	O
reduced	O
after	O
the	O
induction	O
of	O
necroptosis	O
.	O

Thus	O
,	O
autocrine	O
TNFalpha	B-Protein
production	O
,	O
dependent	O
on	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
may	O
create	O
a	O
feedback	O
loop	O
that	O
contributes	O
to	O
the	O
delayed	O
activation	O
of	O
Akt	O
.	O

It	O
is	O
also	O
important	O
to	O
note	O
that	O
we	O
observed	O
an	O
overall	O
increase	O
in	O
the	O
protein	O
level	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
after	O
treatment	O
of	O
L929	O
cells	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
,	O
which	O
was	O
both	O
Akt	O
and	O
mTOR	O
-	O
dependent	O
(	O
Fig	O
.	O
6E	O
,	O
F	O
)	O
.	O

These	O
new	O
data	O
led	O
us	O
to	O
an	O
unexpected	O
,	O
but	O
important	O
conclusion	O
that	O
c	B-Protein
-	I-Protein
Jun	I-Protein
is	O
critical	O
for	O
necroptosis	O
,	O
while	O
JNK	O
activity	O
may	O
serve	O
as	O
a	O
useful	O
marker	O
of	O
pathway	O
activation	O
,	O
but	O
may	O
be	O
either	O
redundant	O
(	O
e	O
.	O
g	O
.	O
phosphorylation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
on	O
a	O
site	O
other	O
than	O
Ser63	O
may	O
occur	O
[	O
44	O
]	O
)	O
or	O
dispensable	O
functionally	O
.	O

In	O
addition	O
,	O
researchers	O
need	O
to	O
use	O
caution	O
when	O
using	O
SP600125	O
due	O
to	O
potantial	O
off	O
-	O
target	O
effects	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
Akt	O
kinase	O
is	O
specifically	O
engaged	O
in	O
the	O
signaling	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
,	O
which	O
exerts	O
its	O
activity	O
through	O
promoting	O
a	O
selective	O
increase	O
in	O
Akt	O
phosphorylation	O
on	O
Thr308	O
.	O

This	O
provides	O
a	O
link	O
connecting	O
RIP1	B-Protein
kinase	O
to	O
downstream	O
signaling	O
and	O
execution	O
events	O
during	O
necroptosis	O
in	O
L929	O
cells	O
,	O
including	O
JNK	O
activation	O
,	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
and	O
eventual	O
cell	O
death	O
.	O

According	O
to	O
our	O
model	O
,	O
phosphorylation	O
of	O
Akt	O
requires	O
two	O
distinct	O
signals	O
.	O

The	O
first	O
input	O
,	O
which	O
is	O
induced	O
by	O
growth	O
factors	O
,	O
leads	O
to	O
the	O
plasma	O
membrane	O
localization	O
of	O
Akt	O
.	O

Expression	O
of	O
constitutively	O
active	O
membrane	O
-	O
targeted	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
overcomes	O
this	O
requirement	O
.	O

At	O
the	O
same	O
time	O
,	O
expression	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
is	O
not	O
sufficient	O
for	O
the	O
induction	O
of	O
necroptosis	O
or	O
efficient	O
activation	O
of	O
JNK	O
and	O
TNFalpha	B-Protein
synthesis	O
.	O

A	O
second	O
,	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
input	O
is	O
required	O
for	O
Thr308	O
phosphorylation	O
of	O
Akt	O
,	O
which	O
in	O
turn	O
is	O
required	O
for	O
necroptotic	O
signaling	O
.	O

Necroptotic	O
phosphorylation	O
of	O
Thr308	O
of	O
Akt	O
is	O
sufficient	O
to	O
increase	O
its	O
activity	O
towards	O
a	O
number	O
of	O
known	O
substrates	O
in	O
L929	O
cells	O
and	O
our	O
data	O
reveal	O
that	O
the	O
Akt	O
effector	O
pathway	O
downstream	O
of	O
mTORC1	O
contributes	O
to	O
necroptosis	O
,	O
thereby	O
identifying	O
a	O
new	O
mediator	O
of	O
this	O
form	O
of	O
cell	O
death	O
.	O

Our	O
results	O
raise	O
some	O
important	O
mechanistic	O
questions	O
relevant	O
to	O
the	O
specific	O
regulation	O
of	O
Akt	O
during	O
necroptosis	O
.	O

First	O
,	O
what	O
is	O
the	O
mechanism	O
of	O
the	O
RIP1	B-Protein
-	O
dependent	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
?	O

One	O
possibility	O
is	O
that	O
RIP1	B-Protein
kinase	O
inhibits	O
a	O
phosphatase	O
that	O
targets	O
Thr308	O
.	O

To	O
our	O
knowledge	O
,	O
PP2A	O
is	O
the	O
only	O
enzyme	O
established	O
to	O
specifically	O
dephosphorylate	O
this	O
residue	O
[	O
45	O
]	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
any	O
effect	O
of	O
the	O
PP2A	O
inhibitor	O
,	O
okadaic	O
acid	O
,	O
on	O
Thr308	O
phosphorylation	O
or	O
activation	O
of	O
necroptosis	O
in	O
L929	O
cells	O
.	O

Another	O
possibility	O
is	O
that	O
the	O
increase	O
in	O
Thr308	O
results	O
from	O
RIP1	B-Protein
kinase	O
targeting	O
PDK1	B-Protein
,	O
Akt	O
or	O
scaffolding	O
factors	O
that	O
bring	O
these	O
two	O
kinases	O
together	O
.	O

Interestingly	O
,	O
we	O
observed	O
phosphorylation	O
of	O
Akt	O
by	O
recombinant	O
RIP1	B-Protein
kinase	O
in	O
vitro	O
on	O
Thr146	O
,	O
195	O
/	O
197	O
,	O
and	O
435	O
and	O
Ser381	O
residues	O
.	O

Furthermore	O
,	O
mutating	O
these	O
residues	O
to	O
Ala	O
in	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
leads	O
to	O
the	O
loss	O
of	O
its	O
ability	O
to	O
promote	O
necroptosis	O
.	O

However	O
,	O
we	O
were	O
not	O
able	O
to	O
confirm	O
phosphorylation	O
of	O
these	O
residues	O
on	O
endogenous	O
Akt	O
in	O
L929	O
cells	O
using	O
either	O
mass	O
spectrometry	O
or	O
western	O
blotting	O
with	O
a	O
phospho	O
-	O
specific	O
antibody	O
raised	O
against	O
Thr435	O
peptide	O
,	O
suggesting	O
that	O
direct	O
phosphorylation	O
of	O
Akt	O
by	O
RIP1	B-Protein
likely	O
represents	O
an	O
in	O
vitro	O
artifact	O
and	O
does	O
not	O
reflect	O
endogenous	O
regulation	O
.	O

Second	O
,	O
what	O
are	O
the	O
key	O
substrates	O
of	O
Akt	O
that	O
promote	O
necrotic	O
death	O
and	O
TNFalpha	B-Protein
synthesis	O
?	O

On	O
the	O
one	O
hand	O
,	O
our	O
data	O
suggest	O
new	O
roles	O
for	O
Akt	O
effector	O
pathways	O
mediated	O
by	O
mTORC1	O
in	O
necroptotic	O
control	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
have	O
observed	O
only	O
modest	O
changes	O
in	O
mTORC1	O
activity	O
under	O
necroptotic	O
conditions	O
,	O
suggesting	O
that	O
additional	O
Akt	O
substrates	O
are	O
likely	O
to	O
be	O
involved	O
.	O

This	O
warrants	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
roles	O
of	O
additional	O
Akt	O
substrates	O
in	O
necroptotic	O
death	O
,	O
since	O
no	O
such	O
connections	O
have	O
been	O
established	O
.	O

Similarly	O
,	O
the	O
mechanisms	O
connecting	O
mTORC1	O
to	O
JNK	O
remain	O
to	O
be	O
elucidated	O
.	O

While	O
there	O
are	O
some	O
recent	O
examples	O
of	O
mTORC1	O
-	O
dependent	O
regulation	O
of	O
JNK	O
,	O
e	O
.	O
g	O
.	O
following	O
ER	O
stress	O
[	O
46	O
]	O
,	O
the	O
exact	O
mechanisms	O
during	O
necroptosis	O
remain	O
to	O
be	O
established	O
.	O

Given	O
the	O
activation	O
of	O
JNK	O
by	O
TNFalpha	B-Protein
and	O
the	O
importance	O
of	O
mTORC1	O
-	O
dependent	O
translational	O
control	O
in	O
necroptosis	O
,	O
one	O
possibility	O
is	O
that	O
mTORC1	O
contributes	O
to	O
the	O
translation	O
of	O
TNFalpha	B-Protein
and	O
forms	O
a	O
positive	O
feed	O
forward	O
loop	O
with	O
JNK	O
.	O

Akt	O
'	O
s	O
role	O
as	O
a	O
key	O
inhibitor	O
of	O
apoptosis	O
is	O
well	O
documented	O
,	O
however	O
,	O
evidence	O
of	O
its	O
contribution	O
as	O
a	O
mediator	O
of	O
cell	O
death	O
under	O
various	O
circumstances	O
has	O
begun	O
to	O
emerge	O
as	O
well	O
[	O
45	O
]	O
,	O
[	O
47	O
]	O
.	O

Our	O
data	O
demonstrates	O
a	O
new	O
mode	O
of	O
necrosis	O
-	O
specific	O
regulation	O
of	O
Akt	O
by	O
RIP1	B-Protein
kinase	O
.	O

Importantly	O
,	O
while	O
it	O
is	O
possible	O
that	O
necroptosis	O
-	O
specific	O
targets	O
of	O
Akt	O
exist	O
,	O
this	O
regulation	O
clearly	O
involves	O
a	O
number	O
of	O
well	O
established	O
Akt	O
targets	O
including	O
mTORC1	O
,	O
and	O
potentially	O
,	O
GSK	O
-	O
3	O
,	O
FoxO1	B-Protein
/	O
4	B-Protein
,	O
and	O
MDM2	B-Protein
.	O

Therefore	O
,	O
it	O
may	O
no	O
longer	O
be	O
safe	O
to	O
assume	O
that	O
activation	O
of	O
Akt	O
universally	O
reflects	O
pro	O
-	O
survival	O
signaling	O
nor	O
that	O
its	O
inhibition	O
will	O
lead	O
to	O
more	O
cell	O
death	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
rather	O
than	O
serving	O
a	O
universally	O
pro	O
-	O
survival	O
role	O
,	O
the	O
Akt	O
pathway	O
may	O
function	O
to	O
promote	O
cell	O
fates	O
alternative	O
to	O
apoptosis	O
,	O
ranging	O
from	O
survival	O
to	O
non	O
-	O
apoptotic	O
cell	O
death	O
.	O

The	O
final	O
decision	O
between	O
survival	O
and	O
death	O
may	O
depend	O
on	O
additional	O
,	O
Akt	O
-	O
independent	O
inputs	O
,	O
such	O
as	O
the	O
status	O
of	O
RIP1	B-Protein
kinase	O
,	O
expression	O
of	O
particular	O
oncogenic	O
factors	O
[	O
45	O
]	O
or	O
excessive	O
metabolic	O
stress	O
[	O
47	O
]	O
.	O

Another	O
mechanism	O
that	O
should	O
be	O
considered	O
in	O
conjunction	O
with	O
the	O
regulation	O
of	O
cell	O
death	O
by	O
Akt	O
is	O
autophagy	O
.	O

Akt	O
activation	O
leads	O
to	O
the	O
inhibition	O
of	O
autophagy	O
through	O
activation	O
of	O
mTOR	O
[	O
48	O
]	O
.	O

The	O
role	O
of	O
autophagy	O
in	O
cell	O
death	O
in	O
general	O
is	O
very	O
complex	O
and	O
it	O
can	O
both	O
promote	O
and	O
inhibit	O
necroptosis	O
in	O
various	O
situations	O
.	O

Several	O
studies	O
suggested	O
that	O
activation	O
of	O
autophagy	O
promotes	O
necroptosis	O
induced	O
by	O
zVAD	O
.	O
fmk	O
in	O
L929	O
cells	O
[	O
11	O
]	O
,	O
[	O
14	O
]	O
.	O

Others	O
,	O
including	O
ourselves	O
in	O
unpublished	O
data	O
,	O
have	O
found	O
that	O
inihibition	O
of	O
autophagy	O
promotes	O
necroptosis	O
by	O
TNFalpha	B-Protein
[	O
49	O
]	O
.	O

This	O
suggests	O
that	O
the	O
inhibition	O
of	O
autophagy	O
by	O
Akt	O
or	O
mTOR	O
in	O
our	O
system	O
may	O
contribute	O
to	O
necroptosis	O
induced	O
by	O
TNFalpha	B-Protein
,	O
however	O
,	O
it	O
is	O
more	O
difficult	O
to	O
reconcile	O
with	O
the	O
positive	O
role	O
of	O
these	O
proteins	O
in	O
zVAD	O
-	O
induced	O
death	O
.	O

Clearly	O
,	O
further	O
identification	O
of	O
the	O
factors	O
differentiating	O
between	O
pro	O
-	O
death	O
and	O
pro	O
-	O
survival	O
autophagy	O
in	O
mammalian	O
cells	O
is	O
required	O
to	O
better	O
understand	O
its	O
role	O
in	O
the	O
regulation	O
necroptosis	O
by	O
Akt	O
pathway	O
.	O

Importantly	O
,	O
our	O
data	O
revealed	O
that	O
RIP1	B-Protein
kinase	O
signaling	O
to	O
Akt	O
is	O
a	O
general	O
feature	O
of	O
necroptotic	O
signaling	O
that	O
is	O
observed	O
in	O
multiple	O
cell	O
types	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
significance	O
of	O
this	O
connection	O
varies	O
in	O
a	O
cell	O
type	O
specific	O
fashion	O
.	O

Importantly	O
,	O
in	O
mouse	O
lung	O
fibroblasts	O
,	O
FADD	B-Protein
-	O
deficient	O
Jurkat	O
cells	O
,	O
and	O
macrophages	O
,	O
Akt	O
signaling	O
contributed	O
more	O
prominently	O
to	O
an	O
increase	O
in	O
TNFalpha	B-Protein
synthesis	O
,	O
rather	O
than	O
cell	O
death	O
per	O
se	O
,	O
unlike	O
its	O
role	O
in	O
L929	O
cells	O
.	O

A	O
recent	O
study	O
[	O
15	O
]	O
has	O
demonstrated	O
that	O
,	O
in	O
addition	O
to	O
its	O
role	O
in	O
necroptosis	O
,	O
RIP1	B-Protein
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
production	O
of	O
TNFalpha	B-Protein
.	O

These	O
data	O
emphasize	O
the	O
emerging	O
complexity	O
of	O
necroptotic	O
signaling	O
mechanisms	O
and	O
highlight	O
the	O
major	O
contribution	O
of	O
Akt	O
to	O
increased	O
inflammatory	O
signaling	O
,	O
specifically	O
accompanying	O
this	O
form	O
of	O
regulated	O
necrosis	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
10	O
]	O
.	O

Robust	O
inflammation	O
is	O
one	O
of	O
the	O
most	O
important	O
consequences	O
of	O
necrotic	O
cell	O
death	O
as	O
well	O
as	O
its	O
regulated	O
subtype	O
,	O
necroptosis	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
1	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
50	O
]	O
,	O
[	O
51	O
]	O
.	O

Our	O
results	O
highlight	O
an	O
important	O
notion	O
that	O
inflammation	O
not	O
only	O
passively	O
accompanies	O
necroptosis	O
in	O
a	O
variety	O
of	O
cellular	O
systems	O
by	O
the	O
virtue	O
of	O
rapid	O
loss	O
of	O
plasma	O
membrane	O
integrity	O
characteristic	O
for	O
necrotic	O
cell	O
death	O
,	O
but	O
also	O
that	O
it	O
is	O
an	O
intrinsic	O
and	O
regulated	O
component	O
of	O
necroptosis	O
due	O
to	O
the	O
specific	O
activation	O
of	O
TNFalpha	B-Protein
synthesis	O
by	O
RIP1	B-Protein
/	O
Akt	O
kinases	O
.	O

Therefore	O
,	O
this	O
pathway	O
may	O
represent	O
a	O
new	O
molecular	O
target	O
for	O
the	O
inhibition	O
of	O
pathologic	O
inflammatory	O
signaling	O
.	O

Initial	O
in	O
vivo	O
data	O
appears	O
to	O
support	O
this	O
notion	O
.	O

Two	O
recent	O
papers	O
showed	O
that	O
the	O
loss	O
of	O
control	O
over	O
RIP1	B-Protein
/	O
RIP3	B-Protein
kinase	O
activities	O
by	O
FADD	B-Protein
and	O
caspase	B-Protein
-	I-Protein
8	I-Protein
in	O
epithelial	O
cells	O
unleashes	O
a	O
feed	O
forward	O
cycle	O
of	O
necroptosis	O
and	O
TNFalpha	B-Protein
production	O
,	O
resulting	O
in	O
the	O
development	O
of	O
intestinal	O
inflammation	O
in	O
mice	O
and	O
,	O
possibly	O
,	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

This	O
increased	O
production	O
of	O
TNFalpha	B-Protein
during	O
necroptosis	O
may	O
also	O
be	O
important	O
for	O
acute	O
necrotizing	O
diseases	O
,	O
such	O
as	O
necrotizing	O
pancreatitis	O
and	O
acute	O
bacterial	O
infections	O
,	O
where	O
hyper	O
-	O
acute	O
inflammation	O
accompanying	O
necrotic	O
cell	O
death	O
is	O
the	O
primary	O
cause	O
of	O
multiple	O
organ	O
failure	O
and	O
patient	O
death	O
.	O

Along	O
these	O
lines	O
,	O
another	O
recent	O
paper	O
by	O
Duprez	O
et	O
al	O
.	O
has	O
shown	O
that	O
RIP1	B-Protein
and	O
RIP3	B-Protein
mediate	O
the	O
cellular	O
damage	O
introduced	O
by	O
TNF	O
-	O
induced	O
SIRS	O
[	O
6	O
]	O
.	O

The	O
role	O
of	O
RIP1	B-Protein
kinase	O
in	O
acute	O
and	O
chronic	O
inflammatory	O
diseases	O
warrants	O
further	O
investigation	O
,	O
as	O
efficient	O
and	O
specific	O
RIP1	B-Protein
kinase	O
inhibitors	O
may	O
offer	O
therapeutic	O
benefit	O
for	O
treating	O
these	O
conditions	O
.	O

Reagents	O
and	O
Chemicals	O

Necrostatin	O
analogs	O
were	O
synthesized	O
as	O
previously	O
described	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

The	O
following	O
reagents	O
and	O
final	O
concentrations	O
(	O
unless	O
otherwise	O
specified	O
in	O
the	O
text	O
/	O
figures	O
)	O
were	O
used	O
in	O
the	O
experiments	O
:	O
Akt	O
inhibitor	O
VIII	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
MK	O
-	O
2206	O
(	O
10	O
microM	O
,	O
Selleck	O
Chem	O
)	O
,	O
Triciribine	O
(	O
100	O
microM	O
,	O
National	O
Cancer	O
Institute	O
)	O
,	O
SP600125	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
JNK	O
inhibitor	O
VIII	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
UO126	O
(	O
10	O
mM	O
,	O
Cayman	O
Chem	O
)	O
,	O
PD169316	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
LiCl	O
(	O
10	O
mM	O
,	O
Sigma	O
)	O
,	O
SB216763	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
BX912	O
(	O
10	O
microM	O
,	O
Axon	O
Med	O
Chem	O
)	O
,	O
PF	O
-	O
4706871	O
(	O
Sigma	O
)	O
,	O
rapamycin	O
(	O
100	O
nM	O
,	O
Santa	O
Cruz	O
)	O
,	O
PI	O
-	O
103	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
Torin	O
-	O
1	O
(	O
500	O
nM	O
,	O
gift	O
of	O
Dr	O
.	O
Nathanael	O
Grey	O
(	O
Harvard	O
Medical	O
School	O
)	O
,	O
LY249002	O
(	O
10	O
microM	O
,	O
Cell	O
Signaling	O
)	O
,	O
PD173074	O
(	O
2	O
microM	O
,	O
Cayman	O
Chem	O
)	O
,	O
PD166866	O
(	O
20	O
microM	O
,	O
Calbiochem	O
)	O
,	O
4EGI	O
-	O
1	O
(	O
50	O
microM	O
,	O
Calbiochem	O
)	O
.	O

Pan	O
-	O
caspase	O
inhibitor	O
zVAD	O
.	O
fmk	O
(	O
20	O
-	O
30	O
microM	O
)	O
was	O
purchased	O
from	O
Bachem	O
.	O

Human	O
and	O
mouse	O
TNFalpha	B-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
human	O
bFGF	B-Protein
(	O
25	O
ng	O
/	O
ml	O
)	O
,	O
EGF	B-Protein
(	O
50	O
ng	O
/	O
ml	O
)	O
,	O
PDGF	O
-	O
BB	O
(	O
20	O
ng	O
/	O
ml	O
)	O
,	O
and	O
IGF	B-Protein
-	I-Protein
1	I-Protein
(	O
50	O
ng	O
/	O
ml	O
)	O
were	O
from	O
Cell	O
Sciences	O
or	O
Peprotech	O
.	O

All	O
other	O
reagents	O
were	O
from	O
Sigma	O
.	O

DNA	O

Cloning	O
of	O
Myr	B-Protein
-	I-Protein
Akt1	I-Protein
,	O
containing	O
c	O
-	O
terminal	O
FLAG	O
tag	O
,	O
has	O
been	O
described	O
[	O
52	O
]	O
.	O

Myr	B-Protein
-	I-Protein
Akt1	I-Protein
-	I-Protein
FLAG	I-Protein
was	O
amplified	O
by	O
PCR	O
and	O
subcloned	O
into	O
the	O
BglII	O
and	O
EcoRI	O
sites	O
of	O
pMSCV	O
-	O
puro	O
retroviral	O
vector	O
(	O
Invitrogen	O
)	O
.	O

Mutant	O
versions	O
of	O
Myr	B-Protein
-	I-Protein
Akt1	I-Protein
were	O
generated	O
using	O
the	O
same	O
strategy	O
.	O

Antibodies	O

The	O
following	O
antibodies	O
were	O
used	O
:	O
phospho	O
-	O
Akt	O
(	O
Thr308	O
)	O
(	O
clone	O
C31E5E	O
)	O
rabbit	O
mAb	O
,	O
phospho	O
-	O
Akt	O
(	O
Ser473	O
)	O
(	O
clone	O
D9E	O
)	O
XP	O
rabbit	O
mAb	O
,	O
Akt	O
(	O
pan	O
)	O
(	O
clone	O
C67E7	O
)	O
rabbit	O
mAb	O
,	O
Akt1	O
(	O
clone	O
C73H10	O
)	O
rabbit	O
mAb	O
,	O
Akt2	O
(	O
clone	O
D6G4	O
)	O
rabbit	O
mAb	O
,	O
Akt3	O
(	O
clone	O
62A8	O
)	O
rabbit	O
mAb	O
,	O
phospho	O
-	O
JNK	O
(	O
Thr183	O
/	O
Tyr185	O
)	O
(	O
81E11	O
)	O
rabbit	O
mAb	O
,	O
SAPK	O
/	O
JNK	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
c	O
-	O
Jun	O
(	O
Ser63	O
)	O
II	O
rabbit	O
pAb	O
,	O
c	O
-	O
Jun	O
(	O
60A8	O
)	O
rabbit	O
mAb	O
,	O
alpha	O
-	O
tubulin	O
(	O
clone	O
DM1A	O
)	O
mouse	O
mAb	O
,	O
phospho	O
-	O
FoxO1	O
(	O
Thr24	O
)	O
/	O
FoxO3a	O
(	O
Thr32	O
)	O
rabbit	O
pAb	O
,	O
FoxO1	O
(	O
L27	O
)	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
FoxO4	O
(	O
Ser193	O
)	O
rabbit	O
pAb	O
,	O
FoxO4	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
MDM2	O
(	O
Ser166	O
)	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
GSK	O
-	O
3alpha	O
/	O
beta	O
(	O
Ser21	O
/	O
9	O
)	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
p70	O
S6	O
Kinase	O
(	O
Thr389	O
)	O
(	O
clone	O
108D2	O
)	O
rabbit	O
mAb	O
,	O
phospho	O
-	O
S6	O
Ribosomal	O
Protein	O
(	O
Ser235	O
/	O
236	O
)	O
(	O
clone	O
D57	O
.	O
2	O
.	O
2E	O
)	O
XP	O
rabbit	O
mAb	O
,	O
S6	O
Ribosomal	O
Protein	O
(	O
clone	O
54D2	O
)	O
mouse	O
mAb	O
,	O
phospho	O
-	O
4E	O
-	O
BP1	O
(	O
Thr37	O
/	O
46	O
)	O
rabbit	O
pAb	O
,	O
mTOR	O
(	O
clone	O
7C10	O
)	O
rabbit	O
mAb	O
,	O
PDK1	O
rabbit	O
pAb	O
(	O
all	O
Cell	O
Signaling	O
)	O
,	O
MDM2	O
rabbit	O
pAb	O
(	O
Bioworlde	O
)	O
.	O

QPCR	O
Primers	O

Mouse	O
TNFalpha	B-Protein
:	O
forward	O
5	O
'	O
-	O
CCCTCACACTCAGATCATCTTCT	O
-	O
3	O
'	O
,	O
reverse	O
5	O
'	O
-	O
GCTACGACGTGGGCTACAG	O
-	O
3	O
'	O
;	O
mouse	O
18S	B-Protein
:	O
forward	O
5	O
-	O
'	O
ATAACAGGTCTGTGATGCCCTTAG	O
-	O
3	O
,	O
reverse	O
5	O
'	O
-	O
CTAAACCATCCAATCGGTAGTAGC	O
-	O
3	O
'	O
;	O
human	O
TNFalpha	B-Protein
:	O
forward	O
5	O
'	O
-	O
ATGAGCACTGAAAGCATGATCC	O
-	O
3	O
'	O
,	O
human	O
TNFalpha	B-Protein
:	O
reverse	O
5	O
'	O
-	O
GAGGGCTGATTAGAGAGAGGTC	O
-	O
3	O
'	O
;	O
human	O
18S	B-Protein
:	O
forward	O
5	O
'	O
-	O
CAGCCACCCGAGATTGAGCA	O
-	O
3	O
,	O
human	O
18S	B-Protein
:	O
reverse	O
5	O
'	O
-	O
TAGTAGCGACGGGCGGTGTG	O
-	O
3	O
'	O
.	O

Cell	O
Lines	O

L929	O
and	O
FADD	B-Protein
-	O
deficient	O
Jurkat	O
cells	O
were	O
obtained	O
from	O
ATCC	O
.	O

Lung	O
fibroblasts	O
were	O
a	O
generous	O
gift	O
of	O
Dr	O
.	O
Philip	O
Tsichlis	O
(	O
Tufts	O
University	O
)	O
[	O
53	O
]	O
.	O

J774A	O
.	O
1	O
(	O
ATCC	O
)	O
cells	O
and	O
RAW264	O
.	O
7	O
(	O
ATCC	O
)	O
cells	O
were	O
generous	O
gifts	O
of	O
Junying	O
Yuan	O
(	O
Harvard	O
University	O
)	O
and	O
Alexander	O
Poltorak	O
(	O
Tufts	O
University	O
)	O
,	O
respectively	O
.	O

Cells	O
were	O
maintained	O
in	O
DMEM	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
and	O
1	O
%	O
antibiotic	O
-	O
antimycotic	O
mixture	O
(	O
Invitrogen	O
)	O
.	O

The	O
mouse	O
lung	O
fibroblast	O
media	O
was	O
additionally	O
supplemented	O
with	O
L	O
-	O
glutamine	O
,	O
non	O
-	O
essential	O
amino	O
acids	O
,	O
and	O
sodium	O
pyruvate	O
.	O

Jurkat	O
cells	O
were	O
maintained	O
in	O
RPMI1640	O
,	O
supplemented	O
with	O
10	O
%	O
FetalPlex	O
(	O
Gemini	O
)	O
and	O
1	O
%	O
antibiotic	O
-	O
antimycotic	O
.	O

Cell	O
Viability	O
Experiments	O

Cells	O
were	O
seeded	O
into	O
white	O
clear	O
bottom	O
96	O
well	O
plates	O
at	O
the	O
density	O
of	O
1x104	O
cells	O
/	O
well	O
and	O
treated	O
as	O
described	O
for	O
western	O
blot	O
experiments	O
.	O

Cell	O
viability	O
was	O
determined	O
using	O
CellTiter	O
-	O
Glo	O
Cell	O
Viability	O
Assay	O
(	O
Promega	O
)	O
.	O

Experiments	O
were	O
performed	O
in	O
duplicate	O
or	O
triplicate	O
.	O

Viability	O
of	O
the	O
control	O
untreated	O
cells	O
was	O
set	O
as	O
100	O
%	O
.	O

Relative	O
viability	O
of	O
cells	O
,	O
induced	O
to	O
undergo	O
necroptosis	O
and	O
treated	O
with	O
the	O
compound	O
relative	O
to	O
the	O
control	O
compound	O
-	O
treated	O
cells	O
,	O
was	O
determined	O
and	O
plotted	O
to	O
exclude	O
the	O
possible	O
effects	O
of	O
non	O
-	O
specific	O
toxicity	O
of	O
the	O
small	O
molecules	O
.	O

siRNA	O
Knockdown	O

siRNAs	O
were	O
purchased	O
from	O
Dharmacon	O
.	O

Mouse	O
ribosomal	O
S6	O
protein	O
(	O
L	O
-	O
040893	O
-	O
00	O
and	O
L	O
-	O
045791	O
-	O
00	O
)	O
,	O
mouse	O
Akt1	B-Protein
(	O
L	O
-	O
040709	O
-	O
00	O
)	O
,	O
mouse	O
Akt2	B-Protein
(	O
L	O
-	O
040782	O
-	O
00	O
)	O
,	O
mouse	O
Akt3	B-Protein
(	O
L	O
-	O
040891	O
-	O
00	O
)	O
,	O
mouse	O
mTOR	O
(	O
L	O
-	O
065427	O
-	O
00	O
)	O
,	O
mouse	O
PDK1	B-Protein
(	O
L	O
-	O
040658	O
-	O
00	O
)	O
,	O
non	O
-	O
coding	O
control	O
(	O
D	O
-	O
001810	O
-	O
10	O
-	O
05	O
)	O
,	O
mouse	O
Mapk8	B-Protein
(	O
J	O
-	O
040128	O
-	O
05	O
)	O
,	O
mouse	O
Mapk9	B-Protein
(	O
J	O
-	O
040134	O
-	O
05	O
)	O
,	O
mouse	O
Jun	O
(	O
L	O
-	O
043776	O
-	O
00	O
)	O
.	O

siRNA	O
were	O
transfected	O
using	O
RNAiMAX	O
reagent	O
(	O
Invitrogen	O
)	O
,	O
according	O
to	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

After	O
72	O
hr	O
,	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
(	O
RNA	O
or	O
Western	O
blot	O
)	O
or	O
24	O
hr	O
(	O
cell	O
viability	O
)	O
.	O

Western	O
Blot	O

For	O
Western	O
blot	O
,	O
4x105	O
adherent	O
cells	O
(	O
1x106	O
Jurkat	O
cells	O
)	O
were	O
seeded	O
into	O
35	O
mm2	O
dishes	O
.	O

After	O
24	O
-	O
48	O
hr	O
,	O
cells	O
were	O
stimulated	O
with	O
30	O
microM	O
zVAD	O
.	O
fmk	O
or	O
10	O
ng	O
/	O
ml	O
mouse	O
TNFalpha	B-Protein
.	O

For	O
treatments	O
under	O
serum	O
free	O
conditions	O
,	O
cells	O
were	O
serum	O
starved	O
for	O
24	O
hr	O
prior	O
to	O
the	O
addition	O
of	O
growth	O
factors	O
,	O
20	O
microM	O
zVAD	O
.	O
fmk	O
or	O
10	O
ng	O
/	O
ml	O
mouse	O
TNFalpha	B-Protein
.	O

Cells	O
were	O
harvested	O
in	O
1xRIPA	O
buffer	O
(	O
Cell	O
Signaling	O
)	O
supplemented	O
with	O
50	O
microg	O
/	O
ml	O
phenylmethanesulfonylfluoride	O
.	O

After	O
brief	O
sonication	O
,	O
cell	O
lysates	O
were	O
spun	O
down	O
for	O
15	O
min	O
at	O
14	O
,	O
000xrpm	O
.	O

Protein	O
concentrations	O
were	O
measured	O
using	O
the	O
Pierce	O
660	O
nm	O
Assay	O
Reagent	O
(	O
Pierce	O
)	O
.	O

Equal	O
amounts	O
of	O
proteins	O
were	O
boiled	O
for	O
5	O
min	O
at	O
95degreesC	O
.	O

Western	O
blotting	O
was	O
performed	O
according	O
to	O
standard	O
protocols	O
.	O

Briefly	O
,	O
SDS	O
-	O
PAGE	O
gels	O
were	O
transferred	O
to	O
PVDF	O
membrane	O
,	O
blocked	O
in	O
3	O
%	O
milk	O
or	O
5	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
TBST	O
buffer	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Primary	O
antibodies	O
were	O
incubated	O
in	O
5	O
%	O
BSA	O
/	O
TBST	O
overnight	O
at	O
4degreesC	O
.	O

Secondary	O
antibodies	O
were	O
incubated	O
in	O
TBST	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Luminata	O
(	O
Millipore	O
)	O
ECL	O
reagents	O
were	O
used	O
to	O
develop	O
the	O
signals	O
.	O

In	O
some	O
cases	O
,	O
membranes	O
were	O
stripped	O
using	O
OneMinute	O
stripping	O
buffer	O
(	O
GM	O
Biosciences	O
)	O
and	O
reprobed	O
with	O
new	O
antibodies	O
.	O

qRT	O
-	O
PCR	O

Cells	O
were	O
treated	O
as	O
described	O
for	O
Western	O
blots	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
ZR	O
Miniprep	O
kit	O
(	O
Zymo	O
Research	O
)	O
.	O

1	O
microg	O
of	O
RNA	O
was	O
converted	O
to	O
cDNA	O
using	O
random	O
primers	O
(	O
M	O
-	O
MuLV	O
cDNA	O
kit	O
,	O
New	O
England	O
Biolabs	O
)	O
.	O

1	O
microL	O
of	O
cDNA	O
was	O
used	O
with	O
500	O
pM	O
primers	O
in	O
qPCR	O
reactions	O
.	O

Reactions	O
were	O
performs	O
using	O
SYBRGreen	O
2xMaster	O
mix	O
(	O
SABiosciences	O
)	O
in	O
a	O
LightCycler480	O
(	O
Roche	O
)	O
.	O

Stable	O
Infection	O
of	O
Myr	B-Protein
-	I-Protein
Akt1	I-Protein

To	O
generate	O
MSCV	O
retroviruses	O
,	O
HEK293FT	O
cells	O
(	O
Invitrogen	O
)	O
were	O
transfected	O
with	O
2	O
microg	O
of	O
viral	O
DNA	O
and	O
1	O
microg	O
of	O
gal	O
/	O
pol	O
and	O
VSV	O
-	O
G	O
accessory	O
plasmids	O
in	O
6	O
well	O
plates	O
using	O
GenJet	O
transfection	O
reagent	O
(	O
Signagen	O
Labs	O
)	O
.	O

Virus	O
-	O
containing	O
media	O
was	O
collected	O
72	O
hr	O
later	O
,	O
filtered	O
through	O
0	O
.	O
45	O
microm	O
filter	O
and	O
applied	O
to	O
L929	O
cells	O
with	O
8	O
microg	O
/	O
ml	O
polybrene	O
.	O

Cells	O
were	O
selected	O
and	O
maintained	O
in	O
10	O
microg	O
/	O
ml	O
puromycin	O
.	O

ELISAOne	O
Assay	O

ELISAOne	O
assays	O
(	O
TGRBio	O
,	O
Hindmarsh	O
,	O
Australia	O
)	O
were	O
performed	O
according	O
to	O
manufacturer	O
'	O
s	O
protocol	O
with	O
the	O
following	O
modifications	O
.	O

Cell	O
lysates	O
were	O
prepared	O
in	O
RIPA	O
buffer	O
as	O
described	O
for	O
Western	O
blots	O
.	O

Five	O
microliters	O
of	O
samples	O
were	O
diluted	O
in	O
45	O
microL	O
of	O
ELISAOne	O
lysis	O
buffer	O
prior	O
to	O
analysis	O
.	O

Primary	O
antibodies	O
to	O
phopsho	O
-	O
Thr308	O
and	O
phopsho	O
-	O
Ser473	O
were	O
incubated	O
with	O
the	O
samples	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
.	O

Primary	O
antibody	O
to	O
pan	O
-	O
Akt	O
was	O
incubated	O
overnight	O
at	O
4degreesC	O
.	O

Signals	O
for	O
phospho	O
-	O
antibodies	O
were	O
normalized	O
based	O
on	O
pan	O
-	O
Akt	O
values	O
.	O

TNFalpha	B-Protein
ELISA	O

Mouse	O
TNFalpha	B-Protein
Quantikine	O
ELISA	O
assays	O
(	O
R	O
&	O
D	O
Systems	O
)	O
were	O
performed	O
according	O
to	O
manufacturer	O
'	O
s	O
descriptions	O
.	O

Cell	O
lysates	O
were	O
prepared	O
from	O
3x106	O
cells	O
plated	O
and	O
treated	O
in	O
a	O
10	O
cm2	O
dish	O
.	O

In	O
vitro	O
Akt	O
Kinase	O
Assay	O

Akt	O
kinase	O
activity	O
was	O
measured	O
using	O
the	O
Akt	O
kinase	O
assay	O
kit	O
(	O
nonradioactive	O
)	O
from	O
Cell	O
Signaling	O
Technology	O
.	O

In	O
brief	O
,	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
was	O
immunoprecipitated	O
from	O
L929	O
cells	O
using	O
anti	O
-	O
FLAG	O
M2	O
magnetic	O
beads	O
(	O
Sigma	O
)	O
.	O

The	O
in	O
vitro	O
assay	O
was	O
performed	O
in	O
the	O
presence	O
of	O
a	O
GSK	O
fusion	O
protein	O
substrate	O
.	O

Phosphorylation	O
of	O
the	O
GSK	O
fusion	O
protein	O
was	O
visualized	O
by	O
western	O
blot	O
.	O

bFGF	B-Protein
and	O
IGF	B-Protein
-	I-Protein
1	I-Protein
promote	O
necroptosis	O
in	O
concert	O
with	O
zVAD	O
.	O
fmk	O
.	O

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
TNFalpha	B-Protein
or	O
zVAD	O
.	O
fmk	O
under	O
normal	O
serum	O
(	O
10	O
%	O
FBS	O
)	O
or	O
serum	O
free	O
conditions	O
.	O

Cell	O
viability	O
was	O
determined	O
after	O
24	O
hr	O
using	O
the	O
CellTiter	O
-	O
Glo	O
Viability	O
assay	O
.	O

The	O
concentrations	O
of	O
all	O
necroptosis	O
-	O
inducing	O
agents	O
are	O
listed	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
or	O
indicated	O
in	O
the	O
figures	O
.	O

(	O
B	O
)	O
Cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
,	O
the	O
indicated	O
growth	O
factors	O
,	O
and	O
Nec	O
-	O
1	O
under	O
serum	O
free	O
conditions	O
for	O
24	O
hrs	O
followed	O
by	O
measurement	O
of	O
cell	O
viability	O
.	O

(	O
C	O
)	O
Cells	O
under	O
serum	O
free	O
conditions	O
were	O
treated	O
with	O
FGF	O
,	O
zVAD	O
.	O
fmk	O
,	O
or	O
both	O
for	O
24	O
hrs	O
followed	O
by	O
viability	O
assay	O
.	O

(	O
D	O
)	O
Cell	O
death	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
under	O
full	O
serum	O
condition	O
in	O
the	O
presence	O
of	O
2	O
microM	O
PD173074	O
and	O
20	O
microM	O
PD166866	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O

Akt	O
contributes	O
to	O
necroptosis	O
induced	O
by	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
.	O

(	O
A	O
,	O
B	O
)	O
Necroptosis	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
(	O
full	O
serum	O
,	O
A	O
)	O
or	O
growth	O
factors	O
/	O
zVAD	O
.	O
fmk	O
(	O
serum	O
free	O
,	O
B	O
)	O
in	O
the	O
presence	O
of	O
inhibitors	O
of	O
Akt	O
(	O
Akt	O
inhibitor	O
VIII	O
)	O
,	O
JNK	O
(	O
SP600125	O
)	O
,	O
p38	O
(	O
PD169316	O
)	O
,	O
and	O
Erk	O
(	O
UO126	O
)	O
.	O

Cell	O
viability	O
was	O
determined	O
after	O
24	O
hrs	O
.	O

(	O
C	O
)	O
L929	O
cells	O
transfected	O
with	O
Akt1	B-Protein
,	O
Akt2	B-Protein
,	O
and	O
Akt3	B-Protein
siRNAs	I-Protein
for	O
72	O
hrs	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hrs	O
.	O

Cell	O
viability	O
and	O
Akt	O
expression	O
levels	O
were	O
determined	O
after	O
24	O
hrs	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O

RIP1	B-Protein
kinase	O
-	O
dependent	O
phosphorylation	O
of	O
Akt	O
and	O
JNK	O
during	O
necroptosis	O
.	O

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
,	O
followed	O
by	O
western	O
blotting	O
with	O
indicated	O
antibodies	O
.	O

(	O
B	O
,	O
C	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
(	O
B	O
)	O
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
(	O
serum	O
free	O
conditions	O
,	O
C	O
)	O
and	O
samples	O
were	O
collected	O
at	O
the	O
indicated	O
time	O
points	O
for	O
western	O
blot	O
.	O

(	O
D	O
)	O
Nec	O
-	O
1	O
was	O
added	O
to	O
the	O
cells	O
stimulated	O
with	O
bFGF	B-Protein
or	O
bFGF	B-Protein
/	O
zVAD	O
(	O
serum	O
free	O
conditions	O
)	O
for	O
15	O
min	O
or	O
9	O
hr	O
followed	O
by	O
western	O
blot	O
with	O
the	O
indicated	O
antibodies	O
.	O

Late	O
Thr308	O
phosphorylation	O
of	O
Akt	O
contributes	O
to	O
necroptosis	O
.	O

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
bFGF	B-Protein
or	O
PDGF	O
,	O
with	O
or	O
without	O
Nec	O
-	O
1	O
,	O
for	O
the	O
indicated	O
periods	O
of	O
time	O
.	O

(	O
B	O
,	O
C	O
)	O
L929	O
cells	O
were	O
stimulated	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
(	O
B	O
)	O
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
(	O
C	O
)	O
.	O

Akt	O
inh	O
.	O

VIII	O
was	O
added	O
15	O
min	O
before	O
necroptotic	O
stimulation	O
(	O
Pre	O
)	O
or	O
at	O
indicated	O
times	O
after	O
stimulation	O
.	O

Viability	O
was	O
measured	O
24	O
hr	O
after	O
activation	O
of	O
necroptosis	O
.	O

(	O
D	O
)	O
L929	O
cells	O
were	O
stimulated	O
with	O
bFGF	B-Protein
/	O
zVAD	O
under	O
serum	O
free	O
conditions	O
.	O

PD173074	O
was	O
added	O
15	O
min	O
before	O
or	O
1	O
hr	O
after	O
FGF	O
/	O
zVAD	O
.	O

Samples	O
for	O
western	O
blot	O
were	O
collected	O
at	O
15	O
min	O
and	O
9	O
hr	O
time	O
points	O
.	O

(	O
E	O
)	O
Cells	O
were	O
pretreated	O
with	O
PD173074	O
or	O
it	O
was	O
added	O
1	O
hr	O
after	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
,	O
followed	O
by	O
viability	O
assessment	O
at	O
24	O
hr	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O

mTORC1	O
contributes	O
to	O
the	O
regulation	O
of	O
necroptosis	O
.	O

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
and	O
harvested	O
for	O
western	O
blot	O
.	O

(	O
B	O
)	O
Cell	O
under	O
serum	O
free	O
condition	O
were	O
treated	O
with	O
bFGF	B-Protein
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
for	O
the	O
indicated	O
amounts	O
of	O
time	O
,	O
followed	O
by	O
western	O
blotting	O
using	O
the	O
indicated	O
antibodies	O
.	O

(	O
C	O
)	O
Necroptosis	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
in	O
L929	O
cell	O
in	O
the	O
presence	O
of	O
inhibitors	O
of	O
Akt	O
(	O
Akt	O
inh	O
.	O
VIII	O
)	O
and	O
mTOR	O
(	O
rapamycin	O
,	O
Torin	O
-	O
1	O
and	O
PI	O
-	O
103	O
)	O
.	O

(	O
D	O
)	O
L929	O
cells	O
with	O
mTOR	O
siRNA	O
knockdown	O
were	O
harvested	O
for	O
western	O
blot	O
or	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
24	O
hrs	O
.	O

Cell	O
viability	O
was	O
determined	O
24	O
hr	O
after	O
activation	O
of	O
necroptosis	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O

Akt	O
and	O
mTORC1	O
control	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
and	O
JNK	O
activation	O
during	O
necroptosis	O
.	O

(	O
A	O
)	O
Cells	O
were	O
treated	O
under	O
serum	O
free	O
conditions	O
with	O
bFGF	B-Protein
or	O
PDGF	O
with	O
or	O
without	O
zVAD	O
.	O
fmk	O
for	O
9	O
hr	O
,	O
followed	O
by	O
qRT	O
-	O
PCR	O
analysis	O
of	O
mTNFalpha	B-Protein
.	O

Data	O
was	O
normalized	O
to	O
mouse	O
18S	B-Protein
RNA	O
.	O

(	O
B	O
)	O
Necroptosis	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
in	O
cells	O
treated	O
with	O
Nec	O
-	O
1	O
,	O
rapamycin	O
(	O
rapa	O
)	O
,	O
or	O
Akt	O
inh	O
.	O

VIII	O
inh	O
.	O
followed	O
by	O
qRT	O
-	O
PCR	O
analysis	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
.	O

(	O
C	O
-	O
F	O
)	O
L929	O
cells	O
with	O
siRNA	O
knockdown	O
of	O
Akt	O
isoforms	O
(	O
C	O
,	O
E	O
)	O
or	O
mTOR	O
(	O
D	O
,	O
F	O
)	O
were	O
stimulated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
,	O
followed	O
by	O
qRT	O
-	O
PCR	O
analysis	O
of	O
mTNFalpha	B-Protein
(	O
C	O
,	O
D	O
)	O
or	O
western	O
blot	O
(	O
E	O
,	O
F	O
)	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O

Over	O
expression	O
of	O
constitutively	O
active	O
Akt	O
restores	O
necroptosis	O
under	O
serum	O
free	O
conditions	O
.	O

(	O
A	O
,	O
B	O
)	O
L929	O
cells	O
were	O
stably	O
infected	O
with	O
empty	O
MSCV	O
retrovirus	O
or	O
viruses	O
encoding	O
Myr	O
-	O
Akt	O
or	O
the	O
catalytically	O
inactive	O
Myr	O
-	O
Akt	O
K179M	O
.	O

Necroptosis	O
was	O
induced	O
by	O
the	O
addition	O
of	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
(	O
A	O
)	O
or	O
serum	O
or	O
serum	O
free	O
conditions	O
with	O
Nec	O
-	O
1	O
(	O
B	O
)	O
.	O

Viability	O
assays	O
were	O
performed	O
after	O
24	O
hr	O
.	O

(	O
C	O
)	O
Myr	O
-	O
Akt	O
and	O
Myr	O
-	O
Akt	O
K179M	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
/	O
or	O
Nec	O
-	O
1	O
under	O
serum	O
free	O
conditions	O
for	O
9	O
hr	O
,	O
followed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

Endogenous	O
Akt	O
(	O
~	O
)	O
and	O
Myr	O
-	O
Akt	O
(	O
*	O
)	O
bands	O
are	O
indicated	O
.	O

(	O
D	O
)	O
L929	O
cells	O
,	O
stably	O
infected	O
with	O
Myr	O
-	O
Akt	O
and	O
Myr	O
-	O
Akt	O
K179KM	O
,	O
were	O
stimulated	O
with	O
zVAD	O
.	O
fmk	O
for	O
9	O
hr	O
under	O
serum	O
free	O
conditions	O
.	O

TNFalpha	B-Protein
mRNA	O
levels	O
were	O
determined	O
by	O
qRT	O
-	O
PCR	O
and	O
normalized	O
using	O
mouse	O
18S	B-Protein
RNA	O
.	O

(	O
E	O
-	O
G	O
)	O
L929	O
cells	O
expressing	O
Myr	O
-	O
Akt	O
and	O
Ala	O
and	O
Asp	O
mutants	O
of	O
Thr308	O
and	O
Ser473	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
,	O
followed	O
by	O
viability	O
assay	O
at	O
24	O
hr	O
(	O
E	O
)	O
,	O
western	O
blot	O
at	O
9	O
hr	O
(	O
F	O
)	O
,	O
or	O
evaluation	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
at	O
9	O
hrs	O
(	O
G	O
)	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O

Akt	O
signaling	O
contributes	O
to	O
autocrine	O
TNFalpha	B-Protein
production	O
in	O
multiple	O
cell	O
types	O
.	O

FADD	B-Protein
deficient	O
Jurkat	O
cells	O
were	O
treated	O
with	O
TNFalpha	B-Protein
followed	O
by	O
measurement	O
of	O
(	O
A	O
)	O
human	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
and	O
normalized	O
using	O
human	O
18S	B-Protein
RNA	O
or	O
(	O
B	O
)	O
western	O
blot	O
at	O
9	O
hr	O
.	O

RAW	O
264	O
.	O
7	O
or	O
J774A	O
.	O
1	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
(	O
100	O
uM	O
or	O
50	O
uM	O
respectively	O
)	O
followed	O
by	O
(	O
C	O
,	O
E	O
)	O
measurement	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
or	O
(	O
D	O
,	O
F	O
)	O
western	O
blot	O
at	O
9	O
hr	O
.	O

(	O
G	O
)	O
Akt	O
null	O
mouse	O
lung	O
fibroblasts	O
expressing	O
Myr	O
-	O
Akt	O
or	O
K179M	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
followed	O
by	O
measurement	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
at	O
9	O
hr	O
.	O

(	O
H	O
)	O
Mouse	O
lung	O
fibroblasts	O
expressing	O
only	O
endogenous	O
Akt1	B-Protein
or	O
Akt2	B-Protein
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
followed	O
by	O
measurement	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
at	O
9	O
hr	O
.	O

Model	O
of	O
RIP1	B-Protein
,	O
Akt	O
and	O
JNK	O
dependent	O
signaling	O
in	O
necroptotic	O
L929	O
cells	O
.	O

Akt	O
phosphorylation	O
at	O
Thr308	O
during	O
necroptosis	O
requires	O
inputs	O
from	O
both	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
.	O

Downstream	O
from	O
Akt	O
,	O
JNK	O
activation	O
leads	O
to	O
TNFalpha	B-Protein
synthesis	O
.	O

Activation	O
of	O
Akt	O
during	O
necroptosis	O
also	O
leads	O
the	O
phosphorylation	O
of	O
several	O
known	O
Akt	O
substrates	O
,	O
such	O
as	O
mTOR	O
,	O
which	O
contribute	O
to	O
the	O
execution	O
of	O
necroptotic	O
death	O
in	O
L929	O
cells	O
.	O

Tumor	O
Suppressor	O
WWOX	B-Protein
and	O
p53	B-Protein
Alterations	O
and	O
Drug	O
Resistance	O
in	O
Glioblastomas	O

Tumor	O
suppressor	O
p53	B-Protein
are	O
frequently	O
mutated	O
in	O
glioblastomas	O
(	O
GBMs	O
)	O
and	O
appears	O
to	O
contribute	O
,	O
in	O
part	O
,	O
to	O
resistance	O
to	O
temozolomide	O
(	O
TMZ	O
)	O
and	O
therapeutic	O
drugs	O
.	O

WW	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
oxidoreductase	I-Protein
WWOX	B-Protein
(	O
FOR	B-Protein
or	O
WOX1	B-Protein
)	O
is	O
a	O
proapoptotic	O
protein	O
and	O
is	O
considered	O
as	O
a	O
tumor	O
suppressor	O
.	O

Loss	O
of	O
WWOX	B-Protein
gene	O
expression	O
is	O
frequently	O
seen	O
in	O
malignant	O
cancer	O
cells	O
due	O
to	O
promoter	O
hypermethylation	O
,	O
genetic	O
alterations	O
,	O
and	O
translational	O
blockade	O
.	O

Intriguingly	O
,	O
ectopic	O
expression	O
of	O
wild	O
type	O
WWOX	B-Protein
preferentially	O
induces	O
apoptosis	O
in	O
human	O
glioblastoma	O
cells	O
harboring	O
mutant	O
p53	B-Protein
.	O

WWOX	B-Protein
is	O
known	O
to	O
physically	O
bind	O
and	O
stabilize	O
wild	O
type	O
p53	B-Protein
.	O

Here	O
,	O
we	O
provide	O
an	O
overview	O
for	O
the	O
updated	O
knowledge	O
in	O
p53	B-Protein
and	O
WWOX	B-Protein
,	O
and	O
postulate	O
potential	O
scenarios	O
that	O
wild	O
type	O
and	O
mutant	O
p53	B-Protein
,	O
or	O
isoforms	O
,	O
modulate	O
the	O
apoptotic	O
function	O
of	O
WWOX	B-Protein
.	O

We	O
propose	O
that	O
triggering	O
WWOX	B-Protein
activation	O
by	O
therapeutic	O
drugs	O
under	O
p53	B-Protein
functional	O
deficiency	O
is	O
needed	O
to	O
overcome	O
TMZ	O
resistance	O
and	O
induce	O
GBM	O
cell	O
death	O
.	O

Glioblastoma	O
multiforme	O
afflicts	O
12	O
,	O
500	O
new	O
patients	O
in	O
the	O
U	O
.	O
S	O
.	O
annually	O
(	O
Friedman	O
et	O
al	O
.	O
,	O
2000	O
;	O
Stupp	O
et	O
al	O
.	O
,	O
2009	O
;	O
Silber	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Glioblastoma	O
(	O
GBM	O
)	O
is	O
highly	O
lethal	O
,	O
and	O
the	O
average	O
survival	O
expectancy	O
is	O
14	O
.	O
6	O
months	O
,	O
and	O
the	O
overall	O
5	O
-	O
year	O
survival	O
rate	O
for	O
GBM	O
is	O
only	O
9	O
.	O
8	O
%	O
(	O
Friedman	O
et	O
al	O
.	O
,	O
2000	O
;	O
Stupp	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

High	O
levels	O
of	O
resistance	O
to	O
current	O
therapeutic	O
modalities	O
and	O
cancer	O
relapse	O
are	O
frequently	O
seen	O
in	O
patients	O
(	O
Haar	O
et	O
al	O
.	O
,	O
2012	O
;	O
Happold	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

The	O
current	O
standard	O
therapy	O
for	O
GBM	O
mainly	O
includes	O
maximum	O
debulking	O
surgery	O
,	O
radiation	O
,	O
and	O
treatment	O
with	O
the	O
monofunctional	O
alkylating	O
agent	O
temozolomide	O
(	O
TMZ	O
)	O
(	O
Friedman	O
et	O
al	O
.	O
,	O
2000	O
;	O
Nishikawa	O
,	O
2010	O
)	O
.	O

Multiple	O
mechanisms	O
are	O
involved	O
in	O
the	O
TMZ	O
resistance	O
,	O
which	O
may	O
include	O
cancer	O
stem	O
cells	O
,	O
microRNAs	O
,	O
drug	O
efflux	O
,	O
DNA	O
damage	O
repair	O
,	O
tumor	O
cells	O
under	O
hypoxia	O
,	O
histone	O
deacetylation	O
,	O
epithelial	O
-	O
mesenchymal	O
transition	O
,	O
STAT3	O
kinase	O
,	O
and	O
many	O
others	O
(	O
Haar	O
et	O
al	O
.	O
,	O
2012	O
;	O
Happold	O
et	O
al	O
.	O
,	O
2012	O
;	O
Johannessen	O
and	O
Bjerkvig	O
,	O
2012	O
;	O
Kitange	O
et	O
al	O
.	O
,	O
2012	O
;	O
Kohsaka	O
et	O
al	O
.	O
,	O
2012	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Temozolomide	O
induces	O
generation	O
of	O
DNA	O
lesions	O
,	O
including	O
O6	O
-	O
methylguanine	O
,	O
N3	O
-	O
methyladenine	O
,	O
and	O
N7	O
-	O
methylguanine	O
(	O
Goellner	O
et	O
al	O
.	O
,	O
2011	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

The	O
O6	O
-	O
methylguanine	O
lesion	O
is	O
known	O
to	O
trigger	O
autophagy	O
,	O
rather	O
than	O
apoptosis	O
,	O
to	O
cause	O
cell	O
death	O
(	O
Kanzawa	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

Also	O
,	O
inhibition	O
of	O
antiapoptotic	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
by	O
a	O
pan	O
-	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
inhibitor	O
(	O
-	O
)	O
-	O
gossypol	O
leads	O
to	O
autophagic	O
death	O
in	O
gliomas	O
and	O
enhances	O
the	O
action	O
of	O
TMZ	O
(	O
Voss	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

However	O
,	O
a	O
recent	O
study	O
demonstrated	O
that	O
TMZ	O
-	O
induced	O
autophagy	O
is	O
pro	O
-	O
survival	O
,	O
and	O
may	O
block	O
the	O
eventual	O
apoptosis	O
in	O
GBM	O
cells	O
(	O
Knizhnik	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O

Also	O
,	O
MAPO2	B-Protein
(	O
C1orf201	B-Protein
)	O
gene	O
participates	O
in	O
the	O
O6	O
-	O
methylguanine	O
lesion	O
-	O
induced	O
apoptosis	O
(	O
Fujikane	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

MAPO2	B-Protein
gene	O
encodes	O
a	O
novel	O
37	O
-	O
kDa	O
protein	O
.	O

It	O
is	O
not	O
determined	O
whether	O
this	O
gene	O
is	O
involved	O
in	O
autophagy	O
.	O

The	O
O6	O
-	O
methylguanine	O
lesion	O
is	O
a	O
substrate	O
for	O
direct	O
repair	O
by	O
O6	B-Protein
-	I-Protein
methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
methyltransferase	I-Protein
(	O
MGMT	B-Protein
)	O
(	O
Pollack	O
et	O
al	O
.	O
,	O
2006	O
;	O
Hegi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Fukushima	O
et	O
al	O
.	O
,	O
2009	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Without	O
MGMT	B-Protein
repair	O
,	O
O6	O
-	O
methylguanine	O
initiates	O
activation	O
of	O
mismatch	O
repair	O
-	O
deficient	O
(	O
MMR	O
)	O
proteins	O
or	O
Rad3	O
-	O
related	O
protein	O
kinase	O
that	O
ultimately	O
leads	O
to	O
apoptotic	O
cell	O
death	O
(	O
Caporali	O
et	O
al	O
.	O
,	O
2004	O
;	O
Wang	O
and	O
Edelmann	O
,	O
2006	O
;	O
Roos	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

High	O
expression	O
of	O
MGMT	B-Protein
or	O
loss	O
of	O
MMR	O
contributes	O
significantly	O
to	O
TMZ	O
resistance	O
in	O
many	O
clinical	O
cases	O
(	O
Pollack	O
et	O
al	O
.	O
,	O
2006	O
;	O
Hegi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Sarkaria	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

The	O
initiation	O
of	O
apoptotic	O
signaling	O
fails	O
in	O
the	O
absence	O
of	O
the	O
MMR	O
system	O
.	O

Sensitivity	O
to	O
TMZ	O
is	O
significantly	O
associated	O
with	O
the	O
methylation	O
status	O
of	O
MGMT	B-Protein
gene	O
promoter	O
in	O
cells	O
committed	O
to	O
differentiation	O
(	O
Villalva	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

An	O
increase	O
in	O
MGMT	B-Protein
gene	O
promoter	O
methylation	O
,	O
which	O
blocks	O
MGMT	B-Protein
protein	O
expression	O
,	O
prolongs	O
cancer	O
patient	O
survival	O
.	O

Intriguingly	O
,	O
overexpressed	O
microRNA	B-Protein
-	I-Protein
21	I-Protein
reduces	O
Bax	B-Protein
/	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
ratio	O
and	O
caspase	B-Protein
-	I-Protein
3	I-Protein
activity	O
,	O
thereby	O
blocking	O
TMZ	O
-	O
induced	O
apoptosis	O
(	O
Shi	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

MicroRNA	B-Protein
-	I-Protein
21	I-Protein
is	O
considered	O
as	O
a	O
pro	O
-	O
survival	O
factor	O
for	O
cancer	O
cells	O
(	O
Li	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Integrins	O
play	O
a	O
role	O
in	O
the	O
resistance	O
of	O
advanced	O
cancers	O
to	O
radiotherapy	O
and	O
chemotherapy	O
.	O

alpha5beta1	O
integrin	O
negatively	O
regulates	O
p53	B-Protein
signaling	O
,	O
and	O
the	O
event	O
induces	O
glioma	O
cell	O
resistance	O
to	O
TMZ	O
(	O
Janouskova	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

alpha5beta1	O
integrin	O
is	O
considered	O
as	O
a	O
therapeutic	O
target	O
for	O
high	O
-	O
grade	O
brain	O
tumors	O
.	O

The	O
base	O
excision	O
repair	O
enzyme	O
alkylpurine	O
-	O
DNA	O
-	O
N	O
-	O
glycosylase	O
(	O
APNG	O
)	O
,	O
which	O
repairs	O
the	O
cytotoxic	O
lesions	O
N3	O
-	O
methyladenine	O
and	O
N7	O
-	O
methylguanine	O
,	O
also	O
participates	O
in	O
the	O
TMZ	O
resistance	O
(	O
Agnihotri	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Upregulation	O
of	O
mitochondrial	O
respiratory	O
chain	O
coupling	O
to	O
suppress	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
regulated	O
by	O
cytochrome	O
c	O
oxidase	O
contributes	O
in	O
part	O
to	O
TMZ	O
resistance	O
in	O
gliomas	O
(	O
Oliva	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Reversal	O
of	O
TMZ	O
resistance	O
may	O
be	O
achieved	O
by	O
MGMT	B-Protein
pseudosubstrates	O
,	O
O6	O
-	O
benzylguanine	O
and	O
lomeguatrib	O
to	O
sensitize	O
tumors	O
to	O
TMZ	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Methoxyamine	O
-	O
blocker	O
of	O
base	O
excision	O
repair	O
contributes	O
significantly	O
to	O
TMZ	O
cytotoxicity	O
particularly	O
when	O
O6	O
-	O
methylguanine	O
adducts	O
are	O
repaired	O
or	O
tolerated	O
(	O
Goellner	O
et	O
al	O
.	O
,	O
2011	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Dual	O
targeting	O
of	O
base	O
excision	O
repair	O
and	O
NAD	O
(	O
+	O
)	O
biosynthesis	O
may	O
reverse	O
TMZ	O
resistance	O
in	O
patients	O
with	O
resistant	O
and	O
recurrent	O
GBM	O
(	O
Goellner	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Interferon	B-Protein
-	I-Protein
beta	I-Protein
(	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
)	O
,	O
levetiracetam	O
(	O
LEV	O
)	O
,	O
resveratrol	O
,	O
and	O
valproic	O
acid	O
(	O
VAP	O
)	O
increase	O
the	O
sensitivity	O
of	O
TMZ	O
through	O
MGMT	B-Protein
-	O
dependent	O
or	O
-	O
independent	O
mechanisms	O
(	O
Nakada	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Resveratrol	O
,	O
a	O
natural	O
polyphenol	O
,	O
reverses	O
TMZ	O
resistance	O
via	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
mechanism	O
(	O
Huang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

STAT3	B-Protein
inhibitor	O
or	O
STAT3	B-Protein
knockdown	O
potentiates	O
TMZ	O
efficacy	O
in	O
resistant	O
GBM	O
cell	O
lines	O
(	O
Kohsaka	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Intratumoral	O
hypoxia	O
is	O
common	O
in	O
GBMs	O
and	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
TMZ	O
resistance	O
.	O

Induced	O
hyperoxia	O
can	O
be	O
utilized	O
to	O
reverse	O
TMZ	O
resistance	O
in	O
GBMs	O
(	O
Sun	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Cancer	O
stem	O
cells	O
are	O
probably	O
the	O
key	O
to	O
failure	O
in	O
TMZ	O
treatment	O
.	O

The	O
concept	O
of	O
cancer	O
stem	O
cell	O
survival	O
from	O
treatment	O
with	O
TMZ	O
and	O
other	O
chemotherapeutic	O
drugs	O
has	O
been	O
more	O
complicated	O
than	O
previously	O
thought	O
(	O
Beier	O
et	O
al	O
.	O
,	O
2011	O
;	O
Chen	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

CD133	B-Protein
-	O
positive	O
cancer	O
stem	O
cells	O
are	O
expressed	O
in	O
both	O
normal	O
stem	O
cells	O
and	O
cancer	O
stem	O
cells	O
(	O
Donovan	O
and	O
Pilkington	O
,	O
2012	O
)	O
.	O

However	O
,	O
the	O
role	O
of	O
CD133	B-Protein
as	O
a	O
marker	O
for	O
glioma	O
cancer	O
stem	O
cells	O
relative	O
to	O
its	O
biological	O
function	O
has	O
yet	O
to	O
be	O
established	O
.	O

Recently	O
,	O
tumor	O
suppressors	O
p53	B-Protein
and	O
WWOX	B-Protein
were	O
shown	O
to	O
regulate	O
the	O
apoptosis	O
of	O
glioblastoma	O
cells	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

WW	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
oxidoreductase	I-Protein
,	O
known	O
as	O
WWOX	B-Protein
,	O
FOR	B-Protein
,	O
or	O
WOX1	B-Protein
,	O
is	O
encoded	O
by	O
human	O
or	O
mouse	O
WWOX	B-Protein
/	O
Wwox	B-Protein
gene	O
.	O

This	O
gene	O
is	O
located	O
in	O
chromosome	O
16q23	O
.	O
3	O
-	O
24	O
.	O
1	O
,	O
an	O
area	O
known	O
as	O
the	O
common	O
fragile	O
site	O
FRA16D	O
.	O

The	O
full	O
-	O
length	O
WWOX	B-Protein
protein	O
is	O
composed	O
of	O
two	O
N	O
-	O
terminal	O
WW	O
domains	O
,	O
a	O
C	O
-	O
terminal	O
short	O
-	O
chain	O
alcohol	O
dehydrogenase	O
/	O
reductase	O
(	O
SDR	O
)	O
domain	O
,	O
and	O
a	O
proapoptotic	O
C	O
-	O
terminal	O
tail	O
D3	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
,	O
2007	O
,	O
2010	O
;	O
Aqeilan	O
et	O
al	O
.	O
,	O
2004	O
,	O
2007	O
;	O
Hong	O
et	O
al	O
.	O
,	O
2007	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
)	O
(	O
Figure	O
1	O
)	O
.	O

WWOX	B-Protein
may	O
act	O
as	O
an	O
alternative	O
receptor	O
for	O
sex	O
steroid	O
hormones	O
,	O
since	O
its	O
SDR	O
domain	O
possesses	O
an	O
NSYK	O
motif	O
capable	O
of	O
interacting	O
with	O
androgen	O
and	O
estrogen	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2005a	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Expression	O
of	O
WWOX	B-Protein
is	O
either	O
altered	O
or	O
lost	O
from	O
epigenetic	O
modification	O
in	O
multiple	O
malignant	O
cancers	O
,	O
such	O
as	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
(	O
Donati	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
hematopoietic	O
malignancies	O
(	O
Ishii	O
and	O
Furukawa	O
,	O
2004	O
)	O
,	O
gastric	O
carcinoma	O
(	O
Aqeilan	O
et	O
al	O
.	O
,	O
2004	O
)	O
,	O
pancreatic	O
carcinoma	O
(	O
Kuroki	O
et	O
al	O
.	O
,	O
2004	O
)	O
,	O
breast	O
carcinoma	O
(	O
Guler	O
et	O
al	O
.	O
,	O
2004	O
;	O
Aqeilan	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
and	O
glioblastoma	O
multiforme	O
(	O
Kosla	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Restoration	O
of	O
WWOX	B-Protein
gene	O
prevents	O
the	O
growth	O
of	O
lung	O
cancer	O
(	O
Fabbri	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
pancreatic	O
cancer	O
(	O
Nakayama	O
et	O
al	O
.	O
,	O
2008	O
)	O
,	O
and	O
prostate	O
cancer	O
(	O
Hong	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

The	O
first	O
WW	O
domain	O
of	O
WWOX	B-Protein
may	O
interact	O
with	O
proteins	O
possessing	O
a	O
PPxY	O
motif	O
(	O
s	O
)	O
such	O
as	O
AP	B-Protein
-	I-Protein
2gamma	I-Protein
,	O
p73	B-Protein
,	O
ErbB4	B-Protein
,	O
Ezrin	B-Protein
,	O
SIMPLE	B-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
RUNX4	B-Protein
,	O
and	O
many	O
others	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
;	O
Figure	O
1	O
)	O
.	O

Transiently	O
overexpressed	O
WWOX	B-Protein
binds	O
transcription	O
factors	O
AP	B-Protein
-	I-Protein
2	I-Protein
,	O
p73	B-Protein
,	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
and	O
block	O
their	O
nuclear	O
relocation	O
in	O
vitro	O
,	O
which	O
suppresses	O
cancer	O
cell	O
survival	O
(	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

In	O
stark	O
contrast	O
,	O
Wwox	B-Protein
co	O
-	O
migrates	O
with	O
proapoptotic	O
and	O
pro	O
-	O
survival	O
transcription	O
factors	O
to	O
the	O
nuclei	O
of	O
neurons	O
upon	O
sciatic	O
nerve	O
axotomy	O
in	O
rats	O
(	O
Li	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

No	O
blocking	O
of	O
translocation	O
of	O
transcription	O
factors	O
to	O
the	O
nuclei	O
by	O
Wwox	B-Protein
was	O
observed	O
.	O

Under	O
stress	O
conditions	O
,	O
WWOX	B-Protein
is	O
activated	O
via	O
phosphorylation	O
at	O
Tyr33	O
,	O
and	O
binds	O
proteins	O
independently	O
of	O
the	O
PPxY	O
motif	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
,	O
2003	O
,	O
2005a	O
,	O
b	O
,	O
2007	O
,	O
2010	O
)	O
.	O

Activated	O
WWOX	B-Protein
physically	O
interacts	O
with	O
serine	O
46	O
-	O
phosphorylated	O
p53	B-Protein
(	O
Figure	O
1	O
)	O
,	O
which	O
stabilizes	O
p53	B-Protein
and	O
its	O
apoptotic	O
function	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2005b	O
)	O
.	O

Also	O
,	O
WWOX	B-Protein
binds	O
Disheveled	O
proteins	O
(	O
Dvl	O
)	O
,	O
which	O
are	O
key	O
components	O
in	O
Wnt	O
/	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
signaling	O
pathway	O
(	O
Figure	O
1	O
)	O
.	O

No	O
PPxY	O
motif	O
is	O
in	O
Dvl	O
.	O

Transiently	O
overexpressed	O
WWOX	B-Protein
sequesters	O
Dvl	B-Protein
-	I-Protein
2	I-Protein
in	O
the	O
cytoplasm	O
and	O
thereby	O
blocks	O
Dvl	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
TCF	O
transcriptional	O
activity	O
(	O
Bouteille	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Overexpressed	O
WWOX	B-Protein
induces	O
apoptosis	O
and	O
inhibits	O
proliferation	O
of	O
human	O
hepatic	O
carcinoma	O
cells	O
(	O
Hu	O
et	O
al	O
.	O
,	O
2012	O
)	O
and	O
many	O
cancer	O
cell	O
types	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
,	O
2010	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

WWOX	B-Protein
enhances	O
the	O
cytotoxic	O
function	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
by	O
down	O
-	O
regulating	O
apoptosis	O
inhibitor	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
and	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
and	O
up	O
-	O
regulating	O
apoptotic	O
p53	B-Protein
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

Also	O
,	O
WWOX	B-Protein
mediates	O
cell	O
death	O
synergistically	O
with	O
p53	B-Protein
.	O

Upon	O
exposure	O
to	O
chemicals	O
or	O
environmental	O
stress	O
,	O
such	O
as	O
UV	O
irradiation	O
and	O
chemotherapeutic	O
drugs	O
,	O
WWOX	B-Protein
undergoes	O
phosphorylation	O
in	O
Tyr33	O
and	O
probably	O
others	O
sites	O
,	O
followed	O
by	O
relocating	O
to	O
mitochondria	O
or	O
nuclei	O
for	O
inducing	O
apoptosis	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
,	O
2010	O
)	O
.	O

WWOX	B-Protein
binds	O
MEK	O
in	O
Jurkat	O
T	O
cells	O
(	O
Lin	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
dissociates	O
the	O
MEK	O
/	O
WWOX	O
complex	O
and	O
induces	O
WWOX	B-Protein
to	O
translocate	O
to	O
the	O
mitochondria	O
to	O
induce	O
apoptosis	O
,	O
whereas	O
MEK	O
relocates	O
to	O
the	O
lipid	O
raft	O
.	O

Inhibition	O
of	O
MEK	O
activity	O
increases	O
TMZ	O
-	O
induced	O
suppression	O
of	O
cancer	O
cell	O
growth	O
(	O
Holt	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Ectopic	O
expression	O
of	O
WWOX	B-Protein
in	O
A549	O
cells	O
induces	O
procaspase	B-Protein
-	I-Protein
3	I-Protein
and	O
procaspase	B-Protein
-	I-Protein
9	I-Protein
activation	O
and	O
induces	O
cytochrome	O
C	O
releasing	O
from	O
the	O
mitochondria	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2012a	O
)	O
.	O

Complement	O
C1q	O
induces	O
ectopic	O
WWOX	B-Protein
phosphorylation	O
in	O
Try33	O
and	O
leads	O
to	O
cell	O
apoptosis	O
independently	O
of	O
the	O
classical	O
complement	O
activation	O
pathway	O
(	O
Hong	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

A	O
portion	O
of	O
WWOX	B-Protein
is	O
anchored	O
in	O
the	O
membrane	O
/	O
cytoskeleton	O
area	O
via	O
binding	O
with	O
hyaluronidase	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
(	O
Hsu	O
et	O
al	O
.	O
,	O
2009	O
)	O
and	O
Phospho	O
-	O
Ezrin	B-Protein
(	O
Jin	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Transforming	B-Protein
growth	I-Protein
factor	I-Protein
beta1	I-Protein
binds	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
as	O
a	O
cognate	O
receptor	O
to	O
signal	O
the	O
formation	O
of	O
the	O
WWOX	O
/	O
Hyal	O
-	O
2	O
/	O
Smad4	O
complex	O
to	O
relocate	O
to	O
the	O
nucleus	O
for	O
enhancing	O
the	O
SMAD	O
-	O
driven	O
promoter	O
activity	O
(	O
Hsu	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Activated	O
p53	B-Protein
mediates	O
apoptosis	O
,	O
cell	O
cycle	O
arrest	O
,	O
senescence	O
,	O
DNA	O
repair	O
,	O
or	O
metabolism	O
(	O
Lane	O
and	O
Levine	O
,	O
2010	O
)	O
.	O

The	O
primary	O
structures	O
of	O
p53	B-Protein
and	O
its	O
isoforms	O
are	O
depicted	O
(	O
Figure	O
2	O
)	O
.	O

p53	B-Protein
induces	O
cell	O
cycle	O
arrest	O
by	O
transactivating	O
genes	O
such	O
as	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	B-Protein
,	O
or	O
microRNA	O
miR34	B-Protein
.	O

p53	B-Protein
induces	O
apoptosis	O
by	O
transactivating	O
proapoptotic	O
genes	O
such	O
as	O
BAX	B-Protein
,	O
PUMA	B-Protein
,	O
SCOTIN	B-Protein
,	O
and	O
FAS	B-Protein
,	O
and	O
inhibiting	O
the	O
antiapoptotic	O
gene	O
BCL	B-Protein
-	I-Protein
2	I-Protein
(	O
Lane	O
and	O
Levine	O
,	O
2010	O
)	O
.	O

p53	B-Protein
triggers	O
pro	O
-	O
survival	O
or	O
cell	O
death	O
response	O
,	O
depending	O
upon	O
cell	O
types	O
,	O
the	O
intensity	O
of	O
the	O
stress	O
signal	O
,	O
and	O
the	O
extent	O
of	O
cellular	O
damage	O
(	O
Menendez	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Also	O
,	O
p53	B-Protein
plays	O
a	O
role	O
in	O
controlling	O
cell	O
motility	O
via	O
regulating	O
the	O
expression	O
of	O
smooth	B-Protein
muscle	I-Protein
alpha	I-Protein
-	I-Protein
actin	I-Protein
(	O
Comer	O
et	O
al	O
.	O
,	O
1998	O
)	O
,	O
collagens	B-Protein
IIalpha1	I-Protein
and	O
VIalpha1	B-Protein
(	O
Sun	O
et	O
al	O
.	O
,	O
1999	O
)	O
,	O
and	O
many	O
others	O
.	O

At	O
least	O
nine	O
isoforms	O
of	O
p53	B-Protein
have	O
been	O
identified	O
due	O
to	O
alternative	O
mRNA	O
splicing	O
,	O
multiple	O
gene	O
promoters	O
,	O
and	O
alternative	O
initiation	O
sites	O
of	O
translation	O
(	O
Ghosh	O
et	O
al	O
.	O
,	O
2004	O
;	O
Ray	O
et	O
al	O
.	O
,	O
2006	O
;	O
Figure	O
2	O
)	O
.	O

In	O
cancers	O
,	O
aberrant	O
expression	O
of	O
p53	B-Protein
isoforms	O
occurs	O
frequently	O
(	O
Bourdon	O
et	O
al	O
.	O
,	O
2005	O
;	O
Bourdon	O
,	O
2007	O
)	O
.	O

Full	O
-	O
length	O
p53	B-Protein
,	O
delta133p53	B-Protein
,	O
and	O
p53beta	B-Protein
are	O
localized	O
mainly	O
in	O
the	O
nucleus	O
,	O
and	O
only	O
few	O
of	O
them	O
are	O
in	O
cytoplasm	O
.	O

p53gamma	B-Protein
and	O
delta133p53beta	B-Protein
are	O
localized	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
.	O

delta133p53gamma	B-Protein
is	O
localized	O
in	O
the	O
cytoplasm	O
(	O
Bourdon	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Co	O
-	O
transfection	O
of	O
p53	B-Protein
and	O
p53beta	B-Protein
increases	O
p53	B-Protein
-	O
mediated	O
apoptosis	O
,	O
whereas	O
co	O
-	O
expression	O
of	O
p53	B-Protein
with	O
delta133p53	B-Protein
suppresses	O
p53	B-Protein
-	O
mediated	O
apoptosis	O
(	O
Bourdon	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

delta133p53	B-Protein
differentially	O
regulates	O
gene	O
expression	O
in	O
p53	B-Protein
-	O
dependent	O
and	O
-	O
independent	O
manners	O
(	O
Aoubala	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Co	O
-	O
expression	O
of	O
delta133p53beta	B-Protein
or	O
delta133p53gamma	B-Protein
with	O
p53	B-Protein
does	O
not	O
affect	O
p53	B-Protein
transcriptional	O
activity	O
on	O
p21	B-Protein
and	O
Bax	B-Protein
promoters	O
,	O
as	O
well	O
as	O
apoptosis	O
.	O

p53	B-Protein
mutants	O
are	O
considered	O
as	O
unfavorable	O
factors	O
for	O
the	O
effectiveness	O
in	O
radiotherapy	O
and	O
TMZ	O
treatment	O
in	O
glioma	O
cells	O
(	O
Gjerset	O
et	O
al	O
.	O
,	O
1995	O
;	O
Hirose	O
et	O
al	O
.	O
,	O
2001	O
;	O
Squatrito	O
et	O
al	O
.	O
,	O
2010	O
;	O
Blough	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Loss	O
of	O
functional	O
p53	B-Protein
confers	O
sensitivity	O
to	O
TMZ	O
in	O
glioma	O
cells	O
,	O
whereas	O
wild	O
type	O
p53	B-Protein
increases	O
the	O
TMZ	O
resistance	O
(	O
Blough	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

p53	B-Protein
mutants	O
reduce	O
TMZ	O
sensitivity	O
in	O
gliomas	O
(	O
Blough	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Altered	O
WWOX	B-Protein
expression	O
is	O
shown	O
in	O
GBMs	O
,	O
in	O
which	O
downregulation	O
of	O
WWOX	B-Protein
is	O
associated	O
with	O
loss	O
of	O
heterozygosity	O
and	O
promoter	O
methylation	O
(	O
Kosla	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
overexpressed	O
WWOX	B-Protein
induces	O
apoptosis	O
of	O
glioblastoma	O
U373	O
-	O
MG	O
cells	O
harboring	O
mutant	O
p53	B-Protein
by	O
causing	O
hypoploidy	O
and	O
DNA	O
fragmentation	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

However	O
,	O
ectopic	O
WWOX	B-Protein
has	O
no	O
effect	O
with	O
U87	O
-	O
MG	O
expressing	O
wild	O
type	O
p53	B-Protein
.	O

Unlike	O
TMZ	O
,	O
WWOX	B-Protein
induces	O
apoptosis	O
of	O
U373	O
-	O
MG	O
cells	O
via	O
a	O
mitochondria	O
-	O
independent	O
and	O
caspase	B-Protein
-	I-Protein
3	I-Protein
-	O
independent	O
pathway	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

While	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
the	O
survival	O
of	O
human	O
glioblastoma	O
cells	O
depends	O
upon	O
interactions	O
between	O
the	O
gain	O
-	O
of	O
-	O
function	O
of	O
p53	B-Protein
mutants	O
and	O
WWOX	B-Protein
.	O

Activated	O
WWOX	B-Protein
binds	O
wild	O
type	O
p53	B-Protein
with	O
Ser46	O
phosphorylation	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2005b	O
)	O
.	O

UV	O
irradiation	O
enhances	O
the	O
binding	O
interactions	O
.	O

Despite	O
the	O
presence	O
of	O
Ser46	O
in	O
delta40p53	B-Protein
,	O
binding	O
of	O
this	O
protein	O
with	O
WWOX	B-Protein
remains	O
to	O
be	O
determined	O
.	O

We	O
postulate	O
that	O
in	O
GBM	O
cells	O
,	O
both	O
wild	O
type	O
p53	B-Protein
and	O
ectopic	O
WWOX	B-Protein
proteins	O
appear	O
to	O
have	O
a	O
functional	O
antagonism	O
,	O
thereby	O
nullifying	O
each	O
other	O
'	O
s	O
function	O
in	O
inducing	O
apoptosis	O
(	O
Figure	O
2	O
)	O
.	O

Mutant	O
p53	B-Protein
proteins	O
cannot	O
bind	O
ectopic	O
WWOX	B-Protein
in	O
GBM	O
cells	O
,	O
and	O
WWOX	B-Protein
is	O
able	O
to	O
induce	O
apoptosis	O
.	O

Whether	O
WWOX	B-Protein
causes	O
apoptosis	O
in	O
GBM	O
expressing	O
p53	B-Protein
isoforms	O
is	O
unknown	O
and	O
remains	O
to	O
be	O
established	O
.	O

Whether	O
WWOX	B-Protein
affects	O
TMZ	O
sensitivity	O
has	O
never	O
been	O
determined	O
.	O

Binding	O
proteins	O
for	O
WWOX	B-Protein
and	O
/	O
or	O
p53	B-Protein
are	O
likely	O
to	O
affect	O
apoptosis	O
and	O
TMZ	O
sensitivity	O
in	O
GBM	O
cells	O
.	O

WWOX	B-Protein
binds	O
MEK	O
,	O
and	O
that	O
PMA	O
dissociates	O
this	O
complex	O
for	O
causing	O
apoptosis	O
of	O
T	O
leukemia	O
cells	O
(	O
Lin	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Thus	O
,	O
appropriate	O
chemicals	O
,	O
which	O
break	O
apart	O
the	O
WWOX	O
/	O
MEK	O
complex	O
,	O
are	O
expected	O
to	O
cause	O
GBM	O
cell	O
death	O
.	O

Preliminary	O
studies	O
from	O
our	O
screening	O
of	O
chemicals	O
have	O
selected	O
certain	O
small	O
molecules	O
that	O
induce	O
apoptosis	O
of	O
many	O
types	O
of	O
cancer	O
cells	O
(	O
Lu	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

Indeed	O
,	O
specific	O
inhibition	O
of	O
MEK	O
by	O
selumetinib	O
enhances	O
TMZ	O
-	O
induced	O
cancer	O
cell	O
death	O
in	O
vivo	O
(	O
Holt	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Serum	O
factors	O
can	O
be	O
utilized	O
for	O
blocking	O
cancer	O
growth	O
.	O

For	O
example	O
,	O
serum	O
complement	O
C1q	O
induces	O
apoptosis	O
of	O
prostate	O
cancer	O
and	O
neuroblastomas	O
cells	O
without	O
participation	O
of	O
downstream	O
proteins	O
in	O
the	O
classical	O
activation	O
pathway	O
(	O
Hong	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

In	O
this	O
event	O
,	O
ectopic	O
WWOX	B-Protein
is	O
activated	O
for	O
inducing	O
apoptosis	O
.	O

Failure	O
of	O
ectopic	O
WWOX	B-Protein
in	O
inducing	O
apoptosis	O
of	O
glioma	O
cells	O
possessing	O
wild	O
type	O
p53	B-Protein
is	O
unusual	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

In	O
most	O
cases	O
,	O
we	O
have	O
shown	O
that	O
p53	B-Protein
functionally	O
interacts	O
with	O
WWOX	B-Protein
,	O
and	O
both	O
proteins	O
induce	O
apoptosis	O
in	O
a	O
synergistic	O
manner	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
,	O
2003	O
,	O
2005a	O
,	O
b	O
,	O
2007	O
,	O
2010	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

A	O
likely	O
scenario	O
is	O
that	O
p53	B-Protein
-	O
binding	O
proteins	O
,	O
which	O
are	O
present	O
in	O
GBMs	O
,	O
may	O
interfere	O
with	O
the	O
apoptotic	O
function	O
of	O
WWOX	B-Protein
and	O
p53	B-Protein
.	O

Functional	O
antagonism	O
among	O
tumor	O
suppressors	O
has	O
never	O
been	O
documented	O
in	O
the	O
literature	O
.	O

However	O
,	O
it	O
is	O
not	O
surprising	O
to	O
find	O
that	O
many	O
tumor	O
suppressor	O
proteins	O
,	O
e	O
.	O
g	O
.	O
,	O
p53	B-Protein
,	O
WWOX	B-Protein
,	O
Smad4	B-Protein
,	O
PTEN	B-Protein
,	O
PP2A	O
,	O
and	O
etc	O
.	O
,	O
are	O
significantly	O
upregulated	O
during	O
the	O
early	O
stage	O
of	O
cancer	O
progression	O
(	O
Lai	O
et	O
al	O
.	O
,	O
2005	O
;	O
Chang	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

Do	O
these	O
proteins	O
act	O
synergistically	O
in	O
blocking	O
cancer	O
progression	O
but	O
lose	O
control	O
eventually	O
?	O

Or	O
,	O
do	O
they	O
counteract	O
each	O
other	O
'	O
s	O
function	O
,	O
thus	O
allowing	O
cancer	O
growth	O
?	O

Whether	O
endogenous	O
WWOX	B-Protein
counteracts	O
with	O
the	O
function	O
of	O
endogenous	O
p53	B-Protein
is	O
unknown	O
and	O
remains	O
to	O
be	O
established	O
.	O

One	O
of	O
the	O
unique	O
characteristics	O
for	O
malignant	O
gliomas	O
is	O
their	O
diffuse	O
infiltration	O
into	O
distant	O
brain	O
tissue	O
.	O

Signal	O
pathways	O
,	O
involving	O
PI3K	O
,	O
Akt	B-Protein
,	O
mTOR	B-Protein
,	O
NF	O
-	O
kappaB	O
,	O
and	O
autophagy	O
,	O
are	O
believed	O
to	O
confer	O
these	O
migrating	O
cells	O
resistant	O
to	O
apoptotic	O
death	O
(	O
Lefranc	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Glioma	O
cells	O
possess	O
CD44	B-Protein
as	O
a	O
receptor	O
for	O
interacting	O
with	O
brain	O
matrix	O
hyaluronan	O
(	O
Murai	O
et	O
al	O
.	O
,	O
2004	O
;	O
Yoshida	O
et	O
al	O
.	O
,	O
2012	O
)	O
,	O
and	O
secrete	O
hyaluronidases	O
and	O
metalloproteinases	O
to	O
facilitate	O
their	O
migration	O
(	O
Delpech	O
et	O
al	O
.	O
,	O
2002	O
;	O
Junker	O
et	O
al	O
.	O
,	O
2003	O
;	O
Hagemann	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Also	O
,	O
lack	O
of	O
WWOX	B-Protein
expression	O
is	O
expected	O
to	O
enhance	O
cell	O
migration	O
.	O

For	O
example	O
,	O
loss	O
of	O
WWOX	B-Protein
facilitates	O
migration	O
of	O
ovarian	O
cancer	O
and	O
osteosarcoma	O
cells	O
(	O
Gourley	O
et	O
al	O
.	O
,	O
2009	O
;	O
Del	O
Mare	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Ectopic	O
expression	O
of	O
TIAF1	B-Protein
(	O
TGF	O
-	O
beta	O
-	O
induced	O
antiapoptotic	O
factor	O
)	O
,	O
p53	B-Protein
,	O
and	O
WWOX	B-Protein
suppresses	O
anchorage	O
-	O
independent	O
growth	O
and	O
cell	O
migration	O
and	O
causes	O
apoptosis	O
in	O
cancer	O
cells	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

We	O
believe	O
that	O
glioma	O
cells	O
,	O
with	O
stem	O
cell	O
-	O
like	O
properties	O
,	O
migrate	O
individually	O
rather	O
than	O
collectively	O
.	O

This	O
assumption	O
is	O
based	O
upon	O
our	O
observations	O
that	O
mouse	O
Wwox	B-Protein
gene	O
knockout	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
embryonic	O
fibroblasts	O
)	O
migrate	O
individually	O
and	O
aggressively	O
.	O

In	O
contrast	O
,	O
wild	O
type	O
cells	O
migrate	O
collectively	O
(	O
Chou	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

While	O
a	O
portion	O
of	O
WWOX	B-Protein
is	O
anchored	O
on	O
the	O
cell	O
membrane	O
/	O
cytoskeleton	O
,	O
WWOX	B-Protein
-	O
negative	O
cells	O
lose	O
recognition	O
by	O
parental	O
WWOX	B-Protein
-	O
positive	O
cells	O
,	O
and	O
this	O
increases	O
the	O
mobility	O
of	O
WWOX	B-Protein
-	O
negative	O
cells	O
to	O
move	O
away	O
from	O
the	O
WWOX	B-Protein
-	O
positive	O
cells	O
.	O

Conceivably	O
,	O
WWOX	B-Protein
-	O
negative	O
glioma	O
cells	O
migrate	O
individually	O
and	O
turn	O
away	O
from	O
WWOX	B-Protein
-	O
expressing	O
brain	O
cells	O
to	O
low	O
WWOX	B-Protein
expression	O
areas	O
.	O

Apparently	O
,	O
the	O
migratory	O
behavior	O
of	O
WWOX	B-Protein
-	O
negative	O
glioma	O
cells	O
may	O
account	O
for	O
the	O
diffuse	O
invasion	O
into	O
distant	O
brain	O
tissue	O
(	O
Chou	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

Metabolic	O
alterations	O
have	O
been	O
shown	O
in	O
Wwox	B-Protein
knockout	O
mice	O
,	O
including	O
postnatal	O
lethality	O
,	O
bone	O
metabolism	O
defects	O
,	O
ataxia	O
,	O
steroidogenesis	O
,	O
and	O
generation	O
of	O
osteosarcomas	O
(	O
Del	O
Mare	O
et	O
al	O
.	O
,	O
2011	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

In	O
a	O
Drosophila	O
model	O
,	O
Wwox	B-Protein
is	O
shown	O
to	O
participate	O
in	O
pathways	O
involving	O
aerobic	O
metabolism	O
and	O
oxidative	O
stress	O
for	O
generation	O
of	O
ROS	O
(	O
O	O
'	O
Keefe	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Under	O
UV	O
stress	O
,	O
functional	O
Wwox	B-Protein
gene	O
expression	O
induces	O
ROS	O
production	O
in	O
Drosophila	O
.	O

Cancer	O
cells	O
are	O
known	O
to	O
overly	O
utilize	O
glycolysis	O
for	O
growth	O
advantage	O
-	O
the	O
so	O
-	O
called	O
Warburg	O
(	O
Moncada	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Conceivably	O
,	O
WWOX	B-Protein
is	O
likely	O
to	O
override	O
glucose	O
consumption	O
in	O
cancer	O
cells	O
and	O
exerts	O
generation	O
of	O
ROS	O
to	O
curb	O
the	O
cancer	O
cell	O
growth	O
and	O
invasion	O
.	O

In	O
summary	O
,	O
in	O
this	O
perspective	O
article	O
we	O
have	O
discussed	O
the	O
potential	O
role	O
of	O
tumor	O
suppressors	O
p53	B-Protein
and	O
WWOX	B-Protein
in	O
regulating	O
TMZ	O
sensitivity	O
in	O
GBM	O
cells	O
.	O

We	O
have	O
shown	O
the	O
role	O
of	O
WWOX	B-Protein
in	O
controlling	O
cell	O
migration	O
and	O
metabolic	O
alterations	O
,	O
and	O
discussed	O
the	O
effects	O
of	O
WWOX	B-Protein
deficiency	O
and	O
TMZ	O
resistance	O
in	O
cancer	O
cells	O
.	O

Ming	O
-	O
Fu	O
Chiang	O
and	O
Chun	O
-	O
I	O
Sze	O
wrote	O
the	O
sections	O
dealing	O
with	O
TMZ	O
;	O
Pei	O
-	O
Yi	O
Chou	O
wrote	O
the	O
review	O
sections	O
for	O
p53	B-Protein
and	O
WWOX	B-Protein
and	O
designed	O
graphs	O
;	O
Wan	O
-	O
Jen	O
Wang	O
managed	O
citations	O
;	O
Nan	O
-	O
Shan	O
Chang	O
conceived	O
ideas	O
,	O
wrote	O
and	O
thoroughly	O
revised	O
the	O
manuscript	O
,	O
and	O
discussed	O
with	O
coauthors	O
.	O

The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O

Schematic	O
diagrams	O
of	O
WWOX	B-Protein
structure	O
and	O
its	O
role	O
in	O
signaling	O
.	O

WWOX	B-Protein
contains	O
two	O
N	O
-	O
terminal	O
WW	O
domains	O
,	O
a	O
C	O
-	O
terminal	O
short	O
-	O
chain	O
alcohol	O
dehydrogenase	O
/	O
reductase	O
(	O
SDR	O
)	O
domain	O
,	O
and	O
a	O
D3	O
region	O
.	O

A	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
is	O
in	O
between	O
the	O
WW	O
domains	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2003	O
,	O
2007	O
;	O
Del	O
Mare	O
et	O
al	O
.	O
,	O
2011	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
;	O
reviews	O
)	O
.	O

The	O
SDR	O
domain	O
possesses	O
a	O
mitochondria	O
-	O
binding	O
region	O
.	O

There	O
are	O
two	O
conserved	O
tyrosine	O
phosphorylation	O
sites	O
,	O
Tyr33	O
and	O
Tyr287	O
.	O

Other	O
phosphorylation	O
sites	O
predicted	O
by	O
NetPhos	O
2	O
.	O
0	O
Server	O
are	O
Tyr6	O
,	O
Thr12	O
,	O
Ser14	O
,	O
Tyr61	O
,	O
Tyr293	O
,	O
and	O
Thr3B3	O
,	O
respectively	O
.	O

Upon	O
stress	O
stimulation	O
,	O
WWOX	B-Protein
is	O
phosphorylated	O
in	O
Tyr33	O
and	O
binds	O
p53	B-Protein
.	O

The	O
WWOX	O
/	O
p53	O
complex	O
then	O
translocates	O
to	O
mitochondria	O
or	O
nucleus	O
to	O
induce	O
apoptosis	O
.	O

WWOX	B-Protein
also	O
binds	O
PPxY	O
motif	O
-	O
containing	O
transcription	O
factors	O
,	O
such	O
as	O
RUNX2	B-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
ERBB4	B-Protein
,	O
via	O
its	O
first	O
WW	O
domain	O
,	O
and	O
the	O
binding	O
blocks	O
the	O
activity	O
of	O
these	O
proteins	O
by	O
retaining	O
them	O
in	O
the	O
cytoplasm	O
.	O

WWOX	B-Protein
binds	O
Tau	B-Protein
via	O
its	O
SDR	O
domain	O
.	O

WWOX	B-Protein
participates	O
in	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signal	O
pathway	O
by	O
binding	O
Dvl	O
and	O
inhibiting	O
its	O
nuclear	O
import	O
.	O

Phorbol	O
ester	O
stimulates	O
the	O
dissociation	O
of	O
MEK	O
/	O
WWOX	O
complex	O
in	O
Jurkat	O
T	O
cell	O
,	O
and	O
the	O
released	O
WWOX	B-Protein
translocates	O
to	O
the	O
mitochondria	O
for	O
causing	O
cell	O
death	O
.	O

WWOX	B-Protein
is	O
recruited	O
to	O
the	O
membrane	O
area	O
by	O
association	O
with	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
and	O
phospho	O
-	O
Ezrin	B-Protein
.	O

Hyal	B-Protein
-	I-Protein
2	I-Protein
is	O
an	O
alternative	O
receptor	O
for	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
.	O

In	O
response	O
to	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
,	O
WWOX	B-Protein
binds	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
and	O
forms	O
a	O
complex	O
,	O
followed	O
by	O
relocating	O
to	O
the	O
nucleus	O
and	O
enhancing	O
the	O
SMAD	O
-	O
driven	O
promoter	O
activity	O
.	O

Ack1	B-Protein
,	O
activated	B-Protein
Cdc42	I-Protein
-	I-Protein
associated	I-Protein
kinase	I-Protein
1	I-Protein
;	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
,	O
hyaluronoglucosaminidase	B-Protein
2	I-Protein
;	O
CKI	O
,	O
casein	O
kinase	O
;	O
GSK	O
,	O
glycogen	O
synthase	O
kinase	O
;	O
PKA	O
,	O
protein	O
kinase	O
A	O
.	O

p53	B-Protein
and	O
WWOX	B-Protein
in	O
GBM	O
cell	O
apoptosis	O
.	O

(	O
A	O
)	O
Full	O
-	O
length	O
p53	B-Protein
possesses	O
two	O
N	O
-	O
terminal	O
transactivation	O
acidic	O
domains	O
,	O
a	O
proline	O
-	O
rich	O
domain	O
,	O
a	O
central	O
DNA	O
-	O
binding	O
region	O
,	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
,	O
containing	O
a	O
nuclear	O
localization	O
signal	O
,	O
an	O
oligomerization	O
domain	O
,	O
and	O
a	O
basic	O
region	O
.	O

N	O
-	O
terminal	O
deletion	O
mutants	O
of	O
p53	B-Protein
are	O
also	O
shown	O
.	O

(	O
B	O
)	O
Three	O
likely	O
scenarios	O
are	O
proposed	O
for	O
WWOX	B-Protein
and	O
p53	B-Protein
to	O
regulate	O
GBM	O
cell	O
death	O
.	O

First	O
,	O
ectopic	O
WWOX	B-Protein
fails	O
to	O
induce	O
apoptosis	O
of	O
GBM	O
cells	O
expressing	O
endogenous	O
wild	O
type	O
p53	B-Protein
.	O

It	O
appears	O
that	O
ectopic	O
WWOX	B-Protein
binds	O
and	O
functionally	O
antagonizes	O
p53	B-Protein
,	O
and	O
both	O
proteins	O
nullify	O
each	O
other	O
'	O
s	O
function	O
in	O
inducing	O
apoptosis	O
.	O

Second	O
,	O
no	O
physical	O
interactions	O
between	O
mutant	O
p53	B-Protein
proteins	O
and	O
WWOX	B-Protein
are	O
expected	O
in	O
GBM	O
cells	O
.	O

Thus	O
,	O
ectopic	O
WWOX	B-Protein
induce	O
apoptosis	O
in	O
mutant	O
p53	B-Protein
-	O
expressing	O
cells	O
.	O

Finally	O
,	O
whether	O
WWOX	B-Protein
binds	O
p53	B-Protein
isoforms	O
is	O
unknown	O
.	O

Also	O
,	O
whether	O
ectopic	O
WWOX	B-Protein
induction	O
of	O
apoptosis	O
in	O
GBM	O
cells	O
expressing	O
p53	B-Protein
isoforms	O
remains	O
to	O
be	O
established	O
.	O

TAD	O
,	O
transactivation	O
domain	O
;	O
PrD	O
,	O
proline	O
domain	O
;	O
NLS	O
,	O
nuclear	O
localization	O
signal	O
;	O
OD	O
,	O
oligomerization	O
domain	O
;	O
BR	O
,	O
basic	O
region	O
.	O

The	O
Transcription	O
Factor	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Mediates	O
Constitutive	O
and	O
LPS	O
-	O
Inducible	O
Transcription	O
of	O
Murine	O
SerpinB2	B-Protein

SerpinB2	B-Protein
or	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
type	I-Protein
2	I-Protein
(	O
PAI	B-Protein
-	I-Protein
2	I-Protein
)	O
is	O
highly	O
induced	O
in	O
macrophages	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
and	O
is	O
linked	O
to	O
the	O
modulation	O
of	O
innate	O
immunity	O
,	O
macrophage	O
survival	O
,	O
and	O
inhibition	O
of	O
plasminogen	O
activators	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
a	O
potent	O
bacterial	O
endotoxin	O
,	O
can	O
induce	O
SerpinB2	B-Protein
expression	O
via	O
the	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
(	O
TLR4	B-Protein
)	O
by	O
~	O
1000	O
-	O
fold	O
over	O
a	O
period	O
of	O
24	O
hrs	O
in	O
murine	O
macrophages	O
.	O

To	O
map	O
the	O
LPS	O
-	O
regulated	O
SerpinB2	B-Protein
promoter	O
regions	O
,	O
we	O
transfected	O
reporter	O
constructs	O
driven	O
by	O
the	O
~	O
5	O
kb	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
and	O
several	O
deletion	O
mutants	O
into	O
murine	O
macrophages	O
.	O

In	O
addition	O
,	O
we	O
compared	O
the	O
DNA	O
sequence	O
of	O
the	O
murine	O
5	O
'	O
flanking	O
sequence	O
with	O
the	O
sequence	O
of	O
the	O
human	O
gene	O
for	O
homologous	O
functional	O
regulatory	O
elements	O
and	O
identified	O
several	O
regulatory	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
human	O
SERPINB2	B-Protein
promoter	O
conserved	O
in	O
the	O
mouse	O
.	O

Mutation	O
analyses	O
revealed	O
that	O
a	O
CCAAT	O
enhancer	O
binding	O
(	O
C	O
/	O
EBP	O
)	O
element	O
,	O
a	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
two	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
response	O
elements	O
in	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
are	O
essential	O
for	O
optimal	O
LPS	O
-	O
inducibility	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMSA	O
)	O
and	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
demonstrated	O
that	O
LPS	O
induces	O
the	O
formation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
containing	O
complexes	O
with	O
the	O
SerpinB2	B-Protein
promoter	O
.	O

Importantly	O
,	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
expression	O
was	O
severely	O
abrogated	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
null	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
primary	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
peritoneal	O
macrophages	O
.	O

Together	O
,	O
these	O
data	O
provide	O
new	O
insight	O
into	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
dependent	O
regulation	O
of	O
inflammation	O
-	O
associated	O
SerpinB2	B-Protein
expression	O
.	O

The	O
inflammatory	O
response	O
is	O
a	O
double	O
-	O
edged	O
sword	O
.	O

Properly	O
orchestrated	O
,	O
it	O
results	O
in	O
the	O
clearing	O
of	O
foreign	O
molecules	O
and	O
invading	O
pathogens	O
from	O
the	O
body	O
.	O

Uncontrolled	O
,	O
it	O
may	O
lead	O
to	O
organ	O
damage	O
,	O
sepsis	O
,	O
and	O
even	O
cancer	O
[	O
1	O
]	O
-	O
[	O
3	O
]	O
.	O

Many	O
of	O
the	O
pathological	O
manifestations	O
of	O
the	O
inflammatory	O
response	O
are	O
mediated	O
by	O
cytokines	O
and	O
other	O
inducible	O
gene	O
products	O
expressed	O
by	O
macrophages	O
upon	O
exposure	O
to	O
the	O
gram	O
-	O
negative	O
bacterial	O
cell	O
wall	O
component	O
LPS	O
.	O

As	O
macrophages	O
are	O
key	O
effectors	O
of	O
pathogen	O
-	O
induced	O
innate	O
immune	O
responses	O
,	O
their	O
survival	O
is	O
critical	O
for	O
initial	O
pathogen	O
neutralization	O
and	O
subsequent	O
development	O
of	O
adaptive	O
immune	O
responses	O
.	O

One	O
of	O
the	O
most	O
LPS	O
-	O
inducible	O
macrophage	O
gene	O
products	O
known	O
is	O
the	O
ovalbumin	O
-	O
like	O
serine	O
protease	O
inhibitor	O
(	O
ov	O
-	O
serpin	O
)	O
SerpinB2	B-Protein
,	O
a	O
widely	O
recognized	O
macrophage	O
survival	O
factor	O
[	O
4	O
]	O
;	O
[	O
5	O
]	O
.	O

SerpinB2	B-Protein
was	O
first	O
identified	O
as	O
an	O
inhibitor	O
of	O
urokinase	B-Protein
-	I-Protein
type	I-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
uPA	B-Protein
)	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
,	O
a	O
serine	O
protease	O
involved	O
in	O
the	O
degradation	O
and	O
turnover	O
of	O
the	O
extracellular	O
matrix	O
through	O
the	O
activation	O
of	O
plasminogen	B-Protein
[	O
7	O
]	O
;	O
[	O
9	O
]	O
.	O

Such	O
function	O
requires	O
SerpinB2	B-Protein
to	O
be	O
secreted	O
from	O
the	O
cell	O
yet	O
SerpinB2	B-Protein
exists	O
primarily	O
as	O
a	O
nonglycosylated	O
intracellular	O
protein	O
[	O
10	O
]	O
.	O

Over	O
the	O
past	O
decade	O
,	O
intracellular	O
roles	O
for	O
SerpinB2	B-Protein
in	O
cell	O
survival	O
[	O
11	O
]	O
-	O
[	O
17	O
]	O
,	O
proliferation	O
and	O
differentiation	O
[	O
18	O
]	O
-	O
[	O
21	O
]	O
,	O
signal	O
transduction	O
[	O
15	O
]	O
;	O
[	O
22	O
]	O
;	O
[	O
23	O
]	O
and	O
innate	O
immunity	O
[	O
24	O
]	O
-	O
[	O
28	O
]	O
,	O
have	O
been	O
described	O
.	O

The	O
SerpinB2	B-Protein
gene	O
is	O
highly	O
regulated	O
in	O
a	O
cell	O
type	O
specific	O
manner	O
analogous	O
to	O
that	O
of	O
cytokines	O
and	O
oncogenes	O
[	O
29	O
]	O
;	O
[	O
30	O
]	O
.	O

It	O
is	O
one	O
of	O
the	O
most	O
responsive	O
genes	O
known	O
[	O
31	O
]	O
,	O
and	O
can	O
be	O
induced	O
over	O
1000	O
-	O
fold	O
by	O
LPS	O
[	O
31	O
]	O
-	O
[	O
32	O
]	O
,	O
and	O
is	O
up	O
-	O
regulated	O
by	O
a	O
range	O
of	O
inflammatory	O
mediators	O
[	O
9	O
]	O
.	O

LPS	O
activates	O
immune	O
responses	O
through	O
multiple	O
signalling	O
pathways	O
.	O

The	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
(	O
TLR4	B-Protein
)	O
is	O
responsible	O
for	O
the	O
recognition	O
of	O
LPS	O
and	O
other	O
microbial	O
products	O
and	O
plays	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
innate	O
immune	O
responses	O
,	O
including	O
cytokine	O
release	O
.	O

The	O
binding	O
of	O
LPS	O
to	O
TLR4	B-Protein
on	O
the	O
surface	O
of	O
macrophages	O
leads	O
to	O
the	O
recruitment	O
of	O
adaptor	O
molecules	O
and	O
the	O
activation	O
of	O
protein	O
kinases	O
,	O
generating	O
signals	O
to	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
/	O
or	O
phosphoinositide	O
3	O
(	O
PI3	O
)	O
-	O
kinase	O
pathways	O
[	O
33	O
]	O
.	O

In	O
studies	O
aimed	O
at	O
identifying	O
LPS	O
-	O
inducible	O
pro	O
-	O
survival	O
factors	O
downstream	O
of	O
p38	O
MAPK	O
,	O
SerpinB2	B-Protein
was	O
identified	O
as	O
a	O
factor	O
whose	O
expression	O
was	O
upregulated	O
by	O
cooperation	O
of	O
the	O
IKKbeta	B-Protein
/	O
NF	O
-	O
kappaB	O
and	O
p38	O
MAPK	O
/	O
CREB	O
pathways	O
[	O
16	O
]	O
.	O

Our	O
previously	O
published	O
data	O
indicated	O
that	O
SerpinB2	B-Protein
is	O
distinctly	O
regulated	O
from	O
other	O
LPS	O
-	O
inducible	O
genes	O
in	O
terms	O
of	O
kinetics	O
,	O
LPS	O
dose	O
response	O
and	O
sensitivity	O
to	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
co	O
-	O
stimulation	O
[	O
4	O
]	O
;	O
however	O
,	O
the	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
SerpinB2	B-Protein
promoter	O
responsible	O
for	O
LPS	O
-	O
dependent	O
transcription	O
in	O
macrophages	O
and	O
the	O
specific	O
LPS	O
-	O
responsive	O
transcription	O
factors	O
that	O
bind	O
the	O
SerpinB2	B-Protein
promoter	O
were	O
not	O
defined	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induction	O
of	O
SerpinB2	B-Protein
is	O
dependent	O
upon	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
in	O
the	O
region	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
539	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
,	O
and	O
is	O
critically	O
dependent	O
upon	O
a	O
C	O
/	O
EBP	O
binding	O
site	O
at	O
-	O
203	O
/	O
-	O
195	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
directly	O
bound	O
to	O
this	O
site	O
in	O
vivo	O
and	O
its	O
deficiency	O
abrogated	O
constitutive	O
SerpinB2	B-Protein
expression	O
and	O
SerpinB2	B-Protein
induction	O
by	O
LPS	O
.	O

Importantly	O
,	O
a	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	O
-	O
acceptor	O
site	O
was	O
found	O
to	O
negatively	O
regulate	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
provide	O
new	O
insight	O
into	O
the	O
transcriptional	O
regulation	O
of	O
the	O
SerpinB2	B-Protein
gene	O
.	O

Cell	O
Culture	O

Murine	O
macrophage	O
RAW	O
264	O
.	O
7	O
cells	O
(	O
ATCC	O
TIB	O
-	O
71	O
)	O
were	O
maintained	O
in	O
RPMI	O
1640	O
media	O
(	O
Gibco	O
BRL	O
)	O
,	O
supplemented	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
(	O
Gibco	O
BRL	O
)	O
,	O
10	O
%	O
serum	O
supreme	O
(	O
BioWhittaker	O
)	O
,	O
200	O
microg	O
/	O
ml	O
penicillin	O
,	O
100	O
microg	O
/	O
ml	O
streptomycin	O
,	O
25	O
mM	O
N	O
-	O
2	O
-	O
hydroxyethylpiperazine	O
-	O
N	O
-	O
2	O
-	O
ethane	O
sulphonic	O
acid	O
(	O
HEPES	O
)	O
and	O
25	O
mM	O
sodium	O
bicarbonate	O
,	O
in	O
5	O
%	O
CO2	O
and	O
95	O
%	O
humidified	O
air	O
atmosphere	O
at	O
37degreesC	O
.	O

Wild	O
-	O
type	O
(	O
Cebpb	B-Protein
+	O
/	O
+	O
)	O
and	O
knockout	O
(	O
Cebpb	B-Protein
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
[	O
34	O
]	O
were	O
grown	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
Invitrogen	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
/	O
glutamate	O
solution	O
(	O
Cellgro	O
)	O
.	O

Primary	O
peritoneal	O
macrophages	O
were	O
obtained	O
by	O
injecting	O
C57BL	O
/	O
6	O
mice	O
with	O
3	O
%	O
thioglycollate	O
broth	O
followed	O
by	O
peritoneal	O
lavage	O
3	O
-	O
5	O
days	O
later	O
,	O
and	O
maintained	O
in	O
50	O
%	O
DMEM	O
/	O
F12	O
media	O
(	O
Gibco	O
BRL	O
)	O
.	O

Precautions	O
were	O
taken	O
to	O
exclude	O
bacterial	O
lipopolysaccharide	O
contamination	O
from	O
all	O
cell	O
cultures	O
through	O
the	O
use	O
of	O
certified	O
LPS	O
-	O
free	O
serum	O
.	O

Cell	O
viability	O
was	O
determined	O
using	O
the	O
trypan	O
blue	O
(	O
Sigma	O
)	O
dye	O
exclusion	O
method	O
.	O

All	O
cultures	O
were	O
routinely	O
checked	O
to	O
exclude	O
Mycoplasma	O
infection	O
by	O
nuclear	O
staining	O
using	O
Hoechst	O
stain	O
33258	O
(	O
Sigma	O
)	O
and	O
the	O
MycoAlert	O
Detection	O
Kit	O
(	O
Lonza	O
)	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
Salmonella	O
minnesota	O
Strain	O
Re595	O
)	O
was	O
obtained	O
from	O
Sigma	O
.	O

Real	O
-	O
time	O
Quantitative	O
PCR	O
(	O
qPCR	O
)	O

The	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
was	O
used	O
to	O
isolate	O
total	O
RNA	O
from	O
cells	O
.	O

For	O
cDNA	O
synthesis	O
,	O
1	O
microg	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
TaqMan	O
(	O
R	O
)	O
Reverse	O
Transcription	O
Reagents	O
(	O
Applied	O
Biosystems	O
)	O
.	O

qPCR	O
was	O
performed	O
using	O
TaqMan	O
(	O
R	O
)	O
Gene	O
Expression	O
20X	O
primers	O
for	O
Serpinb2	B-Protein
/	O
SerpinB2	B-Protein
(	O
Mm00440905	O
_	O
m1	O
)	O
,	O
Cebpb	B-Protein
(	O
Mm00843434	O
_	O
s1	O
)	O
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
Mm00607939	O
_	O
s1	O
)	O
(	O
Applied	O
Biosystems	O
)	O
.	O

DNA	O
Sequence	O
Analysis	O

The	O
DNA	O
sequence	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
was	O
determined	O
by	O
sequencing	O
the	O
pUC	O
-	O
based	O
plasmids	O
pDB9406	O
,	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
,	O
in	O
addition	O
to	O
plasmids	O
prepared	O
from	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
containing	O
deletions	O
introduced	O
by	O
exonuclease	B-Protein
III	I-Protein
digestion	O
.	O

Plasmids	O
pDB9406	O
,	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
containing	O
genomic	O
DNA	O
isolated	O
from	O
a	O
lambdaFIXII	O
(	O
Stratagene	O
)	O
genomic	O
library	O
prepared	O
from	O
a	O
129	O
mouse	O
strain	O
,	O
were	O
kindly	O
provided	O
by	O
Dr	O
.	O
Dominique	O
Belin	O
,	O
University	O
of	O
Geneva	O
.	O

pDB9406	O
contains	O
a	O
4	O
.	O
4	O
kb	O
EcoRI	O
/	O
SpeI	O
genomic	O
fragment	O
spanning	O
the	O
transcription	O
initiation	O
site	O
;	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
contain	O
a	O
1	O
.	O
2	O
kb	O
EcoRI	O
genomic	O
fragment	O
,	O
located	O
immediately	O
upstream	O
of	O
the	O
pDB9406	O
EcoRI	O
fragment	O
,	O
cloned	O
in	O
opposite	O
orientations	O
.	O

Subcloned	O
inserts	O
were	O
verified	O
by	O
restriction	O
enzyme	O
digestion	O
and	O
DNA	O
sequencing	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
4480	O
bp	O
murine	O
SerpinB2	B-Protein
gene	O
5	O
'	O
flanking	O
region	O
was	O
determined	O
using	O
the	O
ABI	O
PRISM	O
dye	O
terminator	O
cycle	O
sequencing	O
ready	O
reaction	O
kit	O
(	O
Perkin	O
-	O
Elmer	O
)	O
and	O
a	O
PE	O
373A	O
sequencer	O
(	O
Perkin	O
-	O
Elmer	O
)	O
.	O

This	O
sequence	O
was	O
deposited	O
in	O
GenBank	O
/	O
EMBL	O
/	O
DDBJ	O
Data	O
Bank	O
with	O
Accession	O
No	O
.	O

AF339731	O
.	O

Western	O
Blot	O
Assays	O

Whole	O
cell	O
lysates	O
were	O
prepared	O
in	O
RIPA	O
buffer	O
(	O
10	O
mM	O
Tris	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
,	O
0	O
.	O
1	O
%	O
SDS	O
)	O
,	O
proteins	O
were	O
separated	O
on	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
NuPAGE	O
gels	O
(	O
Invitrogen	O
)	O
,	O
and	O
transferred	O
to	O
PVDF	O
membranes	O
.	O

Membranes	O
were	O
subsequently	O
blocked	O
with	O
5	O
%	O
milk	O
in	O
PBS	O
-	O
T	O
(	O
1X	O
PBS	O
,	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
)	O
,	O
and	O
incubated	O
with	O
primary	O
antibodies	O
overnight	O
.	O

Affinity	O
purified	O
rabbit	O
anti	O
-	O
mouse	O
SerpinB2	O
antibodies	O
were	O
prepared	O
after	O
immunization	O
with	O
a	O
purified	O
recombinant	O
GST	B-Protein
-	I-Protein
murine	I-Protein
SerpinB2	I-Protein
fusion	I-Protein
protein	I-Protein
produced	O
in	O
E	O
.	O
coli	O
as	O
in	O
[	O
35	O
]	O
.	O

Other	O
antibodies	O
used	O
for	O
western	O
blot	O
assays	O
include	O
:	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	O
sc	O
-	O
150	O
)	O
(	O
Santa	O
Cruz	O
Biotechnologies	O
)	O
,	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
(	O
GAPDH	B-Protein
)	O
and	O
alpha	O
/	O
beta	O
tubulin	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Inc	O
.	O
)	O
.	O

Construction	O
of	O
SerpinB2	B-Protein
Reporter	I-Protein
Gene	I-Protein
Plasmids	O

The	O
PCR	O
primers	O
DW5	O
'	O
LUC	O
,	O
containing	O
a	O
Kpn	O
I	O
restriction	O
site	O
,	O
and	O
DW3	O
'	O
LUC	O
,	O
containing	O
an	O
Xho	O
I	O
restriction	O
site	O
,	O
were	O
used	O
to	O
PCR	O
amplify	O
and	O
clone	O
the	O
SerpinB2	B-Protein
promoter	O
(	O
-	O
3261	O
to	O
+	O
92	O
)	O
from	O
pDB9406	O
into	O
the	O
Kpn	O
I	O
/	O
Xho	O
I	O
polylinker	O
restriction	O
sites	O
of	O
pGL3	O
Basic	O
(	O
Promega	O
)	O
to	O
produce	O
pGLmP	O
-	O
3261	O
.	O

The	O
EcoR	O
I	O
insert	O
of	O
pDB9402	O
-	O
42	O
was	O
sub	O
-	O
cloned	O
immediately	O
upstream	O
of	O
the	O
SerpinB2	B-Protein
promoter	O
EcoR	O
I	O
site	O
(	O
-	O
3261	O
)	O
of	O
pGLmP	O
-	O
3261	O
to	O
produce	O
pGLmP	O
-	O
4480	O
.	O

Additional	O
murine	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
(	O
pGLmP	O
-	O
2751	O
,	O
pGLmP	O
-	O
2614	O
,	O
pGLmP	O
-	O
1686	O
,	O
pGLmP	O
-	O
1341	O
,	O
pGLmP	O
-	O
694	O
,	O
pGLmP	O
-	O
539	O
and	O
pGLmP	O
-	O
189	O
)	O
were	O
generated	O
by	O
digesting	O
pGLmP	O
-	O
3261	O
with	O
EcoR	B-Protein
I	I-Protein
and	O
a	O
second	O
restriction	O
enzyme	O
(	O
Sfi	B-Protein
I	I-Protein
,	O
Apa	B-Protein
I	I-Protein
,	O
BstX	B-Protein
I	I-Protein
,	O
Bsu36	B-Protein
I	I-Protein
,	O
Pac	B-Protein
I	I-Protein
,	O
Hae	B-Protein
III	I-Protein
and	O
Apo	B-Protein
I	I-Protein
respectively	O
)	O
,	O
blunt	O
ending	O
the	O
resultant	O
5	O
'	O
or	O
3	O
'	O
overhangs	O
with	O
T4	B-Protein
DNA	I-Protein
polymerase	I-Protein
(	O
NEB	O
)	O
and	O
re	O
-	O
ligating	O
the	O
vector	O
ends	O
with	O
T4	B-Protein
DNA	I-Protein
ligase	I-Protein
.	O

The	O
PCR	O
primers	O
BSPCR2	O
and	O
DW3	O
'	O
LUC	O
were	O
used	O
to	O
subclone	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
regions	O
-	O
87	O
to	O
+	O
92	O
into	O
the	O
Kpn	O
I	O
/	O
Xho	O
I	O
polylinker	O
restriction	O
sites	O
of	O
pGL3	O
Basic	O
to	O
produce	O
pGLmP	O
-	O
87	O
.	O

The	O
control	O
empty	O
vector	O
was	O
pGL3	O
Basic	O
(	O
Promega	O
)	O
.	O

Luciferase	B-Protein
reporter	I-Protein
constructs	O
containing	O
mutations	O
in	O
the	O
SerpinB2	B-Protein
promoter	O
LPS	O
-	O
responsive	O
regions	O
E	O
box	O
,	O
PU	O
.	O
1	O
,	O
Oct	O
-	O
1	O
and	O
C	O
/	O
EBP	O
(	O
pGLmP	O
-	O
539mEbox	O
,	O
pGLmP	O
-	O
539mPU	O
.	O
1	O
,	O
pGLmP	O
-	O
539mOct	O
and	O
pGLmP	O
-	O
539mC	O
/	O
EBP	O
respectively	O
)	O
were	O
generated	O
as	O
described	O
[	O
36	O
]	O
.	O

The	O
mutant	O
oligonucleotide	O
PCR	O
primer	O
sequences	O
are	O
provided	O
in	O
Fig	O
.	O

S1	O
,	O
and	O
were	O
used	O
as	O
follows	O
:	O
pGLmP	O
-	O
539mEbox	O
:	O
mPAI2mEboxa	O
and	O
mPAI2mEboxb	O
;	O
pGLmP	O
-	O
539mPU	O
.	O
1	O
:	O
mPAI2mPU	O
.	O
1a	O
and	O
mPAI2mPU	O
.	O
1b	O
;	O
pGLmP	O
-	O
539mOct	O
:	O
mPAI2mOct	O
-	O
2a	O
and	O
mPAI2mOct	O
-	O
2b	O
;	O
pGLmP	O
-	O
539mC	O
/	O
EBP	O
:	O
mPAI2mCEBPa	O
and	O
mPAI2mCEBPb	O
.	O

The	O
oligonucleotide	O
PCR	O
primers	O
used	O
to	O
generate	O
mutants	O
,	O
pGLmP	O
-	O
539mCRE	O
,	O
pGLmP	O
-	O
539mAP	O
-	O
1a	O
,	O
and	O
pGLmP	O
-	O
539mAP	O
-	O
1b	O
were	O
reported	O
previously	O
[	O
37	O
]	O
.	O

The	O
flanking	O
oligonucleotide	O
PCR	O
primers	O
were	O
RVprimer3	O
(	O
Promega	O
)	O
and	O
GLprimer2	O
(	O
Promega	O
)	O
.	O

pGLmP	O
-	O
539	O
was	O
used	O
as	O
the	O
template	O
in	O
each	O
case	O
.	O

Recombinant	O
PCR	O
products	O
were	O
digested	O
with	O
EcoR	B-Protein
I	I-Protein
and	O
Xho	B-Protein
I	I-Protein
and	O
cloned	O
between	O
the	O
EcoR	O
I	O
and	O
Xho	O
I	O
restriction	O
sites	O
of	O
pGLmP	O
-	O
539	O
in	O
place	O
of	O
the	O
-	O
539	O
/	O
+	O
92	O
region	O
of	O
the	O
wild	O
-	O
type	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

Sequence	O
verified	O
constructs	O
were	O
used	O
in	O
the	O
experiments	O
.	O

Transient	O
Transfection	O
and	O
Luciferase	B-Protein
Assays	O
(	O
RAW264	O
.	O
7	O
Macrophages	O
)	O

RAW	O
264	O
.	O
7	O
cells	O
(	O
2x107	O
)	O
growing	O
in	O
log	O
phase	O
were	O
transfected	O
with	O
the	O
indicated	O
luciferase	B-Protein
reporter	O
plasmid	O
(	O
20	O
microg	O
)	O
along	O
with	O
the	O
pRL	O
-	O
thymidine	B-Protein
kinase	I-Protein
(	O
TK	B-Protein
)	O
(	O
Promega	O
)	O
internal	O
control	O
reporter	O
plasmid	O
(	O
2	O
microg	O
)	O
by	O
electroporation	O
using	O
a	O
Bio	O
-	O
Rad	O
Gene	O
Pulser	O
with	O
a	O
Capacitance	O
Extender	O
(	O
0	O
.	O
25	O
kV	O
,	O
960	O
microFd	O
)	O
.	O

pGL3	O
control	O
plasmid	O
which	O
encodes	O
the	O
SV40	O
promoter	O
and	O
enhancer	O
was	O
included	O
as	O
a	O
positive	O
control	O
for	O
transfection	O
efficiency	O
,	O
and	O
as	O
an	O
internal	O
standard	O
for	O
promoter	O
and	O
enhancer	O
activities	O
.	O

Transfected	O
cells	O
were	O
transferred	O
to	O
10	O
ml	O
of	O
pre	O
-	O
warmed	O
media	O
in	O
6	O
-	O
well	O
tissue	O
culture	O
plates	O
,	O
divided	O
into	O
two	O
identical	O
cell	O
pools	O
and	O
incubated	O
16	O
hrs	O
in	O
a	O
5	O
%	O
CO2	O
and	O
95	O
%	O
humidified	O
air	O
atmosphere	O
at	O
37degreesC	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
100	O
ng	O
/	O
ml	O
LPS	O
.	O

Luciferase	B-Protein
activity	O
was	O
measured	O
using	O
a	O
Dual	O
-	O
Luciferase	B-Protein
Reporter	O
Assay	O
System	O
kit	O
(	O
Promega	O
)	O
.	O

Measurements	O
represent	O
the	O
results	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

Promoter	O
activity	O
is	O
expressed	O
as	O
the	O
number	O
of	O
firefly	O
luciferase	B-Protein
light	O
units	O
normalized	O
either	O
to	O
pRL	O
-	O
TK	B-Protein
renilla	O
luciferase	B-Protein
light	O
units	O
or	O
to	O
cellular	O
protein	O
concentration	O
(	O
where	O
co	O
-	O
transfected	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
LPS	O
affected	O
pRL	O
-	O
TK	B-Protein
activity	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
the	O
Bio	O
-	O
Rad	O
protein	O
microassay	O
reagent	O
.	O

Lentiviral	O
shRNAs	O
,	O
Packaging	O
and	O
Transduction	O

pLKO	O
.	O
1	O
-	O
puro	O
lentiviral	O
vectors	O
carrying	O
short	O
hairpin	O
RNAs	O
(	O
shRNA	O
)	O
specific	O
for	O
human	O
and	O
mouse	O
cebpb	B-Protein
were	O
used	O
in	O
these	O
studies	O
.	O

Because	O
the	O
human	O
and	O
mouse	O
cebpb	B-Protein
3	O
'	O
untranslated	O
regions	O
are	O
not	O
identical	O
,	O
these	O
species	O
-	O
specific	O
shRNAs	O
cannot	O
knockdown	O
expression	O
of	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
when	O
used	O
on	O
cells	O
of	O
the	O
other	O
species	O
;	O
therefore	O
we	O
used	O
the	O
human	O
CEBPB	O
shRNA	O
as	O
a	O
control	O
in	O
these	O
experiments	O
as	O
in	O
[	O
38	O
]	O
.	O

To	O
produce	O
lentiviral	O
particles	O
,	O
HEK	O
-	O
293T	O
cells	O
were	O
transfected	O
with	O
a	O
mixture	O
of	O
plasmids	O
:	O
each	O
shRNA	O
expression	O
plasmid	O
(	O
1	O
microg	O
)	O
,	O
pCMV	O
-	O
deltaR8	O
.	O
2dvpr	O
packaging	O
plasmid	O
(	O
0	O
.	O
75	O
microg	O
)	O
,	O
and	O
pCMV	O
-	O
VSV	O
-	O
G	O
envelope	O
plasmid	O
(	O
0	O
.	O
25	O
microg	O
)	O
using	O
Lipofectamine	O
2000	O
reagent	O
(	O
Invitrogen	O
)	O
.	O

The	O
lentiviral	O
supernatant	O
was	O
collected	O
48	O
hrs	O
after	O
transfection	O
,	O
cleared	O
by	O
centrifugation	O
at	O
2	O
,	O
000	O
g	O
for	O
10	O
mins	O
and	O
passed	O
through	O
a	O
0	O
.	O
45	O
microm	O
filter	O
.	O

The	O
target	O
cells	O
were	O
treated	O
with	O
the	O
lentiviral	O
supernatant	O
and	O
8	O
microg	O
/	O
ml	O
Polybrene	O
(	O
American	O
Bioanalytical	O
)	O
for	O
24	O
hrs	O
.	O

The	O
lentiviral	O
supernatant	O
was	O
replaced	O
with	O
fresh	O
growth	O
media	O
and	O
incubated	O
further	O
for	O
72	O
hrs	O
to	O
allow	O
for	O
effective	O
gene	O
knockdown	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
knockdown	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
.	O

Transient	O
Transfection	O
and	O
Luciferase	B-Protein
Assays	O
(	O
MEF	O
Cells	O
)	O

Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
(	O
1x105	O
)	O
[	O
34	O
]	O
were	O
transfected	O
with	O
the	O
indicated	O
luciferase	B-Protein
reporter	O
plasmid	O
(	O
400	O
ng	O
)	O
along	O
with	O
a	O
beta	B-Protein
-	I-Protein
actin	I-Protein
-	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
reporter	O
plasmid	O
(	O
200	O
ng	O
)	O
by	O
electroporation	O
using	O
the	O
Invitrogen	O
Neon	O
(	O
TM	O
)	O
system	O
(	O
1	O
pulse	O
,	O
1350	O
V	O
,	O
30	O
msec	O
)	O
.	O

Transfected	O
cells	O
were	O
transferred	O
to	O
pre	O
-	O
warmed	O
media	O
in	O
24	O
well	O
plates	O
and	O
incubated	O
for	O
48	O
hrs	O
prior	O
to	O
incubation	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
4	O
hrs	O
where	O
indicated	O
.	O

In	O
some	O
experiments	O
,	O
plasmids	O
encoding	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
(	O
T188A	B-Protein
,	O
T217A	B-Protein
,	O
S64A	B-Protein
)	O
[	O
38	O
]	O
-	O
[	O
40	O
]	O
or	O
control	O
vector	O
were	O
co	O
-	O
transfected	O
(	O
0	O
.	O
6	O
-	O
1	O
.	O
0	O
microg	O
total	O
DNA	O
)	O
.	O

Luciferase	B-Protein
activity	O
was	O
determined	O
and	O
normalized	O
to	O
that	O
of	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
[	O
38	O
]	O
using	O
the	O
Luciferase	B-Protein
Assay	O
System	O
and	O
beta	B-Protein
-	I-Protein
Galactosidase	I-Protein
Enzyme	O
Assay	O
System	O
Kits	O
,	O
respectively	O
(	O
Promega	O
)	O
.	O

Each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
,	O
and	O
triplicate	O
samples	O
were	O
employed	O
for	O
each	O
sample	O
.	O

Expression	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutant	I-Protein
proteins	O
was	O
checked	O
for	O
equal	O
expression	O
by	O
western	O
blot	O
.	O

Electrophoretic	O
Mobility	O
Shift	O
Assays	O

Radiolabelled	O
,	O
double	O
-	O
stranded	O
oligonucleotide	O
probes	O
for	O
gel	O
shift	O
assays	O
were	O
prepared	O
using	O
T4	B-Protein
polynucleotide	I-Protein
kinase	I-Protein
and	O
[	O
gamma	O
-	O
32P	O
]	O
-	O
ATP	O
.	O

RAW	O
264	O
.	O
7	O
nuclear	O
extracts	O
were	O
prepared	O
by	O
the	O
detergent	O
lysis	O
method	O
[	O
41	O
]	O
.	O

DNA	O
binding	O
reactions	O
(	O
25	O
microl	O
)	O
containing	O
10	O
mM	O
HEPES	O
pH	O
7	O
.	O
9	O
,	O
10	O
microg	O
/	O
ml	O
BSA	O
,	O
2	O
mM	O
DTT	O
,	O
30	O
%	O
glycerol	O
,	O
20	O
%	O
Ficoll	O
-	O
400	O
,	O
1	O
microg	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
,	O
6	O
microg	O
of	O
nuclear	O
extracts	O
and	O
10	O
,	O
000	O
to	O
20	O
,	O
000	O
cpm	O
(	O
0	O
.	O
05	O
to	O
0	O
.	O
2	O
ng	O
)	O
of	O
radiolabelled	O
probe	O
were	O
performed	O
for	O
20	O
minutes	O
at	O
room	O
temperature	O
.	O

Binding	O
reaction	O
products	O
were	O
resolved	O
by	O
electrophoresis	O
at	O
room	O
temperature	O
on	O
5	O
%	O
polyacrylamide	O
gels	O
(	O
29	O
:	O
1	O
acrylamide	O
:	O
bis	O
-	O
acrylamide	O
(	O
Bio	O
-	O
Rad	O
)	O
)	O
in	O
1x	O
TBE	O
at	O
10V	O
/	O
cm	O
.	O

For	O
supershift	O
assays	O
,	O
nuclear	O
extracts	O
were	O
pre	O
-	O
incubated	O
2	O
hrs	O
on	O
ice	O
with	O
4	O
microg	O
of	O
specific	O
C	O
/	O
EBP	O
antibody	O
.	O

Antibodies	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
:	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
alpha	O
(	O
sc	O
-	O
61	O
)	O
,	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
beta	O
(	O
sc	O
-	O
150	O
)	O
,	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
delta	O
(	O
sc	O
-	O
151	O
)	O
and	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
epsilon	O
(	O
sc	O
-	O
158	O
)	O
.	O

Chromatin	O
Immunoprecipitation	O
(	O
ChIP	O
)	O
Assay	O

ChIP	O
assays	O
were	O
performed	O
using	O
a	O
commercially	O
available	O
Magna	O
-	O
ChIP	O
(	O
TM	O
)	O
kit	O
(	O
Millipore	O
)	O
,	O
as	O
recommended	O
by	O
the	O
manufacturer	O
,	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
after	O
crosslinking	O
the	O
chromatin	O
with	O
1	O
%	O
formaldehyde	O
at	O
room	O
temperature	O
for	O
10	O
min	O
and	O
neutralizing	O
with	O
glycine	O
for	O
5	O
min	O
at	O
room	O
temperature	O
,	O
cells	O
were	O
washed	O
with	O
cold	O
PBS	O
,	O
scraped	O
and	O
collected	O
on	O
ice	O
.	O

Cells	O
extracts	O
were	O
prepared	O
using	O
a	O
commercially	O
available	O
kit	O
(	O
Millipore	O
)	O
.	O

Nuclear	O
lysates	O
were	O
sonicated	O
5	O
times	O
for	O
15	O
sec	O
with	O
1	O
min	O
intervals	O
on	O
ice	O
using	O
a	O
Sonic	O
Dismembrator	O
(	O
Fisher	O
)	O
.	O

An	O
equal	O
amount	O
of	O
chromatin	O
was	O
immunoprecipitated	O
at	O
4degreesC	O
overnight	O
with	O
at	O
least	O
1	O
microg	O
of	O
the	O
following	O
antibodies	O
:	O
C	O
/	O
EBP	O
-	O
beta	O
(	O
sc	O
-	O
150X	O
)	O
,	O
p	O
-	O
C	O
/	O
EBP	O
-	O
beta	O
(	O
T217	O
)	O
(	O
sc	O
-	O
16993X	O
)	O
,	O
normal	O
rabbit	O
IgG	O
(	O
sc	O
-	O
2027	O
)	O
(	O
Santa	O
Cruz	O
Biotechnologies	O
)	O
and	O
RNA	O
polymerase	O
II	O
(	O
Clone	O
CTD4H8	O
)	O
(	O
Millipore	O
)	O
.	O

Immunoprecipitated	O
products	O
were	O
collected	O
after	O
incubation	O
with	O
Protein	B-Protein
G	I-Protein
coated	O
magnetic	O
beads	O
(	O
Millipore	O
)	O
.	O

The	O
beads	O
were	O
washed	O
,	O
the	O
bound	O
chromatin	O
was	O
eluted	O
in	O
ChIP	O
Elution	O
Buffer	O
(	O
Millipore	O
)	O
and	O
the	O
proteins	O
were	O
digested	O
with	O
Proteinase	B-Protein
K	I-Protein
for	O
2	O
hrs	O
at	O
62degreesC	O
.	O

The	O
DNA	O
was	O
then	O
purified	O
using	O
the	O
QIAquick	O
PCR	O
Purification	O
Kit	O
(	O
Qiagen	O
)	O
.	O

DNA	O
was	O
amplified	O
by	O
semi	O
-	O
quantitative	O
PCR	O
or	O
by	O
qPCR	O
using	O
the	O
SYBR	O
green	O
method	O
and	O
primers	O
specific	O
for	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
:	O
forward	O
(	O
-	O
338	O
/	O
-	O
315	O
)	O
5	O
'	O
AAGACTCCCACAGATGGTGGCTGT3	O
'	O
;	O
reverse	O
(	O
-	O
5	O
/	O
+	O
19	O
)	O
5	O
'	O
TTCTTGGAAAGCTGGCACTGTGTG3	O
'	O
.	O

Statistical	O
Analysis	O

Data	O
are	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
per	O
group	O
.	O

Results	O
were	O
analyzed	O
using	O
the	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
or	O
Student	O
'	O
s	O
t	O
test	O
where	O
relevant	O
.	O

P	O
-	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

The	O
SerpinB2	B-Protein
Gene	O
is	O
Highly	O
Responsive	O
to	O
LPS	O

When	O
RAW264	O
.	O
7	O
macrophages	O
were	O
exposed	O
to	O
LPS	O
,	O
SerpinB2	B-Protein
mRNA	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
LPS	O
challenge	O
,	O
reaching	O
maximal	O
levels	O
at	O
24	O
hrs	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

A	O
similar	O
strong	O
induction	O
of	O
LPS	O
-	O
inducible	O
SerpinB2	B-Protein
mRNA	O
expression	O
has	O
been	O
reported	O
previously	O
in	O
murine	O
peritoneal	O
macrophages	O
and	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
[	O
4	O
]	O
;	O
[	O
32	O
]	O
.	O

LPS	O
-	O
induced	O
SerpinB2	B-Protein
expression	O
involves	O
both	O
an	O
increase	O
in	O
gene	O
transcription	O
and	O
stabilization	O
of	O
the	O
mRNA	O
[	O
5	O
]	O
;	O
[	O
29	O
]	O
;	O
[	O
42	O
]	O
-	O
[	O
44	O
]	O
.	O

SerpinB2	B-Protein
protein	O
expression	O
was	O
also	O
induced	O
as	O
has	O
been	O
reported	O
in	O
other	O
cell	O
types	O
[	O
31	O
]	O
,	O
and	O
detectable	O
after	O
8	O
hrs	O
of	O
LPS	O
treatment	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
SerpinB2	B-Protein
Proximal	O
Promoter	O
Confers	O
LPS	O
Responsiveness	O

To	O
investigate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
responsive	O
to	O
LPS	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
,	O
nucleotides	O
-	O
4480	O
to	O
+	O
92	O
and	O
a	O
series	O
of	O
generated	O
deletion	O
mutants	O
of	O
the	O
5	O
'	O
flanking	O
region	O
were	O
cloned	O
upstream	O
of	O
a	O
promoter	O
-	O
less	O
firefly	O
luciferase	B-Protein
reporter	O
gene	O
(	O
pGL3	O
Basic	O
)	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

The	O
reporter	O
constructs	O
were	O
then	O
transiently	O
transfected	O
into	O
sub	O
-	O
confluent	O
RAW264	O
.	O
7	O
macrophages	O
and	O
assayed	O
for	O
luciferase	B-Protein
activity	O
in	O
the	O
presence	O
and	O
absence	O
of	O
LPS	O
or	O
PMA	O
,	O
for	O
comparison	O
.	O

PMA	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
regulation	O
has	O
been	O
extensively	O
studied	O
in	O
human	O
macrophage	O
cell	O
lines	O
[	O
45	O
]	O
-	O
[	O
47	O
]	O
,	O
and	O
has	O
been	O
shown	O
to	O
occur	O
through	O
several	O
proximal	O
and	O
distal	O
AP	O
-	O
1	O
responsive	O
elements	O
[	O
30	O
]	O
;	O
[	O
37	O
]	O
;	O
[	O
47	O
]	O
-	O
[	O
51	O
]	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2B	O
,	O
the	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
region	O
from	O
-	O
4480	O
to	O
+	O
92	O
directs	O
both	O
PMA	O
-	O
and	O
LPS	O
-	O
inducible	O
transcription	O
,	O
approximately	O
2	O
-	O
fold	O
and	O
7	O
-	O
fold	O
,	O
respectively	O
.	O

Deletion	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
from	O
-	O
1686	O
to	O
-	O
1341	O
increased	O
LPS	O
-	O
inducibility	O
to	O
approximately	O
16	O
-	O
fold	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
silencer	O
element	O
in	O
this	O
region	O
.	O

Further	O
deletion	O
beyond	O
-	O
539	O
abolished	O
the	O
LPS	O
-	O
response	O
of	O
the	O
promoter	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
essential	O
LPS	O
response	O
element	O
in	O
the	O
region	O
between	O
-	O
539	O
and	O
-	O
189	O
;	O
however	O
,	O
the	O
response	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
to	O
PMA	O
is	O
less	O
affected	O
by	O
this	O
deletion	O
.	O

While	O
deletion	O
of	O
the	O
SerpinB2	B-Protein
promoter	O
from	O
-	O
189	O
to	O
-	O
87	O
eliminated	O
the	O
LPS	O
response	O
and	O
marginally	O
reduced	O
the	O
PMA	O
response	O
,	O
the	O
-	O
87	O
murine	O
SerpinB2	B-Protein
promoter	O
construct	O
was	O
still	O
partially	O
responsive	O
to	O
PMA	O
,	O
indicating	O
that	O
cis	O
-	O
acting	O
elements	O
mediating	O
the	O
response	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
to	O
PMA	O
also	O
lie	O
downstream	O
of	O
nucleotide	O
-	O
87	O
.	O

Sequence	O
Conservation	O
within	O
the	O
Human	O
and	O
Murine	O
SerpinB2	B-Protein
Proximal	O
Promoters	O

To	O
look	O
for	O
potential	O
cis	O
-	O
acting	O
elements	O
that	O
might	O
mediate	O
transcription	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
and	O
the	O
response	O
to	O
LPS	O
,	O
we	O
aligned	O
the	O
murine	O
and	O
human	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
regions	O
.	O

We	O
reasoned	O
that	O
the	O
presence	O
of	O
evolutionarily	O
conserved	O
,	O
potential	O
transcription	O
factor	O
binding	O
sites	O
in	O
this	O
region	O
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
gene	O
expression	O
[	O
52	O
]	O
.	O

The	O
presence	O
of	O
several	O
repetitive	O
sequence	O
elements	O
delineated	O
five	O
broadly	O
homologous	O
regions	O
(	O
A	O
-	O
E	O
)	O
between	O
the	O
human	O
and	O
murine	O
promoters	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

The	O
proximal	O
promoter	O
(	O
Region	O
E	O
)	O
,	O
which	O
contains	O
the	O
essential	O
LPS	O
response	O
element	O
,	O
exhibited	O
the	O
greatest	O
homology	O
.	O

Further	O
analysis	O
of	O
Region	O
E	O
revealed	O
that	O
several	O
of	O
the	O
cis	O
-	O
acting	O
regulatory	O
elements	O
defined	O
in	O
the	O
human	O
SerpinB2	B-Protein
proximal	O
promoter	O
are	O
conserved	O
in	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Specifically	O
,	O
a	O
TATA	O
consensus	O
sequence	O
is	O
located	O
23	O
to	O
29bp	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
,	O
similar	O
to	O
the	O
position	O
of	O
the	O
TATA	O
box	O
of	O
the	O
human	O
SERPINB2	B-Protein
gene	O
[	O
53	O
]	O
;	O
[	O
54	O
]	O
.	O

A	O
putative	O
CCAAT	O
enhancer	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
site	O
is	O
present	O
at	O
-	O
192	O
/	O
-	O
203	O
,	O
two	O
potential	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
sites	O
are	O
found	O
at	O
nucleotides	O
-	O
88	O
/	O
-	O
94	O
and	O
-	O
100	O
/	O
-	O
106	O
,	O
and	O
a	O
putative	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
is	O
present	O
at	O
-	O
172	O
/	O
-	O
177	O
.	O

Both	O
of	O
the	O
AP	O
-	O
1	O
sites	O
are	O
identical	O
in	O
sequence	O
to	O
those	O
identified	O
in	O
the	O
human	O
SERPINB2	B-Protein
promoter	O
,	O
and	O
the	O
CRE	O
differs	O
in	O
the	O
identity	O
of	O
a	O
single	O
central	O
nucleotide	O
[	O
37	O
]	O
;	O
[	O
55	O
]	O
.	O

A	O
consensus	O
E	O
box	O
(	O
-	O
538	O
/	O
-	O
533	O
)	O
,	O
as	O
well	O
as	O
potential	O
binding	O
sites	O
for	O
PU	B-Protein
.	I-Protein
1	I-Protein
(	O
-	O
412	O
/	O
-	O
407	O
)	O
and	O
Oct	B-Protein
-	I-Protein
1	I-Protein
(	O
-	O
296	O
/	O
-	O
288	O
)	O
were	O
also	O
identified	O
within	O
the	O
proximal	O
promoter	O
region	O
(	O
Fig	O
.	O
S2	O
)	O
.	O

Further	O
upstream	O
,	O
a	O
retinoic	O
acid	O
response	O
element	O
at	O
-	O
1349	O
/	O
-	O
1340	O
,	O
a	O
PAUSE	O
-	O
1	O
silencer	O
element	O
at	O
-	O
1540	O
/	O
-	O
1528	O
and	O
a	O
NF	O
-	O
kappaB	O
p65	O
binding	O
site	O
at	O
-	O
1342	O
/	O
-	O
1351	O
(	O
Fig	O
.	O
S2	O
)	O
are	O
also	O
well	O
conserved	O
[	O
16	O
]	O
;	O
[	O
30	O
]	O
;	O
[	O
56	O
]	O
.	O

A	O
C	O
/	O
EBP	O
,	O
CRE	O
and	O
Two	O
AP	O
-	O
1	O
Sites	O
in	O
the	O
Murine	O
SerpinB2	B-Protein
Gene	O
Proximal	O
Promoter	O
are	O
Essential	O
for	O
Optimal	O
LPS	O
-	O
inducible	O
Transcription	O

To	O
investigate	O
regulatory	O
elements	O
between	O
-	O
539	O
and	O
-	O
189	O
essential	O
for	O
LPS	O
-	O
inducible	O
transcription	O
,	O
several	O
candidate	O
binding	O
sites	O
for	O
transcription	O
factors	O
previously	O
reported	O
to	O
mediate	O
LPS	O
-	O
inducible	O
transcription	O
in	O
other	O
genes	O
[	O
57	O
]	O
were	O
targeted	O
by	O
nucleotide	O
substitution	O
designed	O
to	O
disrupt	O
transcription	O
factor	O
binding	O
to	O
the	O
pGLmP	O
-	O
539	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
gene	I-Protein
construct	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

4B	O
,	O
mutation	O
of	O
the	O
consensus	O
E	O
box	O
(	O
-	O
538	O
/	O
-	O
533	O
)	O
,	O
PU	O
.	O
1	O
(	O
-	O
412	O
/	O
-	O
407	O
)	O
,	O
or	O
the	O
variant	O
Oct	O
-	O
1	O
(	O
-	O
296	O
/	O
-	O
288	O
)	O
site	O
did	O
not	O
decrease	O
LPS	O
-	O
induced	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
the	O
C	O
/	O
EBP	O
site	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
completely	O
eliminated	O
promoter	O
activity	O
,	O
similar	O
to	O
the	O
levels	O
observed	O
for	O
the	O
-	O
189	O
SerpinB2	B-Protein
promoter	O
deletion	O
construct	O
.	O

Others	O
have	O
also	O
recently	O
implicated	O
this	O
C	O
/	O
EBP	O
site	O
in	O
LPS	O
-	O
induced	O
activation	O
of	O
the	O
SerpinB2	B-Protein
gene	O
[	O
58	O
]	O
.	O

Considering	O
the	O
conserved	O
sequence	O
and	O
position	O
of	O
the	O
CRE	O
and	O
two	O
AP	O
-	O
1	O
sites	O
in	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
and	O
their	O
demonstrated	O
involvement	O
in	O
the	O
PMA	O
-	O
responsiveness	O
of	O
the	O
human	O
SERPINB2	B-Protein
promoter	O
[	O
37	O
]	O
,	O
these	O
sites	O
were	O
also	O
mutated	O
by	O
nucleotide	O
substitution	O
to	O
investigate	O
whether	O
they	O
played	O
a	O
role	O
in	O
the	O
LPS	O
response	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

4B	O
,	O
mutation	O
of	O
the	O
CRE	O
at	O
-	O
177	O
/	O
-	O
172	O
or	O
either	O
of	O
the	O
two	O
AP	O
-	O
1	O
sites	O
at	O
-	O
106	O
/	O
-	O
100	O
and	O
-	O
94	O
/	O
-	O
88	O
,	O
completely	O
or	O
significantly	O
reduced	O
LPS	O
-	O
inducible	O
luciferase	B-Protein
activity	O
from	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

These	O
data	O
show	O
that	O
the	O
C	O
/	O
EBP	O
element	O
,	O
as	O
well	O
as	O
the	O
CRE	O
and	O
both	O
AP	O
-	O
1	O
cis	O
-	O
acting	O
elements	O
are	O
critical	O
for	O
LPS	O
-	O
inducible	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
.	O

The	O
C	O
/	O
EBP	O
Element	O
is	O
Bound	O
by	O
an	O
LPS	O
-	O
induced	O
Nuclear	O
Factor	O
from	O
RAW	O
264	O
.	O
7	O
Macrophages	O

Nuclear	O
factor	O
binding	O
to	O
the	O
putative	O
C	O
/	O
EBP	O
element	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
was	O
investigated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
using	O
nuclear	O
extracts	O
from	O
untreated	O
and	O
LPS	O
-	O
treated	O
RAW	O
264	O
.	O
7	O
macrophages	O
.	O

Three	O
different	O
double	O
stranded	O
oligonucleotide	O
probes	O
were	O
used	O
for	O
EMSA	O
,	O
representing	O
(	O
1	O
)	O
the	O
putative	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
element	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
,	O
(	O
2	O
)	O
a	O
mutant	O
SerpinB2	B-Protein
element	O
containing	O
the	O
same	O
mutation	O
as	O
in	O
pGLmP	O
-	O
539mC	O
/	O
EBP	O
and	O
(	O
3	O
)	O
the	O
rat	O
albumin	B-Protein
promoter	O
distal	O
element	O
1	O
(	O
DEI	O
)	O
region	O
containing	O
a	O
high	O
affinity	O
C	O
/	O
EBP	O
binding	O
site	O
.	O

Four	O
bands	O
of	O
different	O
mobilities	O
,	O
representing	O
DNA	O
-	O
nuclear	O
protein	O
complexes	O
were	O
detected	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

Three	O
of	O
these	O
bands	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
represent	O
complexes	O
with	O
single	O
stranded	O
DNA	O
(	O
Fig	O
.	O
5A	O
)	O
while	O
the	O
uppermost	O
(	O
slowest	O
migrating	O
)	O
complex	O
was	O
induced	O
by	O
LPS	O
.	O

The	O
LPS	O
-	O
inducible	O
complex	O
was	O
not	O
detected	O
using	O
the	O
mutant	O
C	O
/	O
EBP	O
oligonucleotide	O
probe	O
and	O
could	O
be	O
abolished	O
by	O
an	O
excess	O
of	O
unlabeled	O
double	O
-	O
stranded	O
oligonucleotide	O
,	O
carrying	O
either	O
the	O
same	O
sequence	O
(	O
Fig	O
.	O
5B	O
,	O
lanes	O
4	O
and	O
5	O
)	O
or	O
the	O
sequence	O
of	O
a	O
known	O
C	O
/	O
EBP	O
binding	O
site	O
from	O
the	O
rat	O
albumin	B-Protein
promoter	O
(	O
Fig	O
.	O
5B	O
,	O
lanes	O
8	O
and	O
9	O
)	O
,	O
but	O
not	O
by	O
the	O
mutated	O
oligonucleotide	O
(	O
Fig	O
.	O
5B	O
,	O
lanes	O
6	O
and	O
7	O
)	O
.	O

Together	O
these	O
data	O
indicate	O
that	O
the	O
putative	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
site	O
at	O
-	O
203	O
/	O
-	O
192	O
binds	O
a	O
LPS	O
-	O
inducible	O
complex	O
that	O
is	O
likely	O
to	O
contain	O
a	O
member	O
of	O
the	O
C	O
/	O
EBP	O
family	O
of	O
transcription	O
factors	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
a	O
LPS	O
-	O
induced	O
Nuclear	O
Factor	O
that	O
Binds	O
to	O
the	O
C	O
/	O
EBP	O
Element	O
of	O
the	O
SerpinB2	B-Protein
Proximal	O
Promoter	O

The	O
C	O
/	O
EBP	O
family	O
of	O
basic	O
leucine	O
zipper	O
transcription	O
factors	O
are	O
known	O
for	O
their	O
roles	O
in	O
cellular	O
differentiation	O
and	O
inflammation	O
[	O
59	O
]	O
.	O

Consisting	O
of	O
six	O
members	O
,	O
the	O
C	O
/	O
EBP	O
transcription	O
factors	O
can	O
homo	O
-	O
/	O
heterodimerize	O
and	O
display	O
similar	O
DNA	O
binding	O
specificities	O
[	O
60	O
]	O
.	O

Four	O
family	O
members	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
alpha	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
delta	I-Protein
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
epsilon	I-Protein
,	O
are	O
present	O
in	O
myeloid	O
cells	O
and	O
play	O
different	O
roles	O
in	O
differentiating	O
myeloid	O
cells	O
depending	O
on	O
the	O
extracellular	O
environment	O
[	O
61	O
]	O
.	O

To	O
determine	O
which	O
C	O
/	O
EBP	O
proteins	O
were	O
involved	O
in	O
the	O
formation	O
of	O
the	O
different	O
nucleo	O
-	O
protein	O
complexes	O
,	O
and	O
particularly	O
of	O
the	O
LPS	O
-	O
inducible	O
complex	O
,	O
EMSA	O
was	O
performed	O
after	O
incubating	O
the	O
nucleo	O
-	O
protein	O
complexes	O
with	O
antibodies	O
specific	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
alpha	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
delta	I-Protein
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
epsilon	I-Protein
.	O

Each	O
antibody	O
detects	O
the	O
carboxy	O
-	O
terminal	O
DNA	O
-	O
binding	O
region	O
of	O
the	O
respective	O
protein	O
,	O
so	O
that	O
pre	O
-	O
incubation	O
of	O
antibody	O
with	O
nuclear	O
extract	O
is	O
expected	O
to	O
abolish	O
DNA	O
binding	O
by	O
EMSA	O
[	O
62	O
]	O
.	O

Only	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
abolished	O
the	O
formation	O
of	O
the	O
LPS	O
-	O
inducible	O
complex	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

Taken	O
together	O
these	O
data	O
show	O
that	O
the	O
LPS	O
-	O
induced	O
complex	O
with	O
the	O
C	O
/	O
EBP	O
element	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
contains	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Mediates	O
both	O
Constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
mRNA	O
Expression	O
in	O
MEFs	O
and	O
Inflammatory	O
Primary	O
Macrophages	O

To	O
investigate	O
the	O
importance	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
to	O
endogenous	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
response	O
to	O
LPS	O
,	O
we	O
utilized	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
null	O
(	O
Cebpb	B-Protein
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
MEFs	O
(	O
Cebpb	B-Protein
+	O
/	O
+	O
)	O
,	O
since	O
RAW264	O
.	O
7	O
cells	O
constitutively	O
express	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

Wild	O
-	O
type	O
MEFs	O
express	O
low	O
levels	O
of	O
endogenous	O
SerpinB2	B-Protein
and	O
the	O
absence	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
attenuated	O
endogenous	O
SerpinB2	B-Protein
mRNA	O
expression	O
.	O

LPS	O
stimulated	O
an	O
increase	O
in	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
wild	O
-	O
type	O
MEFs	O
(	O
Fig	O
.	O
6A	O
)	O
,	O
whereas	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
mRNA	O
expression	O
was	O
significantly	O
dampened	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
as	O
compared	O
to	O
wild	O
-	O
type	O
.	O

We	O
next	O
tested	O
if	O
similar	O
effects	O
could	O
be	O
seen	O
in	O
thioglycollate	O
-	O
elicited	O
inflammatory	O
macrophages	O
in	O
which	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
expression	O
was	O
knocked	O
down	O
using	O
species	O
-	O
specific	O
lentiviral	O
shRNAs	O
(	O
Fig	O
.	O
6B	O
,	O
left	O
)	O
.	O

As	O
was	O
observed	O
in	O
MEFs	O
,	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
mRNA	O
expression	O
was	O
significantly	O
decreased	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
inflammatory	O
macrophages	O
(	O
Fig	O
.	O
6B	O
,	O
right	O
)	O
.	O

These	O
data	O
show	O
that	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
critical	O
for	O
mediating	O
constitutive	O
and	O
LPS	O
-	O
inducible	O
transcription	O
of	O
endogenous	O
SerpinB2	B-Protein
mRNA	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Binds	O
the	O
Murine	O
SerpinB2	B-Protein
Proximal	O
Promoter	O
in	O
vivo	O
in	O
an	O
LPS	O
-	O
inducible	O
Manner	O

We	O
investigated	O
the	O
temporal	O
dynamics	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
recruitment	O
to	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
in	O
response	O
to	O
LPS	O
in	O
vivo	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
.	O

RAW	O
264	O
.	O
7	O
cells	O
were	O
stimulated	O
with	O
LPS	O
for	O
up	O
to	O
8	O
hrs	O
,	O
soluble	O
chromatin	O
was	O
immunoprecipitated	O
with	O
antibodies	O
against	O
DNA	O
binding	O
proteins	O
,	O
and	O
the	O
enriched	O
DNA	O
amplified	O
by	O
both	O
semi	O
-	O
quantitative	O
and	O
qPCR	O
using	O
SerpinB2	B-Protein
proximal	O
promoter	O
specific	O
primers	O
(	O
illustrated	O
in	O
fig	O
.	O
4A	O
)	O
.	O

The	O
results	O
showed	O
that	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
constitutively	O
present	O
at	O
the	O
SerpinB2	B-Protein
promoter	O
as	O
demonstrated	O
by	O
its	O
association	O
with	O
the	O
promoter	O
in	O
unstimulated	O
macrophages	O
and	O
increased	O
temporally	O
in	O
response	O
to	O
LPS	O
reaching	O
as	O
much	O
as	O
10	O
-	O
fold	O
over	O
unstimulated	O
cells	O
after	O
8	O
hrs	O
(	O
Fig	O
.	O
7	O
)	O
.	O

Since	O
changes	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phosphorylation	O
states	O
can	O
affect	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
'	O
s	O
ability	O
to	O
transactivate	O
target	O
genes	O
[	O
38	O
]	O
;	O
[	O
63	O
]	O
;	O
[	O
64	O
]	O
,	O
we	O
investigated	O
recruitment	O
to	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
of	O
the	O
T217	O
phosphorylated	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
isoform	O
(	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
)	O
,	O
which	O
has	O
been	O
associated	O
with	O
cell	O
survival	O
[	O
65	O
]	O
.	O

p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
was	O
constitutively	O
bound	O
to	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
and	O
also	O
present	O
after	O
1	O
hr	O
of	O
LPS	O
stimulation	O
(	O
Fig	O
.	O
7	O
)	O
.	O

In	O
contrast	O
to	O
total	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
the	O
binding	O
affinity	O
of	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
for	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
diminished	O
with	O
LPS	O
stimulation	O
at	O
later	O
timepoints	O
(	O
4	O
and	O
8	O
hrs	O
)	O
(	O
Fig	O
.	O
7	O
)	O
.	O

These	O
data	O
show	O
an	O
inverse	O
relationship	O
between	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
recruitment	O
,	O
and	O
indicate	O
that	O
T217	O
-	O
phosphorylated	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
may	O
not	O
be	O
responsible	O
for	O
increased	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
promoter	O
in	O
response	O
to	O
LPS	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Promotes	O
LPS	O
-	O
inducible	O
Murine	O
SerpinB2	B-Protein
Proximal	O
Promoter	O
Activity	O

Since	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
binds	O
to	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
in	O
an	O
LPS	O
-	O
inducible	O
manner	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
we	O
wanted	O
to	O
address	O
the	O
question	O
of	O
whether	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
was	O
an	O
essential	O
factor	O
for	O
driving	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
promoter	O
in	O
cells	O
in	O
response	O
to	O
LPS	O
.	O

The	O
ability	O
of	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
to	O
direct	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
was	O
examined	O
by	O
transfection	O
of	O
the	O
pGLmP	O
-	O
539	O
murine	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
construct	O
into	O
Cebpb	B-Protein
+	O
/	O
+	O
and	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
.	O

We	O
found	O
that	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
promoter	O
activity	O
was	O
significantly	O
increased	O
in	O
Cebpb	B-Protein
+	O
/	O
+	O
MEFs	O
and	O
abrogated	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
(	O
Fig	O
.	O
8A	O
)	O
,	O
indicating	O
that	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
required	O
for	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
.	O

Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
Serine	O
64	O
negatively	O
Regulates	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
Promoter	O
Activity	O

Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
well	O
recognized	O
to	O
modulate	O
its	O
transactivation	O
potential	O
[	O
63	O
]	O
.	O

To	O
investigate	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phosphorylation	O
sites	O
that	O
may	O
be	O
important	O
for	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
(	O
Fig	O
.	O
8B	O
)	O
,	O
we	O
co	O
-	O
expressed	O
several	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
in	O
which	O
the	O
critical	O
threonine	O
or	O
serine	O
residue	O
was	O
mutated	O
to	O
an	O
alanine	O
,	O
along	O
with	O
the	O
pGLmP	O
-	O
539	O
murine	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
.	O

Re	O
-	O
expression	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
significantly	O
stimulated	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
gene	O
expression	O
in	O
the	O
presence	O
of	O
LPS	O
by	O
~	O
3	O
fold	O
(	O
Fig	O
.	O
8C	O
,	O
left	O
)	O
,	O
confirming	O
the	O
importance	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
to	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

Expression	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutant	I-Protein
,	O
C	B-Protein
/	I-Protein
EBPbetaT217A	I-Protein
,	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
did	O
not	O
significantly	O
increase	O
SerpinB2	B-Protein
promoter	O
activity	O
above	O
that	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	O
Fig	O
.	O
8C	O
,	O
right	O
)	O
;	O
confirming	O
that	O
phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
T217	O
is	O
not	O
a	O
major	O
factor	O
in	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
promoter	O
activity	O
in	O
response	O
to	O
LPS	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
contains	O
additional	O
phosphorylation	O
sites	O
,	O
C	O
/	O
EBP	O
-	O
betaT188	O
and	O
C	O
/	O
EBP	O
-	O
betaS64	O
(	O
Fig	O
.	O
8B	O
)	O
,	O
which	O
may	O
be	O
involved	O
in	O
modulating	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
dependent	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

C	O
/	O
EBP	O
-	O
betaT188	O
is	O
implicated	O
in	O
regulating	O
DAPK1	B-Protein
,	O
an	O
IFNgamma	B-Protein
-	O
inducible	O
gene	B-Protein
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
and	O
apoptosis	O
[	O
38	O
]	O
,	O
processes	O
with	O
which	O
SerpinB2	B-Protein
has	O
also	O
been	O
associated	O
[	O
17	O
]	O
.	O

C	O
/	O
EBP	O
-	O
betaS64	O
is	O
important	O
for	O
LPS	O
-	O
induced	O
transcription	O
of	O
the	O
cytokines	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
[	O
64	O
]	O
.	O

Similarly	O
,	O
SerpinB2	B-Protein
is	O
induced	O
by	O
LPS	O
and	O
regulated	O
in	O
a	O
manner	O
similar	O
to	O
cytokines	O
[	O
29	O
]	O
.	O

Given	O
the	O
similarities	O
in	O
the	O
functional	O
significance	O
of	O
these	O
phospho	O
-	O
specific	O
isoforms	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
SerpinB2	B-Protein
,	O
we	O
investigated	O
whether	O
these	O
phospho	O
-	O
acceptor	O
sites	O
may	O
play	O
a	O
role	O
in	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT188A	I-Protein
-	O
transfected	O
MEFs	O
exhibited	O
SerpinB2	B-Protein
promoter	O
activity	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
transfected	O
MEFs	O
,	O
whereas	O
the	O
expression	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaS64A	I-Protein
potentiated	O
SerpinB2	B-Protein
promoter	O
activity	O
in	O
response	O
to	O
LPS	O
(	O
Fig	O
.	O
8C	O
,	O
right	O
)	O
.	O

These	O
data	O
suggest	O
that	O
phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
S64	O
acts	O
to	O
negatively	O
regulate	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
.	O

Macrophages	O
are	O
key	O
mediators	O
of	O
the	O
innate	O
immune	O
response	O
,	O
and	O
consequently	O
provide	O
the	O
first	O
line	O
of	O
defense	O
against	O
pathogens	O
.	O

Pro	O
-	O
inflammatory	O
stimuli	O
,	O
such	O
as	O
the	O
bacterial	O
endotoxin	O
LPS	O
,	O
stimulate	O
macrophages	O
to	O
mount	O
an	O
anti	O
-	O
pathogenic	O
response	O
which	O
involves	O
massive	O
induction	O
of	O
the	O
pro	O
-	O
survival	O
factor	O
SerpinB2	B-Protein
.	O

SerpinB2	B-Protein
is	O
transcriptionally	O
induced	O
by	O
cross	O
talk	O
between	O
the	O
IKKbeta	B-Protein
/	O
NF	O
-	O
kappaB	O
and	O
p38MAPK	O
signaling	O
modules	O
in	O
response	O
to	O
LPS	O
[	O
16	O
]	O
.	O

Here	O
we	O
report	O
that	O
SerpinB2	B-Protein
gene	O
transcription	O
in	O
response	O
to	O
LPS	O
is	O
conferred	O
by	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
and	O
is	O
greatly	O
dependent	O
upon	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

LPS	O
-	O
induced	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
was	O
shown	O
to	O
specifically	O
bind	O
the	O
C	O
/	O
EBP	O
response	O
element	O
in	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
loss	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
abrogates	O
constitutive	O
SerpinB2	B-Protein
gene	O
transcription	O
and	O
the	O
response	O
to	O
LPS	O
.	O

The	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
region	O
between	O
nucleotides	O
-	O
539	O
and	O
+	O
92	O
mediated	O
both	O
PMA	O
-	O
and	O
LPS	O
-	O
inducible	O
gene	O
transcription	O
,	O
with	O
induction	O
by	O
PMA	O
being	O
less	O
intense	O
and	O
more	O
transient	O
than	O
that	O
by	O
LPS	O
.	O

Inspection	O
of	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
sequence	O
shows	O
that	O
a	O
CRE	O
and	O
two	O
AP	O
-	O
1	O
-	O
like	O
elements	O
,	O
demonstrated	O
to	O
mediate	O
PMA	O
-	O
stimulated	O
transcription	O
of	O
the	O
human	O
SERPINB2	B-Protein
gene	O
[	O
37	O
]	O
,	O
also	O
are	O
present	O
in	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
87	O
.	O

These	O
sites	O
may	O
therefore	O
also	O
play	O
a	O
role	O
in	O
mediating	O
PMA	O
-	O
inducible	O
transcription	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
.	O

In	O
contrast	O
to	O
the	O
pattern	O
of	O
incremental	O
increases	O
in	O
PMA	O
-	O
induced	O
transcriptional	O
activity	O
conferred	O
by	O
regions	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
containing	O
these	O
sites	O
,	O
most	O
of	O
the	O
LPS	O
-	O
inducible	O
response	O
is	O
dependent	O
upon	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
in	O
the	O
region	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
539	O
.	O

LPS	O
responsiveness	O
absolutely	O
required	O
the	O
C	O
/	O
EBP	O
binding	O
site	O
located	O
in	O
the	O
region	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
539	O
,	O
with	O
the	O
downstream	O
CRE	O
and	O
AP	O
-	O
1	O
-	O
like	O
elements	O
also	O
being	O
critical	O
.	O

Of	O
note	O
,	O
there	O
are	O
previous	O
reports	O
of	O
combinatorial	O
interactions	O
between	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
CRE	O
binding	O
proteins	O
(	O
CREB	O
)	O
and	O
AP	O
-	O
1	O
[	O
63	O
]	O
,	O
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
has	O
been	O
reported	O
to	O
physically	O
interact	O
with	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kappaB	O
to	O
promote	O
gene	O
expression	O
of	O
inflammatory	O
mediators	O
[	O
63	O
]	O
;	O
[	O
66	O
]	O
.	O

Additionally	O
,	O
CREB	O
has	O
been	O
shown	O
to	O
control	O
transcription	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
gene	O
[	O
67	O
]	O
.	O

In	O
this	O
study	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
was	O
found	O
to	O
be	O
a	O
major	O
requirement	O
for	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

In	O
a	O
previous	O
microarray	O
expression	O
profiling	O
study	O
,	O
SerpinB2	B-Protein
was	O
identified	O
as	O
gene	B-Protein
whose	O
induction	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
peritoneal	O
macrophages	O
by	O
LPS	O
and	O
IFNgamma	B-Protein
was	O
severely	O
impaired	O
compared	O
to	O
wild	O
-	O
type	O
macrophages	O
[	O
68	O
]	O
.	O

Our	O
qPCR	O
results	O
validate	O
this	O
finding	O
,	O
as	O
we	O
found	O
that	O
both	O
constitutive	O
and	O
LPS	O
-	O
inducible	O
SerpinB2	B-Protein
mRNA	O
expression	O
is	O
significantly	O
abrogated	O
in	O
C	O
/	O
EBP	O
-	O
beta	O
-	O
shRNA	O
transduced	O
peritoneal	O
macrophages	O
,	O
emphasizing	O
the	O
link	O
between	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

While	O
C	O
/	O
EBP	O
proteins	O
can	O
act	O
as	O
either	O
homodimers	O
or	O
heterodimers	O
[	O
63	O
]	O
,	O
we	O
identified	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
as	O
the	O
only	O
LPS	O
-	O
inducible	O
C	O
/	O
EBP	O
isoform	O
to	O
bind	O
the	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
response	O
element	O
,	O
suggesting	O
a	O
predominant	O
role	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
in	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
like	O
SerpinB2	B-Protein
,	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
,	O
as	O
it	O
is	O
upregulated	O
by	O
LPS	O
and	O
a	O
host	O
of	O
other	O
inflammatory	O
cytokines	O
[	O
59	O
]	O
;	O
[	O
62	O
]	O
.	O

Furthermore	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
null	O
mice	O
are	O
susceptible	O
to	O
bacterial	O
infection	O
[	O
69	O
]	O
;	O
[	O
70	O
]	O
and	O
SerpinB2	B-Protein
has	O
been	O
demonstrated	O
to	O
protect	O
from	O
bacterial	O
and	O
viral	O
-	O
induced	O
cell	O
death	O
[	O
14	O
]	O
-	O
[	O
16	O
]	O
;	O
[	O
25	O
]	O
.	O

Thus	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
gene	O
expression	O
by	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
consistent	O
with	O
its	O
functional	O
role	O
in	O
inflammation	O
.	O

Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
several	O
different	O
amino	O
acid	O
residues	O
has	O
been	O
shown	O
to	O
modulate	O
transactivation	O
of	O
its	O
target	O
genes	O
[	O
63	O
]	O
;	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phosphorylated	O
on	O
T217	O
has	O
been	O
reported	O
to	O
rescue	O
macrophages	O
from	O
apoptosis	O
induced	O
by	O
Bacillus	O
anthracis	O
lethal	O
toxin	O
(	O
LT	O
)	O
[	O
65	O
]	O
,	O
an	O
activity	O
that	O
has	O
also	O
been	O
attributed	O
to	O
SerpinB2	B-Protein
[	O
16	O
]	O
.	O

However	O
,	O
expression	O
of	O
a	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
site	I-Protein
mutant	I-Protein
,	O
C	B-Protein
/	I-Protein
EBPbetaT217A	I-Protein
,	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
did	O
not	O
increase	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
over	O
that	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
even	O
though	O
recruitment	O
of	O
C	O
/	O
EBP	O
-	O
betaT217	O
to	O
the	O
SerpinB2	B-Protein
promoter	O
was	O
observed	O
to	O
decrease	O
following	O
LPS	O
stimulation	O
of	O
RAW264	O
.	O
7	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
the	O
T217	O
phospho	O
-	O
acceptor	O
site	O
is	O
not	O
important	O
for	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

Similarly	O
,	O
expression	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
site	I-Protein
mutant	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT188A	I-Protein
,	O
did	O
not	O
affect	O
SerpinB2	B-Protein
promoter	O
activity	O
differently	O
from	O
that	O
of	O
wild	O
-	O
type	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaS64A	I-Protein
significantly	O
enhanced	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
promoter	O
activity	O
,	O
indicating	O
that	O
phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
S64	O
negatively	O
regulates	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Since	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
S64	O
is	O
constitutively	O
phosphorylated	O
in	O
both	O
RAW264	O
.	O
7	O
cells	O
and	O
MEFs	O
[	O
73	O
]	O
,	O
it	O
is	O
likely	O
that	O
dephosphorylation	O
at	O
this	O
site	O
may	O
be	O
a	O
critical	O
event	O
during	O
LPS	O
-	O
induced	O
transcription	O
of	O
SerpinB2	B-Protein
to	O
increase	O
its	O
promoter	O
activity	O
.	O

Roy	O
and	O
colleagues	O
demonstrated	O
that	O
Mixed	B-Protein
lineage	I-Protein
kinase	I-Protein
-	I-Protein
3	I-Protein
(	O
MLK3	B-Protein
)	O
-	O
driven	O
dephosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
S64	O
was	O
important	O
for	O
IFNgamma	B-Protein
-	O
regulated	O
signaling	O
pathways	O
[	O
73	O
]	O
.	O

Our	O
data	O
suggest	O
that	O
MLK3	B-Protein
-	O
driven	O
dephosphorylation	O
of	O
S64	O
may	O
also	O
be	O
involved	O
in	O
LPS	O
-	O
signaling	O
pathways	O
.	O

In	O
recent	O
years	O
it	O
has	O
become	O
apparent	O
that	O
persistent	O
infection	O
is	O
integrally	O
linked	O
to	O
chronic	O
inflammation	O
and	O
cancer	O
,	O
and	O
immune	O
cells	O
such	O
as	O
macrophages	O
can	O
either	O
promote	O
or	O
attenuate	O
cancer	O
progression	O
[	O
2	O
]	O
;	O
[	O
74	O
]	O
-	O
[	O
76	O
]	O
.	O

SerpinB2	B-Protein
expression	O
has	O
been	O
associated	O
with	O
both	O
inflammation	O
and	O
cancer	O
,	O
and	O
is	O
a	O
favorable	O
or	O
unfavorable	O
prognostic	O
indicator	O
depending	O
on	O
cancer	O
type	O
[	O
77	O
]	O
.	O

The	O
presence	O
of	O
SerpinB2	B-Protein
has	O
been	O
shown	O
to	O
modulate	O
cytokine	O
profiles	O
which	O
can	O
affect	O
immune	O
cell	O
polarization	O
[	O
27	O
]	O
;	O
[	O
28	O
]	O
;	O
[	O
77	O
]	O
;	O
[	O
78	O
]	O
.	O

Interestingly	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
has	O
also	O
been	O
shown	O
to	O
modulate	O
cytokine	O
secretion	O
from	O
immune	O
cells	O
,	O
thereby	O
modifying	O
their	O
phenotype	O
[	O
27	O
]	O
;	O
[	O
79	O
]	O
-	O
[	O
81	O
]	O
.	O

Our	O
study	O
has	O
demonstrated	O
that	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
plays	O
an	O
important	O
role	O
in	O
mediating	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
transcription	O
of	O
the	O
SerpinB2	B-Protein
gene	O
,	O
which	O
may	O
have	O
implications	O
for	O
the	O
inflammatory	O
phenotype	O
of	O
infiltrating	O
immune	O
cells	O
in	O
the	O
tumor	O
microenvironment	O
.	O

In	O
summary	O
,	O
our	O
studies	O
show	O
that	O
the	O
C	O
/	O
EBP	O
site	O
(	O
-	O
203	O
/	O
-	O
195	O
)	O
in	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
is	O
necessary	O
to	O
support	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

Importantly	O
,	O
we	O
were	O
able	O
to	O
uncover	O
a	O
previously	O
unknown	O
role	O
for	O
C	O
/	O
EBP	O
-	O
betaS64	O
in	O
negatively	O
regulating	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Taken	O
together	O
these	O
data	O
provide	O
new	O
insight	O
into	O
the	O
regulation	O
of	O
inflammation	O
-	O
associated	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

LPS	O
induction	O
of	O
SerpinB2	B-Protein
mRNA	O
and	O
protein	O
expression	O
in	O
murine	O
macrophage	O
cells	O
.	O

RAW264	O
.	O
7	O
macrophages	O
were	O
treated	O
for	O
the	O
indicated	O
times	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
.	O

(	O
A	O
)	O
qPCR	O
analysis	O
of	O
murine	O
SerpinB2	B-Protein
mRNA	O
levels	O
,	O
relative	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
.	O

The	O
plot	O
is	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

(	O
B	O
)	O
Immunoblot	O
analysis	O
of	O
SerpinB2	B-Protein
protein	O
expression	O
in	O
whole	O
cell	O
lysates	O
.	O

Blot	O
was	O
reprobed	O
for	O
GAPDH	B-Protein
as	O
a	O
loading	O
control	O
.	O

Deletion	O
reporter	O
gene	O
analysis	O
of	O
LPS	O
and	O
PMA	O
-	O
responsive	O
regions	O
in	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
and	I-Protein
5	I-Protein
'	I-Protein
deletion	I-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
.	O

The	O
murine	O
5	O
'	O
flanking	O
region	O
from	O
-	O
4480	O
to	O
+	O
92	O
was	O
inserted	O
upstream	O
of	O
the	O
luciferase	B-Protein
reporter	O
gene	O
and	O
5	O
'	O
deletions	O
were	O
generated	O
using	O
restriction	O
enzyme	O
sites	O
or	O
with	O
specific	O
oligonucleotide	O
PCR	O
primers	O
.	O

Construct	O
names	O
indicate	O
the	O
most	O
5	O
'	O
nucleotide	O
of	O
murine	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
sequence	O
.	O

(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
macrophages	O
were	O
transiently	O
transfected	O
with	O
the	O
indicated	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
and	O
control	O
plasmids	O
.	O

Cells	O
were	O
either	O
left	O
untreated	O
or	O
treated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
40	O
ng	O
/	O
ml	O
PMA	O
for	O
16	O
hrs	O
.	O

Shown	O
is	O
the	O
relative	O
luciferase	B-Protein
reporter	O
gene	O
activity	O
following	O
treatment	O
.	O

The	O
results	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
four	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
DNA	O
sequence	O
conservation	O
between	O
the	O
human	O
and	O
murine	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
regions	O
.	O

Schematic	O
representation	O
of	O
the	O
human	O
and	O
murine	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
regions	O
with	O
regions	O
of	O
nucleotide	O
sequence	O
identity	O
indicated	O
by	O
the	O
same	O
colored	O
boxes	O
.	O

Homologous	O
regions	O
are	O
interrupted	O
by	O
repetitive	O
sequence	O
elements	O
in	O
both	O
5	O
'	O
flanking	O
regions	O
.	O

Alu	O
=	O
Alu	O
repeat	O
,	O
ID4	O
=	O
ID4	O
short	O
interspersed	O
nuclear	O
repeat	O
(	O
SINE	O
)	O
,	O
L1	O
=	O
L1	O
long	O
interspersed	O
nuclear	O
element	O
(	O
LINE	O
)	O
,	O
L2	O
=	O
L2	O
LINE	O
,	O
MIR	O
=	O
MIR	O
SINE	O
,	O
MLT1L	O
=	O
MLT1L	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
(	O
TATG	O
)	O
n	O
=	O
TATG	O
tetranucleotide	O
repeat	O
,	O
tis	O
=	O
transcription	O
initiation	O
site	O
.	O

Potential	O
cis	O
-	O
acting	O
regulatory	O
elements	O
in	O
the	O
LPS	O
responsive	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O

-	O
563	O
/	O
-	O
1	O
.	O

Mouse	O
and	O
human	O
nucleotide	O
sequences	O
were	O
aligned	O
using	O
Clustal	O
W	O
software	O
.	O

Cis	O
-	O
acting	O
elements	O
conserved	O
between	O
the	O
human	O
and	O
murine	O
SerpinB2	B-Protein
promoters	O
are	O
boxed	O
and	O
labeled	O
.	O

AP	O
-	O
1	O
=	O
activator	O
protein	O
1	O
;	O
C	O
/	O
EBP	O
=	O
CCAAT	O
enhancer	O
binding	O
protein	O
;	O
CRE	O
=	O
cAMP	O
response	O
element	O
;	O
Oct1	B-Protein
=	O
octamer	B-Protein
transcription	I-Protein
factor	I-Protein
1	I-Protein
/	O
POU2F1	B-Protein
;	O
PU	B-Protein
.	I-Protein
1	I-Protein
=	O
purine	B-Protein
box	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
.	O

The	O
putative	O
transcription	O
initiation	O
site	O
(	O
tis	O
)	O
is	O
indicated	O
and	O
exon	O
1	O
is	O
presented	O
in	O
uppercase	O
.	O

The	O
location	O
of	O
the	O
5	O
'	O
ends	O
of	O
the	O
-	O
539	O
,	O
-	O
189	O
and	O
-	O
87	O
reporter	O
constructs	O
are	O
also	O
shown	O
.	O

Identification	O
of	O
cis	O
-	O
acting	O
elements	O
required	O
for	O
the	O
LPS	O
-	O
responsiveness	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
the	O
-	O
539	O
/	O
+	O
92	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
with	O
the	O
location	O
of	O
candidate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
indicated	O
with	O
boxes	O
.	O

The	O
location	O
of	O
the	O
5	O
'	O
ends	O
of	O
the	O
-	O
539	O
,	O
-	O
189	O
and	O
-	O
87	O
reporter	O
constructs	O
is	O
also	O
shown	O
.	O

Positions	O
of	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
-	O
specific	O
primers	O
,	O
338	O
/	O
-	O
315	O
and	O
-	O
5	O
/	O
+	O
19	O
used	O
in	O
ChIP	O
assays	O
are	O
indicated	O
.	O

(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
macrophages	O
were	O
transiently	O
transfected	O
with	O
the	O
indicated	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
and	O
either	O
left	O
untreated	O
or	O
treated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
for	O
16	O
hrs	O
.	O

The	O
results	O
show	O
relative	O
luciferase	B-Protein
activity	O
following	O
LPS	O
treatment	O
and	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
4	O
-	O
7	O
independent	O
experiments	O
.	O

The	O
LPS	O
-	O
inducible	O
nuclear	O
factor	O
binding	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
C	O
/	O
EBP	O
site	O
contains	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

(	O
A	O
)	O
EMSA	O
with	O
nuclear	O
extracts	O
from	O
untreated	O
(	O
UN	O
)	O
and	O
10	O
hr	O
LPS	O
treated	O
(	O
LPS	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
incubated	O
with	O
either	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
-	O
212	O
/	O
-	O
185	O
probe	O
containing	O
an	O
intact	O
(	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
)	O
or	O
mutated	O
(	O
mutant	O
C	O
/	O
EBP	O
)	O
C	O
/	O
EBP	O
site	O
or	O
with	O
the	O
rat	O
albumin	B-Protein
promoter	O
DEI	O
region	O
C	O
/	O
EBP	O
(	O
rat	O
albumin	B-Protein
C	O
/	O
EBP	O
)	O
probe	O
.	O

(	O
B	O
)	O
Cold	O
competition	O
EMSAs	O
performed	O
with	O
the	O
radiolabelled	O
murine	O
SerpinB2	B-Protein
promoter	O
-	O
212	O
/	O
-	O
185	O
probe	O
and	O
a	O
100	O
-	O
fold	O
molar	O
excess	O
of	O
each	O
of	O
the	O
double	O
stranded	O
oligonucleotides	O
described	O
in	O
(	O
A	O
)	O
demonstrate	O
the	O
specificity	O
of	O
the	O
DNA	O
-	O
protein	O
complexes	O
.	O

(	O
C	O
)	O
Supershift	O
assays	O
were	O
performed	O
with	O
the	O
-	O
212	O
/	O
-	O
185	O
probe	O
by	O
after	O
preincubation	O
with	O
the	O
indicated	O
specific	O
C	O
/	O
EBP	O
antibody	O
.	O

The	O
LPS	O
-	O
inducible	O
complex	O
is	O
indicated	O
with	O
an	O
arrowhead	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
essential	O
for	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
mRNA	O
expression	O
.	O

(	O
A	O
)	O
Endogenous	O
SerpinB2	B-Protein
mRNA	O
expression	O
is	O
abrogated	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
compared	O
to	O
Cebpb	B-Protein
+	O
/	O
+	O
MEFs	O
in	O
the	O
absence	O
and	O
presence	O
of	O
LPS	O
.	O

qPCR	O
analysis	O
of	O
murine	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
untreated	O
Cebpb	B-Protein
+	O
/	O
+	O
and	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
,	O
and	O
after	O
simulation	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
the	O
indicated	O
times	O
.	O

(	O
B	O
)	O
Endogenous	O
SerpinB2	B-Protein
expression	O
is	O
abrogated	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
inflammatory	O
macrophages	O
.	O

Thioglycollate	O
-	O
elicited	O
peritoneal	O
macrophages	O
(	O
TG	O
macs	O
)	O
were	O
infected	O
with	O
human	O
and	O
murine	O
specific	O
lentiviral	O
shRNAs	O
.	O

Human	O
CEBPB	O
shRNA	O
serves	O
as	O
the	O
non	O
-	O
silencing	O
control	O
since	O
it	O
does	O
not	O
target	O
the	O
murine	O
Cebpb	B-Protein
sequence	O
[	O
38	O
]	O
.	O

Lentiviral	O
transduced	O
macrophages	O
were	O
stimulated	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
4	O
hrs	O
.	O

Left	O
:	O
Western	O
blot	O
analysis	O
shows	O
effective	O
knockdown	O
of	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
following	O
infection	O
with	O
murine	O
Cebpb	O
shRNA	O
and	O
not	O
human	O
CEBPB	O
shRNA	O
.	O

Right	O
:	O
qPCR	O
analysis	O
of	O
murine	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
the	O
lentiviral	O
transduced	O
peritoneal	O
macrophages	O
.	O

The	O
results	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
two	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
or	O
triplicate	O
.	O

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
two	O
-	O
way	O
ANOVA	O
)	O
.	O

Differential	O
recruitment	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
C	O
/	O
EBP	O
-	O
betaT217	O
to	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
in	O
vivo	O
.	O

Transcription	O
factor	O
occupancy	O
on	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
in	O
vivo	O
was	O
determined	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
.	O

RAW264	O
.	O
7	O
macrophages	O
were	O
treated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
for	O
the	O
indicated	O
times	O
and	O
chromatin	O
immunoprecipitation	O
performed	O
using	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	I-Protein
T217	I-Protein
)	I-Protein
.	O

Soluble	O
chromatin	O
(	O
600	O
-	O
700	O
ng	O
)	O
was	O
immunoprecipitated	O
with	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	I-Protein
T217	I-Protein
)	I-Protein
,	O
RNA	O
Polymerase	O
II	O
(	O
RNAPII	O
)	O
,	O
or	O
a	O
rabbit	O
IgG	O
(	O
rIgG	O
)	O
control	O
.	O

(	O
A	O
)	O
Typical	O
PCR	O
pattern	O
obtained	O
in	O
ChIP	O
assays	O
using	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
-	O
specific	O
primers	O
,	O
338	O
/	O
-	O
315	O
and	O
-	O
5	O
/	O
+	O
19	O
,	O
as	O
diagrammed	O
in	O
top	O
.	O

Recruitment	O
of	O
RNAPII	O
to	O
the	O
SerpinB2	B-Protein
promoter	O
suggests	O
active	O
transcription	O
following	O
LPS	O
stimulation	O
.	O

Minimal	O
background	O
was	O
detected	O
using	O
the	O
rabbit	O
IgG	O
control	O
,	O
indicative	O
of	O
the	O
specificity	O
of	O
the	O
ChIP	O
reaction	O
.	O

(	O
B	O
)	O
qPCR	O
analysis	O
of	O
chromatin	O
immunoprecipitated	O
with	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	I-Protein
T217	I-Protein
)	I-Protein
,	O
and	O
the	O
rIgG	O
control	O
.	O

The	O
data	O
are	O
represented	O
relative	O
to	O
rIgG	B-Protein
signal	O
using	O
the	O
2	O
-	O
deltadeltaCt	O
method	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
necessary	O
for	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
.	O

(	O
A	O
)	O
The	O
SerpinB2	B-Protein
proximal	O
promoter	O
is	O
significantly	O
activated	O
in	O
LPS	O
-	O
stimulated	O
Cebpb	B-Protein
+	O
/	O
+	O
MEFs	O
and	O
not	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
.	O

Murine	O
SerpinB2	B-Protein
gene	O
promoter	O
activity	O
measured	O
in	O
Cebpb	B-Protein
+	O
/	O
+	O
and	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
expressing	O
the	O
pGLmP	O
-	O
539	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
(	O
100	O
ng	O
/	O
mL	O
)	O
.	O

Cells	O
were	O
co	O
-	O
transfected	O
with	O
the	O
pGLmP	O
-	O
539	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
and	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
reporter	I-Protein
plasmids	O
,	O
and	O
luciferase	B-Protein
units	O
normalized	O
to	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
activity	O
.	O

(	O
B	O
)	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
gene	O
schematic	O
depicting	O
gene	O
structure	O
and	O
phospho	O
-	O
acceptor	O
sites	O
.	O

(	O
C	O
)	O
Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
Serine	O
64	O
negatively	O
regulates	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
were	O
co	O
-	O
transfected	O
with	O
expression	O
plasmids	O
encoding	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
the	O
indicated	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
,	O
along	O
with	O
the	O
pGLmP	O
-	O
539	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
and	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
reporter	I-Protein
plasmids	O
,	O
and	O
stimulated	O
with	O
LPS	O
for	O
4	O
hrs	O
.	O

Luciferase	B-Protein
activity	O
was	O
quantified	O
and	O
normalized	O
to	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
activity	O
.	O

The	O
western	O
blot	O
(	O
below	O
the	O
graphs	O
)	O
confirms	O
the	O
expression	O
of	O
the	O
respective	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
.	O

The	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217A	I-Protein
-	O
transfected	O
MEFs	O
express	O
both	O
the	O
38	O
kDa	O
and	O
35	O
kDa	O
isoforms	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

The	O
results	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
one	O
-	O
way	O
ANOVA	O
)	O
.	O

